id title journal pub_time pmid database_id ncrna_id ncrna_name ncrna_type drug_id drug_name cancer_type method_ncrna method_drug tissue ncrna_exp_pattern sensitive_or_resistant major_targets target_gene pathway evidence_code 1 Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006 16762633 miRBase MI0000342 miR-200b miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma Northern blot miRNA expression in malignant and nonmalignant human cholangiocytes was assessed using a microarray. Expression of selected miRNA and their precursors was evaluated by Northern blots and real-time polymerase chain reaction, respectively. The effect of selected miRNA on cell growth and response to chemotherapy was assessed using miRNA-specific antisense oligonucleotides to decrease miRNA expression or with precursor miRNA to increase cellular expression. cell line (KMCH-1, Mz-ChA-1, TFK) down-regulated sensitive PTPN12 PTPN12 NA validated 2 Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006 16762633 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma Northern blot miRNA expression in malignant and nonmalignant human cholangiocytes was assessed using a microarray. Expression of selected miRNA and their precursors was evaluated by Northern blots and real-time polymerase chain reaction, respectively. The effect of selected miRNA on cell growth and response to chemotherapy was assessed using miRNA-specific antisense oligonucleotides to decrease miRNA expression or with precursor miRNA to increase cellular expression. cell line (KMCH-1, Mz-ChA-1, TFK) down-regulated sensitive PTEN PTEN PI3-kinase signaling validated 3 MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008 18199536 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer Northern blot,qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription-PCR (qRT-PCR) and Northern blot. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (HIOSE) up-regulated resistant PTEN PTEN NA validated 4 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000438 miR-15b miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 5 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000438 miR-15b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 6 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000438 miR-15b miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 7 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000438 miR-15b miRNA DB00773 (APRD00239) Etoposide stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 8 Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008 18803879 miRBase MI0000268 miR-34 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay. cell line (Kato III, AGS, N87, MKN45,WI-38) up-regulated sensitive Bcl-2,Notch,HMGA2 Bcl-2,Notch,HMGA2 p53 signaling pathway validated 9 Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008 18803879 miRBase MI0000268 miR-34 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay. cell line (Kato III, AGS, N87, MKN45,WI-38) up-regulated sensitive Bcl-2,Notch,HMGA2 Bcl-2,Notch,HMGA2 p53 signaling pathway validated 10 Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008 18803879 miRBase MI0000268 miR-34 miRNA DB00441 (APRD00201) Gemcitabine stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay. cell line (Kato III, AGS, N87, MKN45,WI-38) up-regulated sensitive Bcl-2,Notch,HMGA2 Bcl-2,Notch,HMGA2 p53 signaling pathway validated 11 Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008 18803879 miRBase MI0000268 miR-34 miRNA DB01248 (APRD00932) Docetaxel stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay. cell line (Kato III, AGS, N87, MKN45,WI-38) up-regulated sensitive Bcl-2,Notch,HMGA2 Bcl-2,Notch,HMGA2 p53 signaling pathway validated 12 MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010 20406806 miRBase MI0000253 miR-148a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Reverse Transcriptase-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by migration and invasion assay, etc. cell line (LNCaP, PC3, DU145) up-regulated sensitive MSK1 MSK1 MSK1 signaling pathway validated 13 microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 2011 21468550 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin bladder cancer real-time qRT-PCR The expression of miR-21 and its target PTEN was determined by real-time qRT-PCR and western blotting, respectively in tumor tissues as well as adjacent non-tumor mucosa. The effect of miR-21 on cell proliferation and chemosensitivity to doxorubicin were measured using the MTT method. Cell apoptosis induced by doxorubicin was investigated using flow cytometry in the T24 cell line. BCL-2, AKT and pAKT were detected by western blotting for analysis of potential mechanisms. cell line (T24) up-regulated resistant PTEN PTEN PI3K-AKT pathway validated 14 Methylation mediated silencing of miR-23b expression and its role in glioma stem cells. Neurosci Lett 2012 22982144 miRBase MI0000439 miR-23b miRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of miRNA were determined by Methylation-specific PCR (MS-PCR) and stem-loop RT-PCR .Those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (U87) up-regulated sensitive HMGA2 HMGA2 NA validated 15 Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008 18645025 miRBase MI0001729 miR-451 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell survival was analyzed by using the CellTiter-Blue Cell Viability Assay cell line (MCF-7,MCF-7/DOX) up-regulated sensitive mdr1 MDR1 NA validated 16 MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008 18708351 miRBase MI0000298 miR-221 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully used to treat women with estrogen receptor-positive breast cancer. miRNA microarray analysis of MCF-7 cell lines that are either sensitive (parental) or resistant (4-hydroxytamoxifen-resistant (OHT(R))) to tamoxifen showed significant (>1.8-fold) up-regulation of eight miRNAs and marked down-regulation (>50%) of seven miRNAs in OHT(R) cells compared with parental MCF-7 cells. Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR. The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27(Kip1), a known target of miR-221/222, was reduced by 50% in OHT(R) cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27(Kip1) in the resistant OHT(R) cells caused enhanced cell death when exposed to tamoxifen. This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy. This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker. cell line(MCF-7,OHTR) up-regulated resistant p27Kip1 NA NA validated 17 MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008 18708351 miRBase MI0000299 miR-222 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully used to treat women with estrogen receptor-positive breast cancer. miRNA microarray analysis of MCF-7 cell lines that are either sensitive (parental) or resistant (4-hydroxytamoxifen-resistant (OHT(R)) to tamoxifen showed significant (>1.8-fold) up-regulation of eight miRNAs and marked down-regulation (>50%) of seven miRNAs in OHT(R) cells compared with parental MCF-7 cells. Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR. The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27(Kip1), a known target of miR-221/222, was reduced by 50% in OHT(R) cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27(Kip1) in the resistant OHT(R) cells caused enhanced cell death when exposed to tamoxifen. This is the first study demonstrating a relationship between miR-221/222 expression and HER2/neu overexpression in primary breast tumors that are generally resistant to tamoxifen therapy. This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker. cell line(MCF-7,OHTR) up-regulated resistant p27Kip1 NA NA validated 18 MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008 18708351 miRBase MI0000298 miR-221 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR miRNA microarray analysis of MCF-7 cell lines that are either sensitive (parental) or resistant (4-hydroxytamoxifen-resistant (OHTR)) to tamoxifen showed significant (>1.8-fold) up-regulation of eight miRNAs and marked down-regulation (>50%) of seven miRNAs in OHTR cells compared with parental MCF-7 cells. Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR. The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27Kip1, a known target of miR-221/222, was reduced by 50% in OHTR cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27Kip1 in the resistant OHTR cells caused enhanced cell death when exposed to tamoxifen. cell line (MCF-7,OHTR) up-regulated resistant p27Kip1 NA NA validated 19 MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008 18708351 miRBase MI0000299 miR-222 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR miRNA microarray analysis of MCF-7 cell lines that are either sensitive (parental) or resistant (4-hydroxytamoxifen-resistant (OHTR)) to tamoxifen showed significant (>1.8-fold) up-regulation of eight miRNAs and marked down-regulation (>50%) of seven miRNAs in OHTR cells compared with parental MCF-7 cells. Increased expression of three of the most promising up-regulated (miR-221, miR-222, and miR-181) and down-regulated (miR-21, miR-342, and miR-489) miRNAs was validated by real-time reverse transcription-PCR. The expression of miR-221 and miR-222 was also significantly (2-fold) elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to endocrine therapy compared with HER2/neu-negative tissue samples. Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen. The protein level of the cell cycle inhibitor p27Kip1, a known target of miR-221/222, was reduced by 50% in OHTR cells and by 28-50% in miR-221/222-overexpressing MCF-7 cells. Furthermore, overexpression of p27Kip1 in the resistant OHTR cells caused enhanced cell death when exposed to tamoxifen. cell line (MCF-7,OHTR) up-regulated resistant p27Kip1 NA NA validated 20 MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008 18790736 miRBase MI0000298 miR-221 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR The expression levels of miRNA were determined by Reverse Transcription (RT)-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (T47D, BT474, MDA-MB-361, MCF-7, MDA-MB-453, MDA-MB-157, SKBr3, MDA-MB-468, Hs578T, MDA-MB-231, MDA-MB-435s,MCF-10A) down-regulated sensitive ERalpha NA NA validated 21 MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008 18790736 miRBase MI0000299 miR-222 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR The expression levels of miRNA were determined by Reverse Transcription (RT)-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (T47D, BT474, MDA-MB-361, MCF-7, MDA-MB-453, MDA-MB-157, SKBr3, MDA-MB-468, Hs578T, MDA-MB-231, MDA-MB-435s,MCF-10A) down-regulated sensitive ERalpha NA NA validated 22 MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008 18246122 miRBase MI0000298 miR-221 miRNA NA TRAIL therapy lung non-small cell carcinoma qRT-PCR,Northern blot We have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222.Transfection of Pre-miRs and anti-miR miRNA inhibitors in NSCLC cells to find the relationship between miR-221,miR-222 and TRAIL-resistant NSCLC cells cell line (CALU-1, A549) up-regulated resistant Kit,p27(kip1) NA TRAIL signaling validated 23 MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008 18246122 miRBase MI0000299 miR-222 miRNA NA TRAIL therapy lung non-small cell carcinoma qRT-PCR,Northern blot We have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222.Transfection of Pre-miRs and anti-miR miRNA inhibitors in NSCLC cells to find the relationship between miR-221,miR-222 and TRAIL-resistant NSCLC cells cell line (CALU-1, A549) up-regulated resistant Kit,p27(kip1) NA TRAIL signaling validated 24 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000070/MI0000115 miR-16 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 25 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000070/MI0000115 miR-16 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 26 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000070/MI0000115 miR-16 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 27 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008 18449891 miRBase MI0000070/MI0000115 miR-16 miRNA DB00773 (APRD00239) Etoposide stomach cancer qRT-PCR The role of miR-96 in human cancer cells was detected using quantitative RT-PCR,luciferase activity assay, western blot analysis,and apoptosis assay,etc. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive BCL2 BCL2 the mitochondrial pathway validated 28 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00033 (BTD00017, BIOD00017) Interferon-gamma squamous carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 29 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin squamous carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 30 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel squamous carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 31 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00033 (BTD00017, BIOD00017) Interferon-gamma hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 32 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 33 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 34 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00033 (BTD00017, BIOD00017) Interferon-gamma breast adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 35 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 36 Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008 18758960 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A431,HepG2, A10A,MCF-7) up-regulated resistant caspase-3 NA NA validated 37 Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008 18818206 miRBase MI0000651/ MI0000437 miR-1 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung carcinoma RT-PCR In the study, we report that micro-RNA-1 (miR-1), abundant in the cardiac and smooth muscles, is expressed in the lung and is down-regulated in human primary lung cancer tissues and cell lines. In situ hybridization demonstrated localization of miR-1 in bronchial epithelial cells. The tumor suppressor C/EBPalpha, frequently suppressed in lung cancer, reactivated miR-1 expression in the lung cancer cells. Repressed miR-1 was also activated in lung cancer cells upon treatment with a histone deacetylase inhibitor. These observations led us to examine the antitumorigenic potential of miR-1 in lung cancer cells. Expression of miR-1 in nonexpressing A549 and H1299 cells reversed their tumorigenic properties, such as growth, replication potential, motility/migration, clonogenic survival, and tumor formation in nude mice. Exogenous miR-1 significantly reduced expression of oncogenic targets, such as MET, a receptor tyrosine kinase, and Pim-1, a Ser/Thr kinase, frequently up-regulated in lung cancer. Similarly, the levels of two additional targets, FoxP1, a transcription factor with oncogeneic property, and HDAC4 that represses differentiation-promoting genes, were reduced in miR-1-expressing cells. Conversely, depletion of miR-1 facilitated N417 cell growth with concomitant elevation of these targets. Further, ectopic miR-1 induced apoptosis in A549 cells in response to the potent anticancer drug doxorubicin. Enhanced activation of caspases 3 and 7, cleavage of their substrate PARP-1, and depletion of anti-apoptotic Mcl-1 contributed to the sensitivity of miR-1-expressing cells to doxorubicin. cell line (Human lung cancer cell lines,BEAS-2B ) up-regulated sensitive Oncogenic MET MET NA validated 38 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000066 let-7e miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) up-regulated resistant NA NA NA predicted 39 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000066 let-7e miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) up-regulated resistant NA NA NA predicted 40 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000736/MI0000254 miR-30c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 41 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000736/MI0000254 miR-30c miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 42 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000446/MI0000470 miR-125b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 43 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 44 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000448 miR-130a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant M-CSF M-CSF NA validated 45 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant M-CSF M-CSF NA validated 46 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000816 miR-335 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 47 Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008 18823650 miRBase MI0000816 miR-335 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR, Northern blot High-throughput analysis of the miRNA profile in a panel of paclitaxel- (A2780TAX, A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed using a microarray platform and subsequent validation with qPCR and Northern blots. Downstream target validation was performed for miR-130a and the target M-CSF.] cell line (A2780TAX, A2780TC1, A2780TC3,A2780CIS) down-regulated resistant NA NA NA predicted 48 Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells Biochem Biophys Res Commun 2008 18834855 miRBase MI0000268 miR-34a miRNA DB04690 Camptothecin prostate cancer real-time RT-PCR The expression levels of miRNA were determined by real-time RT-PCR and those of protein were by Western blot analysis. Viable cell numbers were determined by trypan blue exclusion assay.To morphologically evaluate apoptosis visualized by fluorescence microscopy cell line (PrEC,LNCaP, PC3, DU145) up-regulated sensitive SIRT1 SIRT1 NA validated 49 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000298 miR-221 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) up-regulated resistant NA NA NA predicted 50 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) up-regulated resistant NA NA NA predicted 51 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000448 miR-130a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) up-regulated resistant NA NA NA predicted 52 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) up-regulated resistant NA NA NA predicted 53 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000737 miR-200a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) down-regulated resistant NA NA NA predicted 54 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000342 miR-200b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) down-regulated resistant NA NA NA predicted 55 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) down-regulated resistant NA NA NA predicted 56 Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR Nan Fang Yi Ke Da Xue Xue Bao 2008 18971180 miRBase MI0003685 miR-421 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells. cell line (MCF-7 and MCF-7/ADR) down-regulated resistant NA NA NA predicted 57 MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008 19074899 miRBase MI0000434 Let-7i miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer RT-PCR In the present study, we performed miRNA microarray to identify the miRNAs associated with chemotherapy response in ovarian cancer and found that let-7i expression was significantly reduced in chemotherapy-resistant patients . This result was further validated by stem-loop real-time reverse transcription-PCR . Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer . This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR and in an independent sample set by in situ hybridization . cell line (SKOV3, 2008, OVCAR10, OVCAR3,HeLa,MCF7, MDA-MB-468) down-regulated resistant NA NA NA validated 58 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000289 miR-213 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 59 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NRP2 NRP2,CALU NA predicted 60 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000289/MI0000269 miR-181a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NRP2 NRP2 NA predicted 61 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000066 Let-7e miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant MAD2L1BP,SLC6A8 MAD2L1BP,SLC6A8 NA predicted 62 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003146 miR-520f miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 63 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant TACSTD1,KLF5,WWC1,MAD2L1BP,ARHGAP29 TACSTD1,KLF5,WWC1,MAD2L1BP,ARHGAP29 NA predicted 64 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003159 miR-518c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant NA NA NA predicted 65 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003186 miR-502 miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 66 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003198 miR-514 miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant TIAL1 TIAL1 NA predicted 67 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000779 miR-371 miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 68 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000746 miR-99b miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant DOHH,BIN1 DOHH,BIN1 NA predicted 69 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase NA miR-518c-AS miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 70 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MIMAT0002826 miR-515-5p miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant BAD,CCS BAD,CCS NA predicted 71 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000449 miR-132 miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant NA NA NA predicted 72 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000289 miR-213 miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 73 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000270/MI0000683 miR-181b miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 74 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000289/MI0000269 miR-181a miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA NA predicted 75 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000803 miR-330 miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant NA NA NA predicted 76 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000815 miR-339 miRNA DB00441 (APRD00201) Gemcitabine ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant NA NA NA predicted 77 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000742 miR-34b miRNA DB01030 (APRD00687) Topotecan ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA p53 signaling pathway predicted 78 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0001721 miR-431 miRNA DB01030 (APRD00687) Topotecan ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant COL6A2,GSR,FGFR1,ITGA3,VIM,CCL2,HTATIP COL6A2,GSR,FGFR1,ITGA3,VIM,CCL2,HTATIP p53 signaling pathway predicted 79 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase NA miR-518c-AS miRNA DB01030 (APRD00687) Topotecan ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant NA NA p53 signaling pathway predicted 80 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MIMAT0000433 miR-142-5p miRNA DB01030 (APRD00687) Topotecan ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant CCL2,SDHB,NFIB CCL2,SDHB,NFIB p53 signaling pathway predicted 81 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003198 miR-514 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant DYRK2,TOP2B DYRK2,TOP2B p53 signaling pathway predicted 82 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000471 miR-126 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant PHTF2,SOX30,PIK3R2,PCDH9 PHTF2,SOX30,PIK3R2,PCDH9 p53 signaling pathway predicted 83 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000746 miR-99b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant DNPEP DNPEP p53 signaling pathway predicted 84 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000735 miR-29c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant DNPEP,KLHDC2,IFI30 DNPEP,KLHDC2,IFI30 p53 signaling pathway predicted 85 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000439 miR-23b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant HNRPU,COASY,SETDB1,NEU1,CCNB2 HNRPU,COASY,SETDB1,NEU1,CCNB2 NA predicted 86 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000789 miR-381 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant ZNF443,RNMT,THRAP1(MED13) ZNF443,RNMT,THRAP1(MED13) NA predicted 87 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000802 miR-340 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant PPL,RTN3,PAM PPL,RTN3,PAM NA predicted 88 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0003146 miR-520f miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) up-regulated resistant AK2,ZNF443 AK2,ZNF443 NA predicted 89 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000812 miR-331 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant NA NA NA predicted 90 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000482 miR-185 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant RBX1,AK2,KLK5,RAE1 RBX1,AK2,KLK5,RAE1 NA predicted 91 MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009 19237188 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression of 335 unique miRNAs was measured in 16 OVCA cell lines. In parallel, the sensitivity of these cell lines to 6 commonly used chemotherapeutic agents (cisplatin, doxorubicin, topotecan, paclitaxel, docetaxel, and gemcitabine) was evaluated by in-vitro cell proliferation assay. MiRNAs associated with cell line drug response were identified by linear regression analysis, and their predicted mRNA targets subject to functional biologic pathway analyses. cell line (OV19, TOV21G, TOV112D,s C13,OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008,OVCAR3,SKOV3) down-regulated resistant KLK5,LAPTM4B,MCM4,MAP4,CNNM3 KLK5,LAPTM4B,MCM4,MAP4,CNNM3 NA predicted 92 MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009 19270061 miRBase MI0000804 miR-328 miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time Reverse Transcription-PCR. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (MCF-7,MCF-7/MX100) down-regulated resistant ABCG2 ABCG2 NA validated 93 microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009 19276373 miRBase MI0000285 miR-205 miRNA DB00317 (APRD00997, DB07998) Gefitinib breast cancer Northern blot,RT-PCR In the study, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. cell line (SKBr3, MCF7, HEK293) up-regulated sensitive HER3 HER3 PI3K/Akt survival pathway validated 94 microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009 19276373 miRBase MI0000285 miR-205 miRNA DB01259 (DB02584) Lapatinib breast cancer Northern blot,RT-PCR In the study, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. cell line (SKBr3, MCF7, HEK293) up-regulated sensitive HER3 HER3 PI3K/Akt survival pathway validated 95 MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009 19435867 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR miR-21 expression was assessed in pancreatic cancer cell lines and pancreatic tissue samples by quantitative real-time reverse transcription-PCR amplification. Moreover, we investigated the proliferation, invasion, and chemoresistance of pancreatic cancer cells transfected with miR-21 precursor or inhibitor. miR-21 was markedly overexpressed in pancreatic cancer cells compared with nonmalignant cells, and miR-21 in cancer tissues was much higher than in nonmalignant tissues. The cancer cells transfected with the miR-21 precursor showed significantly increased proliferation, Matrigel invasion, and chemoresistance for gemcitabine compared with the control cells. In contrast, inhibition of miR-21 decreased proliferation, Matrigel invasion, and chemoresistance for gemcitabine. Moreover, miR-21 positively correlated with the mRNA expression of invasion-related genes, matrix metalloproteinase-2 and -9, and vascular endothelial growth factor. tissue and cell line (AsPC-1, KP-1N, KP-2, KP-3, PANC-1, SUIT-2,MIA PaCa-2,CAPAN-1, CAPAN-2, CFPAC-1, H48N, HS766T, SW1990,NOR-P1,HPDE6-E6E7 clone 6) up-regulated sensitive NA NA NA validated 96 MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009 19435871 miRBase MI0000650 miR-200c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel endometrial cancer Real Time RT-PCR The expression levels of miRNA were determined by Real Time RT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by migration and invasion assay. cell line (Hec50,EEC B37,MCF-7, T47D, ZR75, BT-474, MDA-MB-231, BT-549) up-regulated sensitive ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 NA validated 97 MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009 19435871 miRBase MI0000650 miR-200c miRNA DB03010 (EXPT01349) Epothilone B endometrial cancer Real Time RT-PCR The expression levels of miRNA were determined by Real Time RT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by migration and invasion assay. cell line (Hec50,EEC B37,MCF-7, T47D, ZR75, BT-474, MDA-MB-231, BT-549) up-regulated sensitive ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 NA validated 98 MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009 19435871 miRBase MI0000650 miR-200c miRNA DB00541 (APRD00495) Vincristine endometrial cancer Real Time RT-PCR The expression levels of miRNA were determined by Real Time RT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by migration and invasion assay. cell line (Hec50,EEC B37,MCF-7, T47D, ZR75, BT-474, MDA-MB-231, BT-549) up-regulated sensitive ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 ZEB1,ZEB2,FN1,NTRK2,QKI,TUBB3 NA validated 99 MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009 19559015 miRBase MI0000077 miR-21 miRNA DB00444 (APRD00649) Teniposide glioblastoma RT-PCR The expression levels of miRNA were determined by Real-time PCR . Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (U373 MG) up-regulated resistant LRRFIP1 LRRFIP1 NF-kappaB signaling validated 100 MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009 19581388 miRBase MI0000440 miR-27b miRNA DB00531 (APRD00408) Cyclophosphamide pancreas cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction. Those of protein were by Immunoblot analysis.Luciferase activity assay was used to verify the target genes of miRNAs.Immunoblot Analysis. cell line (PANC1,LS-180) up-regulated resistant CYP3A4 CYP3A4 NA validated 101 MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009 19581388 miRBase MI0000440 miR-27b miRNA DB00531 (APRD00408) Cyclophosphamide colon carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction. Those of protein were by Immunoblot analysis.Luciferase activity assay was used to verify the target genes of miRNAs.Immunoblot Analysis. cell line (PANC1,LS-180) up-regulated resistant CYP3A4 CYP3A4 NA validated 102 MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009 19584283 miRBase MI0000442 miR-122 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocarcinoma Real-time RT-PCR,Semiquantitative RT-PCR The expression levels of miRNA were determined byReal-time RT-PCR analysis and Semiquantitative RT-PCR.Those of protein were by Western blot analysis. p53 activity was investigated by luciferase assay cell line (HepG2,Huh-7) up-regulated sensitive Cyclin G1 NA p53 signaling pathway validated 103 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000342 miR-200b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC) up-regulated sensitive ZEB1 ZEB1 NA validated 104 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000650 miR-200c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC ) up-regulated sensitive ZEB1 ZEB1 NA validated 105 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000063 let-7b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC ) up-regulated sensitive NA NA NA validated 106 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000064 let-7c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC ) up-regulated sensitive NA NA NA validated 107 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000065 let-7d miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC ) up-regulated sensitive NA NA NA validated 108 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009 19654291 miRBase MI0000066 let-7e miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real-time RT-PCR In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with natural agents [3,3-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. cell line (MiaPaCa-2, Panc-1, Aspc-1,L3.6pl, Colo357, BxPC-3, HPAC ) up-regulated sensitive NA NA NA validated 109 miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009 19671845 miRBase NA miR-200 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab bladder cancer RT-PCR miRNA array screening and real-time reverse transcription-polymerase chain reaction were used to identify and validate the differential expression of miRNAs involved in EMT in 9 bladder cancer cell lines. A list of potential miR-200 direct targets was identified through the TargetScan database. The precursor of miR-200b and c were expressed in UMUC3 and T24 cells using a retrovirus or a lentivirus construct, respectively. Protein expression and signaling pathway modulation as well as intracellular distribution of EGFR and ERRFI-1 were validated through western blot analysis and confocal microscopy, whereas ERRFI-1 direct target of miR-200 members was validated by using the wild-type and mutanty 3'UTR/ERRFI-1/Luciferse reporters. cell line (UMUC,253J BV,KU7 ) up-regulated sensitive ERRFI-1 ERRFI-1 EGFR pathway validated 110 MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009 19726678 miRBase MI0000442 miR-122 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma Real Time RT-PCR The expression levels of miRNA were determined by Real Time RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2, Hep3B, SK-Hep-1) up-regulated sensitive SRF,Igf1R SRF NA validated 111 Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009 19734943 miRBase MI0000456 miR-140 miRNA DB00563 (APRD00353) Methotrexate osteosarcoma Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis.Identification of active cells using cell proliferation assays and cell cycles for analysis. cell line (U-2 OS (wt-p53),MG63 (mut-p53),HCT 116 (wt-p53), HCT 116 (null-p53),U-2 OS, HCT 116 (wt-p53), HCT 116 (null-p53),MG63 ) up-regulated sensitive HDAC4 HDAC4 NA validated 112 Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009 19734943 miRBase MI0000456 miR-140 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil osteosarcoma Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis.Identification of active cells using cell proliferation assays and cell cycles for analysis. cell line (U-2 OS (wt-p53),MG63 (mut-p53),HCT 116 (wt-p53), HCT 116 (null-p53),U-2 OS, HCT 116 (wt-p53), HCT 116 (null-p53),MG63 ) up-regulated sensitive HDAC4 HDAC4 NA validated 113 Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009 19734943 miRBase MI0000456 miR-140 miRNA DB00563 (APRD00353) Methotrexate colon cancer Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis.Identification of active cells using cell proliferation assays and cell cycles for analysis. cell line (U-2 OS (wt-p53),MG63 (mut-p53),HCT 116 (wt-p53), HCT 116 (null-p53),U-2 OS, HCT 116 (wt-p53), HCT 116 (null-p53),MG63 ) up-regulated sensitive HDAC4 HDAC4 NA validated 114 Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009 19734943 miRBase MI0000456 miR-140 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis.Identification of active cells using cell proliferation assays and cell cycles for analysis. cell line (U-2 OS (wt-p53),MG63 (mut-p53),HCT 116 (wt-p53), HCT 116 (null-p53),U-2 OS, HCT 116 (wt-p53), HCT 116 (null-p53),MG63 ) up-regulated sensitive HDAC4 HDAC4 NA validated 115 MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009 19843160 miRBase MI0000459 miR-143 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. At the indicated times, general cell death was evaluated by the LDH assay kit.Caspase activity was determined in cytosolic protein extracts after harvesting and homogenization of cells in isolation buffer, cell line (HCT116,SW480, LoVo, SW620) up-regulated sensitive ERK5 NA nuclear factor-kappaB pathways validated 116 E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010 19839049 miRBase MI0000342 miR-200b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription real-time PCR (qRT-PCR) .Those of protein were by Western blot analysis.Cell migration was detected by t invasion assay.Cell survival analysis was used to assay drug sensitivity. cell line (MCF-10-2A, MCF-7, MDA-MB-361, HCC-70, T-47D, CAMA-1, Hs-578T, BT-549, and MDA-MB-231) up-regulated sensitive E-cadherin,ZEB1,ZEB2 ZEB1,ZEB2 p53 apoptotic pathway validated 117 E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010 19839049 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription real-time PCR (qRT-PCR) .Those of protein were by Western blot analysis.Cell migration was detected by t invasion assay.Cell survival analysis was used to assay drug sensitivity. cell line (MCF-10-2A, MCF-7, MDA-MB-361, HCC-70, T-47D, CAMA-1, Hs-578T, BT-549, and MDA-MB-231) up-regulated sensitive E-cadherin,ZEB1,ZEB2 ZEB1,ZEB2 p53 apoptotic pathway validated 118 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0001641 miR-429 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive NA NA NA predicted 119 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000274 miR-187 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive NA NA NA predicted 120 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive NA NA NA predicted 121 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000094 miR-92-2 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive NA NA NA predicted 122 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000087 miR-29a miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 123 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 124 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000239 miR-197 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 125 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000735 miR-29c miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 126 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000074/MI0000075 miR-19b miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 127 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000105/MI0000107 miR-29b miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 128 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase NA miR-91 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 129 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000255 miR-30d miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 130 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000542 miR-320 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 131 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000071 miR-17 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 132 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000439 miR-23b miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 133 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000084 miR-26b miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) down-regulated sensitive NA NA NA predicted 134 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000808 miR-326 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive MRP-1 MRP-1 NA validated 135 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010 19883630 miRBase MI0000808 miR-326 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR,qRT-PCR miRNA microarrays are used to discover different expressions between different cell lines.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Transfection of hsa-mir-326 miRIDIAN mimic and measurement of drug sensitivity. tissue and cell line (MCF-7/WT,MCF-7/VP,MCF-7/MX100) up-regulated sensitive MRP-1 MRP-1 NA validated 136 miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010 19896708 miRBase MI0000476/MI0000455 miR-138 miRNA DB00541 (APRD00495) Vincristine leukemia Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern blot and Quantitative real-time polymerase chain reaction. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Total GST activity of leukemia cells was evaluated by conjugation of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB). cell line ( HL-60,HL-60/VCR) up-regulated sensitive MDR1 MDR1 NA validated 137 miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010 19896708 miRBase MI0000476/MI0000455 miR-138 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern blot and Quantitative real-time polymerase chain reaction. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Total GST activity of leukemia cells was evaluated by conjugation of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB). cell line ( HL-60,HL-60/VCR) up-regulated sensitive MDR1 MDR1 NA validated 138 miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010 19896708 miRBase MI0000476/MI0000455 miR-138 miRNA DB00515 (APRD00359) Cisplatin leukemia Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern blot and Quantitative real-time polymerase chain reaction. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Total GST activity of leukemia cells was evaluated by conjugation of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB). cell line ( HL-60,HL-60/VCR) up-regulated sensitive MDR1 MDR1 NA validated 139 miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010 19896708 miRBase MI0000476/MI0000455 miR-138 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil leukemia Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern blot and Quantitative real-time polymerase chain reaction. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Total GST activity of leukemia cells was evaluated by conjugation of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB). cell line ( HL-60,HL-60/VCR) up-regulated sensitive MDR1 MDR1 NA validated 140 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0000342 miR-200b miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) down-regulated resistant NA NA NA validated 141 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0000488/MI0000732 miR-194 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) down-regulated resistant NA NA NA validated 142 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0000288 miR-212 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) down-regulated resistant NA NA NA validated 143 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0000234 miR-192 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) up-regulated resistant NA NA NA validated 144 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0001446 miR-424 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) up-regulated resistant NA NA NA validated 145 Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010 19900214 miRBase MI0000100 miR-98 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel-resistant human NSCLC cell line (SPC-A1/docetaxel). Then, the changes of miRNAs expression (>2-fold compared with control SPC-A1 cell line) were testified by quantitative real-time RT-PCR (qRT-PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC-A1/docetaxel cells and control SPC-A1 cells (P < 0.01). Six miRNAs (miR-192, 200b, 194, 424, 98 and 212) exhibited more than 2-fold changes in their expression levels, which were validated by qRT-PCR. The expression of three miRNAs (miR-200b, 194 and 212) was significantly down-regulated in SPC-A1/docetaxel cells, while the expression of other three miRNAs (miR-192, 424 and 98) was significantly up-regulated in SPC-A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC-A1/docetaxel and SPC-A1 cells were further confirmed by qRT-PCR and Western blot. cell line (SPC-A1) up-regulated resistant NA NA NA validated 146 Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010 19960259 miRBase MI0000085 miR-27a miRNA DB00541 (APRD00495) Vincristine esophageal squamous cell carcinoma Northern blot,qRT-PCR Here we have firstly investigated the roles of miR-27a in multidrug resistance of esophageal squamous cell carcinoma using MTT assay, flow cytometry assay, and reporter gene assay, etc. cell line (ECA109, TE-13) down-regulated sensitive MDR1 MDR1 NA validated 147 Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010 19960259 miRBase MI0000085 miR-27a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal squamous cell carcinoma Northern blot,qRT-PCR Here we have firstly investigated the roles of miR-27a in multidrug resistance of esophageal squamous cell carcinoma using MTT assay, flow cytometry assay, and reporter gene assay, etc. cell line (ECA109, TE-13) down-regulated sensitive MDR1 MDR1 NA validated 148 Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010 19960259 miRBase MI0000085 miR-27a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma Northern blot,qRT-PCR Here we have firstly investigated the roles of miR-27a in multidrug resistance of esophageal squamous cell carcinoma using MTT assay, flow cytometry assay, and reporter gene assay, etc. cell line (ECA109, TE-13) down-regulated sensitive MDR1 MDR1 NA validated 149 Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010 19960259 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma Northern blot,qRT-PCR Here we have firstly investigated the roles of miR-27a in multidrug resistance of esophageal squamous cell carcinoma using MTT assay, flow cytometry assay, and reporter gene assay, etc. cell line (ECA109, TE-13) down-regulated sensitive MDR1 MDR1 NA validated 150 TGFBeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010 20023698 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time reverse-transcription polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Cell migration was detected by transwell migration and invasion assay.Analysis of oncogenic potential of miR-181b in nude mice cell line ( HCC ) up-regulated resistant TIMP3 TIMP3 TGFBeta signaling pathway validated 151 Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010 20082533 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast carcinoma NA The role of miR-21 in breast carcinoma cells was detected using MTT assay, cell cycle analysis, matrigel invasion assayand western blot, etc. cell line (MCF-7) down-regulated sensitive NA NA AKT pathway validated 152 MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010 20113523 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol glioblastoma RT-PCR Human glioblastoma U251 (PTEN-mutant) and LN229 (PTEN wild-type) cells were treated with taxol and the miR-21 inhibitor (in a poly (amidoamine) (PAMAM) dendrimer), alone or in combination. The 50% inhibitory concentration and cell viability were determined by the MTT assay. The mechanism between the miR-21 inhibitor and the anticancer drug taxol was analyzed using the Zheng-Jun Jin method. Annexin V/PI staining was performed, and apoptosis and the cell cycle were evaluated by flow cytometry analysis. Expression of miR-21 was investigated by RT-PCR, and western blotting was performed to evaluate malignancy related protein alteration. cell line ( U251, LN229) down-regulated sensitive NA NA EGFR/STAT3 signaling validated 153 Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010 20148895 miRBase MI0000077 miR-21 miRNA DB01169 (APRD00171) Arsenic trioxide chronic myelogenous leukemia (CML) qRT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis,etc. cell line ( K562 ) down-regulated sensitive PDCD4 PDCD4 NA validated 154 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 155 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00515(APRD00359) Cisplatin gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 156 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00544(APRD00516,EXPT03204) Fluorouracil gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 157 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00773(APRD00239) Etoposide gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 158 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997(APRD00185,DB05331,DB05847) Adriamycin gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 159 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00541(APRD00495) Vincristine lung cancer RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 160 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00515(APRD00359) Cisplatin lung cancer RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 161 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00544(APRD00516,EXPT03204) Fluorouracil lung cancer RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 162 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00773(APRD00239) Etoposide lung cancer RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 163 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997(APRD00185,DB05331,DB05847) Adriamycin lung cancer RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 164 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000065 let-7d miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 165 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000067/MI0000068 let-7f miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 166 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000433 let-7g miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 167 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000103/MI0000739 miR-101 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 168 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000111/MI0000112 miR-105 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 169 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000266 miR-10a miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 170 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000446/MI0000470 miR-125b miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 171 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000289/MI0000269 miR-181a miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 172 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000271 miR-181c miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 173 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003139 miR-181d miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 174 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MIMAT0004488 miR-15a-3p miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 175 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000438 miR-15b miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 176 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000070/MI0000115 miR-16 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 177 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000292 miR-216a miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 178 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000297/MI0005529/MI0005536 miR-220 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 179 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000091 miR-33a miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 180 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0001729 miR-451 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 181 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003138 miR-497 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 182 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003194 miR-507 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 183 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0005565 miR-543 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 184 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003625 miR-612 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 185 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003757 miR-758 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive NA NA NA predicted 186 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0000098 miR-96 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 187 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MIMAT0000242 miR-129-5p miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 188 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MIMAT0000260 miR-182-3p miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 189 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003134 miR-494 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 190 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003188 miR-503 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 191 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003571 miR-565 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 192 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003615 miR-602 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 193 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003672 miR-663 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 194 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0003761 miR-668 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 195 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase MI0005202 miR-801 miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 196 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase NA miR-886-3p miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 197 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 20162574 miRBase NA miR-886-5p miRNA DB00541(APRD00495) Vincristine gastric adenocarcinoma RT-PCR The expression levels of miRNA were determined by miRNA microarray analysis cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated resistant NA NA NA predicted 198 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR In this study, miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). Three miRNAs of miR-21, -214, and -23a were validated by miRNAs real-time PCR, and intervened by anti-miRNA oligonucleotides (miR-214 and -23a) and pre-miRNA plasmid transfection (miR-21). Further relationship between miR-23a and DNA topoisomerase II Beta (TOP2B) on the chemoresistance against cisplatin was studied. cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA NA NA validated 199 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000079 miR-23a miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR In this study, miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). Three miRNAs of miR-21, -214, and -23a were validated by miRNAs real-time PCR, and intervened by anti-miRNA oligonucleotides (miR-214 and -23a) and pre-miRNA plasmid transfection (miR-21). Further relationship between miR-23a and DNA topoisomerase II Beta (TOP2B) on the chemoresistance against cisplatin was studied. cell line (Tca8113,Tca/cisplatin) up-regulated resistant TOP2B TOP2B NA validated 200 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR In this study, miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). Three miRNAs of miR-21, -214, and -23a were validated by miRNAs real-time PCR, and intervened by anti-miRNA oligonucleotides (miR-214 and -23a) and pre-miRNA plasmid transfection (miR-21). Further relationship between miR-23a and DNA topoisomerase II Beta (TOP2B) on the chemoresistance against cisplatin was studied. cell line (Tca8113,Tca/cisplatin) down-regulated resistant NA NA NA validated 201 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 let-7c miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA TRIM71,Q5FWF1_HUMAN,GALE,MAP2K6,CCND3 NA predicted 202 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 let-7d miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA GALE,PIAS4,RNF20,MAP2K6,CCND3 NA predicted 203 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 let-7e miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA TRIM71,Q5FWF1_HUMAN,TGDS,MAP2K6,CCND3 NA predicted 204 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 let-7g miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA TRIM71,Q5FWF1_HUMAN,GALE,PIAS4,RNF20 NA predicted 205 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-20b miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA BAMBI,PTPN4,NP_219485.1,WEE1,GPR6 NA predicted 206 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-30d miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA MBOAT1,MKRN3,PPARGC1B,MAP3K5,UBAC1 NA predicted 207 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-181d miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA NR6A1,BHLHB2,SLC35E1,ZNF252,TADA1L NA predicted 208 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-188 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA EDG6,SOS1,HPBP1_HUMAN,COQ3,EFNA1 NA predicted 209 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-342 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) down-regulated resistant NA TFDP2,PRPF40B,MMS19L,TMEM35,PRX NA predicted 210 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-373* miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA ASMTL,CNOT10,INPP1,CHD1L,CHD1L NA predicted 211 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-432 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA DHRS9,CSNK1G2,PIP,TAS1R3,RAB3IP NA predicted 212 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-498 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA DCAKD,CHODL,LHX4,DCBLD2,SNX25 NA predicted 213 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-518c* miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA BPY2C,PTGDS,C14orf131,NT5C3L,DPF2 NA predicted 214 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-584 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA C10orf120,PIGW,TMEM34,TAF13,SNTG1 NA predicted 215 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-608 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA RCVRN,AFG3L1,ALDH3A1,GAL3ST1,PXK NA predicted 216 MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010 20219416 miRBase MI0000077 miR-628 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR miRNA microarray was firstly used to compare the differential miRNAs levels between the cisplatin-sensitive tongue squamous cell carcinoma line (Tca8113) and its cisplatin-resistant subline (Tca/cisplatin). cell line (Tca8113,Tca/cisplatin) up-regulated resistant NA RBM9,RSHL2L,MBRD2,APBB1IP,SGCD NA predicted 217 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000474 miR-134 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 218 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000787 miR-379 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 219 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0003135 miR-495 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 220 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000474 miR-134 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 221 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000787 miR-379 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 222 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0003135 miR-495 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 223 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000474 miR-134 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 224 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0000787 miR-379 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 225 Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010 20371173 miRBase MI0003135 miR-495 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung small cell carcinoma Real-time quantitative RT-PCR, Northern blot,RT-PCR In the study, we evaluated the expression of 856 miRNAs and approximately 22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. cell line (NCI-H69,NCI-H69AR) up-regulated sensitive NA NA NA predicted 226 MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010 20371610 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern Blot,and qRT-PCR . Those of protein were by Western blot analysis.Luciferase activity assay was used to verify the target genes of miRNAs. Cell Viability and Apoptosis Assays used to identify the relationship between miR-155 and chemosensitivity by targeting FOXO3a in breast cancer. cell line (BT-474,MDA-MB-157, MDA-MB-435, HS578T) up-regulated resistant FOXO3a FOXO3a factor-Beta/Smad pathway validated 227 MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010 20371610 miRBase MI0000681 miR-155 miRNA DB00773 (APRD00239) Etoposide breast cancer Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern Blot,and qRT-PCR . Those of protein were by Western blot analysis.Luciferase activity assay was used to verify the target genes of miRNAs. Cell Viability and Apoptosis Assays used to identify the relationship between miR-155 and chemosensitivity by targeting FOXO3a in breast cancer. cell line (BT-474,MDA-MB-157, MDA-MB-435, HS578T) up-regulated resistant FOXO3a FOXO3a factor-Beta/Smad pathway validated 228 MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010 20371610 miRBase MI0000681 miR-155 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern Blot,and qRT-PCR . Those of protein were by Western blot analysis.Luciferase activity assay was used to verify the target genes of miRNAs. Cell Viability and Apoptosis Assays used to identify the relationship between miR-155 and chemosensitivity by targeting FOXO3a in breast cancer. cell line (BT-474,MDA-MB-157, MDA-MB-435, HS578T) up-regulated resistant FOXO3a FOXO3a factor-Beta/Smad pathway validated 229 miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010 20388802 miRBase MI0000442 miR-122 miRNA NA TRAIL therapy lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs, etc. cell line (H460) up-regulated sensitive PED NA NA validated 230 Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010 20433742 miRBase MI0000291 miR-215 miRNA DB00563 (APRD00353) Methotrexate osteosarcoma Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis. Luciferase activity assay was used to verify the target genes of miRNAs, etc. cell line (U-2 OS, MG63,HCT 116 (wt-p53) and HCT 116 (null-p53) ) up-regulated resistant DHFR,TS DHFR,TS p53 growth control pathway validated 231 Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010 20433742 miRBase MI0000291 miR-215 miRNA DB00293 (APRD00430, EXPT01092) Tomudex osteosarcoma Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis. Luciferase activity assay was used to verify the target genes of miRNAs, etc. cell line (U-2 OS, MG63,HCT 116 (wt-p53) and HCT 116 (null-p53) ) up-regulated resistant DHFR,TS DHFR,TS p53 growth control pathway validated 232 Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010 20433742 miRBase MI0000291 miR-215 miRNA DB00563 (APRD00353) Methotrexate colon cancer Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis. Luciferase activity assay was used to verify the target genes of miRNAs, etc. cell line (U-2 OS, MG63,HCT 116 (wt-p53) and HCT 116 (null-p53) ) up-regulated resistant DHFR,TS DHFR,TS p53 growth control pathway validated 233 Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010 20433742 miRBase MI0000291 miR-215 miRNA DB00293 (APRD00430, EXPT01092) Tomudex colon cancer Real time qRT-PCR The expression levels of miRNA were determined by Real time qRT-PCR and those of protein were by Western immunoblot analysis. Luciferase activity assay was used to verify the target genes of miRNAs, etc. cell line (U-2 OS, MG63,HCT 116 (wt-p53) and HCT 116 (null-p53) ) up-regulated resistant DHFR,TS DHFR,TS p53 growth control pathway validated 234 miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010 20444541 miRBase MI0000489 miR-195 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR In the study, we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251R and parental cells using miRNA microarrays. miR-195, miR-455-3p and miR-10a( *) were the three most up-regulated miRNAs in the resistant cells. To investigate the functional role of these miRNAs in TMZ resistance, U251R cells were transfected with miRNA inhibitors consisting of DNA/LNA hybrid oligonucleotides. In addition, using in silico analysis combined with cDNA microarray experiment, we present possible mRNA targets of these miRNAs. cell line (U251MG,U87MG, M059K and M059J) up-regulated resistant NA PPP2R1A,AP2A1,SIAH1,HAS2,ALS2CR2,CCNE1,SESN1,WEE1,RANBP3,VAT1 NA predicted 235 miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010 20444541 miRBase MIMAT0004784 miR-455-3p miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR In the study, we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251R and parental cells using miRNA microarrays. miR-195, miR-455-3p and miR-10a( *) were the three most up-regulated miRNAs in the resistant cells. To investigate the functional role of these miRNAs in TMZ resistance, U251R cells were transfected with miRNA inhibitors consisting of DNA/LNA hybrid oligonucleotides. In addition, using in silico analysis combined with cDNA microarray experiment, we present possible mRNA targets of these miRNAs. cell line (U251MG,U87MG, M059K and M059J) up-regulated resistant NA LHX2,ALS2CR8,DIP2A,DYNLL2,C6orf145,FBXL15,LTBR,ASB1,PNPLA6,RTN4,RUSC1,EI24,HSF1,SMAD2,GNL1 NA predicted 236 miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010 20444541 miRBase MIMAT0004555 miR-10a(*) miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR In the study, we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251R and parental cells using miRNA microarrays. miR-195, miR-455-3p and miR-10a( *) were the three most up-regulated miRNAs in the resistant cells. To investigate the functional role of these miRNAs in TMZ resistance, U251R cells were transfected with miRNA inhibitors consisting of DNA/LNA hybrid oligonucleotides. In addition, using in silico analysis combined with cDNA microarray experiment, we present possible mRNA targets of these miRNAs. cell line (U251MG,U87MG, M059K and M059J) up-regulated resistant NA CCL2,SULT1A3,EPHX1,CDK5,GRTP1,BRD7,PDIA5,IDS,PSPC1,RWDD2B,COL6A1,GIYD2,HSPA1B,GRM6,MRPL19 NA predicted 237 MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010 20460378 miRBase MI0000446/MI0000470 miR-125b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR In this study we utilized a miRNA array to compare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay (Promega), etc. cell line (MDA-MB-435 (MDA-435), MDA-MB-231 (MDA-231), MDA-MB-436 (MDA-436), MCF7, SKBr3,BT474,435TR,435TRP) up-regulated resistant Bcl-2,Bak1 Bak1 NA validated 238 MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010 20460378 miRBase MI0000298 miR-221 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR In this study we utilized a miRNA array to compare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay (Promega), etc. cell line (MDA-MB-435 (MDA-435), MDA-MB-231 (MDA-231), MDA-MB-436 (MDA-436), MCF7, SKBr3,BT474,435TR,435TRP) up-regulated resistant NA NA NA predicted 239 MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010 20460378 miRBase MI0000299 miR-222 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR In this study we utilized a miRNA array to compare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay (Promega), etc. cell line (MDA-MB-435 (MDA-435), MDA-MB-231 (MDA-231), MDA-MB-436 (MDA-436), MCF7, SKBr3,BT474,435TR,435TRP) up-regulated resistant NA NA NA predicted 240 MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010 20460378 miRBase MI0005715 miR-923 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR In this study we utilized a miRNA array to compare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay (Promega), etc. cell line (MDA-MB-435 (MDA-435), MDA-MB-231 (MDA-231), MDA-MB-436 (MDA-436), MCF7, SKBr3,BT474,435TR,435TRP) up-regulated resistant NA NA NA predicted 241 MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010 20460539 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR miR-21 expression was evaluated in cells and tissues isolated by laser microdissection.The expression levels of miRNA were determined by Reverse transcription and quantitative PCR analysis . Quantitative PCR analysis of miR-21.The role of miR-21 on the pharmacologic effects of gemcitabine was studied with a specific miR-21 precursor (pre-miR-21). tissue and cell line (LPc006, LPc028, LPc033, LPc067, LPc111, LPc167, and PP437) up-regulated resistant PTEN,Akt PTEN AKT pathway validated 242 Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21 Zhongguo Zhong Xi Yi Jie He Za Zhi 2010 20462046 miRBase MI0000077 miR-21 miRNA DB01169 (APRD00171) Arsenic trioxide leukemia RT-PCR Chemosynthetic AMO-miR-21 was transfected to K562 cells using Lipofectamine TM 2000. The inhibitory effects of As2O3 and AMO-miR-21, used singly or in combining, on cell proliferation were detected by MTT, their inhibition rate and IC50 were calculated. Cell cycle and apoptosis were assessed with PI stain; expression of miRNA-21 in cells was detected quantitatively by real-time PCR, and the potential target gene PDCD, protein expression was detected by immuno-fluorimetry. cell line ( K562 ) up-regulated resistant PDCD4 PDCD4 NA validated 243 The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010 20485139 miRBase MI0000747 miR-296 miRNA DB00541 (APRD00495) Vincristine esophageal squamous cell carcinoma RT-PCR, Northern blot The miRNAs were identified differentially expressed in esophageal cancer tissues, using miRNA microarray, real-time PCR, and Northern blot. The role of target miRNAs was investigated by in vitro and in vivo assay. tissue and cell line ( ECA109) down-regulated sensitive MDR1 MDR1 NA validated 244 The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010 20485139 miRBase MI0000747 miR-296 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal squamous cell carcinoma RT-PCR, Northern blot The miRNAs were identified differentially expressed in esophageal cancer tissues, using miRNA microarray, real-time PCR, and Northern blot. The role of target miRNAs was investigated by in vitro and in vivo assay. tissue and cell line ( ECA109) down-regulated sensitive MDR1 MDR1 NA validated 245 The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010 20485139 miRBase MI0000747 miR-296 miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma RT-PCR, Northern blot The miRNAs were identified differentially expressed in esophageal cancer tissues, using miRNA microarray, real-time PCR, and Northern blot. The role of target miRNAs was investigated by in vitro and in vivo assay. tissue and cell line ( ECA109) down-regulated sensitive MDR1 MDR1 NA validated 246 The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010 20485139 miRBase MI0000747 miR-296 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma RT-PCR, Northern blot The miRNAs were identified differentially expressed in esophageal cancer tissues, using miRNA microarray, real-time PCR, and Northern blot. The role of target miRNAs was investigated by in vitro and in vivo assay. tissue and cell line ( ECA109) down-regulated sensitive MDR1 MDR1 NA validated 247 Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010 20487546 miRBase MI0000087 miR-29a miRNA DB01073 (APRD00594) Fludarabine chronic myeloid leukemia qRT-PCR In the study, we performed an analysis of genomic aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the course of patients treatment with fludarabine.The expression levels of miRNA were determined by Quantitative RT-PCR The CCK-8 assay was used to monitor the growth of the cells,etc. tissue and cell line down-regulated resistant NA NA p53 signaling pathway validated 248 Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010 20487546 miRBase MI0000289/MI0000269 miR-181a miRNA DB01073 (APRD00594) Fludarabine chronic lymphocytic leukemia qRT-PCR In the study, we performed an analysis of genomic aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the course of patients treatment with fludarabine.The expression levels of miRNA were determined by Quantitative RT-PCR The CCK-8 assay was used to monitor the growth of the cells,etc. tissue and cell line up-regulated resistant NA NA p53 signaling pathway validated 249 Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010 20487546 miRBase MI0000298 miR-221 miRNA DB01073 (APRD00594) Fludarabine chronic lymphocytic leukemia qRT-PCR In the study, we performed an analysis of genomic aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the course of patients treatment with fludarabine.The expression levels of miRNA were determined by Quantitative RT-PCR The CCK-8 assay was used to monitor the growth of the cells,etc. tissue and cell line up-regulated resistant NA NA p53 signaling pathway validated 250 Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010 20498843 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR Formalin-fixed paraffin embedded specimens from a cohort of 82 resected Korean PDAC cases were analyzed for protein expression by immunohistochemistry and for microRNA expression using quantitative Real-Time PCR. Cox proportional hazards model analysis in the subgroup of patients treated with adjuvant therapy (N = 52) showed that lower than median miR-21 expression was associated with a significantly lower hazard ratio (HR) for death (HR = 0.316; 95%CI = 0.166-0.600; P = 0.0004) and recurrence (HR = 0.521; 95%CI = 0.280-0.967; P = 0.04). MiR-21 expression status emerged as the single most predictive biomarker for treatment outcome among all 27 biological and 9 clinicopathological factors evaluated. No significant association was detected in patients not treated with adjuvant therapy. In an independent validation cohort of 45 frozen PDAC tissues from Italian cases, all treated with adjuvant therapy, lower than median miR-21 expression was confirmed to be correlated with longer overall as well as disease-free survival. Furthermore, transfection with anti-miR-21 enhanced the chemosensitivity of PDAC cells. cell line ( PL45, BxPC-3) down-regulated sensitive NA NA NA validated 251 Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010 20498843 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Formalin-fixed paraffin embedded specimens from a cohort of 82 resected Korean PDAC cases were analyzed for protein expression by immunohistochemistry and for microRNA expression using quantitative Real-Time PCR. Cox proportional hazards model analysis in the subgroup of patients treated with adjuvant therapy (N = 52) showed that lower than median miR-21 expression was associated with a significantly lower hazard ratio (HR) for death (HR = 0.316; 95%CI = 0.166-0.600; P = 0.0004) and recurrence (HR = 0.521; 95%CI = 0.280-0.967; P = 0.04). MiR-21 expression status emerged as the single most predictive biomarker for treatment outcome among all 27 biological and 9 clinicopathological factors evaluated. No significant association was detected in patients not treated with adjuvant therapy. In an independent validation cohort of 45 frozen PDAC tissues from Italian cases, all treated with adjuvant therapy, lower than median miR-21 expression was confirmed to be correlated with longer overall as well as disease-free survival. Furthermore, transfection with anti-miR-21 enhanced the chemosensitivity of PDAC cells. cell line ( PL45, BxPC-3) down-regulated sensitive NA NA NA validated 252 MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010 20501828 miRBase MIMAT0000232 miR-199a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocarcinoma Real-time reverse transcription-PCR,Semiquantitative reverse transcription-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR . Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by invasion assay, etc. cell line ( HepG2,Huh-7,SNU475) up-regulated sensitive mTOR mTOR mTOR signaling pathway validated 253 MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010 20548249 miRBase MIMAT0004508 miR-92a-2* miRNA DB00958 (APRD00466) Carboplatin lung small cell carcinoma qRT-PCR miRNA microarray profiling was performed on diagnostic SCLC tumor samples, and analysis was performed using XenoBase, a data integration and discovery tool. Confirmation of the top 16 miRNA candidates was performed using quantitative real-time polymerase chain reaction followed by analyses to determine clinical and miRNA biomarkers associated with chemoresistance and survival. tissue up-regulated resistant NA NA NA predicted 254 Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010 20581857 miRBase MI0000077 miR-21 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR A microarray technique was used to determine the miRNA profile in docetaxel-resistant PC3 cells. Real-time PCR was used to confirm the array results. miR-21 mimics and inhibitors were synthesized and introduced to cells using Lipofectamine 2000. Cell proliferation was examined with the CCK-8 assay. Luciferase reporter containing PDCD 3UTR was constructed and the activity was detected by a dual luciferase assay. PDCD4 protein expression was evaluated using Western blot. cell line ( PC3,PC3R ) up-regulated resistant PDCD4 PDCD4 NA validated 255 MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010 20624637 miRBase MI0000085 miR-27a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR Expression of miR-27a in ovarian cancer cell lines A2780 and A2780/Taxol were detected by stem-loop real-time PCR. A2780 and A2780/Taxol cells were transfected with the mimics or inhibitors of miR-27a or negative control RNA (NC) by Lipofectamine 2000. The expression levels of MDR1 mRNA, P-glycoprotein (P-gp) and Homeodomain-interacting protein kinase-2 (HIPK2) proteins were assessed by real-time PCR and western blot respectively. Drug sensitivity was analyzed by MTT assay while apoptosis and the fluorescence intensity of intracellular Rhodamine 123 (Rh-123) were measured by FACS. cell line ( A2780, A2780/Taxol) up-regulated resistant HIPK2 HIPK2 miRNAs/HIPK2/MDR1/P-gp cell signal pathway validated 256 MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010 20633539 miRBase MI0000077 miR-21 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The expression levels of miRNA were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) . Those of protein were by Western blot analysis.Trypan blue dye exclusion test for cell viability. Hoechst 33258 staining for morphological analysis of apoptosis.Caspase-3 activation status was measured using the Caspase-Glo 3 Assay. cell line ( U87MG) up-regulated resistant NA NA NA validated 257 Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells Zhonghua Fu Chan Ke Za Zhi 2010 20646448 miRBase MI0000085 miR-27a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer RT-PCR tem-loop-mediated real-time PCR was used to detect miR-27a expression in A2780 and A2780/Taxol cells. The cells were transfected with the mimics or inhibitors of miR-27a or negative control RNA (NC) by lipofectamine 2000. The expressions of MDR1 gene, P-glycoprotein (P-gp) and homeodomain-interacting protein kinase 2 (HIPK2) protein levels were measured by real-time PCR and western blot respectively. Methyl thiazolyl tetrazolium (MTT) assay was used to analyze drug sensitivity. Apoptosis analysis was measured by fluorescence activated cell sorter (FACS). cell line (A2780 and A2780/Taxol) up-regulated resistant HIPK2 HIPK2 miRNA/HIPK2/MDR1 pathway validated 258 Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010 20670480 miRBase MI0000077 miR-21 miRNA NA Arabinosylcytosine acute myeloid leukemia RT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( HL60) down-regulated sensitive PDCD4 PDCD4 NA validated 259 MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010 20687223 miRBase MI0000268 miR-34a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer RT-PCR Paclitaxel-resistant cells (PC3PR) were generated from hormone-refractory PC3 cells. The expression levels of mRNA and miRNA were determined by reverse transcriptase PCR and those of protein were by Western blot analysis. Transfection of miRNA precursor or siRNA was performed using the liposome-mediated method. cell line (PC3,PC3PR) up-regulated sensitive SIRT1 and Bcl2 SIRT1 and Bcl2 NA validated 260 Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010 20696752 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma methylation-specific PCR The expression levels of miRNA were determined by methylation-specific PCR and those of protein were by Western blot analysis. Cell migration was detected by invasion assay,etc. cell line (Calu-1, NCI H520, SKMES-1,H596,Calu-3, NCI-H522,NCI-H1395,NCI-H1299, NCI-H460 ) up-regulated sensitive NA NA NA validated 261 Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010 20696752 miRBase MI0000650 miR-200c miRNA DB00002 (BTD00071, BIOD00071) Cetuximab lung non-small cell carcinoma methylation-specific PCR The expression levels of miRNA were determined by methylation-specific PCR and those of protein were by Western blot analysis. Cell migration was detected by invasion assay,etc. cell line (Calu-1, NCI H520, SKMES-1,H596,Calu-3, NCI-H522,NCI-H1395,NCI-H1299, NCI-H460 ) up-regulated sensitive NA NA NA validated 262 Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010 20856931 miRBase MI0000288 miR-212 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab head and neck squamous cell carcinoma RT-PCR Genome-wide changes in gene and miR expression were determined in cetuximab-sensitive cell line, SCC1, and its resistant derivative 1Cc8 using DNA microarrays and RT-PCR. The effects of differentially expressed EGFR ligands and miRs were examined by MTS, colony formation, ELISA, and western blot assays. Heparin-binding EGF-like growth factor (HB-EGF) and its regulator, miR-212, were differentially expressed with statistical significance when SCC1 and 1Cc8 were compared for gene and miR expression. Stimulation with HB-EGF induced cetuximab resistance in sensitive cell lines. Inhibition of HB-EGF and the addition of miR-212 mimic induced cetuximab sensitivity in resistant cell lines. MicroRNA-212 and HB-EGF expression were inversely correlated in an additional 33 HNSCC and keratinocyte cell lines. Six tumors and 46 plasma samples from HNSCC patients were examined for HB-EGF levels. HB-EGF plasma levels were lower in newly diagnosed HNSCC patients when compared to patients with recurrent disease. cell line (1Cc8,HaCaT) down-regulated resistant HB-EGF HB-EGF NA validated 263 MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010 20978511 miRBase MI0000077 miR-21 miRNA NA Interferon-alpha hepatocellular carcinoma Real-time qRT-PCR Changes in the sensitivity of HCC cells (PLC/PRF/5 and HepG2) to IFN-alpha/5-FU were examined after transfection with pre-miR-21 or anti-miR-21. The correlation between miR-21 expression level, evaluated by qRT-PCR, and response to the therapy was also investigated in clinical HCC specimens. cell line (PLC/PRF/5, HuH7, HLE, HLF, HepG2 ) up-regulated resistant PETN and PDCD4 PETN and PDCD4 NA validated 264 MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010 20978511 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma Real-time qRT-PCR Changes in the sensitivity of HCC cells (PLC/PRF/5 and HepG2) to IFN-alpha/5-FU were examined after transfection with pre-miR-21 or anti-miR-21. The correlation between miR-21 expression level, evaluated by qRT-PCR, and response to the therapy was also investigated in clinical HCC specimens. cell line (PLC/PRF/5, HuH7, HLE, HLF, HepG2 ) up-regulated resistant PETN and PDCD4 PETN and PDCD4 NA validated 265 miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010 21055388 miRBase MIMAT0000232 miR-199a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma qPCR The expression levels of miRNA were determined by quantitative polymerase chain reaction . CD44 protein expression in 8 pairs of HCC and benign tissue is presented from the immunoblot and the densitometry values of the immunoblot. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by invasion assay. cell line ( Huh7, HepG2, SNU182, PLC/PRF/5, Hep3B, SNU423, SNU449) up-regulated sensitive CD44 CD44 NA validated 266 MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 2010 21078976 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Colo-320 DM, SW620, HCT-116, SW480, RKO) up-regulated resistant hMSH2 hMSH2 NA validated 267 Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 2010 21114921 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin stomach cancer Real Time RT-PCR SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot. cell line (SGC7901,SGC7901/DDP ) up-regulated sensitive E-cadherin, Bcl-2 and Bax E-cadherin, Bcl-2 and Bax PI3K/AKT signaling pathway validated 268 Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 2010 21114921 miRBase MI0000650 miR-200c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Real Time RT-PCR SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot. cell line (SGC7901,SGC7901/DDP ) up-regulated sensitive E-cadherin, Bcl-2 and Bax E-cadherin, Bcl-2 and Bax PI3K/AKT signaling pathway validated 269 Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 2010 21114921 miRBase MI0000650 miR-200c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer Real Time RT-PCR SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot. cell line (SGC7901,SGC7901/DDP ) up-regulated sensitive E-cadherin, Bcl-2 and Bax E-cadherin, Bcl-2 and Bax PI3K/AKT signaling pathway validated 270 Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer 2010 21114921 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer Real Time RT-PCR SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot. cell line (SGC7901,SGC7901/DDP ) up-regulated sensitive E-cadherin, Bcl-2 and Bax E-cadherin, Bcl-2 and Bax PI3K/AKT signaling pathway validated 271 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000298 miR-221 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) up-regulated resistant NA NA NA predicted 272 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) up-regulated resistant NA NA NA predicted 273 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0001729 miR-451 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) up-regulated resistant NA NA NA predicted 274 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000100 miR-98 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 275 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000289/MI0000269 miR-181a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 276 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000067/MI0000068 let-7f miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 277 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0000433 let-7g miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 278 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0001446 miR-424 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 279 Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines Zhonghua Xue Ye Xue Za Zhi 2010 21122348 miRBase MI0003569 miR-563 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia Real Time RT-PCR The drug resistance potency of K562/A02 cells was evaluated by MTT assay. P-gp expression of K562 and K562/A02 cells were detected by flow cytometry (FCM). The differentially expressed microRNAs in K562 and K562/A02 cells were analyzed by microarray technique and Real Time RT-PCR. cell line (K562 and K562/A02) down-regulated resistant NA NA NA predicted 280 Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010 21172025 miRBase MI0000805 miR-342 miRNA DB00675 (APRD00123) Tamoxifen breast tumor Northern blot,qRT-PCR Here we analyzed multiple cell models of tamoxifen resistance derived from MCF-7 cells to examine the influence of microRNAs (miRNAs) on tamoxifen resistance. We compared miRNA expression profiles of tamoxifen sensitive MCF-7 cells and tamoxifen resistant MCF-7/HER2Delta16 cells. We observed significant and dramatic downregulation of miR-342 in the MCF-7/HER2Delta16 cell line as well as the HER2 negative but tamoxifen resistant MCF-7 variants TAMR1 and LCC2. Restoring miR-342 expression in the MCF-7/HER2Delta16 and TAMR1 cell lines sensitized these cells to tamoxifen-induced apoptosis with a dramatic reduction in cell growth. Expression of miR-342 was also reduced in a panel of tamoxifen refractory human breast tumors, underscoring the potential clinical importance of miR-342 downregulation. Towards the goal of identifying direct and indirect targets of miR-342 we restored miR-342 expression in MCF-7/HER2Delta16 cells and analyzed changes in global gene expression by microarray. The impact of miR-342 on gene expression in MCF-7/HER2Delta16 cells was not limited to miR-342 in silica predicted targets. Ingenuity Pathways Analysis of the dataset revealed a significant influence of miR-342 on multiple tumor cell cycle regulators. cell line (MCF-7,MCF-7/HER2, MCF-7/pcDNA,MCF-7/HER2Delta16) down-regulated resistant NA SEMAD,BMP7,GEMIN4 SEMAD,BMP7,GEMIN4 validated 281 Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010 21172025 miRBase MI0000805 miR-342 miRNA DB00675 (APRD00123) Tamoxifen breast tumor Northern blot,qRT-PCR The expression levels of miRNA were determined by Northern Blot and qRT-PCR . Analysis of EVL mRNA by Quantitative Reverse Transcription PCR . Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7,MCF-7/HER2, MCF-7/pcDNA,MCF-7/HER2Delta16) down-regulated resistant NA SEMAD,BMP7,GEMIN4 SEMAD,BMP7,GEMIN4 validated 282 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010 21368878 miRBase MI0000285 miR-205 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. The Cell Death Detection Elisa kit (Roche) was used to detect apoptosis following the manufacturers protocol. cell line (RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB11, WPE1-NB26, PC-3, LNCaP, 22Rv1, VCaP, and Du145) down-regulated resistant Bcl-w Bcl-w NA validated 283 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010 21368878 miRBase MI0000285 miR-205 miRNA DB00515 (APRD00359) Cisplatin prostate cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. The Cell Death Detection Elisa kit (Roche) was used to detect apoptosis following the manufacturers protocol. cell line (RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB11, WPE1-NB26, PC-3, LNCaP, 22Rv1, VCaP, and Du145) down-regulated resistant Bcl-w Bcl-w NA validated 284 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010 21368878 miRBase MI0000089 miR-31 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. The Cell Death Detection Elisa kit (Roche) was used to detect apoptosis following the manufacturers protocol. cell line (RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB11, WPE1-NB26, PC-3, LNCaP, 22Rv1, VCaP, and Du145) down-regulated resistant E2F6 E2F6 NA validated 285 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010 21368878 miRBase MI0000089 miR-31 miRNA DB00515 (APRD00359) Cisplatin prostate cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. The Cell Death Detection Elisa kit (Roche) was used to detect apoptosis following the manufacturers protocol. cell line (RWPE-1, WPE1-NA22, WPE1-NB14, WPE1-NB11, WPE1-NB26, PC-3, LNCaP, 22Rv1, VCaP, and Du145) down-regulated resistant E2F6 E2F6 NA validated 286 miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 2011 20143188 miRBase MI0000077 miR-21 miRNA DB01169 (APRD00171) Arsenic trioxide leukemia RT-PCR In the study, we used a specific precursor miRNA-21 (pre-miR-21) or anti-miRNA-21 oligonucleotide (AMO-miR-21) to study sensitivity of HL60 and K562 cells to ATO. Cell viability and cell cycle were evaluated by MTT assay and PI assay using flow cytometry, respectively. Levels of miR-21 and its target PDCD4 were quantified by real-time PCR and/or western blot. AMO-miR-21 or ATO alone led to growth inhibition, apoptosis and G1 phase arrest of cell cycle. Apoptotic cells were confirmed morphologically with Hoechst staining. Moreover, there was somewhat synergistic effect of AMO-miR-21 and ATO in growth inhibition and apoptosis promotion. Meanwhile, enforced pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. Dual-luciferase reporter vector containing two tandem PDCD4 3 UTR validated that PDCD4 was directly up-regulated by miR-21. Therefore, miRNA-21 by targeting PDCD4 may play a functional role in modulating ATO-induced cell death, and strategy using AMO-miR-21 and its combination with ATO may be useful as a myelogenous leukemia therapy. cell line ( HL60, K562) up-regulated resistant PDCD4 PDCD4 NA validated 287 Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011 21067862 miRBase MI0000268 miR-34a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis.etc. cell line ( DLD-1,DLD-1/5FU) down-regulated resistant SIRT1,E2F3 SIRT1,E2F3 PI3K/AKT signaling pathway validated 288 Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011 21070600 miRBase MIMAT0004700 miR-331-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin leukemia qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western immunoblotting. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( K562/DOX1, K562/DOX2, K562/DOX3,K562/WT ) down-regulated resistant MDR1 MDR1 NA validated 289 Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011 21070600 miRBase MI0000085 miR-27a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin leukemia qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western immunoblotting. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( K562/DOX1, K562/DOX2, K562/DOX3,K562/WT ) down-regulated resistant MDR1 MDR1 NA validated 290 miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011 21177782 miRBase MI0000268 miR-34a miRNA DB00305 (APRD00284) Mitomycin C medulloblastoma RT-PCR In the study, we establish that miR-34a induces apoptosis, G2 arrest, and senescence in medulloblastoma and renders these cells more sensitive to chemotherapeutic agents. These effects are mediated in part by the direct post-transcriptional repression of the oncogenic MAGE-A gene family. We demonstrate that miR-34a directly targets the 3 untranslated regions of MAGE-A genes and decreases MAGE-A protein levels. This decrease in MAGE-A results in a concomitant increase in p53 and its associated transcriptional targets, p21/WAF1/CIP1 and, importantly, miR-34a. This establishes a positive feedback mechanism where miR-34a is not only induced by p53 but increases p53 mRNA and protein levels through the modulation of MAGE-A genes. Additionally, the forced expression of miR-34a or the knockdown of MAGE-A genes by small interfering RNA similarly sensitizes medulloblastoma cells to several classes of chemotherapeutic agents, including mitomycin C and cisplatin. Finally, the analysis of mRNA and micro-RNA transcriptional profiles of a series of primary medulloblastomas identifies a subset of tumors with low miR-34a expression and correspondingly high MAGE-A expression, suggesting the coordinate regulation of these genes. Our work establishes a role for miR-34a in modulating responsiveness to chemotherapy in medulloblastoma and presents a novel positive feedback mechanism involving miR-34a and p53, via direct targeting of MAGE-A. cell line (R262, UW228, UW426, and R300 ) up-regulated sensitive MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 p53 signaling pathway validated 291 miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011 21177782 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin medulloblastoma RT-PCR In the study, we establish that miR-34a induces apoptosis, G2 arrest, and senescence in medulloblastoma and renders these cells more sensitive to chemotherapeutic agents. These effects are mediated in part by the direct post-transcriptional repression of the oncogenic MAGE-A gene family. We demonstrate that miR-34a directly targets the 3 untranslated regions of MAGE-A genes and decreases MAGE-A protein levels. This decrease in MAGE-A results in a concomitant increase in p53 and its associated transcriptional targets, p21/WAF1/CIP1 and, importantly, miR-34a. This establishes a positive feedback mechanism where miR-34a is not only induced by p53 but increases p53 mRNA and protein levels through the modulation of MAGE-A genes. Additionally, the forced expression of miR-34a or the knockdown of MAGE-A genes by small interfering RNA similarly sensitizes medulloblastoma cells to several classes of chemotherapeutic agents, including mitomycin C and cisplatin. Finally, the analysis of mRNA and micro-RNA transcriptional profiles of a series of primary medulloblastomas identifies a subset of tumors with low miR-34a expression and correspondingly high MAGE-A expression, suggesting the coordinate regulation of these genes. Our work establishes a role for miR-34a in modulating responsiveness to chemotherapy in medulloblastoma and presents a novel positive feedback mechanism involving miR-34a and p53, via direct targeting of MAGE-A. cell line (R262, UW228, UW426, and R300 ) up-regulated sensitive MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 p53 signaling pathway validated 292 miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011 21177782 miRBase MI0000268 miR-34a miRNA DB00305 (APRD00284) Mitomycin C medulloblastoma qRT-PCR The expression levels of miRNA were determined by Real-time Quantitative Reverse Transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation.etc. cell line ( R262, UW228, UW426, R300,D556, D384Med, D425Med,D283,HEK 293T/17) up-regulated sensitive MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 p53 signaling pathway validated 293 miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011 21177782 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin medulloblastoma qRT-PCR The expression levels of miRNA were determined by Real-time Quantitative Reverse Transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation.etc. cell line ( R262, UW228, UW426, R300,D556, D384Med, D425Med,D283,HEK 293T/17) up-regulated sensitive MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 MAGE-A2,MAGE-A3,MAGE-A6,and MAGE-A12 p53 signaling pathway validated 294 Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011 21187093 miRBase MI0000077 miR-21 miRNA DB00694 (APRD00521) Daunorubicin leukemia RT-PCR,Northern blot The expression levels of miRNA were determined by Real-time PCR and Northern blot .Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (K562,K562/DNR,HEK293T) up-regulated resistant PTEN PTEN PI3K/Akt pathway validated 295 miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011 21195000 miRBase MI0000272 miR-182 miRNA DB09074 (DB05940) Olaparib breast cancer qPCR The expression levels of miRNA were determined by quantitative PCR . Luciferase activity assay was used to verify the target genes of miRNAs. The xenograft mouse models was used to identify the relationshipe between miR-182 and PARP inhibitor, etc. cell line (HL60, K562,MCF-7) up-regulated sensitive BRCA1 BRCA1 NA validated 296 miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011 21197560 miRBase MI0000459 miR-143 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR The aims of this study were to verify the effect of miR-143 on proliferation and migration abilities of prostate cancer cells. The expression level of miR-143 and its target gene KRAS were measured by realtime PCR and western blotting, respectively. Effects of miR-143 in cell proliferation, migration and chemosensitivity were evaluated by MTT assay, FACS cell cycle analysis, colony formation assay, and transwell migratory assay. cell line (FACS) up-regulated sensitive KRAS KRAS EGFR/RAS/MAPK pathway validated 297 MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011 21224400 miRBase MI0000776 miR-376c miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression levels of miRNA were determined by Rreal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell proliferation and viability were determined using BrdU and WST-1 assays.TUNEL staining was used to detect apoptotic cell death. cell line (OV2008, A2780s) up-regulated resistant ALK7 ALK7 Nodal-ALK7 pathway validated 298 miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011 21242194 miRBase MI0000076 miR-20a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and Semi-quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The bioinformatics method were used to predict miR-20a target genes. cell line (SW620, SW480) down-regulated sensitive BNIP2 BNIP2 NA validated 299 miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011 21242194 miRBase MI0000076 miR-20a miRNA DB00526 (APRD00186) Oxaliplatin colorectal adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and Semi-quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The bioinformatics method were used to predict miR-20a target genes. cell line (SW620, SW480) down-regulated sensitive BNIP2 BNIP2 NA validated 300 miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011 21242194 miRBase MI0000076 miR-20a miRNA DB00444 (APRD00649) Teniposide colorectal adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and Semi-quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The bioinformatics method were used to predict miR-20a target genes. cell line (SW620, SW480) down-regulated sensitive BNIP2 BNIP2 NA validated 301 Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011 21246413 miRBase MI0000253 miR-148a miRNA DB00515 (APRD00359) Cisplatin oesophageal adenocarcinoma RT-PCR Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed. cell line (KYSE410, OE19) up-regulated sensitive NA NA NA validated 302 Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011 21246413 miRBase MI0000253 miR-148a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil oesophageal adenocarcinoma RT-PCR Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed. cell line (KYSE410, OE19) up-regulated sensitive NA NA NA validated 303 Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011 21246413 miRBase MI0000253 miR-148a miRNA DB00515 (APRD00359) Cisplatin squamous cell carcinoma RT-PCR Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed. cell line (KYSE410, OE19) up-regulated sensitive NA NA NA validated 304 Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011 21246413 miRBase MI0000253 miR-148a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil squamous cell carcinoma RT-PCR Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed. cell line (KYSE410, OE19) up-regulated sensitive NA NA NA validated 305 Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011 21248297 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin esophageal cancer qRT-PCR Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with esophageal cancer who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR. Then, we examined the relationship between miRNA expression and prognosis or response to chemotherapy. To investigate the mechanism of miRNA-induced chemoresistance, in vitro assays were carried out using esophageal cancer cells. tissue and cell line (TE8,TE8-R,TE13) up-regulated resistant PPP2R1B PPP2R1B AKT pathway validated 306 Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol 2011 21252292 miRBase MIMAT0002176 miR-485-3p miRNA DB00773 (APRD00239) Etoposide lymphocytic leukemia RT-PCR The expression levels of miRNA were determined by Reverse Transcriptase-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CEM,CEM/VM-1-5,Rh30,Rh30/v1,HEK293T) up-regulated sensitive NF-YB NF-YB NA validated 307 Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol 2011 21252292 miRBase MIMAT0002176 miR-485-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lymphocytic leukemia RT-PCR The expression levels of miRNA were determined by Reverse Transcriptase-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CEM,CEM/VM-1-5,Rh30,Rh30/v1,HEK293T) up-regulated sensitive NF-YB NF-YB NA validated 308 MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011 21289630 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma RT-PCR In this study, we explored the possible role of miRNAs in cisplatin resistance in esophageal squamous cell carcinoma (ESCC). First we assessed the sensitivity of nine human ESCC cell lines (KYSE series) to cisplatin using an in vitro cell viability assay, and then we compared the miRNA profiles of the cisplatin-sensitive and -resistant cell lines by miRNA microarray analysis. The two groups showed markedly different miRNA expression profiles, and 10 miRNAs were found to be regulated differentially between the two groups. When miR-141, which was the most highly expressed miRNA in the cisplatin-resistant cell lines, was expressed ectopically in the cisplatin-sensitive cell lines, cell viability after cisplatin treatment was increased significantly. Furthermore, we found that miR-141 directly targeted the 3-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents, and thus downregulated YAP1 expression. cell line (KYSE) up-regulated resistant YAP1 YAP1 NA validated 309 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000449 miR-132 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 310 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000301 miR-224 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 311 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MIMAT0000763 miR-338-3p miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 312 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0001733 miR-452 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 313 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000457 miR-141 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 314 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000737 miR-200a miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 315 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000342 miR-200b miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 316 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000650 miR-200c miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 317 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MIMAT0000723 miR-371-3p miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 318 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MIMAT0004687 miR-371-5p miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 319 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000780 miR-372 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 320 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000781 miR-373 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 321 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0001641 miR-429 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 322 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000433 let-7g miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 323 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000471 miR-126 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 324 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000238/MI0000279 miR-196a miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 325 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0001150 miR-196b miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 326 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000074/MI0000075 miR-19b miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 327 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000085 miR-27a miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 328 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000089 miR-31 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 329 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000767 miR-365 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 330 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0001446 miR-424 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 331 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 332 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000100 miR-98 miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). up-regulated resistant NA NA NA predicted 333 Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011 21293479 miRBase MI0000746 miR-99b miRNA DB12385 10-hydroxycamptothecin stomach cancer qRT-PCR A sulforhodamine B (SRB) assay was used to analyze the sensitivity to HCPT of six gastric cancer cell lines. The miRNA and mRNA expression signatures in HCPT-resistant cell lines were then identified using DNA microarrays. Gene ontology and pathway analysis was conducted using GenMAPP2. A combined analysis was used to explore the relationship between the miRNAs and mRNAs. cell lines (BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, and AGS). down-regulated resistant NA NA NA predicted 334 Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011 21329503 miRBase MI0001729 miR-451 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR Quantitative RT-PCR assay was performed to detect the expression of miR-451 in 10 pairs of NSCLC and noncancerous tissue samples. pcDNA-GW/EmGFP-miR-451 was stably transfected into NSCLC cell line (A549). Then, the effects of miR-451 upregulation on growth, colony formation and apoptosis of A549 cells were investigated. Finally, the effects of miR-451 upregulation on in vitro and in vivo sensitivity of A549 cells of DDP were also determined. tissue and cell line (A549) up-regulated sensitive NA NA AKT pathway validated 335 MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 2011 21347785 miRBase MIMAT0000433 miR-142-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Two gemcitabine-resistant pancreatic cancer cell lines were established, and global microRNA expression analyses was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Eleven miRNAs were selected as putative predictive markers and analyzed by means of macrodissected formalin-fixed, paraffin-embedded samples obtained from 90 patients with or without gemcitabine treatment after resection of pancreatic cancer. cell line (SUIT-2 and CAPAN-1) up-regulated sensitive NA NA NA validated 336 miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 2011 21354697 miRBase MI0000283 miR-203 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colon cancer Northern blot,RT-PCR The expression levels of miRNA were determined by Northern blot analysis and RT-PCR. Those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HCT-116,HCT-15,HT-29) up-regulated sensitive Akt2 Akt2 PI3K pathway validated 337 Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 2011 21376256 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer NA miR-21 mimics and inhibitor were transfected to MIA PaCa-2 pancreatic cancer cells, respectively. Alteration in Bcl-2/Bax expression was subsequently evaluated. Then, luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3UTRs of Bcl-2 mRNA were co-transfected. Finally, apoptosis, chemosensitivity to gemcitabine and cell proliferation were evaluated. cell line up-regulated resistant Bcl-2 Bcl-2 NA validated 338 A commentary on MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011 21390040 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma RT-PCR In this study, we explored the possible role of miRNAs in cisplatin resistance in esophageal squamous cell carcinoma (ESCC). First we assessed the sensitivity of nine human ESCC cell lines (KYSE series) to cisplatin using an in vitro cell viability assay, and then we compared the miRNA profiles of the cisplatin-sensitive and -resistant cell lines by miRNA microarray analysis. The two groups showed markedly different miRNA expression profiles, and 10 miRNAs were found to be regulated differentially between the two groups. When miR-141, which was the most highly expressed miRNA in the cisplatin-resistant cell lines, was expressed ectopically in the cisplatin-sensitive cell lines, cell viability after cisplatin treatment was increased significantly. Furthermore, we found that miR-141 directly targeted the 3-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents, and thus downregulated YAP1 expression. cell line (KYSE) up-regulated resistant YAP1 YAP1 NA validated 339 Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011 21471222 miRBase MI0000077 miR-21 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-PCR,Northern blot miRNA microarray analysis was done in the parental and resistant BT474 linesThe expression levels of miRNA were determined by Real-time PCR and Northern Blot .Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The nude mice was used to identify the relationship between miR-21 and trastuzumab. cell line (SKBR3, MDA-MB-453, and BT474) up-regulated resistant PTEN PTEN AKT pathway validated 340 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011 21552288 miRBase MI0000452/MI0000453 miR-135a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5) up-regulated resistant HIF1AN HIF1AN NA validated 341 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011 21552288 miRBase MI0000452/MI0000453 miR-135a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer qRT-PCR In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5) up-regulated resistant HIF1AN HIF1AN NA validated 342 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011 21552288 miRBase MI0000452/MI0000453 miR-135a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5) up-regulated resistant HIF1AN HIF1AN NA validated 343 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011 21552288 miRBase MI0000452/MI0000453 miR-135a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel uterine sarcoma qRT-PCR In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5) up-regulated resistant HIF1AN HIF1AN NA validated 344 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011 21552288 miRBase MI0000452/MI0000453 miR-135a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5) up-regulated resistant HIF1AN HIF1AN NA validated 345 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 346 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 347 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000239 miR-197 miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 348 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 349 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000270/MI0000683 miR-181b miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 350 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0003139 miR-181d miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 351 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000489 miR-195 miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 352 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000102 miR-100 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 353 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000448 miR-130a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 354 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000239 miR-197 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 355 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000103/MI0000739 miR-101 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 356 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000270/MI0000683 miR-181b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 357 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0003139 miR-181d miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 358 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000489 miR-195 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 359 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000102 miR-100 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 360 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000448 miR-130a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 361 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000239 miR-197 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 362 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000103/MI0000739 miR-101 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 363 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000270/MI0000683 miR-181b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 364 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0003139 miR-181d miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 365 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000489 miR-195 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 366 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000102 miR-100 miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 367 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000448 miR-130a miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 368 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000239 miR-197 miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 369 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000103/MI0000739 miR-101 miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 370 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000270/MI0000683 miR-181b miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 371 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0003139 miR-181d miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 372 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000489 miR-195 miRNA DB00563 (APRD00353) Methotrexate head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 373 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000102 miR-100 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 374 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000448 miR-130a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 375 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000239 miR-197 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) down-regulated resistant NA NA NA predicted 376 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000103/MI0000739 miR-101 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 377 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 378 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0003139 miR-181d miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 379 MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011 21560177 miRBase MI0000489 miR-195 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma RT-PCR Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. cell line (UMSCC-1 and SQ20B) up-regulated resistant NA NA NA predicted 380 Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011 21569481 miRBase MI0000085 miR-27a miRNA DB00541 (APRD00495) Vincristine stomach cancer RT-PCR The role of miR-27a in gastric cancer cells was detected using MTT assay, soft agar assay, flow cytometry assay, nude mice assay, real-time PCR, western blot and reporter gene assay, etc. cell line (MKN45) down-regulated sensitive cyclin D1 NA NA validated 381 Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011 21569481 miRBase MI0000085 miR-27a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-PCR The role of miR-27a in gastric cancer cells was detected using MTT assay, soft agar assay, flow cytometry assay, nude mice assay, real-time PCR, western blot and reporter gene assay, etc. cell line (MKN45) down-regulated sensitive cyclin D1 NA NA validated 382 Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011 21569481 miRBase MI0000085 miR-27a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR The role of miR-27a in gastric cancer cells was detected using MTT assay, soft agar assay, flow cytometry assay, nude mice assay, real-time PCR, western blot and reporter gene assay, etc. cell line (MKN45) down-regulated sensitive cyclin D1 NA NA validated 383 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0005543 miR-708 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 384 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000748 miR-130b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 385 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0003150 miR-455-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 386 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003137 miR-193b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 387 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 388 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase NA RNU43 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 389 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003150 miR-526b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 390 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000772 miR-302b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 391 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002850 miR-524-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 392 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000267 miR-10b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 393 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000285 miR-205 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 394 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003159 miR-518c miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 395 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0005202 miR-801 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 396 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003153 miR-523 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 397 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0004683 miR-362-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 398 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003146 miR-520f miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 399 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003175 miR-520h miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 400 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0000723 miR-371-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 401 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000781 miR-373 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 402 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002832 miR-519c-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 403 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003177 miR-522 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 404 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003150 miR-526b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 405 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002837 miR-519b-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 406 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0005456 miR-518d-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 407 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003172/MI0003167 miR-516b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 408 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002822 miR-512-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 409 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002846 miR-520c-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 410 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000780 miR-372 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 411 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002823 miR-512-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 412 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003154 miR-518f miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 413 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003162 miR-519d miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 414 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003161 miR-517a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 415 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003166 miR-520g miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 416 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003174 miR-517c miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 417 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002827 miR-515-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 418 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003169 miR-518e miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 419 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002839 miR-525-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 420 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003178/MI0003182 miR-519a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 421 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002863 miR-518a-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 422 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003155 miR-520b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 423 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003165 miR-517b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 424 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003156 miR-518b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 425 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002826 miR-515-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 426 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000461 miR-145 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 427 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 428 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000101 miR-99a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 429 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0003247 miR-582-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 430 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 431 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0004909 miR-450b-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR ree cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 432 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000774 miR-302d miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 433 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000234 miR-192 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 434 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 435 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000816 miR-335 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 436 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 437 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0004796 miR-576-3p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 438 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 439 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0001446 miR-424 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 440 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000738 miR-302a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 441 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000488/MI0000732 miR-194 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 442 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000298 miR-221 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 443 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0005757 miR-935 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 444 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000791 miR-383 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 445 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0003124 miR-489 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 446 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000767 miR-365 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 447 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0004614 miR-193a-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 448 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0000690 miR-296-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 449 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0002468 miR-484 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 450 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0004703 miR-335* miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line down-regulated resistant NA NA NA predicted 451 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 452 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0005715 miR-923 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 453 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MIMAT0002809 miR-146b-5p miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 454 Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011 21575166 miRBase MI0000074 miR-19b-1 miRNA DB00515 (APRD00359) Cisplatin germ cell tumor qRT-PCR Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts, three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known microRNA species of human origin. cell line up-regulated resistant NA NA NA predicted 455 Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 2011 21594648 miRBase MI0000078 miR-22 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colon cancer Northern blot The role of miR-22 in colon cancer cells was detected using Northern blot,MTT assay,Hoechst staining for apoptotic cells,Clonogenic assay, Western blot,etc. cell line ( HT-29, HCT-15,HCT-116 ) up-regulated sensitive PTEN PTEN NA validated 456 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000476/MI0000455 miR-138 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line.The expression levels of miRNA were determined by Real-Time Quantitative RT-PCR and RT-PCR . Those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549,A549/DDP) up-regulated sensitive NA NA nucleotide excision repair (NER) pathway predicted 457 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0006381 miR-1246 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 458 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0007075 miR-1470 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 459 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0003653 miR-638 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 460 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0003672 miR-663 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 461 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000289/MI0000269 miR-181a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 462 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase NA miR-1228? miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 463 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase NA miR-149? miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 464 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0008329 miR-1908 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 465 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated resistant NA NA NA predicted 466 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000301 miR-224 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated sensitive NA NA NA predicted 467 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0005527 miR-886 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated sensitive NA NA NA predicted 468 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated sensitive NA NA NA predicted 469 Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011 21787234 miRBase MI0000488/MI0000732 miR-194 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-Time qRT-PCR MiRNA microarray was used to analyze the miRNA expression profiles in A549 cell line and its drugresistant counterpart, A549/DDP cell line. cell line (A549,A549/DDP) up-regulated sensitive NA NA NA predicted 470 MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011 21802841 miRBase MI0000442 miR-122 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells .Flow cytometry analysis of cell apoptosis and f cell cycle distribution . cell line (Hep3B, HepG2, Huh7, PLC/PRF/5,HEK293) up-regulated sensitive NA NA NA validated 471 MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011 21802841 miRBase MI0000442 miR-122 miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells .Flow cytometry analysis of cell apoptosis and f cell cycle distribution . cell line (Hep3B, HepG2, Huh7, PLC/PRF/5,HEK293) up-regulated sensitive NA NA NA validated 472 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci 2011 21807947 miRBase MIMAT0000232 miR-199a-3p miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. cell line up-regulated sensitive caveolin-2 NA NA validated 473 MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 2011 21816906 miRBase MI0000090 miR-32 miRNA DB00987 (APRD00499) Cytarabine myeloid leukemia qRT-PCR Public web-based prediction sites under miRbase were used to identify miRNA 32 target binding sites in the 3'UTR of human gene transcripts . The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. cell line (HL60-G,U937) down-regulated sensitive Bim NA NA validated 474 MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 2011 21820606 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The half maximal inhibitory concentration (IC(50)) value of ADR in resistant MCF-7/ADR or parental MCF-7 cells was determined by MTT assay. TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-21 and tumor suppressor gene (PTEN) protein. MCF-7 or MCF-7/ADR cell line was transfected with miR-21mimic or inhibitor. The IC(50) value of ADR was determined. Flow cytometry and TUNEL assays were performed to analyze apoptosis. The activity of caspase-3 was analyzed. cell line (MCF-7,MCF-7/ADR) up-regulated resistant PTEN PTEN NA validated 475 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011 21823019 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The different expression of miR-125b in cisplatin-sensitive ovarian cancer cell line (OV2008) and its resistant variant (C13*) was identified by real-time PCR. An in vitro cytotoxicity assay and apoptosis assay using CCK-8 assay and flow cytometry, were carried out to detect the effect of miR-125b and Bak1 on cisplatin resistance of cells. Real-time PCR, Western blotting and luciferase reporter assay were used to detect whether Bak1 is a target of miR-125b. cell line (OV2008,C13*) up-regulated resistant Bak1 Bak1 NA validated 476 let-7 MicroRNAs Induce Tamoxifen Sensitivity by Downregulation of Estrogen Receptor alpha Signaling in Breast Cancer Mol Med 2011 21826373 miRBase NA let-7 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of let-7 in breast cancer cells was detected using quantitative Real-Time PCR, Western blot, MTT assay, Luciferase assay,etc. cell line(184A1,MCF7,ZR-75-1, T47D and HB3396) down-regulated resistant ER-alpha36,ER-alpha66 NA ER-alpha36 mediated nongenomic estrogen signal pathways validated 477 let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med 2011 21826373 miRBase MI0000063 Let-7b miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (184A1,MEGM,MCF7, ZR-75-1, T47D, HB3396,MDA-MB-231, MDA-MB-436, MDA-MB-468, SK-BR-3,MCF7) up-regulated sensitive ER-alpha36 NA ER-alpha36 mediated nongenomic estrogen signal pathways validated 478 let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol Med 2011 21826373 miRBase MI0000434 Let-7i miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (184A1,MEGM,MCF7, ZR-75-1, T47D, HB3396,MDA-MB-231, MDA-MB-436, MDA-MB-468, SK-BR-3,MCF7) up-regulated sensitive ER-alpha36 NA ER-alpha36 mediated nongenomic estrogen signal pathways validated 479 Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011 21853360 miRBase NA miR-19 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR, qRT-PCR We analyzed miRNA expression levels in three MDR cell lines in comparison with their parent cell line, MCF-7, using a miRNA microarray. We investigated whether inhibitor of miR-19 sensitized MDR cells to chemotherapeutic agents in vitro and in vivo. cell line (MCF-7/TX200, MCF-7/VP-16, MCF-7/MX100,MCF7/WT,MCF-7/VP) down-regulated sensitive PTEN PTEN NA predicted 480 Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011 21853360 miRBase NA miR-19 miRNA DB01204 (APRD00371) Mitoxantrone breast cancer RT-PCR, qRT-PCR We analyzed miRNA expression levels in three MDR cell lines in comparison with their parent cell line, MCF-7, using a miRNA microarray. We investigated whether inhibitor of miR-19 sensitized MDR cells to chemotherapeutic agents in vitro and in vivo. cell line (MCF-7/TX200, MCF-7/VP-16, MCF-7/MX100,MCF7/WT,MCF-7/VP) down-regulated sensitive PTEN PTEN NA predicted 481 Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011 21853360 miRBase NA miR-19 miRNA DB00773 (APRD00239) Etoposide breast cancer RT-PCR, qRT-PCR We analyzed miRNA expression levels in three MDR cell lines in comparison with their parent cell line, MCF-7, using a miRNA microarray. We investigated whether inhibitor of miR-19 sensitized MDR cells to chemotherapeutic agents in vitro and in vivo. cell line (MCF-7/TX200, MCF-7/VP-16, MCF-7/MX100,MCF7/WT,MCF-7/VP) down-regulated sensitive PTEN PTEN NA predicted 482 Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol 2011 21864507 miRBase MI0000301 miR-224 miRNA DB00563 (APRD00353) Methotrexate colon cancer qRT-PCR MiRNA microarrays of sensitive and MTX-resistant HT29 colon cancer cells were performed. The results were analyzed using the GeneSpring GX11.5 software. Differentially expressed miRNAs in resistant cells were identified and miR-224, which was one of the most differentially expressed miRNAs and with high raw signal values, was selected for further studies. Putative targets were predicted using TargetScan 5.1 software and integrated with the data from expression microarrays previously performed. Among them CDS2, DCP2, HSPC159, MYST3 and SLC4A4 were validated at the mRNA level by qRT-PCR. Functional assays using an anti-miR against miR-224 desensitized the cells towards MTX, mimicking the resistant phenotype. On the other hand, siRNA treatment against SLC4A4 or incubation of Poly Purine Reverse Hoogsteen (PPRH) hairpins against CDS2 or HSPC159 increased sensitivity to MTX. cell line ( HT29, CaCo-2 and K562 ) down-regulated resistant CDS2,DCP2,HSPC159,MYST3,and SLC4A4 CDS2,DCP2,HSPC159,MYST3,and SLC4A4 NA validated 483 Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011 21880154 miRBase MI0000446/MI0000470 miR-125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute promyelocytic leukemia qRT-PCR In this study, we analyzed miR-125b expression in 169 pediatric acute myelogenous leukemia (AML) samples including 76 APL samples before therapy and 38 APL samples after therapy. The effects of enforced expression of miR-125b were evaluated in leukemic cell and drug-resistant cell lines. cell line (NB4, HL60, K562,NB4-R1, NB4-R2,HL60/DOX,K562/DOX,293 T) up-regulated resistant Bak1 Bak1 NA validated 484 Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 2011 21936961 miRBase MI0000069 miR-15a miRNA DB01234 (APRD00674) Dexamethasone multiple myeloma RT-PCR The role of miR--15a/-16 inmyeloma cells was detected using RT-PCR, transfected, etc. cell line ( U266 and NCI-H929 ) down-regulated resistant NA NA NA validated 485 Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 2011 21936961 miRBase MI0000070/MI0000115 miR-16 miRNA DB01234 (APRD00674) Dexamethasone multiple myeloma RT-PCR The role of miR--15a/-16 inmyeloma cells was detected using RT-PCR, transfected, etc. cell line ( U266 and NCI-H929 ) down-regulated resistant NA NA NA validated 486 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase NA miRplus-F1064 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) up-regulated resistant NA NA NA predicted 487 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0005525 miR-300 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) up-regulated resistant NA NA NA predicted 488 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0003137 miR-193b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) up-regulated resistant NA NA NA predicted 489 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0003657 miR-642 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) up-regulated resistant NA NA NA predicted 490 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0006359 miR-1299 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) up-regulated resistant NA NA NA predicted 491 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0003639 miR-625 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant UBE2NL,UBE2N,FBXW7,SIAH1.etc UBE2NL,UBE2N,FBXW7,SIAH1.etc Ubiquitin mediated proteolysis,p53 signaling pathway.etc predicted 492 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0001519 miR-20b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant NA NA NA predicted 493 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase NA miRPlus-F1147 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant NA NA NA predicted 494 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MI0000064 let-7c miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant NA NA NA predicted 495 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase NA miRPlus-F1231 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant NA NA NA predicted 496 MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011 21939554 miRBase MIMAT0003389 miR-542-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The present study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin. Differential expression patterns of miRNA between cis-platin sensitive and cis-platin resistant cell lines were analyzed using novel LNA technology. cell line (A2780,A2780/CP70) down-regulated resistant NA NA NA predicted 497 MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011 21948564 miRBase MI0001729 miR-451 miRNA DB00762 (APRD00579) Irinotecan colorectal cancer qRT-PCR The role of miR-451 in colorectal cancer cells was detected using cell transfections,cell cytotoxicity assay, qRT-PCR,Immunohistochemistry, western blot, etc. cell line up-regulated sensitive COX-2 COX-2 Wnt pathway validated 498 Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011 21953503 miRBase MI0000447/MI0000727 miR-128 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast tumor qRT-PCR Lentivirus-mediated miR-128 transduction was done in BT-ICs, enriched by mammosphere cultures or CD44(+)CD24(-) fluorescence-activated cell sorting. Apoptosis and DNA damage were determined upon treatment with doxorubicin. Expression of miR-128 in breast cancer tissues was examined by in situ hybridization and correlated with breast tumor response to neoadjuvant chemotherapy and patient survival. cell line (SK-3rd, MCF-7, SKBR3) down-regulated resistant Bmi-1 and ABCC5 Bmi-1 and ABCC5 NA validated 499 miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011 21982769 miRBase MI0000477 miR-146a miRNA NA Interferon-alpha hepatocellular carcinoma qRT-PCR miRNA microarray analysis using IFN-alpha-resistant clones of PLC/PRF/5 (PLC-Rs) and their parental cells (PLC-P) was conducted. Changes in the anti-cancer effects of IFN-alpha were studied after gain-of-function and loss-of-function of the candidate miRNA. cell line ( PLC-P,PLC-Rs ) up-regulated resistant SMAD4 SMAD4 Wnt/Beta signaling pathway validated 500 MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett 2011 22036718 miRBase MI0003193 miR-506 miRNA DB12385 10-hydroxycamptothecin colon cancer RT-PCR We analyzed miRNA expression profiles of SW1116 and its hydroxycamptothecin-resistant variant SW1116/HCPT using a miRNA microarray platform. The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The analysis of miRNA predicted targets was carried out using the algorithm TargetScanS . cell line (SW1116/HCPT, SW1116) up-regulated resistant PPARalpha NA NA validated 501 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003154 miR-518f* miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 502 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003149 miR-520a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated sensitive NA NA NA predicted 503 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MIMAT0002856 miR-520d* miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 504 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MIMAT0002828 miR-519e* miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 505 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0000764 miR-363* miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 506 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003161 miR-517* miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 507 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003154 miR-518f* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 508 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003149 miR-520a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated sensitive NA NA NA predicted 509 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MIMAT0002856 miR-520d* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 510 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MIMAT0002828 miR-519e* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 511 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0000764 miR-363* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 512 miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011 22112324 miRBase MI0003161 miR-517* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Biopsy samples were collected prior to chemotherapy from 90 gastric cancer patients treated with CF and from 34 healthy volunteers. At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders. miRNA expression was determined using a custom-designed Agilent microarray. In order to identify a miRNA signature for chemotherapy resistance, we correlated miRNA expression levels with the time to progression (TTP) of disease after CF therapy. tissue up-regulated resistant NA NA NA predicted 513 Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 2011 22132977 miRBase MI0000803 miR-330 miRNA DB00441 (APRD00201) Gemcitabine colon cancer qRT-PCR The role of miR-330 in cancer cells was detected using qRT-PCR, methylation-specific PCR,RNA isolation, etc. cell line down-regulated sensitive dCK DCK NA validated 514 Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 2011 22132977 miRBase MI0000803 miR-330 miRNA DB00441 (APRD00201) Gemcitabine lung cancer qRT-PCR The role of miR-330 in cancer cells was detected using qRT-PCR, methylation-specific PCR,RNA isolation, etc. cell line down-regulated sensitive dCK DCK NA validated 515 Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011 22156446 miRBase MI0000298 miR-221 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR The expression levels of circulating miR-221 in the plasma of 93 breast cancer patients who previously received NAC and in 32 healthy individuals were assessed. The correlations between miR-221 and clinicopathological features and chemosensitivity were also analysed. cell line (MCF-7,MCF-7/ADR) up-regulated resistant NA NA NA validated 516 A miR-200b/200c/429-binding site polymorphism in the 3 untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011 22194984 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin endometrial cancer NA Using computational programs, we predicted that the 3 untranslated region (UTR) of AP-2alpha gene contains a potential miRNA response element (MRE) for the miR-200b/200c/429 family, and the single nucleotide polymorphism (SNP) site rs1045385 (A or C allele) resided within the predicted MRE. Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3 UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. cell line (HEK293,HEC-1A) up-regulated resistant AP-2alpha AP-2alpha NA validated 517 A miR-200b/200c/429-binding site polymorphism in the 3 untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011 22194984 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin endometrial cancer NA Using computational programs, we predicted that the 3 untranslated region (UTR) of AP-2alpha gene contains a potential miRNA response element (MRE) for the miR-200b/200c/429 family, and the single nucleotide polymorphism (SNP) site rs1045385 (A or C allele) resided within the predicted MRE. Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3 UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. cell line (HEK293,HEC-1A) up-regulated resistant AP-2alpha AP-2alpha NA validated 518 A miR-200b/200c/429-binding site polymorphism in the 3 untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011 22194984 miRBase MI0001641 miR-429 miRNA DB00515 (APRD00359) Cisplatin endometrial cancer NA Using computational programs, we predicted that the 3 untranslated region (UTR) of AP-2alpha gene contains a potential miRNA response element (MRE) for the miR-200b/200c/429 family, and the single nucleotide polymorphism (SNP) site rs1045385 (A or C allele) resided within the predicted MRE. Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3 UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. cell line (HEK293,HEC-1A) up-regulated resistant AP-2alpha AP-2alpha NA validated 519 Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2011 22207897 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time reverse transcription PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (MCF-7, ZR-75, MDA-MB-231) down-regulated sensitive SOCS3 SOCS3 NA validated 520 Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J Int Med Res 2011 22289545 miRBase MI0000077 miR-21 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression of microRNA-21 (miR-21) was determined in 42 patients with colorectal cancer (CRC) using real-time reverse transcription-polymerase chain reaction. The level of miR-21 in CRC tumour tissue was compared with paired normal adjacent tissue (NAT) and the relationships of miR-21 levels to clinicopathological characteristics and pathological tumour response to neoadjuvant chemotherapy were investigated. tissue and cell line up-regulated resistant NA NA NA predicted 521 Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J Int Med Res 2011 22289545 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression of microRNA-21 (miR-21) was determined in 42 patients with colorectal cancer (CRC) using real-time reverse transcription-polymerase chain reaction. The level of miR-21 in CRC tumour tissue was compared with paired normal adjacent tissue (NAT) and the relationships of miR-21 levels to clinicopathological characteristics and pathological tumour response to neoadjuvant chemotherapy were investigated. tissue and cell line up-regulated resistant NA NA NA predicted 522 MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. Pharmazie 2011 22312705 miRBase MI0000442 miR-122 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatoblastoma Real-time RT-PCR MiR-122 and negative miRNA expression vectors were constructed and stably transfected into BEL-7402/5-FU cells. Real-time RT-PCR was used to detect the level of miR-122, Bcl-XL, Bcl-2 and P53 mRNA. Western Blotting was used to detect Bcl-2, Bcl-XL and P53 protein expression. Drug sensitivity of the cells to 5-fluorouracil (5-FU) was analyzed with MTT and flow cytometry. cell line (BEL-7402/5-FU) up-regulated sensitive Bcl-2 Bcl-2 p53 signaling pathway validated 523 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012 21258880 miRBase MI0003138 miR-497 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 524 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012 21258880 miRBase MI0003138 miR-497 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 525 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012 21258880 miRBase MI0003138 miR-497 miRNA DB00541 (APRD00495) Vincristine lung cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 526 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012 21258880 miRBase MI0003138 miR-497 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/VCR,A549,A549/CDDP) up-regulated sensitive BCL2 BCL2 NA validated 527 miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol. 2012 21267675 miRBase MI0000463/MI0000464 miR-153 miRNA DB01169 (APRD00171) Arsenic trioxide leukemia qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( K562 ) up-regulated sensitive NA NA NA validated 528 miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012 21399894 miRBase MI0000268 miR-34a miRNA DB01248 (APRD00932) Docetaxel breast cancer qPCR This study investigated the role of differential miRNA expression in two in vitro breast cancer cell line models (MCF-7, MDA-MB-231) of acquired docetaxel resistance. MiRNA microarray analysis identified 299 and 226 miRNAs altered in MCF-7 and MDA-MB-231 docetaxel-resistant cells, respectively. Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. Computational target prediction revealed eight candidate genes targeted by these miRNAs. Quantitative PCR and western analysis confirmed decreased expression of two genes, BCL-2 and CCND1, in docetaxel-resistant cells, which are both targeted by miR-34a. Modulation of miR-34a expression was correlated with BCL-2 and cyclin D1 protein expression changes and a direct interaction of miR-34a with BCL-2 was shown by luciferase assay. Inhibition of miR-34a enhanced response to docetaxel in MCF-7 docetaxel-resistant cells, whereas overexpression of miR-34a conferred resistance in MCF-7 docetaxel-sensitive cells cell line (MCF-7, MDA-MB-231) down-regulated sensitive BCL-2 BCL-2,CCND1 NA validated 529 Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012 21618519 miRBase NA Let-7 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR The role of let-7 in ovarian cancer cells was detected using Western blots,plasmids, cloning and retroviral transduction,quantitative real-time PCR, cell cycle analysis,cytotoxicity assays,MDR1 activity assays, immunohistochemistry, etc. cell line (NCI/ADR-RES, OVCAR8, T47D, IGROV1, LOX-IMVI ) down-regulated resistant IMP-1 MDR1 NA validated 530 Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012 21618519 miRBase NA Let-7 miRNA DB00570 (APRD00708) Vinblastine ovarian cancer qRT-PCR The role of let-7 in ovarian cancer cells was detected using Western blots,plasmids, cloning and retroviral transduction,quantitative real-time PCR, cell cycle analysis,cytotoxicity assays,MDR1 activity assays, immunohistochemistry, etc. cell line (NCI/ADR-RES, OVCAR8, T47D, IGROV1, LOX-IMVI ) down-regulated resistant IMP-1 MDR1 NA validated 531 MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012 21702042 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR,qRT-PCR The role of miR-34a in bladder cancer cells was detected using RT-PCR, qRT-PCR, transfection,immunoblot analysis, methylation specific PCR, clonogenic assay, senescence assay,flow cytometry, etc. cell line(T24,TCCSuP and 5637) up-regulated sensitive Cdk6 and SIRT-1 Cdk6 NA validated 532 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012 21706050 miRBase MI0000448 miR-130a miRNA NA TRAIL therapy lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by qRT- PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (A549, A459, H1299 ) up-regulated sensitive MET MET PI3K/AKT pathway validated 533 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012 21725369 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin tongue cancer qRT-PCR MicroRNA microarray analyses were performed in CAL27-res cells and CAL27 cells. The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Tumor xenografts was used to identify between miR-200b or miR-15b expression and drug resistant . cell line (CAL27, SCC25,CAL27-res, SCC25-res) down-regulated resistant BMI1 BMI1 transforming growth factor-Beta,Sonic hedgehog-Gli-Snail pathway validated 534 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012 21725369 miRBase MI0000438 miR-15b miRNA DB00515 (APRD00359) Cisplatin tongue cancer qRT-PCR MicroRNA microarray analyses were performed in CAL27-res cells and CAL27 cells. The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Tumor xenografts was used to identify between miR-200b or miR-15b expression and drug resistant . cell line (CAL27, SCC25,CAL27-res, SCC25-res) down-regulated resistant BMI1 BMI1 transforming growth factor-Beta,Sonic hedgehog-Gli-Snail pathway validated 535 MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 2012 21879257 miRBase MI0000470 miR-125b-2 miRNA DB00853 (APRD00557) Temozolomide glioblastoma real-time qRT-PCR The expression levels of miRNA were determined by real-time quantification RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . tissue and cell line up-regulated resistant NA NA the mitochondrial pathway of apoptosis validated 536 miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep 2012 21947305 miRBase MI0000489 miR-195 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-PCR The role of miR-195 in human hepatocellular carcinoma cells was detected using microRNA microarray and hybridization analysis,transfection,Real-time quantitative RT-PCR,miR-195 target prediction,construction of 3-UTR reporter plasmids and luciferase assays,flow cytometry analysis, cytotoxicity analysis,etc. cell line (BEL-7402,BEL-7402/5-FU) up-regulated sensitive Bcl-w Bcl-w NA validated 537 miR-34a predicts survival of Ewings sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012 21960059 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ewing sarcoma qRT-PCR,Northern blot In this study, we analysed the miRNAs discriminating Ewings sarcoma (EWS) patients with different clinical outcomes in order to identify new indicators of prognosis. miRNA expression was investigated in 49 primary EWSs by using the Agilent human miRNA microarray v.2 and/or qRT-PCR. Statistical power of the samples studied for miRNA expression was verified, indicating adequate sample size. Functional analysis of miR-34a in EWS cell lines indicated that when miR-34a expression was enforced, cells were less proliferative, less malignant, and sensitized to doxorubicin and vincristine. Expression of miR-34a could be increased in p53wt cells by treatment with nutlin-3a. cell line up-regulated sensitive NA NA NA validated 538 miR-34a predicts survival of Ewings sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012 21960059 miRBase MI0000268 miR-34a miRNA DB00541 (APRD00495) Vincristine ewing sarcoma qRT-PCR,Northern blot In this study, we analysed the miRNAs discriminating Ewings sarcoma (EWS) patients with different clinical outcomes in order to identify new indicators of prognosis. miRNA expression was investigated in 49 primary EWSs by using the Agilent human miRNA microarray v.2 and/or qRT-PCR. Statistical power of the samples studied for miRNA expression was verified, indicating adequate sample size. Functional analysis of miR-34a in EWS cell lines indicated that when miR-34a expression was enforced, cells were less proliferative, less malignant, and sensitized to doxorubicin and vincristine. Expression of miR-34a could be increased in p53wt cells by treatment with nutlin-3a. cell line up-regulated sensitive NA NA NA validated 539 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000342 miR-200b miRNA DB00541 (APRD00495) Vincristine gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 540 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000650 miR-200c miRNA DB00541 (APRD00495) Vincristine gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 541 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0001641 miR-429 miRNA DB00541 (APRD00495) Vincristine gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 542 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 543 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 544 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0001641 miR-429 miRNA DB00515 (APRD00359) Cisplatin gastric adenocarcinoma qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 545 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000342 miR-200b miRNA DB00541 (APRD00495) Vincristine lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 546 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000650 miR-200c miRNA DB00541 (APRD00495) Vincristine lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 547 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0001641 miR-429 miRNA DB00541 (APRD00495) Vincristine lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 548 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 549 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 550 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012 21993663 miRBase MI0001641 miR-429 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells. cell line (SGC7901,SGC7901/VCR, A549,A549/CDDP) down-regulated resistant BCL2 and XIAP BCL2 and XIAP Fas/FasL pathway validated 551 Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012 22005523 miRBase MI0000748 miR-130b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression of miR-130b was assessed in ovarian tissues and cell lines by qRT-PCR. In vitro, miR-130b level was manipulated by transfection with mimics or inhibitors. Methylation level of miR-130b was evaluated by quantitative methylation-specific PCR (qMSP). CSF-1 expression in ovarian tissues and cells was determined by qRT-PCR, immunohistochemistry and ELISA, respectively. CSF-1 regulated by miR-130b was detected using Dual Luciferase Reporter system. tissue and cell line up-regulated sensitive CSF-1 CSF-1 NA validated 552 Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012 22005523 miRBase MI0000748 miR-130b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR The expression of miR-130b was assessed in ovarian tissues and cell lines by qRT-PCR. In vitro, miR-130b level was manipulated by transfection with mimics or inhibitors. Methylation level of miR-130b was evaluated by quantitative methylation-specific PCR (qMSP). CSF-1 expression in ovarian tissues and cells was determined by qRT-PCR, immunohistochemistry and ELISA, respectively. CSF-1 regulated by miR-130b was detected using Dual Luciferase Reporter system. tissue and cell line up-regulated sensitive CSF-1 CSF-1 NA validated 553 The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol 2012 22015043 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin esophagus adenocarcinoma qRT-PCR he expression of miR-200c in human endometrial tissues was detected by quantitative RT-PCR. The transfection with anti-miRNA (anti-miR) or the premature form of miRNA (pre-miR) was performed to regulate the level of expression of miRNA-200c in endometrial carcinoma cells, HEC-1A and Ishikawa. To identify the target genes for miR-200c, we performed mRNA microarray after pre-miR-200c transfection in HEC-1A cells. cell line (AN3CA, HEC-1A, Ishikawa, KLE,2774,293) up-regulated resistant BRD7 cyclin D1 and c-myc Beta-catenin signaling pathway validated 554 Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012 22101791 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7,MCF-7/ADR) down-regulated resistant MDR1 MDR1 EMT and p53 apoptotic pathway validated 555 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012 22116552 miRBase NA miR-17-92 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin mantle cell lymphoma Real-time RT-PCR Gene expression profiling was performed on 92 patients with cyclin D1-positive MCL.The expression levels of miRNA were determined by real time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A xenograft MCL mouse model was used to identify the relationship between miR-17-92 cluster and drug resistant . cell line ( Z138c, Granta-519, Jeko-1,HEK293T and NIH3T3) up-regulated resistant PHLPP2 PHLPP2 PI3K/AKT pathway validated 556 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012 22116552 miRBase NA miR-17-92 miRNA DB00773 (APRD00239) Etoposide mantle cell lymphoma Real-time RT-PCR Gene expression profiling was performed on 92 patients with cyclin D1-positive MCL.The expression levels of miRNA were determined by real time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A xenograft MCL mouse model was used to identify the relationship between miR-17-92 cluster and drug resistant . cell line ( Z138c, Granta-519, Jeko-1,HEK293T and NIH3T3) up-regulated resistant PHLPP2 PHLPP2 PI3K/AKT pathway validated 557 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012 22116552 miRBase NA miR-17-92 miRNA DB01030 (APRD00687) Topotecan mantle cell lymphoma Real-time RT-PCR Gene expression profiling was performed on 92 patients with cyclin D1-positive MCL.The expression levels of miRNA were determined by real time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A xenograft MCL mouse model was used to identify the relationship between miR-17-92 cluster and drug resistant . cell line ( Z138c, Granta-519, Jeko-1,HEK293T and NIH3T3) up-regulated resistant PHLPP2 PHLPP2 PI3K/AKT pathway validated 558 DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012 22117060 miRBase MIMAT0000459 miR-193a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of miR-193a-3p in hepatocellular carcinoma cells was detected using luciferase reporter assay,qRT-PCR,and in vivo study,etc. cell line (QGY-7703,SMMC-7721,BEL-7402,HepG2,Hep3B,PLC,YY-8103, FOCUS ) up-regulated sensitive SRSF2 and E2F1 SRSF2 and E2F1 NA validated 559 MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012 22120675 miRBase MI0000102 miR-100 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma Real-time qRT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Xenograft transplantation was used to identify the relationship between miR-100 and drug resistant. cell line (SPC-A1,SPC-A1/DTX) up-regulated sensitive Plk1 Plk1 NA validated 560 MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012 22139708 miRBase MI0000342 miR-200b miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma Real-Time qRT-PCR The expression levels of miRNA were determined by Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Analysis of Apoptosis and Cell Cycle. Xenograft Transplantation was uesd to idenntify the relationship between miR-200b and docetaxel resistant. cell line (SPC-A1, A549,SPC-A1/DTX ) up-regulated sensitive E2F3 E2F3 NA validated 561 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 2012 22157765 miRBase MI0000088 miR-30a miRNA DB00515 (APRD00359) Cisplatin cancer Real-time qRT-PCR First, the autophagy activity in cancer cells increased after cis-dichloro-diamine platinum (cis-DDP) or Taxol treatment, as indicated by the enhanced expression of beclin 1, a key regulator of autophagy, and increased number of LC3-positive autophagosomes. Second, miRNA screening using a TaqMan probe-based quantitative RT-PCR assay identified that miR-30a, a miRNA that targets beclin 1, was significantly reduced in tumor cells by cis-DDP treatment. Forced expression of miR-30a significantly reduced beclin 1 and the autophagy activity of tumor cells induced by cis-DDP. Third, the blockade of tumor cell autophagy activity by miR-30a expression or 3-methyladenine significantly increased tumor cell apoptosis induced by cis-DDP treatment. Finally, an in vivo tumor implantation mouse model clearly showed that elevation of miR-30a in implanted tumor cells by administration of the recombinant lentivirus expressing miR-30a strongly enhanced cis-DDP-induced apoptosis of tumor cells. cell line (HeLa, MCF-7, HepG2,HepS,SGC-7091,SGC-7092,) up-regulated sensitive beclin 1 NA NA validated 562 MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012 22193543 miRBase MI0000727 miR-128-2 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (H1299, H1299 clone 41, H1299 clone 23 and H1299 clone pIND ) up-regulated resistant E2F5 E2F5 PI3K/Akt pathway validated 563 MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012 22193543 miRBase MI0000727 miR-128-2 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (H1299, H1299 clone 41, H1299 clone 23 and H1299 clone pIND ) up-regulated resistant E2F5 E2F5 PI3K/Akt pathway validated 564 MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012 22193543 miRBase MI0000727 miR-128-2 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil lung cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (H1299, H1299 clone 41, H1299 clone 23 and H1299 clone pIND ) up-regulated resistant E2F5 E2F5 PI3K/Akt pathway validated 565 miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol 2012 22209977 miRBase MI0000289/MI0000269 miR-181a miRNA DB00987 (APRD00499) Ara-C leukemia RT-PCR miR-181a expression was measured by real-time PCR. Cell viability was detected by MTT assay. Protein expressions were measured by western blotting. Caspase activity was examined by fluorescence assay. cell line (HL-60,HL-60/Ara-C,HEK293T) up-regulated sensitive Bcl-2 NA NA validated 566 MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012 22237007 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR Microarray was employed to compare the expression of miRNAs between A549 and A549/CDDP cells. The effect of a differently expressed miRNA (miR-21) was examined on the sensitivity of cells to platinum. MiR-21 expression in NSCLC tumor tissues and matched plasma sample was also analyzed by Real-time PCR. cell line (A549, A549/CDDP ) up-regulated resistant PTEN, Bcl-2 PTEN NA validated 567 miR-21 inhibitor sensitizes human OSCC cells to cisplatin. Mol Biol Rep 2012 22249446 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR RT-PCR assay was performed to detect the expression of miR-21 in 10 pairs of OSCC and noncancerous tissue samples. Then As-miR-21 oligonucleotides were used to down the miR-21 expression. Finally, the effects of miR-21 downregulation the sensitivity of OSCC cells (CA-27) to cisplatin in vitro were also detected. tissue and cell line (CA-27) down-regulated sensitive NA NA NA validated 568 miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai) 2012 22285729 miRBase MI0000289/MI0000269 miR-181a miRNA DB00694 (APRD00521) Daunorubicin leukemia RT-PCR MicroRNA microarray and stem-loop reverse transcription-polymerase chain reaction were used to detect the expression of miR-181a. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay was performed to quantify the effect of miR-181a on K562 cells growth and viability. Apoptotic cells were quantitatively detected using Annexin V/FITC and PI apoptosis detection kit. BCL-2 protein expression was measured by western blot. Luciferase reporter vector with the putative BCL-2 3 untranslated region was constructed to explore whether BCL-2 was a direct target gene of miR-181a. BCL-2 siRNA was transfected into the cell to explore the relationship between BCL-2 and DNR resistance. cell line (K562,K562/A02) up-regulated sensitive BCL-2 Bcl-2 NA validated 569 Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 2012 22287315 miRBase MI0000461 miR-145 miRNA DB00305 (APRD00284) Mitomycin cervical cancer RT-PCR,Northern blot The role of miR-145 in cervical cancer cells was detected using real-time RT-PCR, Northern blot, western blot, flow cytometry, scratch wound assay and invasion assay, etc. cell line ( C33A ) up-regulated sensitive NA NA p53 signaling pathway validated 570 MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012 22322955 miRBase MI0000267 miR-10b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Quantitative RT-PCR was used to evaluate the clinicopathologic significance of miR-10b expression in 88 colorectal cancer cases. We also investigated the chemotherapeutic sensitivity to 5-FU in miR-10b-overexpressing colorectal cancer cells. To explore the mechanism of chemoresistance in miR-10b transfected cells, we examined whether miR-10b inhibits the pro-apoptotic BH3-only Bcl-2 family member BIM(BCL2L11), a key mediator of chemotherapy-induced cell death. cell line (HCT-116) up-regulated resistant BIM NA miR-10b-BIM pathway validated 571 Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012 22370716 miRBase MI0000286 miR-210 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR Quantitative reverse transcriptase-polymerase chain reaction was used to analyze plasma samples, including samples from patients with breast cancer who were enrolled in a clinical trial of neoadjuvant trastuzumab-based chemotherapy. Expression levels of miR-210, miR-21, miR-29a, and miR-126 were analyzed according to the type of response (pathologic complete response [n = 18] vs residual disease [n = 11]). MicroRNA expression levels also were compared in trastuzumab-sensitive and trastuzumab-resistant breast cancer cells derived from BT474 cells and in an independent set of preoperative plasma samples (n = 39) and postoperative plasma samples (n = 30) from 43 breast cancer patients who did not receive any treatment. tissue and cell line ( BT474,BTR65 ) up-regulated resistant NA NA NA validated 572 Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol 2012 22382630 miRBase MI0000074/MI0000075 miR-19b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR Two types of 5-FU-resistant colon cancer cells were derived from the DLD-1 and KM12C cell lines. The expressions of microRNAs were profiled with a microarray containing 723 microRNAs and validated by quantitative real-time polymerase chain reaction (qRT-PCR). To survey the downstream mediators of microRNA, we used a microRNA:mRNA immunoprecipitation (RIP)-Chip and pathway analysis tool to identify potential direct targets of microRNA. cell line (DLD-1, KM12C,DLD-1/R, KM12C/R) up-regulated resistant SFPQ and MYBL2 SFPQ and MYBL2 NA validated 573 Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012 22395361 miRBase MI0000088 miR-30a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (K562) up-regulated sensitive Beclin 1 and ATG5 ATG5 mitochondria-dependent intrinsic apoptotic pathway validated 574 MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 2012 22453125 miRBase MI0000804 miR-328 miRNA DB12385 10-hydroxycamptothecin colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MThe CCK-8 assay was used to monitor the growth of the cells. Cell migration was detected by invasion assay. cell line (SW1116, LoVo, HCT116, SW480, SW620,SW1116/HCPT) up-regulated sensitive ABCG2 and MMP16 ABCG2 and MMP16 NA validated 575 Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer Sichuan Da Xue Xue Bao Yi Xue Ban 2012 22455133 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR Cisplatin resistant ovarian cancer cell lines were established by stepwise selection with gradual increase of cisplatin. MTT assay was applied to indentify the cisplatin resistant cell lines and determine their resistance index. The expression of miR-130a was measured by SYBR green real-time PCR. cell line (A2780,SKOV3,A2780/CIS1, A2780/CIS2,SKOV3/CIS) up-regulated resistant NA GAX and HOXA5 NA validated 576 Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012 22465665 miRBase MI0000095 miR-93 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR MicroRNA array was used to the different express between OVCAR3/CDDP and SKOV3/CDDP. The target genes of miRNA were predicted by two computer-aided algorithms.The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( OVCAR3, SKOV3 ) up-regulated resistant PTEN PTEN PTEN/AKT signaling pathway validated 577 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 2012 22498306 miRBase MI0000242/MI0000281 miR-199a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined byquantitative real-time PCR and Northern blotting . those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by transwell migration . IF staining analysis for relative protein expression. cell line (CD44+/CD117+) up-regulated sensitive CD44 CD44 NA validated 578 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 2012 22498306 miRBase MI0000242/MI0000281 miR-199a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression levels of miRNA were determined byquantitative real-time PCR and Northern blotting . those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by transwell migration . IF staining analysis for relative protein expression. cell line (CD44+/CD117+) up-regulated sensitive CD44 CD44 NA validated 579 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 2012 22498306 miRBase MI0000242/MI0000281 miR-199a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin ovarian cancer qRT-PCR The expression levels of miRNA were determined byquantitative real-time PCR and Northern blotting . those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by transwell migration . IF staining analysis for relative protein expression. cell line (CD44+/CD117+) up-regulated sensitive CD44 CD44 NA validated 580 MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev 2012 22502680 miRBase MI0000290 miR-214 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma real-time qRT-PCR The expression levels of miRNA were determined by Real-Time Quantitative Reverse Transcription PCR and Northern Blot . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS Assays was used to detect cell proliferation. cell line (HCC827, 293T,HCC827/GR) down-regulated sensitive PTEN PTEN PTEN/AKT signaling pathway validated 581 miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 2012 22510476 miRBase MI0000471 miR-126 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Lung cancer xenograft was used to identify the role of miR-126. cell line (A549) up-regulated sensitive VEGFA VEGFA PI3K/AKT signaling pathway validated 582 miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 2012 22510476 miRBase MI0000471 miR-126 miRNA DB00541 (APRD00495) Vincristine lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Lung cancer xenograft was used to identify the role of miR-126. cell line (A549) up-regulated sensitive VEGFA VEGFA PI3K/AKT signaling pathway validated 583 Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012 22521303 miRBase MI0005523 miR-298 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer Northern blot An miRNA array was used to detected the different express between doxorubicin-sensitive and -resistant breast cancer cells .The expression levels of miRNA were determined by Northern Blot and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MDA-MB-231, MCF-7 ) down-regulated resistant P-gp NA NA validated 584 Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012 22523546 miRBase MI0000446/MI0000470 miR-125b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer RT-PCR Circulating miRNAs in blood serum prior to treatment were determined by quantitative Real-Time PCR in 56 breast cancer patients with invasive ductal carcinoma and pre-operative neoadjuvant chemotherapy. Proliferating cell nuclear antigen (PCNA) immunostaining and TUNEL were performed in surgical samples to determine the effects of chemotherapy on cancer cell proliferation and apoptosis, respectively. cell line (MCF-7, T47D, BT20, MDA-MB-231) up-regulated resistant E2F3 E2F3 p53 signaling pathway validated 585 Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012 22523546 miRBase MI0000446/MI0000470 miR-125b miRNA DB00445 (APRD00361) Epirubicin breast cancer RT-PCR Circulating miRNAs in blood serum prior to treatment were determined by quantitative Real-Time PCR in 56 breast cancer patients with invasive ductal carcinoma and pre-operative neoadjuvant chemotherapy. Proliferating cell nuclear antigen (PCNA) immunostaining and TUNEL were performed in surgical samples to determine the effects of chemotherapy on cancer cell proliferation and apoptosis, respectively. cell line (MCF-7, T47D, BT20, MDA-MB-231) up-regulated resistant E2F3 E2F3 p53 signaling pathway validated 586 Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012 22523546 miRBase MI0000446/MI0000470 miR-125b miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer RT-PCR Circulating miRNAs in blood serum prior to treatment were determined by quantitative Real-Time PCR in 56 breast cancer patients with invasive ductal carcinoma and pre-operative neoadjuvant chemotherapy. Proliferating cell nuclear antigen (PCNA) immunostaining and TUNEL were performed in surgical samples to determine the effects of chemotherapy on cancer cell proliferation and apoptosis, respectively. cell line (MCF-7, T47D, BT20, MDA-MB-231) up-regulated resistant E2F3 E2F3 p53 signaling pathway validated 587 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012 22610076 miRBase MI0000289/MI0000269 miR-181a miRNA DB01073 (APRD00594) Fludarabine chronic lymphocytic leukemia Real-time qRT-PCR We performed miRNA expression profile in six Chinese patients with chronic lymphocytic leukemia (CLL), and in peripheral B cells from pooled 30 healthy donors, using a platform containing 866 human miRNAs. The expression levels of miRNA were determined by Real-time quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line ( CLL B) up-regulated sensitive BCL-2,MCL-1,XIAP-3'UTR BCL-2,MCL-1,XIAP-3'UTR NA validated 588 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012 22610076 miRBase MI0000270/MI0000683 miR-181b miRNA DB01073 (APRD00594) Fludarabine chronic lymphocytic leukemia Real-time qRT-PCR We performed miRNA expression profile in six Chinese patients with chronic lymphocytic leukemia (CLL), and in peripheral B cells from pooled 30 healthy donors, using a platform containing 866 human miRNAs. The expression levels of miRNA were determined by Real-time quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line ( CLL B) up-regulated sensitive BCL-2,MCL-1,XIAP-3'UTR BCL-2,MCL-1,XIAP-3'UTR NA validated 589 Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012 22614869 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer Real-time qRT-PCR The aim of this study was to investigate microRNA expression profiles in cisplatin-resistant ovarian cancer cells and the role of miR-130a in regulating drug resistance. Analysis of differentially expressed miRNAs between SKOV3 and SKOV3/CIS cells was assessed by miRNA microarrays. Target prediction of miRNAs was determined with the help of PicTar or TargetScan. Among these miRNAs, the expression of miR-130a was verified using qRT-PCR. The expression of MDR1 mRNA and P-glycoprotein (P-gp) after cellular transfection was examined using qRT-PCR and western blotting, respectively. Cisplatin sensitivity was detected by the MTT assay. cell line (SKOV3,SKOV3/CIS) up-regulated resistant PTEN PTEN PI3K/Akt/PTEN/mTOR validated 590 microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 2012 22617440 miRBase MI0000088 miR-30a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia NA The role of miR-30a in chronic myelogenous leukemiar cells was detected using western blot,etc. cell line (K562) up-regulated sensitive NA BECN1 and ATG5 intrinsic apoptotic pathway validated 591 miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 2012 22676135 miRBase MI0005775 miR-297 miRNA DB00526 (APRD00186) Oxaliplatin colorectal carcinoma RT-PCR,qRT-PCR We analysed miRNA expression levels between MDR colorectal carcinoma cell line HCT116/L-OHP cells and their parent cell line HCT116 using a miRNA microarray.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow cytometric analysis of DOX fluorescence and apoptosis.The xenografts was used to identify the the role of miR-297 . cell line ( HCT-8,HCT-116,HCT-8/VCR,HCT116/L-OHP) up-regulated sensitive MRP-2 MRP-2 NA validated 592 miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 2012 22676135 miRBase MI0005775 miR-297 miRNA DB00541 (APRD00495) Vincristine colorectal carcinoma RT-PCR, qRT-PCR We analysed miRNA expression levels between MDR colorectal carcinoma cell line HCT116/L-OHP cells and their parent cell line HCT116 using a miRNA microarray.The expression levels of miRNA were determined by RT-PCR and quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow cytometric analysis of DOX fluorescence and apoptosis.The xenografts was used to identify the the role of miR-297 . cell line ( HCT-8,HCT-116,HCT-8/VCR,HCT116/L-OHP) up-regulated sensitive MRP-2 MRP-2 NA validated 593 MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012 22677042 miRBase MI0000299 miR-222 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow cytometric analysis of apoptosis.MiRNA microarray analysis was used to identify the expression in different cell lines. cell line (HCT-8, HCT-116,HCT-8/VCR, HCT-116/L-OHP) up-regulated resistant ADAM-17 ADAM-17 NA validated 594 MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012 22677042 miRBase MI0000299 miR-222 miRNA DB00541 (APRD00495) Vincristine colorectal carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow cytometric analysis of apoptosis.MiRNA microarray analysis was used to identify the expression in different cell lines. cell line (HCT-8, HCT-116,HCT-8/VCR, HCT-116/L-OHP) up-regulated resistant ADAM-17 ADAM-17 NA validated 595 MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012 22677042 miRBase MI0000299 miR-222 miRNA DB00526 (APRD00186) Oxaliplatin colorectal carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow cytometric analysis of apoptosis.MiRNA microarray analysis was used to identify the expression in different cell lines. cell line (HCT-8, HCT-116,HCT-8/VCR, HCT-116/L-OHP) up-regulated resistant ADAM-17 ADAM-17 NA validated 596 Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012 22713463 miRBase MIMAT0000231 miR-199a-5p miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells. cell line ( (Huh7, HepG2,HEK 293) down-regulated resistant ATG7 ATG7 NA validated 597 miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012 22723956 miRBase MIMAT0000754 miR-337-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The role of miR-337-3p in non-small cell lung cancers cells was detected using cell viability assays,flow cytometry, Quantitative RT-PCR (qRT-PCR),western blots,miRNA target prediction,Luciferase reporter assays, mRNA expression profiling,Reverse-Phase Protein Array (RPPA), etc. cell line up-regulated sensitive STAT3 and RAP1A STAT3 and RAP1A NA validated 598 miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012 22723956 miRBase MIMAT0000754 miR-337-3p miRNA NA Taxane lung non-small cell carcinoma qRT-PCR The role of miR-337-3p in non-small cell lung cancers cells was detected using cell viability assays,flow cytometry, Quantitative RT-PCR (qRT-PCR),western blots,miRNA target prediction,Luciferase reporter assays, mRNA expression profiling,Reverse-Phase Protein Array (RPPA), etc. cell line up-regulated sensitive STAT3 and RAP1A STAT3 and RAP1A NA validated 599 miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 2012 22749944 miRBase MIMAT0004777 miR-513a-3p miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma Real-time RT-PCR The expression levels of miRNA were determined by Reverse transcription and real-time PCR analysis (real-time RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line (A549,A549/CDDP,SPC-A-1) up-regulated sensitive GSTP1 GSTP1 NA validated 600 Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther 2012 22752226 miRBase MI0003137 miR-193b* miRNA DB00958 (APRD00466) Carboplatin ovarian cancer qPCR In the study, 60 unrelated HapMap CEU I/II samples were used for our discovery-phase study using high-throughput genome-wide miRNA and gene expression profiling. Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B). We further replicated the relationship between the expression of miR-193b*, CRIM1, IFIT2, KCNMA1, and GRAMD1B, and platinum sensitivity in a separate HapMap CEU III dataset. We then showed that overexpression of miR-193b* in a randomly selected HapMap cell line results in resistance to both carboplatin and cisplatin. This relationship was also found in 7 ovarian cancer cell lines from NCI60 dataset and confirmed in an OVCAR-3 that overexpression of miR-193b* leads to increased resistance to carboplatin. cell line (LCLs,OVCAR-3) up-regulated resistant CRIM1 and IFIT2 CRIM1 and IFIT2 NA validated 601 MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 2012 22753745 miRBase MI0000077 miR-21 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. cell line (D54MG) down-regulated sensitive NA NA NA validated 602 MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 2012 22761336 miRBase MI0000098 miR-96 miRNA DB00515 (APRD00359) Cisplatin cancer RT-PCR The role of miR-96 in human cancer cells was detected using Immunofluorescence microscopy, western blot analysis, Real-time PCR,cell cycle analysis,homologous recombination (HR) assay, crystal violet assay, clonogenic survival assay,xenograft mice study,etc. cell line (U2OS, HeLa, HCC1937, MDA-MB-231,HCT116,PEO1,PEO1 C4-2) up-regulated sensitive RAD51 and REV1 RAD51 and REV1 NA validated 603 Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 2012 22842456 miRBase MI0000460 miR-144 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of miR-144/451 in chronic myelogenous leukemia cell K562 was detected usingImmunofluorescence analysis, MTT assay, Real-time quantitative PCR, reporter assay, quantitative chromatin immunoprecipitation,etc. cell line ( K562, K562R) up-regulated sensitive NA NA NA validated 604 Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 2012 22842456 miRBase MI0001729 miR-451 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of miR-144/451 in chronic myelogenous leukemia cell K562 was detected usingImmunofluorescence analysis, MTT assay, Real-time quantitative PCR, reporter assay, quantitative chromatin immunoprecipitation,etc. cell line ( K562, K562R) up-regulated sensitive NA NA NA validated 605 Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 2012 22846564 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Real-time polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell proliferation assays were performed by using Cell Counting Kit-8. cell line (Huh7, HEK 293) up-regulated resistant RUNX3 RUNX3 Wnt/Beta-catenin pathway validated 606 Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012 22847808 miRBase MI0000064 Let-7c miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR Using pretreatment biopsy samples from 98 patients with esophageal cancer who received preoperative chemotherapy, we measured the expression level of several miRNAs whose expression was altered in cisplatin-resistant esophageal cancer cell lines compared with those parent cell lines and examined the relationship between the miRNA expression and response to chemotherapy. In vitro assays were conducted to clarify the mechanism of miRNA-induced changes in chemosensitivity. cell line (TE1,TE5,TE8,TE9,TE10,TE11,TE13) up-regulated sensitive IL-6 NA IL-6/STAT3 pathway validated 607 MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J 2012 22883469 miRBase MI0000822 miR-133b miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. .Cell migration was detected by migration and invasion assay. tissue and cell line (H1650, A549, PC-9, 293T,H1975) up-regulated sensitive EGFR EGFR EGFR pathway validated 608 MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 2012 22892391 miRBase MI0000284 miR-204 miRNA DB00515 (APRD00359) Cisplatin neuroblastoma Quantitative real-time RT-PCR Neuroblastoma cell lines were transiently transfected with miR-204 mimics and assessed for cell viability using MTS assays. Apoptosis levels in cell lines were evaluated by FACS analysis of Annexin V-/propidium iodide-stained cells transfected with miR-204 mimics and treated with chemotherapy drug or vehicle control. Potential targets of miR-204 were validated using luciferase reporter assays. cell line (Kelly,SK-N-AS,SHSY-5Y,NB1691) up-regulated sensitive BCL2 and NTRK2 BCL2 and NTRK2 PI3K/AKT pathway validated 609 MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 2012 22892391 miRBase MI0000284 miR-204 miRNA DB00773 (APRD00239) Etoposide neuroblastoma Quantitative real-time RT-PCR Neuroblastoma cell lines were transiently transfected with miR-204 mimics and assessed for cell viability using MTS assays. Apoptosis levels in cell lines were evaluated by FACS analysis of Annexin V-/propidium iodide-stained cells transfected with miR-204 mimics and treated with chemotherapy drug or vehicle control. Potential targets of miR-204 were validated using luciferase reporter assays. cell line (Kelly,SK-N-AS,SHSY-5Y,NB1691) up-regulated sensitive BCL2 and NTRK2 BCL2 and NTRK2 PI3K/AKT pathway validated 610 The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer. Int J Biochem Cell Biol 2012 22903020 miRBase MIMAT0000231 miR-199a-5p miRNA DB00541 (APRD00495) Vincristine colorectal cancer RT-PCR and Northern blot The expression levels of miRNA were determined by Real-time PCR and Northern blot . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. miRNA target prediction by computer algorithms . Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. In vitro invasion assays were performed in BD BioCoat Matrigel chambers . Tumorigenicity assays in nude mice was used to test the role of miR-199a-5p . cell line (HCT-8, HCT-8/VCR) up-regulated sensitive CAC1 CAC1 NA validated 611 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012 22942255 miRBase MI0000069 miR-15 miRNA DB00515 (APRD00359) Cisplatin epidermoid carcinoma RT-PCR In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. The expression levels of miRNA were determined by quantitative real-time (RT)-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. miRNAs predicted to target kinases identified by the high throughput screen were identified by using miRanda and TargetScanHuman . cell line(KB-3-1,KB-CP.5,KB-CP20) up-regulated sensitive WEE1 and CHK1 WEE1 and CHK1 NA validated 612 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012 22942255 miRBase MI0000070/MI0000115 miR-16 miRNA DB00515 (APRD00359) Cisplatin epidermoid carcinoma RT-PCR In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. The expression levels of miRNA were determined by quantitative real-time (RT)-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. miRNAs predicted to target kinases identified by the high throughput screen were identified by using miRanda and TargetScanHuman . cell line(KB-3-1,KB-CP.5,KB-CP20) up-regulated sensitive WEE1 and CHK1 WEE1 and CHK1 NA validated 613 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012 22942255 miRBase MI0000489 miR-195 miRNA DB00515 (APRD00359) Cisplatin epidermoid carcinoma RT-PCR In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. The expression levels of miRNA were determined by quantitative real-time (RT)-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. miRNAs predicted to target kinases identified by the high throughput screen were identified by using miRanda and TargetScanHuman . cell line(KB-3-1,KB-CP.5,KB-CP20) up-regulated sensitive WEE1 and CHK1 WEE1 and CHK1 NA validated 614 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012 22942255 miRBase MI0001446 miR-424 miRNA DB00515 (APRD00359) Cisplatin epidermoid carcinoma RT-PCR In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. The expression levels of miRNA were determined by quantitative real-time (RT)-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. miRNAs predicted to target kinases identified by the high throughput screen were identified by using miRanda and TargetScanHuman . cell line(KB-3-1,KB-CP.5,KB-CP20) up-regulated sensitive WEE1 and CHK1 WEE1 and CHK1 NA validated 615 Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012 22942255 miRBase MI0003138 miR-497 miRNA DB00515 (APRD00359) Cisplatin epidermoid carcinoma RT-PCR In this study, we conducted parallel high-throughput screens for microRNAs (miRNA) that could restore sensitivity to cisplatin-resistant cells, and we screened for kinases targeted by miRNAs that mediated cisplatin resistance. The expression levels of miRNA were determined by quantitative real-time (RT)-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. miRNAs predicted to target kinases identified by the high throughput screen were identified by using miRanda and TargetScanHuman . cell line(KB-3-1,KB-CP.5,KB-CP20) up-regulated sensitive WEE1 and CHK1 WEE1 and CHK1 NA validated 616 miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012 22954303 miRBase MI0000476/MI0000455 miR-138 miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR We profiled the expression of 671 miRNAs in formalin fixed paraffin embedded tumors from patients with advanced bladder cancer treated with cisplatin based chemotherapy. We delineated differentially expressed miRNAs in tumors from patients with complete response vs. patients with progressive disease and in tumors form patients with short and long overall survival time. Furthermore, we studied the effect of up- and down regulation of key miRNAs on the cisplatin sensitivity in eight bladder cancer cell lines with different sensitivities to cisplatin. cell line down-regulated sensitive NA NA NA predicted 617 miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012 22954303 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR We profiled the expression of 671 miRNAs in formalin fixed paraffin embedded tumors from patients with advanced bladder cancer treated with cisplatin based chemotherapy. We delineated differentially expressed miRNAs in tumors from patients with complete response vs. patients with progressive disease and in tumors form patients with short and long overall survival time. Furthermore, we studied the effect of up- and down regulation of key miRNAs on the cisplatin sensitivity in eight bladder cancer cell lines with different sensitivities to cisplatin. cell line up-regulated sensitive NA NA NA predicted 618 miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 2012 22954303 miRBase MI0003657 miR-642 miRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR We profiled the expression of 671 miRNAs in formalin fixed paraffin embedded tumors from patients with advanced bladder cancer treated with cisplatin based chemotherapy. We delineated differentially expressed miRNAs in tumors from patients with complete response vs. patients with progressive disease and in tumors form patients with short and long overall survival time. Furthermore, we studied the effect of up- and down regulation of key miRNAs on the cisplatin sensitivity in eight bladder cancer cell lines with different sensitivities to cisplatin. cell line up-regulated sensitive NA NA NA predicted 619 Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol 2012 22957792 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin chronic myeloid leukemia RT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (K562, K562/A02) up-regulated resistant PTEN PTEN PI3K/Akt/mTOR signaling pathway validated 620 MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012 22996741 miRBase MI0000681 miR-155 miRNA DB00515 (APRD00359) Cisplatin lung cancer Real-time RT-PCR The role of miR-155 in lung cancer cells was detected using plasmid construction of Apaf-1-pcDNA3.1, Cell transfection,western blot analysis,Real-time RT-PCR, single cell gel electrophoresis (comet assay), analysis of cellular apoptosis .etc. cell line (A549) down-regulated sensitive Apaf-1 Apaf-1 NA validated 621 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000790 miR-382 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 622 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000439 miR-23b miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 623 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004947 miR-885-5p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 624 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000481 miR-184 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 625 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004694 miR-342-5p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 626 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0002468 miR-484 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 627 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0002807 miR-491-5p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 628 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004693 miR-330-5p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 629 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000105/MI0000107 miR-29b miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 630 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003188 miR-503 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 631 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003130 miR-202 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 632 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004784 miR-455-3p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) up-regulated resistant NA NA NA predicted 633 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0002864 miR-518d-3p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 634 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003530 miR-487b miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 635 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0000446 miR-127-3p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 636 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003153 miR-523 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 637 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000452/MI0000453 miR-135a miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 638 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004605 miR-129-3p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 639 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003154 miR-518f miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 640 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0003389 miR-542-3p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 641 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000240 miR-198 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 642 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000479 miR-150 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 643 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0005523 miR-298 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 644 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000089 miR-31 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 645 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MIMAT0004812 miR-548d-5p miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 646 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0003757 miR-758 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 647 Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012 23028896 miRBase MI0000294/MI0000295 miR-218 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR In this study, we conducted parallel high-throughput screens for between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. cell line (MCF7,MCF7VP) down-regulated resistant NA NA NA predicted 648 Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 2012 23036199 miRBase MI0000681 miR-155 miRNA DB00515 (APRD00359) Cisplatin colon cancer RT-PCR The role of miR-155 in colon cancer HT29 cells was detected using MTT assay, RT-PCR, western blot,NFjB activity examination,FACS analysis, etc. cell line (HT29) up-regulated resistant NF-kappaB NA NF-kappaB signaling validated 649 Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012 23041061 miRBase MI0000650 miR-200c miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-qPCR The expression levels of miRNA were determined by RT-qPCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. cell line ( PC3, DU-145,PC3-DR, DU-145-DR,HBMEC-60) down-regulated resistant NA NA NA validated 650 Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012 23041061 miRBase MI0000285 miR-205 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-qPCR The expression levels of miRNA were determined by RT-qPCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. cell line ( PC3, DU-145,PC3-DR, DU-145-DR,HBMEC-60) down-regulated resistant NA NA NA validated 651 Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012 23074172 miRBase MI0000650 miR-200c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The role of miR-200c in ovarian cancer cells was detected using western blot, anoikis assays,MTT assay, cell-adhesion assay,qRT-PCR, bioluminescent assays, ovarian tumor xenograft and luminescent imaging in mice,Immunohistochemistry, etc. cell line (HEY, SKOV3, OVCA 420, OV 1847, OVCA 433) up-regulated sensitive TUBB3 TUBB3 NA validated 652 Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 2012 23084187 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin neuroblastoma RT-PCR The cell viability of the neuroblastoma cells after cisplatin treatment was analyzed. The expression of the miRNAs and phosphatase and tensin homolog (PTEN) messenger RNA in the neuroblastoma cells was studied by real-time polymerase chain reaction. Overexpression of miRNA or suppression of miRNA expression by antagomir was used to investigate the effects of miRNA on the cisplatin-induced cell death or proliferation. cell line (SH-SY5Y, BE(2)-M17) up-regulated resistant PTEN PTEN NA validated 653 MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res 2012 23085450 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The role of miR-34a in breast cancer cells was detected using MTT assay, flow cytometry assay, real-time PCR and Western blot, etc. The association of miR-34a and Notch1 was analyzed by dual-luciferase reporter assay and Notch1-siRNA technology. Real-time PCR assay was performed to test the expression of miR-34a and Notch1 in 38 selective breast cancer tissue samples. cell line (MCF-7,MCF-7/ADR,MCF-7/DOC) up-regulated sensitive Notch1 Notch1 Notch signaling pathway validated 654 Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 2012 23107361 miRBase MI0000434 let-7i miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR Eighty-six previously untreated LAGC patients who underwent preoperative chemotherapy and radical resection were included in our study. Let-7i expression was examined for pairs of cancer tissues and corresponding normal adjacent tissues (NATs), using quantitative RT-PCR. The relationship of let-7i level to clinicopathological characteristics, pathologic tumor regression grades after chemotherapy, and overall survival (OS) was also investigated. tissue down-regulated resistant NA NA NA predicted 655 Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 2012 23107361 miRBase MI0000434 let-7i miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR Eighty-six previously untreated LAGC patients who underwent preoperative chemotherapy and radical resection were included in our study. Let-7i expression was examined for pairs of cancer tissues and corresponding normal adjacent tissues (NATs), using quantitative RT-PCR. The relationship of let-7i level to clinicopathological characteristics, pathologic tumor regression grades after chemotherapy, and overall survival (OS) was also investigated. tissue down-regulated resistant NA NA NA predicted 656 miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012 23152059 miRBase MI0000284 miR-204 miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer RT-PCR The role ofmiR-204 in gastric cancer cells was detected using plasmid and transfection, wound healing assay,colony formation assay, lysate preparation and immunoblotting analyses, immunohistochemistry, GC xenografts,apoptosis assay,etc. cell line (GTL-16, N87, HEK293, H1299) up-regulated sensitive Bcl-2 Bcl-2 NA validated 657 miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012 23152059 miRBase MI0000284 miR-204 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR The role ofmiR-204 in gastric cancer cells was detected using plasmid and transfection, wound healing assay,colony formation assay, lysate preparation and immunoblotting analyses, immunohistochemistry, GC xenografts,apoptosis assay,etc. cell line (GTL-16, N87, HEK293, H1299) up-regulated sensitive Bcl-2 Bcl-2 NA validated 658 miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One 2012 23209748 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The role of miR-27a in gastric cancer cells was detected using molecular evolution assay, Quantitative RT-PCR, Cell Lysis and Immunoblotting,immunofluorescence, etc. cell line (BT474,MDA-MB 436 ) down-regulated resistant TrkB and Bmi1 Bmi1 NA validated 659 Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One 2012 23284982 miRBase MI0000681 miR-155 miRNA DB00515 (APRD00359) Cisplatin cervical cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. Flow cytometry analysis was used to determine the distribution of cells in cell cycle sub-phases and to measure the apoptosis peak induced by DDP (10 mol/ml) for 24 hours. cell line up-regulated sensitive SMAD2,TCF4 and CCND1 SMAD2,TCF4 and CCND1 NA validated 660 MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci 2012 23443110 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin cervical cancer PCR The role of miR-27a in gastric cancer cells was detected using cell proliferation assay, anchorage-independent colony formation assay, western blotting,caspase activity,in vivo tumorigenesis study, etc. cell line (HeLa) up-regulated sensitive Rictor NA AKT/mTOR pathway validated 661 miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 2013 22121083 miRBase MI0008336 miR-1915 miRNA DB00526 (APRD00186) Oxaliplatin colorectal carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR for miRNA and Semi-Quantitative RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HCT-116,HCT-116/L-OHP) up-regulated sensitive Bcl-2 Bcl-2 NA validated 662 miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2013 22370637 miRBase MIMAT0000686 miR-34c-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qt-RT-PCR The expression levels of miRNA were determined by qt-RT-PCR . Those of protein were by Immunoprecipitation and immunoblotting . Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, H460,A549-FK ) up-regulated resistant Bmf Bmf NA validated 663 Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013 22508479 miRBase MI0000783 miR-375 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. cell line (MCF-7, MDA-MB-231, H1703, H1299,HEK-293FT,Ovcar-5) down-regulated resistant MTDH MTDH NA validated 664 Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013 22508479 miRBase MI0000783 miR-375 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by invasion assay. cell line (MCF-7, MDA-MB-231, H1703, H1299,HEK-293FT,Ovcar-5) up-regulated sensitive MTDH MTDH NA validated 665 MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013 22710713 miRBase MI0003138 miR-497 miRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR The role of miR-497 in human colorectal cancer cells was detected using miR microarray, Quantitative reverse transcription and real-time PCR analysis,array comparative genomic hybridization, plasmid vectors and transfection,small RNA interference, luciferase reporter assays,western blot analysis,matrigel invasion assays,etc. tissue and cell line (HCT116, HCT28, LoVo, Colon205, SW480, SW620) up-regulated sensitive IGF1R IGF1R MEK/ERK signalling pathway,PI3K/Akt pathway validated 666 MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013 22710713 miRBase MI0003138 miR-497 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The role of miR-497 in human colorectal cancer cells was detected using miR microarray, Quantitative reverse transcription and real-time PCR analysis,array comparative genomic hybridization, plasmid vectors and transfection,small RNA interference, luciferase reporter assays,western blot analysis,matrigel invasion assays,etc. tissue and cell line (HCT116, HCT28, LoVo, Colon205, SW480, SW620) up-regulated sensitive IGF1R IGF1R MEK/ERK signalling pathway,PI3K/Akt pathway validated 667 Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int J Colorectal Dis 2013 22892985 miRBase MI0000747 miR-296 miRNA DB01268 (DB07417) Sunitinib colon cancer NA The role of miR-296 in colorectal is verified by changes in miR-296 levels before and after administration and patient prognosis. tissue down-regulated resistant NA NA NA validated 668 Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int J Colorectal Dis 2013 22892985 miRBase MI0000747 miR-296 miRNA DB01101 (APRD00203) Capecitabine colon cancer NA The role of miR-296 in colorectal is verified by changes in miR-296 levels before and after administration and patient prognosis. tissue down-regulated resistant NA NA NA validated 669 MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013 22956424 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma real-time quantitative RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. tissue and cell line (SPC-A1, A549, H2170,16HBE) up-regulated resistant PTEN PTEN PTEN signaling pathway validated 670 MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013 22956424 miRBase MI0000077 miR-21 miRNA DB01248 (APRD00932) Docetaxel lung non-small cell carcinoma real-time quantitative RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. tissue and cell line (SPC-A1, A549, H2170,16HBE) up-regulated resistant PTEN PTEN PTEN signaling pathway validated 671 MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer 2013 22999387 miRBase MIMAT0004679 miR-296-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib glioblastoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by invasion assay. cell line (U251,U251AR) up-regulated sensitive EAG1 EAG1 NA validated 672 MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer 2013 22999387 miRBase MIMAT0004679 miR-296-3p miRNA DB00773 (APRD00239) Etoposide glioblastoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by invasion assay. cell line (U251,U251AR) up-regulated sensitive EAG1 EAG1 NA validated 673 MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer 2013 22999387 miRBase MIMAT0004679 miR-296-3p miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by invasion assay. cell line (U251,U251AR) up-regulated sensitive EAG1 EAG1 NA validated 674 microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm 2013 23036084 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, SBC-5 ) up-regulated sensitive Sitr1 NA NA validated 675 miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013 23045278 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR We compared miRNA expression profiles of an isogenic cisplatin-sensitive and -resistant ovarian cancer cell line to found the different expressed level.The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A2780, A2780 DDP) up-regulated resistant KEAP1 KEAP1 NF-kappaB pathway validated 676 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000069 miR-15 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) down-regulated resistant NA NA NA validated 677 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000474 miR-134 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) down-regulated resistant NA NA NA validated 678 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000285 miR-205 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) down-regulated resistant NA NA NA validated 679 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) down-regulated resistant NA NA NA validated 680 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000090 miR-32 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) down-regulated resistant NA NA NA validated 681 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000459 miR-143 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 682 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000290 miR-214 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 683 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000266 miR-10a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 684 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000267 miR-10b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 685 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000477 miR-146a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 686 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase NA miR-46b-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 687 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000268 miR-34a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 688 miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013 23073476 miRBase MI0000102 miR-100 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer Real time RT-PCR The expression levels of miRNA were determined by Real time RT-PCR MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( PaCa-2,MIA PaCa-2R) up-regulated resistant NA NA NA validated 689 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 2013 23085757 miRBase MI0000255 miR-30d miRNA NA histone deacetylase inhibitor (TSA) cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by Reverse transcription and quantitative real-time PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assay,Cell viability assay and colony formation assay was used in the experiment . cell line (LD419,UROtsa,NK2464,C42B,UM-UC-3, J82, HCT116, HL-60) down-regulated resistant GRP78 NA NA validated 690 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 2013 23085757 miRBase MI0000289/MI0000269 miR-181a miRNA NA histone deacetylase inhibitor (TSA) cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by Reverse transcription and quantitative real-time PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assay,Cell viability assay and colony formation assay was used in the experiment . cell line (LD419,UROtsa,NK2464,C42B,UM-UC-3, J82, HCT116, HL-60) down-regulated resistant GRP78 NA NA validated 691 miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 2013 23085757 miRBase MIMAT0000231 miR-199a-5p miRNA NA histone deacetylase inhibitor (TSA) cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by Reverse transcription and quantitative real-time PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assay,Cell viability assay and colony formation assay was used in the experiment . cell line (LD419,UROtsa,NK2464,C42B,UM-UC-3, J82, HCT116, HL-60) down-regulated resistant GRP78 NA NA validated 692 MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 2013 23142283 miRBase MI0000735 miR-29c miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Annexin V-FITC/PI apoptosis detection by flow cytometry . cell line ( C666-1, CNE1, CNE2, HONE1, HNE2, 5-8F, SUNE1,6-10B) up-regulated sensitive Mcl-1 and Bcl-2 Mcl-1 and Bcl-2 NA validated 693 The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol 2013 23177026 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. Tumorigenicity assays in nude mice and gemcitabine administration was used to identify the role of miR-21 . tissue and cell line (PANC-1, BxPC3) up-regulated resistant FasL FasL FasL/Fas pathway validated 694 miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 2013 23178914 miRBase MI0000454 miR-137 miRNA DB00541 (APRD00495) Vincristine breast cancer RT-PCR The role of miR-137 in multidrug-resistant MCF-7/ADM cells was detected using microRNA transfection assay,stem-loop reverse transcriptase polymerase chain reaction, drug sensitivity assay,Intracellular ADM concentration analysis,apoptosis assay,dual luciferase activity assay, siRNA transfection assay,Western blot ,etc. cell line (MCF-7,MCF-7/ADM) down-regulated resistant YB-1 YB-1 NA validated 695 miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 2013 23178914 miRBase MI0000454 miR-137 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The role of miR-137 in multidrug-resistant MCF-7/ADM cells was detected using microRNA transfection assay,stem-loop reverse transcriptase polymerase chain reaction, drug sensitivity assay,Intracellular ADM concentration analysis,apoptosis assay,dual luciferase activity assay, siRNA transfection assay,Western blot ,etc. cell line (MCF-7,MCF-7/ADM) down-regulated resistant YB-1 YB-1 NA validated 696 miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 2013 23178914 miRBase MI0000454 miR-137 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-PCR The role of miR-137 in multidrug-resistant MCF-7/ADM cells was detected using microRNA transfection assay,stem-loop reverse transcriptase polymerase chain reaction, drug sensitivity assay,Intracellular ADM concentration analysis,apoptosis assay,dual luciferase activity assay, siRNA transfection assay,Western blot ,etc. cell line (MCF-7,MCF-7/ADM) down-regulated resistant YB-1 YB-1 NA validated 697 A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol 2013 23206420 miRBase MI0000457 miR-141 miRNA DB01268 (DB07417) Sunitinib clear cell renal cell carcinoma RT-PCR We performed screening genome-wide microRNA real-time quantitative polymerase chain reaction on 20 freshly frozen clear cell renal cell carcinoma tissue samples of patients who received sunitinib as first line targeted therapy. Nine patients with progressive disease within 6 months after initiating therapy were considered poor responders and 11 with at least 1-year progression-free survival were considered good responders. We studied microRNA-141 function in vitro by stable up-regulation of microRNA-141, quantification of target gene expression and cell viability in normoxic and hypoxic conditions. Relative expression in clinical and cell line samples was determined by real-time quantitative polymerase chain reaction. Localization of microRNA-141 and its targets was assessed by microRNA in situ hybridization and immunohistochemistry. Hypoxia induced cytotoxicity was assessed by a luminescence adenosine triphosphate detection assay. cell line up-regulated sensitive NA NA NA validated 698 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000440 miR-27b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA BAX, P53,Foxo1,KRAS NA validated 699 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000289/MI0000269 miR-181a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 700 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MIMAT0002809 miR-146b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 701 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0003139 miR-181d miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 702 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000477 miR-146a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 703 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA BAX, P53,Foxo1,KRAS NA validated 704 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000289/MI0000269 miR-181a miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 705 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MIMAT0002809 miR-146b-5p miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 706 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0003139 miR-181d miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 707 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 708 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000440 miR-27b miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA BAX, P53,Foxo1,KRAS NA validated 709 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000289/MI0000269 miR-181a miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 710 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MIMAT0002809 miR-146b-5p miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 711 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0003139 miR-181d miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 712 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000477 miR-146a miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 713 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000440 miR-27b miRNA DB00305 (APRD00284) Mitomycin C hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA BAX, P53,Foxo1,KRAS NA validated 714 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000289/MI0000269 miR-181a miRNA DB00305 (APRD00284) Mitomycin C hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 715 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MIMAT0002809 miR-146b-5p miRNA DB00305 (APRD00284) Mitomycin C hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 716 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0003139 miR-181d miRNA DB00305 (APRD00284) Mitomycin C hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 717 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000477 miR-146a miRNA DB00305 (APRD00284) Mitomycin C hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 718 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000440 miR-27b miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA BAX, P53,Foxo1,KRAS NA validated 719 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000289/MI0000269 miR-181a miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 720 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MIMAT0002809 miR-146b-5p miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 721 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0003139 miR-181d miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA PTEN,KRAS,RB1 NA validated 722 Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013 23229111 miRBase MI0000477 miR-146a miRNA DB00541 (APRD00495) Vincristine hepatocellular carcinoma qRT-PCR The HCC Huh-7 cell line was treated with adramycin (ADM), cisplatin (DDP), carboplatin (CBP), mitomycin C (MMC) or vincristine (VCR) at increasing concentrations to develop drug-resistant sublines. The cell viability MTT assay was used to detect drug resistance. Five different drug-resistant HCC sublines, Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR, were established. Cells that were resistant to one drug were also found to be resistant to the other drugs. miRNA microarrays were analyzed to identify differential miRNA expression profiles in these cell lines, and real-time PCR was used to validate miRNA microarray data. cell line (Huh-7,Huh-7/ADM,Huh-7/CBP,Huh-7/DDP,Huh-7/MMC,Huh-7/VCR) up-regulated resistant NA TRAF6,PTGS2 NA validated 723 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013 23275230 miRBase MI0000077 miR-21 miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CRL2631, HEK-293T ) down-regulated sensitive PTEN PTEN PI3K/AKT signaling pathway validated 724 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013 23275230 miRBase MI0000077 miR-21 miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CRL2631, HEK-293T ) down-regulated sensitive PTEN PTEN PI3K/AKT signaling pathway validated 725 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013 23275230 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CRL2631, HEK-293T ) down-regulated sensitive PTEN PTEN PI3K/AKT signaling pathway validated 726 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013 23275230 miRBase MI0000077 miR-21 miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CRL2631, HEK-293T ) down-regulated sensitive PTEN PTEN PI3K/AKT signaling pathway validated 727 MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 2013 23327190 miRBase MI0000469 miR-125a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colon cancer Real-Time RT-PCR The expression levels of miRNA were determined by real-time reverse-transcriptase (RT)-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HCT116, HT29,HT29-taxol) up-regulated sensitive Mcl1 and ALDH1A3 Mcl1 and ALDH1A3 NA validated 728 MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 2013 23327190 miRBase MI0000446/MI0000470 miR-125b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colon cancer Real-Time RT-PCR The expression levels of miRNA were determined by real-time reverse-transcriptase (RT)-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HCT116, HT29,HT29-taxol) up-regulated sensitive Mcl1 and ALDH1A3 Mcl1 and ALDH1A3 NA validated 729 MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 2013 23337879 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. TUNEL staining was used to detect apoptotic cell death.Based on bioinformatic prediction target . tissue and cell line (HeLa,C-33A,HeLa/miR-214, HeLa/Neg-Ctrl) up-regulated sensitive Bcl2l2 Bcl2l2 NA validated 730 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013 23340433 miRBase MI0000736/MI0000254 miR-30c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast tumor RT-PCR The role of miR-30c in human breast tumour cells was detected usingreal-time PCR, cell growth assays, Western blot, luciferase assay,Immunofluorescence, histology, and microscope,Tumour transplantation and chemotherapy in mice,etc. tissue and cell line (T47D, MCF-7, MDA-MB-231, BT-20, HCC-70, HCC-38) up-regulated sensitive TWF1 and IL-11 TWF1 and IL-11 NA validated 731 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013 23340433 miRBase MI0000736/MI0000254 miR-30c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast tumor RT-PCR The role of miR-30c in human breast tumour cells was detected usingreal-time PCR, cell growth assays, Western blot, luciferase assay,Immunofluorescence, histology, and microscope,Tumour transplantation and chemotherapy in mice,etc. tissue and cell line (T47D, MCF-7, MDA-MB-231, BT-20, HCC-70, HCC-38) up-regulated sensitive TWF1 and IL-11 TWF1 and IL-11 NA validated 732 MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem 2013 23364795 miRBase MI0000089 miR-31 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The expression levels of miRNA were determined by Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (MDA-MB-231, MCF-7, MCF10A,HEK293FT) up-regulated sensitive NA PRKCE NF-kappaB pathway validated 733 MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013 23372675 miRBase MI0000298 miR-221 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR, RT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and RT-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell cycle analysis and apoptosis assay by flow cytometry.Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . cell line (SOSP-9607, SOSP-9901,MG63, Saos-2, U2OS, hFOB1.19) up-regulated resistant PTEN PTEN PI3K/Akt pathway validated 734 Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 2013 23423488 miRBase MIMAT0000686 miR-34c-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer qRT-PCR The adenosine triphosphate-based tumor chemosensitivity assay was used to measure drug sensitivity in gastric cancer samples. The expression levels of miRNA were determined by reverse transcriptase polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The methylation status of neighboring CpG islands of miR-34c-5p was analyzed by Bisulfite Sequencing PCR and methylation-specific PCR. cell line (BGC-823, MGC-803, MKN-45, SGC-7901,HEK293T, SGC7901/VCR) up-regulated sensitive MAPT MAPT NA validated 735 The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 2013 23436656 miRBase MI0003672 miR-663 miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer qRT-PCR In the present study, we aimed to clarify the role of miR-663 in regulating the chemoresistance of breast cancer. MicroRNA microarray and quantitative RT-PCR assays were used to identify differentially expressed microRNAs. Cell apoptosis was evaluated by annexin V/propidium iodide staining, TUNEL, and reactive oxygen species generation analysis. The expression of miR-663 and HSPG2 in breast cancer tissues was detected by in situ hybridization and immunohistochemistry. The potential targets of miR-663 were defined by a luciferase reporter assay. Bisulfite sequencing PCR was used to analyze the methylation status. cell line (MDA-MB-231, BT-474,MCF-7,MDA-MB-231/ADM) down-regulated sensitive HSPG2 HSPG2 NA validated 736 The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 2013 23436656 miRBase MI0003672 miR-663 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR In the present study, we aimed to clarify the role of miR-663 in regulating the chemoresistance of breast cancer. MicroRNA microarray and quantitative RT-PCR assays were used to identify differentially expressed microRNAs. Cell apoptosis was evaluated by annexin V/propidium iodide staining, TUNEL, and reactive oxygen species generation analysis. The expression of miR-663 and HSPG2 in breast cancer tissues was detected by in situ hybridization and immunohistochemistry. The potential targets of miR-663 were defined by a luciferase reporter assay. Bisulfite sequencing PCR was used to analyze the methylation status. cell line (MDA-MB-231, BT-474,MCF-7,MDA-MB-231/ADM) down-regulated sensitive HSPG2 HSPG2 NA validated 737 miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol Rep 2013 23440261 miRBase MI0000270/MI0000683 miR-181b miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR In this study, we investigated the effects of miR-181b on the chemosensitivity of PDAC cells to gemcitabine and the underlying molecular events. miR-181b mimics and inhibitors were synthesized for transient gene transfection in vitro. Lentivirus carrying miR-181b mimics were used to infect PDAC cells for nude mouse xenograft assays by implanting infected PDAC cells into recipient mice. Cell viability was determined by MTT assays, while gene expression was assessed using qRT-PCR, western blot analysis and enzyme-linked immunosorbent assay (ELISA). miR-181b targeting BCL-2 expression was assessed by a dual-luciferase activity assay. cell line (SW1990, CFPAC-1,SW1990/GR, CFPAC-1/GR) up-regulated sensitive BCL-2 Bcl-2 NA validated 738 miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013 23466500 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real time-PCR analysis and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/DDP) up-regulated resistant PTEN PTEN PTEN/PI3K/Akt pathway validated 739 MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013 23471579 miRBase MI0000292 miR-216a miRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer Real time qRT-PCR The expression levels of miRNA were determined by Real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The animal studies was used to test the role of miR-216a /217 . tissue and cell line (HepG2, PLC/PRF/5) up-regulated resistant PTEN and SMAD7 PTEN and SMAD7 PI3K/Akt signaling,TGF-Beta pathway validated 740 MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013 23471579 miRBase MI0000293 miR-217 miRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer Real time qRT-PCR The expression levels of miRNA were determined by Real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The animal studies was used to test the role of miR-216a /217 . tissue and cell line (HepG2, PLC/PRF/5) down-regulated resistant PTEN and SMAD7 PTEN and SMAD7 PI3K/Akt signaling,TGF-Beta pathway validated 741 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ewing sarcoma qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 742 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00773 (APRD00239) Etoposide ewing sarcoma qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 743 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00541 (APRD00495) Vincristine ewing sarcoma qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 744 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin primitive neuroectodermal tumor qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 745 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00773 (APRD00239) Etoposide primitive neuroectodermal tumor qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 746 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 2013 23497288 miRBase MI0000446/MI0000470 miR-125b miRNA DB00541 (APRD00495) Vincristine primitive neuroectodermal tumor qRT-PCR We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. cell line (VH-64, WE-68,SK-N-MC,RD-ES, SK-ES, TC-71 ) up-regulated resistant p53 and Bak p53 and Bak miR-125b-p53/Bak pathway validated 747 High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol 2013 23506979 miRBase MIMAT0004808 miR-625-3p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The role of miR-625-3p in colorectal cancer cells was detected using laser-capture microdissection,qRT-PCR, etc. cell line (HCT116, LoVo) up-regulated resistant NA NA NA predicted 748 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000267 miR-10b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 749 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000078 miR-22 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 750 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 751 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000822 miR-133b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 752 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000486 miR-190 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 753 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0003185 miR-501 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 754 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0003628 miR-615 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 755 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0002872 miR-501-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 756 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0004804 miR-615-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) up-regulated resistant NA NA NA predicted 757 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000090 miR-32 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 758 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000239 miR-197 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 759 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0000286 miR-210 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 760 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0003836 miR-766 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 761 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0006319 miR-1229 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 762 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0006328 miR-1238 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 763 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0014151 miR-3131 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 764 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0014176 miR-3149 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 765 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0005459 miR-1224-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 766 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0019213 miR-3162-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 767 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0003205 miR-532 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 768 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0005561 miR-877 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 769 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0019798 miR-4701-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 770 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0018004 miR-5096 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 771 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0019850 miR-4728-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 772 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MI0014254 miR-1273d miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 773 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0004762 miR-486-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 774 microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013 23525256 miRBase MIMAT0019913 miR-4763-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer Quantitative real-time RT-PCR The present study aimed to identify microRNA (miRNA) expression profiles associated with multidrug resistance (MDR) in gastric carcinoma. A 5-fuorouracil (5-Fu) induced MDR gastric cancer cell line was selected and miRNA expression profiling of the cell line was conducted following exposure to 5-Fu. The miRNA expression profiles between the parental and resistant gastric cancer cells were analyzed by Human miRNA OneArray v3 and the results were confirmed by quantitative real-time RT-PCR. cell line (SGC-790,SGC-7901,SGC-7901/5-Fu) down-regulated resistant NA NA NA predicted 775 Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int 2013 23526655 miRBase MI0000447/MI0000727 miR-128 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MDA-MB-231) up-regulated resistant Bax Bax NA validated 776 Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int 2013 23526655 miRBase MI0000447/MI0000727 miR-128 miRNA DB00773 (APRD00239) Etoposide breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MDA-MB-231) up-regulated resistant Bax Bax NA validated 777 cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas. PLoS One 2013 23527180 miRBase MIMAT0000423 miR-125b-5p miRNA DB00188 (APRD00828, DB07475) Bortezomib cutaneous T-cell lymphomas qRT-PCR The role of cMyc/miR-125b-5p signalling in preclinical model of cutaneous T-cell lymphomas was detected using siRNA and miRNA transfection, bioinformatics analysis, plasmids and luciferase reporter vector, gene expression analysis, etc. tissue and cell line (MyLa2000,SeAx) up-regulated resistant MAD4 MAD4 NA validated 778 miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep 2013 23546450 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7, MCF-7/ADR) down-regulated resistant ZEB1 ZEB1 PTEN/Akt signaling pathway validated 779 Identification of ovarian cancer metastatic miRNAs. PLoS One 2013 23554878 miRBase MI0000479 miR-150 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR First,we analyzed the miRNA expression profiles of primary EOC tumors and their respective omental metastases from 9 patients using miRNA Taqman qPCR arrays. Then,the role of miR in ovarian cancer cells was detected using, laser capture microdissection and miRNA measurement, cell viability, survival and spheroid assays, affymetrix microarrays, miRNA ISH,etc. tissue and cell line (OVCAR-8, SKOV-3,IGROV-1) up-regulated resistant NA NA NA validated 780 Identification of ovarian cancer metastatic miRNAs. PLoS One 2013 23554878 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR First,we analyzed the miRNA expression profiles of primary EOC tumors and their respective omental metastases from 9 patients using miRNA Taqman qPCR arrays. Then,the role of miR in ovarian cancer cells was detected using, laser capture microdissection and miRNA measurement, cell viability, survival and spheroid assays, affymetrix microarrays, miRNA ISH,etc. tissue and cell line (OVCAR-8, SKOV-3,IGROV-1) up-regulated resistant NA NA NA validated 781 Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol Cancer Res 2013 23562878 miRBase MI0000064 Let-7c miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line (SPC-A1, NCI-H1299,SPC-A1/DTX,H1299/DTX) up-regulated sensitive Bcl-xL Bcl-xL caspase-3-dependent apoptosis pathway validated 782 MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013 23574723 miRBase MI0000459 miR-143 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . Xenograft tumor model in nude mice was used to identify the role of miR-143 in animal experiment . tissue and cell line (SW1116,HEK293T) up-regulated sensitive IGF-IR NA PI3K/AKT/HIF-1/VEGF pathway validated 783 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000073 miR-19a miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 784 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000073 miR-19a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 785 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000073 miR-19a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 786 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000073 miR-19a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 787 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000074/MI0000075 miR-19b miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 788 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000074/MI0000075 miR-19b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 789 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000074/MI0000075 miR-19b miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 790 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013 23603256 miRBase MI0000074/MI0000075 miR-19b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant PTEN PTEN PTEN-AKT pathway validated 791 miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 2013 23606360 miRBase MI0000446/MI0000470 miR-125b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( MCF-7, T47D, MDA-MB-231,MCF-7/5-FU) up-regulated resistant NA NA NA validated 792 miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 2013 23606360 miRBase MI0000446/MI0000470 miR-125b miRNA DB00445 (APRD00361) Epirubicin breast cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( MCF-7, T47D, MDA-MB-231,MCF-7/5-FU) up-regulated resistant NA NA NA validated 793 miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 2013 23606360 miRBase MI0000446/MI0000470 miR-125b miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer qRT-PCR The role of miR-19a/b in human gastric cancer cells was detected using quantitative RT-PCR, oligonucleotide transfection,cell apoptosis assays,fluorescence intensity assay of intracellular ADR, western blot analysis, etc. cell line ( MCF-7, T47D, MDA-MB-231,MCF-7/5-FU) up-regulated resistant NA NA NA validated 794 Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One 2013 23613955 miRBase MI0000283 miR-203 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (BaF3,BaF3-BCR/ABLT315I) up-regulated sensitive NA NA NA validated 795 MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl) 2013 23619912 miRBase MIMAT0000434 miR-142-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.A mouse xenograft model of human colon cancer was used to identify the function . cell line ( Caco2,HEK293T, SW1116) up-regulated sensitive CD133,ABCG2,and Lgr5 CD133,ABCG2,and Lgr5 NA validated 796 MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol 2013 23625774 miRBase MI0000738 miR-302a miRNA DB00515 (APRD00359) Cisplatin testicular embryonal carcinoma qRT-PCR The expression levels of miRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells.Flow cytometric analysis was used to determine if cells were viable, apoptotic, or necrotic. cell line (NT2, NCCIT) up-regulated sensitive NA NA NA validated 797 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MI0000542 miR-320a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) up-regulated resistant NA NA NA predicted 798 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MI0000078 miR-22 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) up-regulated resistant NA NA NA predicted 799 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MIMAT0000242 miR-129-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) up-regulated resistant NA NA NA predicted 800 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) down-regulated resistant RAB34 RAB34 NA predicted 801 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MI0000681 miR-155 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) down-regulated resistant NA NA NA predicted 802 MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer 2013 23627607 miRBase MI0003655 miR-640 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian serous carcinoma Realtime RT-PCR Deregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA. cell line (SKOV3-TR30,SKOV3) down-regulated resistant NA NA NA predicted 803 miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 2013 23640248 miRBase MI0000452/MI0000453 miR-135a miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR and those of protein were by Western blot analysis.Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549,A549/CDDP) up-regulated sensitive MCL1 MCL1 NA validated 804 miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 2013 23640248 miRBase MI0000810 miR-135b miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549,A549/CDDP) up-regulated sensitive MCL1 MCL1 NA validated 805 miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 2013 23645289 miRBase MI0000270/MI0000683 miR-181b miRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. tissue and cell line (U251, U87) up-regulated sensitive MEK1 MEK1 MAPK signaling pathway validated 806 CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 2013 23676502 miRBase MI0000060/MI0000061/MI0000062 let-7a miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia RT-PCR The role of let-7a in acute myeloid leukemia was detected using miRNA microarray analysis,RT-PCR, lentiviral constructs and stably transduced cells,flow cytometry, western blot, apoptosis analysis, immunofluorescence staining and confocal microscopy,ChIP assay, etc. cell line (OCI-AML3, Molm13 ) up-regulated sensitive NA NA NA validated 807 Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013 23686318 miRBase MI0006353 miR-1291 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin pancreatic carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse Transcription Quantitative Real-Time PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (PANC-1,H69,H69AR,HEK-293 ) up-regulated sensitive ABCC1 ABCC1 NA validated 808 Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013 23686318 miRBase MI0006353 miR-1291 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse Transcription Quantitative Real-Time PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (PANC-1,H69,H69AR,HEK-293 ) up-regulated sensitive ABCC1 ABCC1 NA validated 809 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MI0000764 miR-363 miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant RGS17 and HIPK3 RGS17 and HIPK3 NA predicted 810 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MIMAT0002888 miR-532-5p miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant NA NA NA predicted 811 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MIMAT0000753 miR-342-3p miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant NA NA NA predicted 812 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MI0000764 miR-363 miRNA DB01177 (APRD00126) Idarubicine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant RGS17 and HIPK3 RGS17 and HIPK3 NA predicted 813 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MIMAT0002888 miR-532-5p miRNA DB01177 (APRD00126) Idarubicine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant NA NA NA predicted 814 MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013 23689423 miRBase MIMAT0000753 miR-342-3p miRNA DB01177 (APRD00126) Idarubicine acute myeloid leukemia qRT-PCR We applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. tissue and cell line up-regulated resistant NA NA NA predicted 815 Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. Int J Clin Exp Pathol 2013 23696927 miRBase MI0000783 miR-375 miRNA NA RAWQ01 ovarian cancer qPCR Three human ovarian cancer cell lines were selected, and independently treated with Rawq01+mir-375 and Rawq01+control. MTT assay and flow cytometry were performed to detect the growth of ovarian cancer cells. Western blot was carried out to determine the expression of apoptotic associated proteins. In addition, ovarian cancer xenografts were established to explore whether mir-375 increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01. cell line (OVCAR3, HO-8910,SK-OV-3 ) up-regulated sensitive NA NA NA validated 816 MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie 2013 23700794 miRBase MI0000100 miR-98 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549,A549/DDP) up-regulated sensitive HMGA2 HMGA2 NA validated 817 Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 2013 23721345 miRBase MI0002467 miR-483 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal squamous cell carcinoma qRT-PCR The expression of miR-483 and miR-214 was detected in 104 cases of esophageal cancer tissues and matched adjacent benign esophageal tissues by quantitative real-time PCR. The relation of microRNA expression with survival was statistically analyzed. The roles of miR-483 and miR-214 in MDR of esophageal squamous cell cancer cells were further evaluated. cell line (ECA109) up-regulated resistant NA NA NA validated 818 Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 2013 23721345 miRBase MI0000290 miR-214 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal squamous cell carcinoma qRT-PCR The expression of miR-483 and miR-214 was detected in 104 cases of esophageal cancer tissues and matched adjacent benign esophageal tissues by quantitative real-time PCR. The relation of microRNA expression with survival was statistically analyzed. The roles of miR-483 and miR-214 in MDR of esophageal squamous cell cancer cells were further evaluated. cell line (ECA109) up-regulated resistant NA NA NA validated 819 miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis 2013 23744359 miRBase MI0000252/MI0000473 miR-129 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer Real-time qRT-PCR The expression levels of miRNA were determined by Real-time qRT-PCR and those of protein were by Western immunoblot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (HCT116,RKO,SW480) up-regulated sensitive BCL2 BCL2 NA validated 820 MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One 2013 23750239 miRBase MI0000083/MI0000750 miR-26a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-time PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.The cell apoptosis was detected by Annexin V/PI assay. Cell migration was assessed by wound-healing assay. cell line (MDA-MB-231, MCF-7, MDA-MB-435, MDA-MB-468,MCF-10A, 184A1) up-regulated sensitive MCL-1 MCL-1 NA validated 821 MicroRNA 223 is upregulated in the multistep progression of Barretts esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013 23757351 miRBase MI0000300 miR-223 miRNA DB00515 (APRD00359) Cisplatin esophageal adenocarcinoma qRT-PCR Expression levels of miR-199a/b-3p, -199a-5p, -199b-5p, -200b, -200c, -223, and -375 were determined in microdissected tissues from cardiac mucosa, Barretts esophagus, dysplastic Barretts esophagus, and esophageal adenocarcinoma using quantitative real-time PCR. miR-223 expression was validated in precursors and esophageal adenocarcinomas from 95 patients with esophageal adenocarcinoma by in situ hybridization (ISH). miR-223 was transfected into two esophageal adenocarcinoma cell lines, and in vitro assays were conducted. Target genes were identified using Illumina microarray, and results were validated in cell lines and human specimens. cell line (OE33, JHesoAD1, HEEpiC) up-regulated sensitive PARP1 PARP1 NA validated 822 MicroRNA 223 is upregulated in the multistep progression of Barretts esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013 23757351 miRBase MI0000300 miR-223 miRNA DB00305 (APRD00284) Mitomycin C esophageal adenocarcinoma qRT-PCR Expression levels of miR-199a/b-3p, -199a-5p, -199b-5p, -200b, -200c, -223, and -375 were determined in microdissected tissues from cardiac mucosa, Barretts esophagus, dysplastic Barretts esophagus, and esophageal adenocarcinoma using quantitative real-time PCR. miR-223 expression was validated in precursors and esophageal adenocarcinomas from 95 patients with esophageal adenocarcinoma by in situ hybridization (ISH). miR-223 was transfected into two esophageal adenocarcinoma cell lines, and in vitro assays were conducted. Target genes were identified using Illumina microarray, and results were validated in cell lines and human specimens. cell line (OE33, JHesoAD1, HEEpiC) up-regulated sensitive PARP1 PARP1 NA validated 823 MicroRNA 223 is upregulated in the multistep progression of Barretts esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013 23757351 miRBase MI0000300 miR-223 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin esophageal adenocarcinoma qRT-PCR Expression levels of miR-199a/b-3p, -199a-5p, -199b-5p, -200b, -200c, -223, and -375 were determined in microdissected tissues from cardiac mucosa, Barretts esophagus, dysplastic Barretts esophagus, and esophageal adenocarcinoma using quantitative real-time PCR. miR-223 expression was validated in precursors and esophageal adenocarcinomas from 95 patients with esophageal adenocarcinoma by in situ hybridization (ISH). miR-223 was transfected into two esophageal adenocarcinoma cell lines, and in vitro assays were conducted. Target genes were identified using Illumina microarray, and results were validated in cell lines and human specimens. cell line (OE33, JHesoAD1, HEEpiC) up-regulated sensitive PARP1 PARP1 NA validated 824 Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep 2013 23760062 miRBase MI0000489 miR-195 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Prediction of miRNA targeting genes by computer-based miRNA target detection programs . tissue and cell line (MCF-7,HBL-100,MCF-7/ADR,) up-regulated sensitive Raf-1 Raf-1 Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways validated 825 MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol 2013 23760980 miRBase MI0000737 miR-200a miRNA DB11672 Curcumin hepatocellular carcinoma RT-PCR In the study,we performed miRNA array analyses in two different HCC cell lines (HepG2 and HepJ5). The expression patterns of miR-200 family members were assessed with real-time PCR. We overexpressed miR-200 family members using a lentiviral system and selected stably transduced clones with antibiotics. The anticancer effects of curcumin on J5-200a, J5-200b, and J5-control cells were assessed by MTT assay, flow cytometry cell cycle analysis, and TUNEL assay. cell line (HepJ5, HepG2) up-regulated resistant NA NA NA validated 826 MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol 2013 23760980 miRBase MI0000342 miR-200b miRNA DB11672 Curcumin hepatocellular carcinoma RT-PCR In the study,we performed miRNA array analyses in two different HCC cell lines (HepG2 and HepJ5). The expression patterns of miR-200 family members were assessed with real-time PCR. We overexpressed miR-200 family members using a lentiviral system and selected stably transduced clones with antibiotics. The anticancer effects of curcumin on J5-200a, J5-200b, and J5-control cells were assessed by MTT assay, flow cytometry cell cycle analysis, and TUNEL assay. cell line (HepJ5, HepG2) up-regulated resistant NA NA NA validated 827 miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer 2013 23778521 miRBase MI0000783 miR-375 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer real-time RT-PCR The differentially expressed miRNAs in cervical squamous cell carcinoma tissues were screened by using a microarray platform (uParaflo Sanger miRBase release 13.0). The expression of miR-375 was determined by stem-loop RT-PCR using 23 clinical cervical cancer samples and 2 cervical cancer cell lines. We exogenously upregulated miR-375 expression in SiHa and Caski cells using a pre-miRNA lentiviral vector transfection and observed its impact on paclitaxel sensitivity using MTS. The cells that stably overexpressed miR-375 were subcutaneously injected into mice to determine tumour growth and chemo-sensitivity in vivo. cell line (SiHa,Caski) up-regulated resistant NA NA NA validated 828 MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013 23780685 miRBase MI0000289/MI0000269 miR-181a miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR Microarray analysis was performed to determine the differential expression patterns of miRNAs that target BCRP between the MX-resistant breast cancer cell line MCF-7/MX and its parental MX-sensitive cell line MCF-7. The expression levels of miRNA were determined by Quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.The nude mice xenograft model was used to identify the effect of miR-181a on mitoxantrone resistance. cell line (MCF-7,MCF-7/MX) down-regulated resistant BCRP/ABCG2 BCRP/ABCG2 NA validated 829 microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther 2013 23792642 miRBase MI0000071 miR-17 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The role of miR-17 in human glioblastoma cells was detected using plasmid constructs and luciferase assay , RIP-Assay, viability and clonogenic survival assays, immunoblotting analysis,Real-time PCR, etc. cell line (T98G, U373-MG ) down-regulated sensitive ATG7 ATG7 NA validated 830 miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 2013 23799850 miRBase MI0003778/MI0008191 miR-320c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer real-time qRT-PCR miRNA microarray analysis using gemcitabine-resistant clones of MiaPaCa2 (MiaPaCa2-RGs), PSN1 (PSN1-RGs), and their parental cells (MiaPaCa2-P, PSN1-P) was conducted. Changes in the anti-cancer effects of gemcitabine were studied after gain/loss-of-function analysis of the candidate miRNA. Further assessment of the putative target gene was performed in vitro and in 66 pancreatic cancer clinical samples. cell line (MiaPaCa2, PSN1) up-regulated resistant SMARCC1 SMARCC1 NA validated 831 Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res 2013 23806108 miRBase MI0000063 Let-7b miRNA DB00515 (APRD00359) Cisplatin glioblastoma qRT-PCR Glioblastoma cell line U251 cells were exposed to increasing doses of cisplatin for 6 months to establish cisplatin-resistant cell line U251R. The differential miRNA expression profiles in U251 and U251R cell lines were identified by microarray analysis and confirmed by Q-PCR. MiRNA mimics were transfected into U251R cells, and cellular response to cisplatin-induced apoptosis and cell cycle distribution were examined by FACS analysis. cell line (U251,U251R) down-regulated resistant cyclin D1 cyclin D1 NA validated 832 Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 2013 23807165 miRBase MI0000113 miR-106a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR MicroRNA expression in paclitaxel (PTX)-resistant SKpac sublines was compared with that of the PTX-sensitive, parental SKOV3 ovarian cancer cell line using microarray and qRT-PCR. The function of differentially expressed microRNAs in chemoresistant ovarian cancer was further evaluated by apoptosis, cell proliferation, and migration assays. cell line (SKOV3,SKpac-8, SKpac-10, SKpac-11, SKpac-12, SKpac-16, SKpac-17) up-regulated resistant BCL10 and caspase-7 BCL10 and caspase-7 NA validated 833 Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 2013 23807165 miRBase MI0003603 miR-591 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR MicroRNA expression in paclitaxel (PTX)-resistant SKpac sublines was compared with that of the PTX-sensitive, parental SKOV3 ovarian cancer cell line using microarray and qRT-PCR. The function of differentially expressed microRNAs in chemoresistant ovarian cancer was further evaluated by apoptosis, cell proliferation, and migration assays. cell line (SKOV3,SKpac-8, SKpac-10, SKpac-11, SKpac-12, SKpac-16, SKpac-17) down-regulated resistant ZEB1 ZEB1 NA validated 834 miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother 2013 23816136 miRBase MI0000789 miR-381 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil kidney cancer RT-PCR We investigated the cell survival, cell-cycle and apoptosis of 786-O and HK-2 cells treated with miR-381 and 5-FU. IC50 of 5-FU was calculated. To study apoptosis and G2/M arrest, we determined pHH3, mitotic index and caspase-3/7 activity. cell line (786-O, HK-2) up-regulated sensitive WEE1 WEE1 WEE1/Cdc2 pathway validated 835 Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 2013 23834154 miRBase MI0000077 miR-21 miRNA DB00773 (APRD00239) Etoposide leukemia qRT-PCR The role of miR-21 in leukemia cells was detected using protein expression and immunoprecipitation analysis, microRNA expression analysis, BrdU Proliferation Assay, cell cycle analysis , etc. cell line (K562,KYO-1) down-regulated sensitive Bcl-2 Bcl-2 NA validated 836 Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 2013 23834154 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin leukemia qRT-PCR The role of miR-21 in leukemia cells was detected using protein expression and immunoprecipitation analysis, microRNA expression analysis, BrdU Proliferation Assay, cell cycle analysis , etc. cell line (K562,KYO-1) down-regulated sensitive Bcl-2 Bcl-2 NA validated 837 Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013 23838916 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal cancer qRT-PCR We measured the serum levels of miR-21, miR-145, miR-200c, and let-7c by quantitative RT-PCR in 64 patients with esophageal cancer who underwent neoadjuvant chemotherapy. tissue down-regulated sensitive NA NA NA validated 838 Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013 23838916 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin esophageal cancer qRT-PCR We measured the serum levels of miR-21, miR-145, miR-200c, and let-7c by quantitative RT-PCR in 64 patients with esophageal cancer who underwent neoadjuvant chemotherapy. tissue down-regulated sensitive NA NA NA validated 839 Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013 23838916 miRBase MI0000650 miR-200c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer qRT-PCR We measured the serum levels of miR-21, miR-145, miR-200c, and let-7c by quantitative RT-PCR in 64 patients with esophageal cancer who underwent neoadjuvant chemotherapy. tissue down-regulated sensitive NA NA NA validated 840 Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013 23838916 miRBase MI0000650 miR-200c miRNA DB01248 (APRD00932) Docetaxel esophageal cancer qRT-PCR We measured the serum levels of miR-21, miR-145, miR-200c, and let-7c by quantitative RT-PCR in 64 patients with esophageal cancer who underwent neoadjuvant chemotherapy. tissue down-regulated sensitive NA NA NA validated 841 miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med 2013 23856992 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow cytometry was used to detect the apoptosis . cell line (A549,A549/CDDP) down-regulated resistant Bcl-2 Bcl-2 NA validated 842 Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet 2013 23866735 miRBase MI0000271 miR-181c miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR In the study, we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. tissue down-regulated resistant NA PBX3,HSP90B1,NMT2 and RAD21 NA validated 843 MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013 23879965 miRBase MI0002471 miR-487a miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The expression levels of miRNA were determined by QRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Nude mouse xenograft model was used to identify the effect of miR-487 . cell line (MCF-7,MCF-7/MX) up-regulated sensitive BCRP/ABCG2 BCRP/ABCG2 NA validated 844 Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol 2013 23888996 miRBase MI0000816 miR-335 miRNA DB00860 (APRD00197) Prednisolone paediatric acute lymphoblastic leukaemia Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs The target prediction programs was used to identify the target of MIR335 . cell line (697, Sup-B15 and RS4) up-regulated sensitive MAPK1 MAPK1 MAPK1,NFkappaB pathways validated 845 MicroRNA-29a induces resistance to gemcitabine through the Wnt/Beta-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 2013 23900458 miRBase MI0000087 miR-29a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The role of miR-29a in pancreatic cancer cells was detected using Real-time qRT-PCR, western blot, growth-inhibitory assay, annexin V assay, cell cycle analysis, luciferase reporter assay, etc. cell line (MIAPaCa-2, PSN-1, BxPC-3,Panc-1) down-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 846 MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. J Huazhong Univ Sci Technolog Med Sci 2013 23904379 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The different levels of miR-106a in A2780 cells and their resistant variant A2780/DDP cells were identified by using real-time PCR. MTT assay and flow cytometry were used to analyze the effect of miR-106a on cisplatin resistance of these paired cells. Real-time PCR, Western blotting and luciferase reporter assay were applied to explore whether Mcl-1 was a target of miR-106a. cell line (A2780,A2780/DDP) down-regulated resistant Mcl-1 Mcl-1 NA validated 847 MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res 2013 23915977 miRBase MI0000446/MI0000470 miR-125b miRNA DB00541 (APRD00495) Vincristine acute lymphocytic leukemia RT-qPCR The expression levels of miRNA were determined byy real-time quantitative PCR (RT-qPCR) . The amount of apoptosis was measured using the Annexin-V/propidium iodide staining method .MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293T) up-regulated resistant NA NA NA validated 848 MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res 2013 23915977 miRBase MI0000102 miR-100 miRNA DB00541 (APRD00495) Vincristine acute lymphocytic leukemia RT-qPCR The expression levels of miRNA were determined byy real-time quantitative PCR (RT-qPCR) . The amount of apoptosis was measured using the Annexin-V/propidium iodide staining method .MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293T) up-regulated resistant NA NA NA validated 849 MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res 2013 23915977 miRBase MI0000101 miR-99a miRNA DB00541 (APRD00495) Vincristine acute lymphocytic leukemia RT-qPCR The expression levels of miRNA were determined byy real-time quantitative PCR (RT-qPCR) . The amount of apoptosis was measured using the Annexin-V/propidium iodide staining method .MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293T) up-regulated resistant NA NA NA validated 850 Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci 2013 23924943 miRBase MI0000076 miR-20a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.Cell migration was detected by transwell migration and invasion assay. cell line ( SGC7901, MKN45, NUGC-3,GES-1) up-regulated resistant EGR2 EGR2 EGR2 signaling pathway validated 851 Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci 2013 23924943 miRBase MI0000076 miR-20a miRNA DB01248 (APRD00932) Docetaxel stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.Cell migration was detected by transwell migration and invasion assay. cell line ( SGC7901, MKN45, NUGC-3,GES-1) up-regulated resistant EGR2 EGR2 EGR2 signaling pathway validated 852 MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013 23925649 miRBase MI0000300 miR-223 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR The role of miR-223 in hepatocellular carcinoma cells was detected using plasmid construct , real-time PCR, western blot, EGFP reporter assay, cell viability assay (WST-1 assay), silencing ABCB1 by siRNA transfection, etc. cell line (Hep3B,HCC3, LM-6, SMMC7721,Huh-7, SK-Hep-1,HepG2, BEL-7402) up-regulated sensitive ABCB1 ABCB1 NA validated 853 MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013 23925649 miRBase MI0000300 miR-223 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel hepatocellular carcinoma RT-PCR The role of miR-223 in hepatocellular carcinoma cells was detected using plasmid construct , real-time PCR, western blot, EGFP reporter assay, cell viability assay (WST-1 assay), silencing ABCB1 by siRNA transfection, etc. cell line (Hep3B,HCC3, LM-6, SMMC7721,Huh-7, SK-Hep-1,HepG2, BEL-7402) up-regulated sensitive ABCB1 ABCB1 NA validated 854 MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013 23932924 miRBase MI0000113 miR-106a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/ADR,SGC7901/VCR) up-regulated resistant RUNX3 RUNX3 TGF-Beta family pathway validated 855 MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013 23932924 miRBase MI0000113 miR-106a miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/ADR,SGC7901/VCR) up-regulated resistant RUNX3 RUNX3 TGF-Beta family pathway validated 856 miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 2013 23950211 miRBase MI0000463/MI0000464 miR-153 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-PCR The role of miR-153 in colorectal cancer cells was detected using Cell lysis, real-time PCR, Western blotting, functional assays, tissue microarray development and immunohistochemistry, etc. cell line (SW480, SW620) up-regulated resistant FOXO3a FOXO3a NA validated 857 miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 2013 23950211 miRBase MI0000463/MI0000464 miR-153 miRNA DB00515 (APRD00359) Cisplatin colorectal cancer RT-PCR The role of miR-153 in colorectal cancer cells was detected using Cell lysis, real-time PCR, Western blotting, functional assays, tissue microarray development and immunohistochemistry, etc. cell line (SW480, SW620) up-regulated resistant FOXO3a FOXO3a NA validated 858 Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol 2013 23969999 miRBase MI0000450/MI0000451 miR-133a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer NA The role of miR-133a in human breast cancer cells was detected using low-temperature Fe(III) EPR, immunocytochemistry, drug sensitivity assay, western blot, etc. cell line (MCF-7,MCF-7/DOX,MCF-7/CDDP) up-regulated sensitive FTL FTL NA validated 859 Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol 2013 23969999 miRBase MI0000450/MI0000451 miR-133a miRNA DB00515 (APRD00359) Cisplatin breast cancer NA The role of miR-133a in human breast cancer cells was detected using low-temperature Fe(III) EPR, immunocytochemistry, drug sensitivity assay, western blot, etc. cell line (MCF-7,MCF-7/DOX,MCF-7/CDDP) up-regulated sensitive FTL FTL NA validated 860 miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013 23981989 miRBase MI0000471 miR-126 miRNA DB00526 (APRD00186) Oxaliplatin colon cancer qRT-PCR The expression pattern of miR-126 in high-density human colon cancer tissue microarray was analyzed by in situ hybridization. Further more, the biological function of miR-126 in colon cancer in vitro was investigated by establishing a stable miR-126 over-expression cell lines. cell line (SW480) up-regulated resistant IRS1,SLC7A5 and TOM1 IRS1,SLC7A5 and TOM1 NA validated 861 MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One 2013 23991130 miRBase MI0003665 miR-650 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The activity of caspase-3 was determined using the colorimetric CaspACE Assay System. Flow cytometric detection of apoptosis . tissue and cell line (SPC-A1, NCI-H1299,SPC-A1/DTX, H1299/DTX) down-regulated sensitive ING4 ING4 NA validated 862 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013 23994196 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell apoptosis was determined using an Annexin-V-FITC apoptosis detection kit . cell line (MCF-7, MCF-7/Doc,MCF-7/Adr,MCF-7/S ) up-regulated resistant PTEN PTEN NA validated 863 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013 23994196 miRBase MI0000299 miR-222 miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell apoptosis was determined using an Annexin-V-FITC apoptosis detection kit . cell line (MCF-7, MCF-7/Doc,MCF-7/Adr,MCF-7/S ) up-regulated resistant PTEN PTEN NA validated 864 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013 23994196 miRBase MI0000087 miR-29a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell apoptosis was determined using an Annexin-V-FITC apoptosis detection kit . cell line (MCF-7, MCF-7/Doc,MCF-7/Adr,MCF-7/S ) up-regulated resistant PTEN PTEN NA validated 865 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013 23994196 miRBase MI0000087 miR-29a miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell apoptosis was determined using an Annexin-V-FITC apoptosis detection kit . cell line (MCF-7, MCF-7/Doc,MCF-7/Adr,MCF-7/S ) up-regulated resistant PTEN PTEN NA validated 866 Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013 24009080 miRBase MI0000268 miR-34 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The role of miR-34 in colorectal cancer cells was detected using MTT assay, quantitative real-time PCR, western blot,dual luciferase reporter assays, migration and invasion assays in Boyden chambers, sphere formation assay, etc. cell line (SW480, DLD-1, Colo320, HCT15) up-regulated sensitive c-Kit NA NA validated 867 Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013 24026012 miRBase MI0000268 miR-34a miRNA DB00530 (APRD00951) Erlotinib head and neck cancer RT-qPCR The role of miR-34a head and neck cancer cells was detected by immunoblot,RT-qPCR,cell migration assay,microarray data analysis,etc. cell line (HN5,HN5-ER,FaDu) up-regulated sensitive NA Axl,AXIN2,CA9,CXCL10,FOSL1,FUT8,GAS1,KLF6,and PODXL NA validated 868 A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells. PLoS One 2013 24039897 miRBase MI0000650 miR-200c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer RT-PCR The expression levels of miRNA were determined by Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation. FACS Analysiswas used to determine if cells were viable, apoptotic, or necrotic. cell line (MCF-7, MDA-MB-231, MDA-MB-453,MCF-7/5-Fu ) up-regulated sensitive Bmi1 Bmi1 NA validated 869 A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells. PLoS One 2013 24039897 miRBase MI0000283 miR-203 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer RT-PCR The expression levels of miRNA were determined by Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation. FACS Analysiswas used to determine if cells were viable, apoptotic, or necrotic. cell line (MCF-7, MDA-MB-231, MDA-MB-453,MCF-7/5-Fu ) up-regulated sensitive Bmi1 Bmi1 NA validated 870 Relationship between the expression level of miR-29c and biological behavior of gastric cancer Zhonghua Zhong Liu Za Zhi 2013 24054006 miRBase MI0000735 miR-29c miRNA DB01248 (APRD00932) Docetaxel stomach cancer qRT-PCR MicroRNA microarray was applied to assess the miRNAs expression profile of gastric cancer. Quantitative real-time PCR was used to detect the expression of miR-29c in 64 cases of gastric cancer tissues and corresponding normal gastric epithelium, as well as cell lines GES-1, BGC-823 and SGC-7901 cells. MTT assay and flow cytometry were applied to detect the effects of forced expression of miR-29c in gastric cancer BGC-823 cells including cell proliferation, apoptosis, cell cycle and drug sensitivity. Quantitative real-time PCR, Western blot and luciferase reporter assay were used to explore the targeted relationship between miR-29c and myeloid cell leukemia-1 (Mcl-1) cell line (BGC-823,SGC-7901) up-regulated sensitive Mcl-1 Mcl-1 NA validated 871 Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 2013 24075517 miRBase MI0000270/MI0000683 miR-181b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The effects of overexpression or knockdown of miR-181b on four pancreatic cancer cell lines exposed to gemcitabine were examined. The induction of apoptosis and the changes of the cylindromatosis (CYLD) protein were examined. Furthermore, the effect of small interference RNA for CYLD (siCYLD) on cell viability and the relationship between CYLD and nuclear factor kappa B were investigated. cell line ( BxPC3, MiaPaCa2, Panc1, PSN1) up-regulated resistant CYLD CYLD NF-kappaB pathway validated 872 miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 2013 24084898 miRBase MI0000285 miR-205 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow cytometric analysis of apoptosis.Cell migration was detected by migration and invasion assay. tissue and cell line (A549, SPC-A1, SK-MES-1,16HBE) up-regulated resistant PTEN PTEN PTEN signaling pathway validated 873 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000109 miR-103 miRNA DB00515 (APRD00359) Cisplatin cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 874 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000114 miR-107 miRNA DB00515 (APRD00359) Cisplatin cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 875 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000109 miR-103 miRNA DB04690 Camptothecin cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 876 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000114 miR-107 miRNA DB04690 Camptothecin cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 877 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000109 miR-103 miRNA DB00773 (APRD00239) Etoposide cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 878 Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res 2013 24088786 miRBase MI0000114 miR-107 miRNA DB00773 (APRD00239) Etoposide cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell survival was assessed by crystal violet staining as described . cell line (U2OS, HeLa, H1299) up-regulated sensitive RAD51 and RAD51D RAD51 and RAD51D NA validated 879 MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 2013 24099768 miRBase MI0003560 miR-92b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Enumeration of apoptotic cells was done by using FITC conjugated Annexin V and PI . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (A549,A549/CDDP) down-regulated sensitive PTEN PTEN NA validated 880 Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2013 24100610 miRBase MI0000066 let-7e miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Atomic absorption spectroscopy for detection of cisplatin in tumor tissue . The viability of cells treated with cisplatin after transfection with let-7e agomirs was assessed by Trypan blue exclusion method. cell line (A2780, ES2, SKOV3,A2780/CP) down-regulated resistant EZH2 and CCND1 EZH2 and CCND1 NA validated 881 MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer 2013 24103454 miRBase MI0000079 miR-23a miRNA DB00773 (APRD00239) Etoposide hepatocellular carcinoma qRT-PCR The anti-tumor effect of chemotherapeutic agents in HCC cells were examined in vitro and in vivo xenograft model. Expression of mRNA and miRNAs were determined by quantitative real-time PCR. Protein expression was analyzed by immunoblotting. cell line (HepG2,HEK293T) up-regulated sensitive TOP1 TOP1 NA validated 882 miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai) 2013 24108762 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line (SGC7901,SGC7901/DDP) up-regulated resistant PTEN PTEN PTEN/Akt pathway validated 883 Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai) 2013 24145606 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A2780,A2780/DDP ) down-regulated resistant XIAP XIAP miR-130a/XIAP signaling pathway validated 884 miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One 2013 24147037 miRBase MI0000105/MI0000107 miR-29b miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma NA Microarray analysis was used to determine the miRNA expression profiles of two CCA cell lines, HuH28 and HuCCT1. To determine the effect of candidate miRNAs on Gem sensitivity, expression of each candidate miRNA was modified via either transfection of a miRNA mimic or transfection of an anti-oligonucleotide. Ontology-based programs were used to identify potential target genes of candidate miRNAs that were confirmed to affect the Gem sensitivity of CCA cells. cell line (HuCCT1, HuH28) up-regulated sensitive PIK3R1,MMP-2 PIK3R1,MMP-2 NA validated 885 miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One 2013 24147037 miRBase MI0000285 miR-205 miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma NA Microarray analysis was used to determine the miRNA expression profiles of two CCA cell lines, HuH28 and HuCCT1. To determine the effect of candidate miRNAs on Gem sensitivity, expression of each candidate miRNA was modified via either transfection of a miRNA mimic or transfection of an anti-oligonucleotide. Ontology-based programs were used to identify potential target genes of candidate miRNAs that were confirmed to affect the Gem sensitivity of CCA cells. cell line (HuCCT1, HuH28) up-regulated sensitive NA NA NA validated 886 miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One 2013 24147037 miRBase MI0000298 miR-221 miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma NA Microarray analysis was used to determine the miRNA expression profiles of two CCA cell lines, HuH28 and HuCCT1. To determine the effect of candidate miRNAs on Gem sensitivity, expression of each candidate miRNA was modified via either transfection of a miRNA mimic or transfection of an anti-oligonucleotide. Ontology-based programs were used to identify potential target genes of candidate miRNAs that were confirmed to affect the Gem sensitivity of CCA cells. cell line (HuCCT1, HuH28) up-regulated sensitive PIK3R1 PIK3R1 NA validated 887 MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med 2013 24148180 miRBase MI0000778 miR-370 miRNA DB04865 Homoharringtonine chronic myeloid leukemia qRT-PCR The synergistic action between miR-370 and HHT was examined by flow cytometry. The effect of HHT on miR-370 expression was determined by quantitative RT-PCR (qRT-PCR). The expression of miR-370 and Forkhead box M1 (FoxM1) in 23 patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) and 10 patients with blast-crisis CML (CML-BP) as well as miR-370-targeted FoxM1 was determined by qRT-PCR and western blot analysis. cell line (K562) up-regulated sensitive FoxM1 FoxM1 miR-370-FoxM1 pathway validated 888 miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem Biophys Res Commun 2013 24148247 miRBase MI0000289/MI0000269 miR-181a miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Transwell was selected to test the invasive ability of the cells .Cell migration was assessed by wound-healing assay. cell line (CAL27, SCC15) up-regulated sensitive Twist1 Twist1 miR-181a-Twist1 pathway validated 889 Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 2013 24148817 miRBase MI0000070/MI0000115 miR-16 miRNA DB00642 (APRD00573, EXPT02075) Pemetrexed malignant pleural mesothelioma RT-qPCR MicroRNA expression was analysed by TaqMan-based RT-qPCR in MPM tumour specimens and cell lines. MicroRNA expression was restored in vitro using microRNA mimics, and effects on proliferation, drug sensitivity and target gene expression were assessed. Xenograft-bearing mice were treated with miR-16 mimic packaged in minicells targeted with epidermal growth factor receptor (EGFR)-specific antibodies. tissue and cell line (H28, MSTO-2011H) up-regulated sensitive Bcl-2,CCND1 Bcl-2,CCND1 NA validated 890 Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 2013 24148817 miRBase MI0000070/MI0000115 miR-16 miRNA DB00441 (APRD00201) Gemcitabine malignant pleural mesothelioma RT-qPCR MicroRNA expression was analysed by TaqMan-based RT-qPCR in MPM tumour specimens and cell lines. MicroRNA expression was restored in vitro using microRNA mimics, and effects on proliferation, drug sensitivity and target gene expression were assessed. Xenograft-bearing mice were treated with miR-16 mimic packaged in minicells targeted with epidermal growth factor receptor (EGFR)-specific antibodies. tissue and cell line (H28, MSTO-2011H) up-regulated sensitive Bcl-2,CCND1 Bcl-2,CCND1 NA validated 891 miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst 2013 24168967 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR A bioinformatics-driven microRNA (miR) library screening was used to identify miRs that regulate BRCA1 expression. The effects of miR-9 on cisplatin (cDDP) and PARP inhibitor sensitivity were measured in ovarian cancer cells and C13* xenograft mice (n = 6 per group). The roles of miR-9 on prognosis were assessed in a cohort of ovarian cancer patients (n = 113) with Kaplan-Meier and Cox proportional hazards analyses. All statistical tests were two-sided. tissue and cell line (AG014699) up-regulated sensitive BRCA1 BRCA1 homologous-recombination (HR) pathway validated 892 Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 2013 24169343 miRBase MI0000342 miR-200b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil cholangiocarcinoma RT-qPCR In this study, we identified dysregulated microRNAs (miRNAs, miR) in cholangiocarcinoma tissue by microarray analysis, and subsequent real-time PCR and northern blot analyses validated the expression of candidate miR. We performed functional analyses and investigated the relationship between miR-200b/c expression and the properties of cholangiocarcinoma cells. A dual luciferase assay was applied to examine the effect of miRNAs on the 3'-UTR of target genes, and we demonstrated the function of the target gene by siRNA transfection identifying the downstream pathway via western blotting. tissue and cell line (TFK-1, QBC939) up-regulated sensitive SUZ12 and ROCK2 SUZ12 and ROCK2 NA validated 893 Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 2013 24169343 miRBase MI0000650 miR-200c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil cholangiocarcinoma RT-qPCR In this study, we identified dysregulated microRNAs (miRNAs, miR) in cholangiocarcinoma tissue by microarray analysis, and subsequent real-time PCR and northern blot analyses validated the expression of candidate miR. We performed functional analyses and investigated the relationship between miR-200b/c expression and the properties of cholangiocarcinoma cells. A dual luciferase assay was applied to examine the effect of miRNAs on the 3'-UTR of target genes, and we demonstrated the function of the target gene by siRNA transfection identifying the downstream pathway via western blotting. tissue and cell line (TFK-1, QBC939) up-regulated sensitive SUZ12 and ROCK2 SUZ12 and ROCK2 NA validated 894 Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 2013 24199791 miRBase MI0000342 miR-200b miRNA DB00530 (APRD00951) Erlotinib lung adenocarcinoma Real-Time RT-PCR Hh signaling was inhibited by specific siRNA and by GDC-0449, a small molecule antagonist of G protein coupled receptor smoothened in the Hh pathway. Not all NSCLC patients are likely to benefit from EGFR-TKIs and, therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant EMT cells. Specific pre- and anti-miRNA preparations were used to study the mechanistic involvement of miRNAs in drug resistance mechanism. cell line (A549, H1299,A549M) up-regulated sensitive NA NA Hedgehog pathway validated 895 Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 2013 24199791 miRBase MI0000064 let-7c miRNA DB00530 (APRD00951) Erlotinib lung adenocarcinoma Real-Time RT-PCR Hh signaling was inhibited by specific siRNA and by GDC-0449, a small molecule antagonist of G protein coupled receptor smoothened in the Hh pathway. Not all NSCLC patients are likely to benefit from EGFR-TKIs and, therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant EMT cells. Specific pre- and anti-miRNA preparations were used to study the mechanistic involvement of miRNAs in drug resistance mechanism. cell line (A549, H1299,A549M) up-regulated sensitive NA NA Hedgehog pathway validated 896 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000069 miR-15a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 897 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000070/MI0000115 miR-16 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 898 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000440 miR-27b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 899 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000441 miR-30b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 900 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000477 miR-146a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 901 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MIMAT0002809 miR-146b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 902 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000289/MI0000269 miR-181a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 903 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0003139 miR-181d miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 904 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000488/MI0000732 miR-194 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 905 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000069 miR-15a miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 906 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000070/MI0000115 miR-16 miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 907 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000440 miR-27b miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 908 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000441 miR-30b miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 909 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000477 miR-146a miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 910 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MIMAT0002809 miR-146b-5p miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 911 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000289/MI0000269 miR-181a miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 912 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0003139 miR-181d miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 913 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000488/MI0000732 miR-194 miRNA DB00958 (APRD00466) Carboplatin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 914 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000069 miR-15a miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 915 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000070/MI0000115 miR-16 miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 916 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000440 miR-27b miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 917 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000441 miR-30b miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 918 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000477 miR-146a miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 919 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MIMAT0002809 miR-146b-5p miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 920 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000289/MI0000269 miR-181a miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 921 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0003139 miR-181d miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 922 Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma Zhonghua Bing Li Xue Za Zhi 2013 24314246 miRBase MI0000488/MI0000732 miR-194 miRNA DB00305 (APRD00284) Mitomycin hepatocellular carcinoma RT-qPCR Cellular morphology was observed by histology and transmission electron microscopy. MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) followed by real time quantitative PCR validation. cell line (Huh-7/ADM, Huh-7/CBP, Huh-7/MMC) up-regulated resistant NA NA NA predicted 923 The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cell Physiol Biochem 2013 24335172 miRBase MI0000289/MI0000269 miR-181a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR Cell survival analysis was detected by Cell Counting Kit-8 assay. Apoptotic cells were quantitatively detected using FITC Annexin V apoptosis Detection Kit I. Bcl-2 protein expression was measured by western blot. Luciferase reporter vector with the putative BCL-2 3 untranslated region (3UTR) was constructed to explore whether BCL-2 was a direct target gene of miR-181a. Real-time PCR was performed to test the expression of miR-181a and Bcl-2 in the selected breast cancer tissue samples. cell line (MCF-7,MCF-7/ADR) down-regulated resistant Bcl-2 Bcl-2 NA validated 924 Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Pharmazie 2013 24400442 miRBase MI0000064 Let-7c miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549,A549/DDP) up-regulated sensitive ABCC2 and Bcl-XL ABCC2 and Bcl-XL NA validated 925 Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 2013 24460313 miRBase MI0000073 miR-19a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative real- time PCR. tissue up-regulated resistant NA NA NA validated 926 Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 2013 24460313 miRBase MI0000073 miR-19a miRNA DB00650 (APRD00698) Leucovorin colorectal cancer qRT-PCR To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative real- time PCR. tissue up-regulated resistant NA NA NA validated 927 Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 2013 24460313 miRBase MI0000073 miR-19a miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative real- time PCR. tissue up-regulated resistant NA NA NA validated 928 MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev 2013 24460329 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma RT-qPCR We retrospectively collected 41 cases of advanced pancreatic cancer patients who were sensitive or resistant to gemcitabine and assessed levels of serum circulating miR-21 for correlation with cytotoxic activity. Histone acetylation in the miR-21 promoter was also studied in gemcitabine-sensitive and gemcitabine-resistant PDAC cells. Gemcitabine-resistant HPAC and PANC-1 cells were transfected with pre-miR-21 precursors (pre-miR-21) and antisense oligonucleotides (anti-miR-21), and were treated with TSA. Finally, invasion and metastasis assays were performed and alteration in mir-21, PTEN, AKT and pAKT level was evaluated in these cells. cell line up-regulated resistant PTEN PTEN NA validated 929 Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines Sichuan Da Xue Xue Bao Yi Xue Ban 2013 24490491 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR A2780s and A2780/DDP cells were divided into four groups, and treated with lipo2000 (Lip), miR-negative (miR-NC) control, miR-130a-mimics (miR-130a-M increasing the expression of miR-130a and the agent), and miR-130a-inhibitor (miR-130a-I downregulating miR-130a expression), respectively. The proliferation of cells and their sensitivity to cisplatin were detected by MTT assay. RT-PCR and western blot were performed to examine the levels of MDR1, PTEN mRNA and proteins. cell line (A2780s,A2780/DDP) up-regulated resistant NA NA NA validated 930 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014 23318422 miRBase MI0000462 miR-152 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow cytometry analysis was used to determine if cells were viable, apoptotic, or necrotic. Nude mice model was used to idetify the role of miR-152 and miR-185 . cell line ( SKOV3, A2780,A2780/DDP,SKOV3/DDP) up-regulated sensitive DNMT1 DNMT1 NA validated 931 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014 23318422 miRBase MI0000482 miR-185 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow cytometry analysis was used to determine if cells were viable, apoptotic, or necrotic. Nude mice model was used to idetify the role of miR-152 and miR-185 . cell line ( SKOV3, A2780,A2780/DDP,SKOV3/DDP) up-regulated sensitive DNMT1 DNMT1 NA validated 932 MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014 23438844 miRBase MI0000476/MI0000455 miR-138 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by invasion assay. cell line up-regulated sensitive FAK FAK NA validated 933 MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014 23438844 miRBase MI0000476/MI0000455 miR-138 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by invasion assay. cell line up-regulated sensitive FAK FAK NA validated 934 MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014 23438844 miRBase NA miR-135 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by invasion assay. cell line up-regulated sensitive FAK FAK NA validated 935 MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014 23438844 miRBase NA miR-135 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by invasion assay. cell line up-regulated sensitive FAK FAK NA validated 936 MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res 2014 23821457 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression of miRNA-200c and RhoE were investigated in gastric cancer tissues and cells (SGC7901 and SGC7901/DDP) by qRT-PCR. A luciferase reporter assay was done to understand the potential correlation between miRNA-200c and RhoE. Pre-miR-200c was transfected in SGC7901/DDP cells to confirm whether miRNA-200c could regulate RhoE expression. RhoE was knocked down to explore the role of RhoE on sensitivity of chemotherapy in gastric cancer by MTT. Western blot analysis was performed to further explore the mechanism of RhoE in regulating drug resistance. cell line (SGC7901,SGC7901/DDP) up-regulated sensitive RhoE RhoE NA validated 937 miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs 2014 23857508 miRBase MI0000446/MI0000470 miR-125b miRNA DB00853 (APRD00557) Temozolomide glioblastoma PCR We modified the levels of miR-125b expression in primary GSCs in order to observe the effect on sensitivity to temozolomide on invasion, and we further analyzed the differences in mechanism between miR-125b treatment alone and treatment with miR-125b plus temozolomide using the Cancer PathwayFinder PCR Array. cell line down-regulated sensitive PIAS3 PIAS3 NA validated 938 MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 2014 23862748 miRBase MI0000268 miR-34a miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Huh-7, MHCC97H,HL-7702) up-regulated sensitive Bcl-2 Bcl-2 NA validated 939 miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014 23893241 miRBase MIMAT0004778 miR-508-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer real-time qRT-PCR The expression levels of miRNA were determined by real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated sensitive ABCB1 and ZNRD1 ABCB1 and ZNRD1 NA validated 940 miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014 23893241 miRBase MIMAT0004778 miR-508-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer real-time qRT-PCR The expression levels of miRNA were determined by real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated sensitive ABCB1 and ZNRD1 ABCB1 and ZNRD1 NA validated 941 miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014 23893241 miRBase MIMAT0004778 miR-508-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer real-time qRT-PCR The expression levels of miRNA were determined by real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated sensitive ABCB1 and ZNRD1 ABCB1 and ZNRD1 NA validated 942 miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014 23893241 miRBase MIMAT0004778 miR-508-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer real-time qRT-PCR The expression levels of miRNA were determined by real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated sensitive ABCB1 and ZNRD1 ABCB1 and ZNRD1 NA validated 943 Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer 2014 23904094 miRBase MI0000087 miR-29 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The expression levels of miRNA were determined by reverse transcription and quantitative polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( CP70, A2780, HeyC2, SKOV3,CP70sps) down-regulated resistant COL1A1 COL1A1 NA validated 944 miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 2014 23934188 miRBase MI0000454 miR-137 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma qRT-PCR The role of miR-137 in neuroblastoma cells was detected using quantitative real-time PCR, molecular cloning and assays, chromatin immunoprecipitation assay, cellular assays, soft agar colony-formation assay, mouse xenografts and immunohistochemical analyses, etc. cell line (293T, HepG2, LS174,UKF-NB3, UKF-NB3/Dox-R,) up-regulated sensitive CAR CAR NA validated 945 miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 2014 24038379 miRBase MI0003135 miR-495 miRNA DB12257 Platinum lung non-small cell carcinoma RT-PCR The role of miR-495 in non-small cell lung cancer cells was detected using real-time PCR, drug sensitivity assay , plasmid construct and EGFP reporter , western blot , immunohistochemistry,etc. cell line (H1299, A549,A549/CDDP) down-regulated resistant ATP7A ATP7A NA validated 946 miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 2014 24068565 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow cytometry detection of the effects of miR-34a on the cellular apoptosis of cisplatin-induce gastric cancer cells . cell line (SGC-7901,SGC-7901/DDP) up-regulated sensitive NA NA PI3K/AKT/survivin pathway validated 947 MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 2014 24099915 miRBase MI0000089 miR-31 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-time quantitative RT-PCR The expression levels of miRNA were determined by Real-time quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The apoptosis was analyzed on a FACS Calibur flow cytometer using an Annexin V-FITC/PI . cell line (SPC-A-1, LTEP-a-2, NCI-H460, NCI-H1299 ) up-regulated resistant ABCB9 ABCB9 NA validated 948 MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014 24104394 miRBase MI0000274 miR-187 miRNA DB00188 (APRD00828, DB07475) Bortezomib peripheral T-cell lymphoma real-time quantitative RT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Jurkat, MOLT4, HUT78) up-regulated sensitive NA NA NA validated 949 MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014 24104394 miRBase MI0000274 miR-187 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin peripheral T-cell lymphoma real-time quantitative RT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Jurkat, MOLT4, HUT78) up-regulated resistant NA NA NA validated 950 MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014 24104394 miRBase MI0000274 miR-187 miRNA DB00531 (APRD00408) Cyclophosphamide peripheral T-cell lymphoma real-time quantitative RT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Jurkat, MOLT4, HUT78) up-regulated resistant NA NA NA validated 951 MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014 24104394 miRBase MI0000274 miR-187 miRNA DB00515 (APRD00359) Cisplatin peripheral T-cell lymphoma real-time quantitative RT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Jurkat, MOLT4, HUT78) up-regulated resistant NA NA NA validated 952 MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014 24104394 miRBase MI0000274 miR-187 miRNA DB00441 (APRD00201) Gemcitabine peripheral T-cell lymphoma real-time quantitative RT-PCR The expression levels of miRNA were determined by real-time quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Jurkat, MOLT4, HUT78) up-regulated resistant NA NA NA validated 953 High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 2014 24122631 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The role of miR-21 in colon cancer cells was detected using qRT-PCR, MSI analysis, etc. tissue up-regulated resistant NA NA NA validated 954 miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol 2014 24145123 miRBase MI0000283 miR-203 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR The expression levels of miRNA were determined by quantitative real-time PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability quantification by trypan blue staining . cell line (HT29, RKO, HCT116,HT29-OxR, RKO-OxR, HCT116-OxR) up-regulated resistant ATM ATM NA validated 955 The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol 2014 24154840 miRBase MI0000077 miR-21 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab stomach cancer qRT-PCR Correlations between the expression levels of miR-21, PTEN, and p-AKT were analyzed by real-time PCR and Western blot test in HER2-positive GC cell lines. The effects of overexpression or suppression of miR-21 on the sensitivity of GC cells to trastuzumab were also analyzed in vitro. cell line (MKN45, NUGC4, NCI-N87) up-regulated resistant PTEN PTEN miR-21/PTEN pathway validated 956 MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res 2014 24183997 miRBase MI0000289/MI0000269 miR-181a miRNA DB00515 (APRD00359) Cisplatin cervical squamous cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction and those of protein were by Western blot analysis.Assessment of cell viability and proliferation using the Cell Counting Kit-8 . Cell apoptosis was determined by assessing the activation of caspase-3 and caspase-7 . Flow cytometric analysis of cell cycle distribution . tissue and cell line (SiHa, Me180) up-regulated resistant PRKCD PRKCD NA validated 957 MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother 2014 24210072 miRBase MI0000087 miR-29a miRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma qRT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Three online programs, miRanda, TargetScan and TarBase, were used in combination with previous reports, for predicting the target of miRNAs .Cell migration was detected by transwell invasion assay.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (sSCC-4, SCC-9, SCC25) down-regulated resistant MMP2 MMP2 NA validated 958 MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014 24211739 miRBase MI0000103/MI0000739 miR-101 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR MiR-101 and EZH2 expressions were evaluated in tumor tissues of 99 HCC patients and 7 liver cancer cell lines by real-time PCR. Luciferase reporter assay was employed to validate whether EZH2 represents a target gene of miR-101. The effect of miR-101 on HCC growth as well as programmed cell death was studied in vitro and in vivo. cell line up-regulated sensitive EZH2 EZH2 NA validated 959 MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014 24211739 miRBase MI0000103/MI0000739 miR-101 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-PCR MiR-101 and EZH2 expressions were evaluated in tumor tissues of 99 HCC patients and 7 liver cancer cell lines by real-time PCR. Luciferase reporter assay was employed to validate whether EZH2 represents a target gene of miR-101. The effect of miR-101 on HCC growth as well as programmed cell death was studied in vitro and in vivo. cell line up-regulated sensitive EZH2 EZH2 NA validated 960 MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal 2014 24216611 miRBase MI0000767 miR-365 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer NA We employed the Agilent Whole Human Genome Oligo DNA microarray to compare the gene expression profiles between miR-365-introduced and control miR-introduced Panc-1 or AsPC-1 cells. The protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The potential target site of hsa-miR-365 was identified using TargetScan. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (s Panc-1, AsPC-1) up-regulated resistant SHC1,BAX SHC1,BAX NA validated 961 MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors. Acta Biochim Biophys Sin (Shanghai) 2014 24217767 miRBase MI0000542 miR-320a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor qRT-PCR In this study, we applied the SYBR-green quantitative polymerase chain reaction-based array approach to screen the differentially expressed miRNAs between primary GIST patients and imatinib-resistant patients. The selected candidate miRNAs were validated in a cohort of 12 GIST patients. tissue down-regulated resistant NA NA NA validated 962 Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol 2014 24248543 miRBase MI0000461 miR-145 miRNA DB08881 (DB05238) Vemurafenib colorectal cancer RT-PCR The expression levels of miRNA were determined by Real-time polymerase chain reaction (PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.TUNEL staining was used to detect apoptotic cell death. TUNEL staining was used to detect apoptotic cell death. The xenograft of tumor tissues was used to test the role of miR-145 . cell line (colo205, colo205/V ) up-regulated sensitive NA NA NA validated 963 MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem 2014 24249161 miRBase MI0000079 miR-23a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The miR-23a expression in 5-FU-treated and untreated colon cancer cells and tissues was assessed using real-time PCR analysis. To determine the function of miR-23a in the regulation of 5-FU induced apoptosis, cell proliferation, cytotoxicity,and apoptosis analyses were performed. Dual luciferase reporter assay was used to identify the apoptosis-related target gene for miR-23a. The activity of caspases-3, -7, and -9 were also assessed in miR-23a antisense and 5-FU treated tumor cells. A xenograft tumor model was established to evaluate the biological relevance of altered miR-23a expression to the 5-FU-based chemotherapy in vivo. cell line ( HCT116 and HT29) up-regulated sensitive APAF-1 APAF-1 APAF-1/caspase-9 apoptotic pathway validated 964 MiR-134/487b/655 cluster regulates TGF-Beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 2014 24258346 miRBase MI0000474 miR-134 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse transcription PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, LC2/ad, PC3, PC9, RERF-LCKJ, RERF-LCMS, PC14, ABC-1) up-regulated resistant MAGI2 MAGI2 NA validated 965 MiR-134/487b/655 cluster regulates TGF-Beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 2014 24258346 miRBase MI0003530 miR-487b miRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse transcription PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549,LC2/ad,PC3,PC9,RERF-LCKJ,RERF-LCMS,PC14,ABC-1) up-regulated resistant MAGI2 MAGI2 NA validated 966 Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. Biomed Pharmacother 2014 24268810 miRBase MI0000064 let-7c miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined byreverse transcription (RT)-PCR and quantitative real-time (qRT)-PCR . Those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . cell line (H1975) up-regulated sensitive NA NA PI3K/Akt pathway,ERK signaling pathways. validated 967 Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 2014 24275137 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HT-29,HT-29/5-FU) up-regulated resistant hMSH2 hMSH2 NA validated 968 MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 2014 24286315 miRBase MI0000298 miR-221 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR The expression levels of miRNA were determined byQuantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. Metastasis assay in nude mice was used to text the role of miR-221 . tissue and cell line (SK-BR-3 ) up-regulated resistant PTEN PTEN NA validated 969 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014 24304648 miRBase MI0000076 miR-20a miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR We studied differential miRNA expression by miRNA array from serum of 253 patients who had chemotherapy treatment. We screened the differentially expressed serum miRNAs with TaqMan low-density arrays using pooled CRC patient serum samples. Differential expression was validated using hydrolysis probe-based stem-loop quantitative reverse transcription PCR in individual samples. We performed additional unsupervised cluster to analyse the differential expression of serum miRNA between the chemosensitive and chemoresistant patients. A distinct miRNA expression signature in response to chemotherapy was identified. tissue up-regulated resistant NA NA NA predicted 970 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014 24304648 miRBase NA miR-130 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR We studied differential miRNA expression by miRNA array from serum of 253 patients who had chemotherapy treatment. We screened the differentially expressed serum miRNAs with TaqMan low-density arrays using pooled CRC patient serum samples. Differential expression was validated using hydrolysis probe-based stem-loop quantitative reverse transcription PCR in individual samples. We performed additional unsupervised cluster to analyse the differential expression of serum miRNA between the chemosensitive and chemoresistant patients. A distinct miRNA expression signature in response to chemotherapy was identified. tissue up-regulated resistant NA NA NA predicted 971 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014 24304648 miRBase MI0000461 miR-145 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR We studied differential miRNA expression by miRNA array from serum of 253 patients who had chemotherapy treatment. We screened the differentially expressed serum miRNAs with TaqMan low-density arrays using pooled CRC patient serum samples. Differential expression was validated using hydrolysis probe-based stem-loop quantitative reverse transcription PCR in individual samples. We performed additional unsupervised cluster to analyse the differential expression of serum miRNA between the chemosensitive and chemoresistant patients. A distinct miRNA expression signature in response to chemotherapy was identified. tissue up-regulated resistant NA NA NA predicted 972 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014 24304648 miRBase MI0000292 miR-216 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR We studied differential miRNA expression by miRNA array from serum of 253 patients who had chemotherapy treatment. We screened the differentially expressed serum miRNAs with TaqMan low-density arrays using pooled CRC patient serum samples. Differential expression was validated using hydrolysis probe-based stem-loop quantitative reverse transcription PCR in individual samples. We performed additional unsupervised cluster to analyse the differential expression of serum miRNA between the chemosensitive and chemoresistant patients. A distinct miRNA expression signature in response to chemotherapy was identified. tissue up-regulated resistant NA NA NA predicted 973 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014 24304648 miRBase MI0000780 miR-372 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR We studied differential miRNA expression by miRNA array from serum of 253 patients who had chemotherapy treatment. We screened the differentially expressed serum miRNAs with TaqMan low-density arrays using pooled CRC patient serum samples. Differential expression was validated using hydrolysis probe-based stem-loop quantitative reverse transcription PCR in individual samples. We performed additional unsupervised cluster to analyse the differential expression of serum miRNA between the chemosensitive and chemoresistant patients. A distinct miRNA expression signature in response to chemotherapy was identified. tissue up-regulated resistant NA NA NA predicted 974 Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Lett 2014 24316511 miRBase MI0003175 miR-520h miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.The cell viability was measured by MTS . cell line (MKN45, MKN28) up-regulated sensitive HDAC1 HDAC1 NA validated 975 miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncol Rep 2014 24317363 miRBase MI0000342 miR-200b miRNA DB01248 (APRD00932) Docetaxel prostate cancer Real-time quantitative RT-PCR The expression levels of miRNA were determined by Real-time quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . tissue and cell line (LNCaP, PC3, DU145) up-regulated sensitive Bmi-1 Bmi-1 NA validated 976 p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. Mol Cancer Res 2014 24324033 miRBase MI0000298 miR-221 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The methylation status of neighboring CpG islands of miR-221 was analyzed by Bisulfite Sequencing PCR and methylation-specific PCR.Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay . cell line (HepG2, Hep3B) down-regulated sensitive MDM2 MDM2 NA validated 977 MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 2014 24331411 miRBase MI0000077 miR-21 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR EGFR-TKI-sensitive human lung adenocarcinoma cell line PC9 and the acquired resistant cell line, PC9R, were used. Lentiviral vectors were used to infect PC9 or PC9R to regulate the miR-21 expression. The expression of targeted proteins PTEN and PDCD4 was controlled by RNA interference. MicroRNA array, RT-PCR and TaqMan MicroRNA Assays were used to detect miR-21 expression. The MTT and Annexin V assays were used to determine proliferation and apoptosis. Western Blot and immunohistochemistry were used to analyze target protein expression (PTEN, PDCD4, Akt, p-Akt). We also constructed PC9R xenograft tumor model to observe the relationship between miR-21 and EGFR-TKI resistance in vivo and validated it in the clinical serum specimens of NSCLC patients treated with EGFR-TKI. cell line (PC9,PC9R) up-regulated resistant PTEN, PDCD4 PTEN, PDCD4 PI3K/Akt pathway validated 978 Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol 2014 24345332 miRBase MI0000255 miR-30d miRNA DB00515 (APRD00359) Cisplatin anaplastic thyroid carcinoma Real-time RT-PCR,qRT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and qRT-PCR .Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The ATC xenograft mouse model was used to idnentify the role of miR-30d . cell line (SW1736, 8305C ) up-regulated sensitive beclin 1 beclin 1 NA validated 979 microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett 2014 24348845 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The present study investigated the role of miR-106a in the development of drug resistance in ovarian cancer cells. The expression of miR-106a in the ovarian cancer OVCAR3 cell line and the cisplatin (CDDP)-resistant ovarian cancer OVCAR3/CIS cell line was detected using stem-loop quantitative (q)PCR. The OVCAR3 and OVCAR3/CIS cells were transfected with mimics or inhibitors of miR-106a or with negative control (NC) RNA using lipofectamine 2000. Luciferase reporter assays were used to determine whether PDCD4 was a direct target of miR-106a in the OVCAR3 cells. The expression levels of the PDCD4 proteins were assessed using qRT-PCR and western blotting, respectively. Drug sensitivity was analyzed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, while apoptosis was determined by fluorescence-activating cell sorting analysis. cell line (OVCAR3,OVCAR3/CIS) up-regulated resistant PDCD4 PDCD4 NA validated 980 Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci 2014 24350829 miRBase MI0000293 miR-217 miRNA DB01254 Dasatinib Ph(+) leukemia RT-PCR The expression levels of miRNA were determined by reverse transcription-polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Methylation analysis by methylation-specific PCR, cell line (K562,K562DR) up-regulated sensitive DNMT3A DNMT3A NA validated 981 Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci 2014 24350829 miRBase MI0000293 miR-217 miRNA DB04868 Nilotinib Ph(+) leukemia RT-PCR The expression levels of miRNA were determined by reverse transcription-polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Methylation analysis by methylation-specific PCR, cell line (K562,K562DR) up-regulated sensitive DNMT3A DNMT3A NA validated 982 miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol 2014 24370341 miRBase MI0000285 miR-205 miRNA DB00515 (APRD00359) Cisplatin prostate cancer Real-time RT-PCR The role of miR-205 in prostate cancer cells was detected using Caspase-3 catalytic activity assay, Real-time RT-PCR, immunoblotting analysis, fluorescence microscopy analyses, gene expression analysis, etc. cell line ( DU145, PC-3 ) up-regulated sensitive RAB27A and LAMP3 RAB27A and LAMP3 NA validated 983 miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev 2014 24377569 miRBase MI0000471 miR-126 miRNA DB00290 (APRD00453, EXPT00718) Bleomycin cervical cancer qRT-PCR In the study, we compared the expression of miR-126 in cervical cancer tissues (n = 20) with that in normal cervical tissue (n = 20) using quantitative RT-PCR. The viability of Siha cervical cancer cells was further measured by MTT assay after transfection with miR-126 mimic (Siha-miR-126 mimic) or microRNA mimic negative control (Siha-miR mimic NC) and after treatment with various concentrations of bleomycin (BLM). tissue and cell line up-regulated sensitive NA NA NA validated 984 microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014 24394555 miRBase MI0000289/MI0000269 miR-181a miRNA DB12257 Platinum ovarian cancer qRT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. cell line (A2780,SKOV3) up-regulated resistant Smad7 Smad7 TGF-Beta signalling pathway validated 985 The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells Zhongguo Fei Ai Za Zhi 2014 24398307 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR MTS assay was employed to determine the effect of miR-503 on A549/DDP sensitivity to cisplatin. Apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry, the expression of multi-drugs resistant proteins MDR1 and MRP1, ERCC1, RhoE, Survivin and Bcl-2 were determined by Western blot and real time PCR. The phosphorylation of Akt was analyzed by Western blot, the transcriptional activities of NF-kappaB and AP-1 were detected by dual-luciferase reporter gene systems. cell line (A549,A549/DDP) up-regulated sensitive NA NA PI3K/Akt pathway validated 986 miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One 2014 24400121 miRBase MI0000300 miR-223 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (HEK293, MDAMB231, MCF7, HeLa ) up-regulated sensitive STAT5A STAT5A NA validated 987 miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One 2014 24400121 miRBase MI0000300 miR-223 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (HEK293, MDAMB231, MCF7, HeLa ) up-regulated sensitive STAT5A STAT5A NA validated 988 MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed Pharmacother 2014 24412084 miRBase MI0000454 miR-137 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma RT-PCR The role of miR--137 in small cell lung cancer cells was detected using RT-PCR, western blot , drug sensitivity assay and cell apoptosis assay, etc. cell line (H446,H446/CDDP) up-regulated sensitive KIT KIT NA validated 989 Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer 2014 24423412 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin bladder cancer qPCR miR-34a expression in MIBC cell lines and patient tissues was investigated using qPCR. The methylation analysis of miR-34a promoter region was performed by MassARRAY. Synthetic short single or double stranded RNA oligonucleotides and lentiviral vector were used to regulate miR-34a expression in MIBC cells to investigate its function in vitro and in vivo. cell line (5637, T24, J82, HT1376 ) down-regulated sensitive CD44 CD44 NA validated 990 Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. J Biol Chem 2014 24425875 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The role of miR-146a in human lung cancer cells was detected using quantitative real-time PCR, western blot analysis, immunoprecipitation, cytotoxicity assay, catalase activity detection, etc. cell line (A549, H460) down-regulated resistant NA NA NA validated 991 Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene 2014 24447717 miRBase MI0000272 miR-182 miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time polymerase chain reaction and those of protein were by Western blot analysis. Lciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293, HepG2, HepG2-R) up-regulated resistant TP53INP1 TP53INP1 miR-182/TP53INP1 signaling validated 992 MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS One 2014 24454732 miRBase MI0000262 miR-147 miRNA DB00317 (APRD00997, DB07998) Gefitinib colorectal cancer qRT-PCR miR-147 was transfected into colon cancer cells (HCT116, SW480) as well as lung cancer cells (A-549). The cells were assessed for morphological changes, and evaluated for effects on invasion, motility, and the expression of key EMT markers. Resistance to chemotherapy was evaluated by treating cells with gefitinib, an EGFR inhibitor. The downstream genes regulated by miR-147 were assayed using the Affymetrix GeneChip U133 Plus2.0 platform. cell line (HCT116, SW480,A549) up-regulated sensitive NA NA NA validated 993 MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS One 2014 24454732 miRBase MI0000262 miR-147 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer qRT-PCR miR-147 was transfected into colon cancer cells (HCT116, SW480) as well as lung cancer cells (A-549). The cells were assessed for morphological changes, and evaluated for effects on invasion, motility, and the expression of key EMT markers. Resistance to chemotherapy was evaluated by treating cells with gefitinib, an EGFR inhibitor. The downstream genes regulated by miR-147 were assayed using the Affymetrix GeneChip U133 Plus2.0 platform. cell line (HCT116, SW480,A549) up-regulated sensitive NA NA NA validated 994 miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 2014 24468065 miRBase MI0000091 miR-33a miRNA DB00515 (APRD00359) Cisplatin osteosarcoma real-time qRT-PCR OS patients who showed <90% tumor necrosis after neochemotherapy were defined as poor responders (chemoresistant), and those who showed ¡Ý90% tumor necrosis were defined as good responders (control). miRNA microarray analysis was carried out with a discovery cohort (n=12) of age-, sex- and tumor stage-matched chemoresistant and control OS patients. cell line (Saos-2, MG-63) up-regulated resistant TWIST TWIST NA validated 995 The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 2014 24472409 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR We used parental and cisplatin resistant ovarian cell lines to demonstrate the role of miR-21 in drug resistance and investigated the gene targets of miR-21. Fresh tumor specimens were used to validate our in vitro findings. cell line ( A2780,A2780-CP,SKOV3) up-regulated resistant PDCD4 PDCD4 NA validated 996 Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014 24475095 miRBase MI0005767 miR-942 miRNA DB01268 (DB07417) Sunitinib renal cell carcinoma qRT-PCR We screened 673 microRNAs using TaqMan Low-density-Arrays (TLDAs) in tumors from MRCC patients with extreme phenotypes of marked efficacy and resistance to sunitinib, selected from an identification cohort (n = 41). The most relevant differentially expressed microRNAs were selected using bioinformatics-based target prediction analysis and quantified by qRT-PCR in tumors from patients presenting similar phenotypes selected from an independent cohort (n = 101). In vitro experiments were conducted to study the role of miR-942 in sunitinib resistance. cell line (Caki-2) up-regulated resistant PDGFR PDGFR NA validated 997 Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014 24475095 miRBase MIMAT0004809 miR-628-5p miRNA DB01268 (DB07417) Sunitinib renal cell carcinoma qRT-PCR We screened 673 microRNAs using TaqMan Low-density-Arrays (TLDAs) in tumors from MRCC patients with extreme phenotypes of marked efficacy and resistance to sunitinib, selected from an identification cohort (n = 41). The most relevant differentially expressed microRNAs were selected using bioinformatics-based target prediction analysis and quantified by qRT-PCR in tumors from patients presenting similar phenotypes selected from an independent cohort (n = 101). In vitro experiments were conducted to study the role of miR-942 in sunitinib resistance. cell line (Caki-2) up-regulated resistant NA NA NA validated 998 Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014 24475095 miRBase MI0000450/MI0000451 miR-133a miRNA DB01268 (DB07417) Sunitinib renal cell carcinoma qRT-PCR We screened 673 microRNAs using TaqMan Low-density-Arrays (TLDAs) in tumors from MRCC patients with extreme phenotypes of marked efficacy and resistance to sunitinib, selected from an identification cohort (n = 41). The most relevant differentially expressed microRNAs were selected using bioinformatics-based target prediction analysis and quantified by qRT-PCR in tumors from patients presenting similar phenotypes selected from an independent cohort (n = 101). In vitro experiments were conducted to study the role of miR-942 in sunitinib resistance. cell line (Caki-2) up-regulated resistant NA NA NA validated 999 Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014 24475095 miRBase MI0002468 miR-484 miRNA DB01268 (DB07417) Sunitinib renal cell carcinoma qRT-PCR We screened 673 microRNAs using TaqMan Low-density-Arrays (TLDAs) in tumors from MRCC patients with extreme phenotypes of marked efficacy and resistance to sunitinib, selected from an identification cohort (n = 41). The most relevant differentially expressed microRNAs were selected using bioinformatics-based target prediction analysis and quantified by qRT-PCR in tumors from patients presenting similar phenotypes selected from an independent cohort (n = 101). In vitro experiments were conducted to study the role of miR-942 in sunitinib resistance. cell line (Caki-2) up-regulated resistant NA NA NA validated 1000 Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem Biophys Res Commun 2014 24486548 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma real time RT-PCR In the present study, the level of miR-503 expression in NSCLC was evaluated using realtime PCR, and the DNA methylation status within miR-503 promoter was analyzed by Combined Bisulfite Restriction Analysis (COBRA) or bisulfite-treated DNA sequencing assays (BSP). Luciferase activity assay was used to verify the target genes of miRNAs. cell line (A549,H466,H1650,H1299,A549/cis) down-regulated resistant FANCA FANCA NA validated 1001 miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014 24510775 miRBase MI0000461 miR-145 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell cycle assays and apoptosis were performed by flow cytometry (FCM) .Nude mouse modelwas used to identify the role of miR-145 . tissue and cell line (A2780, SKOV3,A2780/PTX, SKOV3/PTX,MCF-7,MCF-7/ADM,HOEC) up-regulated sensitive Sp1,Cdk6 Sp1,Cdk6 NA validated 1002 Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 2014 24516043 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR miRNA expression in paired cisplatin-resistant and -sensitive cell lines was measured. Dysregulated miRNAs were further studied for their ability to mediate resistance. The nature of the cisplatin-resistant phenotype was established by measurement of cisplatin/DNA adducts and intracellular glutathione (GSH). Candidate miRNAs were examined for their ability to (i) mediate resistance and (ii) alter the expression of a candidate target protein (SLC7A11); direct regulation of SLC7A11 was confirmed using a luciferase assay. SLC7A11 protein and mRNA, and miRNA-27a were quantified in patient tumor material. cell line (EJ/T24, RT112,A2780-DDP) up-regulated sensitive SLC7A11 SLC7A11 NA validated 1003 Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res 2014 24519092 miRBase MI0000736/MI0000254 miR-30c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . The bearing nude mouse model was used to identify the role of miR-30c . cell line (MCF-7, MDA-MB-231,MCF-7/ADR,MDA-MB-231/ADR) down-regulated resistant YWHAZ YWHAZ p38MAPK pathway validated 1004 In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One 2014 24551227 miRBase MI0000268 miR-34a miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma qRT-PCR In the study, we investigated the relationship of miR-34a and erlotinib and determined the therapeutic activity of the combination in NSCLC cells with primary and acquired erlotinib resistance. The drug combination was also tested in a panel of hepatocellular carcinoma cells (HCC), a cancer type known to be refractory to erlotinib. Using multiple analytical approaches, drug-induced inhibition of cancer cell proliferation was determined to reveal additive, antagonistic or synergistic effects. cell line (A549, H460, H1299, H226, HCC827,HCC827res) up-regulated sensitive NA NA NA validated 1005 Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer 2014 24559685 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69,NCI-H69AR) up-regulated resistant HOXA1 HOXA1 NA validated 1006 Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer 2014 24559685 miRBase MI0000102 miR-100 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69,NCI-H69AR) up-regulated resistant HOXA1 HOXA1 NA validated 1007 Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer 2014 24559685 miRBase MI0000102 miR-100 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69,NCI-H69AR) up-regulated resistant HOXA1 HOXA1 NA validated 1008 MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer 2014 24565101 miRBase MI0000084 miR-26b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma real-time quantitative RT-PCR The effects of miR-26b on the NF-kappaB signaling pathway and the chemosensitivity of cancer cells were examined in two HCC cell lines, QGY-7703 and MHCC-97H, using both gain- and loss-of-function studies. The correlation between miR-26b level and apoptosis rate was further investigated in clinical HCC specimens. cell line (QGY-7703, MHCC-97H) up-regulated sensitive TAK1 and TAB3 TAK1 and TAB3 NF-kappaB pathway validated 1009 MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev 2014 24568519 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin chondrosarcoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (CHON-001, C-28/l2,CH-2879 ) up-regulated sensitive mTOR mTOR mTOR signaling pathway validated 1010 Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R BMC Cancer 2014 24571711 miRBase MI0000783 miR-375 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR Trastuzumab-resistant breast cancer SKBr-3 cells were generated by long-term in vitro culture of SKBr-3 cells in the presence of trastuzumab. Among the differentially expressed microRNAs (miRNAs) screened by microarray analysis, candidate miRNA(s) predicted to target IGF1R was studied for its role in conferring trastuzumab resistance. The mechanism underlying decreased expression of IGF1R-targeted miRNA in refractory cells was also addressed. cell line(SKBr-3,HEK293) down-regulated resistant IGF1R IGF1R PI3K/Akt pathway validated 1011 miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol 2014 24573637 miRBase MI0000289/MI0000269 miR-181a miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration . cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1012 miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol 2014 24573637 miRBase MI0000270/MI0000683 miR-181b miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration . cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1013 miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol 2014 24573637 miRBase MI0000271 miR-181c miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration . cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1014 miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol 2014 24573637 miRBase MI0003139 miR-181d miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration . cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1015 miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 2014 24582749 miRBase MIMAT0000430 miR-138-5p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The role of miR-138-5p in non-small cell lung cancer cells was detected using cell growth inhibition assay, microRNA microarray, Quantitative real-time PCR, western blot,immunohistochemistry, plasmid construction and dual-luciferase reporter assay, etc. cell line (PC9, H1975, PC9GR) up-regulated sensitive GPR124 NA NA validated 1016 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003675 miR-411 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1017 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003672 miR-663 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1018 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003636 miR-622 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1019 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003662 miR-647 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1020 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MIMAT0003386 miR-376a* miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1021 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase NA HS_188 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1022 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase NA HS_254 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) up-regulated resistant NA NA NA predicted 1023 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003599 miR-589 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1024 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003161 miR-517* miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1025 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0000114 miR-107 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1026 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase NA HS_279-a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1027 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase NA HS_160 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1028 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0000489 miR-195 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1029 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0000274 miR-187 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1030 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase NA HS_303-b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1031 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0000764 miR-363 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1032 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 2014 24591819 miRBase MI0003138 miR-497 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR miRNAs that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify target genes of selected miRNAs. Kaplan-Meier survival analysis was applied to identify dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. cell line (KF, KFr-Tx, TUOS-3, TUOS-4, SKOV3,IOSE386, IOSE397) down-regulated resistant NA NA NA predicted 1033 microRNA-125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep 2014 24604579 miRBase MI0000446/MI0000470 miR-125b miRNA DB00694 (APRD00521) Daunorubicin leukemia qPCR The expression levels of miRNA were determined by quantitative polymerase chain reaction (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (K562, THP-1, Jurkat, REH,HEK293T ) up-regulated resistant GRK2 and PUMA GRK2 and PUMA NA validated 1034 MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev 2014 24606471 miRBase MI0000448 miR-130a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by real-time polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Annexin V/PI assay was performed using the Annexin V/PI assay kit . The CCK-8 assay was used to monitor the growth of the cells . cell line ( A549,H1975, Pc9, Pc9 GR) up-regulated sensitive met MET NA validated 1035 Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer 2014 24606718 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer PCR The role of miR-21 in breast cancer cells was detected using chromatin immunoprecipitation assay, immunofluorescence staining, tumor cell growth and apoptosis assays, etc. cell line (MDA-MB-468) down-regulated sensitive BCL2 BCL2 c-Jun signaling validated 1036 MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4. Mol Cell Biochem 2014 24609942 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR In this study, we investigated the effects and molecular mechanisms of miR-21 in chemosensitivity of tongue squamous cell carcinoma cells (TSCC) to cisplatin. miR-21 expression was detected in tongue cancer tissue using RT-PCR and PDCD4 protein expression was measured using immunohistochemistry. miR-21 and(or) PDCD4 depleted cell lines were generated using miR-21 inhibitor and(or) siRNA. The viabilities of treated cells were analyzed using MTT assay. RT-PCR was used to detect miR-21 expression and immunoblotting was used to detect protein levels. Cell cycle and apoptosis were analyzed using propidium iodide (PI) staining and Annexin V/PI staining, respectively. cell line (Tca8113, CAL-27) up-regulated resistant PDCD4 PDCD4 NA validated 1037 MiR-200c suppresses TGF-Beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer 2014 24615544 miRBase MI0000650 miR-200c miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR The role of miR-200c in breast cancer cells was detected using Quantitative RT-PCR, plasmid construction, preparation of lentivirus, MTT assay and soft agar colony formation assay, apoptosis assay, wound healing assay, matrigel invasion analysis, western blot analysis, construction of ZEB1 and ZNF217 untranslated region luciferase plasmids and reporter assay, etc. cell line (SKBr-3) up-regulated sensitive ZNF217 and ZEB1 ZNF217 and ZEB1 TGF-Beta/ZEB1 signaling validated 1038 Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter 2014 24628843 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Quantitative real-time PCR (qRT-PCR) was utilized to determine the expression profile of miR-141 in H. pylori infected cells and tissues and their respective controls. qRT-PCR and Western blot were used to determine the expression level of KEAP-1. Luciferase reporter assays were used to determine whether KEAP-1 was a direct target of miR-141 in the gastric cancer cells. MTT and apoptosis assay were performed to detect the survival of cells under cisplatin treatment. cell line (7901,7901/DDP ) down-regulated sensitive KEAP1 KEAP1 NA validated 1039 miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol 2014 24643683 miRBase MI0000446/MI0000470 miR-125b miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The role of miR-125b in glioblastoma stem cells was detected using oligonucleotide transfection, RT-PCR, cell viability assay, cell cycle analysis, western blot, luciferase targeting assay, in vivo tumor model, etc. tissue and cell line ( CD133/1,CD133/2-PE) up-regulated resistant Bak1 Bak1 NA validated 1040 MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumour Biol 2014 24648265 miRBase MI0001733 miR-452 miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-PCR Real-time quantitative PCR (RT-qPCR) were used to identify the differential expression of miRNA-452 between MCF-7/DOC and MCF-7 cells. MiRNA-452 mimic was transfected into MCF-7 cells and miRNA-452 inhibitor was transfected into MCF-7/DOC cells. The role of miRNA-452 in these transfected cells was evaluated using RT-qPCR, MTT assay, and flow cytometry assay. The relationship of miRNA-452 and its predictive target gene anaphase-promoting complex 4 (APC4) was analyzed by RT-qPCR and Western blot. cell line (MCF-7,MCF-7/DOC) up-regulated resistant APC4 APC4 NA validated 1041 miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 2014 24655723 miRBase MI0003644 miR-630 miRNA DB01259 (DB02584) Lapatinib breast cancer qPCR We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to their corresponding drug sensitive cell lines, using qPCR. To support the role of miR-630 in breast cancer, we examined the clinical relevance of this miRNA in breast cancer tumours versus matched peritumours. Transfection of miR-630 mimics and inhibitors was used to manipulate the expression of miR-630 to assess effects on response to HER-targeting drugs (lapatinib, neratinib and afatinib). Other phenotypic changes associated with cellular aggressiveness were evaluated by motility, invasion and anoikis assays. TargetScan prediction software, qPCR, immunoblotting and ELISAs, were used to assess miR-630s regulation of mRNA, proteins and their phosphorylated forms. cell line (SKBR3, HCC1954, SKBR3-Ag, HCC1954-Ag) up-regulated sensitive IGF1R IGF1R NA validated 1042 miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 2014 24655723 miRBase MI0003644 miR-630 miRNA DB11828 Neratinib breast cancer qPCR We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to their corresponding drug sensitive cell lines, using qPCR. To support the role of miR-630 in breast cancer, we examined the clinical relevance of this miRNA in breast cancer tumours versus matched peritumours. Transfection of miR-630 mimics and inhibitors was used to manipulate the expression of miR-630 to assess effects on response to HER-targeting drugs (lapatinib, neratinib and afatinib). Other phenotypic changes associated with cellular aggressiveness were evaluated by motility, invasion and anoikis assays. TargetScan prediction software, qPCR, immunoblotting and ELISAs, were used to assess miR-630s regulation of mRNA, proteins and their phosphorylated forms. cell line (SKBR3, HCC1954, SKBR3-Ag, HCC1954-Ag) up-regulated sensitive IGF1R IGF1R NA validated 1043 miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 2014 24655723 miRBase MI0003644 miR-630 miRNA DB08916 Afatinib breast cancer qPCR We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to their corresponding drug sensitive cell lines, using qPCR. To support the role of miR-630 in breast cancer, we examined the clinical relevance of this miRNA in breast cancer tumours versus matched peritumours. Transfection of miR-630 mimics and inhibitors was used to manipulate the expression of miR-630 to assess effects on response to HER-targeting drugs (lapatinib, neratinib and afatinib). Other phenotypic changes associated with cellular aggressiveness were evaluated by motility, invasion and anoikis assays. TargetScan prediction software, qPCR, immunoblotting and ELISAs, were used to assess miR-630s regulation of mRNA, proteins and their phosphorylated forms. cell line (SKBR3, HCC1954, SKBR3-Ag, HCC1954-Ag) up-regulated sensitive IGF1R IGF1R NA validated 1044 Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014 24659709 miRBase MIMAT0000263 miR-199b-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer quantitative real-time RT-PCR The expression levels of miRNA were determined by quantitative real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability was evaluated by XTT assay and Focus formation assay. in situ hybridization (ISH) was performed to evaluate the miR-199b-5p expression in a commercial tissue array (OVC1021, Pantomics) using the miRCURY LNA microRNA ISH Optimization Kit 5 (FFPE) . cell line (A2780s, A2780cp, OV2008, C13*,SKOV3, OVCA433, ES-2) down-regulated resistant JAG1 JAG1 JAG1-Notch1 signaling validated 1045 Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene 2014 24680705 miRBase MI0000282 miR-199b miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-PCR A total of 150 CML patients were analyzed to identify 9q deletion. Fluorescent in-situ hybridization (FISH) was performed using BCR/ABL dual color, dual fusion probe to study the signal pattern and BAC probes for miR-199b and miR-219-2 to study the miRNA deletions. The expression level of miRNA was analyzed by real-time polymerase chain reaction (RT-PCR). FISH analysis revealed 9q34.1 deletion in 34 (23%) CML patients. The deletions were not detected using BAC probes for miRNAs in 9q deleted patients. The expression analysis showed down-regulation of miR-199b and miR-219-2 in the 9q deleted patients (34 CML) as compared to a pool of patients without deletion. However, miR-199b (9q34.11) was significantly (p=0.001) down-regulated compared to miR-219-2. The follow-up study showed that the miR-199b was found to be strongly associated with imatinib resistance. tissue down-regulated resistant NA NA NA validated 1046 MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs 2014 24686007 miRBase MI0003124 miR-489 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time RT-PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( SKOV3, OVCAR3, SKOV3/CDDP, OVCAR3/CDDP) down-regulated resistant Akt3 Akt3 NA validated 1047 Integrative omic analysis for tamoxifen sensitivity through cell based models. PLoS One 2014 24699530 miRBase MI0000434 let-7i miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR An integrative omic approach developed by our group was used to investigate relationships among endoxifen (an active metabolite of tamoxifen) sensitivity, SNP genotype, mRNA and microRNA expressions in 58 HapMap YRI lymphoblastoid cell lines. We identified 50 SNPs that associate with cellular sensitivity to endoxifen through their effects on 34 genes and 30 microRNA expression. cell line ( LCLs,ZR-75-1) up-regulated sensitive NA NA NA predicted 1048 Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014 24720529 miRBase MI0000286 miR-210 miRNA DB00694 (APRD00521) Daunorubicin pediatric acute lymphoblastic leukemia real-time qRT-PCR In the current study, using real-time qRT-PCR to detect miR-210 expression in bone marrow samples from 114 children at initial diagnosis of ALL, we investigated the prognostic significance of miR-210 and determined its associations with common clinical characteristics and treatment outcome. We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines. cell line (TEL/AML1+ Reh,MLL/AF4+ RS4;11) up-regulated sensitive NA NA NA validated 1049 Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014 24720529 miRBase MI0000286 miR-210 miRNA DB01234 (APRD00674) Dexamethasone pediatric acute lymphoblastic leukemia real-time qRT-PCR In the current study, using real-time qRT-PCR to detect miR-210 expression in bone marrow samples from 114 children at initial diagnosis of ALL, we investigated the prognostic significance of miR-210 and determined its associations with common clinical characteristics and treatment outcome. We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines. cell line (TEL/AML1+ Reh,MLL/AF4+ RS4;11) up-regulated sensitive NA NA NA validated 1050 Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014 24720529 miRBase MI0000286 miR-210 miRNA DB00023 (BTD00011, BIOD00011) L-asparaginase pediatric acute lymphoblastic leukemia real-time qRT-PCR In the current study, using real-time qRT-PCR to detect miR-210 expression in bone marrow samples from 114 children at initial diagnosis of ALL, we investigated the prognostic significance of miR-210 and determined its associations with common clinical characteristics and treatment outcome. We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines. cell line (TEL/AML1+ Reh,MLL/AF4+ RS4;11) up-regulated sensitive NA NA NA validated 1051 Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014 24720529 miRBase MI0000286 miR-210 miRNA DB00541 (APRD00495) Vincristine pediatric acute lymphoblastic leukemia real-time qRT-PCR In the current study, using real-time qRT-PCR to detect miR-210 expression in bone marrow samples from 114 children at initial diagnosis of ALL, we investigated the prognostic significance of miR-210 and determined its associations with common clinical characteristics and treatment outcome. We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines. cell line (TEL/AML1+ Reh,MLL/AF4+ RS4;11) up-regulated sensitive NA NA NA validated 1052 MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFBetaR2 in NSCLC. PLoS One 2014 24722426 miRBase MI0000071 miR-17 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR Total RNA samples of A549 cells and A549/DDP cells were allowed to compare the miRNA expression by microarray assay. The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration . The CCK-8 assay was used to monitor the growth of the cells . cell line (A549,A549/DDP) down-regulated resistant TGFBetaR2 NA TGF-Beta signalling pathway validated 1053 Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol 2014 24723223 miRBase MI0000441 miR-30b miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-PCR In this study, we analyzed the protein level of Dicer between gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) non-small-cell lung cancer (NSCLC) cell lines by Western blot analysis. Silence and overexpression of the Dicer were performed to investigate the effects on gefitinib sensitivity, as assessed by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay and sub-G1 assay of flow cytometry. To further explore the mechanism of chemoresistance, we examined whether Dicer knockdown led to modulating specific miRNAs and its miRNA target genes. cell line (PC9/WT, PC9/GR, A549, H1299) down-regulated sensitive NA NA NA validated 1054 Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol 2014 24723223 miRBase MI0000736/MI0000254 miR-30c miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-PCR In this study, we analyzed the protein level of Dicer between gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) non-small-cell lung cancer (NSCLC) cell lines by Western blot analysis. Silence and overexpression of the Dicer were performed to investigate the effects on gefitinib sensitivity, as assessed by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay and sub-G1 assay of flow cytometry. To further explore the mechanism of chemoresistance, we examined whether Dicer knockdown led to modulating specific miRNAs and its miRNA target genes. cell line (PC9/WT, PC9/GR, A549, H1299) down-regulated sensitive NA NA NA validated 1055 Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol 2014 24723223 miRBase MI0000298 miR-221 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-PCR In this study, we analyzed the protein level of Dicer between gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) non-small-cell lung cancer (NSCLC) cell lines by Western blot analysis. Silence and overexpression of the Dicer were performed to investigate the effects on gefitinib sensitivity, as assessed by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay and sub-G1 assay of flow cytometry. To further explore the mechanism of chemoresistance, we examined whether Dicer knockdown led to modulating specific miRNAs and its miRNA target genes. cell line (PC9/WT, PC9/GR, A549, H1299) down-regulated sensitive NA NA NA validated 1056 Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol 2014 24723223 miRBase MI0000299 miR-222 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-PCR In this study, we analyzed the protein level of Dicer between gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) non-small-cell lung cancer (NSCLC) cell lines by Western blot analysis. Silence and overexpression of the Dicer were performed to investigate the effects on gefitinib sensitivity, as assessed by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay and sub-G1 assay of flow cytometry. To further explore the mechanism of chemoresistance, we examined whether Dicer knockdown led to modulating specific miRNAs and its miRNA target genes. cell line (PC9/WT, PC9/GR, A549, H1299) down-regulated sensitive NA NA NA validated 1057 Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia 2014 24727676 miRBase MI0000300 miR-223 miRNA DB12362 DAPT(GSI IX) acute T cell leukemia RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cleaved caspase-3 and -7 activity was determined by luminescence using the Caspase-Glo 3/7 assay from Promega. cell line (Jurkat, Jurkat IKKgamma-/-, DND41, Molt3 , TALL-1) up-regulated resistant FBXW7 FBXW7 Notch and NF-kB signaling pathways validated 1058 Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol 2014 24740829 miRBase MI0000738 miR-302 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qPCR Among three miRNAs (miR-200c, miR-302s, and miR-369s) that were previously presented for miRNAmediated reprogramming, miR-302 was expressed at low levels in HCC cells. After transfecting three times with miR-302, the cells were incubated in ES medium for 3 weeks and then characterized. cell line (PLC/PRF/5,HuH7,HLE, HLF, HepG2,Hep3B) down-regulated sensitive AOF2 (LSD1,KDM1) NA NA validated 1059 Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol 2014 24740829 miRBase MI0000738 miR-302 miRNA NA Interferon-alpha hepatocellular carcinoma qPCR Among three miRNAs (miR-200c, miR-302s, and miR-369s) that were previously presented for miRNAmediated reprogramming, miR-302 was expressed at low levels in HCC cells. After transfecting three times with miR-302, the cells were incubated in ES medium for 3 weeks and then characterized. cell line (PLC/PRF/5,HuH7,HLE, HLF, HepG2,Hep3B) down-regulated sensitive AOF2 (LSD1,KDM1) NA NA validated 1060 MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 2014 24752803 miRBase MI0003178/MI0003182 miR-519a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of miR-519a in ER+ breast cancer cells was detected using quantitative RT-PCR, cell viability and cell cycle assays, apoptosis assay, PI staining, miRNA target prediction, etc. cell line(MCF-7 WT,TamR,HEK-293FT,BT-474,CAMA-1) up-regulated resistant NA NA NA validated 1061 MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 2014 24752803 miRBase MI0003178/MI0003182 miR-519a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of miR-519a in ER+ breast cancer cells was detected using quantitative RT-PCR, cell viability and cell cycle assays, apoptosis assay, PI staining, miRNA target prediction, etc. cell line (MCF-7 WT, TamR, ) up-regulated resistant NA NA NA validated 1062 miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One 2014 24755562 miRBase MIMAT0000070 miR-17-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qRT-PCR In this study, we used microRNA (miRNA) arrays to screen differentially expressed miRNAs between paclitaxel sensitive lung cancer cells A549 and its paclitaxel-resistant cell variant (A549-T24). The expression levels of miRNA were determined by Quantitative Real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Trypan Blue Exclusion Assay for Cell Viability. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549,NCI-H596) down-regulated resistant beclin1 beclin1 NA validated 1063 miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1 Int J Oncol 2014 24756163 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by Quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . cell line (K562, HL-60, K562/A02, HL-60/ADM) up-regulated sensitive HMGB1 and Mcl-1 HMGB1 and Mcl-1 NA validated 1064 miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1 Int J Oncol 2014 24756163 miRBase MI0000270/MI0000683 miR-181b miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by Quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . cell line (K562, HL-60, K562/A02, HL-60/ADM) up-regulated sensitive HMGB1 and Mcl-1 HMGB1 and Mcl-1 NA validated 1065 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000243 miR-148a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1066 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000257 miR-181b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1067 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000256 miR-181a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1068 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000689 miR-99b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1069 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000066 let-7e-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1070 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000753 miR-342-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1071 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000098 miR-100-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1072 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000443 miR-125a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1073 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000252 miR-7-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1074 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0022742 miR-1273g-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1075 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0016769 miR-4430 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1076 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000732 miR-378a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1077 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0003393 miR-425-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1078 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0003134 miR-494 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1079 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0006381 miR-1246 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1080 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000243 miR-148a-3p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1081 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000257 miR-181b-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1082 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000256 miR-181a-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1083 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000689 miR-99b-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1084 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000066 let-7e-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1085 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000753 miR-342-3p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1086 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000098 miR-100-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1087 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000443 miR-125a-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1088 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000252 miR-7-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) down-regulated resistant NA NA NA predicted 1089 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0022742 miR-1273g-3p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1090 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0016769 miR-4430 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1091 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0000732 miR-378a-3p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1092 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MIMAT0003393 miR-425-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1093 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0003134 miR-494 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1094 Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett 2014 24759738 miRBase MI0006381 miR-1246 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR In this study, mRNA and miRNA expression profiling of the drug resistant sublines, SGC7901/VCR and SGC7901/ADR, and their parental gastric cancer cell line SGC7901 were performed. A significant number of genes and a limited subset of miRNAs were commonly dysregulated, which were further validated using qRT-PCR. GO and KEGG pathway analyses of the commonly dysregulated genes indicated that the MAPK signalling pathway may be involved in multidrug resistance, which was further validated using immunoblotting and MTT assay. Finally a primary multidrug resistance network in gastric cancer, consisting of the commonly dysregulated genes and miRNAs, was established and functional miRNA-mRNA pairs were identified. cell line (SGC7901,SGC7901/VCR, SGC7901/ADR) up-regulated resistant NA NA NA predicted 1095 MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 2014 24763054 miRBase MI0000482 miR-185 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. Subcutaneous tumor xenograft model was used to test the role of miR-185 . cell line (GES-1,NCI-N87, MGC-803, BGC-823, AGS,) up-regulated sensitive ARC NA NA validated 1096 MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 2014 24763054 miRBase MI0000482 miR-185 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.TUNEL staining was used to detect apoptotic cell death. Subcutaneous tumor xenograft model was used to test the role of miR-185 . cell line (GES-1,NCI-N87, MGC-803, BGC-823, AGS,) up-regulated sensitive ARC NA NA validated 1097 Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014 24767251 miRBase MI0000105/MI0000107 miR-29b miRNA DB00515 (APRD00359) Cisplatin ovarian carcinoma RT-PCR The role of miR-29b in ovarian carcinoma cells was detected using Real-time polymerase chain reaction, hematoxylin and eosin staining and immunohistochemistry, etc. cell line (OVCAR-3) up-regulated sensitive ATG9A MCL1,ATG9A,and MAPK10 NA validated 1098 Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014 24767251 miRBase MI0000105/MI0000107 miR-29b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian carcinoma RT-PCR The role of miR-29b in ovarian carcinoma cells was detected using Real-time polymerase chain reaction, hematoxylin and eosin staining and immunohistochemistry, etc. cell line (OVCAR-3) up-regulated sensitive ATG9A MCL1,ATG9A,and MAPK10 NA validated 1099 Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014 24767251 miRBase MI0000105/MI0000107 miR-29b miRNA DB12257 Platinum ovarian carcinoma RT-PCR The role of miR-29b in ovarian carcinoma cells was detected using Real-time polymerase chain reaction, hematoxylin and eosin staining and immunohistochemistry, etc. cell line (OVCAR-3) up-regulated sensitive ATG9A MCL1,ATG9A,and MAPK10 NA validated 1100 Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014 24767251 miRBase MI0000105/MI0000107 miR-29b miRNA DB00531 (APRD00408) Cyclophosphamide ovarian carcinoma RT-PCR The role of miR-29b in ovarian carcinoma cells was detected using Real-time polymerase chain reaction, hematoxylin and eosin staining and immunohistochemistry, etc. cell line (OVCAR-3) up-regulated sensitive ATG9A MCL1,ATG9A,and MAPK10 NA validated 1101 Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Exp Mol Pathol 2014 24769353 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69, H69AR) up-regulated sensitive ZEB2 ZEB2 NA validated 1102 MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. Neuropathology 2014 24780067 miRBase MI0000298 miR-221 miRNA DB00262 (APRD00006) Carmustine glioblastoma qRT-PCR and RT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and RT-PCR. Those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells .Flow Cytometric Assay was used to determine if cells were viable,apoptotic, or necrotic.Caspase-3 activation status was measured using the Caspase-Glo3 Assay. cell line (U87, U251,SWOZ1, SWOZ2) up-regulated resistant NA NA PI3-K/PTEN/Akt signaling axis validated 1103 MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett 2014 24786471 miRBase MI0003124 miR-489 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR The role of miR-489 in breast cancer cells was detected using quantitative real-time PCR, western blot, immunofluorescence staining, migration assays, xenograft tumors, etc. cell line (MCF-7/WT,MCF-7/ADM) up-regulated sensitive SMAD3 SMAD3 epithelial mesenchymal transition pathway validated 1104 MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014 24788655 miRBase MIMAT0000425 miR-130a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In this study, we conducted miRNAs profile comparison between triple-negative breast cancer (TNBCs) and normal breast tissues by microRNA array. Quantitative real-time PCR (qRT-PCR) was utilized to confirm the specific deregulated miRNAs change trend. We used starBase 2.1 and GOrilla to predict the potential targets of the specific miRNAs. Cells viability and apoptosis assays were employed to determine the effect of alteration of the specific miRNAs in TNBC cells on the chemosensitivity. cell line (MCF 10A,MDA-MB-231, BT-549, Hs 578T ) up-regulated sensitive NA NA NA predicted 1105 MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014 24788655 miRBase MI0001729 miR-451a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In this study, we conducted miRNAs profile comparison between triple-negative breast cancer (TNBCs) and normal breast tissues by microRNA array. Quantitative real-time PCR (qRT-PCR) was utilized to confirm the specific deregulated miRNAs change trend. We used starBase 2.1 and GOrilla to predict the potential targets of the specific miRNAs. Cells viability and apoptosis assays were employed to determine the effect of alteration of the specific miRNAs in TNBC cells on the chemosensitivity. cell line (MCF 10A,MDA-MB-231, BT-549, Hs 578T ) up-regulated sensitive NA NA NA predicted 1106 Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. Pharmazie 2014 24791593 miRBase MI0000433 let-7g miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Bel-7402/5-Fu) up-regulated sensitive NA NA NA validated 1107 MiR-34c inhibits osteosarcoma metastasis and chemoresistance. Med Oncol 2014 24802328 miRBase MI0000743 miR-34c miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (MG-63, U2OS, HeLa) down-regulated resistant Notch1,LEF1 Notch1,LEF1 NA validated 1108 Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells. Gynecol Oncol 2014 24802724 miRBase MI0001641 miR-429 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer Real-time PCR We established and characterized a new primary cell line (OCI-984) from free-floating OC cells isolated from the ascites fluid of an advanced stage OC patient. miR-429 was ectopically over-expressed in these cells. cell line (OCI-984) up-regulated sensitive NA NA NA predicted 1109 HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget 2014 24830600 miRBase MI0000342 miR-200b miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. ChIP assay was performed with Immunoprecipitation Assay Kits . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Xenograft transplantation in nude mice was used to test the role of miR-200b . tissue and cell line (SPC-A1/DTX,H1299/DTX,) up-regulated sensitive E2F3 E2F3 HDAC1/4/Sp1/miR-200b/E2F3 pathway validated 1110 The TGFBeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 2014 24830724 miRBase NA miR-200 miRNA DB00530 (APRD00951) Erlotinib cancer qPCR,RT-PCR The role of TGFBeta-miR200-MIG6 pathway in cancer cells was detected using reverse transcription and real-time PCR , cell viability assay , xenograft generation , etc. cell line (H226, H292, H358, H1838, A549, Calu6, H460, H1703, H1915, H1299, Calu3, H1437, H23,5637, SCaBER, UMUC-3, T24, HT-1376, BFTC-905, J82) up-regulated sensitive MIG6 MIG6 TGFBeta-miR200-MIG6 pathway validated 1111 Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis 2014 24832599 miRBase MI0000782 miR-374a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-qPCR The expression levels of miRNA were determined by RT-qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Xenograft models in nude mice was used to test the role of miR-374a and miR-548b . cell line (HCC827, Calu1) up-regulated sensitive Wnt5a Wnt5a NA validated 1112 Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis 2014 24832599 miRBase MI0003596 miR-548b miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-qPCR The expression levels of miRNA were determined by RT-qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Xenograft models in nude mice was used to test the role of miR-374a and miR-548b . cell line (HCC827, Calu1) down-regulated sensitive CCNB1 CCNB1 NA validated 1113 MiR-192 confers cisplatin resistance by targeting Bim in lung cancer Zhongguo Fei Ai Za Zhi 2014 24854555 miRBase MI0000234 miR-192 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR We performed miRNA microarray and RT-PCR to obtain the aberrant differential expressed miRNAs between A549 and its paired Cisplatin-resistant cell line A549/DDP cells, and then we investigated the biological functions of miR-192, which is the aberrant differential expressed miRNA. After transfection of the miR-192 into A549 cells, we measured the half inhibition concentration (IC50), cell apoptosis of the trasfectant cells, and then we used biological softwares and dual-luciferase report assay to explore the target gene of the miR-192, which was further validated by RT-PCR and Western blot. cell line (A549,A549/DDP) up-regulated resistant Bim Bim NA validated 1114 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000301 miR-224 miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1115 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0004784 miR-455-3p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1116 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0006326 miR-1236 miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1117 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0002856 miR-520d-3p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1118 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000091 miR-33a miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1119 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000301 miR-224 miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1120 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0004784 miR-455-3p miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1121 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0006326 miR-1236 miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1122 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0002856 miR-520d-3p miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1123 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000091 miR-33a miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1124 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000301 miR-224 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1125 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0004784 miR-455-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1126 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0006326 miR-1236 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1127 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0002856 miR-520d-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1128 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000091 miR-33a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1129 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000301 miR-224 miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1130 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0004784 miR-455-3p miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1131 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0006326 miR-1236 miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1132 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0002856 miR-520d-3p miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1133 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000091 miR-33a miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1134 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000301 miR-224 miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1135 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0004784 miR-455-3p miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1136 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0006326 miR-1236 miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1137 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MIMAT0002856 miR-520d-3p miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated resistant NA NA NA predicted 1138 Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 2014 24858372 miRBase MI0000091 miR-33a miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR We analyzed the miRNA expression profiles to investigate the role of serum miRNA in predicting response to rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) treatment in diffuse large B cell lymphoma (DLBCL) patients. The present study proceeded through three phases. In the discovery phase, real-time polymerase chain reaction (PCR)-based miRNA profiling was used to test the difference in levels of serum miRNAs between 20 patients with complete remission after 6 cycles of R-CHOP treatment and 20 patients with primary refractory disease matched by age, sex, and stage. After the marker selection phase, the selected serum miRNAs were validated in 133 patients using the quantitative reverse transcriptase-PCR assays during the validation phases. tissue up-regulated sensitive NA NA NA predicted 1139 Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One 2014 24865582 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The role of miR-21 in ovarian cance cells was detected using RNA isolation and cDNA synthesis, Polymerase Chain Reaction (PCR), SYBR-I-based real-time PCR, western blot, chromatin immunoprecipitation (ChIP), In vitro invasion assay, etc. cell line (SKOV3ip1, HEYA8, A2780CP20,A2780, A2780CIS ) up-regulated resistant PDCD4 PDCD4 JNK-1/c-Jun pathway validated 1140 Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep 2014 24865963 miRBase MI0000446/MI0000470 miR-125b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( SMMC-7221, Huh7, MHCC-97L, HepG2, HepG3, BEL-7402,THLE-2, THLE-3) up-regulated sensitive hexokinase II NA NA validated 1141 MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin. Tumour Biol 2014 24870597 miRBase MIMAT0002833 miR-520a-5p miRNA DB06774 (DB05674, DB05318) Capsaicin chronic myeloid leukemia qRT-PCR The role of miR-520a-5p in chronic myelogenous leukemia cells was detected using cell proliferation assay, qRT-PCR, transient transfection, western blot, apoptosis assay, etc. cell line (K562) down-regulated sensitive STAT3 STAT3 JAK/STAT signaling pathway validated 1142 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem 2014 24875127 miRBase MI0003814 miR-1271 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time Polymerase Chain Reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( GES-1,MKN45, MGC803, BGC823,SGC7901,SGC7901/DDP) down-regulated resistant IGF1R,IRS1,mTOR,and BCL2 IGF1R,IRS1,mTOR,and BCL2 IGF1R/IRS1 pathway validated 1143 Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys 2014 24898807 miRBase MI0000442 miR-122 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR The role of miR-429 in ovarian cancer cells was detected using Real-time PCR, flow cytometry analysis, spheroid formation assay, colony formation assay, migration, invasion and anchorage-independent growth assays, drug sensitivity assay, tumor growth in nude mice, etc. cell line ( OVCAR-3) up-regulated sensitive PKM2 PKM2 NA validated 1144 miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 2014 24901050 miRBase MI0000446/MI0000470 miR-125b miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The role of miR-125b in glioblastomas cells was detected using lentiviral and retroviral, transduction, luciferase activity assays, cell cycle analysis, apoptosis assay, cell viability assay,Real-time PCR, western blot, etc. cell line ( U87 MG, LN-18, U251, HS683, T98G) down-regulated sensitive TNFAIP3, NKIRAS2 TNFAIP3, NKIRAS2 NF-kappaB pathway validated 1145 Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet 2014 24906642 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma real-time qRT-PCR The expression levels of miRNA were determined byQuantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . Animal experiments was used to test the role of miR-21. cell line (A549, SK-MES-1) down-regulated sensitive NA NA NA validated 1146 MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014 24912422 miRBase MIMAT0000070 miR-17-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR By microarray analysis, we studied miRNAs expression profiles in CRC patient, comparing chemoresistant and chemosensitive groups. The miRNAs of interest were validated and the impact on clinical outcomes was assessed in a cohort of 295 patients. To search for potential targets of these miRNAs, tissue samples were subject to in situ hybridization and immunohistochemistry analysis. Colorectal adenocarcinoma cells were also used for in vitro experimentation, where cellular invasiveness and drug resistance were examined in miRNA-transfected cells. cell line ( COLO205,SW480) up-regulated resistant PTEN PTEN PTEN/AKT/PI3K pathway validated 1147 MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014 24912422 miRBase MIMAT0000070 miR-17-5p miRNA DB00762 (APRD00579) Irinotecan colorectal cancer qRT-PCR By microarray analysis, we studied miRNAs expression profiles in CRC patient, comparing chemoresistant and chemosensitive groups. The miRNAs of interest were validated and the impact on clinical outcomes was assessed in a cohort of 295 patients. To search for potential targets of these miRNAs, tissue samples were subject to in situ hybridization and immunohistochemistry analysis. Colorectal adenocarcinoma cells were also used for in vitro experimentation, where cellular invasiveness and drug resistance were examined in miRNA-transfected cells. cell line ( COLO205,SW480) up-regulated resistant PTEN PTEN PTEN/AKT/PI3K pathway validated 1148 MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014 24912422 miRBase MIMAT0000070 miR-17-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR By microarray analysis, we studied miRNAs expression profiles in CRC patient, comparing chemoresistant and chemosensitive groups. The miRNAs of interest were validated and the impact on clinical outcomes was assessed in a cohort of 295 patients. To search for potential targets of these miRNAs, tissue samples were subject to in situ hybridization and immunohistochemistry analysis. Colorectal adenocarcinoma cells were also used for in vitro experimentation, where cellular invasiveness and drug resistance were examined in miRNA-transfected cells. cell line ( COLO205,SW480) up-regulated resistant PTEN PTEN PTEN/AKT/PI3K pathway validated 1149 Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer Zhong Nan Da Xue Xue Bao Yi Xue Ban 2014 24921394 miRBase MIMAT0000753 miR-342-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR Tissue samples were collected from January 2011 to August 2013 samples in Jiangsu Cancer Hospital from a total of 32 triple-negative breast cancer patients with preoperative chemotherapy, with 5 cases of complete response (CR) and 27 cases of partial response (PR). We detected miR-342-3p expression of TNBC with RT-PCR. We transfected has-miR-342-3p mimic and inhibitor into breast cancer cell lines MDA-MB-231 by lipofection transfection and set up negative control mim-NC and inhi-NC. Group of mimic, mim-NC, inhibitor and inhi-NC were cultivated with 2 umol /L paclitaxel, cisplatin or 4 umol/L doxorubicin for 48 h. The cell growth rates were measured by CCK8 reagent kit, and the cell apoptosis rate by flow cytometry. tissue and cell line (MDA-MB-231) up-regulated sensitive NA NA NA validated 1150 Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer Zhong Nan Da Xue Xue Bao Yi Xue Ban 2014 24921394 miRBase MIMAT0000753 miR-342-3p miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR Tissue samples were collected from January 2011 to August 2013 samples in Jiangsu Cancer Hospital from a total of 32 triple-negative breast cancer patients with preoperative chemotherapy, with 5 cases of complete response (CR) and 27 cases of partial response (PR). We detected miR-342-3p expression of TNBC with RT-PCR. We transfected has-miR-342-3p mimic and inhibitor into breast cancer cell lines MDA-MB-231 by lipofection transfection and set up negative control mim-NC and inhi-NC. Group of mimic, mim-NC, inhibitor and inhi-NC were cultivated with 2 umol /L paclitaxel, cisplatin or 4 umol/L doxorubicin for 48 h. The cell growth rates were measured by CCK8 reagent kit, and the cell apoptosis rate by flow cytometry. tissue and cell line (MDA-MB-231) up-regulated sensitive NA NA NA validated 1151 MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G-/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer 2014 24921914 miRBase MI0000301 miR-224 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR On the basis of miRNA microarray data, miR-224 was identified as the most upregulated miRNA in cisplatin (DDP; cis-diamminedichloroplatinum II)-resistant A549 cells compared with parental A549 cells. The aim of our study was to investigate the roles of miR-224 in the formation of DDP-resistant phenotype of LA cells and its possible molecular mechanisms. tissue and cell line (A549,A549/DDP,SPC-A1,SPC-A1/DDP) up-regulated resistant p21(WAF1/CIP1) p21(WAF1/CIP1) p21(WAF1/CIP1)-pRb pathway,the intrinsic mitochondrial death pathway validated 1152 Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther 2014 24924200 miRBase MI0000298 miR-221 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . cell line (MCF-7,MDA-MB-231) down-regulated sensitive TIMP3 TIMP3 NA validated 1153 Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther 2014 24924200 miRBase MI0000299 miR-222 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . cell line (MCF-7,MDA-MB-231) down-regulated sensitive TIMP3 TIMP3 NA validated 1154 MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J (Engl) 2014 24931256 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR MiR-503 expression was measured by quantitative real-time PCR. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) and clonogenic assays were used to examine changes in cell viability and the drug resistance phenotype of cancer cells associated with upregulation or downregulation of the miRNA. A dual-luciferase activity assay was used to verify target genes of miR-503. Immunohistochemistry, Western blotting analysis, and a flow cytometric apoptosis assay were used to elucidate the mechanism by which miR-503 modulates drug resistance in cancer cells. cell line ( MKN45, MGC803, BGC823, SGC7901,SGC7901/DDP ) up-regulated sensitive IGF1R and BCL2 IGF1R and BCL2 IGF1R signal pathway validated 1155 miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2014 24940696 miRBase MI0000287 miR-211 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR Cell migration was detected by transwell migration and invasion assay. cell line (SUIT2,SUIT2-007,SUIT2-028) up-regulated sensitive RRM2 RRM2 NA validated 1156 Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis 2014 24967963 miRBase MI0001446 miR-424 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin melanoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . TUNEL stining was used to detect apoptotic cell death. Xenograft tumor model was used to test the role of miR-424 . cell line ( A375, U251, HCT116,HEK293T) up-regulated resistant PDCD4 PDCD4 NA validated 1157 Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis 2014 24967963 miRBase MI0001446 miR-424 miRNA DB00773 (APRD00239) Etoposide melanoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . TUNEL stining was used to detect apoptotic cell death. Xenograft tumor model was used to test the role of miR-424 . cell line ( A375, U251, HCT116,HEK293T) up-regulated resistant PDCD4 PDCD4 NA validated 1158 Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis 2014 24967963 miRBase MI0001446 miR-424 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colon cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . TUNEL stining was used to detect apoptotic cell death. Xenograft tumor model was used to test the role of miR-424 . cell line ( A375, U251, HCT116,HEK293T) up-regulated resistant PDCD4 PDCD4 NA validated 1159 Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis 2014 24967963 miRBase MI0001446 miR-424 miRNA DB00773 (APRD00239) Etoposide colon cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . TUNEL stining was used to detect apoptotic cell death. Xenograft tumor model was used to test the role of miR-424 . cell line ( A375, U251, HCT116,HEK293T) up-regulated resistant PDCD4 PDCD4 NA validated 1160 miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget 2014 24970806 miRBase MI0005767 miR-942 miRNA NA TRAIL therapy cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. In vivo animal experiments was used to test the role of miR-942 . cell line (Huh7, LH86,HLCZ01,HLCZ02) up-regulated resistant ISG12a ISG12a NA validated 1161 MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett 2014 24983493 miRBase MI0000268 miR-34a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer qRT-PCR The role of miR-34a in EGFR mutant lung cancer cells was detected using cell proliferation assay, cell apoptosis assay, Quantitative RT-PCR, ELISA, immunoblotting, vector construction and dual-luciferase reporter assay, animal experiments, etc. cell line (HCC827,MRC-5,PC-9,HCC827 ) up-regulated sensitive MET MET NA validated 1162 SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer Sci 2014 24989082 miRBase MI0000071 miR-17 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin synovial sarcoma RT-PCR The expression levels of miRNA were determined by RT-PCR Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by migration and invasion assay. Xenograft model was used to test the role of miR-17 . cell line (SYO-1, Fuji, HS-SYII,HSC-2, HSC-3, HSC-4,LNCap,HT1080,Saos-2,293T) up-regulated resistant p21 CDKN1A,p21 NA validated 1163 Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget 2014 25004126 miRBase MI0000283 miR-203 miRNA NA AG1478(TKIs) prostate cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation . Cell migration was detected by invasion assay. cell line (DU145/RasG37, DU145) down-regulated sensitive AREG,EREG,TGFA AREG,EREG,TGFA EGFR pathway validated 1164 Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget 2014 25004126 miRBase MI0000283 miR-203 miRNA NA CI1033(TKIs) prostate cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation . Cell migration was detected by invasion assay. cell line (DU145/RasG37, DU145) down-regulated sensitive AREG,EREG,TGFA AREG,EREG,TGFA EGFR pathway validated 1165 Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat 2014 25007959 miRBase MI0000298 miR-221 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qPCR Transmission electron microscopy analysis and nanoparticle tracking analysis were performed to determine the exosomes difference between MCF-7(TamR) (tamoxifen resistant) and MCF-7(wt) (tamoxifen sensitive) cells. PKH67 fluorescent labeling assay was used to detect exosomes derived from MCF-7(TamR) cells entering into MCF-7(wt) cells. The potential function of exosomes on tamoxifen resistance transmission was analyzed with cell viability, apoptosis,and colony formation. MiRNA microarrays and qPCR were used to detect and compare the miRNAs expression levels in the two cells and exosomes. As the targets of miR-221/222, p27 and ERalpha were analyzed with western blot and qPCR. cell line (MCF-7(TamR),MCF-7(wt)) up-regulated resistant p27 and Era NA NA validated 1166 Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat 2014 25007959 miRBase MI0000299 miR-222 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qPCR Transmission electron microscopy analysis and nanoparticle tracking analysis were performed to determine the exosomes difference between MCF-7(TamR) (tamoxifen resistant) and MCF-7(wt) (tamoxifen sensitive) cells. PKH67 fluorescent labeling assay was used to detect exosomes derived from MCF-7(TamR) cells entering into MCF-7(wt) cells. The potential function of exosomes on tamoxifen resistance transmission was analyzed with cell viability, apoptosis,and colony formation. MiRNA microarrays and qPCR were used to detect and compare the miRNAs expression levels in the two cells and exosomes. As the targets of miR-221/222, p27 and ERalpha were analyzed with western blot and qPCR. cell line (MCF-7(TamR),MCF-7(wt)) up-regulated resistant p27 and Era NA NA validated 1167 miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med 2014 25009614 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qPCR The expression levels of miRNA were determined by quantitative polymerase chain reaction (qPCR) and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells . cell line (Saos-2, MG-63) up-regulated resistant NA NA NA validated 1168 MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol 2014 25012722 miRBase MI0000272 miR-182 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-182 and programmed cell death 4 (PDCD4) protein. miR-182 and (or) PDCD4 depleted cell lines were generated using miR-182 inhibitor and (or) siRNA. The viabilities of treated cells were analyzed using MTT assay. cell line (A549) up-regulated resistant PDCD4 PDCD4 NA validated 1169 Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. ScientificWorldJournal 2014 25013866 miRBase MI0000103/MI0000739 miR-101 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma NA The role of miR-101 in osteosarcoma cells was detected using quantitative GFP-LC3 analysis, western blot,and in vitro viability assay, etc. cell line (U-2 OS) up-regulated sensitive NA NA NA validated 1170 miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. Cell Signal 2014 25014664 miRBase MI0000067 let-7f-1 miRNA DB00515 (APRD00359) Cisplatin medulloblastoma RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (D425,UW228) down-regulated resistant HMGB1 HMGB1 NA validated 1171 Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. Oncol Rep 2014 25017423 miRBase MIMAT0000281 miR-224-5p miRNA DB00515 (APRD00359) Cisplatin ovarian papillary serous carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Cellular apoptosis assay by assessing the activation of caspase-3 and -7, and with TUNEL . Computational approaches were used to analyze target prediction of miRNAs . tissue and cell line (A2780CP/A2780S, C13/OV2008) up-regulated resistant PRKCD PRKCD PRKCD pathway validated 1172 miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep 2014 25017996 miRBase MI0000447/MI0000727 miR-128 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Wound closure assay and transwell migration assay were performed to examine the capacity of cell migration. cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1173 miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep 2014 25017996 miRBase MI0000478 miR-149 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Wound closure assay and transwell migration assay were performed to examine the capacity of cell migration. cell line (U251, U87) up-regulated sensitive Rap1B Rap1B NA validated 1174 Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 2014 25031750 miRBase MI0000284 miR-204 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR First,In order to explore the role of miR-204 in breast carcinogenesis, the expression patterns of miR-204 in 39 pairs of human breast cancer tissues and adjacent normal breast tissues were analyzed using qRT-PCR. To further investigate the clinicopathological and prognostic significance of miR-204 levels in patients with breast cancer, the levels of miR-204 in a large cohort of 129 breast cancer tissues were examined by real-time PCR. Finally, To determine whether the miR-204 expression levels were associated with chemotherapeutic efficacy, therapeutic response was evaluated by radiologic Response Evaluation Criteria in Solid Tumors (RECIST). tissue down-regulated resistant Bcl-2 Bcl-2 NA validated 1175 Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 2014 25031750 miRBase MI0000284 miR-204 miRNA DB00445 (APRD00361) Epirubicin breast cancer qRT-PCR First,In order to explore the role of miR-204 in breast carcinogenesis, the expression patterns of miR-204 in 39 pairs of human breast cancer tissues and adjacent normal breast tissues were analyzed using qRT-PCR. To further investigate the clinicopathological and prognostic significance of miR-204 levels in patients with breast cancer, the levels of miR-204 in a large cohort of 129 breast cancer tissues were examined by real-time PCR. Finally, To determine whether the miR-204 expression levels were associated with chemotherapeutic efficacy, therapeutic response was evaluated by radiologic Response Evaluation Criteria in Solid Tumors (RECIST). tissue down-regulated resistant Bcl-2 Bcl-2 NA validated 1176 Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 2014 25031750 miRBase MI0000284 miR-204 miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer qRT-PCR First,In order to explore the role of miR-204 in breast carcinogenesis, the expression patterns of miR-204 in 39 pairs of human breast cancer tissues and adjacent normal breast tissues were analyzed using qRT-PCR. To further investigate the clinicopathological and prognostic significance of miR-204 levels in patients with breast cancer, the levels of miR-204 in a large cohort of 129 breast cancer tissues were examined by real-time PCR. Finally, To determine whether the miR-204 expression levels were associated with chemotherapeutic efficacy, therapeutic response was evaluated by radiologic Response Evaluation Criteria in Solid Tumors (RECIST). tissue down-regulated resistant Bcl-2 Bcl-2 NA validated 1177 Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett 2014 25034398 miRBase MI0003137 miR-193b miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatitis B virus-associated hepatocellular carcinoma qRT-PCR Cytotoxicity to sorafenib was evaluated in HBV-positive/negative HCC cell lines. Expression of miR-193b and myeloid cell leukemia-1 (Mcl-1) protein were assessed by Q-PCR, in situ hybridization and western blot, immunohistochemistry, respectively. A luciferase reporter of Mcl-1 3-UTR was used for validation as a target of miR-193b. Cell apoptosis was measured by flow cytometry, caspase-3 activity assay and DAPI staining. cell line (L02, HepG2, HepG2.2.15) up-regulated sensitive MCL-1 MCL-1 NA validated 1178 Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev 2014 25040964 miRBase MI0001733 miRNA-452 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (RT-qPCR) and those of protein were by Western blot analysis. RT-qPCR Analysis for Target Gene Expression . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MCF-7,MCF-7/ADR) down-regulated resistant IGF-1R NA NA validated 1179 miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 2014 25053345 miRBase MI0000268 miR-34a miRNA DB01248 (APRD00932) Docetaxel prostate cancer qPCR Following global miRNA profiling of cell line models of docetaxel-resistance and their corresponding exosomes, we investigated the clinical relevance of four selected miRNAs (miR-598, miR-34a, miR-146a, miR-148a) in four publically available clinical cohorts representing both primary and advanced disease in tissue and urine specimens. One of these miRNAs, miR-34a was selected for functional evaluation by miRNA inhibition and over-expression in vitro. We further assessed the panel of miRNAs for their combined clinical relevance as a biomarker signature by examining their common predicted targets. cell line (22Rv1,DU145,22Rv1RD, DU145RD, PC3RD,22Rv1, DU145,PC3) down-regulated resistant Bcl-2 Bcl-2 NA validated 1180 Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One 2014 25058005 miRBase MI0000077 miR-21 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells.Xenograft tumor model in nude mice was used to test the role of miR-21 . cell line (PC-9,PC-9/GR,HEK293T) up-regulated resistant PTEN PTEN AKT and ERK pathway validated 1181 MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett 2014 25063739 miRBase MI0000778 miR-370 miRNA DB00515 (APRD00359) Cisplatin endometrioid ovarian cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by Quantitative RT-PCR and Northern blot . Those of protein were by Western blot analysis. Bioinformatics method was used to predict the target genes of miR-370. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. In vivo tumor xenograft studies was used to test the role of miR-370 . cell line (SKOV3, UWB1.289,HEY, OV2008,IGROV1 TOV112D,ES-2, TOV21G) up-regulated sensitive ENG ENG NA validated 1182 Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett 2014 25080009 miRBase MI0003138 miR-497 miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. ChIP assays were performed using the ChIP Assay kit . Apoptosis was measured using flow cytometry . cell line (U87, U251,HEK293T) up-regulated resistant PDCD4 PDCD4 NA validated 1183 miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol 2014 25096647 miRBase MI0000299 miR-222 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma real-time RT-PCR The expression levels of miRNA were determined by real-time RT-PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells .TUNEL staining was used to detect apoptotic cell death. A wound healing assay was performed to examine the capacity of cell migration. Cell migration was detected by transwell migration and invasion assay. cell line (HepG2,HL-7702 ) up-regulated resistant NA NA PI3K/AKT signaling pathway validated 1184 Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. Mol Med Rep 2014 25109742 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin bladder cancer qPCR The expression levels of miRNA were determined by Quantitative polymerase chain reaction (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Nude mouse xenografts was used to test the role of miR-101 . cell line (T24,T24/CDDP) up-regulated sensitive COX-2 COX-2 COX-2 pathway validated 1185 MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer 2014 25117811 miRBase MI0006381 miR-1246 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer real-time qRT-PCR We established gemcitabine-resistant Panc1 cells, and induced CSC-like properties through sphere formation. Candidate miRNAs were selected through microarray analysis. The overexpression and knockdown experiments were performed by evaluating the in vitro cell growth and in vivo tumourigenicity. The expression was studied in 24 pancreatic cancer samples after laser captured microdissection and by immunohistochemical staining. cell line (Panc1-P, Panc1-GR ) up-regulated resistant CCNG2 CCNG2 NA validated 1186 MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer 2014 25117811 miRBase MI0006381 miR-1246 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer real-time qRT-PCR We established gemcitabine-resistant Panc1 cells, and induced CSC-like properties through sphere formation. Candidate miRNAs were selected through microarray analysis. The overexpression and knockdown experiments were performed by evaluating the in vitro cell growth and in vivo tumourigenicity. The expression was studied in 24 pancreatic cancer samples after laser captured microdissection and by immunohistochemical staining. cell line (Panc1-P, Panc1-GR ) up-regulated resistant CCNG2 CCNG2 NA validated 1187 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014 25137071 miRBase MI0000073 miR-19a miRNA DB00445 (APRD00361) epirubicin breast cancer RT-PCR Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80'C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency. tissue up-regulated resistant NA NA NA predicted 1188 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014 25137071 miRBase MI0000285 miR-205 miRNA DB00445 (APRD00361) epirubicin breast cancer RT-PCR Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80'C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency. tissue up-regulated resistant NA NA NA predicted 1189 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014 25137071 miRBase MI0000073 miR-19a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80'C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency. tissue up-regulated resistant NA NA NA predicted 1190 Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014 25137071 miRBase MI0000285 miR-205 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80'C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency. tissue up-regulated resistant NA NA NA predicted 1191 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000342 miR-200b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1192 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000293 miR-217 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1193 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000342 miR-200b miRNA NA Celastrol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1194 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000293 miR-217 miRNA NA Celastrol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1195 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000816 miR-335 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1196 miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 2014 25138213 miRBase MI0000816 miR-335 miRNA NA Celastrol melanoma qRT-PCR The expression levels of miRNA were determined by Quantitative Real Time PCR (qRT-PCR) and those of protein were by Western blot analysis. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Cell migration was detected by migration and invasion assay. cell line (SNU387/SNU387R or Malme3M/Malme3MR) up-regulated sensitive NA NA NA validated 1197 MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol 2014 25139024 miRBase MI0000475 miR-136 miRNA DB00515 (APRD00359) Cisplatin glioma qRT-PCR The expression levels of miRNA were determined by quantitative real-time RT-PCR (qRT-PCR) and those of protein were by Western blot analysis. Cell migration was detected by transwell migration and invasion assay. MTS assay was used to test cell proliferation . Luciferase activity assay was used to verify the target genes of miRNAs. Targets gene analysis of miR-136 was performed by integrating the online databases . tissue and cell line (U87, U251, U373) up-regulated sensitive E2F1 E2F1 E2F1-EZH2-caspase-3 signaling pathway validated 1198 MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 2014 25149530 miRBase MI0003138 miR-497 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Transwell was selected to test the invasive ability of the cells . Animal experiments was used to test the role of miR-497 . cell line (SW1990, MiaPaCa-2, SW1990/GEM) up-regulated sensitive FGF2 and FGFR1 FGF2 and FGFR1 FGF/FGFR signaling pathway validated 1199 MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 2014 25149530 miRBase MI0003138 miR-497 miRNA DB00530 (APRD00951) Erlotinib pancreatic cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Transwell was selected to test the invasive ability of the cells . Animal experiments was used to test the role of miR-497 . cell line (SW1990, MiaPaCa-2, SW1990/GEM) up-regulated sensitive FGF2 and FGFR1 FGF2 and FGFR1 FGF/FGFR signaling pathway validated 1200 MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 2014 25150313 miRBase MI0000650 miR-200c miRNA DB00398 (APRD01304, DB07438) Sorafenib renal cell carcinoma qPCR The expression levels of miRNA were determined by quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HEK293, SN12C, ACHN,786-O, Caki-1) up-regulated sensitive HO-1 HO-1 NA validated 1201 MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 2014 25150313 miRBase MI0000650 miR-200c miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib renal cell carcinoma qPCR The expression levels of miRNA were determined by quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HEK293, SN12C, ACHN,786-O, Caki-1) up-regulated sensitive HO-1 HO-1 NA validated 1202 MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer 2014 25151861 miRBase MI0000270/MI0000683 miR-181b miRNA DB00444 (APRD00649) Teniposide glioma RT-PCR MiR-181b expression was measured in 90 glioma patient tissues and its relationship to prognosis of these patients was analyzed. Cell sensitivity to teniposide was tested in 48 primary cultured glioma samples. Then miR-181b stably overexpressed U87 cells were generated. The candidate genes of miR-181b from our previous study were reanalyzed, and the interaction between miR-181b and target gene MDM2 was confirmed by dual luciferase assay. Cell sensitivity to teniposide was detected on miR-181b over expressed and MDM2 down regulated cells. cell line (U87) up-regulated sensitive MDM2 MDM2 NA validated 1203 MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol 2014 25155039 miRBase MI0000748 miR-130b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription polymerase chain reaction and those of protein were by Western blot analysis.The CCK-8 assay was used to monitor the growth of the cells . cell line (A2780,A2780/Taxol ) up-regulated resistant NA NA NA validated 1204 MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol 2014 25155039 miRBase MI0000748 miR-130b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription polymerase chain reaction and those of protein were by Western blot analysis.The CCK-8 assay was used to monitor the growth of the cells . cell line (A2780,A2780/Taxol ) up-regulated resistant NA NA NA validated 1205 Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J 2014 25156775 miRBase MI0000478 miR-149 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR,RT-PCR In this study, we found that miR-149 was downregulated and involved in chemoresistance in adriamycin (ADM)-resistant human breast cancer cells (MCF-7/ADM). Downregulation of miR-149 was related to hypermethylation of its 5-UTR; this methylation also affected the expression of the glypican 1 gene, which is both the host and the target gene of miR-149. Furthermore, we found that miR-149 modulated chemoresistance through targeting the expression of GlcNAc N-deacetylase/N-sulfotransferase-1 (NDST1). With downregulated miR-149, NDST1 expression was increased in chemoresistant MCF-7/ADM cells versus control MCF-7 wild-type cells. The increased NDST1 then activated a heparan sulfate-related pathway involving activation of heparanase. Finally, expression of miR-149 and NDST1 was confirmed in clinical chemoresistant samples of breast cancers receiving anthracycline/taxane-based chemotherapies. The high expression of NDST1 was also an unfavorable predictor for distant relapse-free survival in Her2 and basal breast cancers. Taken together, our findings demonstrate that miR-149 is regulated by methylation, and is a modulator of cancer chemoresistance by targeting NDST1. cell line (MCF-7/WT, MCF-7/ADM, MCF-7/PTX, HCT-8/5-FU) down-regulated resistant NDST1 NSTD1 NA validated 1206 Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J 2014 25156775 miRBase MI0000478 miR-149 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and real-time PCR. Those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Targetscan online software was applied to predict the putative target gene of miR-149. cell line (MCF-7/WT, MCF-7/ADM, MCF-7/PTX, HCT-8/5-FU) down-regulated resistant NDST1 NSTD1 NA validated 1207 Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J 2014 25156775 miRBase MI0000478 miR-149 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and real-time PCR. Those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Targetscan online software was applied to predict the putative target gene of miR-149. cell line (MCF-7/WT, MCF-7/ADM, MCF-7/PTX, HCT-8/5-FU) down-regulated resistant NDST1 NSTD1 NA validated 1208 Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J 2014 25156775 miRBase MI0000478 miR-149 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and real-time PCR. Those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Targetscan online software was applied to predict the putative target gene of miR-149. cell line (MCF-7/WT, MCF-7/ADM, MCF-7/PTX, HCT-8/5-FU) down-regulated resistant NDST1 NSTD1 NA validated 1209 A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol 2014 25159093 miRBase MI0000542 miR-320a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative Reverse-Transcription Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction. Those of protein were by Western blot analysis.CpG plot online software was used to analyze CpGis on promoters.Immunohistochemical analysis was performed on TissueTek OCT-frozen sections using either TRPC5 or NFATC3 mAb (Abcam) . cell line (MCF-7/WT,HCT-8, MCF-7/ADM, MCF-7 PTX) up-regulated sensitive TRPC5 and NFATC3 TRPC5 and NFATC3 the TRPC5 signaling pathway validated 1210 A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol 2014 25159093 miRBase MI0000542 miR-320a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative Reverse-Transcription Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction. Those of protein were by Western blot analysis.CpG plot online software was used to analyze CpGis on promoters.Immunohistochemical analysis was performed on TissueTek OCT-frozen sections using either TRPC5 or NFATC3 mAb (Abcam) . cell line (MCF-7/WT,HCT-8, MCF-7/ADM, MCF-7 PTX) up-regulated sensitive TRPC5 and NFATC3 TRPC5 and NFATC3 the TRPC5 signaling pathway validated 1211 MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol 2014 25170221 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin stomach cancer real-time RT-PCR A miRNA microarray containing human mature and precursor miRNA sequences was used to compare expression profiles in serum samples of 5 patients with AGC before and after CRS + HIPEC. The upregulation of miR-218 was confirmed by real-time reverse transcription polymerase chain reaction and its expression was analyzed in SGC7901 gastric cancer cells. cell line (SGC7901) up-regulated sensitive mTOR mTOR mTOR signaling pathway validated 1212 MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol 2014 25174983 miRBase MI0000105 miR-29b-1 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma real-time RT-PCR The expression levels of miRNA were determined by real-time RT-PCR and those of protein were by Western blot analysis. Flow cytometry analysis of Ki-67 expression . cell line (3AB-OS) up-regulated sensitive NA NA NA validated 1213 MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells. Tumour Biol 2014 25179844 miRBase MI0001648 miR-449a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow cytometry analysis of cell apoptosis . cell line ( SKOV3, A2780,SKOV3/CDDP, A2780/CDDP) up-regulated sensitive NOTCH1 NOTCH1 NOTCH pathway validated 1214 The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis 2014 25188512 miRBase MIMAT0000459 miR-193a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel bladder cancer RT-PCR The role of miR-193a-3p in bladder cancer cells was detected using luciferase reporter assay, real-time PCR, western blotting, BSP analysis, bioinformatics analysis and the in vivo studies, etc. cell line (EJ,T24,5637,H-bc,Biu87) up-regulated resistant SRSF2,PLAU and HIC2 SRSF2,PLAU and HIC2 DNA damage, Notch, NF-kappaB, Myc/Max, and Oxidative Stress validated 1215 Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget 2014 25226615 miRBase MI0003134 miR-494 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69, NCI-H446,NCI-H69AR) up-regulated sensitive SCGN SCGN Bcl-2 pathway validated 1216 Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget 2014 25226615 miRBase MI0003134 miR-494 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69, NCI-H446,NCI-H69AR) up-regulated sensitive SCGN SCGN Bcl-2 pathway validated 1217 Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget 2014 25226615 miRBase MI0003134 miR-494 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCI-H69, NCI-H446,NCI-H69AR) up-regulated sensitive SCGN SCGN Bcl-2 pathway validated 1218 miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res 2014 25228385 miRBase MI0003653 miR-638 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR Formalin-fixed, paraffin-embedded (FFPE) breast cancer samples were microdissected into normal epithelial and invasive ductal carcinoma (IDC) cells, and total RNA was isolated. Several breast cancer cell lines were used for the functional analysis. miR-638 target genes were identified by TARGETSCAN-VERT 6.2 and miRanda. The expression of miR-638 and its target genes was analyzed by real-time qRT-PCR and Western blotting. Dual-luciferase reporter assay was employed to confirm the specificity of miR-638 target genes. The biological function of miR-638 was analyzed by MTT chemosensitivity, matrigel invasion and host cell reactivation assays. cell line (MDA-MB-231, Hs578T, MCF-7, T47D ) up-regulated sensitive BRCA1 BRCA1 DNA repair pathway validated 1219 MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncol Rep 2014 25231602 miRBase MI0000787 miR-379 miRNA DB02546 (EXPT02902) Vorinostat malignant pleural mesothelioma real-time qRT-PCR The role of MiR-379/411 cluster in malignant pleural mesothelioma cells was detected using drugs and growth-inhibition assay, real-time quantitative reverse transcription-PCR,luciferase assay, invasion assay, GeneChip and miRNA array analysis, etc. cell line (NCI-H28, NCI-H2452, ACC-MESO4,ACC-MESO1,MSTO-211H) up-regulated sensitive IL-18 IL-18 NA validated 1220 MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncol Rep 2014 25231602 miRBase MI0003675 miR-411 miRNA DB02546 (EXPT02902) Vorinostat malignant pleural mesothelioma real-time qRT-PCR The role of MiR-379/411 cluster in malignant pleural mesothelioma cells was detected using drugs and growth-inhibition assay, real-time quantitative reverse transcription-PCR,luciferase assay, invasion assay, GeneChip and miRNA array analysis, etc. cell line (NCI-H28, NCI-H2452, ACC-MESO4,ACC-MESO1,MSTO-211H) up-regulated sensitive IL-18 IL-18 NA validated 1221 MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells 2014 25234467 miRBase MI0000293 miR-217 miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR This study aims to evaluate the function of miR-217 in lung cancer and investigate its effect on the sensitivity of lung cancer cells to cisplatin. The expression of miR-217 was detected in 100 patients by real-time PCR. The effects of miR-217 overexpression on the proliferation, apoptosis, migration and invasion of SPC-A-1 and A549 cells were investigated. The target gene of miR-217 was predicted by Targetscan online software, screened by dual luciferase reporter gene assay and demonstrated by Western blot. Finally, the effects of miR-217 up-regulation on the sensitivity of A549 cells to cisplatin were determined. tissue and cell line (SPC-A-1, A549 ) up-regulated sensitive KRAS KRAS PI3K/Akt pathway validated 1222 Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer 2014 25248111 miRBase MI0000447/MI0000727 miR-128 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression of miR-128 RNA and its targeted genes, the polycomb ring finger oncogene Bmi-1 and ATP-binding cassette subfamily C member 5 (ABCC5), were investigated in the epithelial ovarian cancer cells and ovarian carcinomas. cell line (SKOV3, OVCAR3, PEO14,SKOV3/CP) down-regulated resistant Bmi-1 and ABCC5 Bmi-1 and ABCC5 NA validated 1223 SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther 2014 25249558 miRBase MI0000461 miR-145 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The expression levels of miRNA were determined by Reverse Transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (DLD1, HCT116, LS174T, HT29 and SW620) up-regulated sensitive NA NA NA validated 1224 miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol 2014 25260883 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse-transcriptase polymerase chain reaction analysis (qRT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. cell line (A2780, SKOV3,A2780/DDP, SKOV3/DDP) up-regulated sensitive EZH2 EZH2 NA validated 1225 Role and mechanisms of microRNA-503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Mol Med Rep 2014 25269574 miRBase MI0003188 miR-503 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qPCR The expression levels of miRNA were determined by qPCR and those of protein were by Western blot analysis. MTS detection of the effect of miR-503 on tumor cell drug resistance . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Liquidchip assay to detect drug resistance-related cytokines . Double fluorescent reporter gene assay to detect the transcriptional activity of NF-kappaB and AP-1 . cell line (HepG2,HepG2/ADM) up-regulated sensitive NA NA PI3K/Akt pathway validated 1226 miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 2014 25277203 miRBase MI0000650 miR-200c miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The role of miR-200c in non-small cell lung cancer cells was detected using quantitative reverse-transcriptase polymerase chain reaction, MTT assay, western blot, immunocytochemistry and EGFR mutation analysis, etc. cell line (PC9, PC9/R, H23, A549, H1975, H460, H1299) up-regulated sensitive ZEB1 ZEB1 PI3K/AKT and MEK/ERK pathways validated 1227 Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol 2014 25280517 miRBase MI0000450/MI0000451 miR-133a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel esophageal squamous cell carcinoma qRT-PCR The aim of this study was to investigate the correlation of miR-133a/b expression with efficacy of paclitaxel-based chemotherapy and clinical outcome of ESCC patients. miR-133a expression and miR-133b expression were examined in 100 newly diagnosed ESCC patients prior to treatment by quantitative real-time PCR. Then, the patients received four cycles of paclitaxel-based chemotherapy, the short-term treatment efficacy was evaluated, and a 3-year follow-up was performed. tissue down-regulated sensitive NA NA NA predicted 1228 Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol 2014 25280517 miRBase MI0000822 miR-133b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel esophageal squamous cell carcinoma qRT-PCR The aim of this study was to investigate the correlation of miR-133a/b expression with efficacy of paclitaxel-based chemotherapy and clinical outcome of ESCC patients. miR-133a expression and miR-133b expression were examined in 100 newly diagnosed ESCC patients prior to treatment by quantitative real-time PCR. Then, the patients received four cycles of paclitaxel-based chemotherapy, the short-term treatment efficacy was evaluated, and a 3-year follow-up was performed. tissue down-regulated sensitive NA NA NA predicted 1229 Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep 2014 25284075 miRBase MIMAT0014990 miR-3127-5p miRNA DB01254 Dasatinib lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Immunodeficient mouse xenograft tumor model was used to test the role of miR-3127-5p . cell line (293T,A549, H292, ) up-regulated resistant ABL1 ABL1 Abl/Ras/ERK pathway validated 1230 miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit 2014 25287716 miRBase MI0000479 miR-150 miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR miR-150 expression was quantified by qRT-PCR in two MIBC cell lines (5637 and T24). After successful miR-150 inhibition by transfection, MTS and transwell assays were used to assess the MIBC's cisplatin sensitivity and cell invasiveness, respectively. The TargetScan database and a luciferase reporter system were used to identify whether the programmed cell death 4 protein (PDCD4) is a direct target of miR-150 in MIBC cells. cell line (5637, T24) down-regulated sensitive PDCD4 PDCD4 NA validated 1231 MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett 2014 25289099 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qPCR The expression levels of miRNA were determined by Quantitative polymerase chain reaction (qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (A549, H1395,95C and 95D ) up-regulated sensitive NA NA NA validated 1232 miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res 2014 25294901 miRBase MIMAT0000265 miR-204-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer Real-time qRT-PCR We measured the expression of miR-204-5p and determined its correlation with patient prognoses. Ectopic expression in colorectal cancer cells, xenografts, and pulmonary metastasis models was used to evaluate the effects of miR-204-5p on proliferation, migration, and chemotherapy sensitivity. Luciferase assay and Western blotting were performed to validate the potential targets of miR-204-5p after the preliminary screening by a microarray analysis and computer-aided algorithms. cell line (Caco2, DLD1, HCT8, HCT116, HT29, LoVo, SW480, SW620) down-regulated sensitive RAB22A RAB22A miR204-5p/RAB22A signaling validated 1233 microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. J Ovarian Res 2014 25297343 miRBase MIMAT0002806 miR-490-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer real-time RT-PCR The human ovarian carcinoma cell line A2780 and A2780/Taxol were exposed to paclitaxel in the presence or absence of microRNA 490-3P transfection, after which cell viability were performed by CCK-8 assay. Reverse transcription polymerase chain reaction (RT-PCR) and western blotting were used to assess the mRNA and protein expression levels of GST-Pi, MDR1 or P-gp. cell line (A2780,A2780/Taxol) up-regulated resistant NA NA NA validated 1234 MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer 2014 25310895 miRBase MI0001729 miR-451 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. A wound healing assay was performed to examine the capacity of cell migration. Cell migration was detected by transwell migration and invasion assay. cell line (SPC-A1, H1299,SPC-A1/DTX, H1299/DTX) down-regulated resistant c-Myc NA miR-451/c-Myc/ERK/GSK-3Beta signalling validated 1235 miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer 2014 25311867 miRBase MIMAT0000459 miR-193a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel bladder cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (5637,T24,UM-UC-3, Biu87) up-regulated resistant LOXL4 LOXL4 Oxidative Stress pathway validated 1236 Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. Oncol Rep 2014 25322930 miRBase MIMAT0000428 miR-135a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-PCR In the present study, we determined whether miRNA-135a-5p expression was increased in gastric cancer compared with adjacent non-tumor tissues using 20 pairs of gastric cancer and para-carcinoma tissue samples which were assessed via microarray and bioinformatics analysis, and western blotting. The protein content detection showed that miRNA-135a-5p expression was inversely correlated with AP-2alpha. Bioinformatics analysis revealed that AP-2alpha contains a putative miRNA-135a-5p target, which was confirmed as a direct target using the 3-UTR luciferase reporter system. Additionally, an increase and decrease of miRNA-135a-5p inhi-bited or impaired adriamycin-induced apoptosis in BGC-823 cells , respectively. Luciferase reporter experiments confirmed that AP-2alpha bound to the BCL-2 promoter and affected its transcription. cell line (BGC-823) up-regulated resistant AP-2alpha AP-2alpha miR-135a-5p-AP-2alpha-BCL2 pathway validated 1237 miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS One 2014 25330011 miRBase MI0000783 miR-375 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer Real-Time RT-PCR The expression levels of miRNA were determined by Real-Time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. MTS assay was used to test cell proliferation . cell line (SiHa and CaSki ) up-regulated resistant Ecadherin Ecadherin NA validated 1238 MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumour Biol 2014 25344675 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin pancreatic cancer qRT-PCR The role of miR-100 in pancreatic cancer cells was detected using quantitative real-time reverse transcription-PCR (qRT-PCR), cell proliferation assay, luciferase reporter assays and transfection of siRNA, etc. tissue and cell line (AsPC1,BxPc-3, Capan-1, Capan-2, CFPAC-1, PANC-1, MIA, PaCa-2, and SW1990) up-regulated sensitive FGFR3 FGFR3 NA validated 1239 miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget 2014 25344865 miRBase MI0000790 miR-382 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Animal experiments was uesed to test the role of miR-382 . cell line (MNNG/HOS, U2OS, MG63) down-regulated resistant KLF12 and HIPK3 KLF12 and HIPK3 NA validated 1240 miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget 2014 25344865 miRBase MI0000790 miR-382 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Animal experiments was uesed to test the role of miR-382 . cell line (MNNG/HOS, U2OS, MG63) down-regulated resistant KLF12 and HIPK3 KLF12 and HIPK3 NA validated 1241 miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget 2014 25344865 miRBase MI0000790 miR-382 miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Animal experiments was uesed to test the role of miR-382 . cell line (MNNG/HOS, U2OS, MG63) down-regulated resistant KLF12 and HIPK3 KLF12 and HIPK3 NA validated 1242 Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget 2014 25344911 miRBase MIMAT0000242 miR-129-5p miRNA DB00541 (APRD00495) Vincristine stomach cancer RT-PCR The role of miR-129-5p in gastric cancer cells was detected using intracellular ADR intensity analysis, in vitro drug sensitivity assay, in vivo drug sensitivity assay, Real-time PCR, western blot and immunohistochemistry, etc. cell line (SGC7901,SGC7901/VCR,SGC7901/ADR,SGC7901-Luc ) up-regulated sensitive ABCB1, ABCC5 and ABCG1 ABCB1, ABCC5 and ABCG1 NA validated 1243 Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget 2014 25344911 miRBase MIMAT0000242 miR-129-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer RT-PCR The role of miR-129-5p in gastric cancer cells was detected using intracellular ADR intensity analysis, in vitro drug sensitivity assay, in vivo drug sensitivity assay, Real-time PCR, western blot and immunohistochemistry, etc. cell line (SGC7901,SGC7901/VCR,SGC7901/ADR,SGC7901-Luc ) up-regulated sensitive ABCB1, ABCC5 and ABCG1 ABCB1, ABCC5 and ABCG1 NA validated 1244 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000745 miR-301a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1245 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000736/MI0000254 miR-30c miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1246 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0002809 miR-146b-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1247 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000443 miR-125a-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant PTPN18 PTPN18 NA validated 1248 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0003137 miR-193b miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1249 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000082 miR-25 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1250 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000065 let-7d miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1251 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000767 miR-365 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1252 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000088 miR-30a-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1253 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0002173 miR-483-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1254 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000066 let-7e miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1255 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000109 miR-103 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1256 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000705 miR-362-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1257 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000438 miR-15b miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1258 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000757 miR-151-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1259 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000067/MI0000068 let-7f miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1260 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000761 miR-324-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1261 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000441 miR-30b miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1262 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000060/MI0000061/MI0000062 let-7a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1263 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000434 let-7i miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1264 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0004697 miR-151-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1265 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000748 miR-130b miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1266 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0003684 miR-660 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1267 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000114 miR-107 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1268 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0002888 miR-532-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1269 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000290 miR-214 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1270 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000459 miR-143 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) up-regulated resistant NA NA NA predicted 1271 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0004795 miR-574-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1272 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0000474 miR-134 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1273 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0003653 miR-638 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1274 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0003892 miR-762 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1275 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0005458 miR-1224-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1276 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0005572 miR-1225-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1277 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0004610 miR-150-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1278 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0005871 miR-1207-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1279 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0008336 miR-1915 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1280 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0006405 miR-1268 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1281 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0004552 miR-139-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1282 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0003672 miR-663 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1283 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0006384 miR-1249 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1284 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000690 miR-296-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1285 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MIMAT0000457 miR-188-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1286 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0005761 miR-939 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1287 microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014 25349971 miRBase MI0006318 miR-1228 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The expression levels of microRNAs were quantified using microarray and RT-qPCR in GIST specimens from patients treated with neoadjuvant imatinib. The functional roles of miR-125a-5p and PTPN18 were evaluated in GIST cells. PTPN18 expression was quantified by western blotting in GIST samples. cell line (GIST882 and GIST48) down-regulated resistant NA NA NA predicted 1288 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000256 miR-181a-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1289 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000443 miR-125a-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1290 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000066 let-7e-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1291 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000257 miR-181b-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1292 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000318 miR-200b-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1293 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000089 miR-31-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1294 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004571 miR-200b-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1295 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004784 miR-455-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1296 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000440 miR-191-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1297 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003653 miR-638 miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1298 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004792 miR-92b-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1299 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000078 miR-23a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1300 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000682 miR-200a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1301 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004679 miR-296-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1302 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000062 let-7a-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1303 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0000283 miR-203a miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1304 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003672 miR-663a miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1305 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002888 miR-532-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1306 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0000542 miR-320a miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1307 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003776/MI0003839 miR-320b miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1308 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003778/MI0008191 miR-320c miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1309 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004945 miR-744-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1310 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000689 miR-99b-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1311 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000092 miR-92a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1312 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004498 miR-25-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1313 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000764 miR-339-5p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1314 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002891 miR-18a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1315 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002819 miR-193b-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1316 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000425 miR-130a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1317 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000089 miR-31-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1318 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000222 miR-192-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA TYMS,ABCC3 NA predicted 1319 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000460 miR-194-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1320 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000732 miR-378a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA CBL-B NA predicted 1321 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000279 miR-222-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1322 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000267 miR-210-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1323 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002891 miR-18a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA KRAS NA predicted 1324 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004494 miR-21-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1325 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0006405 miR-1268a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1326 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004498 miR-25-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1327 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000419 miR-27b-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA KRAS NA predicted 1328 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000070 miR-17-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1329 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002819 miR-193b-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA KRAS NA predicted 1330 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000071 miR-17-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1331 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0003150 miR-455-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1332 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0006415 miR-1275 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1333 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0000283 miR-203a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1334 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003672 miR-663a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1335 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0004800 miR-550a-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1336 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0005757 miR-935 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1337 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0003257 miR-550a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1338 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000689 miR-99b-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1339 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002891 miR-18a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA KRAS NA predicted 1340 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0005577 miR-1226-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1341 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0005943 miR-1292-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) up-regulated resistant NA NA NA predicted 1342 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000443 miR-125a-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA ERBB2 NA predicted 1343 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0002171 miR-410-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1344 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0000760 miR-331-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1345 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MI0003672 miR-663a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1346 MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014 25356050 miRBase MIMAT0001080 miR-196b-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR,qRT-PCR An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. cell line (OE19,KYSE410) down-regulated resistant NA NA NA predicted 1347 Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 2014 25368020 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Surface marker analysis by flow cytometry . Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 activation status was measured using the Caspase-Glo 3 Assay . Lentiviral-mediated miRNA overexpression and xenograft was used to test the role of miR-34a . cell line (MCF7, MCF7/ADR) up-regulated sensitive NOTCH1 NOTCH1 NA validated 1348 MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int J Clin Exp Pathol 2014 25400759 miRBase MI0003649 miR-634 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharyngeal carcinoma qRT-PCR In this study, based on miRNA microarray screening and qRT-PCR validation, we found six differentially expressed miRNAs in our induced paclitaxel-resistant NPC CNE-1/Taxol cells. Furthermore, we clarified the role of miR-634, most significantly downregulated in the paclitaxel-resistant CNE-1/Taxol, in regulating the paclitaxel sensitivity in NPC cells. We restored miR-634 expression in the CNE-1/Taxol cells by lentivirus infection, and found restoration of miR-634 re-sensitized the CNE-1/Taxol cells to paclitaxel in vitro by MTT assay and colony formation assay. In xenograft mouse model, we found that miR-634 inhibited tumor growth and enhanced paclitaxel sensitivity. cell line (CNE-1) up-regulated sensitive NA NA NA validated 1349 miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int J Clin Exp Pathol 2014 25400821 miRBase MI0000114 miR-107 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma real-time qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse transcription-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549) up-regulated sensitive CDK8 CDK8 NA validated 1350 MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol 2014 25416050 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin breast cancer qPCR The expression levels of miRNA were determined by quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MDA-MB-231, MDA-MB-435,MCF-7,MCF-10A) up-regulated sensitive Mcl-1 Mcl-1 miR-363/Mcl-1 pathway validated 1351 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000457 miR-141 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) up-regulated resistant NA NA NA validated 1352 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000650 miR-200c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) up-regulated resistant NA NA NA validated 1353 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000089 miR-31 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) up-regulated resistant NA NA NA validated 1354 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000066 let-7e miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1355 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MIMAT0004796 miR-576-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1356 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000446 miR-125b-1 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1357 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000778 miR-370 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1358 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0000461 miR-145 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1359 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0005116 miR-765 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1360 miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014 25451164 miRBase MI0005567 miR-760 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Students t-test, and a P value less than 0.05 was considered statistically significant. cell line (MCF-7,MCF-/Adr) down-regulated resistant NA NA NA validated 1361 MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother 2014 25465153 miRBase MI0000098 miR-96 miRNA DB00515 (APRD00359) Cisplatin esophageal cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Apoptosis was analyzed by flow cytometry using Annexin V/PI double staining. The CCK-8 assay was used to monitor the growth of the cells . Tumor formation assay in nude mouse models was used to test the role of miR-96 . tissue and cell line (TE-1, ECa-109, EC-9706,HEEC) up-regulated sensitive RECK RECK NA validated 1362 MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin. Int J Mol Sci 2014 25474084 miRBase MI0000299 miR-222 miRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (UM1) up-regulated sensitive PUMA PUMA NA validated 1363 Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol 2014 25510179 miRBase MI0000471 miR-126 miRNA NA Epigallocatechin-3-gallate (EGCG) osteosarcoma NA The cell viability, apoptosis and cycle distribution were analyzed using MTT assay and flow cytometry. cell line (MG63, U2OS) up-regulated sensitive NA NA NA validated 1364 MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1alpha. PLoS One 2014 25531114 miRBase MIMAT0000763 miR-338-3p miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocarcinoma RT-PCR The expression levels of miRNA were determined by real time PCR (RT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. MTS assay was used to test cell proliferation cell line (HepG2, SMMC-7721, BEK-7402, Hep3B, Huh-7, L02) up-regulated sensitive HIF-1alpha HIF-1alpha HIF signaling pathway validated 1365 MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One 2014 25532106 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-PCR The role of miR-7 in breast cancer cells was detected using micro RNA expression profiling, western blot, colony formation assay, cell cycle and cell migration analysis, etc. cell line (MCF-7) up-regulated sensitive NA NA NA validated 1366 miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac J Cancer Prev 2014 25556489 miRBase MI0000802 miR-340 miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells, cell line (HepG2,HepG2/CDDP) up-regulated sensitive Nrf2 Nrf2 Nrf2-dependent Antioxidant Pathway validated 1367 miR-34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1 Zhonghua Zhong Liu Za Zhi 2014 25623761 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qPCR The expression of miR-34a in MCF-7 and MCF-7/ADR cells were detected by real-time fluorescence quantitative PCR. Cells were transfected with miR-34a mimics or inhibitor using Lipofectamine 2000. Expression of Notch1 in the two groups before and after transfection was detected by real-time fluorescence quantitative PCR and Western blot. MTT test and apoptosis assay were performed to observe the impact of miR-34a expression on the sensitivity of breast cancer cells to ADR. cell line (MCF-7, MCF-7/ADR) up-regulated sensitive Notch1 Notch1 NA validated 1368 miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells Zhonghua Zhong Liu Za Zhi 2014 25623762 miRBase MI0000069 miR-15 miRNA DB00541 (APRD00495) Vincristine colon cancer RT-qPCR Mimics or inhibitors of miR-15a and miR-16 were transfected into HCT8 or HCT8/VCR cells with the help of Lipofectamine 2000. The expressions of miR-15a and miR-16 mRNA were detected by RT-qPCR. The levels of bcl-2 and P-gp proteins were measured by Western blot. The inhibitory effects of VCR on growth of HCT8 and HCT8/VCR cells were detected by CCK8. cell line (HCT8, HCT8/VCR) up-regulated sensitive bcl-2 bcl-2 NA validated 1369 miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells Zhonghua Zhong Liu Za Zhi 2014 25623762 miRBase MI0000070/MI0000115 miR-16 miRNA DB00541 (APRD00495) Vincristine colon cancer RT-qPCR Mimics or inhibitors of miR-15a and miR-16 were transfected into HCT8 or HCT8/VCR cells with the help of Lipofectamine 2000. The expressions of miR-15a and miR-16 mRNA were detected by RT-qPCR. The levels of bcl-2 and P-gp proteins were measured by Western blot. The inhibitory effects of VCR on growth of HCT8 and HCT8/VCR cells were detected by CCK8. cell line (HCT8, HCT8/VCR) up-regulated sensitive bcl-2 bcl-2 NA validated 1370 Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am J Cancer Res 2014 25628933 miRBase MI0000077 miR-21 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin glioblastoma qRT-PCR The role of miR-21 in glioblastoma cells was detected using expression study, MTT assay, TUNEL assay and qRT-PCR, etc. cell line (A172, U87MG, T98G, U87MG, T98G) down-regulated sensitive NA NA NA validated 1371 MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol 2015 23526568 miRBase MI0000489 miR-195 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colon cancer qRT-PCR In this study, we utilized microRNA array and real-time PCR to identify that some microRNAs different expression level in cell lines. In vitro cell viability assay showed that the role of miR-195 in colon cancer cells . cell line ( HT29, LOVO,HT29/DOX, LOVO/DOX ) up-regulated sensitive BCL2L2 BCL2L2 NA validated 1372 MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int 2015 25040368 miRBase MIMAT0001343 miR-425-3p miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qPCR We profiled 522 miRNA in a series of 26 HCC patients treated with sorafenib (training set) and validated the results in an independent series of 58 patients (validation set). Formalin-fixed paraffin-embedded tumour and cirrhotic liver biopsies were used for RNA extraction and miRNAs profiling with TaqMan Arrays technology. Statistical analyses were used to correlate miRNA levels with clinical outcome, including time to progression (TTP), progression free (PFS), and overall survival. Cell viability and cell motility of HuH-7 or HepG2 HCC cells were tested in vitro after transfection with specific miRNA precursor, inhibitor or controls and sorafenib treatment. tissue and cell line ( HuH-7) up-regulated sensitive NA NA NA validated 1373 Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer 2015 25137037 miRBase MI0003146 miR-520f miRNA DB00515 (APRD00359) Cisplatin neuroblastoma qRT-PCR The role of miR-520f in neuroblastoma SK-N-AS cells was detected using apoptosis assays, toxicity assay, invasion assay, molecular cloning and assays, quantitative real-time PCR and western blot, etc. cell line (SK-N-AS) down-regulated resistant NAIP NAIP NA validated 1374 The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer 2015 25159729 miRBase MI0000300 miR-223 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time reverse transcription-PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow cytometric analysis of cell cycle distribution and apoptosis .The CCK-8 assay was used to monitor the growth of the cells . cell line (MKN45, NUGC3, NUGC4, kato3, NCI-N87) up-regulated resistant FBXW7 FBXW7 miR-223/FBXW7 pathway validated 1375 MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett 2015 25305453 miRBase MI0000749 miR-30e miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The expression levels of miRNA were determined by real time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line ( K562,HL-60,THP-1) up-regulated sensitive ABL ABL NA validated 1376 Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol Med Rep 2015 25323306 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung cancer qPCR The role of miR-21in A549/DDP human lung cancer cells was detected using quantitative PCR , antisense oligonucleotide transfection assay, cell viability detection assay, apoptosis and cell cycle assays, oxidative damage detection assay, cystathione and glutathione (GSH) detection assay, dual luciferase assay, etc. cell line (A549, A549/DDP) up-regulated resistant NA NA AKT pathway validated 1377 Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Mol Med Rep 2015 25333573 miRBase MI0000268 miR-34a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (DLD-1) up-regulated sensitive LDHA LDHA NA validated 1378 Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3UTR is associated with fluorouracil resistance of hepatocellular carcinoma. Mol Med Rep 2015 25333670 miRBase MI0000063 Let-7b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma NA The role of Let-7b in hepatocellular carcinoma cells was detected using western blot, cell counting kit 8 (CCK8) assay, construction of the vector and dual-luciferase reporter assay, etc cell line (BEL-7402,) up-regulated sensitive Bcl-xl NA NA validated 1379 MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep 2015 25339370 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Enumeration of apoptotic cells was performed using fluorescein isothiocyanate (FITC)-conjugated Annexin V and PI. cell line (A549, A549/DDP) up-regulated resistant ABCA1 ABCA1 NA validated 1380 MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Mol Med Rep 2015 25339453 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qPCR The aim of the present study was to establish, characterize and elucidate the potential mechanisms of acquired gefitinb resistance, using the A549 human lung cancer cell line. A gefitinib-resistant A549 sub-clone was established by exposure to escalating gefitinib concentrations over a period of 16-24 months. Half maximal inhibitory concentration (IC50) values were quantified using a real time cytotoxicity assay. The expression profiles of the parent and resistant sub-clone A549 cells were detected using the -Paraflo- Microfluidics Biochip microRNA (miRNA) Microarray. The ArrayPro software was used to analyze the differential expression levels of the miRNA, and bioinformatics software was used to predict the potential target genes of the differentially expressed miRNAs. Quantitative polymerase chain reaction (qPCR) was used to confirm the results of the miRNA microarray. A miRNA mimic was transfected into the gefitinib-resistant cells, in order to predict target gene interaction effects, following gefitinib treatment. Protein expression level differences were confirmed by western-blot analysis. cell line (A549) up-regulated sensitive EGFR EGFR NA validated 1381 MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol 2015 25394901 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The role of miR-218 in breast cancer cells was detected using quantitative real-time PCR, cell viability, apoptosis assays, and colony growth assay, luciferase assay, comet assay and western blot analysis, etc. cell line (MCF-7,HEK-293, MCF-7/DDP) up-regulated sensitive BRCA1 BRCA1 NA validated 1382 miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol 2015 25407491 miRBase MI0000109 miR-103 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin gastric carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Tumor xenograft studies was used to test the role of miR-103/107 . cell line ( SGC7901,SGC7901/ADR) up-regulated sensitive Cav-1 Cav-1 NA validated 1383 miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol 2015 25407491 miRBase MI0000114 miR-107 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin gastric carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Tumor xenograft studies was used to test the role of miR-103/107 . cell line ( SGC7901,SGC7901/ADR) up-regulated sensitive Cav-1 Cav-1 NA validated 1384 Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42. Tumour Biol 2015 25432132 miRBase MI0000082 miR-25 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Lung cancer xenograft was used to test the role of miR-25 . cell line (H520, H460, A549,MRC5) down-regulated sensitive CDC42 CDC42 NA validated 1385 MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal 2015 25435430 miRBase MI0000070/MI0000115 miR-16 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (Type II,A549, NCI-H596,NCI-H1734, NCI-H1299) up-regulated sensitive Bcl-2 Bcl-2 PI3K/ Akt/ mTOR pathway validated 1386 MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett 2015 25444900 miRBase MIMAT0000459 miR-193a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel bladder cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Animal experiments was used to test the role of miR-193a-3p . cell line ( 5637, H-bc) up-regulated resistant HOXC9,SRSF2,PLAU,HIC2 HOXC9,SRSF2,PLAU,HIC2 DNA damage response/oxidative stress pathway axis validated 1387 miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 2015 25446103 miRBase MI0000542 miR-320 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line ( HCT116, HT-29) up-regulated sensitive FOXM1 FOXM1 Wnt/Beta-catenin pathway validated 1388 miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 2015 25446103 miRBase MI0000542 miR-320 miRNA DB00526 (APRD00186) Oxaliplatin colon cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line ( HCT116, HT-29) up-regulated sensitive FOXM1 FOXM1 Wnt/Beta-catenin pathway validated 1389 MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 2015 25449431 miRBase MI0000078 miR-22 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription and real-time PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability was assessed by trypan blue exclusion .The flow cytometry was used to monitor the apoptosis level by staining the cells. cell line (SW620, RKO ) up-regulated sensitive BTG1 BTG1 NA validated 1390 Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep 2015 25482209 miRBase MI0000475 miR-136 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by quantitative real-time PCR .Cell migration was detected by transwell migration and invasion assay. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.A wound healing assay was performed to examine the capacity of cell migration. cell line (EOC, OV2008, C13) down-regulated resistant NA NA NA validated 1391 Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol 2015 25492481 miRBase MI0000459 miR-143 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR,RT-PCR miR-143 was detected by quantitative real-time PCR. Cisplatin resistance changes of cells was tested via MTT assay. Target genes of miR-143 were verified by dual-luciferase activity assay. Immunohistochemistry, immunofluorescence staining, Western blot, cell proliferation, and clonogenic and apoptosis assay were used to elucidate the mechanism of miR-143 in cisplatin resistance formation. cell line ( GES-1, MKN45, MGC803, BGC823, SGC7901,SGC7901/DDP) up-regulated sensitive IGF1R,BCL2 IGF1R,BCL2 IGF1R signal pathway validated 1392 miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist. Oncol Rep 2015 25501015 miRBase MI0000079 miR-23a miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma real-time qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse transcription PCR and those of protein were by Western blot analysis. Cell apoptosis was analyzed with an Annexin V-EGFP apoptosis detection kit coupled with flow cytometric analysis . cell line (SCC-4, Tca8113) up-regulated resistant Twist NA JNK signaling pathway validated 1393 Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. Arch Pharm Res 2015 25502560 miRBase MI0000098 miR-96 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Acid phosphatase (APH) assay for drug response . A wound healing assay was performed to examine the capacity of cell migration. cell line (HT-29, DLD-1, HCT-116) up-regulated sensitive NA NA NA validated 1394 MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 2015 25503932 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colorectal cancer quantitative real-time RT-PCR The role of miR-7 in colorectal cancer cells was detected using plasmid construction, luciferase assay, immunohistochemistry, western blot and proliferation assay, etc. cell line (HCT116, SW480,HT29) up-regulated sensitive EGFR and RAF-1 EGFR and RAF-1 NA validated 1395 MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3. Mol Med Rep 2015 25515700 miRBase MI0000283 miR-203 miRNA DB00853 (APRD00557) Temozolomide glioma qPCR The expression levels of miRNA were determined by qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. MTS assay was used to test cell proliferation . Cell migration was detected by transwell migration and invasion assay. cell line (A172, U87MG, U251MG,HEK-293T) up-regulated sensitive E2F3 E2F3 NA validated 1396 MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood 2015 25515961 miRBase MI0002470/MI0023622 miR-486 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of miR-486 in CML was detected using transduction and transfection of CD34+ cells,Cell proliferation, differentiation, cell cycle, and apoptosis assays, luciferase reporter, luciferase assays, western blot and immunodeficient mouse engraftment studies, etc. cell line (293T, TF-1,TF-1-BA) down-regulated resistant NA RFFL,EMP1,and DCBLD2 NA validated 1397 MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene 2015 25531331 miRBase MI0005564 miR-873 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR The role of miR-873 in breast cancer cells was detected using Real-time PCR, chromatin immunoprecipitation, MTT assay, soft agar assay, co-immunoprecipitation, GST pull-down assay, Kinase assay, immunohistochemistry staining and animal experiments, etc. cell line ( MCF-7, ZR75-1, T47D, SKBR3, MDAMB-231, HEK293T,MCF-7/TamR) down-regulated resistant CDK3 CDK3 NA validated 1398 The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015 25542424 miRBase MIMAT0000459 miR-193a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel bladder cancer qRT-PCR The role of miR-193a-3p in bladder cancer cells was detected using chemotherapeutics, western analysis, apoptosis analysis and luciferase reporter assay, etc. cell line (5637, H-bc ) up-regulated resistant PSEN1 PSEN1 DNA damage response pathway validated 1399 The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015 25542424 miRBase MIMAT0000459 miR-193a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin bladder cancer qRT-PCR The role of miR-193a-3p in bladder cancer cells was detected using chemotherapeutics, western analysis, apoptosis analysis and luciferase reporter assay, etc. cell line (5637, H-bc ) up-regulated resistant PSEN1 PSEN1 DNA damage response pathway validated 1400 The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015 25542424 miRBase MIMAT0000459 miR-193a-3p miRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR The role of miR-193a-3p in bladder cancer cells was detected using chemotherapeutics, western analysis, apoptosis analysis and luciferase reporter assay, etc. cell line (5637, H-bc ) up-regulated resistant PSEN1 PSEN1 DNA damage response pathway validated 1401 The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015 25542424 miRBase MIMAT0000459 miR-193a-3p miRNA DB11616 Pirarubicin bladder cancer qRT-PCR The role of miR-193a-3p in bladder cancer cells was detected using chemotherapeutics, western analysis, apoptosis analysis and luciferase reporter assay, etc. cell line (5637, H-bc ) up-regulated resistant PSEN1 PSEN1 DNA damage response pathway validated 1402 The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta 2015 25542424 miRBase MIMAT0000459 miR-193a-3p miRNA DB00445 (APRD00361) Epirubicin hydrochloride bladder cancer qRT-PCR The role of miR-193a-3p in bladder cancer cells was detected using chemotherapeutics, western analysis, apoptosis analysis and luciferase reporter assay, etc. cell line (5637, H-bc ) up-regulated resistant PSEN1 PSEN1 DNA damage response pathway validated 1403 MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep 2015 25560734 miRBase MIMAT0003239 miR-574-3p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qPCR,qRT-PCR The role of miR-22 was detected by qPCR, qRT-PCR,cell growth assay, and luciferase reporter assay. cell line(MCF-7,T47D, 293T,OHTR) down-regulated resistant CLTC CLTC NA validated 1404 MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep 2015 25560734 miRBase MIMAT0003239 miR-574-3p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qPCR,qRT-PCR The role of miR-574-3p in breast cancer cells was detected using miRNA target prediction, qPCR, qRT-PCR, cell growth assay and luciferase reporter assay, etc. cell line (MCF-7, T47D, 293T ) down-regulated resistant CLTC CLTC NA validated 1405 microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma. Exp Biol Med (Maywood) 2015 25576341 miRBase MI0000459 miR-143 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-PCR The role of miR-143 in osteosarcoma cells was detected using MTT assay, matrigel colony assay, Real-time PCR, western blot, hoechst staining and animal experiment, etc. tissue and cell line (SAOS-2, U2OS,FOB1.19) down-regulated resistant NA NA NA validated 1406 The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol 2015 25579119 miRBase MIMAT0004494 miR-21-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR We used microarrays to measure miRNA levels in the ovarian cancer cell line A2780 and its cisplatin-resistant derivative CP70. The role of miRNAs and the mRNA targets were tested using transfected miRNA mimics and siRNAs, respectively. Potential in vivo significance was investigated by analysing RNA levels in cohorts of ovarian cancer patients. cell line (A2780,CP70, OVCAR5, OVCAR8, IGROV1) up-regulated resistant NAV3 NAV3 NA validated 1407 MiRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncol Rep 2015 25586125 miRBase MIMAT0003389 miR-542-3p miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SKBR3, MCF7/HER2) down-regulated resistant NA NA PI3K-AKT pathway validated 1408 MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-Beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep 2015 25586740 miRBase MI0000266 miR-10a miRNA DB00515 (APRD00359) Cisplatin lung cancer qPCR The expression levels of miRNA were determined by qPCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Transforming growth factor (TGF)-Beta detection was performed using an ELISA kit . cell line (A549,A549/DDP ) down-regulated sensitive NA NA TGF-Beta/Smad2/STAT3/STAT5 pathway validated 1409 Inhibition of microRNA-23a increases cisplatin sensitivity of ovarian cancer cells: the possible molecular mechanisms Nan Fang Yi Ke Da Xue Xue Bao 2015 25613625 miRBase MI0000079 miR-23a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer NA The drug-resistant ovarian cancer A2780 cells were exposed to cisplatin alone or in combination with antagomir-23a. The cell inhibition rates after the treatments were detected using MTT assay, cell cycle changes assessed with flow cytometry; and apoptotic cells observed using Hoechst33258 staining. The changes in glycoprotein P-gp expression in the cells were detected using Western blotting. cell line (A2780) down-regulated sensitive RUNX3 RUNX3 NA validated 1410 MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015 25616665 miRBase MI0003166 miR-520g miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR The expression levels of miRNA were determined by Real-time Quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. In Vivo Xenograft Model was used to test the role of miR-520g . cell line (RKO, HCT116, FET, GEO,HCT116 p53-/-) up-regulated resistant p21 NA NA validated 1411 MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015 25616665 miRBase MI0003166 miR-520g miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR The expression levels of miRNA were determined by Real-time Quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. In Vivo Xenograft Model was used to test the role of miR-520g . cell line (RKO, HCT116, FET, GEO,HCT116 p53-/-) up-regulated resistant p21 NA NA validated 1412 Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget 2015 25638153 miRBase MI0000300 miR-223 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. A wound healing assay was performed to examine the capacity of cell migration. cell line ( AsPC-1, PANC-1,AsPC-1 GR, PANC-1 GR. ) down-regulated sensitive Fbw7 NA NA validated 1413 The expression and functional study of miR-181a in pediatric acute lymphoblastic leukemia Zhonghua Xue Ye Xue Za Zhi 2015 25641148 miRBase MI0000289/MI0000269 miR-181a miRNA DB04690 Camptothecin pediatric acute lymphoblastic leukemia qRT-PCR BM samples were obtained from 18 patients where matched samples at initial diagnosis and first BM relapse or complete remission were available. BM samples and cord blood samples (normal controls) were used to confirm the differential expression of miRNA-181a by quantitative real-time polymerase chain reaction (qRT-PCR). The expressions of miR-181a in both CCRF-CEM and its mutidrug-resistant counterpart CEM-C1 cells were also detected. Then, CCK-8 assay was performed to quantify the effects of miR-181a on CEM-C1 and CCRF-CEM cells growth and viability. cell line (CCRF-CEM,CEM-C1) down-regulated sensitive NA NA NA validated 1414 Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin. Biomed Pharmacother 2015 25661353 miRBase MI0005567 miR-760 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer real-time RT-PCR In order to explore the potential mechanism of miR-760 in human breast cancer, gene microarray was carried out to detect the whole coding gene expression pattern after miR-760 overexpressed . The expression levels of miRNA were determined by Real-time RT-PCR . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. GO function and KEGG enrichment for differentially expressed genes were used to identify the significantly enriched biological terms and pathways. cell line (MCF-7,MCF-7/Adr) up-regulated resistant RHOB,ANGOTL4,ABCA1 RHOB,ANGOTL4,ABCA1 Wnt pathway validated 1415 Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. Oncotarget 2015 25669981 miRBase MI0000060/MI0000061/MI0000062 let-7a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The role of let-7a in metastatic breast cancer cells was detected using quantitative real-time PCR, microarray analysis, western blotting, stable isotope labeling with amino acids in cell culture (SILAC), cell cycle analysis and doxorubicin experiment, etc. cell line (MDA-MB-231,WM239) up-regulated sensitive NA NA NA validated 1416 MicroRNA-10a expression in FAB different subtype of acute myeloid leukemia and its relationship with drug resistance Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015 25687041 miRBase MI0000266 miR-10a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia (except M3) RT-PCR Forty de novo patients with AML, 16 patients with non-malignant hematologic disease and three AML cell lines HL-60, U937 and HL-60/ADR were enrolled in this study, the MiR-10a expression in bone marrow mononuclear cells of above-mentioned patients and 3 AML cell lines was detected by TaqMan RT-PCR. The correlation of miR-10a with clinicopathological factors of AML patients was analyzed. cell line (HL-60,U937, HL-60 /ADR) up-regulated resistant NA NA NA validated 1417 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003649 miR-634 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1418 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000273 miR-183 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1419 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000076 miR-20a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1420 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0008332 miR-1911 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1421 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0001519 miR-20b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1422 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003135 miR-495 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1423 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000482 miR-185 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1424 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000446 miR-127-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1425 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000723 miR-371-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1426 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0002176 miR-485-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1427 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004784 miR-455-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1428 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000780 miR-372 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1429 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004701 miR-338-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1430 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003634 miR-620 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1431 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003619 miR-606 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1432 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000253 miR-148a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1433 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1434 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006313 miR-1226 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1435 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1436 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000808 miR-326 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1437 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003657 miR-642a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1438 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003639 miR-625 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1439 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0001518 miR-18b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1440 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004502 miR-28-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1441 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003654 miR-639 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1442 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0001639 miR-409-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1443 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000788 miR-380 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1444 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0005455 miR-520c-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1445 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005543 miR-708 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1446 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003650 miR-635 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1447 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003188 miR-503 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1448 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000775 miR-367 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1449 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003157/MI0003168 miR-526a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive NA NA NA predicted 1450 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005755 miR-933 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1451 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006649 miR-513c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1452 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005538 miR-892b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1453 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005756 miR-934 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1454 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000454 miR-137 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1455 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000476/MI0000455 miR-138 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1456 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000753 miR-342-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1457 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005716 miR-924 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1458 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000069 miR-15a* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1459 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004555 miR-10a* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1460 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006323/MI0015973 miR-1233 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1461 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006359 miR-1299 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1462 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006401 miR-1265 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1463 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006324 miR-1234 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1464 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0005948 miR-664* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1465 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003584 miR-577 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1466 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0008336 miR-1915* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1467 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000077 miR-21* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1468 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000418 miR-23b* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1469 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0002877 miR-513a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1470 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000082 miR-25* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1471 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004605 miR-129-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1472 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000103/MI0000739 miR-101 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1473 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase NA miR-886-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1474 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005757 miR-935 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1475 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004597 miR-140-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1476 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000291 miR-215 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1477 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000286 miR-210 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1478 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000431 miR-140-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1479 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000287 miR-211 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1480 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0001519 miR-20b* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1481 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000070 miR-17* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1482 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006318 miR-1228* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1483 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003137 miR-193b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1484 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0005577 miR-1226* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1485 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0000075 miR-20a* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1486 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004552 miR-139-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1487 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0007260 miR-1539 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1488 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0007259 miR-1538 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1489 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005534 miR-891b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1490 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000787 miR-379 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1491 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000283 miR-203 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1492 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0006387 miR-1253 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1493 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0008332 miR-1911* miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1494 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003635 miR-621 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1495 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0008336 miR-1915 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1496 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004677 miR-34c-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1497 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0003906 miR-802 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1498 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000100 miR-98 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1499 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005712 miR-920 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1500 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0005714 miR-922 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1501 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004777 miR-513a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1502 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0003887 miR-769-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1503 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MIMAT0004948 miR-885-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1504 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000290 miR-214 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated resistant NA NA NA predicted 1505 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway predicted 1506 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1507 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1508 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00445 (APRD00361) Epirubicin kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1509 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00445 (APRD00361) Epirubicin liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1510 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00773 (APRD00239) Etoposide kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1511 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00773 (APRD00239) Etoposide liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1512 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00317 (APRD00997, DB07998) Gefitinib kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1513 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00317 (APRD00997, DB07998) Gefitinib liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1514 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00398 (APRD01304, DB07438) Sorafenib kidney cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1515 miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015 25698578 miRBase MI0000440 miR-27b miRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer qPCR Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. cell line (HepG2, HeLa, Tong,HEK-293FT,SNU-182, SNU-739, 769-P,786-O) up-regulated sensitive CCNG1 CCNG1 p53 signaling pathway validated 1516 MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun 2015 25712526 miRBase MI0000088 miR-30a miRNA DB00398 (APRD01304, DB07438) Sorafenib renal cell carcinoma RT-PCR The role of miR-30a in renal cell carcinoma cells was detected using MTT assay, real-time PCR, Annexin V assay, western blots and RNA interference, etc. cell line (786-0, A498, SK-RC-44) up-regulated sensitive Beclin-1 Beclin-1 autophagy-dependent pathway validated 1517 Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target 2015 25714665 miRBase MI0000450/MI0000451 miR-133a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time reverse transcription PCR analysis and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( HepG2) up-regulated sensitive ABCC1 ABCC1 NA validated 1518 Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target 2015 25714665 miRBase MI0000808 miR-326 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time reverse transcription PCR analysis and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( HepG2) up-regulated sensitive ABCC1 ABCC1 NA validated 1519 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0006382 miR-1247 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1520 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000471 miR-126 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1521 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0014197 miR-1260b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1522 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0006396 miR-1261 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1523 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0006349 miR-1287 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1524 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003815 miR-1301 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1525 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000457 miR-141 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1526 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003782 miR-1468 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1527 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000477 miR-146a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1528 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000462 miR-152 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1529 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000438 miR-15b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1530 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000269 miR-181a-2 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1531 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000234 miR-192 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1532 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000487 miR-193a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1533 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000286 miR-210 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1534 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003939 miR-2113 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1535 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000301 miR-224 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1536 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0014162 miR-3139 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1537 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003646 miR-33b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1538 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000743 miR-34c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1539 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016001 miR-3611 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1540 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016077 miR-3676 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1541 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000779 miR-371a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1542 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017393 miR-371b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1543 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000780 miR-372 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1544 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000781 miR-373 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1545 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0000786 miR-378a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1546 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0015825 miR-378c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1547 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016964 miR-3960 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1548 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016790 miR-4447 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1549 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016801 miR-4455 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1550 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016844 miR-4483 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1551 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0005531 miR-450b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1552 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016882 miR-4516 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1553 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0001733 miR-452 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1554 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0016887 miR-4521 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1555 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017271 miR-4644 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1556 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017277/MI0017278 miR-4650 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1557 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017377 miR-4739 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1558 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017438 miR-4791 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1559 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0017448 miR-4800 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1560 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0002467 miR-483 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1561 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003686 miR-542 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1562 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003583 miR-576 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1563 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003599 miR-589 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1564 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0020364 miR-6087 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1565 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0021279 miR-6134 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1566 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003658 miR-643 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1567 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0005416 miR-675 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated sensitive NA NA NA predicted 1568 Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol 2015 25722110 miRBase MI0003560 miR-92b miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR By exposing SW1990 pancreatic cancer cells to long-term gemcitabine with increasing concentrations, we established a gemcitabine-resistant cell line (SW1990/GEM) with a high IC50 (the concentration needed for 50 % growth inhibition, 847.23 ). The mRNA and microRNA expression profiles of SW1990 cells and SW1990/GEM cells were determined using RNA-seq analysis. By comparing the results in control SW1990 cells, 507 upregulated genes and 550 downregulated genes in SW1990/GEM cells were identified as differentially expressed genes correlated with gemcitabine sensitivity. Gene ontology (GO) analysis showed that the differentially expressed genes were related to diverse biological processes. The upregulated genes were mainly associated with drug response and apoptosis, and the downregulated genes were correlated with cell cycle progression and RNA splicing. Concurrently, the differentially expressed microRNAs, which are the important player in drug resistance development, were also examined in SW1990/GEM cells, and 56 differential microRNAs were identified. Additionally, the expression profiles of selected genes and microRNAs were confirmed by using Q-PCR assays. Furthermore, combining the differentially expressed microRNAs and mRNAs as well as the predicted targets for these microRNAs, a core microRNA-mRNA regulatory network was constructed cell line ( SW1990,SW1990/GEM) up-regulated resistant NA NA NA predicted 1569 MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun 2015 25727016 miRBase MI0000745 miR-301a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR,Northern blot The expression levels of miRNA were determined by Quantitative RT-PCR and Northern blot . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( U2OS, MG-63) up-regulated resistant AMPKalpha1 AMPKalpha1 NA validated 1570 MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRGamma. Sci Rep 2015 25736597 miRBase MI0000542 miR-320a miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR To investigate the role of miR-320a in the development of resistance to tamoxifen, we established tamoxifen-resistant (TamR) models by continually exposing MCF-7 or T47D breast cancer cells to tamoxifen, and identified microRNA(miRNA)-320a as a down-regulated miRNA in tamoxifen resistant cells. Re-expression of miR-320a was sufficient to sensitize TamR cells to tamoxifen by targeting cAMP-regulated phosphoprotein (ARPP-19) and estrogen-related receptor gamma as well as their downstream effectors, c-Myc and Cyclin D1. Furthermore, progesterone (P4) promoted the expression of miR-320a by repressing c-Myc expression, while estrogen (E2) exerted the opposite effect. tissue down-regulated resistant ARPP-19,ERRGamma ARPP-19 c-Myc and Cyclin D1 pathways validated 1571 MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo. Cancer Biol Ther 2015 25756509 miRBase MI0006337 miR-1204 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharyngeal carcinoma qRT-PCR The role of miR-1204 in nasopharyngeal carcinoma cells was detected using MTT assay, MiRNA microarray analysis, quantitative reverse transcribed PCR (qRT-PCR), colony formation assay and animal treatments, etc. cell line (CNE-1, HNE-2,5-8F) up-regulated sensitive NA NA NA validated 1572 Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep 2015 25759982 miRBase MIMAT0000444 miR-126-5p miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia RT-PCR In the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated. The expression levels of miRNA were determined by Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (KG-1, K562,HK-2) up-regulated resistant Klotho NA AKT pathway validated 1573 MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci 2015 25783790 miRBase MI0000268 miR-34a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell migration and invasion assay. cell line (MCF-7) up-regulated sensitive Notch1 Notch1 Notch1 signaling pathway validated 1574 miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol Rep 2015 25813250 miRBase MI0000457 miR-141 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7, MDA-MB-231) up-regulated resistant EIF4E EIF4E NA validated 1575 Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci U S A 2015 25831546 miRBase MI0000095 miR-93 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Xenograft Tumor Growth was used to test the role of miR-93 . cell line (C13,SKOV3) up-regulated sensitive NA NA NA validated 1576 MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumour Biol 2015 25833695 miRBase MI0000239 miR-197 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line ( A2780,SKOV3, A2780/Tax,IOSE386, IOSE397) up-regulated resistant NLK NLK Wnt pathway validated 1577 miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. Cancer Lett 2015 25843291 miRBase MIMAT0004761 miR-483-5p miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay . A TSCC xenograft mouse model was used to test the role of miR-483-5p . cell line (CAL27, SCC9 ) up-regulated resistant FIS1 FIS1 mitochondrial apoptotic pathway validated 1578 p85alpha is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res 2015 25846727 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR PDAC tumor cells overexpressing p85alpha were generated by viral transduction, and the effect of p85a overexpression on sensitivity to gemcitabine was tested by MTT assay. Primary human PDAC tumors were stained for p85alpha and miR-21 via immunohistochemistry and in situ hybridization, respectively. Additionally, PDAC cells were treated with miR-21 mimic, and changes in p85alpha and phospho-AKT were assessed by Western blot. Finally, a luciferase reporter assay system was used to test direct regulation of p85alpha by miR-21. cell line (TCs, PANC-1, MiaPaCa-2, Hs766T) down-regulated sensitive P85alpha NA PI3K-AKT pathway validated 1579 MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumour Biol 2015 25846738 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The role of miR-9 in primary epithelial ovarian cancer cells was detected using clonal formation assay, drug sensitivity assay, quantitative polymerase chain reaction (qPCR), etc. cell line up-regulated sensitive NA NA NA validated 1580 MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015 25871397 miRBase MI0000283 miR-203 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib glioblastoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The CCK-8 assay was used to monitor the growth of the cells . cell line (U251, U87,U251AR, U87AR) down-regulated resistant SNAI2 SNAI2 NA validated 1581 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0006352 miR-1290 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1582 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0003651 miR-636 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1583 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0009983 miR-1973 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1584 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0016088/MI0031515 miR-3687 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1585 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0016012 miR-3621 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1586 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000617 miR-200c-3p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1587 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000461 miR-195-5p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1588 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000095 miR-96-5p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1589 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000432 miR-141-3p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1590 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0004765 miR-491-3p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1591 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0014156 miR-3135a miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1592 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0004609 miR-149-3p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1593 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0014176 miR-3149 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) up-regulated resistant NA NA NA predicted 1594 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MI0005755 miR-933 miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) down-regulated resistant NA NA NA predicted 1595 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000414 let-7g-5p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) down-regulated resistant NA NA NA predicted 1596 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase MIMAT0000415 let-7i-5p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) down-regulated resistant NA NA NA predicted 1597 MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J Gynaecol Oncol 2015 25872328 miRBase NA miRPlus-G1246-3p miRNA DB12257 Platinum ovarian cancer qRT-PCR The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR). cell line (COC1, COC1/DDP) down-regulated resistant NA NA NA predicted 1598 MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life 2015 25873402 miRBase MI0003134 miR-494 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Bioinformatics method was used to predict potential miR-494 targets. TUNEL staining was used to detect apoptotic cell death. In Vivo Tumor Xenograft Studies was used to test the role of miR-494 . cell line (HCT116, HCT15, HCT8, HT-29, LOVO,SW480, SW620) up-regulated sensitive DPYD DPYD NA validated 1599 miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Mol Cancer 2015 25889892 miRBase MI0001150 miR-196b miRNA DB00773 (APRD00239) Etoposide hepatocellular carcinoma RT-qPCR TaqMan low-density array was used to identify changes in miRNA expression when cells were exposed to etoposide under hypoxia or normoxia. The effects of miR-196b overexpression on apoptosis and cell proliferation were studied in HepG2 cells. miR-196b target mRNAs were identified by proteomic analysis, luciferase activity assay, RT-qPCR and western blot analysis. cell line (HepG2) up-regulated sensitive IGF2BP1 IGF2BP1 c-myc-independent pathway validated 1600 miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat 2015 25900794 miRBase MI0000294/MI0000295 miR-218 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The role of miR-218 in breast cancer cells was detected using MTT assay, drug resistance clonogenic assay, gene expression analysis, western blot, annexin V staining and caspase activity, etc. cell line (MCF-7, Cal51, MCF-7/ADR,CALDOX) up-regulated sensitive survivin NA NA validated 1601 miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat 2015 25900794 miRBase MI0000294/MI0000295 miR-218 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-PCR The role of miR-218 in breast cancer cells was detected using MTT assay, drug resistance clonogenic assay, gene expression analysis, western blot, annexin V staining and caspase activity, etc. cell line (MCF-7, Cal51, MCF-7/ADR,CALDOX) up-regulated sensitive survivin NA NA validated 1602 MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer. APMIS 2015 25908215 miRBase MI0000294/MI0000295 miR-218 miRNA DB00877 (APRD00178, DB02439) Rapamycin cervical cancer RT-PCR The role of miR-218 in cervical cancer cells was detected using Taqman PCR, western blot,MTT assay, Apoptosis analysis, cell cycle analysis, mice model and immunohistochemical staining,etc. cell line (HeLa, SiHa, Caski,and C33A) up-regulated sensitive Rictor Rictor mTOR signaling pathway validated 1603 Phospho-DeltaNp63alpha-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure. FEBS Lett 2015 25910754 miRBase MIMAT0000099 miR-101-3p miRNA DB00515 (APRD00359) Cisplatin squamous cell carcinoma NA The role of miR-miR-101 in squamous cell carcinoma cells was detected using MTT assay, Immunoblotting, immunoprecipitation and luciferase reporter assays,etc. cell line (SCC-11,SCC-25 ) up-regulated resistant NA NA NA validated 1604 Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumour Biol 2015 25913620 miRBase MI0000461 miR-145 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR Here, we show that RAD18 is highly expressed in human 5-fluorouracil (5-FU)-resistant cancer cells after 5-FU treatment. In addition, RAD18 increases in CRC cells could induce DNA damage repair, suggesting that RAD18 might be a possible target for overcoming drug resistance. Moreover, the expression of tumor suppressor microRNA-145 (miR-145) was negatively correlated with RAD18 expression in CRC tissues of 140 patients. Using luciferase reporters carrying the 3-untranslated region of RAD18 combined with Western blotting, we identified RAD18 as a direct target of miR-145. Also of interest, suppression of RAD18 by miR-145 enhanced DNA damage in CRC cells after 5-FU treatment. Finally, the 5-FU-resistant cancer cells could be selectively ablated by treatment with miR-145. Taken together, these results suggest that miR-145 can act as an RAD18 inhibitor and contribute as an important factor in reversing drug resistance after chemotherapy. cell line (SW620, 5-FuR SW620 ) down-regulated resistant RAD18 RAD18 NA validated 1605 Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumour Biol 2015 25913620 miRBase MI0000461 miR-145 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis was measured using the Apoptosis Detection Kit I . Animal models was used to test the role of miR-145 . cell line (SW620, 5-FuR SW620 ) up-regulated sensitive RAD18 RAD18 NA validated 1606 The establishment of Raji drug-resistant cell line and analyses of prohibitin and miR-27a expression Zhonghua Xue Ye Xue Za Zhi 2015 25916297 miRBase MI0000085 miR-27a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin cancer RT-PCR Built ADR-resistant Raji cells, detected their resistant index and drug-resistant spectrum and stability, observed their morphology and growth characteristics in general; evaluated the expression of phb mRNA and miR-27a in ADR-resistant cells (Raji/A) and sensitive cells (Raji/S) via real-time quantitative polymerase chain reaction (RT-PCR). cell line (Raji/A) up-regulated resistant NA NA NA validated 1607 MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer 2015 25919696 miRBase MI0000301 miR-224 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR We used TaqMan low-density array (TLDA) qRT-PCR analysis to identify miRNAs differentially expressed in normal colorectal mucosa, adenomas and cancers and in isogeneic KRAS WT and mutant HCT116 cells, and used a variety of phenotypic assays to assess the influence of miRNA expression on KRAS activity, chemosensitivity, proliferation and invasion. cell line (HCT116) down-regulated sensitive NA NA NA validated 1608 miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1. Jpn J Clin Oncol 2015 25921099 miRBase MI0000447/MI0000727 miR-128 miRNA DB00515 (APRD00359) Cisplatin prostate cancer real-time RT-PCR The miR-128 expression pattern of prostate cancer cell lines and tissues was detected by real-time reverse transcriptase-polymerase chain reaction, while the mRNA and protein expression levels of zinc-finger E-box-binding homeobox 1 were measured by real-time reverse transcriptase-polymerase chain reaction and western blot assay, respectively. Dual-luciferase reporter gene assay was used to find the direct target of miR-128. Furthermore, prostate cancer cells were treated with miR-128 mimic or zinc-finger E-box-binding homeobox 1-siRNA, and then the cells chemosensitivity and invasion were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and transwell assay, respectively. cell line (DU-145, LNCaP, HEK-293T) up-regulated sensitive ZEB1 ZEB1 NA validated 1609 miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med 2015 25927928 miRBase MI0000811 miR-148b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR This study was performed in two lung cancer cell lines (A549 and SPC-A1). The levels of miR-148b and DNMT1 mRNA expression were determined by using Quantitative Real-Time PCR. Proteins of DNMTs are represented by western blot assay. Cell viability was assessed by MTT assay. Cell apoptosis was evaluated using flow cytometry. cell line (A549, SPC-A1, A549/DDP, SPC-A1/DDP) up-regulated sensitive DNMT1 DNMT1 NA validated 1610 miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug. Curr Protein Pept Sci 2015 25929865 miRBase MI0003138 miR-497 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells cell line (LoVo, HCT116,SW480 ) up-regulated sensitive Smurf1 Smurf1 NA validated 1611 Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. Drug Metab Dispos 2015 25934574 miRBase MI0006353 miR-1291 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin pancreatic carcinoma RT-PCR The role of miR-1291 in Human Carcinoma cells was detected using Reverse-Transcription Quantitative Real-Time PCR, immunoblot Analysis and cytotoxicity assays, etc. cell line (MCF-7,PANC-1) up-regulated sensitive NA ABCC1, FOXA2, and MeCP2 NA predicted 1612 Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. Drug Metab Dispos 2015 25934574 miRBase MI0006353 miR-1291 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The role of miR-1291 in Human Carcinoma cells was detected using Reverse-Transcription Quantitative Real-Time PCR, immunoblot Analysis and cytotoxicity assays, etc. cell line (MCF-7,PANC-1) up-regulated sensitive NA ABCC1, FOXA2, and MeCP2 NA predicted 1613 Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One 2015 25946136 miRBase MI0000063 let-7b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel KRAS mutant tumor qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Apoptosis was assessed by detecting the externalization of phosphatidyl serine using Annexin V . A wound healing assay was performed to examine the capacity of cell migration. Cell invasion was evaluated using a Boyden chamber system with a polycarbonate membrane . cell line (A549, NIH-H1975,Panc-1, BxPC-3,MDA-MB-231, MCF-7,MRC-5,MCF-10A ) up-regulated sensitive TUBB3 and RRM2 TUBB3 and RRM2 NA validated 1614 Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS One 2015 25946136 miRBase MI0000063 let-7b miRNA DB00441 (APRD00201) Gemcitabine KRAS mutant tumor qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Apoptosis was assessed by detecting the externalization of phosphatidyl serine using Annexin V . A wound healing assay was performed to examine the capacity of cell migration. Cell invasion was evaluated using a Boyden chamber system with a polycarbonate membrane . cell line (A549, NIH-H1975,Panc-1, BxPC-3,MDA-MB-231, MCF-7,MRC-5,MCF-10A ) up-regulated sensitive TUBB3 and RRM2 TUBB3 and RRM2 NA validated 1615 Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumour Biol 2015 25953263 miRBase MI0011285 miR-2278 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of miR-2278 in leukemic cells was detected using qRT-PCR, western blot assay, apoptosis assays, Genome-wide microRNA array analysis, Genome-wide mRNA array analysis, miRNA validation and mRNA validation, etc. cell line ( K562) up-regulated sensitive AKT2, STAM2, STAT5A AKT2, STAM2, STAT5A JAK/STAT signaling pathway validated 1616 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000446 miR-125b-1 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1617 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000479 miR-150 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1618 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0000457 miR-188-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1619 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000284 miR-204 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1620 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0002872 miR-501-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1621 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0002869 miR-519a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1622 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0003887 miR-769-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1623 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000446 miR-125b-1 miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1624 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000479 miR-150 miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1625 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0000457 miR-188-5p miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1626 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MI0000284 miR-204 miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1627 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0002872 miR-501-5p miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1628 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0002869 miR-519a-3p miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) up-regulated resistant NA NA NA predicted 1629 Identification of miRNAs contributing to neuroblastoma chemoresistance. Comput Struct Biotechnol J 2015 25973145 miRBase MIMAT0003887 miR-769-3p miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-qPCR ndividual subcultures of chemosensitive SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant to doxorubicin (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput quantitative polymerase chain reaction (RT-qPCR) miRNA profiling platform for a total of 668 miRNAs. cell line (SH-SY5Y, UKF-NB-3) down-regulated resistant NA NA NA predicted 1630 Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res 2015 25975752 miRBase MI0003646 miR-33b miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma qRT-PCR In the present study, we investigated the expression pattern of miR-33b in 58 newly diagnosed, 11 relapsed, 12 remission MM patients and 18 health donors by quantitative real-time PCR. tissue down-regulated resistant NA NA NA validated 1631 miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Arch Gynecol Obstet 2015 25986891 miRBase MI0000479 miR-150 miRNA DB06366 Pertuzumab ovarian cancer qRT-PCR We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not. miR-150 knockdown impacts on pertuzumab treatment were analyzed by cell proliferation assay, apoptosis analysis and cell cycle analysis. Cell signal pathway was examined by western blot assay. cell line ( SKOV3, SNU119) down-regulated resistant NA NA PI3K-Akt pathway validated 1632 Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 2015 25995442 miRBase MI0003193 miR-506 miRNA DB00515 (APRD00359) Cisplatin ovarian serous carcinoma RT-PCR The expression levels of miRNA were determined by Real-time Polymerase Chain Reaction Analysis and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Animal orthotopic in vivo model was used to test the role of miR-506 . cell line (HeyA8, OVCA433, SKOV3) up-regulated sensitive RAD51 RAD51 NA validated 1633 Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 2015 25995442 miRBase MI0003193 miR-506 miRNA DB09074 (DB05940) Olaparib ovarian serous carcinoma RT-PCR The expression levels of miRNA were determined by Real-time Polymerase Chain Reaction Analysis and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Animal orthotopic in vivo model was used to test the role of miR-506 . cell line (HeyA8, OVCA433, SKOV3) up-regulated sensitive RAD51 RAD51 NA validated 1634 miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis 2015 25996293 miRBase MIMAT0000418 miR-23b-3p miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive ATG12 and HMGB2 ATG12 and HMGB2 NA validated 1635 miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis 2015 25996293 miRBase MIMAT0000418 miR-23b-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive ATG12 and HMGB2 ATG12 and HMGB2 NA validated 1636 miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis 2015 25996293 miRBase MIMAT0000418 miR-23b-3p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (SGC7901,SGC7901/VCR) up-regulated sensitive ATG12 and HMGB2 ATG12 and HMGB2 NA validated 1637 miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3. Mol Cells 2015 25997740 miRBase MI0000816 miR-335 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. A wound healing assay was performed to examine the capacity of cell migration. Viable cell number counting was carried out by trypan blue exclusion assays. Apoptosis determination was carried out by using annexin V-FITC. cell line (SNU387R, Malme3MR, SNU387R-taxol, Malme3MR-Taxol, SNU387R-Vinblastine) up-regulated sensitive SIAH2 SIAH2 NA validated 1638 Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer. Neoplasma 2015 25997962 miRBase MI0000737 miR-200a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . In vivo xenograft experiments was used to test the tole of miR-200a . cell line (OVCAR-3) up-regulated sensitive NA NA NA validated 1639 Has-miR-125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent manner by targeting p53 mRNA. Mol Med Rep 2015 26017674 miRBase MI0000469 miR-125a miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. The CCK-8 assay was used to monitor the growth of the cells . cell line (TW03, CNE-1, CNE-2 NPC,NP69) up-regulated sensitive p53 p53 p53 signaling pathway validated 1640 Has-miR-125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent manner by targeting p53 mRNA. Mol Med Rep 2015 26017674 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. The CCK-8 assay was used to monitor the growth of the cells . cell line (TW03, CNE-1, CNE-2 NPC,NP69) up-regulated sensitive p53 p53 p53 signaling pathway validated 1641 The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol 2015 26025631 miRBase MI0000650 miR-200c miRNA DB00958 (APRD00466) Carboplatin ovarian carcinoma qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (qPCR) and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (OVCAR-3,MES-OV,OVCAR-3/TP, MES-OV/TP) up-regulated resistant NA NA NA validated 1642 The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol 2015 26025631 miRBase MI0000650 miR-200c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian carcinoma qPCR The expression levels of miRNA were determined by Real-time quantitative PCR (qPCR) and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (OVCAR-3,MES-OV,OVCAR-3/TP, MES-OV/TP) up-regulated resistant NA NA NA validated 1643 miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015 26026166 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin esophageal cancer qRT-PCR The aim of this study was to examine the role of extracellular miRNA in the response to chemotherapy in esophageal cancer. First, serum expression of miRNAs selected by miRNA array was measured by quantitative reverse transcription-polymerase chain reaction in 68 patients with esophageal cancer who received cisplatin-based chemotherapy to examine the relationship between miRNA expression and response to chemotherapy. The serum expression levels of 18 miRNAs were different between responders and non-responders by miRNA array. Of these, high expression levels of miR-27a/b correlated with poor response to chemotherapy in patients with esophageal cancer. Next, in vitro assays were conducted to investigate the mechanism of miRNA-induced chemoresistance. cell line (TE10) up-regulated sensitive NA NA NA validated 1644 miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015 26026166 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin esophageal cancer qRT-PCR The aim of this study was to examine the role of extracellular miRNA in the response to chemotherapy in esophageal cancer. First, serum expression of miRNAs selected by miRNA array was measured by quantitative reverse transcription-polymerase chain reaction in 68 patients with esophageal cancer who received cisplatin-based chemotherapy to examine the relationship between miRNA expression and response to chemotherapy. The serum expression levels of 18 miRNAs were different between responders and non-responders by miRNA array. Of these, high expression levels of miR-27a/b correlated with poor response to chemotherapy in patients with esophageal cancer. Next, in vitro assays were conducted to investigate the mechanism of miRNA-induced chemoresistance. cell line (TE10) up-regulated sensitive NA NA NA validated 1645 MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One 2015 26043084 miRBase MI0000448 miR-130a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer Real-time qRT-PCR We profiled miRNAs differentially expressed in cisplatin-resistant human ovarian cancer cell line A2780/DDP compared with parental A2780 cells using microarray. The expression levels of miRNA were determined by Real-time qRT-PCR and those of protein were by Western blot analysis. Potential targets of differentially expressed miRNAs were predicted with the help of PicTar or TargetScan . cell line (A2780, A2780/DDP) up-regulated resistant NA NA NA validated 1646 MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One 2015 26043084 miRBase MI0000782 miR-374a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer Real-time qRT-PCR We profiled miRNAs differentially expressed in cisplatin-resistant human ovarian cancer cell line A2780/DDP compared with parental A2780 cells using microarray. The expression levels of miRNA were determined by Real-time qRT-PCR and those of protein were by Western blot analysis. Potential targets of differentially expressed miRNAs were predicted with the help of PicTar or TargetScan . cell line (A2780, A2780/DDP) up-regulated resistant NA NA NA validated 1647 MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. Mol Med Rep 2015 26043974 miRBase MI0003177 miR-522 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colon cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Fluorescent reporter assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HT29) up-regulated sensitive ABCB5 ABCB5 NA validated 1648 miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Prostate 2015 26074357 miRBase MI0000448 miR-130a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer qRT-PCR In order to identify miRNAs related to taxane-resistance, miRNA profiling was performed using prostate cancer PC-3 cells and paclitaxel-resistant PC-3 cell lines established from PC-3 cells. Microarray analysis of mRNA expression was also conducted to search for potential target genes of miRNA. Luciferase reporter assay was performed to examine miRNA binding to the 3-UTR of target genes. The effects of ectopic expression of miRNA on cell growth, tubulin polymerization, drug sensitivity, and apoptotic signaling pathway were investigated in a paclitaxel-resistant PC-3 cell line. cell line (PC-3) down-regulated resistant SLAIN1 SLAIN1 NA validated 1649 CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep 2015 26079799 miRBase MIMAT0000232 miR-199a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma NA The role of miR-199a-3p inosteosarcoma cells was detected using MTT assay, western blot,and Immunohistochemistry, etc. cell line (HOB-c,U-2OS) up-regulated sensitive CD44 CD44 NA validated 1650 A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A 2015 26080425 miRBase MI0000102 miR-100 miRNA NA TRAIL therapy lung cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by qRT-PCR and Northern blot . Those of protein were by Western blot analysis. Soft Agar Colony Formation Assay were performed to determine the in vitro tumorigenicity of the cells. Animal studies were used to test the role of microrna. cell line (H460S/R, H292S/R, HEK293, Calu-1,A549) up-regulated resistant NA NA NA predicted 1651 A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A 2015 26080425 miRBase MI0000077 miR-21 miRNA NA TRAIL therapy lung cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by qRT-PCR and Northern blot . Those of protein were by Western blot analysis. Soft Agar Colony Formation Assay were performed to determine the in vitro tumorigenicity of the cells. Animal studies were used to test the role of microrna. cell line (H460S/R, H292S/R, HEK293, Calu-1,A549) up-regulated resistant NA NA NA predicted 1652 A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A 2015 26080425 miRBase MI0000736/MI0000254 miR-30c miRNA NA TRAIL therapy lung cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by qRT-PCR and Northern blot . Those of protein were by Western blot analysis. Soft Agar Colony Formation Assay were performed to determine the in vitro tumorigenicity of the cells. Animal studies were used to test the role of microrna. cell line (H460S/R, H292S/R, HEK293, Calu-1,A549) up-regulated resistant NA NA NA predicted 1653 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000231 miR-199a-5p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant HLPP1 HLPP1 AKT pathway validated 1654 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000783 miR-375 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant HLPP1 HLPP1 AKT pathway validated 1655 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000283 miR-203 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1656 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000444 miR-126* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1657 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000231 miR-199a-5 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1658 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0004679 miR-296-3p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1659 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000754 miR-337-3p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1660 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0004563 miR-199b-3p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1661 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0001729 miR-451 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1662 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000764 miR-339-5p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1663 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000298 miR-221 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1664 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000735 miR-29c miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1665 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000462 miR-152 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1666 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000440 miR-27b miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1667 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000443 miR-125a-5p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1668 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000272 miR-182 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1669 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase NA miR-219-2-3p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1670 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000065 let-7d* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1671 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000067 let-7f-1* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1672 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000074/MI0000075 miR-19b miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1673 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0000070 miR-17* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1674 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000746 miR-99b* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1675 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0003655 miR-640 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1676 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MIMAT0002891 miR-18a* miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1677 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000083/MI0000750 miR-26a miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1678 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase NA miR-768-5p miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1679 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0000077 miR-21 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1680 MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015 26107137 miRBase MI0005202 miR-801 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer qRT-PCR We investigated the miRNA expression profile of GEO human colon carcinoma cells, sensitive to the EGFR inhibitor Cetuximab (CTX) and their CTX-resistant counterpart (GEO CR) by using a miRNA chip. cell line up-regulated resistant NA NA NA predicted 1681 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB04690 Camptothecin breast cancer real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1682 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1683 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00773 (APRD00239) Etoposide breast cancer real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1684 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA NA IR breast cancer real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1685 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB04690 Camptothecin osteosarcoma real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1686 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1687 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00773 (APRD00239) Etoposide osteosarcoma real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1688 The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity. PLoS One 2015 26115122 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA NA IR osteosarcoma real-time RT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Potential direct miR-124 targets were predicted using the PicTar, TargetScan 5.1 and miRanda . The alkaline comet assay used a CometAssay kit . cell line (MDA-MB-231, HCC1937, T-47D, ZR-75-1,MDA-MB-453, MCF-7, Hs 578T,MDA-MB-361) up-regulated sensitive ATMIN and PARP1 ATMIN and PARP1 NA validated 1689 Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Gene 2015 26143754 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qPCR The expression levels of miRNA were determined by Quantitative PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2,HepG2-R) down-regulated resistant Mcl-1 Mcl-1 miR-363/Mcl-1 pathway validated 1690 MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Mol Cell 2015 26145175 miRBase MI0000103/MI0000739 miR-101 miRNA DB00188 (APRD00828, DB07475) Bortezomib cancer qRT-PCR The role of miR-101 in tumor cancer cells was detected using qRT-PCR, microarray analysis and animal studies, etc. cell line (U2OS, HeLa, HepG2, HCT116) up-regulated sensitive POMP POMP NA validated 1691 MicroRNA-197 reverses the drug resistance of fluorouracil-induced SGC7901 cells by targeting mitogen-activated protein kinase 1. Mol Med Rep 2015 26151540 miRBase MI0000239 miR-197 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC-7901,SGC7901/5-FU) down-regulated resistant MAPK1 MAPK1 MAPK signaling pathway validated 1692 PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/Beta-catenin signaling pathway. In Vitro Cell Dev Biol Anim 2015 26170223 miRBase MI0000446/MI0000470 miR-125b miRNA DB00853 (APRD00557) Temozolomide glioblastoma real-time quantification RT-PCR The expression levels of miRNA were determined by real-time quantification RT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line down-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 1693 MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. Cytogenet Genome Res 2015 26184032 miRBase MI0000737 miR-200a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A wound healing assay and cell Invasion assay were performed to examine the capacity of cell migration. cell line ( MRC-5, CCD-19Lu,H3255, H1975,HCC827) up-regulated sensitive EGFR and c-Met EGFR NA validated 1694 Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer 2015 26206152 miRBase MI0000267 miR-10b miRNA DB00675 (APRD00123) Tamoxifen breast cancer Real-time RT-PCR To dileneate a role of miR-10b in tamoxifen-resistance, we over-expressed miR-10b in MCF-7 cells and down-regulated its levels in MCF7TR cells. The mechanistic role of HDAC4 in miR-10b-mediated tamoxifen resistance was studied using HDAC4 cDNA and HDAC4-specific siRNA in appropriate models. cell line (MCF-7,T47D) up-regulated resistant HDAC4 HDAC4 NA validated 1695 Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer. PLoS One 2015 26218285 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00445 (APRD00361) epirubicin breast cancer qRT-PCR The expression levels of miRNA were determined by real-time quantitative reverse transcription PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SKBR3,SK-3rd) down-regulated resistant NA NA NA validated 1696 p53-p66(shc)/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicol Lett 2015 26222667 miRBase MI0000077 miR-21 miRNA DB12480 (DB05910) Betulinic acid hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Chromatin Immunoprecipitations (CHIP) was conducted by a Thermo Scientific Pierce Agarose ChIP Kit . TUNEL staining was used to detect apoptotic cell death. Animal treatment was used to test the role of miR-21 . tissue and cell line (SMMC-7721, Huh-7, HepG2) down-regulated resistant NA NA p53-p66shc/miR-21-Sod2 signaling validated 1697 MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res 2015 26223974 miRBase MI0000478 miR-149 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR This study investigated the relationship between miRNA-149 expression and the sensitivity of ovarian cancer A2780 cells to paclitaxel treatment. To achieve the down-regulation of miRNA-149 gene expression in A2780 cell line, the cells were infected with lentivirus carrying inhibitor of miRNA-149. Western blot and qRT-PCR were used to detect relevant protein levels and the expressions of mRNAs of interest. Cell proliferation was measured by CCK-8 assay. Flow cytometry was used to measure cell cycle and apoptosis. Transwell migration assay was used to observe the change of migration of transfected cells. cell line (A2780) down-regulated resistant MyD88 MyD88 TLR/MyD88 signaling pathway validated 1698 miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncol Rep 2015 26238082 miRBase NA miR-219-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR Potential interaction between Sall4 and miR-219-5p is predicted by TargetScan. CCK-8 test was used for evaluation of cell proliferation and cell survival rates. Western blot analysis and real-time PCR were applied for detection of target molecules. Luciferase assay was a direct confirmation of mutual interaction. Wound healing assay and transwell assay were conducted for cell migration and invasion tests. Flow cytometry was used for cell apoptosis analysis. Tissue specimens and cell lines were explored for miR-219-5p inhibition on colon cancer proliferation, migration, invasion, apoptosis and drug resistance by targeting Sall4. tissue and cell line (HT-29, Caco-2, DLD-1, SW480, SW620 ) up-regulated sensitive Sall4 Sall4 NA validated 1699 miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncol Rep 2015 26238082 miRBase NA miR-219-5p miRNA DB00526 (APRD00186) Oxaliplatin colon cancer qRT-PCR Potential interaction between Sall4 and miR-219-5p is predicted by TargetScan. CCK-8 test was used for evaluation of cell proliferation and cell survival rates. Western blot analysis and real-time PCR were applied for detection of target molecules. Luciferase assay was a direct confirmation of mutual interaction. Wound healing assay and transwell assay were conducted for cell migration and invasion tests. Flow cytometry was used for cell apoptosis analysis. Tissue specimens and cell lines were explored for miR-219-5p inhibition on colon cancer proliferation, migration, invasion, apoptosis and drug resistance by targeting Sall4. tissue and cell line (HT-29, Caco-2, DLD-1, SW480, SW620 ) up-regulated sensitive Sall4 Sall4 NA validated 1700 MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large. Mol Med Rep 2015 26239225 miRBase MI0000450/MI0000451 miR-133a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2) up-regulated sensitive Bcl-xL Bcl-xL NA validated 1701 MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large. Mol Med Rep 2015 26239225 miRBase MI0000808 miR-326 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2) up-regulated sensitive Bcl-xL Bcl-xL NA validated 1702 MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large. Mol Med Rep 2015 26239225 miRBase MI0000450/MI0000451 miR-133a miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2) up-regulated sensitive Bcl-xL Bcl-xL NA validated 1703 MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large. Mol Med Rep 2015 26239225 miRBase MI0000808 miR-326 miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2) up-regulated sensitive Bcl-xL Bcl-xL NA validated 1704 MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis 2015 26247730 miRBase MI0003595 miR-587 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR,RT-qPCR The expression levels of miRNA were determined by RT-PCR and real-time Q-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (RKO, HCT116, FET and GEO) down-regulated sensitive PPP2R1B PPP2R1B miR-587/PPP2R1B/pAKT/XIAP signaling validated 1705 MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Dis 2015 26247730 miRBase MI0003595 miR-587 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR, qRT-PCR The expression levels of miRNA were determined by RT-PCR and real-time Q-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (RKO, HCT116, FET, GEO) down-regulated sensitive PPP2R1B PPP2R1B miR-587/PPP2R1B/pAKT/XIAP signaling validated 1706 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0000242/MI0000281 miR-199a miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1707 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0000242/MI0000281 miR-199a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1708 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0000242/MI0000281 miR-199a miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1709 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0003138 miR-497 miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1710 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0003138 miR-497 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1711 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. Int J Mol Sci 2015 26251897 miRBase MI0003138 miR-497 miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma RT-PCR The role ofmiR-199a and miR-497 in Diffuse Large B-Cell Lymphoma was detected using Real-Time PCR, cell Viability and apoptosis assay, etc. cell line (SUDHL-4, RI-1, U2932, Karpas) up-regulated sensitive NA NA NA validated 1712 Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells. Int J Clin Exp Pathol 2015 26261488 miRBase MI0000472 miR-127 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin glioma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (U251,U87-MG,U251/Adr, U87-MG/Adr) down-regulated sensitive NA NA AKT pathway validated 1713 MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol 2015 26261515 miRBase MI0000294/MI0000295 miR-218 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/ADM, SGC7901/L-OHP) up-regulated sensitive SMO SMO Hedgehog pathway validated 1714 MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol 2015 26261515 miRBase MI0000294/MI0000295 miR-218 miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/ADM, SGC7901/L-OHP) up-regulated sensitive SMO SMO Hedgehog pathway validated 1715 MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol 2015 26261515 miRBase MI0000294/MI0000295 miR-218 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/ADM, SGC7901/L-OHP) up-regulated sensitive SMO SMO Hedgehog pathway validated 1716 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) up-regulated resistant NA C1orf21, DACT1, DCLK1, EPHA3, IL20RB, FOXP2, PI15 Ascorbate and aldarate metabolism predicted 1717 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MIMAT0000231 miR-199a-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, DCLK1, EPHA7, IL20RB, MAB21L1, PI15 NA predicted 1718 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, DCLK1, IL20RB PI3K-Akt Signaling pathway predicted 1719 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MIMAT0004563 miR-199b-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, DCLK1, IL20RB Ubiquitin mediated proteolysis predicted 1720 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0000816 miR-335 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, CCR5, TPM1 Long-term potentiation predicted 1721 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0000291 miR-215 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, CD55, CNN1, GSG1 TSLP ErbB signaling pathway predicted 1722 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, DCLK1 Regulation of actin cytoskeleton predicted 1723 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0001518 miR-18b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA EPHA7, PI15 Gap junction predicted 1724 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 2015 26261572 miRBase MI0003660 miR-645 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The drug resistant-related microRNA microarray dataset GS54665 and mRNA dataset GSE33482, GSE28646, and GSE15372 were downloaded from the Gene Expression Omnibus database. Dysregulated microRNAs/genes were screened with GEO2R and were further identified in SKOV3 (SKOV3/DDP) and A2780 (A2780/DDP) cells by real-time quantitative PCR (qRT-PCR), and then their associations with drug resistance was analyzed by comprehensive bioinformatic analyses. Biological process annotation and pathway enrichment analysis of the 9 microRNAs and 38 genes identified several drug resistant-related signaling pathways, and the microRNA-mRNA interaction revealed the existence of a targeted regulatory relationship between the 9 microRNAs and most of the 38 genes. cell line ( SKOV3, A2780,A2780/DDP ) down-regulated resistant NA C1orf21, FILIP1 Calcium signaling pathway,MAPK signaling pathway predicted 1725 Bone Marrow MicroRNA-335 Level Predicts the Chemotherapy Response and Prognosis of Adult Acute Myeloid Leukemia. Medicine (Baltimore) 2015 26287405 miRBase MI0000816 miR-335 miRNA DB00987 (APRD00499) Cytarabine acute myeloid leukemia Real-Time Quantitative RT-PCR A total of 204 adult AML patients were collected. The miR-335 levels in serum and bone marrow samples from these patients were determined. All patients received Ara-C-based standard induction chemotherapy regimens. The treatment response to Ara-C-based chemotherapy was evaluated. All patients were followed for prognostic analyses. tissue up-regulated resistant NA NA NA validated 1726 MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochem Biophys Res Commun 2015 26299922 miRBase MIMAT0000250 miR-139-5p miRNA DB01248 (APRD00932) Docetaxel breast cancer Real-time quantitative PCR MiR-139-5p expression in MCF-7, MCF-7/Doc cells and in selected breast cancer tissue samples was confirmed by real-time PCR; cell viability was analyzed by Cell Counting Kit-8 assay; apoptosis and cell cycle were analyzed by flow cytometry; control of metastasis and invasion of breast cancer cells was measured by transwell assay; expression of Notch1 was measured by western blot; a luciferase reporter vector was constructed to identify the miR-139-5p target gene. cell line (MCF-7,MCF-7/Doc) down-regulated sensitive Notch1 Notch1 Notch signaling pathway validated 1727 MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett 2015 26318721 miRBase MI0000474 miR-134 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive ABCC1 ABCC1 NA validated 1728 MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol 2015 26323558 miRBase MI0005564 miR-873 miRNA DB00515 (APRD00359) Cisplatin glioma qPCR The expression levels of miRNA were determined by qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by migration and invasion assay. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay . cell line (U87, U251,U87/DDP,U251/DDP) up-regulated sensitive Bcl-2 Bcl-2 NA validated 1729 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000758 miR-135b-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1730 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000646 miR-155-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1731 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000256 miR-181a-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant PTEN PTEN PI3 kinase/Akt pathway validated 1732 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000688 miR-301a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1733 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000073 miR-19a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1734 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000266 miR-205-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1735 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000258 miR-181c-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1736 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000257 miR-181b-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1737 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000418 miR-23b-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1738 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000095 miR-96-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) up-regulated resistant NA NA NA predicted 1739 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000414 let-7g-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1740 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase NA miR-128-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1741 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000440 miR-191-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1742 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000617 miR-200c-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1743 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase MIMAT0000081 miR-25-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1744 MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015 26323677 miRBase NA miR-128-5p miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The metastatic properties of the cells were assessed using wound-healing assays, migration assays, invasion assays, morphological examination, and western blot analysis/RT-PCR of genes associated with the epithelial-mesenchymal transition (EMT). To identify novel regulators of EMT in A549 cells, differentially expressed miRNAs in drug-resistant cells were identified by microarray analysis. The role of miR-181a was established by transfection with specific mimic and inhibitor followed by functional assays. Luciferase assays were performed to assess the ability of miR-181a to target the PTEN promoter, and regulation of PTEN expression by miR-181a was assessed by western blot analysis and RT-PCR. cell line (A549, A549/PTX, A549/DDP) down-regulated resistant NA NA NA predicted 1745 Up-regulation of miR-125b reverses epithelial-mesenchymal transition in paclitaxel-resistant lung cancer cells. Biol Chem 2015 26351908 miRBase MI0000446/MI0000470 miR-125b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer Real-time RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. Cell migration was detected by transwell invasion assay. Tumor xenograft model was used to test the role of miR-125b . cell line (A549, H460 ) up-regulated sensitive Sema4C Sema4C NA validated 1746 Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel. Eur J Gynaecol Oncol 2015 26390698 miRBase MI0000301 miR-224 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer RT-PCR The expression of miR-224 pre- and post-paclitaxel treatment was determined by using stem-loop real-time reverse transcription polymerase chain reaction (RT-PCR). The authors exogenously upregulated miR-224 expression in SiHa cells using miRIDIAN miR-224 mimic transfection and observed its impact on paclitaxel sensitivity using Cytotoxicity assays. cell line (SiHa) up-regulated sensitive NA NA NA validated 1747 MicroRNA-133b targets glutathione S-transferase Pi expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther 2015 26396496 miRBase MI0000822 miR-133b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR We examined the levels of miR-133b expression in ovarian carcinoma tissues and the human ovarian carcinoma cell lines (A2780, A2780/DDP and A2780/Taxol, respectively). We determined the cell viability of these cell lines treated with cisplatin or paclitaxel in the presence or absence of miR-133b or anti-miR-133b transfection using the MTT assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the mRNA and protein expression levels of two drug-resistance-related genes: glutathione S-transferase (GST)-Pi and multidrug resistance protein 1 (MDR1). The dual-luciferase reporter assay was used to detect the promoter activity of GST-Pi in the presence and absence of miR-133b. cell line (A2780, A2780/DDP, A2780/Taxol) up-regulated sensitive GST-Pi GST-Pi NA validated 1748 MicroRNA-133b targets glutathione S-transferase Pi expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther 2015 26396496 miRBase MI0000822 miR-133b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR We examined the levels of miR-133b expression in ovarian carcinoma tissues and the human ovarian carcinoma cell lines (A2780, A2780/DDP and A2780/Taxol, respectively). We determined the cell viability of these cell lines treated with cisplatin or paclitaxel in the presence or absence of miR-133b or anti-miR-133b transfection using the MTT assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the mRNA and protein expression levels of two drug-resistance-related genes: glutathione S-transferase (GST)-Pi and multidrug resistance protein 1 (MDR1). The dual-luciferase reporter assay was used to detect the promoter activity of GST-Pi in the presence and absence of miR-133b. cell line (A2780, A2780/DDP, A2780/Taxol) up-regulated sensitive GST-Pi GST-Pi NA validated 1749 miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015 26416415 miRBase MI0000474 miR-134 miRNA DB00515 (APRD00359) Cisplatin breast cancer qPCR The role of miR-134 in triple-negative breast cancer cells was detected using immunoblotting, qPCR, Migration and invasion analysis, bioinformatics analysis, etc. cell line (Hs578T,Hs578Ts(i)8) up-regulated sensitive NA NA NA validated 1750 Drug resistance of colon cancer cells to 5-fluorouracil mediated by microRNA-21 Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2015 26418978 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the effect of 5-FU on the viability of RKO cells with knockout of miR-21 or high expression of PDCD4. Real-time was used to determine the expression of PDCD4, ABCC5 and CD44 in RKO cell after knockout of miR-21. cell line (RKO,RKO-WT) up-regulated resistant PDCD4 PDCD4 P13K/AKT pathway validated 1751 MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015 26452030 miRBase MI0000077 miR-21 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SKBR3) up-regulated resistant PTEN and PDCD4 PTEN and PDCD4 PI3K pathway validated 1752 MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol 2015 26458859 miRBase MI0000083/MI0000750 miR-26a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression level of miRNA-26a in cisplatin-resistant SGC-7901/DDP cells and parent SGC-7901 cells was evaluated by qRT-PCR. The effect of miR-26a on sensitivity of GC cells to cisplatin was assayed using MTS method. The effect of miR-26a on cisplatin-induced apoptosis were determined by Annexin V/propidium iodide (PI) double staining method and flow cytometry. The targets of miR-26a were identified using a luciferase activity assay and miR-26a-mediated target genes expression analysis. Furthermore, the role of the targets neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and E2F2 on sensitivity of chemotherapy in GC by MTS and apoptotic cell analysis was assessed. cell line (SGC-7901,SGC7901/DDP) up-regulated sensitive NRAS and E2F2 NRAS and E2F2 NA validated 1753 Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther 2015 26494558 miRBase MI0000448 miR-130a miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR We in this study aimed to investigate the function of miR130a in p53 tumor suppressor signaling pathway. We performed microRNA (miRNA) expression profile analysis in CML cancer stem cells of 38 cases and extracted total RNA from peripheral blood of 143 cases. Standard curves of U6 and miRNA were made from 10-fold serial dilutions of the cDNA, which were quantified using real-time quantitative PCR with SYBR Green by ABI 7300. The p53 mutations and BCR/ABL mutation status analysis in CML patients were detected by PCR and direct sequencing. Candidate targets of miR130a of putative relevance in CML pathogenesis were analyzed by bioinformatics approach. We then used dual-luciferase activity assay to verify the target genes of miR130a and used western blot analysis to elucidate the mechanism of miR130a on modulating drug resistance. cell line up-regulated sensitive BCL-2, MCL-1 and XIAP BCL-2, MCL-1 and XIAP NA validated 1754 MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon) 2015 26500892 miRBase MIMAT0000070 miR-17-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian carcinoma Real-time RT-PCR The proliferation of ovarian cancer cells was assessed by MTT assay. The Caspase-Glo3/7 and TUNEL assay were used to examine the effect of miR-17-5p on paclitaxel-induced apoptosis in ovarian cancer cells. The migration and invasion of ovarian cancer cells were analyzed by BD matrigel assays. Western blot was performed to evaluate the expression of apoptotic proteins and epithelial-mesenchymal transition markers in ovarian cancer cells. cell line (OVCAR-3, SKOV-3) up-regulated resistant PTEN PTEN PTEN signaling pathway validated 1755 miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1. Biomed Res Int 2015 26526790 miRBase MI0003137 miR-193b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR The expression levels of miRNA were determined by Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7,MCF-7/DOXR) up-regulated sensitive MCL-1 MCL-1 miR-193b-MCL-1-apoptosis pathway validated 1756 MiR-143 enhances the antitumor activity of shikonin by targeting BAG3 expression in human glioblastoma stem cells. Biochem Biophys Res Commun 2015 26541455 miRBase MI0000459 miR-143 miRNA NA Shikonin glioblastoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. In vivo xenograft study was used to test the role of miR-143 . tissue and cell line up-regulated sensitive BAG3 BAG3 NA validated 1757 Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression. Int J Clin Exp Med 2015 26550261 miRBase MI0000079 miR-23a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer NA The ovarian cancer cell lines A2780 was administrated with antagomir-23a and platinum, and then the cell proliferation inhibition rate was determined by MTT assay. The cell cycle distribution was detected by flow cytometric analysis. The apoptotic morphological changes were analyzed by Hoechst33258 staining. The glycoprotein P-gp expression changes were detected by Western blot analysis. cell line (A2780) down-regulated sensitive NA NA NA validated 1758 Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression. Int J Clin Exp Med 2015 26550261 miRBase MI0000079 miR-23a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer NA The ovarian cancer cell lines A2780 was administrated with antagomir-23a and platinum, and then the cell proliferation inhibition rate was determined by MTT assay. The cell cycle distribution was detected by flow cytometric analysis. The apoptotic morphological changes were analyzed by Hoechst33258 staining. The glycoprotein P-gp expression changes were detected by Western blot analysis. cell line (A2780) down-regulated sensitive NA NA NA validated 1759 Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells Zhejiang Da Xue Xue Bao Yi Xue Ban 2015 26555418 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR Paclitaxel-resistant human breast cancer cell lines MCF-7/PR and SKBR-3/PR were established by stepwise selection in increasing concentration of paclitaxel. Cellular morphology, mRNA and protein level of MDR1, BCRP and MRP1 in MCF-7/PR and SKBR-3/PR cells were determined. The expression of Bax, Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting. The synthetic miR-21 inhibitor or miR-21 mimic were transfected into MCF-7/PR, SKBR-3/PR and MCF-7, SKBR-3 cells with Lipofectamine 2000. The miR-21 levels were determined by RT-PCR, and P-gp, Bcl-2 and Bax protein levels were examined by Western blotting. MTT assay was used to measure the cell viability, and flow cytometry was performed to analyze the cell cycle and apoptosis. cell line (MCF-7/PR, SKBR-3/PR, MCF-7, SKBR-3) down-regulated sensitive NA NA NA validated 1760 Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015 26560033 miRBase NA miR-200 miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by migration and invasion assay. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line (Tri-PyMT) up-regulated sensitive NA NA NA validated 1761 Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget 2015 26561204 miRBase MI0000271 miR-181c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The expression levels of miRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (PANC-1, BXPC3) up-regulated resistant MST1, LATS2, MOB1 and SAV1 MST1, LATS2, MOB1 and SAV1 Hippo signaling pathway validated 1762 Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget 2015 26561204 miRBase MI0000271 miR-181c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR The expression levels of miRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (PANC-1, BXPC3) up-regulated resistant MST1, LATS2, MOB1 and SAV1 MST1, LATS2, MOB1 and SAV1 Hippo signaling pathway validated 1763 Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget 2015 26561204 miRBase MI0000271 miR-181c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel pancreatic cancer qRT-PCR The expression levels of miRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. cell line (PANC-1, BXPC3) up-regulated resistant MST1, LATS2, MOB1 and SAV1 MST1, LATS2, MOB1 and SAV1 Hippo signaling pathway validated 1764 miR-29b Reduces Cisplatin Resistance of Gastric Cancer Cell by Targeting PI3K/Akt Pathway Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2015 26564501 miRBase MI0000105/MI0000107 miR-29b miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression of miR-29b in gastric cancer cell line treated with cisplatin concentration gradient was detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blotting. CCK8 was used to measure the cell viability after cisplatin treatment in condition of miR-29b knock-down and overexpression. cell line (SGC7901,HGC-27) up-regulated sensitive AKT2 AKT2 PI3K/Akt pathway validated 1765 VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin. Tumour Biol 2015 26566625 miRBase MI0000460 miR-144 miRNA DB00515 (APRD00359) Cisplatin prostate cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line ( PC3, LNCap) down-regulated resistant Beclin-1 Beclin-1 autophagy pathway validated 1766 miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer 2015 26576679 miRBase MI0003649 miR-634 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR Differentially expressed microRNAs between cisplatin sensitive and resistant cancer cell line pairs were determined using microarrays. Mimics were used to study the role of microRNAs in drug sensitivity of ovarian cancer cell lines and patient derived tumor cells. Luciferase reporter constructs were used to establish regulation of target genes by microRNAs. cell line (A2780,HCT8,T24,A2870 DDP, HCT8 DDP,T24 DDP10,OV56, OAW42,TOV112D, TOV21G) up-regulated sensitive NA NA Ras-MAPK pathway validated 1767 miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer 2015 26576679 miRBase MI0003649 miR-634 miRNA DB00958 (APRD00466) Carboplatin ovarian cancer RT-PCR Differentially expressed microRNAs between cisplatin sensitive and resistant cancer cell line pairs were determined using microarrays. Mimics were used to study the role of microRNAs in drug sensitivity of ovarian cancer cell lines and patient derived tumor cells. Luciferase reporter constructs were used to establish regulation of target genes by microRNAs. cell line (A2780,HCT8,T24,A2870 DDP, HCT8 DDP,T24 DDP10,OV56, OAW42,TOV112D, TOV21G) up-regulated sensitive NA NA Ras-MAPK pathway validated 1768 miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer 2015 26576679 miRBase MI0003649 miR-634 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin ovarian cancer RT-PCR Differentially expressed microRNAs between cisplatin sensitive and resistant cancer cell line pairs were determined using microarrays. Mimics were used to study the role of microRNAs in drug sensitivity of ovarian cancer cell lines and patient derived tumor cells. Luciferase reporter constructs were used to establish regulation of target genes by microRNAs. cell line (A2780,HCT8,T24,A2870 DDP, HCT8 DDP,T24 DDP10,OV56, OAW42,TOV112D, TOV21G) up-regulated sensitive NA NA Ras-MAPK pathway validated 1769 MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One 2015 26599571 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.TUNEL staining was used to detect apoptotic cell death. tissue and cell line (5637,T24 , HEK 293T) up-regulated sensitive Bcl-w, Survivin Bcl-w, Survivin NA validated 1770 Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells Nan Fang Yi Ke Da Xue Xue Bao 2015 26607088 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The SKOV3/DDP cells were transfected with the mimics or inhibitor of miR-100 or negative control RNA (NC) or inhibitor negative control RNA (inhibitor NC) by lipofectamine 2000. The experiment was divided into six groups: SKOV3 group, SKOV3/DDP group, miR-100 mimices group, NC group, miR-100 inhibitor group and inhibitor NC group. The expression of miR-100 and the cisplatin IC50 were measured by real-time PCR and CCK8 assay respectively. cell line (SKOV3,SKOV3/DDP) up-regulated sensitive NA NA NA validated 1771 MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1. Int J Clin Exp Pathol 2015 26617714 miRBase MIMAT0000687 miR-299-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung cancer qRT-PCR In the present study, miR-299-3p was down-expressed in doxorubicin-resistant or -sensitive lung cancer samples and it was identified to directly targeted adenosine triphosphate binding cassette E1 (ABCE1) 3-untranslated region (UTR) in lung cancer H69 cells by luciferase assay. After transfection of miR-299-3p mimics or ABCE1-siRNA, MTT assay confirmed that the H69/ADR cell proliferation was inhibited, as well as the enhanced cell inhibitory rate in the presence of doxorubicin. H69/ADR cell apoptosis rate was promoted after miR-299-3p or ABCE1-siRNA transfection. The results indicated that miR-299-3p promotes the sensibility of lung cancer to doxorubicin through suppression of ABCE1, at least partly. Therefore, the disordered decreased of miR-299-3p and resulting ABCE1 up-expression may contribute to chemoresistance of lung cancer, and miR-299-3p-ABCE1 may represent a new potential therapeutic target for the treatment of chemoresistance of lung cancer. cell line (NCI-H69 ) down-regulated resistant ABCE1 ABCE1 NA validated 1772 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MI0014165 miR-3141 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1773 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000098 miR-100-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1774 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0004284 miR-675-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1775 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0004592 miR-125b-1-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1776 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000423 miR-125b-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1777 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000437 miR-145-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1778 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0003247 miR-582-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1779 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0006790 miR-675-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1780 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000275 miR-218-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1781 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000272 miR-215-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1782 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0004797 miR-582-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1783 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MI0016088/MI0031515 miR-3687 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1784 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MI0020364 miR-6087 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1785 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase NA chr16-11501 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1786 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase NA chr19-16126 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1787 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase NA chr15-10055 miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) up-regulated resistant NA NA NA predicted 1788 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000270 miR-181a-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1789 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0022721 miR-1247-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1790 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0003218 miR-92b-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1791 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0005899 miR-1247-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1792 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000444 miR-126-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1793 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0004513 miR-101-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1794 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0004512 miR-100-3p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1795 Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells. Int J Clin Exp Pathol 2015 26617885 miRBase MIMAT0000449 miR-146a-5p miRNA DB00541 (APRD00495) Vincristine colon cancer PCR HCT-8 colon carcinoma cells were cultured and treated with different VCR concentrations to establish an HCT-8/VCR resistant cell line. Whole-genome screens, HiSeq 2500 sequencing, and bioinformatics methods were used to detect and analyze differences in miRNA expression between the drug-resistant HCT-8/VCR cells and non-resistant HCT-8 cells. Differential expression profiles of miRNAs were constructed based on sequencing result. cell line (HCT-8, HCT-8/VCR) down-regulated resistant NA NA NA predicted 1796 MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFBetaR1/Smad signaling pathway in NSCLC. Sci Rep 2015 26620926 miRBase MI0000270/MI0000683 miR-181b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by Real time-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. A wound healing assay was performed to examine the capacity of cell migration. Cell migration was detected by transwell migration and invasion assay. cell line (A549, A549/DDP, H1650 ) up-regulated sensitive TGFBetaR1 NA TGFBetaR1/Smad signaling pathway validated 1797 MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res 2015 26626440 miRBase MI0000483 miR-186 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (OVCAR3,A2780,A2780/DDP,A2780/Taxol,A2780/DDP, A2780/Taxol, OVCAR3) up-regulated sensitive ABCB1 ABCB1 NA validated 1798 MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res 2015 26626440 miRBase MI0000483 miR-186 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (OVCAR3,A2780,A2780/DDP,A2780/Taxol,A2780/DDP, A2780/Taxol, OVCAR3) up-regulated sensitive ABCB1 ABCB1 NA validated 1799 Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One 2015 26636340 miRBase MI0000114 miR-107 miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MKN-28, MKN-45) up-regulated sensitive NA NA NA validated 1800 Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One 2015 26636340 miRBase MI0000114 miR-107 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MKN-28, MKN-45) up-regulated sensitive NA NA NA validated 1801 Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One 2015 26636340 miRBase MI0000114 miR-107 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MKN-28, MKN-45) up-regulated sensitive NA NA NA validated 1802 Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One 2015 26636340 miRBase MI0000114 miR-107 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The expression levels of miRNA were determined by Real-time quantitative PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MKN-28, MKN-45) up-regulated sensitive NA NA NA validated 1803 MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer 2015 26666173 miRBase MI0000290 miR-214 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR Experiments were performed in ER(+) and estrogen/TAM-sensitive MCF7 cells and antiestrogen-resistant MCF7/LCC9 cells. The expression of miR-214 and uncoupling protein 2 (UCP2) was determined by RT-qPCR and Western blot in breast cancer cells and human breast cancer tissue specimens. Cell autophagy was examined by fluorescent probe monodansyl cadaverine (MDC) and GFP-LC3-II-positive punctate identified by confocal microscopy. Apoptotic cells were determined by Annexin V-FITC/PI staining. The potential regulatory target of miR-214 was determined by prediction tool, target protein expression and luciferase reporter assay. cell line ( MCF7,MCF7/LCC9) up-regulated sensitive UCP2 UCP2 PI3K-Akt-mTOR pathway validated 1804 MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer 2015 26666173 miRBase MI0000290 miR-214 miRNA DB00947 (APRD00654) Fulvestrant breast cancer RT-qPCR Experiments were performed in ER(+) and estrogen/TAM-sensitive MCF7 cells and antiestrogen-resistant MCF7/LCC9 cells. The expression of miR-214 and uncoupling protein 2 (UCP2) was determined by RT-qPCR and Western blot in breast cancer cells and human breast cancer tissue specimens. Cell autophagy was examined by fluorescent probe monodansyl cadaverine (MDC) and GFP-LC3-II-positive punctate identified by confocal microscopy. Apoptotic cells were determined by Annexin V-FITC/PI staining. The potential regulatory target of miR-214 was determined by prediction tool, target protein expression and luciferase reporter assay. cell line ( MCF7,MCF7/LCC9) up-regulated sensitive UCP2 UCP2 PI3K-Akt-mTOR pathway validated 1805 MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res 2015 26692956 miRBase MI0000681 miR-155 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR This study investigated the mechanism of TAM resistance of mir-155 in breast cancer.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs tissue and cell line (MCF7, SKBR3 ) up-regulated resistant SOCS6 SOCS6 SOCS6-STAT3 signalling pathway validated 1806 MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res 2015 26692956 miRBase MI0000681 miR-155 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( MCF7, SKBR3) down-regulated sensitive SOCS6 SOCS6 SOCS6-STAT3 signalling pathway validated 1807 Involvement of miR-199a in cisplatin resistance of ovarian cancer cell through modulating expression of mTOR Zhonghua Yi Xue Za Zhi 2015 26711828 miRBase MI0000242/MI0000281 miR-199a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR Real-time polymerase chain reaction(PCR) and Western blot were applied to detect the expression level changes of mammalian target of rapamycin (mTOR) in OV2008 and C13* cells before and after transfecting the cells with the mimics and inhibitor of miR-199a with Lipofectamine 2000.We constructed luciferase reporter vectors of mTOR and then transfected OV2008 cells with the mimics of miR-199a with Lipofectamine 2000 to study the regulation of miR-199as downstream target genes. cell line ( OV2008, C13* ) down-regulated resistant mTOR mTOR mTOR signaling pathway validated 1808 MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol 2015 26722459 miRBase MI0000070/MI0000115 miR-16 miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR In present study, we first examined the sensitivity to temozolomide in six glioma cell lines, and established a resistant variant, U251MG/TR cells from TMZ-sensitive glioma cell line, U251MG. We then performed a comprehensive analysis of miRNA expressions in U251MG/TR and parental cells using cancer microRNA PCR Array. Among the downregulated microRNAs was miR-16, members of miR-15/16 family, whose expression was further validated by qRT-PCR in U251MG/TR and U251MG cells. The selective microRNA, miR-16 mimics or inhibitor was respectively transfected into U251MG/TR cells and AM38 cell. We found that treatment with the mimics of miR-16 greatly decreased the sensitivity of U251MG/TR cells to temozolomide, while sensitivity to these drugs was increased by treatment with the miR-16 inhibitor. In addition, the downregulation of miR-16 in temozolomide-sensitive AM38 cells was concurrent with the upregulation of Bcl-2 protein. Conversely, overexpression of miR-16 in temozolomide-resistant cells inhibited Bcl-2 expression and decreased temozolomide resistance. cell line (U-138MG, A172,LN382, AM-38, U-251MG, KMG4) up-regulated resistant BCL-2 BCL-2 NA validated 1809 Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel. Cell Biochem Biophys 2015 27040946 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901) down-regulated sensitive P-gp NA NA validated 1810 MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line. Ir J Med Sci 2016 25381586 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MG-63) up-regulated resistant NA NA NA validated 1811 miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene 2016 25982274 miRBase MI0003175 miR-520h miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. MTS assay was used to test cell viability . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (MDA-MB-231, MDA-MB-468, Hs578T,BT483, T47D, MCF-7, MDA-MB-361, MDA-MB-453 and HBL-100) up-regulated resistant DAPK2 DAPK2 NA validated 1812 TGF-Beta1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma. J Cancer Res Clin Oncol 2016 26276504 miRBase MI0003130 miR-202 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR miR-202 expression was measured by real-time PCR in patient tissues, cell lines or cells treated with TGF-Beta1, using siRNA to knock down the expression of Smad2, Smad3 and Smad4. miR-202 mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on cell apoptosis and drug resistance. Moreover, relationships of miR-202 level with PDCD4 were investigated by luciferase reporter assay, real-time PCR and Western blotting. cell line (U2OS, G293) up-regulated resistant PDCD4 PDCD4 TGF-Beta1 pathway validated 1813 Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Tumour Biol 2016 26376998 miRBase MI0000238/MI0000279 miR-196a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect expression differences of miR-196a in the drug-resistant A549/DDP NLCLC cell line and the parental A549 cell line, and expressions of miR-196a in the A549/DDP NLCLC cell line transfected with miR-196a inhibitor (anti-miR-196a group) and the miR-196a negative control (miR-NC) group and blank group (without transfection). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was applied in examining the cell viability of A549/DDP cell line before and after transfection. Clonogenic assay was used to detect cell proliferation ability. Flow cytometry was applied in detecting apoptosis rate of assayed tumor cell and rhodamine-123 changes in cells. Western blot was applied in detecting proteins of drug-resistant related gene in A549/DDP cell line. cell line (A549, A549/DDP) down-regulated sensitive NA NA NA validated 1814 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000707 miR-363-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1815 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000095 miR-96-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1816 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0002806 miR-490-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1817 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0005565 miR-543 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1818 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004703 miR-335-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1819 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0001639 miR-409-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1820 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0016825 miR-4473 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1821 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000097 miR-99a-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1822 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0003338 miR-660-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1823 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000076 miR-21-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1824 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000449 miR-146a-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1825 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0016423 miR-3917 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1826 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000418 miR-23b-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1827 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000222 miR-192-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1828 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000420 miR-30b-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1829 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0005949 miR-664a-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1830 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0016053 miR-3653 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1831 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004501 miR-27a-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1832 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000062 let-7a-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1833 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0006355 miR-1293 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1834 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000424 miR-128-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1835 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000063 let-7b-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1836 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0003393 miR-425-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1837 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0000064 let-7c miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1838 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0016051 miR-3651 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1839 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000750 miR-340-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1840 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000703 miR-361-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1841 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004594 miR-132-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1842 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004497 miR-24-2-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1843 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004507 miR-92a-1-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1844 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000646 miR-155-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1845 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0000542 miR-320a miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1846 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000066 let-7e-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1847 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000098 miR-100-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1848 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000078 miR-23a-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1849 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000760 miR-331-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1850 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004588 miR-27b-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1851 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0017985 miR-3607-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) up-regulated resistant NA NA NA predicted 1852 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0006353 miR-1291 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1853 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0006349 miR-1287 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1854 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0000481 miR-184 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1855 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0002874 miR-503-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1856 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000252 miR-7-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1857 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0000804 miR-328 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1858 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0003189 miR-504 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1859 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0019879 miR-4745-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1860 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0005567 miR-760 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1861 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0019878 miR-4745-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1862 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0010251 miR-449c-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1863 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0017352 miR-2277-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1864 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0019738 miR-4664-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1865 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000455 miR-185-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1866 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0004749 miR-424-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1867 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0003249 miR-584-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1868 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0003886 miR-769-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1869 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0016818 miR-4467 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1870 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MI0003815 miR-1301 miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1871 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0002874 miR-503-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1872 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0015085 miR-3200-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1873 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0015069 miR-3187-3p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1874 Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery 2016 26456124 miRBase MIMAT0000245 miR-30d-5p miRNA NA PLX4720 thyroid cancer qRT-PCR miRNA expression profiles in the human anaplastic thyroid cancer cell line (8505c) were compared with its PLX4720-resistant counterpart (8505c-R) by the use of Illumina deep sequencing. We conducted a functional annotation and pathway analysis of the putative and experimentally validated target genes of the significantly altered miRNAs. cell line (8505c(v600E/-), BCPAP(v600E/wt)) down-regulated resistant NA NA NA predicted 1875 Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther 2016 26492332 miRBase MI0000083/MI0000750 miR-26a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma Real-time RT-PCR In this study, we analyzed expressional profiles of CDDP resistance-related mRNA, miRNA, and transcription factors (TF) that regulate miRNA expression in NSCLC. A549 cells were treated with CDDP, miR-26a mimic, or miR-26a inhibitor, and followed by biological analysis including drug sensitivity assay, colony formation assay, terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL) assay, and cell cycle analysis. Luciferase assay was used to determine the target of miR-26a. The regulation of miR-26a in Akt pathway was measured by western blot. cell line (A549,A549/CDDPres ) down-regulated resistant HMGA2 HMGA2 E2F1-Akt pathway validated 1876 A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res 2016 26527748 miRBase MI0000298 miR-221 miRNA DB01042 (APRD00118) Melphalan multiple myeloma qRT-PCR Here we studied the potential utility of miR-221/222 inhibition in sensitizing refractory multiple myeloma cells to melphalan. cell line ( NCI-H929 t(4;14), RPMI-8226 t(14;16) and U266 t(11;14) ) up-regulated resistant PUMA and BBC3 PUMA/BBC3 NA validated 1877 MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1. J Biol Chem 2016 26542803 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The role of miR-7 in lung cancer cells was detected using WST-1 cell viability assay, luciferase assays, Annexin-V FITC apoptosis assay, Real Time quantitative PCR and microRNA targeting prediction, etc. cell line (A549, H1299, H1975, HCC827,HEK293T ) down-regulated sensitive SMARCD1 SMARCD1 NA validated 1878 miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3. Oncol Rep 2016 26549292 miRBase MIMAT0002809 miR-146b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR To confirm the role of miR-146b-5p in osteosarcoma, the study was divided into three steps: first, miR-146b-5p in paired samples were assessed using a quantitative real-time PCR (qRT-PCR) assay from osteosarcoma patients. Second, to confirm the role of miR-146b-5p, we applied lentivirus system to overexpression and knockdown of miR-146b-5p, respectively, in MG-63 osteosarcoma cell line. Third, luciferase assays were performed to determine whether Wnt/Beta-catenin pathway participated in the role of miR-146b-5p on chemoresistance. tissue and cell line (hFOB1.19, MG-63 and U-2 OS ) up-regulated resistant ZNRF3 ZNRF3 NA validated 1879 miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3. Oncol Rep 2016 26549292 miRBase MIMAT0002809 miR-146b-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR To confirm the role of miR-146b-5p in osteosarcoma, the study was divided into three steps: first, miR-146b-5p in paired samples were assessed using a quantitative real-time PCR (qRT-PCR) assay from osteosarcoma patients. Second, to confirm the role of miR-146b-5p, we applied lentivirus system to overexpression and knockdown of miR-146b-5p, respectively, in MG-63 osteosarcoma cell line. Third, luciferase assays were performed to determine whether Wnt/Beta-catenin pathway participated in the role of miR-146b-5p on chemoresistance. tissue and cell line (hFOB1.19, MG-63 and U-2 OS ) up-regulated resistant ZNRF3 ZNRF3 NA validated 1880 miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3. Oncol Rep 2016 26549292 miRBase MIMAT0002809 miR-146b-5p miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR To confirm the role of miR-146b-5p in osteosarcoma, the study was divided into three steps: first, miR-146b-5p in paired samples were assessed using a quantitative real-time PCR (qRT-PCR) assay from osteosarcoma patients. Second, to confirm the role of miR-146b-5p, we applied lentivirus system to overexpression and knockdown of miR-146b-5p, respectively, in MG-63 osteosarcoma cell line. Third, luciferase assays were performed to determine whether Wnt/Beta-catenin pathway participated in the role of miR-146b-5p on chemoresistance. tissue and cell line (hFOB1.19, MG-63 and U-2 OS ) up-regulated resistant ZNRF3 ZNRF3 NA validated 1881 MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep 2016 26572075 miRBase MI0000270/MI0000683 miR-181b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-10A, T-47D, MCF-7, MDA-MB-231, MDA-MB-435) up-regulated resistant Bim Bim miR-181b-Bim-MMP-caspase pathway validated 1882 MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C. Mol Med Rep 2016 26573417 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SNU5, HGC27, BGC823, SGC7901, AGS) up-regulated sensitive VEGF-C VEGF-C NA validated 1883 MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C. Mol Med Rep 2016 26573417 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Bioinformatics analyses were performed to predict the putative target genes of miR-101 using TargetScan software .Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SNU5, HGC27, BGC823, SGC7901,AGS,SGC7901/DDP,GES1) up-regulated sensitive VEGF-C VEGF-C NA validated 1884 MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 2016 26573761 miRBase NA miR-106~25 miRNA DB01394 Colchicine breast cancer NA The role of miR-106b~25 cluster in breast cancer cells was detected using drug resistance clonogenic assay, drug efflux assay, P-glycoprotein expression assay, Gene expression analysis, caspase-9 and -3/-7 using Caspase-Glo assays, etc. cell line up-regulated resistant EP300 EP300 miR-106b~25 cluster/EP300/E-cadherin pathway validated 1885 MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 2016 26573761 miRBase NA miR-106~25 miRNA DB00091 (BTD00003, BIOD00003) Cyclosporin A breast cancer NA The role of miR-106b~25 cluster in breast cancer cells was detected using drug resistance clonogenic assay, drug efflux assay, P-glycoprotein expression assay, Gene expression analysis, caspase-9 and -3/-7 using Caspase-Glo assays, etc. cell line up-regulated resistant EP300 EP300 miR-106b~25 cluster/EP300/E-cadherin pathway validated 1886 MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 2016 26573761 miRBase NA miR-106~25 miRNA DB00773 (APRD00239) Etoposide breast cancer NA The role of miR-106b~25 cluster in breast cancer cells was detected using drug resistance clonogenic assay, drug efflux assay, P-glycoprotein expression assay, Gene expression analysis, caspase-9 and -3/-7 using Caspase-Glo assays, etc. cell line up-regulated resistant EP300 EP300 miR-106b~25 cluster/EP300/E-cadherin pathway validated 1887 MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 2016 26573761 miRBase NA miR-106~25 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA The role of miR-106b~25 cluster in breast cancer cells was detected using drug resistance clonogenic assay, drug efflux assay, P-glycoprotein expression assay, Gene expression analysis, caspase-9 and -3/-7 using Caspase-Glo assays, etc. cell line up-regulated resistant EP300 EP300 miR-106b~25 cluster/EP300/E-cadherin pathway validated 1888 MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment. Tumour Biol 2016 26581910 miRBase MI0000459 miR-143 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colorectal cancer qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription PCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation., The volume of nude mouse gastric tumor xenografts was used to identify the relationship between miR-182a and cisplation. cell line (SW48,LoVo ) up-regulated sensitive NA NA NA validated 1889 MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment. Tumour Biol 2016 26581910 miRBase MI0000459 miR-143 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colorectal cancer qRT-PCR The role of miR-27a in gastric cancer cells was detected using qRT-PCR, immunoblot analysis, MTT assay, apoptosis assay, cell proliferation assay, transwell migration and invasion assays,etc. cell line (SW48,LoVo) up-regulated sensitive NA NA NA validated 1890 MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene 2016 26589846 miRBase MI0000289/MI0000269 miR-181a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-181a in gastric cancer cells was detected usingquantitative reverse transcription PCR, western blot analysis, GFP-LC3 analysis, ransmission electron microscopy, MTS assay and animal xenograft model,etc. cell line (SGC7901/CDDP) up-regulated sensitive ATG5 ATG5 NA validated 1891 miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget 2016 26623722 miRBase MI0000772 miR-302b miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation. cell line (MDA-MB-231, BT549, T47D) up-regulated sensitive E2F1 E2F1 NA validated 1892 miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol 2016 26644266 miRBase MI0000738 miR-302a miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The differential miRNA expression profiling in parental MCF-7 cells and its derivative mitoxantrone (MX)-resistant MCF-7 (MCF-7/MX) cells was determined by the microarray analysis. The levels of miR-302S family and BCRP mRNA expression were determined by using Quantitative Real-Time PCR. The targeting effect between the individuals of miR-302S and BCRP mRNA-3UTR were detected by dual-luciferase reporter assay. Proteins of BCRP are represented by Western blot assay. Cell viability was assessed by MTS assay. Efflux capacity was evaluated using flow cytometry. cell line (MCF-7,MCF-7/MX) up-regulated sensitive BCRP NA NA validated 1893 miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol 2016 26644266 miRBase MI0000772 miR-302b miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The differential miRNA expression profiling in parental MCF-7 cells and its derivative mitoxantrone (MX)-resistant MCF-7 (MCF-7/MX) cells was determined by the microarray analysis. The levels of miR-302S family and BCRP mRNA expression were determined by using Quantitative Real-Time PCR. The targeting effect between the individuals of miR-302S and BCRP mRNA-3UTR were detected by dual-luciferase reporter assay. Proteins of BCRP are represented by Western blot assay. Cell viability was assessed by MTS assay. Efflux capacity was evaluated using flow cytometry. cell line (MCF-7,MCF-7/MX) up-regulated sensitive BCRP NA NA validated 1894 miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol 2016 26644266 miRBase MI0000773 miR-302c miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The differential miRNA expression profiling in parental MCF-7 cells and its derivative mitoxantrone (MX)-resistant MCF-7 (MCF-7/MX) cells was determined by the microarray analysis. The levels of miR-302S family and BCRP mRNA expression were determined by using Quantitative Real-Time PCR. The targeting effect between the individuals of miR-302S and BCRP mRNA-3UTR were detected by dual-luciferase reporter assay. Proteins of BCRP are represented by Western blot assay. Cell viability was assessed by MTS assay. Efflux capacity was evaluated using flow cytometry. cell line (MCF-7,MCF-7/MX) up-regulated sensitive BCRP NA NA validated 1895 miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol 2016 26644266 miRBase MI0000774 miR-302d miRNA DB01204 (APRD00371) Mitoxantrone breast cancer qRT-PCR The differential miRNA expression profiling in parental MCF-7 cells and its derivative mitoxantrone (MX)-resistant MCF-7 (MCF-7/MX) cells was determined by the microarray analysis. The levels of miR-302S family and BCRP mRNA expression were determined by using Quantitative Real-Time PCR. The targeting effect between the individuals of miR-302S and BCRP mRNA-3UTR were detected by dual-luciferase reporter assay. Proteins of BCRP are represented by Western blot assay. Cell viability was assessed by MTS assay. Efflux capacity was evaluated using flow cytometry. cell line (MCF-7,MCF-7/MX) up-regulated sensitive BCRP NA NA validated 1896 MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10. J Cell Mol Med 2016 26647742 miRBase MIMAT0003393 miR-425-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR Microarray analysis was performed in isogenic chemosensitive and chemoresistant HCT116 cell lines to identify differentially expressed miRNAs. miRNA quantitative real-time PCR was used to detect miR-425-5p expression levels between drug resistant and parental cancer cells. MiR-425-5p mimic and inhibitor were transfected, followed by CellTiter-Glo assay to examine drug sensitivity in these two cell lines. Western Blot and luciferase assay were performed to investigate the direct target of miR-425-5p. Xenograft mouse models were used to examine in vivo function of miR-425-5p. cell line ( HCT116) down-regulated sensitive PDCD10 PDCD10 NA validated 1897 MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10. J Cell Mol Med 2016 26647742 miRBase MIMAT0003393 miR-425-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-PCR Microarray analysis was performed in isogenic chemosensitive and chemoresistant HCT116 cell lines to identify differentially expressed miRNAs. miRNA quantitative real-time PCR was used to detect miR-425-5p expression levels between drug resistant and parental cancer cells. MiR-425-5p mimic and inhibitor were transfected, followed by CellTiter-Glo assay to examine drug sensitivity in these two cell lines. Western Blot and luciferase assay were performed to investigate the direct target of miR-425-5p. Xenograft mouse models were used to examine in vivo function of miR-425-5p. cell line ( HCT116) down-regulated sensitive PDCD10 PDCD10 NA validated 1898 BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett 2016 26655271 miRBase MI0000433 let-7g miRNA DB00515 (APRD00359) Cisplatin esophageal carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Apoptosis assay was performed with Annexin V-FITC/PI Apoptosis Detection Kit . cell line (EC109, TE10) up-regulated sensitive ABCC10 ABCC10 NA validated 1899 BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett 2016 26655271 miRBase MI0000434 let-7i miRNA DB00515 (APRD00359) Cisplatin esophageal carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Apoptosis assay was performed with Annexin V-FITC/PI Apoptosis Detection Kit . cell line (EC109, TE10) up-regulated sensitive ABCC10 ABCC10 NA validated 1900 MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett 2016 26655273 miRBase MI0000442 miR-122 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR The miRNA microarray data to identify the level of miR-122 expression in sorafenib-resistnant cell.The expression levels of miRNA were determined by Quantitative Real-Time PCR. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The Target Scan Release 6.2 was uesed to predict miR-122 target genes. tissue and cell line up-regulated sensitive IGF-1R IGF-1R RAS/RAF/ERK signaling pathway validated 1901 miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol 2016 26662313 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR In this study, upregulation of miR-27a was validated by real-time PCR analysis in breast cancer (BC) cell lines and samples of BC patients. A negative correlation between miR-27a and bak was also observed in normal breast epithelial cell line MCF-10A and BC cell lines, suggesting that the bak is the potential target of miR-27a. miR-27a could modulate the growth and metastasis of BC cells. More importantly, we found that knockdown of miR-27a by the specific inhibitors significantly increased the sensitivity of T-47D cells to cisplatin (CDDP) treatment. After further investigation, we indicated that the knockdown of miR-27a promoted the apoptosis via mitochondrial pathway in T-47D cells treated with CDDP, depending on the BAK-second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (SMAC/DIABLO)-X-linked inhibitor of apoptosis (XIAP) axis. cell line ( MCF-10A,T-47D ) down-regulated sensitive bak bak BAK-SMAC/DIABLO-XIAP pathway validated 1902 MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biol 2016 26666820 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells. Cell migration was detected by transwell migration and invasion assay. cell line (MDA-MB-231, MCF-7,) up-regulated resistant PTEN PTEN PTEN/Akt pathway validated 1903 MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget 2016 26673620 miRBase MI0003138 miR-497 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by reverse transcription PCR and quantitative real time-PCR . Luciferase activity assay was used to verify the target genes of miRNAs.A wound healing assay was performed to examine the capacity of cell migration.The CCK-8 assay was used to monitor the growth of the cells. cell line (SW1116,HEK293T) up-regulated sensitive KSR1 KSR1 NA validated 1904 miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget 2016 26675258 miRBase MI0000088 miR-30a miRNA DB00515 (APRD00359) Cisplatin ovarian carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.TUNEL staining was used to detect apoptotic cell death. Xenografts in nude mice was used to test the role of miR-30a . cell line (A2780,A2780 CIS, A2780 TAX,2008C13 (CIS),SKOV-3 ) up-regulated sensitive ETAR NA NA validated 1905 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0005951 miR-1307-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1906 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000253 miR-10a-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1907 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0004748 miR-423-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1908 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MI0000542 miR-320a miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1909 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MI0003776/MI0003839 miR-320b miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1910 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0004792 miR-92b-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1911 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0004507 miR-92a-1-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1912 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000265 miR-204-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1913 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000252 miR-7-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1914 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0022693 miR-204-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) up-regulated resistant NA NA NA predicted 1915 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0001635 miR-452-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1916 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000076 miR-21-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1917 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000086 miR-29a-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1918 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000279 miR-222-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1919 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000078 miR-23a-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1920 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000281 miR-224-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1921 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000098 miR-100-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1922 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0004558 miR-181a-2-3p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1923 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0000423 miR-125b-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1924 Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines. Oncol Rep 2016 26676926 miRBase MIMAT0004588 miR-27b-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qPCR Expression levels of known miRNAs in SCLC cell line H446 and its multidrug-resistant cell line H446/CDDP were analyzed using the next generation high through-put Illumina Solexa sequencing technology, and expression of a group of specific miRNAs was validated by quantitative polymerase chain reaction (qPCR). Furthermore, novel miRNAs and their putative target genes in the two SCLC cell lines were predicted with the help of software developed by Beijing Genomics Institute and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. cell line (H446, H446/CDDP ) down-regulated resistant NA NA NA predicted 1925 Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 2016 26684239 miRBase MI0000268 miR-34a miRNA DB08881 (DB05238) Vemurafenib melanoma qRT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR analysis (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (the melanoma cell lines,the PLX4032-resistant cell line ) down-regulated sensitive NA NA NA validated 1926 Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 2016 26684239 miRBase MI0000102 miR-100 miRNA DB08881 (DB05238) Vemurafenib melanoma qRT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR analysis (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (the melanoma cell lines,the PLX4032-resistant cell line ) down-regulated sensitive NA NA NA validated 1927 Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 2016 26684239 miRBase MI0000446/MI0000470 miR-125b miRNA DB08881 (DB05238) Vemurafenib melanoma qRT-PCR The expression levels of miRNA were determined by Real-time reverse transcription-PCR analysis (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (the melanoma cell lines,the PLX4032-resistant cell line ) down-regulated sensitive NA NA NA validated 1928 Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner. Tumour Biol 2016 26687759 miRBase NA let-7 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR In this study, we detected the expression of Lin28A in colon cancer patients and tested the effect of Lin28A on the chemotherapeutic sensitivity of colon cancer cells to 5-fluorouracil (5-FU). The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Cell migration was detected invasion assay. tissue and cell line ( HCT116,293TN) up-regulated sensitive NA NA NA validated 1929 Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells. Pathol Oncol Res 2016 26689580 miRBase MI0003130 miR-202 miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-PCR In this study, we characterized the role of miR-202 in multiple myeloma (MM) drug sensitivity. The potential binding site of miR-202 and B cell-activating factor (BAFF) was confirmed by luciferase reporter assay. MM cells were transfected with miR-202 mimics and inhibitor. Cells growth was measured by WST-1 cell proliferation assay and Annexin V-FLUOS apoptosis assay. BAFF and miR-202 mRNA levels were measured by real-time PCR. Meanwhile, BAFF, Bcl-2 family survival proteins and MAPK pathway proteins were measured by Western blot. It was found that miR-202 was functioned as a modulator of BAFF expression. miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex). miR-202 mimics in combination with Bort inhibited MM cell survival more effectively as compared with Bort treatment alone. Our study also provided experimental evidence that JNK/SAPK signaling pathway was involved in the regulatory effect of miR-202 on drug resistance of MM cells. cell line (U266) up-regulated sensitive BAFF NA JNK/SAPK signaling pathway validated 1930 Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells. Pathol Oncol Res 2016 26689580 miRBase MI0003130 miR-202 miRNA DB01041 (APRD01251) Thalidomide multiple myeloma RT-PCR In this study, we characterized the role of miR-202 in multiple myeloma (MM) drug sensitivity. The potential binding site of miR-202 and B cell-activating factor (BAFF) was confirmed by luciferase reporter assay. MM cells were transfected with miR-202 mimics and inhibitor. Cells growth was measured by WST-1 cell proliferation assay and Annexin V-FLUOS apoptosis assay. BAFF and miR-202 mRNA levels were measured by real-time PCR. Meanwhile, BAFF, Bcl-2 family survival proteins and MAPK pathway proteins were measured by Western blot. It was found that miR-202 was functioned as a modulator of BAFF expression. miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex). miR-202 mimics in combination with Bort inhibited MM cell survival more effectively as compared with Bort treatment alone. Our study also provided experimental evidence that JNK/SAPK signaling pathway was involved in the regulatory effect of miR-202 on drug resistance of MM cells. cell line (U266) up-regulated sensitive BAFF NA JNK/SAPK signaling pathway validated 1931 Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells. Pathol Oncol Res 2016 26689580 miRBase MI0003130 miR-202 miRNA DB01234 (APRD00674) Dexamethasone multiple myeloma RT-PCR In this study, we characterized the role of miR-202 in multiple myeloma (MM) drug sensitivity. The potential binding site of miR-202 and B cell-activating factor (BAFF) was confirmed by luciferase reporter assay. MM cells were transfected with miR-202 mimics and inhibitor. Cells growth was measured by WST-1 cell proliferation assay and Annexin V-FLUOS apoptosis assay. BAFF and miR-202 mRNA levels were measured by real-time PCR. Meanwhile, BAFF, Bcl-2 family survival proteins and MAPK pathway proteins were measured by Western blot. It was found that miR-202 was functioned as a modulator of BAFF expression. miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex). miR-202 mimics in combination with Bort inhibited MM cell survival more effectively as compared with Bort treatment alone. Our study also provided experimental evidence that JNK/SAPK signaling pathway was involved in the regulatory effect of miR-202 on drug resistance of MM cells. cell line (U266) up-regulated sensitive BAFF NA JNK/SAPK signaling pathway validated 1932 The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. Curr Mol Med 2016 26695693 miRBase MIMAT0007890 miR-1914* miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 1915. Effects of stable and transient expression of 2 microRNAs in human chemoresistant CRC cell lines were analyzed. Tumor formation and chemoresistance in HCT116/5-Fu/OXA that did or did not express 2 microRNAs were analyzed in mice. Nuclear factor I/X (NFIX) was predicted to target the gene of 2 miRNAs and verified in vivo and in vitro. cell line ( LoVo, SW620, HCT-116, HCT116/5-Fu/OXA ) up-regulated sensitive NFIX NFIX NA validated 1933 The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. Curr Mol Med 2016 26695693 miRBase MIMAT0007890 miR-1914* miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 1915. Effects of stable and transient expression of 2 microRNAs in human chemoresistant CRC cell lines were analyzed. Tumor formation and chemoresistance in HCT116/5-Fu/OXA that did or did not express 2 microRNAs were analyzed in mice. Nuclear factor I/X (NFIX) was predicted to target the gene of 2 miRNAs and verified in vivo and in vitro. cell line ( LoVo, SW620, HCT-116, HCT116/5-Fu/OXA ) up-regulated sensitive NFIX NFIX NA validated 1934 The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. Curr Mol Med 2016 26695693 miRBase MI0008336 miR-1915 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 1915. Effects of stable and transient expression of 2 microRNAs in human chemoresistant CRC cell lines were analyzed. Tumor formation and chemoresistance in HCT116/5-Fu/OXA that did or did not express 2 microRNAs were analyzed in mice. Nuclear factor I/X (NFIX) was predicted to target the gene of 2 miRNAs and verified in vivo and in vitro. cell line (HCT116/5-Fu/OXA) up-regulated sensitive NFIX NFIX NA validated 1935 The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. Curr Mol Med 2016 26695693 miRBase MI0008336 miR-1915 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 1915. Effects of stable and transient expression of 2 microRNAs in human chemoresistant CRC cell lines were analyzed. Tumor formation and chemoresistance in HCT116/5-Fu/OXA that did or did not express 2 microRNAs were analyzed in mice. Nuclear factor I/X (NFIX) was predicted to target the gene of 2 miRNAs and verified in vivo and in vitro. cell line (HCT116/5-Fu/OXA) up-regulated sensitive NFIX NFIX NA validated 1936 Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene 2016 26701615 miRBase MIMAT0009198 miR-224-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The expression levels of miRNA were determined by Real time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( MCF-7,T47D, MCF-7/ADR, T47D/ADR) up-regulated sensitive FUT4 FUT4 NA validated 1937 MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy. Oncol Rep 2016 26708607 miRBase MI0000088 miR-30a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR In this study, our aim was to clarify microRNA (miRNA)-related mechanisms underlying Beclin-1-mediated autophagy followed by chemotherapy in osteosarcoma. First, miRNA screening using qRT-PCR identified that miR-30a was significantly reduced in Dox-resistant osteosarcoma cells. Second, the autophagy activity in Dox-resistant increased while miR-30a expression reduced after chemotherapy agents as indicated by the enhanced expression of Beclin-1, the increased conversion of microtubule-associated protein LC3-I to LC3-II. Furthermore, overexpression of miR-30a significantly promoted chemotherapy-induced apoptosis and reduced autophagy activity responding to chemotherapy. Moreover, rapamycin, an autophagy promoter was able to partly reverse the effect of miR-30a and Luciferase reporter assay identified that miR-30a directly binds to the 3-UTR of Beclin-1 gene, which further confirmed that miR-30a reduced chemoresistance via suppressing Beclin-1-mediated autophagy. cell line ( MG-63,MG-63/Dox) down-regulated resistant Beclin-1 Beclin-1 NA validated 1938 MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1. Mol Med Rep 2016 26718267 miRBase MI0000103/MI0000739 miR-101 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-qPCR Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) analysis of miR-101 and Mcl-1 mRNA expression.Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HepG2, Hep3B, Huh7 and PLC human HCC cell lines and the L-O2 normal liver cell line ) up-regulated sensitive Mcl-1 Mcl-1 NA validated 1939 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene 2016 26743123 miRBase MIMAT0000459 miR-193a-3p miRNA DB01248 (APRD00932) Docetaxel oesophageal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (KYSE150, KYSE410, KYSE450,KYSE510) up-regulated resistant PSEN1 PSEN1 NA validated 1940 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene 2016 26743123 miRBase MIMAT0000459 miR-193a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel oesophageal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (KYSE150, KYSE410, KYSE450,KYSE510) up-regulated resistant PSEN1 PSEN1 NA validated 1941 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene 2016 26743123 miRBase MIMAT0000459 miR-193a-3p miRNA DB00361 (APRD00101) Vinorelbine oesophageal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (KYSE150, KYSE410, KYSE450,KYSE510) up-regulated resistant PSEN1 PSEN1 NA validated 1942 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene 2016 26743123 miRBase MIMAT0000459 miR-193a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil oesophageal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (KYSE150, KYSE410, KYSE450,KYSE510) up-regulated resistant PSEN1 PSEN1 NA validated 1943 MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma. Technol Cancer Res Treat 2016 26744308 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Real-Time Reverse Transcription-Polymerase Chain Reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HOS, U2OS, Saos-2, MG-63,NHOst) up-regulated sensitive Bcl-2 Bcl-2 NA validated 1944 MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget 2016 26744318 miRBase MI0000102 miR-100 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR The expression levels of miRNA were determined by RT-PCR and real-time PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells.Tumor development in nude mice demonstrated the relationship between miR-100 expression and paclitaxel treatment in endoluminal breast cancer. cell line (T-47D, MCF-7, ZR-75-1, BT-549, MDA-MB-231 and Hs578T) up-regulated sensitive mTOR mTOR NA validated 1945 Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol 2016 26753960 miRBase NA miR-193-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The role of miR-193-3p was detected by qRT-PCR, MTT assay, Wound-healing migration assay, chemoresistance assay, tumorigenicity assay, luciferase reporter assay, Western blot assay, and PTEN downregulation assay. cell line (AGS, NIC-N87, SNU-1,SNU5,SNU-16,MKN-45, SGC-7901, BGC-823, MKN-28, GES-1 ) down-regulated sensitive PTEN PTEN NA validated 1946 MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. Acta Biochim Biophys Sin (Shanghai) 2016 26758190 miRBase MI0000469 miR-125a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The role of miR-125a was detected by qRT-PCR, western blot assay, cell proliferation assay, and luciferase reporter assay. tissue and cell line (SW1990, HEK293T) up-regulated resistant A20 NA NA validated 1947 miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. Biochem Biophys Res Commun 2016 26772886 miRBase MI0006275 miR-1182 miRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR In this study, we report that miR-1182 is deregulated in bladder cancer tissues and cell lines. To characterize the role of miR-1182 in bladder cancer cells, we performed functional assays. The overexpression of miR-1182 significantly inhibits bladder cancer cell proliferation, colony formation, and invasion. Moreover, its up-regulation induced cell cycle arrest and apoptosis and mediated chemosensitivity to cisplatin in bladder cancer. Furthermore, a luciferase reporter assay and a rescue experiment indicated that miR-1182 directly targets hTERT by binding its 3UTR. cell line (Hcv29, BIU-87, T24) up-regulated sensitive hTERT NA NA validated 1948 MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells. Tumour Biol 2016 26779627 miRBase MI0000681 miR-155 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR 4,6-Diamidino-2-phenylindole (DAPI) staining and terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) techniques were used to determine the effects of a miR-155 mimic or inhibitor on the apoptotic ratio of ovarian cancer cells induced by cisplatin. Bioinformatic predictions, the dual-luciferase reporter assay, and western blot analysis were used to detect how miR-155 regulates X-linked inhibitor of apoptosis protein (XIAP). We demonstrated that a miR-155 mimic could decrease the IC50 value of cisplatin in SKOV3 ovarian cancer cells. Subsequently, gain- and loss-of-function analyses with a miR-155 mimic and inhibitor showed that miR-155 sensitizes ovarian cancer cells to cisplatin. Furthermore, the results from the luciferase assays and western blot analysis identified XIAP as the direct target of miR-155. In addition, introducing XIAP cDNA without a three prime untranslated region (3-UTR) rescued the miR-155 promotion of apoptosis. cell line (SKOV3, A2780,293T) up-regulated sensitive XIAP XIAP NA validated 1949 miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci Rep 2016 26781643 miRBase MI0000786 miR-378 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma RT-PCR The objectives of the study were to determine the role of miR-378 in the sensitivity of lung adenocarcinoma cells to cisplatin (cDDP) and its working mechanism. With TargetScan and luciferase assay, miR-378 was found to directly target sCLU. miR-378 and sCLU were regulated in A549/cDDP and Anip973/cDDP cells to investigate the effect of miR-378 on the sensitivity and apoptotic effects of cDDP. The effect of miR-378 upregulation on tumor growth was analyzed in a nude mouse xenograft model. The correlation between miR-378 and chemoresistance was tested in patient samples. We found that upregulation of miR-378 in A549/cDDP and Anip973/cDDP cells significantly down-regulated sCLU expression, and sensitized these cells to cDDP. miR-378 overexpression inhibited tumor growth and sCLU expression in a xenograft animal model. Analysis of human lung adenocarcinoma tissues revealed that the cDDP sensitive group expressed higher levels of miR-378 and lower levels of sCLU. miR-378 and sCLU were negatively correlated. cell line ((A549, Anip973, A549/cDDP, Anip973/cDDP) up-regulated sensitive sCLU NA NA validated 1950 miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. Int J Oncol 2016 26783187 miRBase NA miR-200 miRNA DB09079 Nintedanib lung non-small cell carcinoma qRT-PCR The role of miR-125a was detected by MTT assay, Hoechst staining assay, RNA extraction and RT-PCR assay, Western blot, dual luciferase activityassay and animal experiment. cell line (A549, PC-3, PC-9, PC-14, NCI-HCC827, NCI-H1650, NCI-H1975, LC-2/ad, RERF-LC-KJ adeno-carcinoma (AC),PC-1, PC-10, LK-2, SQ5, QG56, EBC-1,SQ) up-regulated sensitive ZEB1 ZEB1 NA validated 1951 MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis. Pharmacogenomics 2016 26786897 miRBase MIMAT0002881 miR-509-3p miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer RT-PCR The regulation of XIAP by miR-509-3p was investigated by luciferase reporter assay, real-time PCR and immunobloting, and the roles of miR-509-3p in cellular proliferation and apoptosis were accessed through MTT and DAPI assays. cell line (HEK-293T, A2780 and, up-regulated sensitive XIAP XIAP the apoptotic pathway validated 1952 Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother 2016 26796263 miRBase MI0000077 miR-21 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Levels of phosphatidylserine on cell surface were quantitatively estimated by using Annexin V-fluorescein isothiocyanate (FITC) and Propidium Iodide (PI) apoptosis detection kit. cell line (MCF-7) down-regulated sensitive PDCD4,PTEN, and Bcl-2 PDCD4,PTEN, and Bcl-2 PI3K-AKT-mTOR pathway validated 1953 Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother 2016 26796263 miRBase MI0000077 miR-21 miRNA DB00947 (APRD00654) Fulvestrant breast cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Levels of phosphatidylserine on cell surface were quantitatively estimated by using Annexin V-fluorescein isothiocyanate (FITC) and Propidium Iodide (PI) apoptosis detection kit. cell line (MCF-7) down-regulated sensitive PDCD4,PTEN, and Bcl-2 PDCD4,PTEN, and Bcl-2 PI3K-AKT-mTOR pathway validated 1954 miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. Oncotarget 2016 26799283 miRBase MI0003132 miR-493 miRNA DB00515 (APRD00359) Cisplatin stomach cancer real-time RT-PCR The expression levels of miRNA were determined by real-time RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTS assay was used to test cell proliferation.Cell migration was detected by transwell migration . cell line (SGC-7901, MKN28, AGS, MGC-803) up-regulated resistant DKK1 DKK1 miR-493/DKK1 signaling pathway validated 1955 miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget 2016 26824186 miRBase MI0000459 miR-143 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer Northern blot The expression levels of miRNA were determined by Northern blot . Cell migration was detected by wound healing assay,transwell migration and invasion assay.Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay (Promega). cell line (HCT116, SW480, SW48) up-regulated sensitive NA NA NA validated 1956 miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget 2016 26824186 miRBase MI0000461 miR-145 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab colon cancer Northern blot The expression levels of miRNA were determined by Northern blot . Cell migration was detected by wound healing assay,transwell migration and invasion assay.Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay (Promega). cell line (HCT116, SW480, SW48) up-regulated sensitive NA NA NA validated 1957 MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett 2016 26828016 miRBase MIMAT0000099 miR-101-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In the study, the established and primary human PDA cell lines PANC-1, AsPC-1, MIA-PaCa2, AsanPaCa, BxPC-3 and three gemcitabine-resistant subclones were examined. A gene expression profiling revealed that the ribonucleotide reductase M1 (RRM1) was upregulated in gemcitabine-resistant cells, which was confirmed by qRT-PCR, Western blot analysis and immunostaining. Inhibition of RRM1 by lipotransfection of siRNA reduced its expression and reversed gemcitabine resistance. The expression of RRM1 correlated to gemcitabine resistance in vitro and was higher in malignant patient pancreas tissue compared to non-malignant pancreas tissue. By microRNA expression profiling, we identified microRNA-101-3p as top-downregulated candidate. Lipotransfection of microRNA-101-3p mimics inhibited the expression of RRM1, reduced the luciferase activity of its 3UTR and sensitized for gemcitabine-induced cytotoxicity. cell line (PANC-1, AsPC-1, MIA-PaCa2, AsanPaCa, BxPC-3) up-regulated sensitive RRM1 RRM1 NA validated 1958 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 2016 26842910 miRBase MI0000738 miR-302a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase reporter assay was performed to examine miRNA binding to the 3-UTR of target genes. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive MEKK1 MEKK1 ERK pathway validated 1959 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 2016 26842910 miRBase MI0000772 miR-302b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase reporter assay was performed to examine miRNA binding to the 3-UTR of target genes. cell line (MCF-7 and MCF-7/ADR) up-regulated sensitive MEKK1 MEKK1 ERK pathway validated 1960 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 2016 26842910 miRBase MI0000773 miR-302c miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase reporter assay was performed to examine miRNA binding to the 3-UTR of target genes. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive MEKK1 MEKK1 ERK pathway validated 1961 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res 2016 26842910 miRBase MI0000774 miR-302d miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase reporter assay was performed to examine miRNA binding to the 3-UTR of target genes. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive MEKK1 MEKK1 ERK pathway validated 1962 miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF. Curr Cancer Drug Targets 2016 26845432 miRBase MI0000454 miR-137 miRNA DB01234 (APRD00674) Dexamethasone multiple myeloma Real Time RT-PCR In this study, the target gene and the potential effect of miR-137 in MM were investigated. . cell line ( RPMI-8266, U226 ) up-regulated sensitive MITF MITF NA validated 1963 miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer. DNA Cell Biol 2016 26845645 miRBase MIMAT0004909 miR-450b-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (SW480, SW620, HT-29,HCT-116, ) down-regulated resistant SOX2 SOX2 NA validated 1964 MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1 Tumour Biol 2016 26850595 miRBase MI0005564 miR-873 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Experiments in a mouse xenograft model confirmed that the relationship between miR-873 and cisplatin in ovarian cancer in vivo cell line ( OVCAR3, A2780) up-regulated sensitive ABCB1 ABCB1 NA validated 1965 MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1 Tumour Biol 2016 26850595 miRBase MI0005564 miR-873 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR The expression levels of miRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Experiments in a mouse xenograft model confirmed that the relationship between miR-873 and cisplatin in ovarian cancer in vivo cell line ( OVCAR3, A2780) up-regulated sensitive ABCB1 ABCB1 NA validated 1966 miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumour Biol 2016 26852750 miRBase MI0000461 miR-145 miRNA DB00515 (APRD00359) Cisplatin gallbladder cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293FT, GBC-SD,SGC996) up-regulated sensitive MRP1 MRP1 NA validated 1967 High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma Exp Hematol 2016 26854484 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma RT-qPCR To identify biomarkers for cytotoxic response assessment, microRNAs (miRNAs) associated with doxorubicin sensitivity were determined by combining global miRNA expression profiling with systematic dose-response screens in 15 human DLBCL cell lines. One candidate, miR-34a, was tested in functional in vitro studies and in vivo in a retrospective clinical cohort. High expression of miR-34a was observed in cell lines sensitive to doxorubicin, and upregulation of miR-34a is documented here to increase doxorubicin sensitivity in in vitro lentiviral transduction assays. High expression of miR-34a had a prognostic impact using overall survival as outcome. With risk stratification of DLBCL samples based on resistance gene signatures (REGS), doxorubicin-responsive samples had statistically significant upregulated miR-34a expression. Classification of the DLBCL samples into subset-specific B cell-associated gene signatures (BAGS) revealed differentiation-specific expression of miR-34a. Our data further support FOXP1 as a target of miR-34a, suggesting that downregulation of FOXP1 may sensitize DLBCL cells to doxorubicin. cell line (DB, MC-116, NU-DHL-1, SU-DHL-4, SUDHL-5,FARAGE, HBL-1, OCI-Ly3,OCI-Ly7, OCI-Ly19, RIVA, SU-DHL-8, and U2932) up-regulated sensitive FOXP1 FOXP1 NA validated 1968 MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med 2016 26864640 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR The role of miR-21 in human pancreatic cells was detected by qRT-PCR,cell proliferation assayss,cell wound-healing assay,cell migration assay,cell invasion assay, and western blotting. cell line (PATU8988, PANC-1, 293TN) up-regulated resistant PTEN and PDCD4 PTEN and PDCD4 NA validated 1969 MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget 2016 26887050 miRBase MI0000476/MI0000455 miR-138 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In the study, we investigated the role of microRNA (miRNA) alterations as mediators of alkylator resistance in glioblastoma cells. Using microarray-based miRNA expression profiling of parental and TMZ-resistant cultures of three human glioma cell lines, we identified a set of differentially expressed miRNA candidates. From these, we selected miR-138 for further functional analyses as this miRNA was not only upregulated in TMZ-resistant versus parental cells, but also showed increased expression in vivo in recurrent glioblastoma tissue samples after TMZ/RT-TMZ treatment. Transient transfection of miR-138 mimics in glioma cells with low basal miR-138 expression increased glioma cell proliferation. Moreover, miR-138 overexpression increased TMZ resistance in long-term glioblastoma cell lines and glioma initiating cell cultures. The apoptosis regulator BIM was identified as a direct target of miR-138, and its silencing mediated the induced TMZ resistance phenotype. Altered sensitivity to apoptosis played only a minor role in this resistance mechanism. Instead, we identified the induction of autophagy to be regulated downstream of the miR-138/BIM axis and to promote cell survival following TMZ exposure. cell line ( LN-18, LN-229, LN-308, LN-319, LN-428, D247MG, A172, U87MG, T98G,LN-18-R, LN-229-R and LN-308-R,ZH-161, ZH-305, T-325, T-269 and S-24 ) up-regulated resistant BIM BIM NA validated 1970 miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int J Oncol 2016 26891588 miRBase NA miR-17-92 miRNA DB00515 (APRD00359) Cisplatin prostate cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL staining was used to detect apoptotic cell death. Ki-67 was used to detect cellular activity. cell line up-regulated resistant NA NA AKT pathway validated 1971 MicroRNA-205 increases the sensitivity of docetaxel in breast cancer. Oncol Lett 2016 26893700 miRBase MI0000285 miR-205 miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-PCR In the present study, The expression levels of miRNA were determined by reverse transcription-polymerase chain reaction (RT-PCR) .The reintroduction of miR-205 is shown to inhibit cell proliferation and clonogenic potential, and increase the sensitivity of MCF-7 and MDA-MB-231 cells to docetaxel. miR-205 also shows a synergistic effect with docetaxel in vivo. cell line ( MDA-MB-231, MCF-7,293T ) up-regulated sensitive NA NA NA validated 1972 Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncol Lett 2016 26893712 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin lung cancer RT-qPCR The expression levels of miRNA were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549,A549/dox) down-regulated sensitive NA NA AKT and ERK pathway validated 1973 Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3Zeta, estrogen receptor alpha, and autophagy. Life Sci 2016 26896688 miRBase MI0001729 miR-451a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR TAM sensitive cells (MCF-7) and resistant cells (LCC2) were employed in the study. The lentivirus vectors of Lv-miR-451a, Lv-miR-451a sponge, and Lv-miR-451a NC were employed to increase or decrease the expression of miR-451a, respectively. SiRNA to 14-3-3Zeta was used to inhibit expression of 14-3-3Zeta. MTT assay was utilized to detect breast cancer cell proliferation. AnnexinV-FITC binding assay was used to detect apoptosis. Expression of ERalpha, 14-3-3Zeta and miR-451a were measured by qRT-PCR and Western blot analysis. Interactions between 14-3-3Zeta and ERa were investigated by co-immunoprecipitation. LC3-II surface expression and intracellular autophagosomes were observed by Western blot and electron microscopy. cell line (MCF-7,LCC2) up-regulated sensitive NA NA NA validated 1974 miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget 2016 26909612 miRBase MI0000488/MI0000732 miR-194 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. Cell migration was detected by transwell migration and invasion assay. tissue and cell line (A549, SPC-A1, 95C, 95D, NCI-H1299, SK-MES-1,16HBE) up-regulated sensitive FOXA1 FOXA1 NA validated 1975 miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol Med 2016 26935807 miRBase MIMAT0001639 miR-409-3p miRNA DB00526 (APRD00186) Oxaliplatin colon cancer RT-qPCR The role of miR-409-3p was detected by RT-qPCR, dual-luciferase reporter assay, Western blot, Cell viability and colony formation assays, Cell viability assay, and tumorigenicity assay. cell line (293,LoVo, HCT 116, DLD-1, SW480, HT-29,RKO,FHC and CCD-18Co) up-regulated sensitive Beclin-1 Beclin-1 NA validated 1976 Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment. Int J Mol Med 2016 26936095 miRBase MI0000238/MI0000279 miR-196a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The aim of this study was to evaluate the effects of miRNA-196a on the sensitivity of NSCLC cells to cisplatin in vitro and in vivo. RT-qPCR was used to detect miRNA-196a expression. Synthesized locked nucleic acid (LNA)-anti-miRNA-196a oligonucleotide was transiently transfected into the SPC-A-1 and A549 lung cancer cells to examine the effects of miRNA-196a on the growth of and colony formation inthe cisplatin-treated cells. The effects of miRNA-196a on the sensitivity of SPC-A-1 cells to cisplatin in vivo were determined using BALB/c nude mice. The expression of miRNA-196a was significantly higher in both the lung cancer tissues and cell lines. The LNA-based knockdown of miRNA-196a significantly inhibited SPC-A-1 and A549 cell growth and induced apoptosis. Moreover, the downregulation of miRNA-196a sensitized the SPC-A-1 and A549 NSCLC cells to cisplatin in vitro and in vivo, by inducing apoptosis. tissue and cell line (A549, SPC-A-1, NCI-H1650, NCI-H1299,SK-MES-1) down-regulated sensitive HOXA5 HOXA5 NA validated 1977 MicroRNA-141 and its associated gene FUS modulate proliferation, migration and cisplatin chemosensitivity in neuroblastoma cell lines. Oncol Rep 2016 26936280 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin neuroblastoma qRT-PCR The role of miR-141 was detected by quantitative real-time PCR, MTT assay, cell cycle assay, Wound healing assay, Cisplatin sensitivity assay, In vivo tumor growth assay, luciferase reporter assay, and FUS downregulation assay. cell line (IMR-32, SH-SY5Y, S-K-NAS,NB-1691, LAN-5, LAN-6) up-regulated sensitive NA NA NA validated 1978 MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep 2016 26936591 miRBase MI0006431 miR-1284 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative reverse transcription real-time polymerase chain reaction and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by invasion assay. A wound healing assay was performed to examine the capacity of cell migration. tissue and cell line (SGC7901/VCR ) up-regulated sensitive EIF4A1 EIF4A1 NA validated 1979 miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. Biochem Biophys Res Commun 2016 26946357 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (Tca8113 ) up-regulated sensitive PIK3CA PIK3CA PIK3CA pathway validated 1980 miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. Drug Des Devel Ther 2016 26966351 miRBase MI0000446/MI0000470 miR-125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin chondrosarcoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (CSPG, OUMS-27, CH-2879, JJ012, CS-1, SW1353,SNM83) down-regulated resistant ErbB2 ErbB2 glucose metabolism pathway validated 1981 MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget 2016 26989074 miRBase MI0000454 miR-137 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by reverse transcription PCR and quantitative real time-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549, A549/PTX, A549/CDDP ) up-regulated sensitive NUCKS1 NUCKS1 PI3K/AKT pathway validated 1982 MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget 2016 26989074 miRBase MI0000454 miR-137 miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR,qRT-PCR The expression levels of miRNA were determined by reverse transcription PCR and quantitative real time-PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549, A549/PTX, A549/CDDP ) up-regulated sensitive NUCKS1 NUCKS1 PI3K/AKT pathway validated 1983 MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget 2016 26993770 miRBase MI0000070/MI0000115 miR-16 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (MDA-MB-231, MCF-7 ) up-regulated sensitive IKBKB IKBKB NF-kappaB pathway validated 1984 MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget 2016 27013583 miRBase MI0001446 miR-424 miRNA NA TRAIL therapy acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (HL-60, HL-60/ADM, K562, K562/A02, NB4 ) up-regulated sensitive PLAG1 PLAG1 apoptotic pathway validated 1985 MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget 2016 27013583 miRBase MI0000085 miR-27a miRNA NA TRAIL therapy acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (HL-60, HL-60/ADM, K562, K562/A02, NB4 ) up-regulated sensitive PLAG1 PLAG1 apoptotic pathway validated 1986 miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget 2016 27014910 miRBase MI0000490 miR-206 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The aims of this study were to explore the potential role of miR-206 in governing cisplatin resistance and EMT in lung cancer cells.The expression levels of miRNA were determined by Quantitative real-time PCR analysis and those of protein were by Western blot analysis. luciferase activity assay was used to verify the target genes of miRNAs. cell line (A549, H1299 and A549/DDP) down-regulated resistant MET MET PI3K/AKT /mTOR signaling pathway validated 1987 miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget 2016 27014910 miRBase MI0000490 miR-206 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. Finally, the effect of mir-206 on cisplatin sensitivity was verified in a mouse model cell line (A549, H1299, A549/DDP, H1299/DDP) up-regulated sensitive MET MET PI3K/AKT /mTOR signaling pathway validated 1988 MicroRNA-421 regulated by HIF-1alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget 2016 27016414 miRBase MI0003685 miR-421 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. Cell migration was detected by transwell migration and invasion assay. cell line (AGS, SGC-7901, NCI-N87, HGC-27, HEK293T ) up-regulated resistant E-cadherin and caspase-3 E-cadherin and caspase-3 NA validated 1989 MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. PLoS One 2016 27019355 miRBase MI0000476/MI0000455 miR-138 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.Cell migration was detected by invasion assay. tissue and cell line (NHOst, hFOB1.19,HOS, Saos-2, MG-63, U2OS) up-regulated sensitive EZH2 EZH2 NA validated 1990 Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 2016 27021436 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR In the study, using next-generation sequencing technology, we identify significantly higher levels of microRNA-21 (miR21) isomiRNAs in exosomes and tissue lysates isolated from cancer-associated adipocytes (CAAs) and fibroblasts (CAFs) than in those from ovarian cancer cells. Functional studies reveal that miR21 is transferred from CAAs or CAFs to the cancer cells, where it suppresses ovarian cancer apoptosis and confers chemoresistance by binding to its direct novel target, APAF1. These data suggest that the malignant phenotype of metastatic ovarian cancer cells can be altered by miR21 delivered by exosomes derived from neighbouring stromal cells in the omental tumour microenvironment, and that inhibiting the transfer of stromal-derived miR21 is an alternative modality in the treatment of metastatic and recurrent ovarian cancer. tissue and cell line (A2780,ALST,OVCA432, OVCA433,OVCAR5,HeyA8, HeyA8-MDR, SKOV3ip, SKOV3-TR ) up-regulated resistant APAF1 APAF1 NA validated 1991 Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 2016 27034004 miRBase MI0000077 miR-21 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR In the study,to investigate which lncRNAs contribute to trastuzumab resistance, we screened a microarray of lncRNAs involved in the malignant phenotype of trastuzumab-resistant SKBR-3/Tr cells. The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SKBR-3) up-regulated resistant NA NA mTOR signaling pathway validated 1992 MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3Beta/Beta-Catenin Signaling Pathway. PLoS One 2016 27045586 miRBase MI0016046 miR-3646 miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-qPCR The role of miR-3646 was detected by RT-qPCR, Cell transfection and survival analysis, Flow cytometric analysis, Immunofluorescence analysis, and western blot analysis,. cell line (MDA-MB-231, MCF-7,MDA-MB-231/Doc, MCF-7/Doc MDA-MB-231/S, MCF-7/S,) up-regulated resistant GSK-3Beta NA GSK-3Beta/Beta-Catenin Signaling Pathway validated 1993 LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 2016 27046651 miRBase MIMAT0000265 miR-204-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by qRT-PCR and Northern blotting. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. RIP assay was used to determines target information cell line (HEK-293T, HCT8, HCT116, HT29, LoVo, SW480) down-regulated resistant CREB1 CREB1 NA validated 1994 MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. Eur Rev Med Pharmacol Sci 2016 27049260 miRBase MI0000476/MI0000455 miR-138 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung non-small cell carcinoma RT-PCR Cell proliferation was determined by MTT assay. Real-time PCR and western blot were performed to detect the mRNA and protein expression levels. The target of miR-138 was validated by luciferase activity assay. cell line (A549,NCI-H23,A549/adriamycin, NCI-H23/ADM ) up-regulated sensitive ZEB2 ZEB2 NA validated 1995 MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget 2016 27049921 miRBase MI0003166 miR-520g miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer qRT-PCR In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions. In vivo, overexpression or downregulation of miR-520g respectively generated larger or smaller subcutaneous xenografts in nude mice. Death-associated protein kinase 2 (DAPK2) was a direct target of miR-520g. In 116 EOC tissue samples, miR-520g expression was significantly lower following DAPK2 overexpression. DAPK2 overexpression or miR-520g knockdown reduced EOC cell proliferation, invasion, wound healing and chemoresistance. tissue and cell line (A2780, SKOV3, OVA433, ES-2, OV2008, CaOV-3, MCAS, OVK18) up-regulated resistant DAPK2 DAPK2 MAPK and AKT pathway validated 1996 MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget 2016 27049921 miRBase MI0003166 miR-520g miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel epithelial ovarian cancer qRT-PCR In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions. In vivo, overexpression or downregulation of miR-520g respectively generated larger or smaller subcutaneous xenografts in nude mice. Death-associated protein kinase 2 (DAPK2) was a direct target of miR-520g. In 116 EOC tissue samples, miR-520g expression was significantly lower following DAPK2 overexpression. DAPK2 overexpression or miR-520g knockdown reduced EOC cell proliferation, invasion, wound healing and chemoresistance. tissue and cell line (A2780, SKOV3, OVA433, ES-2, OV2008, CaOV-3, MCAS, OVK18) up-regulated resistant DAPK2 DAPK2 MAPK and AKT pathway validated 1997 MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin alpha5. Oncotarget 2016 27050274 miRBase MI0000089 miR-31 miRNA DB00305 (APRD00284) Mitomycin C bladder urothelial carcinoma qRT-PCR The expression level of the miRNA was determined by quantitative real-time PCR (qRT-PCR), and the expression level of the protein was determined by Western blot analysis. Luciferase activity assays were used to validate target genes for miRNAs. MTT assays are used to test for drug-resistant phenotypic changes in cancer cells by over-regulation of miRNAs. and so on tissue and cell line (T24, 5637) up-regulated sensitive ITGA5 ITGA5 AKT and ERK pathway validated 1998 MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer. J Mol Med (Berl) 2016 27055844 miRBase MI0000077 miR-21 miRNA NA Pingyangmycin tongue cancer RT-PCR The expression levels of miRNAs and mRNAs were determined by Real-time PCR. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( SCC-25, CAL-27) up-regulated resistant CADM1 CADM1 NA validated 1999 MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer. J Mol Med (Berl) 2016 27055844 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin tongue cancer RT-PCR The expression levels of miRNAs and mRNAs were determined by Real-time PCR. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( SCC-25, CAL-27) up-regulated resistant CADM1 CADM1 NA validated 2000 MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget 2016 27056900 miRBase MIMAT0000255 miR-34a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR From a RNA-seq-based miR-omic analysis of the G-292, MG63.2 and SJSA-1 cell lines, we found that more than twenty miRNAs were differentially expressed by more than two-fold. Among them, miR-34a-5p was one of the most differentially expressed miRNAs in these cells. The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability assay was used to monitor the growth of the cells cell line (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, MNNG/HOS) up-regulated resistant CD117 CD117 MEF2 signaling pathway validated 2001 MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget 2016 27056900 miRBase MIMAT0000255 miR-34a-5p miRNA DB00773 (APRD00239) Etoposide osteosarcoma qRT-PCR From a RNA-seq-based miR-omic analysis of the G-292, MG63.2 and SJSA-1 cell lines, we found that more than twenty miRNAs were differentially expressed by more than two-fold. Among them, miR-34a-5p was one of the most differentially expressed miRNAs in these cells. The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability assay was used to monitor the growth of the cells cell line (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, MNNG/HOS) up-regulated resistant CD117 CD117 MEF2 signaling pathway validated 2002 MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget 2016 27056900 miRBase MIMAT0000255 miR-34a-5p miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR From a RNA-seq-based miR-omic analysis of the G-292, MG63.2 and SJSA-1 cell lines, we found that more than twenty miRNAs were differentially expressed by more than two-fold. Among them, miR-34a-5p was one of the most differentially expressed miRNAs in these cells. The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability assay was used to monitor the growth of the cells cell line (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, MNNG/HOS) up-regulated resistant CD117 CD117 MEF2 signaling pathway validated 2003 MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget 2016 27056900 miRBase MIMAT0000255 miR-34a-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR From a RNA-seq-based miR-omic analysis of the G-292, MG63.2 and SJSA-1 cell lines, we found that more than twenty miRNAs were differentially expressed by more than two-fold. Among them, miR-34a-5p was one of the most differentially expressed miRNAs in these cells. The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability assay was used to monitor the growth of the cells cell line (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, MNNG/HOS) up-regulated resistant CD117 CD117 MEF2 signaling pathway validated 2004 MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget 2016 27056900 miRBase MIMAT0000255 miR-34a-5p miRNA DB00958 (APRD00466) Carboplatin osteosarcoma qRT-PCR From a RNA-seq-based miR-omic analysis of the G-292, MG63.2 and SJSA-1 cell lines, we found that more than twenty miRNAs were differentially expressed by more than two-fold. Among them, miR-34a-5p was one of the most differentially expressed miRNAs in these cells. The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability assay was used to monitor the growth of the cells cell line (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, MNNG/HOS) up-regulated resistant CD117 CD117 MEF2 signaling pathway validated 2005 Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomark 2016 27062696 miRBase MI0001729 miR-451 miRNA DB00445 (APRD00361) Epirubicin breast cancer qRT-PCR Eighty-two BC patients who underwent NACT were recruited in our study, including 41 NACT-sensitive patients (NACT-sensitive group) and 41 NACT-resistant patients (NACT-resistant group). Additionally, 60 healthy subjects were selected as normal controls. Epirubicin-resistant MCF-7 BC cell line (MCF-7/EPI) and docetaxel-resistant MCF-7 BC cell line (MCF-7/DOC) were cultured in our study. MTT assay was applied to calculate the survival rates of MCF-7 cells, MCF-7/DOC cells and MCF-7/EPI cells. The expression levels of miR-451 in normal controls, NACT-sensitive group, NACT-resistant group, MCF-7 cells, MCF-7/DOC cells and MCF-7/EPI cells were measured by qRT-PCR method. cell line (MCF-7,MCF-7/EPI,MCF-7/DOC) down-regulated resistant NA NA NA validated 2006 Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomark 2016 27062696 miRBase MI0001729 miR-451 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR Eighty-two BC patients who underwent NACT were recruited in our study, including 41 NACT-sensitive patients (NACT-sensitive group) and 41 NACT-resistant patients (NACT-resistant group). Additionally, 60 healthy subjects were selected as normal controls. Epirubicin-resistant MCF-7 BC cell line (MCF-7/EPI) and docetaxel-resistant MCF-7 BC cell line (MCF-7/DOC) were cultured in our study. MTT assay was applied to calculate the survival rates of MCF-7 cells, MCF-7/DOC cells and MCF-7/EPI cells. The expression levels of miR-451 in normal controls, NACT-sensitive group, NACT-resistant group, MCF-7 cells, MCF-7/DOC cells and MCF-7/EPI cells were measured by qRT-PCR method. cell line (MCF-7,MCF-7/EPI,MCF-7/DOC) down-regulated resistant NA NA NA validated 2007 Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance Sichuan Da Xue Xue Bao Yi Xue Ban 2016 27062783 miRBase MI0000448 miR-130a miRNA DB12257 Platinum epithelial ovarian cancer RT-PCR 32 patients with platinum resistance and 30 patients without platinum resistance were recruited in this study. Real-time PCR was performed to detect the expression of miR-130a in the serum samples of the patients. ELISA was used to measure the expression level of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and B-cell lymphoma-2 (BCL-2). tissue and cell line up-regulated resistant PTEN PTEN PI3K/AKT signaling pathway validated 2008 Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget 2016 27092874 miRBase MI0005543 miR-708 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin kidney cancer RT-PCR,Real-time quantitative RT-PCR The expression levels of miRNA were determined by RT-PCR and Real-time quantitative RT-PCR .Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. tissue and cell line up-regulated sensitive c-FLIP NA NA validated 2009 miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun 2016 27095304 miRBase MI0014232 miR-3188 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil nasopharyngeal carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.We evaluated the in vivo anti-tumour efficacy of 5-FU in mice bearing tumours . tissue and cell line (5-8F, 6-10B, CNE1, CNE2, C666-1, HONE1, HNE1, SUNE1, HEK293T) up-regulated sensitive mTOR mTOR p-PI3K/p-AKT/p-mTOR pathway validated 2010 Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. Autophagy 2016 27097054 miRBase MIMAT0000686 miR-34c-5p miRNA DB11616 Pirarubicin cervical cancer qRT-PCR The expression levels of miRNA were determined by Quantitative PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.We detected the effect of THP on the growth of cervical cancer xenograft in nude mice. cell line (C33A) up-regulated sensitive NA NA MIR34C-5p-ATG4B-autophagy pathway validated 2011 miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated Autophagy. DNA Cell Biol 2016 27097129 miRBase MIMAT0026614 miR-487b-5p miRNA DB00853 (APRD00557) Temozolomide lung cancer RT-PCR We investigated miRNA-487b-5p (miR-487b-5p) was highly expressed in A549 and H1299 cells which acquired TMZ resistance. Suppression of miR487b-5p had overt effects on cellular proliferation and migration in the presence of TMZ. On the other hand, knockdown of miR-487b-5p resulted in increased survival and moderate tumor growth in vivo. In addition, the decreased cellular proliferation following miR-487b-5p suppression was linked to enhanced autophagy, evident by drastically increased levels of LC3-II, BECLIN1, and LAMP2 when miR-487b-5p was knocked down. Further analysis revealed that LAMP2 might be the target gene of miR-487b-5p. cell line (A549, H1299) up-regulated resistant LAMP2 LAMP2 NA validated 2012 miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression. Int J Mol Med 2016 27121102 miRBase MI0000450/MI0000451 miR-133a miRNA DB00515 (APRD00359) Cisplatin cancer RT-qPCR In the present study, we treated Hep-2 cells and in-house-developed vincristine-resistant Hep-2v cells with 50, 100, or 200 -M cisplatin and assessed cell viability after 24 or 48 h. Hep-2v cells were shown to be resistant to 50-200 -M cisplatin. Furthermore, using immunofluorescence staining and western blot analysis, we noted that ATP7B, but not copper-transporting ATPase 1 (ATP7A), expression was significantly increased in Hep-2v cells, and this increase was maintained at a higher level compared with Hep-2 cells. As ATP7B is a target of microRNA 133a (miR-133a), the ability of miR-133a to influence cisplatin sensitivity in Hep-2v cells was then assessed by CCK-8 assay. We noted that miR-133a expression was lower in both Hep-2 and Hep-2v cells compared with epithelial NP69 cells. Following treatment with 50 -M cisplatin, in Hep-2v cells expressing exogenous miR-133a we noted reduced ATP7B expression, and these cells had a significantly lower survival rate compared with the control. The present study demonstrates that miR-133a enhances the sensitivity of multidrug-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression. cell line (Hep-2, NP69) up-regulated sensitive ATP7B ATP7B NA validated 2013 miR-146a Inhibits Proliferation and Enhances Chemosensitivity in Epithelial Ovarian Cancer via Reduction of SOD2. Oncol Res 2016 27131313 miRBase MI0000477 miR-146a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel epithelial ovarian cancer RT-PCR The expression levels of miRNA were determined by Real-Time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.The CCK-8 assay was used to monitor the growth of the cells.TUNEL staining was used to detect apoptotic cell death. cell line ( OVCAR3, CAOV3, HEY) up-regulated sensitive SOD2 SOD2 miR-146a/SOD2/ROS pathway validated 2014 MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism. PLoS One 2016 27138141 miRBase MI0000442 miR-122 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (L-02,Huh7, Hep3B, HepG2, PLC,Huh7/R) up-regulated sensitive PKM2 PKM2 miR-122-PKM2 pathway validated 2015 miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016 27147225 miRBase MI0001446 miR-424 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The production of T-cell cytokines was detected with a cytokine ELISA using the human or mouse ELISA kit.A normalized mRNA expression data set for ovarian cancer was downloaded from the cBioPortal for cancer genomics and used to evaluate PFS and PD-L1, CD80, PD-1, CTLA-4 and miR-424(322) transcript levels. tissue and cell line (OVCAR-3, Skov3 and Skov3) up-regulated sensitive PD-L1 and CD80 PD-L1 and CD80 PD-L1/PD-1 signalling pathway validated 2016 miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016 27147225 miRBase NA miR-322 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The production of T-cell cytokines was detected with a cytokine ELISA using the human or mouse ELISA kit.A normalized mRNA expression data set for ovarian cancer was downloaded from the cBioPortal for cancer genomics and used to evaluate PFS and PD-L1, CD80, PD-1, CTLA-4 and miR-424(322) transcript levels. tissue and cell line (OVCAR-3, Skov3 and Skov3) up-regulated sensitive PD-L1 and CD80 PD-L1 and CD80 PD-L1/PD-1 signalling pathway validated 2017 Expression of miR-34a in Bone Marrow of Adult Acute Lymphoblastic Leukemia and Its Significance in Cell Drug Resistance Zhongguo Shi Yan Xue Ye Xue Za Zhi 2016 27150988 miRBase MI0000268 miR-34a miRNA DB04690 Camptothecin acute lymphocytic leukemia qRT-PCR Forty-seven cases of newly diagnosed adult ALL were selected and their bone marrow samples were taken at the time of newly diagnosed and relapsed or complete remission; 26 pairs of specimens were in newly diagnosed-complete remission group, and 21 pairs of specimens were in newly diagnosed-relapse group. The expressions of miR-34a in bone marrow samples, CCRF-CEM cells and resistant CEM-C1 cell strains were detected by real-time quantitative PCR. The expression of miR-34a in CCRF-CEM cells was inhibited and was increased in CEM-C1 cells detected by electroporation transfection method. All the cells were incubated at different concentration of camptothecin. The cell survival was analyzed by CCK-8 method, the cell proliferation inhibition rate (%) and resistance index (RI) were calculated. cell line ( CEM-C1,CCRF-CEM ) down-regulated resistant NA NA NA validated 2018 miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget 2016 27167197 miRBase MI0000764 miR-363 miRNA DB01248 (APRD00932) Docetaxel stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HGC-27, MGC-803, SGC-7901, BGC-823) up-regulated resistant FBW7 FBW7 NA validated 2019 miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget 2016 27167197 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HGC-27, MGC-803, SGC-7901, BGC-823) up-regulated resistant FBW7 FBW7 NA validated 2020 miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget 2016 27167197 miRBase MI0000764 miR-363 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HGC-27, MGC-803, SGC-7901, BGC-823) up-regulated resistant FBW7 FBW7 NA validated 2021 Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol 2016 27171498 miRBase MI0003124 miR-489 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR In this study, we describe that 16 miRNAs were found to be significantly down-regulated and 11 up-regulated in drug-resistant breast cancer tissues compared with drug-sensitive tissues, using a miRNA microarray. The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (MCF-7, MDA-MB-231,MDA-MB-468, T47D and MCF-7/ADM) up-regulated sensitive SPIN1, VAV3, BCL2 and AKT3 SPIN1, VAV3, BCL2 and AKT3 PI3K-Akt signalling pathway validated 2022 miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. Pathol Res Pract 2016 27173050 miRBase MIMAT0000250 miR-139-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer real-time qRT-PCR The expression levels of miRNA were determined by real-time qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HCT-116, LoVo, HCT-8,HCT-116/5-FU, HCT-8/5-FU) up-regulated sensitive NOTCH-1 NOTCH-1 miR-139-5p/NOTCH-1 pathway validated 2023 miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med 2016 27177336 miRBase MI0000300 miR-223 miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma RT-qPCR The role of miR-223 was detected by RT-qPCR, CCK-8,Western blot, apoptosis analysis, In vivo experiments cell line ( PC-9 ) up-regulated sensitive IGF-1R NA IGF-1R/Akt/S6 signaling pathway validated 2024 miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res 2016 27186308 miRBase MIMAT0004679 miRNA-296-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil lung cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549, H157, NIH-H358, Calu-3, LAX, HCC827, LTEP-2, D6, SPCA1,BEAS-2B) up-regulated sensitive CX3CR1 CX3CR1 NA validated 2025 miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res 2016 27186308 miRBase MIMAT0004679 miRNA-296-3p miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549, H157, NIH-H358, Calu-3, LAX, HCC827, LTEP-2, D6, SPCA1,BEAS-2B) up-regulated sensitive CX3CR1 CX3CR1 NA validated 2026 miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res 2016 27186308 miRBase MIMAT0004679 miRNA-296-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (A549, H157, NIH-H358, Calu-3, LAX, HCC827, LTEP-2, D6, SPCA1,BEAS-2B) up-regulated sensitive CX3CR1 CX3CR1 NA validated 2027 MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci 2016 27212164 miRBase MI0000088 miR-30a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR 20 advanced gastric cancer patients who received platinum-based chemotherapy were recruited. Chemosensitivity was assessed after completion of the therapy. MiR-30a expression was quantified and compared between chemosensitive and chemoresistant groups. SGC-7901 cells and SGC-7901/DDP cells were further used for the in-vitro gain-and-loss study to investigate the effect of miR-30a on EMT and cisplatin sensitivity. cell line ( SGC-7901, SGC-7901/DDP ) up-regulated sensitive NA NA NA validated 2028 MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein. Oncol Rep 2016 27221209 miRBase MI0005532 miR-874 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The role of miR-874 was detected by RT-qPCR, MTT assay, Luciferase assays, Western blotting, Tumor xenograft treatment model,ect. cell line ( LoVo, SW1116, SW480, HCT-116,NCM460 ) up-regulated sensitive XIAP XIAP NA validated 2029 MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor. Mol Med Rep 2016 27221512 miRBase MI0000440 miR-27b miRNA DB01248 (APRD00932) Docetaxel lung non-small cell carcinoma RT-qPCR The role of miR-27b was detected by RT-qPCR, Western blot, dual luciferase reporter assay, MTT assay, and flow cytometry. tissue and cell line ( A549 ) up-regulated resistant EGFR EGFR EGFR pathway validated 2030 MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1. Med Sci Monit 2016 27222034 miRBase MI0000481 miR-184 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR qRT-PCR was used to analyze the expression level of miR-184 in OS cell line U-2 OS and MG-63 treated with doxorubicin. MiR-184 agomir or miR-184 antagomir was transferred into cells to regulated miR-184. The target of miR-184 was predicted by TargetScan and confirmed by luciferase reporter assay. Bcl-2-like protein 1 (BCL2L1) expression was detected by Western blot. Cell apoptosis was determined by Annexin V staining and analysis by flow cytometry. cell line (U-2 OS, MG-63) up-regulated resistant BCL2L11 BCL2L11 NA validated 2031 MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med 2016 27222381 miRBase MI0000301 miR-224 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells tissue and cell line (MG-63, U2OS, SOSP-9607 and SAOS-2) up-regulated sensitive Rac1 Rac1 NA validated 2032 MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells. PLoS One 2016 27228340 miRBase MI0003815 miR-1301 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR In this report, using shRNA to downregulate RanGAP1 expression level augmented K562 cell apoptosis by approximately 40% after treatment with 250 nM IM. Immunofluorescence assay also indicated that three-fold of nuclear BCR-ABL was detected. These data suggest that BCR-ABL nuclear entrapment induced by RanGAP1 downregulation can be used to improve IM efficacy. Moreover, our qRT-PCR data indicated a trend of inverse correlation between the RanGAP1 and microRNA (miR)-1301 levels in CML patients. MiR-1301, targeting the RanGAP1 3 untranslated region, decreased by approximately 100-fold in K562 cells compared with that in normal cells. RanGAP1 downregulation by miR-1301 transfection impairs BCR-ABL nuclear export to increase approximately 60% of cell death after treatment of 250 nM IM. This result was almost the same as treatment with 1000 nM IM alone. Furthermore, immunofluorescence assay demonstrated that Tyr-99 of nuclear P73 was phosphorylated accompanied with nuclear entrapment of BCR-ABL after transfection with RanGAP1 shRNA or miR-1301 in IM-treated K562 cells. cell line (K562, KU812,HEK293) up-regulated sensitive RanGAP1 RanGAP1 NA validated 2033 Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells. Cancer Gene Ther 2016 27229158 miRBase MI0005566 miR-374b miRNA DB00515 (APRD00359) Cisplatin pancreatic cancer NA To evaluate the potential contribution of miRNAs in acquired resistance to cisplatin in pancreatic cancer, we compared levels of more than 2000 human miRNAs in a cisplatin-resistant cell line (BxPC3-R) derived from parental (BxPC3) cells by step-wise exposure to increasing concentrations of the drug over more than 20 passages. The acquired drug resistance was accompanied by significant changes in the expression of 57 miRNAs, of which 23 were downregulated and 34 were upregulated. Employing a hidden Markov model (HMM) algorithm, we identified downregulation of miR-374b as likely being directly involved in acquisition of the drug-resistant phenotype. Consistent with this prediction, ectopic overexpression of miR-374b in the resistant BxPC3-R cells restored cisplatin sensitivity to levels approaching those displayed by the BxPC3 parental cells. cell line (BxPC3-R,BxPC3) down-regulated resistant NA NA NA validated 2034 Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget 2016 27229528 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell migration was detected by transwell migration and invasion assay. tissue and cell line ( HBE,A549, NCI-520, NCI-460, NCI-H596 ) up-regulated sensitive ROCK2 ROCK2 NA validated 2035 Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). Tumour Biol 2016 27236538 miRBase MI0000283 miR-203 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel colorectal cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( CCD-18Co, CCD-33Co, LoVo, CaCo2,T-84, SW480, DLD-1,NCIN87,SKBR3, LNCaP, SK-MEL-30, SW-1271, SKOV3 ) up-regulated sensitive SIK2 SIK2 NA validated 2036 miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. Sci Rep 2016 27244080 miRBase MIMAT0000250 miR-139-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, miRNA microarray analysis was performed to screen crucial miRNAs involved in CRC progress, and miR-139-5p was chosen for further study. The functional roles of miR-139-5p in colon cancer were demonstrated by CCK-8 proliferation assay, cell invasion and migration, cell apoptosis and in a KO mouse study. miR-139-5p expression was significantly decreased in cancer tissues compared to normal tissues. The miR-139-5p expression level was associated with tumour stage (P-<-0.01). Function studies revealed that miR-139-5p was significantly correlated with the metastasis potential and drug resistance of colon cancer cells by affecting the epithelial-mesenchymal transition (EMT). Then, we identified BCL2 as a direct target of miR-139-5p cells in vitro. The patient samples and KO mice model showed that BCL2 expression was inversely correlated with the expression of miR-139-5p. cell line (HT-29, HCT116, SW480, SW620, RKO, COLO205, Ls174T and LoVo ) up-regulated sensitive BCL2 BCL2 BCL2 pathway validated 2037 miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. Sci Rep 2016 27244080 miRBase MIMAT0000250 miR-139-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR In this study, miRNA microarray analysis was performed to screen crucial miRNAs involved in CRC progress, and miR-139-5p was chosen for further study. The functional roles of miR-139-5p in colon cancer were demonstrated by CCK-8 proliferation assay, cell invasion and migration, cell apoptosis and in a KO mouse study. miR-139-5p expression was significantly decreased in cancer tissues compared to normal tissues. The miR-139-5p expression level was associated with tumour stage (P-<-0.01). Function studies revealed that miR-139-5p was significantly correlated with the metastasis potential and drug resistance of colon cancer cells by affecting the epithelial-mesenchymal transition (EMT). Then, we identified BCL2 as a direct target of miR-139-5p cells in vitro. The patient samples and KO mice model showed that BCL2 expression was inversely correlated with the expression of miR-139-5p. cell line (HT-29, HCT116, SW480, SW620, RKO, COLO205, Ls174T and LoVo ) up-regulated sensitive BCL2 BCL2 BCL2 pathway validated 2038 Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci 2016 27247490 miRBase MI0014193 miR-3163 miRNA DB00515 (APRD00359) Cisplatin retinoblastoma cancer RT-PCR To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line was successfully established based on the high expression level of ABCG2 on the surface of RCSCs. To further explore the molecular mechanism of ABCG2 on RCSCs, a microRNA that specifically targets ABCG2 was predicted. Subsequently, miR-3163 was selected and confirmed as the ABCG2-regulating microRNA. Overexpression of miR-3163 led to a significant decrease in ABCG2 expression. Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells. Our data suggest that miR-3163 has a significant impact on ABCG2 expression and can influence proliferation, apoptosis, and drug resistance in RCSCs. cell line (WERI-Rb1 ) up-regulated sensitive ABCG2 ABCG2 NA validated 2039 Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci 2016 27247490 miRBase MI0014193 miR-3163 miRNA DB00958 (APRD00466) Carboplatin retinoblastoma cancer RT-PCR To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line was successfully established based on the high expression level of ABCG2 on the surface of RCSCs. To further explore the molecular mechanism of ABCG2 on RCSCs, a microRNA that specifically targets ABCG2 was predicted. Subsequently, miR-3163 was selected and confirmed as the ABCG2-regulating microRNA. Overexpression of miR-3163 led to a significant decrease in ABCG2 expression. Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells. Our data suggest that miR-3163 has a significant impact on ABCG2 expression and can influence proliferation, apoptosis, and drug resistance in RCSCs. cell line (WERI-Rb1 ) up-regulated sensitive ABCG2 ABCG2 NA validated 2040 Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci 2016 27247490 miRBase MI0014193 miR-3163 miRNA DB00541 (APRD00495) Vincristine retinoblastoma cancer RT-PCR To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line was successfully established based on the high expression level of ABCG2 on the surface of RCSCs. To further explore the molecular mechanism of ABCG2 on RCSCs, a microRNA that specifically targets ABCG2 was predicted. Subsequently, miR-3163 was selected and confirmed as the ABCG2-regulating microRNA. Overexpression of miR-3163 led to a significant decrease in ABCG2 expression. Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells. Our data suggest that miR-3163 has a significant impact on ABCG2 expression and can influence proliferation, apoptosis, and drug resistance in RCSCs. cell line (WERI-Rb1 ) up-regulated sensitive ABCG2 ABCG2 NA validated 2041 Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci 2016 27247490 miRBase MI0014193 miR-3163 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin retinoblastoma cancer RT-PCR To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line was successfully established based on the high expression level of ABCG2 on the surface of RCSCs. To further explore the molecular mechanism of ABCG2 on RCSCs, a microRNA that specifically targets ABCG2 was predicted. Subsequently, miR-3163 was selected and confirmed as the ABCG2-regulating microRNA. Overexpression of miR-3163 led to a significant decrease in ABCG2 expression. Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells. Our data suggest that miR-3163 has a significant impact on ABCG2 expression and can influence proliferation, apoptosis, and drug resistance in RCSCs. cell line (WERI-Rb1 ) up-regulated sensitive ABCG2 ABCG2 NA validated 2042 Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. J Korean Med Sci 2016 27247490 miRBase MI0014193 miR-3163 miRNA DB00773 (APRD00239) Etoposide retinoblastoma cancer RT-PCR To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line was successfully established based on the high expression level of ABCG2 on the surface of RCSCs. To further explore the molecular mechanism of ABCG2 on RCSCs, a microRNA that specifically targets ABCG2 was predicted. Subsequently, miR-3163 was selected and confirmed as the ABCG2-regulating microRNA. Overexpression of miR-3163 led to a significant decrease in ABCG2 expression. Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells. Our data suggest that miR-3163 has a significant impact on ABCG2 expression and can influence proliferation, apoptosis, and drug resistance in RCSCs. cell line (WERI-Rb1 ) up-regulated sensitive ABCG2 ABCG2 NA validated 2043 MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci 2016 27249598 miRBase MI0000289/MI0000269 miR-181a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression profile of miR-181a in normal and ovarian cancer tissues was firstly quantified using qRT-PCR analysis. Then, human ovarian cancer cell line SKOV3 were transfected for miR-181a overexpression and the paclitaxel-resistant variant SKOV3/PTX cells were transfected for miR-181a knockdown. The effect of miR-181a overexpression/knockdown on EMT and PTX sensitivity were studied. cell line (SKOV3,SKOV3/PTX) up-regulated resistant NA NA NA validated 2044 MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1alpha feedback loop. Eur Rev Med Pharmacol Sci 2016 27249600 miRBase MI0000273 miR-183 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular cancer qRT-PCR The association between miR-183 and HIF-1alpha in HCC cell line BEL-7402 and the multidrug-resistant variant BEL-7402/5-fluorouracil (BEL-7402/5-FU) were studied using qRT-PCR and Western blot analysis. The mediators involved in feedback regulation between miR-183 and HIF-1alpha were further studied. Then, the effect of the miR-183-SOCS6 axis on IC50 of BEL-7402/5-FU cells to 5-FU were investigated by MTT assay. cell line (BEL-7402,BEL-7402/5-FU ) down-regulated sensitive SOCS6 SOCS6 NA validated 2045 Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma. Mol Med 2016 27254108 miRBase MI0000274 miR-187 miRNA DB00515 (APRD00359) Cisplatin esophageal adenocarcinoma qPCR In this study, we performed global miRNA profiling of EAC patient tumors to identify miRNAs that may be involved in tumor resistance to neoadjuvant CRT. We identified miR-187 as a potential novel biomarker of treatment response and a potential therapeutic target that could enhance patient sensitivity to radiotherapy and chemotherapy. cell line (OE33 P, OE33 R ,OE33, SK-GT-4) up-regulated sensitive NA NA NA validated 2046 The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain Zhonghua Yi Xue Za Zhi 2016 27266356 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to determine the mRNA level of miR-21 both in the chemo-sensitivity cell strain A549 and the chemo-resistance cell strain A549/DDP (primary A549/DDP cells). The miR-21 interference sequence was synthesized and transfected into A549/DDP cells by liposome as the carrier. The miR-21 expression level was knocked down and the change of chemo-sensitivity of cells was detected. Effects of miR-21 on the cell apoptosis and cell cycle in miR-21-depleted A549/DDP cells were analyzed by flow cytometry to elucidate the involvement of miR-21 in MDR reversal in NSCLC. The expression of multidrug-resistant proteins Survivin, Cyclin D1, Epidermal growth factor receptor (EGFR), Multidrug resistance-associated protein1 (MRP1) and Lipoprotein receptor-related protein (LRP) were detected by Western blot. cell line (A549,A549/DDP) down-regulated sensitive NA NA NA validated 2047 Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. Oncotarget 2016 27270310 miRBase MI0000266 miR-10a miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of miRNA were determined byquantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (U87, U251,U87TR and U251TR) up-regulated resistant NA NA NA validated 2048 NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget 2016 27270317 miRBase MIMAT0000096 miR-98-5p miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR The role of NEAT1 in lung cancer cells was detected using reverse transcription and real-time RT-PCR, luciferase activity assay, nude mouse xenograft studies, hematoxylin and eosin and immunohistochemistry staining,etc. cell line (A549,H460,H1299,A549/cDDP) down-regulated sensitive CTR1 CTR1 NA validated 2049 MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Sci Rep 2016 27279541 miRBase MI0000542 miR-320a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer RT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line ( PANC-1,PATU8988,293TN) up-regulated resistant PDCD4 PDCD4 NA validated 2050 Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel. Med Sci Monit 2016 27279639 miRBase MI0000080/MI0000081 miR-24 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel endometrial carcinoma qRT-PCR The expression of miR-24 in EC tissues was detected by quantitative real-time PCR. The proliferation ability and chemotherapy sensitivity were analyzed by MTT assay. Bioinformatics software was used to predict some potential target genes of miR-24. Luciferase activity assay was used to verify the relationship between target genes and miR-24. S100A8 protein expression was detected by Western blot analysis. cell line (HEC-1A, HEK293T ) up-regulated sensitive S100A8 S100A8 NA validated 2051 miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression. Gene 2016 27282281 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR In the study, miR-222 inhibitors or mimics were transfected into MCF-7 cell lines. RT-qPCR and western blot were used to detect the expression of p27(kip1). Immunofluorescence showed that miR-222 altered the subcellular location of p27(kip1) in nucleus. MTT was employed to verify the sensitivity of breast cancer cell lines to Adr. Flow cytometry showed the apoptosis and cell cycles of the cells after adding Adr. cell line (MCF-7/S,MCF-7/Adr) down-regulated sensitive p27(kip1) p27(kip1) NA validated 2052 miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13. Oncotarget 2016 27285768 miRBase MI0000083/MI0000750 miR-26a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.We finally evaluated the role of miR-26a in the responsiveness of in vivo NSCLCs to TKI treatment in nude mice. cell line (BEAS-2B,A549, H520, SW900, H2170,PC-9 ) up-regulated resistant PTPN13 PTPN13 EGFR pathway validated 2053 MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci 2016 27338043 miRBase MI0000072 miR-18 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR 20 TNBC patients who received neoadjuvant chemotherapy before surgery were recruited. MiR-18a expression was quantified using QRT-PCR. The effects of miR-18a overexpression or knockdown on cell viability and apoptosis of PTX sensitive MDA-MB-231 cells and PTX resistant MDA-MB-231 cells after PTX treatment were studied. The influence of miR-18a overexpression on Dicer expression was measured by qRT-PCR and Western blot analysis. cell line (MB-231,MDA-MB-468,MCF-10A,) up-regulated resistant NA NA NA validated 2054 miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep 2016 27357419 miRBase MI0000076 miR-20a miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The role of miR-20a was detected by RT-qPCR, drug sensitivity assay, Dual-luciferase activity assay, Immunohistochemistry, Western blot analysis, and apoptosis assay. cell line (SGC7901,SGC7901/DDP) up-regulated resistant CYLD CYLD NF-kappaB pathway validated 2055 miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 2016 27362808 miRBase MI0000285 miR-205 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR The role of miR-205 was detected by MTT assay, Drug resistance clonogenic assay, Gene expression analysis, Annexin V staining, Caspase activity, Enzyme-linked immunosorbent assay (ELISA), etc. cell line (MCF-7,MCF-7/A02,K562, HL60, BJAB) up-regulated sensitive VEGFA and FGF2 VEGFA and FGF2 PI3K/AKT signaling pathway validated 2056 miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 2016 27362808 miRBase MI0000285 miR-205 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The role of miR-205 was detected by MTT assay, Drug resistance clonogenic assay, Gene expression analysis, Annexin V staining, Caspase activity, Enzyme-linked immunosorbent assay (ELISA), etc. cell line (MCF-7,MCF-7/A02,K562, HL60, BJAB) up-regulated sensitive VEGFA and FGF2 VEGFA and FGF2 PI3K/AKT signaling pathway validated 2057 miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 2016 27362808 miRBase MI0000285 miR-205 miRNA DB00531 (APRD00408) Cyclophosphamide breast cancer qRT-PCR The role of miR-205 was detected by MTT assay, Drug resistance clonogenic assay, Gene expression analysis, Annexin V staining, Caspase activity, Enzyme-linked immunosorbent assay (ELISA), etc. cell line (MCF-7,MCF-7/A02,K562, HL60, BJAB) up-regulated sensitive VEGFA and FGF2 VEGFA and FGF2 PI3K/AKT signaling pathway validated 2058 MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. Biochem Biophys Res Commun 2016 27363334 miRBase MI0000440 miR-27b miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR By performing MSP assay and QRT-PCR analysis with the use of 5-AZA-dC, a DNA methyltransferase inhibitor, we observed that TamR MCF-7 cells had significantly higher levels of methylation in the miR-27b promoter region than tamoxifen sensitive MCF-7 (TamS) cells and demethylation restored miR-27b expression. Re-expression of miR-27b sensitized TamR MCF-7 cells to tamoxifen, inhibited invasion and reversed epithelial-mesenchymal transition (EMT)-like properties. By using bioinformatics analysis and following dual luciferase and western blot analysis, this study confirmed a direct regulation of miR-27b on HMGB3 expression by binding to the 3UTR. In addition, this study also found that silencing of HMGB3 indeed partially phenocopied the effects of miR-27b in reducing tamoxifen resistance and cell invasion and in reversing EMT-like properties. Therefore, we infer that HMGB3 is a functional target of miR-27b in modulation of tamoxifen resistance and EMT. cell line (MCF-7) down-regulated resistant HMGB3 HMGB3 NA validated 2059 Evidence for miR-17-92 and miR-134 gene cluster regulation of ovarian cancer drug resistance. Eur Rev Med Pharmacol Sci 2016 27383301 miRBase NA miR-17-92 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In this study, microarray analysis was used to compare the expression profiles of miRNAs in paclitaxel-resistant and paclitaxel-sensitive ovarian cancer cell lines, We chose to further investigate the miR17-92 and miR-134 clusters given their correlation with drug resistance. Real-time PCR showed that miR-17-92 expression was increased, while miR134 expression was decreased in drug resistant ovarian cancer cells, suggesting that both clusters may be involved in drug resistance. To further investigate the mechanism underlying cancer drug resistance, we used bioinforma tics analysis software to predict the target genes of miR-17-92 and miR-134 clusters. cell line (SKOV3,SKOV3-TR30) up-regulated resistant NA PTEN, ABCA1, and BIM NA predicted 2060 Evidence for miR-17-92 and miR-134 gene cluster regulation of ovarian cancer drug resistance. Eur Rev Med Pharmacol Sci 2016 27383301 miRBase MI0000474 miR-134 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In this study, microarray analysis was used to compare the expression profiles of miRNAs in paclitaxel-resistant and paclitaxel-sensitive ovarian cancer cell lines, We chose to further investigate the miR17-92 and miR-134 clusters given their correlation with drug resistance. Real-time PCR showed that miR-17-92 expression was increased, while miR134 expression was decreased in drug resistant ovarian cancer cells, suggesting that both clusters may be involved in drug resistance. To further investigate the mechanism underlying cancer drug resistance, we used bioinforma tics analysis software to predict the target genes of miR-17-92 and miR-134 clusters. cell line (SKOV3,SKOV3-TR30) down-regulated resistant NA Cdc42, MRP1/ABCC1, and c-Myc NA predicted 2061 Inhibition of miR-141 reverses cisplatin resistance in non-small cell lung cancer cells via upregulation of programmed cell death protein 4. Eur Rev Med Pharmacol Sci 2016 27383306 miRBase MI0000457 miR-141 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR MiR-141 expression in A549 and A549/DDP cell lines have been quantified by real-time PCR. Protein level of PDCD4 and caspase-3 have been determined by Western blot analysis. Drug sensitivity and apoptosis have been determined by MTT assay and TUNEL assay, respectively. Luciferase activity assay was employed to validate the relationship between 3UTR of PDCD4 mRNA and miR-141. cell line (A549,A549/DDP) up-regulated resistant PDCD4 PDCD4 NA validated 2062 miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. Oncotarget 2016 27384876 miRBase MI0000735 miR-29c miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( U251,U251/TR ) up-regulated sensitive SP1 MGMT NA validated 2063 miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Sci 2016 27384977 miRBase MI0000289/MI0000269 miR-181a miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative-RT PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells. cell line ( HepG2, Hep3B ) down-regulated sensitive RASSF1 RASSF1 NA validated 2064 The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget 2016 27409664 miRBase MI0003659 miR-644a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by invasion assay.miRNA target prediction by three databases. cell line (MDA-MB-231, MCF-7, BT474, SK-BR-3, ZR-75-1, MCF-10A, MCF-12A ) up-regulated sensitive CTBP1 CTBP1 NA validated 2065 The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget 2016 27409664 miRBase MI0003659 miR-644a miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by invasion assay.miRNA target prediction by three databases. cell line (MDA-MB-231, MCF-7, BT474, SK-BR-3, ZR-75-1, MCF-10A, MCF-12A ) up-regulated sensitive CTBP1 CTBP1 NA validated 2066 MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1 Cell Physiol Biochem 2016 27415661 miRBase MI0000478 miR-149 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The qRT-PCR assay was performed to detect the expression of miR-149 in 5-FU-resistant CRC cells (HCT-8/5-FU and LoVo/5-FU) and their parental CRC cells (HCT-8 and LoVo). Also, the effects of miR-149 expression on the sensitivity of CRC cells to 5-FU were determined by gain- and loss-of-function assays. Finally, whether miR-149 regulates the 5-FU resistance of CRC cells by targeting the mammalian Forkhead Box M1 (FOXM1) was investigated. cell line ( HCT-8/5-FU, LoVo/5-FU,HCT-8 and LoVo ) up-regulated sensitive FOXM1 FOXM1 NA validated 2067 miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade. Biochem Biophys Res Commun 2016 27422604 miRBase MI0000290 miR-214 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (MCF7, MDA-MB-157, MDA-MB-468) up-regulated sensitive RFWD2 RFWD2 p53 signaling pathway validated 2068 Over expression of miR-200c suppresses invasion and restores methotrexate sensitivity in lung cancer A549 cells. Gene 2016 27432063 miRBase MI0000650 miR-200c miRNA DB00563 (APRD00353) Methotrexate lung cancer RT-PCR This study aims to evaluate the function of miR-200c in lung cancer A549 cells. The data presented in our study demonstrated that the expression of miR-200c was down-regulated in methotrexate-resistant A549 cells. Over expression of miR-200c could significantly inhibit cell proliferation, induce G0/G1 cell cycle arrest and induce cell apoptosis. RT-PCR and Western blot assays showed that the expression of P53 and P21 were significantly increased with miR-200c overexpression. These results indicated that over expression of miR-200c might enhance the sensitivity of A549 cells to methotrexate through the P53/P21 pathway. Furthermore, miR-200c overexpression significantly inhibited cell migration and invasion with increasing the expression of E-cad and decreasing the expression of EZH2. cell linen (A549) up-regulated sensitive NA NA P53/P21 pathway validated 2069 miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget 2016 27448964 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB08881 (DB05238) Vemurafenib melanoma qRT-PCR We used microarray analysis to comprehensively study the miRNA expression profiling of vemurafenib resistant (VemR) A375 melanoma cells in relation to parental A375 melanoma cells. MicroRNA-7 (miR-7) was identified to be the most significantly down-regulated miRNA in VemR A375 melanoma cells. We also found that miR-7 was down-regulated in Mel-CVR cells (vemurafenib resistant Mel-CV melanoma cells). Reestablishment of miR-7 expression could reverse the resistance of both cells to vemurafenib. We showed that epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R) and CRAF were over-expressed in VemR A375 melanoma cells. Introduction of miR-7 mimics could markedly decrease the expressions of EGFR, IGF-1R and CRAF and further suppressed the activation of MAPK and PI3K/AKT pathway in VemR A375 melanoma cells. Furthermore, tumor growth was inhibited in an in vivo murine VemR A375 melanoma tumor model transfected with miR-7 mimics. cell line (A375,Mel-CV) up-regulated sensitive EGFR, IGF-1R and CRAF EGFR, IGF-1R and CRAF MAPK and PI3K/AKT pathway validated 2070 MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget 2016 27449101 miRBase MIMAT0003948 miR-770-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR,RT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR (qRT-PCR) and Reverse transcription PCR .Those of protein were by Western blot analysis. A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. cell line ( A2780S, OV2008, A2780CP, C13) down-regulated resistant ERCC2 ERCC2 NA validated 2071 miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1. Tumour Biol 2016 27460077 miRBase MI0000808 miR-326 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Animal studies was used to test the role of miR-326 . tissue and cell line (A549,A549/CDDP) up-regulated sensitive SP1 SP1 miR-326/SP1 pathway validated 2072 MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1. Eur Rev Med Pharmacol Sci 2016 27466996 miRBase MI0000783 miR-375 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR MiR-375 expression and promoter methylation status were studied by retrieving data in NCBI GEO Datasets, qRT-PCR and Methylation-Specific PCR (MSP) assay. Drug sensitivity of the cancer cells was assessed using MTT assay. The binding between miR-375 and YBX1 gene was predicted using Targetscan 7.1 and verified using western blot and dual luciferase assay. cell line ( MCF-7,MCF-7/ADM,MCF-7/PTX ) up-regulated sensitive YBX1 YBX1 NA validated 2073 MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1. Eur Rev Med Pharmacol Sci 2016 27466996 miRBase MI0000783 miR-375 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR MiR-375 expression and promoter methylation status were studied by retrieving data in NCBI GEO Datasets, qRT-PCR and Methylation-Specific PCR (MSP) assay. Drug sensitivity of the cancer cells was assessed using MTT assay. The binding between miR-375 and YBX1 gene was predicted using Targetscan 7.1 and verified using western blot and dual luciferase assay. cell line ( MCF-7,MCF-7/ADM,MCF-7/PTX ) up-regulated sensitive YBX1 YBX1 NA validated 2074 miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget 2016 27487127 miRBase MI0000461 miR-145 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription (RT)-polymerase chain reaction (PCR) and real-time PCR . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, MCF-10A, MDA-kb2, and MCF-7/ADR) up-regulated sensitive MRP1 MPR1 NA validated 2075 miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. Ann Surg 2016 27501171 miRBase MI0000298 miR-221 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal adenocarcinoma qRT-PCR Four pairs of esophageal adenocarcinoma (EAC) cell lines and corresponding 5-FU resistant variants were established. The expression levels of miRNAs previously shown to be involved in the general regulation of stem cell pathways were analyzed by qRT-PCR. The effects of selected miRNAs on proliferation, apoptosis, and chemosensitivity were evaluated both in vitro and in vivo. We identified a particular miRNA and analyzed its putative target genes in 14 pairs of human EC tumor specimens with surrounding normal tissue by qRT-PCR as well as Wnt pathway associated genes by immunohistochemistry in another 45 EAC tumor samples. tissue and cell line (EC) down-regulated sensitive DKK2 DKK2 Wnt/Beta-catenin-EMT pathway validated 2076 MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. Surgery 2016 27506865 miRBase MIMAT0004550 miR-30c-2* miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR We examined whether expression of human papillomavirus 16/18 oncoprotein and miR-30c-2*-associated genes could be linked to patient outcome by collecting 319 lung tumors from patients with non-small cell lung cancer to determine expression of human papillomavirus 16/18 E6 protein, miR-30c-2*, and miR-30c-2* downstream metastasis-associated protein-1 mRNA by immunohistochemical and real-time polymerase chain reaction analysis. cell line (TL1, TL4) up-regulated sensitive MTA-1 MTA-1 NA validated 2077 miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. Future Oncol 2016 27513190 miRBase MIMAT0000080 miR-24-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma RT-PCR Growth rate and colony formation assays were performed after transfection with miR-24-3p mimic and inhibitor in cultured SCC-15 cells, followed by a CellTiter-Glo- assay. Western blot and luciferase assays were performed to investigate the direct target of miR-24-3p. Xenograft mouse model was used to evaluate combinatorial effects of miR-24-3p inhibitor and 5-fluorouracil. cell line ( SCC-15 ) up-regulated sensitive CHD5 CHD5 NA validated 2078 MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells PLoS One 2016 27513462 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma Northern blot The role of miR-21 was detected by miRNA Northern blot, Immunoblot, luciferase assay, Scratch assay, and cell viability assay, etc. cell line (U2OS, MG63, 143B, HOS and SaOS2) up-regulated sensitive NA NA NA validated 2079 Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep 2016 27513895 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SGC7901,SGC7901/DDP) up-regulated sensitive MET MET NA validated 2080 miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes. Tumour Biol 2016 27517565 miRBase MI0000103/MI0000739 miR-101 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR In the study, we transduced the K562 cell line with a miR-101-overexpressing vector and evaluated the Jak2 mRNA level. Our results showed that miR-101 overexpression in Bcr-Abl+ cells reduced the Jak2 mRNA level. Moreover, imatinib treatment and miR-101 upregulation led to miR-23a overexpression, which has putative binding site(s) on 3-untranslated regions (3-UTRs) of STAT5, CCND1, and Bcl-2 genes. Our results also indicated that miR-101 overexpression inhibited cell proliferation indicated by the MTT assay and promoted apoptosis detected via flow cytometry. Importantly, mRNA expression of NF-kappa B-regulated anti-apoptotic (Bcl-2, Bcl-xl, MCL-1, XIAP, and survivin) and proliferative (c-Myc and CCND1) genes was decreased. These findings suggest that miR-101 acts as a tumor suppressor by downregulating Jak2 expression and sensitizing K562 cells to imatinib. cell line ( K562 ) up-regulated sensitive Jak2 and MCL-1 Jak2 and MCL-1 NA validated 2081 MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3Beta signaling pathway. Gene 2016 27523474 miRBase MI0000087 miR-29a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR ADR-resistant MCF-7 breast cancer cell subline (MCF-7/ADR) was successfully established in vitro through a stepwise increase of ADR concentrations in the culture based on parental MCF-7 cell lines (MCF-7/S). We used TargetScan (a wide use of target prediction algorithms) in conjunction with pathway enrichment analyses to predict the mRNAs that were most likely to involve in miR-29a-mediated drug resistance in cancers. We confirmed the effects of miR-29a-mediated ADR resistance through MTT and apoptosis assays, and further investigated the activities of two target genes, PTEN and GSK3Beta, by RT-qPCR analyses and western blot assays. cell line ( MCF-7/AD,MCF-7/S ) down-regulated sensitive PTEN and GSK3Beta PTEN and GSK3Beta PTEN/AKT/GSK3Beta signaling pathway validated 2082 miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nat Commun 2016 27526785 miRBase MIMAT0004808 miR-625-3p miRNA DB00526 (APRD00186) Oxaliplatin colorectal adenocarcinoma qRT-PCR In the study, we show that miR-625-3p functionally induces oxaliplatin resistance in CRC cells, and identify the signalling networks affected by miR-625-3p. We show that the p38 MAPK activator MAP2K6 is a direct target of miR-625-3p, and, accordingly, is downregulated in non-responder patients of oxaliplatin therapy. miR-625-3p-mediated resistance is reversed by anti-miR-625-3p treatment and ectopic expression of a miR-625-3p insensitive MAP2K6 variant. In addition, reduction of p38 signalling by using siRNAs, chemical inhibitors or expression of a dominant-negative MAP2K6 protein induces resistance to oxaliplatin. Transcriptome, proteome and phosphoproteome profiles confirm inactivation of MAP2K6-p38 signalling as one likely mechanism of oxaliplatin resistance. Our study shows that miR-625-3p induces oxaliplatin resistance by abrogating MAP2K6-p38-regulated apoptosis and cell cycle control networks, and corroborates the predictive power of miR-625-3p. cell line (HEK293 Flp pFRT/eGFP) up-regulated resistant MAP2K6 MAP2K6 MAP2K6-p38 signalling validated 2083 Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget 2016 27527856 miRBase MI0000271 miR-181c miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin chronic myelocytic leukemia RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells, cell line (K562, KCL22, KU812,K562/ADR, KCL22/ADR, and KU812/ADR) up-regulated sensitive ST8SIA4 ST8SIA4 PI3K/AKT pathway validated 2084 DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1. Cell Cycle 2016 27559850 miRBase MIMAT0004811 miR-33b-3p miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-qPCR The present study has attempted to identify differentially expressed miRNAs in cisplatin induced DNA damage response in lung cancer cells, and probe into the effects of the misexpressed miRNAs on cisplatin sensitivity. The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell viability used to monitor the growth of the cells cell line (A549,A549/DDP,HEK293T) down-regulated sensitive p21 NA NA validated 2085 Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget 2016 27566568 miRBase MI0000064 Let-7c miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by transwell migration and invasion assay. cell line (SPC-A1, H1299,SPC-A1/DTX and H1299/DTX) up-regulated sensitive Bcl-xL Bcl-xL NA validated 2086 miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1. Oncotarget 2016 27577078 miRBase MI0000300 miR-223 miRNA DB01248 (APRD00932) Docetaxel gallbladder cancer qRT-PCR We examined miR-223 expression in GBC tissue and GBC cell lines using qRT-PCR. The effects of modulated miR-223 expression in GBC cells were assayed using Cell Counting Kit-8 (CCK8), flow cytometry, and wound-healing and invasion assays. Susceptibility to docetaxel was evaluated in miR-223/STMN1-modulated GBC cells and xenograft tumor models. The protein expression of relevant genes was examined by Western blotting. cell line (GBC-SD, NOZ ) up-regulated sensitive STMN1 STMN1 NA validated 2087 A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. Oncotarget 2016 27589832 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (5-8F, 6-10B, and SUNE1 ) up-regulated sensitive ZEB2 ZEB2 NA validated 2088 MiroRNA-127-3p targets XRCC3 to enhance the chemosensitivity of esophageal cancer cells to a novel phenanthroline-dione derivative. Int J Biochem Cell Biol 2016 27590853 miRBase MIMAT0000446 miR-127-3p miRNA NA L203 esophageal cancer qRT-PCR In the study, we firstly analyzed the roles of microRNA-127-3p in regulating the growth of esophageal cancer cells both in vitro and in vivo. Afterwards, using the microRNA-targeted gene prediction software and the dual-luciferase reporter assays, we confirmed that microRNA-127-3p specifically reduced the expression of X-ray repair complementing defective repair in Chinese hamster cells 3, one of RAD51 recombinase paralogs, at both mRNA and protein levels. Furthermore, using the homologous recombination repair and non-homologous end joining repair reporter systems, we found that microRNA-127-3p specifically compromised the homologous recombination repair and significantly increased DNA double strand breaks in cells. Besides, it statistically increased the chemosensitivity of esophageal cancer cells to a novel phenanthroline-dione derivative in vivo by mechanistically impairing the recruitment of RAD51 to the damage sites. cell line ( EC1, EC109, EC9706, TE1, KYSE150, 293T) up-regulated sensitive XRCC3 XRCC3 NA validated 2089 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 2016 27591936 miRBase MIMAT0000226 miR-196a-5p miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell vitality assay and Apoptosis assay sed to test the drug-resistant phenotype changes in cancer cells. cell line (5637, UMUC-2,5637 ) up-regulated resistant p27kip1 NA NA validated 2090 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 2016 27591936 miRBase MIMAT0000226 miR-196a-5p miRNA DB00441 (APRD00201) Gemcitabine bladder cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell vitality assay and Apoptosis assay sed to test the drug-resistant phenotype changes in cancer cells. cell line (5637, UMUC-2,5637 ) up-regulated resistant p27kip1 NA NA validated 2091 Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Sci Rep 2016 27595933 miRBase MIMAT0000722 miR-370-3p miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR Our study aims to investigate potential miRNA biomarkers in GBM. Sixty GBM patients, which were given temozolomide (TMZ) chemotherapy and recurrent radiotherapy, were recruited. miRNA array was performed in cancerous and in paired normal tissues. Microarray results were further validated by a quantitative real-time PCR in selected tissues and GBM cell lines. TMZ resistance cells were developed and cell proliferation along with colony formation assays was determined. tissue and cell line ( NHA,U87, LN229, LN18, SHG44, U373 and U251, T98G ) up-regulated sensitive MGMT MGMT NA validated 2092 Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncol Lett 2016 27602140 miRBase MIMAT0000087 miR-30a-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The present study aimed to explore the expression of microRNA (miRNA or miR) in drug-resistant and drug-sensitive ovarian cancer cell lines, and to seek the potential therapeutic target of ovarian cancer drug-resistant mechanism in order to improve drug resistance by altering miRNA levels. The drug-resistant characteristics of SKOV3/DDP, SKOV3, COC1/DDP and COC1 cell lines were studied. The miRNAs that were differentially expressed between cisplatin-resistant cells and its parental cells in ovarian cancer were screened with a miRNA chip. The effect of miRNAs was detected, and their drug-resistant mechanism was investigated by transfection and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide methods. Among the expression screening of miRNAs, 41 mRNAs, including Homo sapiens (hsa)-miR-30a-5p and hsa-miR-34c-5p, were highly expressed in the drug-resistant cells, whereas 44 miRNAs, including hsa-miR-96-5p and hsa-miR-200c-3p, were lowly expressed. The expression levels of hsa-miR-30a-5p in two types of ovarian cancer chemotherapy-resistant cell lines were significantly higher than those in chemotherapy-sensitive cell lines, which was associated with ovarian cancer chemotherapy resistance. In conclusion, high expression of miRNA-30a-5p was able to promote cell growth and colony forming ability, and enhance cell migration and invasion. Thus, miRNA-30a-5p is expected to become a meaningful novel target for ovarian cancer resistant treatment. cell line (SKOV3, COC1,SKOV3/DDP,COC1/DDP) up-regulated resistant NA NA NA validated 2093 Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. Cancer Lett 2016 27609068 miRBase MI0003660 miR-645 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and RT-PCR, those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells.LC-MS/MS analysis was used to protein identification and quantitation cell line ( MG-63, U2OS) up-regulated resistant NA NA NA validated 2094 Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget 2016 27612424 miRBase MI0000789 miR-381 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. tissue and cell line ( MG-63 ) down-regulated sensitive LRRC4 LRRC4 mTOR signaling pathway validated 2095 MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. PLoS One 2016 27618431 miRBase MI0000300 miR-223 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcriptase real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-10A,MCF-7, SKBR3,MDA-MB-231 and MDA-MB-435 ) up-regulated sensitive HAX-1 HAX-1 NA validated 2096 MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. PLoS One 2016 27618431 miRBase MI0000300 miR-223 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcriptase real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-10A,MCF-7, SKBR3,MDA-MB-231 and MDA-MB-435 ) up-regulated sensitive HAX-1 HAX-1 NA validated 2097 MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun 2016 27622325 miRBase MI0000471 miR-126 miRNA DB00541 (APRD00495) Vincristine stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay .The CCK-8 assay was used to monitor the growth of the cells . cell line (SGC7901/VCR,SGC7901/ADR,SGC7901) up-regulated sensitive EZH2 EZH2 NA validated 2098 MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun 2016 27622325 miRBase MI0000471 miR-126 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Caspase-3 and -7 activation status was measured using the Caspase-Glo 3/7 Assay .The CCK-8 assay was used to monitor the growth of the cells . cell line (SGC7901/VCR,SGC7901/ADR,SGC7901) up-regulated sensitive EZH2 EZH2 NA validated 2099 Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1alpha feedback regulatory loop. Tumour Biol 2016 27629141 miRBase MI0000072 miR-18a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. The putative microRNA (miRNA) binding sites in UCA1 was predicted by using PITA and RNAhybrid . Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( MCF-7, BT474, LCC2, and LCC9) up-regulated sensitive HIF1alpha NA NA validated 2100 miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. Biomed Pharmacother 2016 27643554 miRBase MI0000810 miR-135b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR To identify the mechanism of miR-135b and FZD1 in NSCLC chemoresistance and to observe their biological functions, we detected the expression levels of miR-135b and FZD1 by conducting quantitative real-time polymerase chain reaction (RT-qPCR) and modified the expressions of miR-135b and FZD1 by transiently transfecting cells with miR-135b mimics or FZD1-siRNA. The 3-untranslated region (3-UTR) of FZD1 combined with miR-135b was verified through dual-luciferase reporter assay. cell line (A549,A549/DDP) up-regulated sensitive FZD1 FZD1 NA validated 2101 Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem 2016 27644195 miRBase MIMAT0000432 miR-141-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer RT-PCR The role of miR-141-3p in human normal esophageal epithelial cells was detected by Real-time PCR, microarray analyses,apoptosis assay,Immuno-blot analysis,luciferase assay, and Xenograft experiments. cell line ( EC109, EC9706, TE-1 and KYSE-150 ) up-regulated resistant PTEN PTEN NA validated 2102 Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem 2016 27644195 miRBase MIMAT0000432 miR-141-3p miRNA DB00526 (APRD00186) Oxaliplatin esophageal cancer RT-PCR The role of miR-141-3p in human normal esophageal epithelial cells was detected by Real-time PCR, microarray analyses,apoptosis assay,Immuno-blot analysis,luciferase assay, and Xenograft experiments. cell line ( EC109, EC9706, TE-1 and KYSE-150 ) up-regulated resistant PTEN PTEN NA validated 2103 Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma. Am J Cancer Res 2016 27648358 miRBase MI0000442 miR-122 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatic carcinoma RT-PCR,RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and RT-PCR. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SNU-449, MHCC97, HepG2 and SMMC-7721) up-regulated resistant PCDH20 PCDH20 NA validated 2104 miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2). Eur Rev Med Pharmacol Sci 2016 27649657 miRBase MI0000077 miR-21 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR We examined the expression of miRNA-21 and B-cell lymphoma 2 (Bcl-2) in GIST specimens by the real-time quantitative PCR assay (RT-qPCR). Then we explored the regulation by miRNA-21 on the Bcl-2 expression by the RT-qPCR assay, Western blotting assay and the luciferase assay in GIST-T1 cells. In addition, we examined the influence of miRNA-21 on the sensitivity to Imatinib of GIST-T1 cells with colony forming assay and apoptotic assay cell line ( GIST-T1 ) up-regulated sensitive Bcl-2 Bcl-2 NA validated 2105 miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. Mol Med Rep 2016 27666124 miRBase MI0000650 miR-200c miRNA DB08865 (DB08700) Crizotinib lung cancer RT-qPCR The role of miR-200c in human lung cancer cells was detected by RT?qPCR, cell viability and invasion assays,and lLuciferase reporter assay.etc. cell line (NCI-2228, A549, H460) up-regulated sensitive ZEB1 ZEB1 NA validated 2106 miR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget 2016 27683111 miRBase MI0000452/MI0000453 miR-135a miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR We analyzed GC samples and matched non-tumorous control stomach tissues from 280 patients and found that miR-135a was overexpressed in GC samples relative to control tissues. Tumors with high miR-135a expression were more likely to have aggressive characteristics (high levels of carcino-embryonic antigen, vascular invasion, lymphatic metastasis, and poor differentiation) than those with low levels. Patients with greater tumoral expression of miR-135a had shorter overall survival times and times to disease recurrence. Furthermore, miR-135a, which promotes the proliferation and invasion of OXA-resistant GC cells, inhibited E2F transcription factor 1 (E2F1)-induced apoptosis by downregulating E2F1 and Death-associated protein kinase 2 (DAPK2) expression. Our results indicate that higher levels of miR-135a in GC are associated with shorter survival times and reduced times to disease recurrence. The mechanism whereby miR-135a promotes GC pathogenesis appears to be the suppression of E2F1 expression and Sp1/DAPK2 pathway signaling. cell line (SNU-5, NCI-N87,SGC7901/OXA, MGC-803/OXA, SGC7901, and MGC-803) up-regulated resistant NA NA Sp1/DAPK2 signaling pathway validated 2107 The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol 2016 27686228 miRBase MI0000284 miR-204 miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR QRT-PCR was performed to detect UCA1, miR-204 and Sirt1 mRNA expression. Western blot assay was performed to assess Sirt1, P-gp and caspase-3 expression. The regulative effect of UCA1/miR-204/Sirt1 axis on docetaxel sensitivity of prostate cancer cells was examined by measurement of docetaxel IC50, dictation of cleaved caspase-3 and flow cytometric analysis of cell apoptosis. cell line ( PNT2, LNCaP, 22RV1, 22RV1/DR) down-regulated sensitive NA NA UCA1/miR-204/Sirt1 validated 2108 MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1. Mol Cell Biochem 2016 27686452 miRBase MI0001729 miR-451 miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, A549/DPP) down-regulated resistant Mcl-1 Mcl-1 miR-451/Mcl-1/DPP validated 2109 The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine 2016 27688096 miRBase MIMAT0000719 miR-367-3p miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma NA In the study, we searched for some AR enhancers to increase the efficacy of Sorafenib chemotherapy, and identified the microRNA (miR)-367-3p, whose expression is positively correlated with AR expression in advanced HCC, as an HCC metastasis suppressor. Combining miR-367-3p with Sorafenib showed better efficacy to suppress HCC cell invasion in vitro and in vivo. Cell migration was detected by invasion assay. The targeting protein of miR-524-5p was identified by luciferase reporter assay. tissue and cell line ( SKhep1, HA22T, and HepG2 ) up-regulated sensitive MDM2 MDM2 MDM2/AR-FKBP5/PHLPP/(pAKT and pERK) signaling pathway validated 2110 MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget 2016 27690301 miRBase MI0000447/MI0000727 miR-128 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (PC9,PC9-CSCs) up-regulated sensitive C-met NA PI3K/Akt pathway validated 2111 Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Biochem Biophys Res Commun 2016 27693788 miRBase MIMAT0004602 miR-125a-3p miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. tissue and cell line (MCF-7, MCF-7/LCC2, MDA-MB-468, MDA-MB-231, MDA-MB-468/R, MCF-7/R,MDA-MB-468/S, MCF-7/S) up-regulated sensitive BRCA1 BRCA1 NA validated 2112 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 miRBase MI0000440 miR-27b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) down-regulated resistant NA NA NA validated 2113 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) down-regulated resistant NA NA NA validated 2114 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 miRBase MI0000440 miR-27b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) down-regulated resistant NA NA NA validated 2115 miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway. Tumour Biol 2016 27699665 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR The role of miR-222 in human breast cancer cells was detected by qRT-PCR, MTT assay,flow cytometry.western blot,and Immunofluorescence microscope.etc. cell line (MCF-7/Adr,MCF-7/S) up-regulated resistant NA NA PTEN/Akt/p27kip1 pathway validated 2116 miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst 2016 27714074 miRBase MI0000483 miR-186 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma RT-PCR To examine the effects of miR-186 on chemosensitivity in NSCLC, an miR-186 mimic and inhibitor were transfected, followed by CellTiter-Glo- assay in NSCLC cell lines. Western blot and luciferase assay were performed to investigate the direct targeting of miR-186. A xenograft mouse model was used to examine the in vivo chemosensitizing function of miR-186. We found that overexpression of miR-186 sensitized A549 and H1299 cells to paclitaxel, whereas inhibition of miR-186 conferred resistance in these cells. MAPT was the direct target of miR-186 which was required for the regulatory role of miR-186 in chemoresistance. This chemosensitizing function was partially due to the induction of the p53 mediated apoptotic pathway. The miR-186 mimic enhanced the tumor growth inhibitory effects of paclitaxel in A549 xenografts. In addition, miR-186 was found to be down-regulated in NSCLC patients who were chemoresistant and this down-regulation was associated with poor survival. cell line (A549 and H1299) up-regulated sensitive MAPT MAPT p53 signaling pathway validated 2117 microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Life Sci 2016 27717846 miRBase MI0003514 miR-539 miRNA DB01169 (APRD00171) Arsenic trioxide hepatocellular carcinoma qRT-PCR The expression of miR-539 in human HCC tissues and cell lines was examined. The effects of miR-539 overexpression on cell growth, tumorigenicity, arsenic trioxide resistance of HCC cells were determined. The signaling pathways involved in the action of miR-539 in HCC were also investigated. tissue and cell line (PLC/PRF/5, HepG2, Huh7, Sk-Hep-1, and Hep3B) up-regulated sensitive NA NA NA validated 2118 MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1. Tumour Biol 2016 27726102 miRBase MIMAT0000278 miR-221-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . A wound healing assay was performed to examine the capacity of cell migration. cell line ( PANC-1,PATU8988,293TN ) up-regulated resistant RB1 RB1 NA validated 2119 Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance. Acta Biochim Biophys Sin (Shanghai) 2016 27733346 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549 and SPCA-1) up-regulated sensitive ZEB2 ZEB2 NA validated 2120 MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget 2016 27738333 miRBase MIMAT0000250 miR-139-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal carcinoma qRT-PCR The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.our in vivo experiments using mouse showed that in CD44+/CD133+ CSC-like cells, miR-139-5p could reverse MDR by downregulating NOTCH1.. cell line (HCT116, HCT8) up-regulated sensitive NOTCH1 NOTCH1 NA validated 2121 MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget 2016 27738333 miRBase MIMAT0000250 miR-139-5p miRNA DB00541 (APRD00495) Vincristine colorectal carcinoma qRT-PCR The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.our in vivo experiments using mouse showed that in CD44+/CD133+ CSC-like cells, miR-139-5p could reverse MDR by downregulating NOTCH1.. cell line (HCT116, HCT8) up-regulated sensitive NOTCH1 NOTCH1 NA validated 2122 MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells. Oncotarget 2016 27738333 miRBase MIMAT0000250 miR-139-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal carcinoma qRT-PCR The expression levels of miRNA were determined byqRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells.our in vivo experiments using mouse showed that in CD44+/CD133+ CSC-like cells, miR-139-5p could reverse MDR by downregulating NOTCH1.. cell line (HCT116, HCT8) up-regulated sensitive NOTCH1 NOTCH1 NA validated 2123 Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 2016 27743201 miRBase MI0003575 miR-551b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR The expression levels of miRNA were determined by qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by invasion assay. our in vivo experiments using mouse xenograft models showed that inhibiting miR-551b significantly increased the susceptibility of OVCa cells to cisplatin and prolonged the survival of the host mice. cell line (OVCa,HEK293T,SK-OV-3 and 8910 ) up-regulated sensitive Foxo3 and TRIM31 Foxo3 and TRIM31 NA validated 2124 miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep 2016 27748936 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer qRT-PCR The present study was conducted to investigate whether microRNA-100 (miR-100) can be used to modulate the tolerance to cisplatin in EOC. Expression of miR-100 was compared between ovarian cancer cells tolerant and not tolerant to cisplatin. Mimic and antisense were used to study the roles and related mechanisms of miR-100 in cisplatin sensitivity in EOC. The alternation in the cisplatin sensitivity was investigated using grafted tumors derived from SKOV3/DDP cells with upregulated or downregulated miR-100 expression. miR-100 was lower in cisplatin resistant cell line SKOV3/DDP than in cisplatin sensitive cell line SKOV3. miR-100 might increase cisplatin sensitivity by inhibiting cell proliferation and conversion from G1 to S phase and increasing apoptosis. We showed that mTOR and PLK1 are targets of miR-100 and the cells were resensitized probably due to targeted downregulation of mTOR and PLK1 by miR-100. In vivo study with nude mice showed that tumors derived from miR-100 mimic-transfected cells were more sensitive to cisplatin and had reduced expression of mTOR and PLK1. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin probably by inhibiting cell proliferation, inducing apoptosis and arresting cell cycle and by targeted downregulation of mTOR and PLK1 expression. cell line ( SKOV3,SKOV/DDP) down-regulated resistant mTOR, PLK1 mTOR, PLK1 NA validated 2125 miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther 2016 27757042 miRBase MIMAT0003258 miR-590-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Quantitative real-time polymerase chain reaction was performed to measure endogenous miR-590-5p levels in GC cells and tissues. Overexpression or knockdown of miR-590-5p in GC cells was performed by transfection with mimics or an inhibitor, respectively. MTT, matrigel transwell, and Western blot assays were used to assess the effects of miR-590-5p on cell proliferation, invasion, chemosensitivity of GC cells, and the AKT pathway, respectively. In silico prediction and luciferase reporter activity were used to identify potential targets of miR-590-5p. A xenograft model was also established to evaluate the function of miR-590-5p in vivo. cell line (SGC-7901, MKN-28, MKN-45, BGC-823, AGS, and MGC-803) up-regulated resistant RECK RECK AKT/ERK pathway validated 2126 miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther 2016 27757042 miRBase MIMAT0003258 miR-590-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer qRT-PCR Quantitative real-time polymerase chain reaction was performed to measure endogenous miR-590-5p levels in GC cells and tissues. Overexpression or knockdown of miR-590-5p in GC cells was performed by transfection with mimics or an inhibitor, respectively. MTT, matrigel transwell, and Western blot assays were used to assess the effects of miR-590-5p on cell proliferation, invasion, chemosensitivity of GC cells, and the AKT pathway, respectively. In silico prediction and luciferase reporter activity were used to identify potential targets of miR-590-5p. A xenograft model was also established to evaluate the function of miR-590-5p in vivo. cell line (SGC-7901, MKN-28, MKN-45, BGC-823, AGS, and MGC-803) up-regulated resistant RECK RECK AKT/ERK pathway validated 2127 MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget 2016 27765914 miRBase MI0000461 miR-145 miRNA DB00441 (APRD00201) Gemcitabine pancreatic adenocarcinoma RT-PCR, qRT-PCR The expression levels of miRNA were determined by reverse transcription PCR and quantitative real time- PCR, those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line ( Panc-1 and Bxpc-3) up-regulated sensitive P70S6K1 NA NA validated 2128 Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells. Oncol Rep 2016 27779704 miRBase MI0001444 miR-422a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel osteosarcoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Transwell was selected to test the invasive ability of the cells. tissue and cell line (MG-63, Saos-2, U-2 0S,hFOB) up-regulated sensitive TGFBeta2 NA NA validated 2129 Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells. Oncol Rep 2016 27779704 miRBase MI0001444 miR-422a miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qPCR The expression levels of miRNA were determined by Quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Transwell was selected to test the invasive ability of the cells. tissue and cell line (MG-63, Saos-2, U-2 0S,hFOB) up-regulated sensitive TGFBeta2 NA NA validated 2130 Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. Oncol Rep 2016 27779719 miRBase MI0000294/MI0000295 miR-218 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( HEK293T,HCT-116,HCT-116/L-OHP ) down-regulated resistant YEATS4 YEATS4 NA validated 2131 Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. Cancer Chemother Pharmacol 2016 27785603 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Pancreatic cancer cell lines PANC-1 and MIAPaCa-2 cells were used as in vitro model. Autophagy was assessed by western blot of LC3 I/II and observation GFP-LC3 puncta. Cell viability was examined using CCK-8 assay. Cell apoptosis was examined by flow cytometric analysis of Annexin V/PI staining. QRT-PCR, RNA fluorescence in situ hybridization and dual luciferase assay were used to study the expression and the binding between linc-ROR and miR-124. cell line ( PANC-1 and MIAPaCa-2 ) up-regulated sensitive NA NA NA validated 2132 MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3Beta in glioblastoma. Oncotarget 2016 27792996 miRBase MI0000103/MI0000739 miR-101 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. tissue and cell line (A172, T98G, U-251MG ) up-regulated sensitive GSK3Beta GSK3Beta NA validated 2133 Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis 2016 27809310 miRBase MIMAT0000419 miR-27b-3p miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( MCF-7,T47D,BT-549, SK-BR-3, MDA-MB-231 and MCF-10A ) down-regulated resistant NR5A2 and CREB1 NR5A2 and CREB1 NA validated 2134 MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget 2016 27825112 miRBase MI0000089 miR-31 miRNA DB00515 (APRD00359) Cisplatin gallbladder cancer qRT-PCR The microarray was used to select the candidate miRNA in two DDP-resistant GBC cell lines. The effect of regulated expression of the miRNA on cell migration, invasion, proliferation and apoptosis was examined by wound healing, transwell assays, CCK-8 assays, colony formation and flow cytometry assays, respectively. Xenograft tumor models were used to validate the function of the downstream target. cell line (NOZ, GBC-SD,NOZ/DDP,GBC-SD/DDP) up-regulated sensitive Src Src miR-31/Src/Akt/Bax/Bcl-2 pathway validated 2135 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis 2016 27831559 miRBase MI0000071 miR-17 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-PCR In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells. Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance. Subsequently, we investigated whether NCOA3 expression was regulated by miRNAs in breast cancer. By bioinformatics prediction in combination with the data of previous report, miR-17 and miR-20b were selected as the potential miRNAs targeting NCOA3. By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells. In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models. Furthermore, by luciferase reporter assays, we further validated that both miR-17 and miR-20b directly binded the 3-untranslated region of NCOA3 mRNA and inhibited its expression in breast cancer cells. Finally, both miR-17 and miR-20b levels were found to be significantly negatively correlated with NCOA3 mRNA levels in breast cancer tissues. Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels. cell line ( MCF-7, MDA-MB-231,MCF-7/Tax1, MCF-7/Tax2, 231/Tax1 and 231/Tax2) down-regulated resistant NCOA3 NCOA3 NA validated 2136 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis 2016 27831559 miRBase MI0001519 miR-20b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-PCR In this study, nuclear receptor coactivator 3 (NCOA3) was found to be significantly increased in taxol-resistant breast cancer tissues and cells. Moreover, overexpression of NCOA3 enhanced breast cancer cell resistance to taxol, whereas depletion of NCOA3 decreased taxol resistance. Subsequently, we investigated whether NCOA3 expression was regulated by miRNAs in breast cancer. By bioinformatics prediction in combination with the data of previous report, miR-17 and miR-20b were selected as the potential miRNAs targeting NCOA3. By real-time PCR analysis, we found that miR-17 and miR-20b were significantly reduced in taxol-resistant breast cancer tissues and cells. In addition, we provided some experimental evidences that miR-17 and miR-20b attenuated breast cancer resistance to taxol in vitro and in vivo models. Furthermore, by luciferase reporter assays, we further validated that both miR-17 and miR-20b directly binded the 3-untranslated region of NCOA3 mRNA and inhibited its expression in breast cancer cells. Finally, both miR-17 and miR-20b levels were found to be significantly negatively correlated with NCOA3 mRNA levels in breast cancer tissues. Together, our results indicated that loss of miR-17 and miR-20b enhanced breast cancer resistance to taxol by upregulating NCOA3 levels. cell line ( MCF-7, MDA-MB-231,MCF-7/Tax1, MCF-7/Tax2, 231/Tax1 and 231/Tax2) down-regulated resistant NCOA3 NCOA3 NA validated 2137 MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. Eur Rev Med Pharmacol Sci 2016 27831649 miRBase MIMAT0000242 miR-129-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR Immunoprecipitation (IP) and Chromatin Immunoprecipitation (ChIP) assay were performed to detect the association among SOX4, EZH2 and H3K27me3 and their enrichment in the promoter region of miR-129-2. Western blot and immunofluorescent staining were performed to detect the expression of epithelial and mesenchymal markers. MTT assay was applied to test drug sensitivity. cell line ( MCF-7, MCF-7/ADM ) up-regulated sensitive SOX4 SOX4 NA validated 2138 MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. Eur Rev Med Pharmacol Sci 2016 27831649 miRBase MIMAT0000242 miR-129-5p miRNA DB00541 (APRD00495) Vincristine breast cancer qRT-PCR Immunoprecipitation (IP) and Chromatin Immunoprecipitation (ChIP) assay were performed to detect the association among SOX4, EZH2 and H3K27me3 and their enrichment in the promoter region of miR-129-2. Western blot and immunofluorescent staining were performed to detect the expression of epithelial and mesenchymal markers. MTT assay was applied to test drug sensitivity. cell line ( MCF-7, MCF-7/ADM ) up-regulated sensitive SOX4 SOX4 NA validated 2139 MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. Eur Rev Med Pharmacol Sci 2016 27831649 miRBase MIMAT0000242 miR-129-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR Immunoprecipitation (IP) and Chromatin Immunoprecipitation (ChIP) assay were performed to detect the association among SOX4, EZH2 and H3K27me3 and their enrichment in the promoter region of miR-129-2. Western blot and immunofluorescent staining were performed to detect the expression of epithelial and mesenchymal markers. MTT assay was applied to test drug sensitivity. cell line ( MCF-7, MCF-7/ADM ) up-regulated sensitive SOX4 SOX4 NA validated 2140 miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer 2016 27832783 miRBase MI0000783 miR-375 miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR We first compared miR-375 expression level between prostate cancer tissues and normal prostate tissues using data from The Cancer Genome Atlas (TCGA). To examine the role of miR-375 in docetaxel resistance, we transfected miR-375 using a pre-miRNA lentiviral vector and examined the effects of exogenously overexpressed miR-375 on cell growth in two prostate cancer cell lines, DU145 and PC-3. To determine the effect of overexpressed miR-375 on tumor growth and chemo-resistance in vivo, we injected prostate cancer cells overexpressing miR-375 into nude mice subcutaneously and evaluated tumor growth rate during docetaxel treatment. Lastly, we utilized qRT-PCR and Western blot assay to examine two miR-375 target genes, SEC23A and YAP1, for their expression changes after miR-375 transfection. cell line ( DU145 and PC-3 ) up-regulated resistant SEC23A and YAP1 SEC23A and YAP1 NA validated 2141 Expression of MicroRNA-301a and its Functional Roles in Malignant Melanoma. Cell Physiol Biochem 2016 27855389 miRBase MI0000745 miR-301a miRNA DB00515 (APRD00359) Cisplatin melanoma qRT-PCR Quantitative real-time PCR (qRT-PCR) assay was performed to detect the expression of miR-301a in MM tissues, and analyze its correlation with metastasis and prognosis of MM patients. In vitro, miR-301a was ectopically expressed using overexpression and knock-down strategies, and the effects of miR-301a expression on growth, apoptosis, migration, invasion and chemosensitivity of MM cells were further investigated. Furthermore, the potential and functional target gene was identified by luciferase reporter, qRT-PCR, Western blot assays. cell line (SK-MEL-1, A-375) up-regulated resistant PTEN PTEN Akt and FAK signaling pathway validated 2142 Expression of MicroRNA-301a and its Functional Roles in Malignant Melanoma. Cell Physiol Biochem 2016 27855389 miRBase MI0000745 miR-301a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin melanoma qRT-PCR Quantitative real-time PCR (qRT-PCR) assay was performed to detect the expression of miR-301a in MM tissues, and analyze its correlation with metastasis and prognosis of MM patients. In vitro, miR-301a was ectopically expressed using overexpression and knock-down strategies, and the effects of miR-301a expression on growth, apoptosis, migration, invasion and chemosensitivity of MM cells were further investigated. Furthermore, the potential and functional target gene was identified by luciferase reporter, qRT-PCR, Western blot assays. cell line (SK-MEL-1, A-375) up-regulated resistant PTEN PTEN Akt and FAK signaling pathway validated 2143 MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells. Med Sci Monit 2016 27876712 miRBase MI0000088 miR-30a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR We recruited 20 patients with advanced gastric cancer. Chemosensitivity was assessed after completion of the chemotherapy. SGC-7901 and SGC-7901/DDP cells were transfected for miR-30a overexpression or knockdown. Then, MTT assay was performed to assess the IC50 of DPP and 5-FU in SGC-7901 and SGC-7901/DDP cells. Flow cytometry analysis was used to detect DPP- and 5-FU-induced cell apoptosis. Western blot analysis and immunofluorescence staining were used to assess EMT of the cells. cell line ( SGC-7901 and SGC-7901/DDP ) up-regulated sensitive NA NA NA validated 2144 MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells. Med Sci Monit 2016 27876712 miRBase MI0000088 miR-30a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR We recruited 20 patients with advanced gastric cancer. Chemosensitivity was assessed after completion of the chemotherapy. SGC-7901 and SGC-7901/DDP cells were transfected for miR-30a overexpression or knockdown. Then, MTT assay was performed to assess the IC50 of DPP and 5-FU in SGC-7901 and SGC-7901/DDP cells. Flow cytometry analysis was used to detect DPP- and 5-FU-induced cell apoptosis. Western blot analysis and immunofluorescence staining were used to assess EMT of the cells. cell line ( SGC-7901 and SGC-7901/DDP ) up-regulated sensitive NA NA NA validated 2145 Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget 2016 27880721 miRBase MI0000469 miR-125a miRNA DB00515 (APRD00359) Cisplatin laryngeal cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Hep-2) up-regulated sensitive HAX-1 NA NA validated 2146 Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget 2016 27880721 miRBase MI0000469 miR-125a miRNA DB00541 (APRD00495) Vincristine laryngeal cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Hep-2) up-regulated sensitive HAX-1 NA NA validated 2147 Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget 2016 27880721 miRBase MI0000469 miR-125a miRNA DB00773 (APRD00239) Etoposide laryngeal cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Hep-2) up-regulated sensitive HAX-1 NA NA validated 2148 Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget 2016 27880721 miRBase MI0000469 miR-125a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin laryngeal cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (Hep-2) up-regulated sensitive HAX-1 NA NA validated 2149 MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget 2016 27893429 miRBase MI0003607 miR-595 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. he CCK-8 assay was used to monitor the growth of the cells. cell line (HG-SOC, HO8910, SKOV-3, HO8910PM, ES2,FTE187) up-regulated sensitive ABCB1 ABCB1 NA validated 2150 MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines. Front Genet 2016 27895663 miRBase MIMAT0000087 miR-30a-5p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma NA Protein expression was detected by Western blot.Use wound healing tests to assess cell migration and so on. cell line (NCI-H460 and NCI-H1975) up-regulated sensitive NA NA PI3K/AKT signaling pathway validated 2151 MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines. Front Genet 2016 27895663 miRBase MIMAT0000087 miR-30a-5p miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma NA Protein expression was detected by Western blot.Use wound healing tests to assess cell migration and so on. cell line (NCI-H460 and NCI-H1975) up-regulated sensitive NA NA PI3K/AKT signaling pathway validated 2152 Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett 2016 27895747 miRBase MI0000080/MI0000081 miR-24 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast carcinoma RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( MCF-7, SKBR3) up-regulated sensitive ABCB9 ABCB9 NA validated 2153 MicroRNA-199a-5p inhibits cisplatin-induced drug resistance via inhibition of autophagy in osteosarcoma cells. Oncol Lett 2016 27895792 miRBase MIMAT0000231 miR-199a-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MG63) up-regulated sensitive Beclin1 Beclin1 NA validated 2154 MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci 2016 27906433 miRBase MIMAT0000455 miR-185-5p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR Real-time PCR or Western blot assay was performed to detect the expression of mature miR-185-5p and ATP-binding cassette, subfamily C, member 1 (ABCC1) protein. Cell lines with abnormal expression of miR-185-5p were generated using miR-185-5p inhibitor and mimics. The viabilities of treated cells were analyzed using MTT assay. Cell apoptosis was evaluated by TUNEL assay. Apoptosis-related protein expressions were tested by Western blot. Dual-luciferase assay was applied to assess the target gene of miRNA. cell line (A549,A549/DDP) up-regulated sensitive ABCC1 ABCC1 NA validated 2155 miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci 2016 27924500 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription- polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (A549, Pc9 ) up-regulated sensitive SNAI2 and STAT3 SNAI2 and STAT3 NA validated 2156 miR-146a Inhibits Proliferation and Enhances Chemosensitivity in Epithelial Ovarian Cancer via Reduction of SOD2. Oncol Res 2016 27931283 miRBase MI0000477 miR-146a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. TUNEL assay was used to detect apoptosis cell line ( OVCAR3, CAOV3,HEY ) up-regulated sensitive SOD2 SOD2 miR-146a/SOD2/ROS pathway validated 2157 Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. Onco Targets Ther 2016 27932893 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00002 (BTD00071, BIOD00071) Cetuximab hepatocellular carcinoma RT-qPCR The cytotoxicity of cetuximab on HCC cell lines (Huh7, Hep3B, HepG2, SNU449, and SNU387) was evaluated using a cell viability assay (the Cell Counting Kit-8 assay) and a cell proliferation assay (the Click-iT EdU Imaging Kit) in the presence of a control, a let-7a mimic, and a let-7a inhibitor. Small interfering RNA to knockdown the expression of signal transducer and activator of transcription 3 (STAT3) were employed. Protein and mRNA expression levels were determined using quantitative polymerase chain reaction and Western blot analysis. cell line (Huh7, Hep3B, HepG2, SNU449, SNU387) up-regulated sensitive STAT3 STAT3 NA validated 2158 miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. Eur Rev Med Pharmacol Sci 2016 27981531 miRBase MI0005567 miR-760 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR Real-time PCR was performed to measure the mRNA expression of miR-760 and Nanog. Western blot was used to determine the protein expression of Nanog and mesenchymal and epithelial markers. Cell viability was measured by the CCK-8 assay. cell line ( Bcap37, MCF-7, MDA-MB-231) up-regulated sensitive Nanog Nanog NA validated 2159 MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int J Biol Sci 2016 27994509 miRBase MI0000101 miR-99a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR In order to investigate if miRNA involves in cisplatin resistance of human gastric cancer, we first screened and compared the expression of miRNAs between cisplatin resistant gastric cancer cell lines SGC-7901/DDP and BGC-823/DDP and their sensitive parental cells by miRNAs microarray and followed by analysis of 2D-GE/MS to identify their target proteins. We found both miR-99a and miR-491 were upregulated while their target gene calpain small subunit 1 (CAPNS1) was downregulated in resistant gastric cancer cells. Dual-luciferase- reporter assays with wild-type and mutated CAPNS1 3-UTR confirmed their specificity of targeting. Inhibition of miR-99a and miR-491, or overexpress CAPNS1 can enhance cisplatin sensitivity of the resistant cells while transfection of two miRNAs mimics or si-CAPNS1 in the sensitive cells can induce their resistance. Moreover, our results demonstrated CAPNS1 positively regulated calpain1 and calpain2, the catalytic subunits of CAPNS1, and cleaved caspase3 which further cleaved PARP1 and directly induced apoptosis. cell line (SGC-7901, BGC-823,SGC-7901/DDP and BGC-823/DDP) up-regulated resistant CAPNS1 CAPNS1 NA validated 2160 MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int J Biol Sci 2016 27994509 miRBase MI0003126 miR-491 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR In order to investigate if miRNA involves in cisplatin resistance of human gastric cancer, we first screened and compared the expression of miRNAs between cisplatin resistant gastric cancer cell lines SGC-7901/DDP and BGC-823/DDP and their sensitive parental cells by miRNAs microarray and followed by analysis of 2D-GE/MS to identify their target proteins. We found both miR-99a and miR-491 were upregulated while their target gene calpain small subunit 1 (CAPNS1) was downregulated in resistant gastric cancer cells. Dual-luciferase- reporter assays with wild-type and mutated CAPNS1 3-UTR confirmed their specificity of targeting. Inhibition of miR-99a and miR-491, or overexpress CAPNS1 can enhance cisplatin sensitivity of the resistant cells while transfection of two miRNAs mimics or si-CAPNS1 in the sensitive cells can induce their resistance. Moreover, our results demonstrated CAPNS1 positively regulated calpain1 and calpain2, the catalytic subunits of CAPNS1, and cleaved caspase3 which further cleaved PARP1 and directly induced apoptosis. cell line (SGC-7901, BGC-823,SGC-7901/DDP and BGC-823/DDP) up-regulated resistant CAPNS1 CAPNS1 NA validated 2161 miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway Zhonghua Xue Ye Xue Za Zhi 2016 27995886 miRBase MI0003130 miR-202 miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-PCR miR-202 and BAFF mRNA levels were detected by real-time PCR. U266 cells were transfected with miR-202-mimics, miR-202-inhibitor, siBAFF and their negative controls. After above treatments, protein levels of Bcl-2 family and MAPK signaling pathway were detected by Western blot analysis, and the proliferation and apoptosis ability of MM cells were examined by WST-1, Annexin V-FLUOS assay, respectively. cell line (U266) up-regulated sensitive BAFF BAFF JNK/SAPK signaling pathway validated 2162 Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway. Eur Rev Med Pharmacol Sci 2016 28051262 miRBase MI0000787 miR-379 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR Raw data of a microarray that compared transcriptional gene profile between 3-paired HCC tissue samples and adjacent normal tissues were downloaded from Expression Atlas (E-GEOD-33006). The raw data was reanalyzed to identify the significantly dysregulated genes, which were further used for PPI network and KEGG pathway analysis. The regulative effect of miR-379 on IGF1R expression was studied by dual luciferase assay and Western blotting. The functional role of miR-379 in chemosensitivity of HCC cells was studied by drug sensitivity and flow cytometric assay. cell line ( Huh7,HepG2) up-regulated sensitive IGF1R IGF1R IGF1/IGF1R signaling pathway validated 2163 Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway. Eur Rev Med Pharmacol Sci 2016 28051262 miRBase MI0000787 miR-379 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel hepatocellular carcinoma qRT-PCR Raw data of a microarray that compared transcriptional gene profile between 3-paired HCC tissue samples and adjacent normal tissues were downloaded from Expression Atlas (E-GEOD-33006). The raw data was reanalyzed to identify the significantly dysregulated genes, which were further used for PPI network and KEGG pathway analysis. The regulative effect of miR-379 on IGF1R expression was studied by dual luciferase assay and Western blotting. The functional role of miR-379 in chemosensitivity of HCC cells was studied by drug sensitivity and flow cytometric assay. cell line ( Huh7,HepG2) up-regulated sensitive IGF1R IGF1R IGF1/IGF1R signaling pathway validated 2164 Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway. Eur Rev Med Pharmacol Sci 2016 28051262 miRBase MI0000787 miR-379 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma qRT-PCR Raw data of a microarray that compared transcriptional gene profile between 3-paired HCC tissue samples and adjacent normal tissues were downloaded from Expression Atlas (E-GEOD-33006). The raw data was reanalyzed to identify the significantly dysregulated genes, which were further used for PPI network and KEGG pathway analysis. The regulative effect of miR-379 on IGF1R expression was studied by dual luciferase assay and Western blotting. The functional role of miR-379 in chemosensitivity of HCC cells was studied by drug sensitivity and flow cytometric assay. cell line ( Huh7,HepG2) up-regulated sensitive IGF1R IGF1R IGF1/IGF1R signaling pathway validated 2165 miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1. Pharmazie 2016 29441968 miRBase MI0000478 miR-149 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR In the study, we detected miR-149 expression by using RT-PCR and found that expression of miR-149 was downregulated in SGC7901/DDP cells compared with SGC7901cells, indicating a role of miR-149 in determining cisplatin-resistance of GC cells. Then, SGC7901/DDP cells were tansfected with miR-149 mimics, MTT assay was performed to determine SGC7901/DDP cell viability, and showed that overexpression of miR-149 inhibited the cell viability after cisplatin treatment, suggesting that up-regulation of miR-149 enhanced SGC7901/DDP cell sensitivity to cisplatin. Furthermore, we confirmed that Forkhead box M1 (FoxM1) is a direct target of miR-149 in SGC7901/DDP cells by using luciferase reporter assay. Besides, we also demonstrated that miR-149 enhances SGC7901/DDP cell sensitivity to cisplatin by downregulating FoxM1 expression. cell line (SGC7901, SGC7901/DDP) up-regulated sensitive FoxM1 FoxM1 NA validated 2166 MicroRNA-132 sensitizes nasopharyngeal carcinoma cells to cisplatin through regulation of forkhead box A1 protein. Pharmazie 2016 29442000 miRBase MI0000449 miR-132 miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( CNE2 ) up-regulated sensitive FOXA1 FOXA1 NA validated 2167 MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung Cancer 2017 27372519 miRBase MI0000113 miR-106a miRNA DB11805 Saracatinib lung cancer qPCR We screened autophagic activity in A549, H460, and H1299 NSCLC cell lines treated with two different Src-TKIs (saracatinib, dasatinib) or shRNA targeting SRC. The autophagy response was determined by LC3B-I to -II conversion, increased ULK1 epxression and increased GFP-LC3B dot formation. Autophagy was inhibited by pharmacological (bafilomycin A, chloroquine) or genetic (ULK1 shRNA) means. Expression of miR-106a and miR-20b was analyzed by qPCR, and we used different lentivral vectors for ectopic expression of either miR-106a mimetics, anti-sense miR-106a or different miR-106a-363 cluster constructs. cell line ( A549, H460, H1299) up-regulated sensitive ULK1 ULK1 NA validated 2168 MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung Cancer 2017 27372519 miRBase MI0000113 miR-106a miRNA DB01254 Dasatinib lung cancer qPCR We screened autophagic activity in A549, H460, and H1299 NSCLC cell lines treated with two different Src-TKIs (saracatinib, dasatinib) or shRNA targeting SRC. The autophagy response was determined by LC3B-I to -II conversion, increased ULK1 epxression and increased GFP-LC3B dot formation. Autophagy was inhibited by pharmacological (bafilomycin A, chloroquine) or genetic (ULK1 shRNA) means. Expression of miR-106a and miR-20b was analyzed by qPCR, and we used different lentivral vectors for ectopic expression of either miR-106a mimetics, anti-sense miR-106a or different miR-106a-363 cluster constructs. cell line ( A549, H460, H1299) up-regulated sensitive ULK1 ULK1 NA validated 2169 miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol 2017 27471108 miRBase MIMAT0004748 miR-423-5p miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR, qRT-PCR Real-time PCR was used to analyze the expression of microRNA-423-5p (miR-423-5p) in human glioma samples and normal brain tissue. Apoptosis, cell cycle, proliferation, immunostaining, transwell, in vitro 2D and 3D migration, and chemosensitivity assays were performed to assess the phenotypic changes in glioma cells overexpressing miRNA-423-5p. Western blotting was used to determine the expression of inhibitor of growth 4 (ING-4)in glioma tissues, and a luciferase reporter assay was conducted to confirm whether ING-4 is a direct target of miR-423-5p. Western blotting was used to identify the potential signaling pathways that are affected in glioma cell growth by miR-423-5p. Xenograft tumors were examined in vivo for the carcinogenic effects of miR-423-5p in glioma tissues. cell line (U87 and U251) up-regulated resistant ING-4 ING-4 AKT and ERK1/2 pathway validated 2170 Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer. Mol Carcinog 2017 27500472 miRBase MIMAT0004749 miR-424-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR In the study, to investigate the role of miR-424 in non-small cell lung cancer (NSCLC), we have detected the expression of miR-424-3p and -5p in NSCLC tissues and paired normal control. Moreover, to explore the role of miR-424-3p in NSCLC cells, miR-424-3p and -5p were both re-expressed and knocked down using transient transfection with their respective mimics and inhibitors. Cell viability, migration, and invasion were evaluated using MTT, wound-healing and Transwell assays, respectively. It was found that down-regulation of miR-424-3p was pronouncedly associated with NSCLC progression and overall prognosis; and that both miR-424-3p and -5p were markedly capable of preventing the proliferation, migration, and invasion in NSCLC cells. Additionally, it is miR-424-3p but not miR-424-5p that enhances the chemo-sensitivity of NSCLC cells through targeting YAP1. Mechanistically, YAP1 was identified as down-stream target of miR-424-3p. cell line (s H827, H2172, H441, A549, H1975 and PC14 ) up-regulated sensitive YAP1 YAP1 NA validated 2171 miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells. J Drug Target 2017 27633093 miRBase MIMAT0000070 miR-17-5p miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time reverse transcription PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (A549) down-regulated resistant EZH1 EZH1 NA validated 2172 MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells. J Cell Physiol 2017 27696394 miRBase MI0003134 miR-494 miRNA DB01204 (APRD00371) Mitoxantrone acute myeloid leukemia RT-PCR The role of miR-494 in acute myeloid leukemia cells was detected by real-time PCR, microRNA array analysis.western blot analysis,MTT assay,apoptosis analysis,subcutaneous tumor formation assay,and Xenograft mouse model.etc. tissue and cell line up-regulated sensitive NA NA NA validated 2173 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_015399 BRMS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2174 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004236 COPS2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2175 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_030667 PTPRO miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2176 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001627 ALCAM miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2177 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003071 HLTF miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2178 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001048201 UHRF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2179 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001218 CA12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2180 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006024 TAX1BP1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2181 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_181861 APAF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2182 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004557 NOTCH4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2183 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000782 CYP24A1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2184 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003941 WASL miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2185 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000059 BRCA2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2186 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000442 PECAM1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2187 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002178 IGFBP6 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2188 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_013398 ZNF224 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2189 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_021111 RECK miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2190 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_017817 RAB20 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2191 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_173084 TRIM59 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2192 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001962 EFNA5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2193 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000572 IL10 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2194 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001171092 CLDN2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2195 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016370 RAB9B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2196 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002528 NTHL1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2197 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002426 MMP12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2198 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002084 GPX3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2199 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005802 TOPORS miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2200 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_030753 WNT3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2201 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_199320 JADE1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2202 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000906 NPR1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2203 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002759 EIF2AK2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2204 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005225 E2F1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2205 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005556 KRT7 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2206 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000462 UBE3A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2207 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003472 DEK miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2208 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004330 BNIP2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2209 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005406 ROCK1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2210 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000425 L1CAM miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2211 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005113 GOLGA5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2212 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006378 SEMA4D miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2213 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006705 GADD45G miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2214 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014002 IKBKE miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2215 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_078468 BCCIP miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2216 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_020771 HACE1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2217 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016578 RSF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2218 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000314 PTEN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2219 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005537 ING1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2220 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_173842 IL1RN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2221 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014452 TNFRSF21 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2222 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002412 MGMT miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2223 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014739 BCLAF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2224 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002634 PHB miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2225 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005732 RAD50 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2226 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001198777 CUL2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2227 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000251 MSH2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2228 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001628 AKR1B1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2229 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001105562 UBE4B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2230 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_007034 DNAJB4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2231 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005985 SNAI1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2232 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006306 SMC1A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2233 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004688 NMI miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2234 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005235 ERBB4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2235 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004075 CRY1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2236 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_153253 SIPA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2237 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014708 KNTC1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2238 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016530 RAB8B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2239 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000930 PLAT miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2240 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002513 NME3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2241 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001136201 ISOC2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2242 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006806 BTG3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2243 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_013355 PKN3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2244 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001113491 SEPTIN9 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2245 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_022173 TIA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2246 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000460 THPO miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2247 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_012242 DKK1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2248 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005348 HSP90AA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2249 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005657 TP53BP1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2250 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001955 EDN1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2251 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_212472 PRKAR1A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2252 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_178448 SAPCD2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2253 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005234 NR2F6 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2254 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014708 KNTC1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2255 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006826 YWHAQ miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2256 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016836 RBMS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2257 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002434 MPG miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2258 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003474 ADAM12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2259 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004415 DSP miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2260 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_138761 BAX miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2261 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_199294 CENPS miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2262 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001356 DDX3X miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2263 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_015313 ARHGEF12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2264 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016478 ZC3HC1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2265 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004322 BAD miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2266 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000413366 PRKCA-202 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2267 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_022162 NOD2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2268 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004364 CEBPA miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2269 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004628 XPC miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2270 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004060 CCNG1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2271 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000782 CYP24A1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2272 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003211 TDG miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2273 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006785 MALT1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2274 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003461 ZYX miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2275 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002312 LIG4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2276 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005851 CDK2AP2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2277 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_012239 SIRT3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2278 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_052850 GADD45GIP1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2279 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000316843 LLGL1-201 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2280 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_018046 AGGF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2281 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005749 TOB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2282 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005754 G3BP1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2283 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005346 HSPA1B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2284 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000165 GJA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2285 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_020165 RAD18 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2286 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002687 PNN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2287 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004760 STK17A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2288 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014002 IKBKE miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2289 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_013258 PYCARD miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2290 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002412 MGMT miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2291 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002434 MPG miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2292 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_013258 PYCARD miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2293 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000320476 SCRIB-201 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2294 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_025235 TNKS2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2295 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001134398 VAV2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2296 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_012153 EHF miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2297 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003592 CUL1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2298 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000304636 COL3A1-201 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2299 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002128 HMGB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2300 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002084 GPX3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2301 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001620 AHNAK miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2302 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001530 HIF1A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2303 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005633 SOS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2304 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_018046 AGGF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2305 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001253 CDC5L miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2306 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005190 CCNC miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2307 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004094 EIF2S1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2308 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004690 LATS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2309 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001136201 ISOC2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2310 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000392142 MAP3K4-204 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2311 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_014750 DLGAP5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2312 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_020247 COQ8A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2313 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_134268 CYGB miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2314 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005245 FAT1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2315 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001254 CDC6 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2316 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004447 EPS8 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2317 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001992 F2R miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2318 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001913 CUX1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2319 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_172027 ABTB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2320 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001530 HIF1A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2321 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_032982 CASP2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2322 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003015 SFRP5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2323 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003079 SMARCE1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2324 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006207 PDGFRL miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2325 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016207 CPSF3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2326 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002165 ID1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2327 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_022777 IFT22 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2328 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000534 PMS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2329 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005994 TBX2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2330 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001620 AHNAK miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2331 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_022740 HIPK2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2332 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005378 MYCN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2333 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_145040 CAVIN3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2334 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002923 RGS2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2335 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002647 PIK3C3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2336 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002994 CXCL5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2337 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001184 ATR miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2338 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000396 CTSK miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2339 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002485 NBN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2340 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000489 ATRX miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2341 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_134323 TARBP2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2342 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001001924 MTUS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2343 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_032415 CARD11 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2344 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005234 NR2F6 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2345 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_052876 NACC1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2346 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001218 CA12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2347 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001254738 RND3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2348 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000359671 FN1-206 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2349 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_182663 RASSF5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2350 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003590 CUL3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2351 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001760 CCND3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2352 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016009 SH3GLB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2353 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000359671 FN1-206 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2354 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002775 HTRA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2355 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000101 CYBA miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2356 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004878 PTGES miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2357 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_004496 FOXA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2358 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002417 MKI67 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2359 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001760 CCND3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2360 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006325 RAN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2361 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000416 IFNGR1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2362 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000660 TGFB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2363 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016577 RAB6B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2364 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006838 METAP2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2365 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001096 ACLY miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2366 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016037 UTP11 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2367 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_022094 CIDEC miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2368 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003977 AIP miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2369 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_145040 CAVIN3 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2370 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002634 PHB miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2371 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001973 ELK4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2372 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_015560 OPA1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2373 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003377 VEGFB miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2374 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002276 KRT19 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2375 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003256 TIMP4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2376 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003840 TNFRSF10D miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2377 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005346 HSPA1B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2378 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_017489 TERF1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2379 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002835 PTPN12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2380 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_015399 BRMS1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2381 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001654 ARAF miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2382 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000371485 CEP55-201 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2383 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001177701 IFT27 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2384 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_006826 YWHAQ miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2385 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_001014831 PAK4 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2386 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000660 TGFB1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2387 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000314 PTEN miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2388 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_016381 TREX1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2389 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_007027 TOPBP1 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2390 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_021873 CDC25B miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2391 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_031934 RAB34 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2392 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_003474 ADAM12 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2393 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_058216 RAD51C miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2394 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_005560 LAMA5 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2395 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002866 RAB3A miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2396 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002423 MMP7 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2397 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_000251 MSH2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2398 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NM_002923 RGS2 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 2399 MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene 2017 27746366 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR Through pathway enrichment analyses for miR-222, we found that PTEN/Akt/FOXO1 signaling pathway may be of importance. RT-qPCR analyses and western blot assays confirmed the relationship between miR-222 expression and target genes. Immunofluorescence further visually displayed the location of FOXO1. When blocking PTEN/Akt/FOXO1 signaling pathway, we demonstrated the effects of miR-222-mediated ADR resistance by MTT and apoptosis assays. cell line ( MCF-7/S,MCF-7/ADR ) up-regulated resistant FOXO1 FOXO1 PTEN/Akt/FOXO1 pathway validated 2400 miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Biochem Biophys Res Commun 2017 27836543 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin lung cancer qPCR This study explored the role of miR-34a in regulating sensitivity of NSCLC cells to cisplatin and its downstream targets. The quantitative PCR result showed that miR-34a expression was upregulated in cisplatin sensitive NSCLC patients compared cisplatin insensitive NSCLC controls. By applying loss-and-gain function analysis, we demonstrated that miR-34a directly targeted to MYCN to sensitize NSCLC cells to cisplatin. In addition, p53 was found to monitor the expression of miR-34a in NSCLC cells after cisplatin treatment. cell line ( HEK293T, H226, H1299, A549, H1975,HCC827) up-regulated sensitive MYCN MYCN NA validated 2401 Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol 2017 27837435 miRBase MI0000298 miR-221 miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR This study aims at validating microRNA-221 (miR-221) as a biomarker for glioblastoma, and understanding how miR-221 regulates glioblastoma progression. Using clinical samples, miR-221 expression was analyzed by quantitative reverse-transcriptase PCR (qPCR). SHG-44 cells were treated with anti-miR-221 or U87MG-derived exosomes followed by monitoring changes in cell viability, migration and temozolomide (TMZ) resistance. Bioinformatics approach was used to identify targets of miR-221. The interaction between miR-221 and its target, DNM3 gene, was studied with dual-luciferase reporter assay, Spearmans correlation analysis, and western blotting. To verify that RELA regulates miR-221 expression, RELA-expressing vector or shRNA was introduced into SHG-44 cells and its effect on miR-221 expression was monitored. Both tissue-level and exosomal miR-221 expression increased with glioma grades. In SHG-44 cells, downregulating miR-221 expression inhibited cell proliferation, migration, and TMZ resistance, whereas incubation with U87MG-derived exosomes exerted tumor-promoting effects. DNM3 gene is a target of miR-221. RELA induced miR-221 expression. In glioma, elevated miR-221 expression is a biomarker for glioma. DNM3 is a target of miR-221 and RELA regulates miR-221 expression. The RELA/miR-221 axis is a target for glioma diagnosis and therapy. cell line (SHG-44 ) down-regulated sensitive DNM3 DNM3 NA validated 2402 miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. Oncol Rep 2017 27840955 miRBase MI0000457 miR-141 miRNA DB01248 (APRD00932) Docetaxel lung non-small cell carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (H1299 and H2009) down-regulated sensitive EIF4E EIF4E EIF4E, VEGF, c-Myc and Bax signaling pathway validated 2403 miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5-fluorouracil by targeting EIF4E. Oncol Rep 2017 27840964 miRBase MI0003188 miR-503 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-qPCR miR-503 was found in HCC tissues and cell lines using quantitative real-time PCR (RT-qPCR). Western blot analyses and the luciferase reporter assay were used to determine the miR-503 potential target in the HCC cells. We used MTT to analyze cell proliferation activity and noted that there was a considerable decrease of miR-503 in HCC tissues and cell lines when measured against the controls. miR-503 upregulation decreased expression of eukaryotic translation initiation factor 4E (EIF4E), and reduced HCC cell proliferation and sensitized HCC cells to anticancer drugs. miR-503 overexpression hindered luciferase activity of EIF4E 3 untranslated region-based reporter construct among HepG2, BEL-7402, and SMMC-7721 cells, revealing that miR-503 may increase sensitivity to therapies at least partially through targeting EIF4E suppression of HCC proliferation. cell line ( HepG2, BEL-7402, SMMC-7721,L-02) up-regulated resistant EIF4E EIF4E NA validated 2404 MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. Oncol Rep 2017 27840990 miRBase MI0000738 miR-302a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR In this study, we used two human colon cancer cell lines, HCT116 and HT29, and evaluated the influence of miR-302a on 5-fluorouracil (5-FU)-induced cell death and viability inhibition. With bioinformatics tools, we hypothesized that insulin-like growth factor-1 receptor (IGF-1R) is a novel target of miR-302a, which we confirmed using a luciferase reporter assay and immunoblotting. Then, we designed siRNA against IGF-1R and found that si-IGF-1R resembled the effect of miR-302a on 5-FU treatment. Both miR-302a and si-IGF-1R inhibited Akt signaling. In conclusion, miR-302a targeted IGF-1R and enhanced 5-FU-induced cell death and viability inhibition in human colon cancer cells. cell line (HCT116 and HT29) up-regulated sensitive IGF-1R IGF-1R PI3K/Akt pathway validated 2405 Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia 2017 27857131 miRBase MI0000454 miR-137 miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma qRT-PCR In this study, we demonstrated that miR-137 was significantly downregulated in MM and negatively correlated with clinical prognosis. Moreover, we described the epigenetic regulation of miR-137 and its association with progression-free survival in MM patients. Furthermore, overexpression of miR-137 in MM cell line (miR-137 OE) increased its sensitivity to bortezomib and eprirubicin in vitro. Also, some high-risk genetic abnormalities in MM, including deletion of chromosome 1p22.2, 14q or 17p13, and gain of chromosome 1p22.2 were detected in NCI-H929 empty vector (NCI-H929 EV) treated cells but not in the NCI-H929 miR-137 overexpression (NCI-H929 miR-137 OE) cells. Luciferase reporter assays demonstrated that miR-137 targeted AURKA. Ectopic expression of miR-137 strongly reduced the expression of AURKA and p-ATM/Chk2 in MM cells, and increased the expression of p53, and p21. Importantly, miR-137 overexpression together with bortezomib treatment significantly inhibited tumor growth in MM xenograft model. cell line ( NCI-H929, MM1S, U266, KMS11, OPM2, and PRMI 8226 ) up-regulated sensitive AURKA AURKA NA validated 2406 Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia 2017 27857131 miRBase MI0000454 miR-137 miRNA DB00445 (APRD00361) Epirubicin multiple myeloma qRT-PCR In this study, we demonstrated that miR-137 was significantly downregulated in MM and negatively correlated with clinical prognosis. Moreover, we described the epigenetic regulation of miR-137 and its association with progression-free survival in MM patients. Furthermore, overexpression of miR-137 in MM cell line (miR-137 OE) increased its sensitivity to bortezomib and eprirubicin in vitro. Also, some high-risk genetic abnormalities in MM, including deletion of chromosome 1p22.2, 14q or 17p13, and gain of chromosome 1p22.2 were detected in NCI-H929 empty vector (NCI-H929 EV) treated cells but not in the NCI-H929 miR-137 overexpression (NCI-H929 miR-137 OE) cells. Luciferase reporter assays demonstrated that miR-137 targeted AURKA. Ectopic expression of miR-137 strongly reduced the expression of AURKA and p-ATM/Chk2 in MM cells, and increased the expression of p53, and p21. Importantly, miR-137 overexpression together with bortezomib treatment significantly inhibited tumor growth in MM xenograft model. cell line ( NCI-H929, MM1S, U266, KMS11, OPM2, and PRMI 8226 ) up-regulated sensitive AURKA AURKA NA validated 2407 MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. Gene 2017 27871924 miRBase MI0000816 miR-335 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The role of miR-335 in the regulation of chemosensitivity and radiosensitivity of small cell lung cancer (SCLC) was investigated. miR-335 was significantly downregulated in multi-drug-resistant SCLC H69AR and H446DDP cells compared with parental cells as detected by qRT-PCR. Then, we demonstrated the negative correlation between miR-335 expression and the chemo-radiosensitivity of SCLC cells, including cell proliferation, cell clonality and cell apoptosis. In addition, miR-335 overexpression inhibited cell migration in vitro and tumor growth in vivo, whereas inhibition of miR-335 promoted cell migration and tumor growth. The underlying mechanism was further studied. Poly [ADP-ribose] polymerase 1 (PARP-1) was identified as a direct target gene of miR-335 in SCLC by bioinformatics analysis and validated via luciferase reporter assay. Overexpression of miR-335 decreased the expression of PARP-1 mRNA and protein, and NF-kappaB protein levels were correspondingly downregulated, thus regulating the chemo-radiosensitivity of SCLC. cell line (H69AR, H446DDP) down-regulated resistant PARP-1 PARP-1 NF-kappaB pathway validated 2408 MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. Gene 2017 27871924 miRBase MI0000816 miR-335 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma qRT-PCR The role of miR-335 in the regulation of chemosensitivity and radiosensitivity of small cell lung cancer (SCLC) was investigated. miR-335 was significantly downregulated in multi-drug-resistant SCLC H69AR and H446DDP cells compared with parental cells as detected by qRT-PCR. Then, we demonstrated the negative correlation between miR-335 expression and the chemo-radiosensitivity of SCLC cells, including cell proliferation, cell clonality and cell apoptosis. In addition, miR-335 overexpression inhibited cell migration in vitro and tumor growth in vivo, whereas inhibition of miR-335 promoted cell migration and tumor growth. The underlying mechanism was further studied. Poly [ADP-ribose] polymerase 1 (PARP-1) was identified as a direct target gene of miR-335 in SCLC by bioinformatics analysis and validated via luciferase reporter assay. Overexpression of miR-335 decreased the expression of PARP-1 mRNA and protein, and NF-kappaB protein levels were correspondingly downregulated, thus regulating the chemo-radiosensitivity of SCLC. cell line (H69AR, H446DDP) down-regulated resistant PARP-1 PARP-1 NF-kappaB pathway validated 2409 MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. Gene 2017 27871924 miRBase MI0000816 miR-335 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR The role of miR-335 in the regulation of chemosensitivity and radiosensitivity of small cell lung cancer (SCLC) was investigated. miR-335 was significantly downregulated in multi-drug-resistant SCLC H69AR and H446DDP cells compared with parental cells as detected by qRT-PCR. Then, we demonstrated the negative correlation between miR-335 expression and the chemo-radiosensitivity of SCLC cells, including cell proliferation, cell clonality and cell apoptosis. In addition, miR-335 overexpression inhibited cell migration in vitro and tumor growth in vivo, whereas inhibition of miR-335 promoted cell migration and tumor growth. The underlying mechanism was further studied. Poly [ADP-ribose] polymerase 1 (PARP-1) was identified as a direct target gene of miR-335 in SCLC by bioinformatics analysis and validated via luciferase reporter assay. Overexpression of miR-335 decreased the expression of PARP-1 mRNA and protein, and NF-kappaB protein levels were correspondingly downregulated, thus regulating the chemo-radiosensitivity of SCLC. cell line (H69AR, H446DDP) down-regulated resistant PARP-1 PARP-1 NF-kappaB pathway validated 2410 miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. Oncol Rep 2017 27878272 miRBase MI0001519 miR-20b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-qPCR In the present study, we first determined the expression of miR-20b by RT-PCR and the levels of a disintegrin and metalloprotease 9 (ADAM9) and epidermal growth factor receptor (EGFR) by western blotting in CC and adjacent non-cancerous tissues from 5-FU-sensitive or -resistant CC patients. Subsequently, 5-FU-sensitive (HCT116) and -resistant (HCT116-R) cells were obtained, and the levels of miR-20b, ADAM9 and EGFR were detected. Meanwhile, the 5-FU resistance of the cells was examined by assessing cell viability (by MTT assay) and apoptosis (by flow cytometry). After transfection of miR-20b into HCT116-R cells, drug resistance was reexamined. We then confirmed the relationship between miR-20b and ADAM9 by luciferase reporter assay. Finally, 5-FU resistance in HCT116 and HCT116-R cells was compared after transfection with miR-20b. cell line ( HCT116 ) up-regulated sensitive ADAM9 ADAM9 ADAM9/EGFR signaling pathway validated 2411 Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget 2017 27880941 miRBase MIMAT0002849 miR-524-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Expressions of MiR-524-5p was detected in GC tissues and cell lines by qRT-PCR. Cell proliferation was observed by MTT assay; Cell migration was detected by transwell migration and invasion assay. The targeting protein of miR-524-5p was identified by luciferase reporter assay and western blot. cell line ( SC-M1, AGS, AZ521 ) up-regulated sensitive SOX9 SOX9 NA validated 2412 MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett 2017 27887917 miRBase MI0000475 miR-136 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR To identify microRNAs (miRNAs) regulating Notch3 expression in association with paclitaxel resistance, candidate miRNAs targeting Notch3 were predicted using TargetScan. We found that miR-136 directly targets Notch3, and miR-136 was significantly downregulated in OSC tissues relative to normal control tissues, and low expression of miR-136 correlated with poor overall in ovarian cancer patients. Artificial miR-136 overexpression significantly reduced cell viability, proliferation, Cancer stem cell (CSC) spheroid formation, and angiogenesis, and increased apoptosis in paclitaxel-resistant SKpac cells compared with the effects of paclitaxel alone. miR-136 overexpression downregulated cell survival- (survivin, DNA-PK, pS6, S6) and cell cycle- (Cyclin D1, NF-kappaB) related proteins, and anti-apoptotic proteins (BCL2, and BCL-XL), and upregulated pro-apoptotic proteins (Bim, Bid, and Bax). Taken together, miR-136 targets the Notch3 oncogene and functions as a tumor suppressor. miR-136 overexpression resensitized paclitaxel-resistant ovarian cancer cells and reduced CSC activities, suggesting a promising new target for the treatment of chemoresistant ovarian cancers. cell line (SKOV3) up-regulated sensitive Notch3 Notch3 NA validated 2413 MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. Gene 2017 27913185 miRBase MI0000826 miR-346 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR In our study, miR-346 mimic, inhibitor, negative control or si-SRCIN1 were transfected into MCF-7 and MCF-7/Doc cells, respectively. Quantitative real time PCR (qRT-PCR) was used to measure miR-346 and SRCIN1 mRNA expressions and western blot was used to detect the expression of SRCIN1 in protein level. CCK-8 and colony formation were employed to verify cell viability and proliferation. Flow cytometry showed the apoptosis. Transwell was performed to detect migration and invasion. The luciferase reporter assay data showed the target correlation of miR-346 and SRCIN1. cell line ( MCF-7, HBL-100 ) up-regulated sensitive SRCIN1 SRCIN1 NA validated 2414 MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. J Cell Biochem 2017 27918099 miRBase MI0003137 miR-193b miRNA DB00515 (APRD00359) Cisplatin urothelial carcinoma qRT-PCR In current study, a large-scale PCR-based miRNA screening was performed to identify CEBPD-associated miRNAs in urothelial carcinoma cell line NTUB1. Eleven miRNAs were selected with more than twofold changes. MiR-193b-3p, a known tumor suppressor, down-regulated proto-oncogenes Cyclin D1, and ETS1 expression and led to cell cycle arrest, cell invasion, and migration inhibition. The expression of miR-193b-3p was associated with the DNA binding ability of CEBPD in CDDP response. CEBPD knocking-down approach provided a strong evidence of the positive correlation between CEBPD and miR-193b-3p. CDDP-induced CEBPD trans-activated miR-193b-3p expression and it directly targeted the 3-UTR of Cyclin D1 and ETS1 mRNA, and silenced the protein expression. In addition, miR-193b-3p also inhibited cell migration activity, arrested cell at G1 phase, and sensitized NTUB1 to CDDP treatment. cell line ( NTUB1 ) up-regulated sensitive ETS1 and Cyclin D1 ETS1 and Cyclin D1 NA validated 2415 MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget 2017 27926502 miRBase MIMAT0001627 miR-433-3p miRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR In the study, we investigate the potential role of miR-433 in glioma. Quantitative real-time PCR demonstrated that miR-433-3p and miR-433-5p were low expressed in glioma tissues and cell lines. Functional studies suggested that the overexpression of miR-433-3p suppressed proliferation, induced apoptosis and inhibited invasion and migration of human glioma cells. But the growth and metastasis of glioma cells were not significantly influenced by overexpression of miR-433-5p. In a xenograft model, we also showed that miR-433-3p had an inhibitory effect on the growth of glioma. Bioinformatics coupled with luciferase and western blot assays revealed that CREB is a direct target of miR-433-3p, and the overexpression of CREB can rescue the phenotype changes induced by miR-433-3p overexpression. Besides, miR-433-3p could increase chemosensitivity of glioma to temozolomide by targeting CREB in vitro and in vivo. cell line (U251, U87, LN229, SNB19, LN308) up-regulated sensitive CREB CREB NA validated 2416 miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. Biomed Pharmacother 2017 27930974 miRBase MI0000650 miR-200c miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR We explored the role of miR-200c in modulating the sensitivity of gefitinib-resistant NSCLC cells and examined the underlying mechanism. The gefitinib-resistant cell line PC-9-ZD and its parental PC-9 cells were used. Growth inhibition was detected by MTT assay. The cell apoptosis was detected by Annexin V/PI assay. Cell migration was assessed by wound-healing assay. RT-PCR was used to detected levels of miR-200c and ZEB1. The PI3k, Bcl-2, Bax, caspase-3 and ZEB1 protein expression were detected using Western blot analysis, and TUNEL, Immunohistochemistry for xenograft model. cell line (PC-9,PC-9-ZD) up-regulated sensitive ZEB1 ZEB1 PI3K/AKT signaling pathway validated 2417 microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Cancer Lett 2017 27940128 miRBase MI0000286 miR-210 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR By microarray and qRT-PCR, we observed significant downregulation of microRNA-210 in gemcitabine-resistant cells. The overexpression of microRNA-210 was toxic to gemcitabine-resistant cells and enhanced gemcitabine sensitivity. MicroRNA-210 overexpression induced caspase-3-mediated apoptosis, and inhibited colony formation. Computationally, ABCC5, a highly expressed gene in our array data, was identified as a potential target of microRNA-210 and the overexpression of ABCC5 in gemcitabine-resistant cells was confirmed by qRT-PCR. MicroRNA-210 overexpression reduced ABCC5 mRNA levels and inhibited a luciferase reporter expressing the ABCC5 3 UTR. The expression pattern of microRNA-210 and ABCC5 was mirrored in all of 5 pancreatic cancer cell lines used. Likewise, microRNA-210 transfection nearly totally inhibited tumor xenograft growth, proliferation and metastasis without obvious side effects in vivo. Also, an absence or low expression of microRNA-210 correlated to high ABCC5 expression in the majority of malignant patient tissues from a total of 101 patient tissues examined. tissue and cell line ( BxPC-3, AsPC-1 and MIA-PaCa2 ) up-regulated sensitive ABCC5 ABCC5 NA validated 2418 mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27. Oncotarget 2017 27974673 miRBase MI0000295 miR-218-2 miRNA NA Beta-lapachone glioblastoma RT-PCR MiRNA expression was detected by reverse transcription-quantitative polymerase chain reaction (rt-qpcr) and protein expression was detected by Western blot.Luciferase activity assay was used to verify the target genes of mirna.MTT assay detects changes in drug-resistant phenotypes of cancer cells by over-regulating mirnas., etc. cell line ( HA-1800,U251, U87, U118 ) up-regulated resistant CDC27 CDC27 APC ubiquitin-proteasome pathway validated 2419 micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. Biochem Biophys Res Commun 2017 27988337 miRBase MI0000103/MI0000739 miR-101 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Apoptosis was detected by caspase-3 activity cell line ( PANC-1 ) up-regulated sensitive DNA-PKcs NA NA validated 2420 MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma. Oncotarget 2017 27992364 miRBase MI0000749 miR-30e miRNA DB00317 (APRD00997, DB07998) Gefitinib lung carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (PC9, PC9G, HCC827, HCC827/GR,293T ) up-regulated sensitive HOXA1 HOXA1 NA validated 2421 hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Oncol Rep 2017 28000886 miRBase MI0003645 miR-631 miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-PCR This study demonstrated, for the first time, that UbcH10 is highly expressed in BTZ-resistant myeloma cell lines U-266/BTZ, NCI-H929/BTZ and RPMI-8226/BTZ, which is attributed to the inactivation of post-transcriptional control. The in-depth study revealed that during the development of BTZ resistance in these cells, the hsa-miR-631 levels were decreased, which resulted in the increased expression of the target gene UbcH10. We also found that the multiple drug-resistant protein MDR1 exhibited a positive correlation with UbcH10 due to the reduced ubiquitination of MDR1, which was caused by high UbcH10 expression. Following overexpression of miR-631, both BTZ sensitivity and BTZ-induced apoptosis were enhanced in the resistant cells. Meanwhile, resensitization by miR-631 overexpression was blocked by exogenous expression of UbcH10, which was not regulated by intracellular miR-631. In conclusion, the miR-631/UbcH10/MDR1 pathway is closely associated with the development of BTZ resistance in myeloma cells, and the overexpression of miR-631 can significantly improve BTZ sensitivity in resistant myeloma cells. cell line (U-266, NCI-H929, RPMI-8226, 293T) up-regulated sensitive UbcH10 UbcH10 miR-631/UbcH10/MDR1 pathway validated 2422 miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer. Oncol Rep 2017 28004114 miRBase MI0000076 miR-20a miRNA NA TRAIL therapy colorectal cancer qRT-PCR In the present study, we demonstrated significant upregulation of miR-20a in the serum of colorectal cancer patients, tumor tissues and cell lines by quantitative RT-PCR analysis. Furthermore, we found that the TRAIL-induced apoptosis was associated with the expression level of miR-20a in colorectal cancer. The knockdown of miR-20a by inhibitors increased the antitumor effect of TRAIL via caspase-8 dependent pathway. BID, which is a pro-apoptotic member of the Bcl-2 family, was found to be directly regulated by miR-20a in SW480 cells. The knockdown of miR-20a inhibited the translocation of tBID to the mitochondria, which induced the mitochondrial pathway of apoptosis. Notably, we found that the knockdown of miR-20a also reversed the resistance of TRAIL in established TRAIL-resistant SW480 cells by tBID-mitochondria pathway. cell line (SW480, SW948, NCI-H508, HT-29 ) down-regulated sensitive BID BID NA validated 2423 MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett 2017 28008602 miRBase MIMAT0000765 miR-335-5p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Quantitative information of cell relative density was obtained by crystal violet assay cell line ( MCF-7,MCF-7-TR and MCF-7-FR ) up-regulated resistant ERalpha NA ERalpha signaling pathway validated 2424 MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett 2017 28008602 miRBase MIMAT0004703 miR-335-3p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Quantitative information of cell relative density was obtained by crystal violet assay cell line ( MCF-7,MCF-7-TR and MCF-7-FR ) up-regulated resistant ERalpha NA ERalpha signaling pathway validated 2425 MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother 2017 28012924 miRBase MI0000252/MI0000473 miR-129 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT- PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line up-regulated sensitive P-gp NA the intrinsic apoptotic pathway validated 2426 MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomark 2017 28035913 miRBase MI0000454 miR-137 miRNA DB00526 (APRD00186) Oxaliplatin colon cancer qRT-PCR In this study, we utilized microRNA microarray analysis and real-time PCR to verify that miR-93, miR-191, miR-137, miR-181 and miR-491-3p were significantly down-regulated and that miR-96, miR-21, miR-22, miR-15b and miR-92 were up-regulated in both HCT-15/OXA and SW480/OXA cell lines. Blocking miR-137 caused a significant inhibition of OXA-induced cytotoxicity, therefore, miR-137 was chosen for further research. An in vitro cell viability assay showed that knockdown of miR-137 in HCT-15 and SW480 cells caused a marked inhibition of OXA-induced cytotoxicity. Moreover, we found that miR-137 was involved in repression of YBX1 expression through targeting its 3-untranslated region. Furthermore, down-regulation of miR-137 conferred OXA resistance in parental cells, while over-expression of miR-137 sensitized resistant cells to OXA, which was partly rescued by YBX1 siRNA. cell line ( HCT15, SW480) up-regulated sensitive YBX1 YBX1 NA validated 2427 MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer. Mol Carcinog 2017 28052414 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin prostate cancer PCR In this study, we explored miR-218 increased the chemosensitivity to cis-diaminedichloroplatinum treatment of prostate cancer. We found that the expression level of miR-218 was down-regulated in the human prostate cancer specimens. Moreover, overexpression of miR-218 inhibited cell viability, migration and invasion in PC3 and DU145 cells. Furthermore, we demonstrated that the tumor suppressive role of miR-218 was mediated by negatively regulating branched-chain amino acid transaminase 1 (BCAT1) protein expression. Importantly, overexpression of BCAT1 decreased the chemosensitivity to CDDP treatment of PC3 and DU145 cells. cell line (PC3, DU145 ) down-regulated resistant BCAT1 BCAT1 NA validated 2428 MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget 2017 28061479 miRBase MI0000080/MI0000081 miR-24 miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription- polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (T47D, BT-549, MDA-MB-231, and MCF-7) up-regulated resistant FIH1 FIH1 FIH1/HIFalpha pathway validated 2429 Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother Pharmacol 2017 28063065 miRBase MI0000285 miR-205 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR Breast epithelial (MCF10A), breast cancer (MCF7), and natural tamoxifen-resistant breast cancer (MDA-MB-231) cell lines were selected, and the relative lncRNA-ROR expressions were detected using quantitative real-time polymerase chain reaction (qRT-PCR). In vitro induction of TR5 cell line was performed. There were six groups: MCF7, MCF7/TR5, MDA-MB-231, MCF7-ROR, MCF7/TR5 ROR-siRNA, and the MDA-MB-231 ROR-siRNA groups. CCK-8 assay was conducted to assess the changes in drug resistance of each group. The expression of the epithelial mesenchymal transition (EMT) marker was detected using Western blotting. Transwell was selected to test the invasive ability of the cells. Expressions of microRNA-205 (miR-205) and ZEB1/2 were detected using qRT-PCR . cell line (MCF7, MCF7/TR5, MDA-MB-231, MCF7-ROR, MCF7/TR5 ROR-siRNA, and the MDA-MB-231) up-regulated sensitive ZEB1 and ZEB2 ZEB1 and ZEB2 NA validated 2430 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun 2017 28063929 miRBase MI0000253 miR-148a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of miR-148a and miR-152 in ERt breast cancer cells was detected by qRT-PCR, western blot analysis,dual luciferase assay, and follow cytometric analysis.etc. tissue and cell line ( MCF-7 ) up-regulated sensitive ALCAM ALCAM NA validated 2431 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun 2017 28063929 miRBase MI0000462 miR-152 miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of miR-148a and miR-152 in ERt breast cancer cells was detected by qRT-PCR, western blot analysis,dual luciferase assay, and follow cytometric analysis.etc. tissue and cell line ( MCF-7 ) up-regulated sensitive ALCAM ALCAM NA validated 2432 Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer Med 2017 28064447 miRBase MI0003138 miR-497 miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SF295, SHG-44, U138, LN382, U87, U251, HEK-293) up-regulated resistant mTOR/Bcl-2 mTOR/Bcl-2 IGF1R/IRS1 pathway validated 2433 MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 Mol Cancer Ther 2017 28069878 miRBase MI0000294/MI0000295 miR-218 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-PCR, qRT-PCR The role of MALAT1 in colorectal cancer cells was detected using quantitative real-time PCR and RT-qPCR, cell viability assay, immunofluorescence analysis and western blot,etc. cell line (HT29, SW480, SW620,FHC) up-regulated sensitive NA NA NA validated 2434 MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 Mol Cancer Ther 2017 28069878 miRBase MI0000294/MI0000295 miR-218 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR, qRT-PCR The role of MALAT1 in colorectal cancer cells was detected using quantitative real-time PCR and RT-qPCR, cell viability assay, immunofluorescence analysis and western blot,etc. cell line (HT29, SW480, SW620,FHC) up-regulated sensitive NA NA NA validated 2435 MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 Mol Cancer Ther 2017 28069878 miRBase MI0000294/MI0000295 miR-218 miRNA DB00650 (APRD00698) Leucovorin colorectal cancer RT-PCR, qRT-PCR The role of MALAT1 in colorectal cancer cells was detected using quantitative real-time PCR and RT-qPCR, cell viability assay, immunofluorescence analysis and western blot,etc. cell line (HT29, SW480, SW620,FHC) up-regulated sensitive NA NA NA validated 2436 The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer 2017 28073349 miRBase MIMAT0000255 miR-34a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR A RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells was performed to detect the levels of miR-34a-5p. Bioinformatics analysis revealed that AGTR1 is one of the target genes of miR-34a-5p. The mRNA and protein levels of AGTR1 were detected in both the miR-34a-5p-mimic transfected G-292 and miR-34a-5p-antagomiR transfected SJSA-1 cells. The involvement of AGTR1 with OS chemoresistance was validated by the experiments with siRNA-mediated repression or overexpression of the AGTR1 gene. cell line (SJSA-1 (ATCC NO. CRL-2098,G-292) up-regulated resistant AGTR1 AGTR1 NA validated 2437 The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer 2017 28073349 miRBase MIMAT0000255 miR-34a-5p miRNA DB00773 (APRD00239) Etoposide osteosarcoma qRT-PCR A RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells was performed to detect the levels of miR-34a-5p. Bioinformatics analysis revealed that AGTR1 is one of the target genes of miR-34a-5p. The mRNA and protein levels of AGTR1 were detected in both the miR-34a-5p-mimic transfected G-292 and miR-34a-5p-antagomiR transfected SJSA-1 cells. The involvement of AGTR1 with OS chemoresistance was validated by the experiments with siRNA-mediated repression or overexpression of the AGTR1 gene. cell line (SJSA-1 (ATCC NO. CRL-2098,G-292) up-regulated resistant AGTR1 AGTR1 NA validated 2438 The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer 2017 28073349 miRBase MIMAT0000255 miR-34a-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR A RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells was performed to detect the levels of miR-34a-5p. Bioinformatics analysis revealed that AGTR1 is one of the target genes of miR-34a-5p. The mRNA and protein levels of AGTR1 were detected in both the miR-34a-5p-mimic transfected G-292 and miR-34a-5p-antagomiR transfected SJSA-1 cells. The involvement of AGTR1 with OS chemoresistance was validated by the experiments with siRNA-mediated repression or overexpression of the AGTR1 gene. cell line (SJSA-1 (ATCC NO. CRL-2098,G-292) up-regulated resistant AGTR1 AGTR1 NA validated 2439 The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer 2017 28073349 miRBase MIMAT0000255 miR-34a-5p miRNA DB00958 (APRD00466) Carboplatin osteosarcoma qRT-PCR A RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells was performed to detect the levels of miR-34a-5p. Bioinformatics analysis revealed that AGTR1 is one of the target genes of miR-34a-5p. The mRNA and protein levels of AGTR1 were detected in both the miR-34a-5p-mimic transfected G-292 and miR-34a-5p-antagomiR transfected SJSA-1 cells. The involvement of AGTR1 with OS chemoresistance was validated by the experiments with siRNA-mediated repression or overexpression of the AGTR1 gene. cell line (SJSA-1 (ATCC NO. CRL-2098,G-292) up-regulated resistant AGTR1 AGTR1 NA validated 2440 MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep 2017 28074905 miRBase MI0003123 miRNA-488 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Quantitative Reverse transcription-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Using bioinformatics analysis prediction and confirmation with dual-luciferase reporter assays, we found the target genes of miRNAs cell line ( A549 and H1299) up-regulated resistant eIF3a eIF3a NER pathway validated 2441 miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep 2017 28075453 miRBase MI0000783 miR-375 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MCF-7) up-regulated sensitive HOXB3 HOXB3 NA validated 2442 MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 2017 28079894 miRBase MI0000083/MI0000750 miR-26a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-qPCR In the study, we found that chemotherapeutic drug doxorubicin (Dox) induced autophagy but decreased the level of miR-26a/b in HCC cells. Activating autophagy using rapamycin can directly downregulate the level of miR-26a/b in HCC cells. In turn, restoring the expression of miR-26a/b inhibited autophagy induced by Dox and promoted apoptosis in HCC cells. Further mechanistic study identified that miR-26a and miR-26b target ULK1, a critical initiator of autophagy, at post-transcriptional level. Results from 30 cases of patients with HCC also showed that tumor cellular levels of miR-26a and miR-26b are significantly downregulated as compared with the corresponding control tissues and negatively correlated with the protein level of ULK1 but are not correlated to the mRNA level of ULK1. Gain- and loss-of-function assay confirmed that miR-26a/b inhibited autophagic flux at the initial stage through targeting ULK1. Overexpression of miR-26a/b enhanced the sensitivity of HCC cells to Dox and promoted apoptosis via inhibiting autophagy in vitro. Using xenograft models in nude mice, we confirmed that miR-26a/b, via inhibiting autophagy, promoted apoptosis and sensitized hepatomas to Dox treatment in vivo. Our findings demonstrate for the first time that miR-26a/b can promote apoptosis and sensitize HCC to chemotherapy via suppressing the expression of autophagy initiator ULK1, and provide the reduction of miR-26a/b in HCC as a novel mechanism of tumor chemoresistance. cell line (HepG2, Huh-7, 293T,HepG2/Dox) up-regulated sensitive ULK1 ULK1 NA validated 2443 MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 2017 28079894 miRBase MI0000084 miR-26b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-qPCR In the study, we found that chemotherapeutic drug doxorubicin (Dox) induced autophagy but decreased the level of miR-26a/b in HCC cells. Activating autophagy using rapamycin can directly downregulate the level of miR-26a/b in HCC cells. In turn, restoring the expression of miR-26a/b inhibited autophagy induced by Dox and promoted apoptosis in HCC cells. Further mechanistic study identified that miR-26a and miR-26b target ULK1, a critical initiator of autophagy, at post-transcriptional level. Results from 30 cases of patients with HCC also showed that tumor cellular levels of miR-26a and miR-26b are significantly downregulated as compared with the corresponding control tissues and negatively correlated with the protein level of ULK1 but are not correlated to the mRNA level of ULK1. Gain- and loss-of-function assay confirmed that miR-26a/b inhibited autophagic flux at the initial stage through targeting ULK1. Overexpression of miR-26a/b enhanced the sensitivity of HCC cells to Dox and promoted apoptosis via inhibiting autophagy in vitro. Using xenograft models in nude mice, we confirmed that miR-26a/b, via inhibiting autophagy, promoted apoptosis and sensitized hepatomas to Dox treatment in vivo. Our findings demonstrate for the first time that miR-26a/b can promote apoptosis and sensitize HCC to chemotherapy via suppressing the expression of autophagy initiator ULK1, and provide the reduction of miR-26a/b in HCC as a novel mechanism of tumor chemoresistance. cell line (HepG2, Huh-7, 293T,HepG2/Dox) up-regulated sensitive ULK1 ULK1 NA validated 2444 Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. Cancer Biomark 2017 28085008 miRBase MI0000439 miR-23b miRNA DB00515 (APRD00359) Cisplatin chondrosarcoma qRT-PCR The expression levels of miRNA were determined by Quantitative RT PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SW1353, OUMS-27, CH-2879, CHON-001, C-28/l2) up-regulated sensitive Src Src Src-Akt pathway validated 2445 MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovarian Res 2017 28086946 miRBase MI0006444 miR-1307 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol ovarian cancer qRT-PCR IC50 determination was used to test the chemoresistance profling in ovarian cancer cells. QRT-PCR or western blot was used to validate the expression level of miR-1307 and candidate gene or protein. Colony formation assay and FITC-labeled enhanced Annexin V immunofluorescence were used to compare cell proliferation and apoptosis ability, respectively. The potential target gene and its biological function of miRNA-1307 were also analyzed. Bioinformatics and Luciferase Reporter Gene Assay were conducted to validate the regulation of miRNA-1307 on the ING5 expression. Xenografts assay was used to demonstrate the inhibiting effect of miR-1307 ASO and Taxol therapy against ovarian cancer in vivo. cell line (A2780, SKOV3,A2780/Taxol,SKOV3) up-regulated resistant ING5 ING5 NA validated 2446 Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by hsa-miR-125a-3p via Modulation of Metastasis-Associated Protein 1 Signaling. Urology 2017 28088556 miRBase MIMAT0004602 miR-125a-3p miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR The expression levels of hsa-miR-125a-3p were assessed in chemoresistant PCa tissues and experimentally established chemoresistant cells using quantitative reverse transcription-polymerase chain reaction. The effect of hsa-miR-125a-3p knockdown or hsa-miR-125a-3p overexpression on the Dox-induced cell death was evaluated using apoptosis ELISA in chemosensitive PC-3 cells or in chemoresistant PC-3 cells (PC-3R). Finally, using multiple assays, the regulation of metastasis-associated protein 1 (MTA1), an essential component of the Mi-2-nucleosome remodeling deacetylation complex, by hsa-miR-125a-3p was studied at both molecular and functional levels. cell line (PECs, LNCaP,PC-3) down-regulated resistant MTA1 MTA1 MTA1 pathway validated 2447 In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Clin Cancer Res 2017 28096271 miRBase MI0000298 miR-221 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma RT-PCR A chemically induced HCC rat model and a xenograft mouse model, together with HCC-derived cell lines were employed to analyze miR-221 modulation by Sorafenib treatment. Data from the functional analysis were validated in tissue samples from surgically resected HCCs. The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC. cell line (HepG2, Hep3B, PLC/PRF/5,SNU398, SNU449, SNU182, SNU475, and Huh-7) up-regulated resistant Caspase-3 caspase-3 NA validated 2448 miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. Int J Oncol 2017 28098870 miRBase MI0000253 miR-148a miRNA DB00515 (APRD00359) Cisplatin kidney cancer RT-PCR The expression levels of miRNA were determined byreverse transcriptase-polymerase chain reaction (RT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line up-regulated sensitive Rab14 Rab14 the caspase-dependent pathway validated 2449 MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. Mol Med Rep 2017 28112364 miRBase MI0000457 miR-141 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Cell viability was used to test the drug-resistant phenotype changes in cancer cells tissue and cell line (HT29,SW620,Y and HT29) up-regulated sensitive Cyclin D2 Cyclin D2 NA validated 2450 MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. Mol Med Rep 2017 28112364 miRBase MI0000457 miR-141 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Cell viability was used to test the drug-resistant phenotype changes in cancer cells tissue and cell line (HT29,SW620,Y and HT29) up-regulated sensitive Cyclin D2 Cyclin D2 NA validated 2451 Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer 2017 28114937 miRBase MI0005761 miR-939 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (AGS, BGC-823, HGC-27, MGC-803, MNK-45, SGC-7901,GES-1) down-regulated resistant SLC34A2 SLC34A2 Raf/MEK/ERK pathway validated 2452 Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. FEBS Lett 2017 28117895 miRBase MI0000787 miR-379 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In the study, we show that miR-379 expression is significantly downregulated in chemoresistant nonsmall cell lung cancer (NSCLC) tissues and cells. Manipulation of miR-379 levels could alter the in vitro and in vivo cisplatin (CDDP) resistance in lung cancer (LCa) cells. Mechanistically, miR-379 potentiated LCa chemosensitivity via modulation of CDDP-induced apoptosis by directly targeting the EIF4G2 3'UTR. Additionally, we observed an inverse correlation between miR-379 and EIF4G2 expression in LCa tissues from patients with CDDP-based chemotherapy. tissue and cell line (SPC-A1, SK-MES-1, H1299, A549,16HBE) up-regulated sensitive EIF4G2 EIF4G2 NA validated 2453 LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. J Cell Biochem 2017 28121023 miRBase MI0000289/MI0000269 miR-181a miRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (U251, U373, SNB19, U118 and LN229) down-regulated sensitive PTEN PTEN PTEN Pathway validated 2454 miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. Oncol Lett 2017 28123579 miRBase MI0000459 miR-143 miRNA DB00441 (APRD00201) Gemcitabine bladder cancer RT-qPCR In the present study, we observed that miR-143 expression was downregulated in human bladder cancer tissues and cells, and that its levels were negatively correlated with bladder cancer clinical stages. We further demonstrated that insulin-like growth factor-1 receptor (IGF-1R) is a functional target of miR-143. Their expression levels were inversely correlated in bladder cancer samples. Overexpression of miR-143 inhibited cell proliferation and promoted chemosensitivity of bladder cancer 5637 cells to gemcitabine. Consistently, small interfering RNA-mediated knockdown of IGF-1R phenocopied miR-143 overexpression. Notably, the expression of IGF-1R is a predictor of patient prognosis. cell line ( T24, 5637) up-regulated sensitive IGF-1R IGF-1R NA validated 2455 MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM) Biomed Pharmacother 2017 28126676 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative reverse transcription- polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (MDA-MB-231,MDA-MB-231/DDP ) up-regulated sensitive TFAM TFAM NA validated 2456 MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 2017 28138700 miRBase MI0002465 miR-410 miRNA DB00877 (APRD00178, DB02439) Rapamycin osteosarcoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (U2OS, MG-63,hFOB 1.19,293T) up-regulated sensitive ATG16L1 ATG16L1 NA validated 2457 MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 2017 28138700 miRBase MI0002465 miR-410 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (U2OS, MG-63,hFOB 1.19,293T) up-regulated sensitive ATG16L1 ATG16L1 NA validated 2458 MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep 2017 28138700 miRBase MI0002465 miR-410 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (U2OS, MG-63,hFOB 1.19,293T) up-regulated sensitive ATG16L1 ATG16L1 NA validated 2459 microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol 2017 28150434 miRBase MI0003584 miR-577 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SW480, SW620, CaCo2, HT29, Lovo, HCT-116, NCM460) up-regulated sensitive HSP27 HSP27 NA validated 2460 MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep 2017 28165066 miRBase MI0000748 miR-130b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.he CCK-8 assay was used to monitor the growth of the cells. tissue and cell line (MCF-7 and the MCF-7/ADR) up-regulated resistant PTEN PTEN PI3K/AKT signaling pathway validated 2461 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027550 miR-6825-5p miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2462 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027590 miR-6845-5p miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2463 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027673 miR-6886-3p miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2464 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027550 miR-6825-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2465 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027590 miR-6845-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2466 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027673 miR-6886-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2467 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027550 miR-6825-5p miRNA DB11616 Pirarubicin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2468 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027590 miR-6845-5p miRNA DB11616 Pirarubicin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2469 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 miRBase MIMAT0027673 miR-6886-3p miRNA DB11616 Pirarubicin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR,western blot, SiRNA assay, dual-luciferase reporter assay, confocal microscopy, Co-IP assay and Xenograft tumor assay in nude mice, etc. tissue and cell line down-regulated resistant USP22 USP22 NA validated 2470 CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer. Sci Rep 2017 28176874 miRBase MI0000446/MI0000470 miR-125b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. We hypothesized that miRNAs might be critical downstream mediators of CXCL12/CXCR4 axis involved in cancer invasion and chemoresistance in CRC. In human CRC cells, we found that the activation of CXCL12/CXCR4 axis promoted epithelial-mesenchymal transition (EMT) and concurrent upregulation of miR-125b. Overexpression of miR-125b robustly triggered EMT and cancer invasion, which in turn enhanced the expression of CXCR4. Importantly, the reciprocal positive feedback loop between CXCR4 and miR-125b further activated the Wnt/Beta-catenin signaling by targeting Adenomatous polyposis coli (APC) gene. There was a negative correlation of the expression of miR-125b with APC mRNA in paired human colorectal tissue specimens. Further experiments indicated a role of miR-125b in conferring 5-fluorouracil (5-FU) resistance in CRC probably through increasing autophagy both in vitro and in vivo. MiR-125b functions as an important downstream mediator upon the activation of CXCL12/CXCR4 axis that involved in EMT, invasion and 5-FU resistance of CRC. cell line (SW620 and HCT116) up-regulated sensitive APC APC Wnt/Beta-catenin pathway validated 2471 STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells Oncotarget 2017 28178652 miRBase MIMAT0000070 miR-17-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of miRNA were determined by Quantitative real time RT-PCR and those of protein were by Western blot analysis. In the study, we observed that STAT3 exerted anti-apoptotic effects in breast cancer cells. On the other hand, miR-17-5p induced apoptosis in breast cancer cells, and overexpression of miR-17-5p sensitized MCF-7 cells to paclitaxel-induced apoptosis via STAT3. Overexpression of STAT3 in MCF-7 cells decreased paclitaxel-induced apoptosis, but STAT3 knockout abolished the miR-17-5p-induced increases in apoptosis. Finally, miR-17-5p promoted apoptosis by increasing p53 expression, which was inhibited by STAT3. cell line (MCF-7 and MDA-MB-231) up-regulated sensitive STAT3 STAT3 STAT3/p53 pathway validated 2472 MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1. Toxicol In Vitro 2017 28185889 miRBase MI0000105/MI0000107 miR-29b miRNA DB00773 (APRD00239) Etoposide human negroid cervix epitheloid carcinoma RT-PCR In the study, we used several systems to evaluate the effect of miR-29 family on etoposide toxicity in HeLa cells. We show that miR-29b significantly increases etoposide toxicity in HeLa cells. Because Mcl-1 protein has been recognized as a miR-29 family target, we evaluated downregulation of Mcl-1 protein splicing variant expression induced by miR-29 precursors and confirmed a key role of Mcl-1 protein in enhancing etoposide toxicity. Despite downregulation of Mcl-1 by all three miR-29 family members, only miR-29b significantly enhanced etoposide toxicity. We hypothesized that this difference may be linked to the change in Mcl-1L/Mcl-1S ratio induced by miR-29b. We hypothesized that the change could be due to miR-29b nuclear shuttling. Using specifically modified miR-29b sequences with enhanced cytosolic and nuclear localization we show that there is a difference, albeit statistically non-significant. cell line ( HeLa) up-regulated sensitive Mcl-1 Mcl-1 NA validated 2473 MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 2017 28187000 miRBase MI0000283 miR-203 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line ( U87 and U251) up-regulated sensitive thymidylate synthase (TS) NA miR-203-TS pathway validated 2474 H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells. Neoplasia 2017 28189050 miRBase MIMAT0004284 miR-675-5p miRNA DB11094 1,25(OH)2D3 colon cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR (qRT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HT-29, DLD-1) up-regulated resistant NA NA Wnt/Beta-catenin pathway validated 2475 LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. Biomol Ther (Seoul) 2017 28190319 miRBase MI0000077 miR-21 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR The expression levels of miRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . cell line ( K562 ) down-regulated sensitive NA NA NA validated 2476 MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep 2017 28198398 miRBase MI0000681 miR-155 miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR qRT-PCR to detect microRNA and messenger RNA expression.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Immunoblotting or immunocytochemistry was performed to evaluate protein expression.Electron microscopy was used to visualize multivesicular bodies. cell line ( Panc1, MiaPaCa2, PSN1) up-regulated sensitive NA NA NA validated 2477 Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer 2017 28202053 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The effect of overexpression of miR-146a and/or knockdown of cyclin J (CCNJ) in A549/DDP and SPC-A1/DDP cells were investigated as follows. The cellular sensitivity to DDP, cell apoptosis, cell cycle and cell mobility were detected by CCK-8, flow cytometry, hoechst staining and cell invasion/migration assay, respectively. The effects of miR-146a overexpression in NSCLC resistant cells were further analyzed in a nude mouse xenograft model. cell line ( 293T,A549,A549/DDP,SPC-A and SPC-A1/DDP) up-regulated sensitive CCNJ CCNJ NA validated 2478 miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Prolif 2017 28217977 miRBase MI0003193 miR-506 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR In this study, miR-506 levels were measured in 74 patients with colon cancer via quantitative real-time polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). We subsequently analysed the relationship between miR-506 expression and CRC patient survival via the Kaplan-Meier method. MTT assay demonstrated the fractional survival rates and cell viability of HCT116-OxR, HCT116-OxR-miR-Ctrl and HCT116-OxR-miR-506 cells treated with oxaliplatin at different concentrations. Cell proliferation and apoptosis were assessed via flow cytometry (FCM) analysis and apoptosis assay. MDR1 mRNA expression and P-gp protein expression were assessed via qRT-PCR and Western blotting (WB) respectively. Immunofluorescence (IF) staining demonstrated P-gp expression in HCT116-OxR and HCT116-OxR-miR-506 cells. qRT-PCR and WB were used to detect Wnt/Beta-catenin pathway activity after miR-506 overexpression. cell line ( HCT-116, HCT116-OxR) up-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 2479 Targeting miR155 restores chemotherapy sensitivity in drug-resistant myeloma cell-line RPMI8226/DOX cells Zhonghua Xue Ye Xue Za Zhi 2017 28219227 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin multiple myeloma qRT-PCR Drug-resistant myeloma cell-line RPMI8226/DOX was established by culturing RPMI8226 cells with continuous low concentration and intermittent gradually increasing concentration of doxorubicin in vitro; The levels of miR155 mRNA were measured by qRT-PCR, and both proteins FOXO3a and BCL-2 expressions were detected by Western blot in cell-lines RPMI8226/S and RPMI8226/Dox. RPMI8226/DOX cells were transfected by miR155 inhibitor and mimic using gene transfer method, and then CCK-8 was used to measure proliferation and inhibition ratio, the changes of miR155 expression were detected by RT-PCR. Proteins FOXO3a and BCL-2 were detected by Western blot. cell line (RPMI8226/S,RPMI8226/DOX) down-regulated sensitive FOXO3a FOXO3a NA validated 2480 MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem 2017 28222430 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin Bladder Cancer qRT-PCR qRT-PCR was used to detect miR-218 and its target Glut1 expression in bladder cancer cell lines T24 and EJ. CCK-8 method was utilized to measure the cell viability. IC 50 was calculated via a probit regression model. Glut1 was detected by western blotting for analysis of potential mechanism. Luciferase reporter assay was utilized to validate Glut1 as a direct target gene of miR-218. The intracellular level of GSH and ROS were determined using a commercial colorimetric assay kit and 2, 7-dichlorodihydro-fluorescein diacetate, respectively. cell line ( T24 ) up-regulated sensitive Glut1 Glut1 miR-218-Glut1 Pathway validated 2481 A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. Cell Physiol Biochem 2017 28222434 miRBase MIMAT0000087 miR-30a-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR qRT-PCR was used to compare differential expression levels of miR-30 family members in ovarian cancer cell line A2780 and its cisplatin-resistant derivative CP70. Changes of cisplatin-sensitivity in miR-30a-5p- and miR-30c-5p-overexpressed-CP70 cells and miR-30a-5p- and miR-30c-5p-inhibited-A2780 cells were examined by CCK8 assay and apoptosis analysis using flow cytometry; targets of miR-30a/c-5p were analyzed by western blotting and luciferase reporter assay; methylation regulation of pre-miR-30a/c-5p was examined by methylation specific PCR. cell line (A2780) up-regulated sensitive Snail and DNMT1 DNMT1 NA validated 2482 A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. Cell Physiol Biochem 2017 28222434 miRBase MIMAT0000244 miR-30c-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR qRT-PCR was used to compare differential expression levels of miR-30 family members in ovarian cancer cell line A2780 and its cisplatin-resistant derivative CP70. Changes of cisplatin-sensitivity in miR-30a-5p- and miR-30c-5p-overexpressed-CP70 cells and miR-30a-5p- and miR-30c-5p-inhibited-A2780 cells were examined by CCK8 assay and apoptosis analysis using flow cytometry; targets of miR-30a/c-5p were analyzed by western blotting and luciferase reporter assay; methylation regulation of pre-miR-30a/c-5p was examined by methylation specific PCR. cell line (A2780) up-regulated sensitive Snail and DNMT1 DNMT1 NA validated 2483 miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys Res Commun 2017 28242198 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The role of miR-124 in glioblastoma cells was detected using quantitative real-time PCR, western blot and immunohistochemistry (IHC), cell proliferation assay, In vivo studies and dual luciferase assay, etc. tissue and cell line (U-118 MG, LN229, T98G, U138MG, U-87 MG, M059K, M059J,A-172) up-regulated sensitive AURKA AURKA NA validated 2484 miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Sci Rep 2017 28256505 miRBase MIMAT0000423 miR-125b-5p miRNA DB00515 (APRD00359) Cisplatin gallbladder cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. tissue and cell line ( HEK293FT, NOZ, GBC-SD,SGC-996 ) up-regulated sensitive Bcl2 BCL2 miR-125b-5p-Bcl2 pathway validated 2485 microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. Mol Med Rep 2017 28260044 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR In the present study, miR-125b expression in cisplatin (DDP) -resistant CNE2 cells (CNE2/DDP) was compared with parental counterparts, using reverse transcription-quantitative polymerase chain reaction. A >3-fold reduction in miR-125b expression levels was observed in CNE2/DDP cells compared with parental CNE2 cells. Ectopic expression of miR-125b by transfecting CNE2/DDP cells with miR-125b mimics, increased DDP-induced cytotoxicity, apoptosis and chemosensitivity. By contrast, suppression of miR-125b by transfecting CNE2 cells with miR-125b inhibitors, reduced DDP-induced cytotoxicity and apoptosis, and facilitated cisplatin resistance. The results suggest that miR-125b may regulate the sensitivity of NPC cells to DDP by modulating the expression levels of antiapoptotic factor B-cell CLL/lymphoma 2. cell line ( CNE2, CNE2/DDP) up-regulated sensitive Bcl-2 Bcl-2 NA validated 2486 miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. Oncol Rep 2017 28260112 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin chronic myeloid leukemia RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. etc cell line ( K562,K562/ADR) up-regulated sensitive ABCB1 ABCB1 NA validated 2487 MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther 2017 28281524 miRBase MI0005569 miR-216b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR In the study, we compared the expression profiles of miRs between cisplatin-resistant and cisplatin-sensitive ovarian cancer cells, and found that miR-216b was significantly downregulated in cisplatin-resistant ovarian cancer cells. To investigate its molecular mechanism, we performed cell viability and apoptosis assays in cisplatin-resistant ovarian cells, and found that miR-216b reduced cell viability and promoted apoptosis. Although 4 potential targets were obtained through bioinformatics, only the mRNA level of poly(ADP-ribose) polymerase (PARP)-1 was significantly regulated by miR-216b. Disruption of the complementary binding sequence of miR-216b on the 3-untranslated region (3-UTR) of the PARP1 led to the loss of miR-216b targeting. Spearmans correlation coefficient of the levels of miR-216b and PARP1 mRNA from 51 human ovarian cancer specimens also showed a significantly negative correlation between them. Importantly, the improved cisplatin sensitivity induced by miR-216b was markedly reversed by PARP1 overexpression. Tumor formation assay in nude mice further provided an evidence on the suppressive role of miR-216b in tumor growth. Taken together, this study demonstrated that a new miRNA, miR-216b, was involved in cisplatin resistance in ovarian cancer, which could be regarded as a potential sensitizer in cisplatin chemotherapy. cell line (SKOV3,SKOV3/CDDP) up-regulated sensitive PARP1 PARP1 NA validated 2488 MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep 2017 28281638 miRBase MIMAT0000255 miR-34a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR This study was performed in two multi-chemosensitive (G-292 and MG63.2) and two resistant (SJSA-1 and MNNG/HOS) OS cell lines. MiR-34a-5p promotes OS multi-chemoresistance via its repression of the Delta-like ligand 1 (DLL1) gene, the ligand of the Notch pathway, and thus negatively correlates with OS chemoresistance. The siRNA-mediated repression of the DLL1 gene suppressed cell apoptosis and de-sensitized G-292 and MG63.2 cells, while overexpression of DLL1 sensitized SJSA-1 and MNNG/HOS cells to drug-induced cell death. In agreement with the changes in the drug-induced cell death, the activity of the ATF2/ATF3/ATF4 signaling pathway was significantly altered by a forced reversal of miR-34a-5p or DLL1 levels in OS cells. DLL1 is a target of miR-34a-5p and negatively regulates the multi-chemoresistance of OS. cell line (G-292,SJSA-1,MNNG/HOS ) up-regulated resistant DLL1 DLL1 ATF2/ATF3/ATF4 signaling pathway validated 2489 MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep 2017 28281638 miRBase MIMAT0000255 miR-34a-5p miRNA DB00773 (APRD00239) Etoposide osteosarcoma qRT-PCR This study was performed in two multi-chemosensitive (G-292 and MG63.2) and two resistant (SJSA-1 and MNNG/HOS) OS cell lines. MiR-34a-5p promotes OS multi-chemoresistance via its repression of the Delta-like ligand 1 (DLL1) gene, the ligand of the Notch pathway, and thus negatively correlates with OS chemoresistance. The siRNA-mediated repression of the DLL1 gene suppressed cell apoptosis and de-sensitized G-292 and MG63.2 cells, while overexpression of DLL1 sensitized SJSA-1 and MNNG/HOS cells to drug-induced cell death. In agreement with the changes in the drug-induced cell death, the activity of the ATF2/ATF3/ATF4 signaling pathway was significantly altered by a forced reversal of miR-34a-5p or DLL1 levels in OS cells. DLL1 is a target of miR-34a-5p and negatively regulates the multi-chemoresistance of OS. cell line (G-292,SJSA-1,MNNG/HOS ) up-regulated resistant DLL1 DLL1 ATF2/ATF3/ATF4 signaling pathway validated 2490 MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep 2017 28281638 miRBase MIMAT0000255 miR-34a-5p miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR This study was performed in two multi-chemosensitive (G-292 and MG63.2) and two resistant (SJSA-1 and MNNG/HOS) OS cell lines. MiR-34a-5p promotes OS multi-chemoresistance via its repression of the Delta-like ligand 1 (DLL1) gene, the ligand of the Notch pathway, and thus negatively correlates with OS chemoresistance. The siRNA-mediated repression of the DLL1 gene suppressed cell apoptosis and de-sensitized G-292 and MG63.2 cells, while overexpression of DLL1 sensitized SJSA-1 and MNNG/HOS cells to drug-induced cell death. In agreement with the changes in the drug-induced cell death, the activity of the ATF2/ATF3/ATF4 signaling pathway was significantly altered by a forced reversal of miR-34a-5p or DLL1 levels in OS cells. DLL1 is a target of miR-34a-5p and negatively regulates the multi-chemoresistance of OS. cell line (G-292,SJSA-1,MNNG/HOS ) up-regulated resistant DLL1 DLL1 ATF2/ATF3/ATF4 signaling pathway validated 2491 MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. Sci Rep 2017 28281638 miRBase MIMAT0000255 miR-34a-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR This study was performed in two multi-chemosensitive (G-292 and MG63.2) and two resistant (SJSA-1 and MNNG/HOS) OS cell lines. MiR-34a-5p promotes OS multi-chemoresistance via its repression of the Delta-like ligand 1 (DLL1) gene, the ligand of the Notch pathway, and thus negatively correlates with OS chemoresistance. The siRNA-mediated repression of the DLL1 gene suppressed cell apoptosis and de-sensitized G-292 and MG63.2 cells, while overexpression of DLL1 sensitized SJSA-1 and MNNG/HOS cells to drug-induced cell death. In agreement with the changes in the drug-induced cell death, the activity of the ATF2/ATF3/ATF4 signaling pathway was significantly altered by a forced reversal of miR-34a-5p or DLL1 levels in OS cells. DLL1 is a target of miR-34a-5p and negatively regulates the multi-chemoresistance of OS. cell line (G-292,SJSA-1,MNNG/HOS ) up-regulated resistant DLL1 DLL1 ATF2/ATF3/ATF4 signaling pathway validated 2492 Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance. Med Sci Monit 2017 28291769 miRBase MIMAT0000091 miR-33a-5p miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-qPCR We established stable Hep3B and 97L HCC cell strains resistant to CDDP, both in vitro and in vivo. A combination of microRNA microarray and RT-qPCR experiments were used to screen differentially expressed miRNAs in HCC cell strains. A CCK-8 assay was carried out to detect and calculate the survival rates and relative inhibitory rates. Oligonucleotide transfection was used to confirm the regulatory function of the miRNA in HCC drug resistance. cell line ( Hep3B, 97L) up-regulated sensitive HSPA8 HSPA8 NA validated 2493 LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target 2017 28296507 miRBase MI0000489 miR-195 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer qRT-PCR The role of PVT1and miR-195 in cervical cancer cells was detected using bioinformatics analysis, qRT-PCR analysis, CCK-8 analysis, RNA pull-down assay, dual luciferase assay, western blot analysis and flow cytometric analysis, etc. cell line(HPV-16-positive CaSki and SiHa) up-regulated resistant NA NA NA validated 2494 TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495. Biochem Biophys Res Commun 2017 28302484 miRBase MI0003135 miR-495 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The role of TSPAN12 and miR-495 in small cell lung cancer cells was detected using quantitative RT-PCR, western blot, CCK-8 assays, cell migration assay, tumor xenograft experiment and dual luciferase reporter assay, etc. cell line (NCI-H69, NCI-H446,NCI-H69AR) up-regulated sensitive TSPAN12 TSPAN12 NA validated 2495 TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495. Biochem Biophys Res Commun 2017 28302484 miRBase MI0003135 miR-495 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR The role of TSPAN12 and miR-495 in small cell lung cancer cells was detected using quantitative RT-PCR, western blot, CCK-8 asssay, cell migration assay, tumor xenograft experiment and dual luciferase reporter assay, etc. cell line (NCI-H69, NCI-H446,NCI-H69AR) up-regulated sensitive TSPAN12 TSPAN12 NA validated 2496 TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun 2017 28302487 miRBase MI0000483 miR-186 miRNA DB00563 (APRD00353) Methotrexate colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HT-29-P/HT-29-R,HCT-8) down-regulated resistant CPEB2 CPEB2 NA validated 2497 MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. Cell Biol Int 2017 28328082 miRBase MIMAT0004763 miR-488-3p miRNA DB00515 (APRD00359) Cisplatin melanoma qRT-PCR In this study, we demonstrated that miR-488-3p is significantly downregulated in MM clinical specimens and cell lines. Ectopic expression of miR-488-3p resulted in markedly increased drug sensitivity of MM cells in vitro and in vivo. The DNA-activated, catalytic polypeptide (PRKDC), which encodes DNA-dependent protein kinase catalytic subunit (DNA-PKcs), was identified as a direct target of miR-488-3p using luciferase reporter assays, qRT-PCR, and western blotting analyses. PRKDC knockdown by small interfering RNA (siRNA) alone promoted sensitivity of MM cells to cisplatin (DDP) while overexpression of PRKDC partially rescued the miR-488-3p-mediated acceleration of sensitivity to DDP in MM cells. cell line ( A375, B16, SK-MEL-28, WM451,HEMn-LP ) up-regulated sensitive PRKDC PRKDC NA validated 2498 MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. J Cell Biochem 2017 28332226 miRBase MI0000300 miR-223 miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR The expression levels of miRNA were determined by real-time PCR and those of protein were by Western blot analysis.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line up-regulated resistant PAX6 PAX6 PI3K/Akt Pathway validated 2499 MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. Sci Rep 2017 28341864 miRBase MIMAT0000431 miR-140-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR In this report, we used high-throughput microRNA (miRNA) expression analysis to reveal that expression of miR-140-5p was associated with chemosensitivity in osteosarcoma. The exact roles of miR-140-5p in the chemoresistance of osteosarcoma were then investigated, we found that knockdown of miR-140-5p enhanced osteosarcoma cells resistance to multiple chemotherapeutics while overexpression of miR-140-5p sensitized tumors to chemotherapy in vitro. Moreover, in vivo, knockdown of miR-140-5p also increased the osteosarcoma cells resistance to chemotherapy. Luciferase assay and Western blot analysis showed that HMGN5 was the direct target of miR-140-5p which could positively regulated autophagy. Silencing these target genes by siRNA or inhibition of autophagy sensitized osteosarcoma cells to chemotherapy. These findings suggest that a miR-140-5p/HMGN5/autophagy regulatory loop plays a critical role in chemoresistance in osteosarcoma. In conclusion, our data elucidated that miR-140-5p promoted autophagy mediated by HMGN5 and sensitized osteosarcoma cells to chemotherapy. cell line (hFOB1. 19,MG-63, U-2 OS) down-regulated resistant HMGN5 HMGN5 NA validated 2500 Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1. Oncol Rep 2017 28350100 miRBase MI0000283 miR-203 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The present study was designed to focus on miR-203 and Dickkopf-1 (DKK1), investigating the potential mechanisms involved in cisplatin resistance in tissues of lung adenocarcinoma and A549/H460 cell lines. In DDP-sensitive NSCLC samples, miR-203 was expressed at a higher level when compared with this level in DDP-insensitive samples, while DKK1 mRNA was expressed at a relatively low level as indicated by qRT-PCR. Dual luciferase reporter assay revealed that DKK1 is a target gene of miR-203 in A549 and H460 cells. Upregulation of miR-203 reduced the IC50 value of cisplatin in the A549 and H460 cells by inhibiting cell growth and promoting cell apoptosis. Similar effects of tumor inhibition and cisplatin sensitization were verified in vivo. Further research showed that both overexpression of miR-203 and knockdown of DKK1 increased the sensitization to DDP with a lower IC50 value. Upon DKK1 knockdown, overexpression of miR-203 had no added effects on the sensitivity of the cells. In addition, miR-203 was unable to sensitize cells with DKK1 that lacked the 3 untranslated region (3UTR). We conclude that miR-203 targets the 3UTR of DKK1, and increases cisplatin sensitivity in A549/H460 cell lines. cell line (A549, H460,NHBE ) up-regulated sensitive DKK1 DKK1 NA validated 2501 miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer. Oncol Rep 2017 28350138 miRBase MI0000438 miR-15b miRNA DB00515 (APRD00359) Cisplatin oral tongue squamous cell cancer RT-PCR The expression levels of miRNA were determined byReal-time PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( SCC25,SCC25-res) up-regulated sensitive TRIM14 TRIM14 NA validated 2502 Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. Oncol Rep 2017 28350139 miRBase MI0000454 miR-137 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. etc cell line ( Huh7,Huh7-R) down-regulated sensitive ANT2 ANT2 NA validated 2503 Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1S-1-acetoxychavicol acetate via regulating RSU1. Onco Targets Ther 2017 28356756 miRBase MI0003643 miR-629 miRNA NA 1S-1-acetoxychavicol acetate cervical cancer RT-qPCR The miR-629 expression following transfection with miR-629 hairpin inhibitor and hairpin inhibitor negative control was measured using quantitative real-time polymerase chain reaction (RT-qPCR). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to investigate sensitivity toward ACA. Apoptosis was detected using Annexin V/propidium iodide and Caspase 3/7 assays. The gene target for miR-629 was identified using miRNA target prediction programs, luciferase reporter assay and Western blots. Gene overexpression studies were performed to evaluate its role in regulating response toward ACA. cell line down-regulated sensitive RSU1 RSU1 NA validated 2504 LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle 2017 28358263 miRBase MI0000289/MI0000269 miR-181a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharynx cancer qRT-PCR This study aimed to investigate whether long non-coding RNA CCAT1 was involved in Paclitaxel resistance in nasopharyngeal carcinoma (NPC). qRT-PCR was used for testing the expression of CCAT1, miR-181a and CPEB2 in tumor tissues and NPC cancers. NPC cells were transfected with siRNAs to suppress the mRNA level of CCAT1 in NPC cells. MTT assays and flow cytometry analysis were used to assess the sensitivity of paclitaxel in NPC cells. Luciferase reporter assays were used to examine the interaction of CCAT1 or CPEB2 to miR-181a. cell line (CNE1 and CNE2) up-regulated sensitive CPEB2 CPEB2 CCAT1/miR-181a/CPEB2 validated 2505 miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase. Biochem Biophys Res Commun 2017 28373071 miRBase MI0005569 miR-216b miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression levels of miRNA were determined by Quantitative RT-PCR (qRT-PCR). Western blotting and luciferase reporter gene assay were employed to identify the target gene and signal pathways. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (COLO-678, HT29, HT55, LS1034, SW1417, SW403, SW48,HCT8, COLO-205, LOVO, SW620, SW480, HCT116,CRL-1459) down-regulated resistant PBK PBK NA validated 2506 Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res 2017 28376831 miRBase MI0000066 Let-7e miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. tissue and cell line ( A2780, HO8910, ES2, CAOV3 and SKOV3 ) up-regulated sensitive NA NA NA validated 2507 Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells Nan Fang Yi Ke Da Xue Xue Bao 2017 28377359 miRBase MI0000490 miR-206 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil ovarian cancer RT-PCR Real-time PCR was used to detect the expression of miR-206 in ovarian cancer and normal ovarian tissues. Ovarian cancer SKOV3 cells were transfected with a miR-206 mimic or a specific inhibitor of miR-206, and MTT assay and flow cytometry were used to detect the changes in cell growth and cell cycle transition. Western blotting and luciferase reporter gene assay were employed to identify the target gene and signal pathways of miR-206. The effect of miR-206 on the sensitivity of ovarian cancer cells to 5-Fu was assessed. tissue and cell line ( SKOV3 ) up-regulated sensitive CDK4 CDK4 NA validated 2508 miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway. Tumour Biol 2017 28381178 miRBase MIMAT0004748 miR-423-5p miRNA DB07352 Apigenin glioma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line down-regulated sensitive NA NA the mitochondrial pathway validated 2509 Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines. Tumour Biol 2017 28381182 miRBase MI0000469 miR-125a miRNA DB00694 (APRD00521) Daunorubicin leukemia qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs . cell line ( HL-60, K562, THP-1, and HEK293T) up-regulated resistant GRK2 and Puma GRK2 and Puma NA validated 2510 Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog 2017 28383763 miRBase MI0000449 miR-132 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The CCK-8 assay was used to monitor the growth of the cells . cell line (MKN45 and MKN28) up-regulated resistant SIRT1 SIRT1 SIRT1/CREB/ABCG2 signaling pathway validated 2511 MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res 2017 28386339 miRBase MIMAT0002806 miR-490-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The purpose of this study was to determine the roles and molecular mechanism of miR-490-3p in the CDDP resistance in ovarian cancer. We found that miR-490-3p was downregulated in CDDP-resistant OVCAR3/CDDP and SKOV3/CDDP cells, which was due to the hypermethylation of miR-490-3p promoter. Functional studies demonstrated that miR-490-3p increased the cell response to CDDP in OVCAR3, SKOV3 and CDDP-resistant cells, while miR-490-3p inhibition resulted in opposite effects. Luciferase assay, real-time PCR and Western blot as well as immunohistochemistry validated that ABCC2 was a direct target of miR-490-3p and miR-490-3p downregulated ABCC2 expression via binding to its 3UTR. Importantly, silencing of ABCC2 alleviated CDDP resistance induced by miR-490-3p inhibition, while ABCC2 overexpression restored CDDP resistance inhibited by miR-490-3p. In vivo study showed that miR-490-3p enhanced the cytotoxicity of CDDP. Finally, we found that miR-490-3p was downregulated in CDDP-resistant ovarian cancer tissues, while ABCC2 was upregulated. In conclusion, our data indicate that miR-490-3p enhances CDDP sensitivity of ovarian cancer cells through downregulating ABCC2 expression, and suggest that delivery of miR-490-3p might be a potential therapeutic strategy for patients with CDP-resistant ovarian cancer. cell line (OVCAR3, SKOV3, OVCAR3/CDDP, SKOV3/CDDP) up-regulated sensitive ABCC2 ABCC2 NA validated 2512 Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res 2017 28386361 miRBase MI0001641 miR-429 miRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer qRT-PCR Using miRNA profiles of a panel of cisplatin-resistant (SKOV3/DDP) cells, we validated data using quantitative real time-PCR (QRT-PCR), and studied the effects of miR-429 on cancer cell chemo-sensitivity, using gain- and loss-of-function studies. cell line ( SKOV3,SKOV3/DDP) up-regulated sensitive ZEB1 ZEB1 NA validated 2513 Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. Oncotarget 2017 28388536 miRBase MI0000461 miR-145 miRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR In this study, we tried to make clarification of lincRNA-related mechanisms underlying EMT followed by acquired resistance to chemotherapy in LAD. In order to hit the mark, we made use of multiple methods including microarray analysis, qRT-PCR, western blotting analysis, loss/gain-of-function analysis, luciferase assays, drug sensitivity assays, wound-healing assay and invasion assay. We found that decreased expression of linc-ROR effectively reversed EMT in docetaxel-resistant LAD cells and sensitized them to chemotherapy. The function of linc-ROR exerted in LAD cells depended on the sponging of miR-145, therefore, releasing the miR-145 target FSCN1, and thus contributing to the acquisition of chemoresistance and EMT phenotypes of docetaxel-resistant LAD cells. cell line (SPC-A1, H1299) down-regulated resistant FSCN1 FSCN1 epithelial mesenchymal transition pathway validated 2514 Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. Sci Rep 2017 28396596 miRBase MI0000290 miR-214 miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma qRT-PCR This study aimed to examine the role of miR-214 in the acquired resistance to erlotinib in NSCLC, and elucidate the underlying mechanisms. qRT-PCR assay detected higher miR-214 expression in the plasma of NSCLC patients with acquired EGFR-TKI resistance than prior to EGFR-TKI therapy, and in the generated erlotinib-resistant HCC827 (HCC827/ER) cells than in HCC827 cells. Bioinformatics analysis and dual-luciferase reporter assay indentified LHX6 as a direct target gene of miR-214, and LHX6 expression was detected to be down-regulated in erlotinib-resistant HCC827 cells. Transwell invasion assay revealed that overexpressing LHX6 reversed the increase in the invasive ability of HCC827 cells induced by miR-214 overexpression, and the CRISPR-Cas9 system-mediated LHX6 knockdown reversed the reduction in the invasion of erlotinib-resistant HCC827 cells caused by miR-214 down-regulation. The results of the present study demonstrate that down-regulation of miR-214 may reverse acquired resistance to erlotinib in NSCLC through mediating its direct target gene LHX6 expression. cell line ( HCC827 ) down-regulated sensitive LHX6 LHX6 NA validated 2515 miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. Am J Cancer Res 2017 28401017 miRBase MI0003135 miR-495 miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR In this study, we investigated whether miR-495 regulates the chemoresistance of SCLC through the epithelial-mesenchymal transition (EMT) via Epithelial and endothelial tyrosine kinase (Etk/BMX) using two drug-resistant cell lines. Loss- and gain-of-function experiments showed miR-495 regulated cell proliferation, tumor growth and drug resistance. miR-495 suppression or Etk/BMX elevation in SCLC specimens was correlated with poor pathologic stage and survival time. Etk/BMX was one of the directly targeted genes of miR-495. Ectopic expression of Etk/BMX obviously rescued the miR-495 elevation elevation-induced inhibition of drug resistance. Etk/BMX over-expression led to higher levels of EMT mesenchymal factors (Zeb-2, Twist, Vim) and lower levels of the epithelial molecule Beta-catenin, while suppression of Etk/BMX showed the opposite trend. Knockdown of Zeb-2 and Twist inhibited the chemoresistance of cells. Our study revealed that miR-495 promoted the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. cell line (NCI-H446, NCI-H69,H69/AR,H446/AR) up-regulated resistant Etk/BMX Etk/BMX NA validated 2516 miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. Am J Cancer Res 2017 28401017 miRBase MI0003135 miR-495 miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR In this study, we investigated whether miR-495 regulates the chemoresistance of SCLC through the epithelial-mesenchymal transition (EMT) via Epithelial and endothelial tyrosine kinase (Etk/BMX) using two drug-resistant cell lines. Loss- and gain-of-function experiments showed miR-495 regulated cell proliferation, tumor growth and drug resistance. miR-495 suppression or Etk/BMX elevation in SCLC specimens was correlated with poor pathologic stage and survival time. Etk/BMX was one of the directly targeted genes of miR-495. Ectopic expression of Etk/BMX obviously rescued the miR-495 elevation elevation-induced inhibition of drug resistance. Etk/BMX over-expression led to higher levels of EMT mesenchymal factors (Zeb-2, Twist, Vim) and lower levels of the epithelial molecule Beta-catenin, while suppression of Etk/BMX showed the opposite trend. Knockdown of Zeb-2 and Twist inhibited the chemoresistance of cells. Our study revealed that miR-495 promoted the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. cell line (NCI-H446, NCI-H69,H69/AR,H446/AR) up-regulated resistant Etk/BMX Etk/BMX NA validated 2517 miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. Am J Cancer Res 2017 28401017 miRBase MI0003135 miR-495 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma qRT-PCR In this study, we investigated whether miR-495 regulates the chemoresistance of SCLC through the epithelial-mesenchymal transition (EMT) via Epithelial and endothelial tyrosine kinase (Etk/BMX) using two drug-resistant cell lines. Loss- and gain-of-function experiments showed miR-495 regulated cell proliferation, tumor growth and drug resistance. miR-495 suppression or Etk/BMX elevation in SCLC specimens was correlated with poor pathologic stage and survival time. Etk/BMX was one of the directly targeted genes of miR-495. Ectopic expression of Etk/BMX obviously rescued the miR-495 elevation elevation-induced inhibition of drug resistance. Etk/BMX over-expression led to higher levels of EMT mesenchymal factors (Zeb-2, Twist, Vim) and lower levels of the epithelial molecule Beta-catenin, while suppression of Etk/BMX showed the opposite trend. Knockdown of Zeb-2 and Twist inhibited the chemoresistance of cells. Our study revealed that miR-495 promoted the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. cell line (NCI-H446, NCI-H69,H69/AR,H446/AR) up-regulated resistant Etk/BMX Etk/BMX NA validated 2518 Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res 2017 28407783 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR M2 polarized macrophages were obtained from mouse bone marrow or human PBMCs stimulated with IL-4 and IL-13. Exosomes isolated from M2 macrophages culture medium were characterized, and miRNA expression profiles of M2 derived exosomes (M2-exos) were analyzed using miRNA microarray. In vitro cell coculture was further conducted to investigate M2-exos mediated crosstalk between TAMs and tumor cells. Moreover, the in vivo experiments were performed using a subcutaneous transplantation tumor model in athymic nude mice. cell line (MFC, MGC-803) up-regulated resistant PTEN PTEN PI3K/AKT signaling pathway validated 2519 miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med 2017 28411377 miRBase MI0003135 miR-495 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( A2780, SGC7091,A2780DX5,SGC7901R) up-regulated sensitive ABCB1 ABCB1 NA validated 2520 miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med 2017 28411377 miRBase MI0003135 miR-495 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( A2780, SGC7091,A2780DX5,SGC7901R) up-regulated sensitive ABCB1 ABCB1 NA validated 2521 Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun 2017 28412359 miRBase MI0003653 miR-638 miRNA DB01248 (APRD00932) Docetaxel breast cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis measurement was used to test the drug-resistant phenotype changes in cancer cells cell line (T47D, MCF-7, MDA-MB-231 and MDA-MB-468) up-regulated sensitive STARD10 STARD10 STARD10 pathway validated 2522 Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget 2017 28415557 miRBase MI0000286 miR-210 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( Saos-2, U-2OS, MG-63, MG-63/DOX) down-regulated sensitive NA NA NA validated 2523 MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2. Oncotarget 2017 28416774 miRBase MI0000102 miR-100 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR We detected significantly higher levels of ZNRF2, a ubiquitin ligase of the RING superfamily, and significantly lower levels of miR-100 in the OS specimens, compared to the paired normal bone tissues. The levels of ZNRF2 and miR-100 inversely correlated in the OS specimens. In addition, low miR-100 levels are associated with poor prognosis of the OS patients. Either ZNRF2 overexpression or miR-100 depletion increased in vitro OS cell growth and improved cell survival at the presence of Doxorubicin. Mechanistically, with the help of bioinformatics analysis and luciferase-reporter assay, we found that miR-100 might bind to the 3¡¯-UTR of ZNRF2 mRNA to prevent its protein translation. Thus, our data suggest that re-expression of miR-100 may inhibit OS cell growth and decrease OS cell chemo-resistance. tissue and cell line ( U2OS ) up-regulated sensitive ZNRF2 ZNRF2 NA validated 2524 Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a Beijing Da Xue Xue Bao Yi Xue Ban 2017 28416841 miRBase MI0000072 miR-18a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR qRT-PCR was performed to detect UCA1 and miR-18a expression in breast cancer cells. Dual luciferase assay was performed to detect the binding between miR-18a and UCA1 3UTR. Tamoxifen sensitive MCF-7 cells were transfected with UCA1 expression vector or miR-18a inhibitors. Tamoxifen resistant LCC9 and BT474 cells were transfected with UCA1 siRNA or miR-18a mimics. CCK-8 assay was performed to detect cell viability. Soft agar assay was performed to assess cell colony formation. Flow cytometric analysis was performed to check cell cycle distribution. cell line ( BT-474) up-regulated sensitive NA NA NA validated 2525 MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1. Oncotarget 2017 28422725 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin cholangiocarcinoma RT-PCR In this study, we demonstrate the essential role and mechanism of miR-199a-3p in regulating cisplatin sensitivity in cholangiocarcinoma cell lines. Using a CCK-8 cell counting assay we found that expression of miR-199a-3p was positively correlated with cisplatin sensitivity in cholangiocarcinoma cell lines. MiR-199a-3p overexpression could decrease the proliferation rate and increase apoptosis of cholangiocarcinoma cells in the presence of cisplatin, while miR-199a-3p inhibition had the opposite effect. Further study demonstrated that mTOR was the target gene of miR-199a-3p, and that miR-199a-3p mimics could inhibit expression of mTOR, which consequently reduced the phosphorylation of its downstream proteins 4EBP1 and p70s6k. Rescue experiments proved that miR-199a-3p could increase the cisplatin sensitivity of cholangiocarcinoma cell lines by regulating mTOR expression. Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. In conclusion, miR-199a-3p could increase cisplatin sensitivity of cholangiocarcinoma cell lines by inhibiting the activity of the mTOR signaling pathway and decreasing the expression of MDR1. cell line (RBE, GBC-SD ) up-regulated sensitive mTOR mTOR mTOR signaling pathway validated 2526 Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex. Oncotarget 2017 28423356 miRBase MI0000085 miR-27a miRNA NA TRAIL therapy colorectal cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line (HT29 and SW480 ) up-regulated sensitive Apaf-1 Apaf-1 NA validated 2527 miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget 2017 28423513 miRBase MIMAT0002874 miR-503-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal carcinoma qRT-PCR In the study, we investigated the possible role of microRNA (miR)-503-5p in drug resistant CRC cells. Unbiased microRNA array screening revealed that miR-503-5p is up-regulated in two oxaliplatin (OXA)-resistant CRC cell lines. Overexpression of miR-503-5p conferred resistance to OXA-induced apoptosis and inhibition of tumor growth in vitro and in vivo through down-regulation of PUMA expression. miR-503-5p knockdown sensitized chemoresistant CRC cells to OXA. Our studies indicated that p53 suppresses miR-503-5p expression and that deletion of p53 upregulates miR-503-5p expression. Inhibition of miR-503-5p in p53 null cells increased their sensitivity to OXA treatment. Importantly, analysis of patient samples showed that expression of miR-503-5p negatively correlates with PUMA in CRC. These results indicate that a p53/miR-503-5p/PUMA signaling axis regulates the CRC response to chemotherapy, and suggest that miR-503-5p plays an important role in the development of MDR in CRC by modulating PUMA expression. cell line (HCT116, HT29, HCT116-OxR and HT29-OxR) down-regulated sensitive PUMA PUMA P53/PUMA pathway validated 2528 MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget 2017 28423543 miRBase MI0003162 miR-519d miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR In this paper, we demonstrated significant decrease of miR-519d in breast cancer stem cells by quantitative RT-PCR analysis. Furthermore, we found the enforced expression of miR-519d in T-47D-cancer stem cells significantly increased their sensitivity to cisplatin through the apoptosis pathway. In addition, the gene of MCL-1, which is a member of pro-apoptotic Bcl-2 family, was found to be the target of miR-519d in T-47D-cancer stem cells. Our date demonstrated that enforced miR-519d expression enhanced the cisplatin-induced apoptosis through the MCL-1 dependent mitochondria pathway in breast cancer stem cells. cell line (T-47D, MCF-7, SKBR3 and the MCF-10A ) up-regulated sensitive MCL-1 MCL-1 the mitochondria pathway validated 2529 MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neurooncol 2017 28425046 miRBase MI0000240 miR-198 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In this study, we report that miR-198 levels were greatly downregulated in glioblastoma specimens and decreased expression of miR-198 was associated with poor prognosis in patients with glioblastoma. And overexpression of miR-198 increased chemosensitivity to temozolomide in vitro and in vivo. O6-methylguanine-DNA methyltransferase (MGMT) was identified as a direct target of miR-198, and miR-198 overexpression prevented the protein translation of MGMT. Furthermore, overexpression of MGMT restored miR-198-induced chemosensitivity to temozolomide. Moreover, the protein levels of MGMT were upregulated in clinical glioblastoma specimens and inversely correlated with miR-198 levels. cell line ( A172, U87, U251, U118,LN229, U138, T98) up-regulated sensitive MGMT MGMT NA validated 2530 MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. Cell Physiol Biochem 2017 28427045 miRBase MIMAT0000434 miR-142-3p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In the current study, we investigated the regulatory role of microRNA-142-3p (miR-142-3p) in HMGB1-mediated autophagy of NSCLC cells and its impact on drug resistance of NSCLC in vitro and in vivo. HMGB1 was identified as a putative target gene of miR-142-3p by in silico analysis. Our luciferase reporter assay results confirmed that miR-142-3p directly targets the 3-UTR of HMGB1 in NSCLC cells cell line (HBE,A549) up-regulated sensitive HMGB1 HMGB1 PI3K/Akt/mTOR pathway validated 2531 MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. Cell Physiol Biochem 2017 28427045 miRBase MIMAT0000434 miR-142-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung non-small cell carcinoma qRT-PCR In the current study, we investigated the regulatory role of microRNA-142-3p (miR-142-3p) in HMGB1-mediated autophagy of NSCLC cells and its impact on drug resistance of NSCLC in vitro and in vivo. HMGB1 was identified as a putative target gene of miR-142-3p by in silico analysis. Our luciferase reporter assay results confirmed that miR-142-3p directly targets the 3-UTR of HMGB1 in NSCLC cells cell line (HBE,A549) up-regulated sensitive HMGB1 HMGB1 PI3K/Akt/mTOR pathway validated 2532 MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol 2017 28428713 miRBase MI0000461 miR-145 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR, qRT-PCR The levels of CD44 and miR-145 were determined in gastric cancer cells. Quantitative real-time polymerase chain reaction was used to measure to the level of CD44 mRNA. A luciferase reporter assay and western blotting were performed to examine the effect of miR-145 on CD44 expression. Tumor sphere and MTT assays were carried out to evaluate the self-renewal and chemo-resistance properties of gastric cancer cells. cell line (MGC-803) down-regulated resistant CD44 CD44 NA validated 2533 MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol 2017 28428713 miRBase MI0000461 miR-145 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR, qRT-PCR The levels of CD44 and miR-145 were determined in gastric cancer cells. Quantitative real-time polymerase chain reaction was used to measure to the level of CD44 mRNA. A luciferase reporter assay and western blotting were performed to examine the effect of miR-145 on CD44 expression. Tumor sphere and MTT assays were carried out to evaluate the self-renewal and chemo-resistance properties of gastric cancer cells. cell line (MGC-803) down-regulated resistant CD44 CD44 NA validated 2534 MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Exp Biol Med (Maywood) 2017 28429654 miRBase MI0001729 miR-451 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin renal cell carcinoma qRT-PCR This study aims to explore the mechanism of miR-451 as a target to regulate chemotherapy resistance, which is crucial for further exploring novel therapy for RCC. Two human cell lines (ACHN and GRC-1) were performed in this study and adriamycin (ADM) was used to construct MDR cell lines. qRT-PCR was used to determine the mRNA expression of miR-451 and ATF-2. Weston blot was used to determine protein expression. MTT assay and flow cytometry were used for assessing cell viability and apoptosis, individually. Luciferase reporter assay was used to detect the targeting of miR-451 and ATF-2. cell line (GRC-1 and ACHN) up-regulated resistant ATF-2 ATF-2 NA validated 2535 MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression. J Drug Target 2017 28436711 miRBase MIMAT0003301 miR-33b-5p miRNA DB01248 (APRD00932) Docetaxel stomach cancer qRT-PCR This study focused on tumor-suppressive miR-33b-5p expression as well as its role in gastric cancer. MiR-33b-5p was found low expression in gastric cancer cell lines. Functionally, western blots and the luciferase reporter assay were used to confirm that HMGA2 was the potential target of miR-33b-5p. Next, we used CCK-8 kits to analyze the effect of miR-33b-5p combined chemotherapy drugs on cell inhibition rate, and flow cytometry to analyze cells apoptosis. Colony formation ability was determined by plating at 500 cells per well into six-well plates and culturing for 15-d. The results showed that upregulation of miR-33b-5p decreased expression of HMGA2 and inhibited gastric cancer cell growth as well as sensitized gastric cancer cells to chemotherapy drugs. MiR-33b-5p overexpression hindered luciferase activity of HMGA2,3-untranslated region-based reporter construct in 293-T cells. These data demonstrate that miR-33b-5p may be a potential therapeutic target for gastric cancer and function as tumor-suppressive miRNA through targeting HMGA2 in gastric cancer. cell line ( SGC-7901, MGC-803,GES-1) up-regulated sensitive HMGA2 HMGA2 NA validated 2536 MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression. J Drug Target 2017 28436711 miRBase MIMAT0003301 miR-33b-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR This study focused on tumor-suppressive miR-33b-5p expression as well as its role in gastric cancer. MiR-33b-5p was found low expression in gastric cancer cell lines. Functionally, western blots and the luciferase reporter assay were used to confirm that HMGA2 was the potential target of miR-33b-5p. Next, we used CCK-8 kits to analyze the effect of miR-33b-5p combined chemotherapy drugs on cell inhibition rate, and flow cytometry to analyze cells apoptosis. Colony formation ability was determined by plating at 500 cells per well into six-well plates and culturing for 15-d. The results showed that upregulation of miR-33b-5p decreased expression of HMGA2 and inhibited gastric cancer cell growth as well as sensitized gastric cancer cells to chemotherapy drugs. MiR-33b-5p overexpression hindered luciferase activity of HMGA2,3-untranslated region-based reporter construct in 293-T cells. These data demonstrate that miR-33b-5p may be a potential therapeutic target for gastric cancer and function as tumor-suppressive miRNA through targeting HMGA2 in gastric cancer. cell line ( SGC-7901, MGC-803,GES-1) up-regulated sensitive HMGA2 HMGA2 NA validated 2537 MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATBeta in osteosarcoma. Braz J Med Biol Res 2017 28443990 miRBase MIMAT0004692 miR-340-5p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line ( MG-63, Saos-2,MG-63/CDDP,Saos-2/CDDP) up-regulated sensitive LPAATBeta LPAATBeta NA validated 2538 miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells. Mol Med Rep 2017 28447761 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer RT-qPCR The present study aimed to investigate the role and the molecular mechanisms underlying the effects of microRNA-21 (miR-21) on the proliferation, apoptosis and colony formation of cervical cancer cells, and to examine the role of miR-21 in mediating the sensitivity of cervical cancer cells to paclitaxel (PTX). Reverse transcription-quantitative polymerase chain reaction was employed to determine the level of miR-21 in various cervical cancer and normal cervical cells. The results revealed that the expression levels of miR-21 in cervical cancer cells were markedly higher when compared with normal cervical cells. Subsequently, a miR-21 inhibitor or negative control (NC) was transfected into cervical cancer cells. Cell viability, colony formation and apoptosis were then analyzed using an MTT assay, crystal violet and Annexin V-fluorescein isothiocyanate/propidium iodide staining, respectively. The protein expression level of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X (Bax), programmed cell death 4 (PDCD4), survivin, c-myc, phosphatase and tensin homolog (PTEN) and phosphorylated (p)-AKT were determined by western blot analysis. The sensitivity of cervical cancer cells to PTX (25, 50 and 100 -g/ml) was characterized using an MTT assay. The results demonstrated that the miR-21 inhibitor promoted apoptosis of cervical cancer cells and suppressed their proliferation and colony formation when compared with the NC. In addition, the expression levels of Bcl-2, survivin, c-myc and p-AKT were significantly downregulated in cells transfected with the miR-21 inhibitor, whilst the expression levels of Bax, PDCD4 and PTEN were significantly upregulated. Furthermore, the miR-21 inhibitor significantly enhanced the inhibition efficacy of PTX at a range of concentrations in cervical cancer cells. cell line (C-33A, CaSki, SiHa, HeLa and ME-180) up-regulated sensitive PTEN PTEN PTEN/AKT pathway validated 2539 miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis 2017 28459431 miRBase MIMAT0000686 miR-34c-5p miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qRT-PCR To explore the stemness characteristics of ovarian cancer stem cells, we successfully enriched ovarian cancer stem-like cells from an established ovarian cancer cell line (SKOV-I6) and a fresh ovarian tumor-derived cell line (OVS1). These ovarian cancer stem-like cells possess important cancer stemness characteristics including sphere-forming and self-renewing abilities, expressing important ovarian cancer stem cell and epithelial-mesenchymal transition markers, as well as increased drug resistance and potent tumorigenicity. Microarray analysis of OVS1-derived sphere cells revealed increased expression of amphiregulin (AREG) and decreased expression of its conserved regulatory microRNA, miR-34c-5p, when compared with the OVS1 parental cells. Overexpression of AREG and decreased miR-34c-5p expression in SKOV-I6 and OVS1 sphere cells were confirmed by quantitative real-time PCR analysis. Luciferase reporter assay and mutant analysis confirmed that AREG is a direct target of miR-34c-5p. Furthermore, AREG-mediated increase of sphere formation, drug resistance toward docetaxel and carboplatin, as well as tumorigenicity of SKOV-I6 and OVS1 cells could be abrogated by miR-34c-5p. We further demonstrated that miR-34c-5p inhibited ovarian cancer stemness through downregulation of the AREG-EGFR-ERK pathway. Overexpression of AREG was found to be correlated with advanced ovarian cancer stages and poor prognosis. Taken together, our data suggest that AREG promotes ovarian cancer stemness and drug resistance via the AREG-EGFR-ERK pathway and this is inhibited by miR-34c-5p. cell line (SKOV-I6, OVS1) up-regulated sensitive AREG AREG AREG-EGFR-ERK pathway validated 2540 miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis 2017 28459431 miRBase MIMAT0000686 miR-34c-5p miRNA DB00958 (APRD00466) Carboplatin ovarian cancer qRT-PCR To explore the stemness characteristics of ovarian cancer stem cells, we successfully enriched ovarian cancer stem-like cells from an established ovarian cancer cell line (SKOV-I6) and a fresh ovarian tumor-derived cell line (OVS1). These ovarian cancer stem-like cells possess important cancer stemness characteristics including sphere-forming and self-renewing abilities, expressing important ovarian cancer stem cell and epithelial-mesenchymal transition markers, as well as increased drug resistance and potent tumorigenicity. Microarray analysis of OVS1-derived sphere cells revealed increased expression of amphiregulin (AREG) and decreased expression of its conserved regulatory microRNA, miR-34c-5p, when compared with the OVS1 parental cells. Overexpression of AREG and decreased miR-34c-5p expression in SKOV-I6 and OVS1 sphere cells were confirmed by quantitative real-time PCR analysis. Luciferase reporter assay and mutant analysis confirmed that AREG is a direct target of miR-34c-5p. Furthermore, AREG-mediated increase of sphere formation, drug resistance toward docetaxel and carboplatin, as well as tumorigenicity of SKOV-I6 and OVS1 cells could be abrogated by miR-34c-5p. We further demonstrated that miR-34c-5p inhibited ovarian cancer stemness through downregulation of the AREG-EGFR-ERK pathway. Overexpression of AREG was found to be correlated with advanced ovarian cancer stages and poor prognosis. Taken together, our data suggest that AREG promotes ovarian cancer stemness and drug resistance via the AREG-EGFR-ERK pathway and this is inhibited by miR-34c-5p. cell line (SKOV-I6, OVS1) up-regulated sensitive AREG AREG AREG-EGFR-ERK pathway validated 2541 miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 2017 28459992 miRBase MI0000463/MI0000464 miR-153 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Cell apoptosis analysis was performed using flow cytometry assay. Quantitative real-time PCR was used to investigate the level of microRNA and the mRNA expression of its target, Snail. Snail expression was measured by immunoblotting and immunohistochemistry. A xenografted tumor model was used to test the in vivo effects of miR-153 on chemosensitivity to gemcitabine. cell line (BxPC-3, Panc-1, Capan-2, SW1990, Paca-2, AsPc-1, CFPAC-1,HPDE,HEK293T) up-regulated sensitive Snail Snail NA validated 2542 Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer. Int J Gynecol Cancer 2017 28472815 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression of GAS5 and microRNA 21 (miR-21) was detected in primary cervical cancer tissue specimens, as well as in cervical cancer cell lines. We identified the interaction of GAS5 and miR-21 by quantitative polymerase chain reaction, Western blot, and dual-luciferase reporter assay. We also studied the functions of GAS5 in proliferation, apoptosis, migration, and invasion in cervical cancer cells in vitro and vivo. Finally, the impact of GAS5 on cisplatin resistance and its mechanism in cervical cancer cells was also identified. cell line (HeLa, SiHa, and CaSki) up-regulated resistant GAS5 GAS5 PI3K/Akt Pathway validated 2543 MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate 2017 28485104 miRBase MI0000289/MI0000269 miR-181a miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR Real-time PCR was used to measure miR-181a expression in parental and docetaxel resistant C4-2B and DU145 cells (TaxR and DU145-DTXR). miR-181a expression was modulated in parental or docetaxel resistant cells by transfecting them with miR-181a mimics or antisense, respectively. Following transfection, cell number was determined after 48h with or without docetaxel. Cross resistance to cabazitaxel induced by miR-181a was also determined. Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity. Phospho-p53 expression was assessed by Western blot and apoptosis was measured by ELISA in C4-2B TaxR and PC3 cells with inhibited or overexpressed miR-181a expression with or without docetaxel. cell line ( C4-2B, C4-2B) up-regulated resistant NA NA NA validated 2544 miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J Mol Med (Berl) 2017 28487996 miRBase MIMAT0000087 miR-30a-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line ( A549, H460) up-regulated sensitive BCL-2 BCL-2 NA validated 2545 miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis 2017 28492560 miRBase MIMAT0000275 miR-218-5p miRNA DB00441 (APRD00201) Gemcitabine gallbladder cancer qRT-PCR In this study, we show that miR-218-5p plays a critical role in gemcitabine resistance of GBC. miR-218-5p levels were significantly lower in GBC than adjacent non-cancer tissues, and which were also associated with patient prognosis. While miR-218-5p overexpression abrogated gemcitabine resistance of GBC cells, silencing of which exhibited the opposite effects. Via six microRNA targets prediction algorithms, we found that PRKCE is a potential target of miR-218-5p. Moreover, miR-218-5p overexpression repressed the luciferase activity of reporter constructs containing 3-UTR of PRKCE and also reduced PRKCE expression. Further studies revealed that miR-218-5p promotes sensitivity of gemcitabine by abolishing PRKCE-induced upregulation of MDR1/P-gp. Taken together, our results imply that an intimate correlation between miR-218-5p and PRKCE/MDR1 axis abnormal expression is a key determinant of gemcitabine tolerance, and suggest a novel miR-218-5p-based clinical intervention target for GBC patients. cell line (GBC-SD,SGC-996,NOZ) up-regulated sensitive PRKCE PRKCE PRKCE/MDR1 pathway validated 2546 microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression. Exp Mol Med 2017 28496200 miRBase MIMAT0000682 miR-200a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-qPCR In the study, we investigated whether microRNAs (miRNAs) function as pivotal regulators in the acquisition of anti-cancer drug resistance to 5-fluorouracil (5-FU). A survey using a lentivirus library containing 572 precursor miRNAs revealed that five miRNAs promoted cell survival after 5-FU treatment in human hepatocellular carcinoma Hep3B cells. Among the five different clones, the clone expressing miR-200a-3p (Hep3B-miR-200a-3p) was further characterized as a 5-FU-resistant cell line. The cell viability and growth rate of Hep3B-miR-200a-3p cells were higher than those of control cells after 5-FU treatment. Ectopic expression of a miR-200a-3p mimic increased, while inhibition of miR-200a-3p downregulated, cell viability in response to 5-FU, doxorubicin, and CDDP (cisplatin). We also showed that dual-specificity phosphatase 6 (DUSP6) is a novel target of miR-200a-3p and regulates resistance to 5-FU. Ectopic expression of DUSP6 mitigated the pro-survival effects of miR-200a-3p. Taken together, these results lead us to propose that miR-200a-3p enhances anti-cancer drug resistance by decreasing DUSP6 expression. cell line ( Hep3B-CTRL, Hep3B-miR-200a and Hep3B ) up-regulated resistant DUSP6 DUSP6 NA validated 2547 Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression. Oncol Rep 2017 28498474 miRBase MI0006379/MI0015974/MI0015975/MI0031511 miR-1244 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The aim of this study was to investigate the function of miR-1244 in cisplatin-treated non-small cell lung cancer . The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, NCI-H522) up-regulated sensitive MEF2D MEF2D NA validated 2548 Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. Biochim Biophys Acta Mol Cell Res 2017 28499919 miRBase MI0000083 miR-26a miRNA DB00515 (APRD00359) Cisplatin glioblastoma qRT-PCR The role of AC023115.3 and miR-26a in malignant glioma cells was detected using western blot, microarray and computational analysis, dual-luciferase reporter assay, MTT assay, RIP assay,Real-time RT-PCR and RT-PCR, fluorescence microscopy and transmission electron microscopy,etc. cell line (U87MG, U251MG) down-regulated sensitive GSK3Beta GSK3Beta miR-26a-GSK3Beta-Mcl1 pathway validated 2549 MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. J Neurooncol 2017 28501897 miRBase MI0000270/MI0000683 miR-181b miRNA DB00853 (APRD00557) Temozolomide glioblastoma multiforme qRT-PCR In this study, quantitative real-time reverse transcription PCR (qRT-PCR) data indicated that miR-181b was significantly downregulated in recurrent GBM tissues compared with initial GBM tissues. We also found that miR-181b overexpression increased the chemo-sensitivity of GBM cells to TMZ and potentiated TMZ-induced apoptosis in vitro and in vivo. Moreover, we demonstrated that the epidermal growth factor receptor (EGFR) was a direct target of miR-181b: restoration of EGFR rescued the inhibitory effects of miR-181b and TMZ treatment. cell line ( U87, U251, HEK293T) up-regulated sensitive EGFR EGFR EGFR pathway validated 2550 Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. Biosci Rep 2017 28507201 miRBase MI0000300 miR-223 miRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma qRT-PCR The levels of miR-223 in parental cell line (HCC827) and erlotinib resistant HCC827 cell line (HCC827/ER) were detected by qRT-PCR. HCC827/ER cells were treated with MK-2206 to block the Akt signaling pathway or RO4929097 to block the Notch signaling pathway, and then transfected with an miR-223 inhibitor or interference expression plasmid of F-Box/WD repeat-containing protein 7 (FBXW7) or insulin-like growth factor 1 receptor (IGF1R). HCC827 cells were transfected with miR-223 mimics. Next, CCK-8, colony formation, and flow cytometric apoptosis assays were used to assess cell resistance to erlotinib. When compared with its expression in HCC827 cells, miR-223 expression was significantly up-regulated in HCC827/ER cells. Blocking either the Akt or Notch signaling pathway and reducing miR-223 expression resulted in decreased resistance in HCC827/ER cells. Conversely, increasing miR-223 expression induced cell resistance to erlotinib in HCC827 cells. miR-223 enhanced resistance to erlotinib by down-regulating FBXW7 expression. Reducing FBXW7 expression lowered resistance to erlotinib in HCC827/ER cells, while interference with expression of IGF1R produced no significant effect. This study demonstrated that NSCLC cells can up-regulate their levels of miR-223 expression via the Akt and Notch signaling pathways. miR-223 may serve as an important regulator of erlotinib sensitivity in NSCLC cells by targeting FBXW7. cell line ( HCC827,293T) up-regulated resistant FBXW7 FBXW7 Notch/miR-223/FBXW7 pathway validated 2551 Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem Biophys Res Commun 2017 28511796 miRBase MIMAT0000721 miR-369-3p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In the study, we established for the time the up-regulation of miR-369-3p in cisplatin (DDP)-resistant nonsmall cell lung cancer (NSCLC) tissues and cells. Its deregulation was found to be correlated to the magnitude of malignancy in well-characterized LCa cells. Functionally, inhibition of miR-369-3p sensitized LCa cells to DDP and suppressed the invasive capability in the presence of DDP treatment, whereas miR-369-3p overexpression promoted DDP resistance and thereby enhanced LCa cells invasiveness. Mechanistically, bioinformatics coupled with luciferase and gain-of-function, loss-of-function assays revealed that miR-369-3p may regulate DDP chemoresistance by directly targeting the 3 untranslated region (UTR) of human solute carrier 35F5 (SLC35F5), as application of miR-369-3p inhibitors or reintroduction of epigenetically silenced SLC35F5 both individually sensitized LCa cells to DDP, but combined treatment with miR-369-3p inhibitors and SLC35F5 overexpression failed to sensitized LCa cells further to DDP-elicited cell death. cell line ( SPC-A1, SK-MES-1, H1299, A549,16HBE) down-regulated sensitive SLC35F5 SLC35F5 miR-369-3p/SLC35F5 pathway validated 2552 Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene 2017 28512058 miRBase MI0000301 miR-224 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR In current study we initially explored N-glycan profiles on the surface of CML cell lines and bone marrow mononuclear cells (BMMC) of CML patients by using mass spectrometry (MS) analysis. An elevated sialylation was detected in K562R cells (CML cells with imatinib resistance phenotype) compare to K562 cells. By quantitative real time-PCR (qRT-PCR) and western blotting analysis we observed that imatinib resistant K562R cells exhibited marked high levels of CMP-N-acetylneuraminate-Beta-galactosamide-alpha-2,3-sialyltransferase (ST3Gal IV) as compared to imatinib sensitive K562 cells. Further studies revealed that manipulated expression of ST3GAL IV led to the significant alterations of cell cycle distribution, apoptotic signal, cell proliferation and the effectiveness of imatinib treatment. Using microRNA array, miRNA database searching and luciferase reporter assay, we identified that miR-224 and let-7i directly regulate the expression of ST3GAL IV gene. Moreover, engineered expression of miR-224 and let-7i in K562 and K562R cells could significantly affect ST6Gal IV-induced proliferation rate and drug-resistance. cell line ( K562, K562R) down-regulated resistant ST3GAL IV ST3GAL IV NA validated 2553 Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene 2017 28512058 miRBase MI0000434 let-7i miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR In current study we initially explored N-glycan profiles on the surface of CML cell lines and bone marrow mononuclear cells (BMMC) of CML patients by using mass spectrometry (MS) analysis. An elevated sialylation was detected in K562R cells (CML cells with imatinib resistance phenotype) compare to K562 cells. By quantitative real time-PCR (qRT-PCR) and western blotting analysis we observed that imatinib resistant K562R cells exhibited marked high levels of CMP-N-acetylneuraminate-Beta-galactosamide-alpha-2,3-sialyltransferase (ST3Gal IV) as compared to imatinib sensitive K562 cells. Further studies revealed that manipulated expression of ST3GAL IV led to the significant alterations of cell cycle distribution, apoptotic signal, cell proliferation and the effectiveness of imatinib treatment. Using microRNA array, miRNA database searching and luciferase reporter assay, we identified that miR-224 and let-7i directly regulate the expression of ST3GAL IV gene. Moreover, engineered expression of miR-224 and let-7i in K562 and K562R cells could significantly affect ST6Gal IV-induced proliferation rate and drug-resistance. cell line ( K562, K562R) down-regulated resistant ST3GAL IV ST3GAL IV NA validated 2554 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0000086 miR-29a-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib mesylate chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant TET2 TET2 NA validated 2555 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0002816 miR-494-3p miRNA DB08901 (DB06300) Ponatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line down-regulated resistant c-MYC c-MYC NA validated 2556 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0003338 miR-660-5p miRNA DB01254 Dasatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant EPAS1 EPAS1 NA validated 2557 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0000086 miR-29a-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib mesylate chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant TET2 TET2 NA validated 2558 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0002816 miR-494-3p miRNA DB08901 (DB06300) Ponatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line down-regulated resistant c-MYC c-MYC NA validated 2559 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0003338 miR-660-5p miRNA DB01254 Dasatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant EPAS1 EPAS1 NA validated 2560 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0000086 miR-29a-3p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib mesylate chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant TET2 TET2 NA validated 2561 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0002816 miR-494-3p miRNA DB08901 (DB06300) Ponatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line down-regulated resistant c-MYC c-MYC NA validated 2562 Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017 28533480 miRBase MIMAT0003338 miR-660-5p miRNA DB01254 Dasatinib chronic myeloid leukemia qRT-PCR In this work, we investigated the microRNA (miRNA) expression profile of different subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-CD38- cells. These cell fractions have been previously shown to be endowed with TKI intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL kinase activity and therefore are likely to be involved in the BCR-ABL-independent resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-resistance observed in these cell populations, and support the development of novel therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to effectively eradicate CML LSCs. cell line up-regulated resistant EPAS1 EPAS1 NA validated 2563 MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98 Zhonghua Wei Chang Wai Ke Za Zhi 2017 28534337 miRBase MI0000461 miR-145 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-qPCR L-OHP-resistant human colorectal cancer cell line (HCT116/L-OHP) was established in vitro by exposing to increased concentrations of L-OHP in cell culture medium. MiR-145-mimics and its negative control (NC-miRNA) were transfected into HCT116/L-OHP cells using liposome to establish HCT116/L-OHPmimics over-expressing miR-145 and HCT116/L-OHPNC. The target genes of miR-145 were predicted by bioinformatic analysis, and validated by dual luciferase activity assay. After determination of G protein coupled receptor 98(GPR98) as target gene, corresponding plasmids were constructed and transfected to establish HCT116/L-OHPGPR98 over-expressing GPR98 and HCT116/L-OHPcontrol. HCT116/L-OHP cells over-expressing both GPR98 and miR-145 (HCT116/L-OHPmimics+GPR98) were acquired through modification of the binding sites of GPR98 cDNA with miR-145. CCK-8 assay was used to assess the proliferation (A value) and sensitivity to L-OHP (the lower the IC50, the stronger the sensitivity) in HCT116/L-OHP cells. Real-time quantitative PCR was used to measure the mRNA expression of miR-145 and GPR98. Western blot was used to examine the protein expression of GPR98 and drug-resistant associated protein, such as P-glycoprotein (gp), multiple drug-resistance protein 1(MRP1), cancer-inhibition gene PTEN. cell line ( HCT116/L-OHP ) up-regulated sensitive GPR98 GPR98 NA validated 2564 The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. J BUON 2017 28534369 miRBase MIMAT0000070 miR-17-5p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR The human NSCLC cell line A549 and its drug resistant strain A549/GR (Gefitinib Resistant) was used in this study. The expression of miR-17-5p, miR-92a, and let-7b in different NSCLC cell lines was detected before and after transfection using real-time fluorescent PCR. Cell viability was detected using the CCK8 method. Cell cloning was performed to examine cell proliferation; cell apoptosis before and after transfection was evaluated using flow cytometry. cell line (A549 and A549/GR) up-regulated resistant NA NA NA validated 2565 The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. J BUON 2017 28534369 miRBase MI0000093/MI0000094 miR-92a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR The human NSCLC cell line A549 and its drug resistant strain A549/GR (Gefitinib Resistant) was used in this study. The expression of miR-17-5p, miR-92a, and let-7b in different NSCLC cell lines was detected before and after transfection using real-time fluorescent PCR. Cell viability was detected using the CCK8 method. Cell cloning was performed to examine cell proliferation; cell apoptosis before and after transfection was evaluated using flow cytometry. cell line (A549 and A549/GR) up-regulated resistant NA NA NA validated 2566 The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. J BUON 2017 28534369 miRBase MI0000063 let-7b miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR The human NSCLC cell line A549 and its drug resistant strain A549/GR (Gefitinib Resistant) was used in this study. The expression of miR-17-5p, miR-92a, and let-7b in different NSCLC cell lines was detected before and after transfection using real-time fluorescent PCR. Cell viability was detected using the CCK8 method. Cell cloning was performed to examine cell proliferation; cell apoptosis before and after transfection was evaluated using flow cytometry. cell line (A549 and A549/GR) down-regulated resistant NA NA NA validated 2567 MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. Oncol Rep 2017 28534959 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-200c in gastric cancer cells was detected by qRT-PCR, Immunohistochemistry,western blot analysis,and MTT assay.etc. tissue and cell line (SGC7901,SGC7901/DDP) up-regulated sensitive ZEB2 ZEB2 ZEB2 signaling pathway validated 2568 hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med 2017 28535002 miRBase MIMAT0002175 miR-485-5p miRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma qRT-PCR In this study, we showed that overexpression of p21 (RAC1) activated kinase 1 (PAK1) induced epithelial to mesenchymal transition (EMT) and significantly promoted the invasion and migration of oral squamous cell carcinoma SCC25 cells. Emerging evidence indicates a strong link between resistance to therapy and the induction of EMT in cancer. We showed that overexpression of PAK1 induced cisplatin resistance in SCC25 cells. ERCC1 and YAP can promote cisplatin resistance in human OSCC. We showed that ERCC1 and YAP protein were upregulated by PAK1 in SCC25 cells. -We found that miR-485-5p inhibited PAK1 protein expression in the SCC25 cells. Contrary to PAK1, we demonstrated that overexpression of miR-485-5p reversed EMT and significantly inhibited invasion and migration. Moreover, its overexpression sensitized SCC25-CR cells (cisplatin-resistant cells) to cisplatin. Thus, we conclude that miR-485-5p reverses EMT and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. This study suggests that PAK1 plays an essential role in the progression of OSCC and it is a potential therapeutic target for OSCC. cell line ( SCC25, SCC25-res ) up-regulated sensitive PAK1 PAK1 NA validated 2569 Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett 2017 28536008 miRBase MI0000285 miR-205 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, we observed differential downregulation of miR-205 (miR-205-5p) in human pancreatic cancer tissues and cells. Compared to GEM-sensitive MIA PaCa-2 cells, miR-205 was highly downregulated in GEM-resistant MIA PaCa-2R cells. Lentivirus-mediated overexpression of miR-205 inhibits MIA PaCa-2R cell proliferation after GEM-treatment. Further investigation confirmed that miR-205 alone significantly reduces the proliferation of CSCs and tumor growth in mouse models. However, miR-205 in combination with GEM was more efficient in reducing the proliferation of CSCs and 3D spheroids. Moreover, miR-205 overexpressing MIA PaCa-2R cells induced orthotopic tumor growth was significantly inhibited after intravenous administration of GEM-conjugated methoxy poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate)-graft-gemcitabine-graft-dodecanol (mPEG-b-PCC-g-GEM-g-DC) (mPEG-b-PCC-g-GEM-g-DC) polymeric micelles. Also, a reduction in CSCs, EMT and chemoresistance markers was observed in miR-205 overexpressing MIA PaCa-2R cells. Immunohistochemical analysis of orthotopic tumors showed a decrease in drug resistance protein caveolin-1 and cell proliferation marker Ki-67 in combination treatment. tissue and cell line ( PaCa-2R,HPAF-II and BXPC-3) up-regulated sensitive NA NA NA validated 2570 Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine 2017 28553110 miRBase MIMAT0000098 miR-100-5p miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR A549 resistance to DDP (A549/DDP) was established. Microarray was used to analyze microRNA (miRNA) expression profiles of A549 cells, A549/DDP cells, A549 exosomes, and A549/DDP exosomes. There was a strong correlation of miRNA profiles between exosomes and their maternal cells. A total of 11 miRNAs were significantly upregulated both in A549/DDP cells compared with A549 cells and in exosomes derived from A549/DDP cells in contrast to exosomes from A549 cells. A total of 31 downregulated miRNAs were also observed. miR-100-5p was the most prominent decreased miRNA in DDP-resistant exosomes compared with the corresponding sensitive ones. Downregulated miR-100-5p was proved to be involved in DDP resistance in A549 cells, and mammalian target of rapamycin (mTOR) expression was reverse regulated by miR-100-5p. Exosomes confer recipient cells resistance to DDP in an exosomal miR-100-5p-dependent manner with mTOR as its potential target both in vitro and in vivo. Exosomes from DDP-resistant lung cancer cells A549 can alter other lung cancer cells sensitivity to DDP in exosomal miR-100-5p-dependent manner. cell line (A549,A549/DDP) down-regulated resistant mTOR mTOR NA validated 2571 Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation. Oncol Rep 2017 28560419 miRBase MI0000103/MI0000739 miR-101 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR This study investigated the effect of miR-101 on proliferation, migration, invasion, and chemotherapy sensitivity in colon cancer cell lines HT-29 and RKO. MicroRNAs are a class of small noncoding RNA molecules, which play important roles in diverse biological processes of human cancers, such as carcinogenesis, development, differentiation, and apoptosis. The expression of miR-101 in colon cancer and adjacent non-tumor tissues were examined by quantitative real-time polymerase chain reaction. The expression of miR-101 was upregulated by recombinant adenovirus Ad-miR-101. Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cloning methods. Cell migration and invasion potential were examined using Transwell migration and Matrigel invasion chamber assays. Drug sensitivity to 5-fluorouracil (5-FU) and cisplatin (DDP) was explored using MTT assays and l acridine orange/ethidium bromide double staining. The expression of miR-101 decreased in colon cancer tissues compared with adjacent non-tumor tissues. The upregulated expression of miR-101 suppressed cell proliferation and inhibited cell migration and invasion in HT-29 and RKO colon cancer cell lines. The overexpression of miR-101 promoted the inhibitory effect of 5-FU and DDP on HT-29 cells. The expression of miR-101 was downregulated in colon cancer. The upregulated expression of miR-101 inhibited proliferation and migration, and increased the sensitivity of colon cancer cells to chemotherapy. cell line (HT-29, RKO ) up-regulated sensitive NA NA NA validated 2572 Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation. Oncol Rep 2017 28560419 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin colon cancer qRT-PCR This study investigated the effect of miR-101 on proliferation, migration, invasion, and chemotherapy sensitivity in colon cancer cell lines HT-29 and RKO. MicroRNAs are a class of small noncoding RNA molecules, which play important roles in diverse biological processes of human cancers, such as carcinogenesis, development, differentiation, and apoptosis. The expression of miR-101 in colon cancer and adjacent non-tumor tissues were examined by quantitative real-time polymerase chain reaction. The expression of miR-101 was upregulated by recombinant adenovirus Ad-miR-101. Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cloning methods. Cell migration and invasion potential were examined using Transwell migration and Matrigel invasion chamber assays. Drug sensitivity to 5-fluorouracil (5-FU) and cisplatin (DDP) was explored using MTT assays and l acridine orange/ethidium bromide double staining. The expression of miR-101 decreased in colon cancer tissues compared with adjacent non-tumor tissues. The upregulated expression of miR-101 suppressed cell proliferation and inhibited cell migration and invasion in HT-29 and RKO colon cancer cell lines. The overexpression of miR-101 promoted the inhibitory effect of 5-FU and DDP on HT-29 cells. The expression of miR-101 was downregulated in colon cancer. The upregulated expression of miR-101 inhibited proliferation and migration, and increased the sensitivity of colon cancer cells to chemotherapy. cell line (HT-29, RKO ) up-regulated sensitive NA NA NA validated 2573 MicroRNA-146a-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Int J Oncol 2017 28560455 miRBase MIMAT0000449 miR-146a-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer NA In this study, the role of miR-146a-5p in cisplatin-induced apoptosis of ovarian cancer cells was assessed by DAPI staining, MTT assays, and monitoring expression of XIAP, BCL2L2, BIRC2 and BIRC5 through a dual-luciferase assay. Our results show that miR-146a-5p can regulate three important anti-apoptotic genes including XIAP, BCL2L2 and BIRC5 via their 3UTRs. Not only can overexpression of miR-146a-5p downregulate the expression of XIAP in SKOV3 cells, but it also lowers the IC50 values of cisplatin in OVCAR3 and SKOV3 cells and enhances the susceptibility of OVCAR3, SKOV3 and primary ovarian cancer cells to cisplatin-induced apoptosis. The effect of XIAP rescuing cisplatin-induced apoptosis accelerated by miR-146a-5p further supports our conclusion. Our results suggest that the regulation of three anti-apoptotic genes by miR-146-5p enhances the therapeutic effects of cisplatin. cell line ( OVCAR3 and SKOV3 ) up-regulated sensitive XIAP, BCL2L2 and BIRC5 XIAP, BCL2L2 and BIRC5 NA validated 2574 Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Ann Surg Oncol 2017 28560603 miRBase MIMAT0000425 miR-130a-3p miRNA DB00441 (APRD00201) Gemcitabine cholangiocarcinoma qRT-PCR We performed miRNA microarray analysis for two CCA cell lines (CCLP-1 and MzChA-1) and their gemcitabine-resistant (GR) cells. An miR-130a-3p mimic was induced into CCA cells using lipofection, and we used pioglitazone as a peroxisome proliferator-activated receptor-r (PPARr) agonist in vitro. The expression of miR-130a-3p was studied in 27 intrahepatic CCA samples after laser capture microdissection (LCM) and by immunohistochemistry from patients who had undergone curative resection from March 2004 to November 2012 at Osaka University Hospital cell line ( CCLP-1, MzChA-1 ) up-regulated resistant PPARG PPARG NA validated 2575 MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J Steroid Biochem Mol Biol 2017 28578002 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA NA Glucocorticoid acute lymphocytic leukemia qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( Human CCRF-CEM, Jurkat and CEM/C1) up-regulated resistant NR3C1 NR3C1 NA validated 2576 Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. Oncol Lett 2017 28588724 miRBase MI0000459 miR-143 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer qPCR The present study aimed to evaluate the therapeutic potential of miR-143 as a treatment for drug-resistant breast cancer via the downregulation of CIAPIN1 in vitro. The expression levels of miR-143 were measured using quantitative polymerase chain reaction and the expression levels of CIAPIN1 were detected via western blot analysis. Bioinformatic analyses was additionally conducted to search for miR-143, which may potentially target CIAPIN1. Luciferase reporter plasmids were created and used to verify direct targeting. In addition, Taxol-induced drug-resistant (TDR) breast cancer cell proliferation was evaluated using the Cell Counting Kit-8 assay in vitro. cell line (MCF-7, MDA-MB-231, MDA-MB-453,HEK-293) up-regulated sensitive CIAPIN1 CIAPIN1 miR-143/CIAPIN1 pathway validated 2577 Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget 2017 28591704 miRBase MIMAT0001080 miR-196b-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The role of miR-196b-5p in colorectal cancer cells was detected by RT-PCR,western blot analysis,side population analysis,flow cytometric analysis,Caspase-9 or -3 activity assays,tumor xenografts,and lLuciferase assay.etc. cell line ( Caco-2, COLO 205, COLO 320DM, CW-2, DLD-1, HCT15, HCT116, HT-29, NCI-H716, LS 174T, LoVo, RKO, SW480, SW620, SW948 and SW1116) down-regulated sensitive SOCS1 and SOCS3 SOCS1 and SOCS3 STAT3 signaling pathway validated 2578 miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met. Sci Rep 2017 28592790 miRBase MI0000073 miR-19a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR In this study, we show that miR-19a is significantly down-regulated in gefitinib-resistant NSCLC cell lines compared with gefitinib-sensitive cell lines. In addition, the down-regulation of miR-19a suppressed the expression of epithelial markers but induced the expression levels of mesenchymal markers. A mechanistic analysis revealed that miR-19a regulated c-Met expression by directly targeting the c-Met 3UTR. Overexpression of miR-19a decreased c-Met expression and re-sensitized gefitinib-resistant NSCLC cells in vitro and in vivo. Consistent with the in vitro findings, the miR-19a serum level was significantly decreased in NSCLC patients with acquired gefitinib resistance compared with the level observed prior to the acquisition of resistance in each patient, indicating that miR-19a expression may be a valuable biomarker for the prediction of acquired gefitinib resistance in a clinical setting. Our data demonstrate that the miR-19a/c-Met pathway plays a critical role in acquired resistance to gefitinib and that the manipulation of miR-19a might provide a therapeutic strategy for overcoming acquired gefitinib resistance. cell line (HCC827, H1975, A549, Pc9 and Pc9 GR) up-regulated resistant c-Met NA miR-19a/c-Met pathway validated 2579 Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. Clin Exp Dermatol 2017 28597996 miRBase MI0000283 miR-203 miRNA DB00853 (APRD00557) Temozolomide melanoma qRT-PCR Using quantitative reverse transcription PCR, we measured the expression of miR-203 in an MM cell line. Cell viability of MM cells in response to TMZ treatment was measured by MTT assay. Glutamine metabolism and level of glutaminase (GLS) were assessed. cell line ( HT144 ) up-regulated sensitive GLS GLS NA validated 2580 Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett 2017 28599480 miRBase MI0003188 miR-503 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR The role of miR-503 in human breast cancer cells was detected by RT-qPCR, western blot analysis,MTT,luciferase reporter assay, and flow cytometry. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive eIF4G eIF4G NA validated 2581 Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett 2017 28599480 miRBase MI0003188 miR-503 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR The role of miR-503 in human breast cancer cells was detected by RT-qPCR, western blot analysis,MTT,luciferase reporter assay, and flow cytometry. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive eIF4G eIF4G NA validated 2582 Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett 2017 28599480 miRBase MI0003188 miR-503 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-qPCR The role of miR-503 in human breast cancer cells was detected by RT-qPCR, western blot analysis,MTT,luciferase reporter assay, and flow cytometry. cell line (MCF-7,MCF-7/ADR) up-regulated sensitive eIF4G eIF4G NA validated 2583 MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncol Lett 2017 28599501 miRBase MI0000293 miR-217 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia qPCR The expression of miR-217 was determined by quantitative polymerase chain reaction (qPCR). Following transfection with miR-217 mimics, an MTT assay, chemosensitivity assay, cell apoptosis assay and western blot analysis were performed in AML cell lines. Functional assays were also performed to explore the effects of endogenous Kirsten rat sarcoma viral oncogene homolog (KRAS) in AML. The results revealed that miR-217 was downregulated in patients with AML. Overexpression of miR-217 inhibited cellular proliferation and enhanced cell chemosensitivity to doxorubicin by the cell apoptosis pathway in AML cells. A dual-luciferase reporter assay demonstrated that KRAS was a direct target gene of miR-217 in vitro. qPCR and western blot analysis revealed that miR-217 negatively regulated KRAS protein expression, but had no impact on KRAS mRNA expression. Knockdown of KRAS expression markedly suppressed AML cellular proliferation, and enhanced cell chemosensitivity to doxorubicin via the cell apoptosis pathway. These findings indicate that miR-217 functions as a tumor suppressor in AML by directly targeting KRAS. cell line ( HL-60,K562) up-regulated sensitive KRAS KRAS NA validated 2584 miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother 2017 28609840 miRBase MI0000103/MI0000739 miR-101 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expressions of miR-101 and Annexin A2 (ANXA2) in GC tissues and cells were detected by qRT-PCR and western blot. The effects of miR-101 overexpression on P-glycoprotein (P-gp) at mRNA and protein levels, cell viability, and apoptosis in drug-resistant GC cells were examined by qRT-PCR, western blot, MTT and flow cytometry analysis, respectively. Luciferase reporter assay, RNA immunoprecipitation (RIP) and qRT-PCR were applied to confirm whether miR-101 could target ANXA2 and regulate its expression. Rescue experiment was performed to verify the mechanism by which miR-101 involved in chemoresistance. tissue and cell line (SGC7901,SGC7901/DDP,SGC7901/VCR) up-regulated sensitive ANXA2 ANXA2 p38MAPK and AKT pathways validated 2585 miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother 2017 28609840 miRBase MI0000103/MI0000739 miR-101 miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expressions of miR-101 and Annexin A2 (ANXA2) in GC tissues and cells were detected by qRT-PCR and western blot. The effects of miR-101 overexpression on P-glycoprotein (P-gp) at mRNA and protein levels, cell viability, and apoptosis in drug-resistant GC cells were examined by qRT-PCR, western blot, MTT and flow cytometry analysis, respectively. Luciferase reporter assay, RNA immunoprecipitation (RIP) and qRT-PCR were applied to confirm whether miR-101 could target ANXA2 and regulate its expression. Rescue experiment was performed to verify the mechanism by which miR-101 involved in chemoresistance. tissue and cell line (SGC7901,SGC7901/DDP,SGC7901/VCR) up-regulated sensitive ANXA2 ANXA2 p38MAPK and AKT pathways validated 2586 Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma. Cell Physiol Biochem 2017 28618418 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR Quantitative real-time PCR (qRT-PCR) assay was performed to determine miR-7 expression in 108 paired of LA tissues and analyze its correlations with clinicopathological factors of patients. The patient survival data were collected retrospectively by Kaplan-Meier analyses, and multivariate analysis was performed using the Cox proportional hazards model to determine the prognostic significance of miR-7 expression. The effects of miR-7 expression on the chemosensitivity of LA cells to CDDP and its possible mechanisms were evaluated by MTT, flow cytometry, Western blot and luciferase assays. cell line (SPC-A1) up-regulated sensitive Bcl-2 Bcl-2 NA validated 2587 MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1. Biochem Biophys Res Commun 2017 28619508 miRBase MIMAT0000242 miR-129-5p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (A549, and H460) up-regulated sensitive DLK1 DLK1 NA validated 2588 MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma. Tumour Biol 2017 28631568 miRBase MI0000273 miR-183 miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma qRT-PCR The expression of miR-183 and metastasis-associated protein 1 at messenger RNA and protein levels in nasopharyngeal carcinoma tissues and cells was evaluated using quantitative reverse transcription real-time polymerase chain reaction and western blotting, respectively. CNE1 and CNE2 cells were transfected with miR-183 mimic, miR-183 inhibitor, pcDNA-metastasis-associated protein 1, or respective controls. The effects of miR-183 and metastasis-associated protein 1 overexpression on cell proliferation, invasion, and DDP-induced apoptosis were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, Transwell invasion assay, and flow cytometry analysis, respectively. Luciferase reporter assay was performed to explore whether miR-183 directly targeted metastasis-associated protein 1. cell line (C666-1,CNE1,CNE2,HONE1, 5-8F) up-regulated sensitive MTA1 MTA1 NA validated 2589 Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer 2017 28633632 miRBase MIMAT0004784 miR-455-3p miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma RT-PCR A chemoresistant patient-derived xenograft (PDX) model of human esophageal squamous cell carcinoma (ESCC) was employed to identify microRNAs that contribute to ESCC aggressiveness. The oncogenic effects of microRNA-455-3p (miR-455-3p) on ESCC chemoresistance and tumorigenesis were examined by in vivo and in vitro chemoresistance, tumorsphere formation, side-population, and in vivo limiting dilution assays. The roles of miR-455-3p in activation of the Wnt/Beta-catenin and transforming growth factor-Beta (TGF-Beta)/Smad pathways were determined by luciferase and RNA immunoprecipitation assays. cell line (Eca109, Kyse30,H157,AGS ) up-regulated resistant NA NA NA validated 2590 Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer 2017 28633632 miRBase MIMAT0004784 miR-455-3p miRNA DB01248 (APRD00932) Docetaxel esophageal squamous cell carcinoma RT-PCR A chemoresistant patient-derived xenograft (PDX) model of human esophageal squamous cell carcinoma (ESCC) was employed to identify microRNAs that contribute to ESCC aggressiveness. The oncogenic effects of microRNA-455-3p (miR-455-3p) on ESCC chemoresistance and tumorigenesis were examined by in vivo and in vitro chemoresistance, tumorsphere formation, side-population, and in vivo limiting dilution assays. The roles of miR-455-3p in activation of the Wnt/Beta-catenin and transforming growth factor-Beta (TGF-Beta)/Smad pathways were determined by luciferase and RNA immunoprecipitation assays. cell line (Eca109, Kyse30,H157,AGS ) up-regulated resistant NA NA NA validated 2591 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biol Chem 2017 28637868 miRBase MI0000083/MI0000750 miR-26a miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR In the study, we reported that the ERBB2 expression is regulated at the post-transcriptional level by miR26a/b and the RNA-binding protein human antigen R (HuR), both of which associate with the 3-UTR of the ERBB2 transcripts. We demonstrated that miR26a/b inhibits the translation of ERBB2 mRNA, whereas HuR enhances the stability of the ERBB2 mRNA. In TAMR ER+ breast cancer cells with elevated ERBB2 expression, we observed a decrease in the level of miR26a/b and an increase in the level of HuR. The forced expression of miR26a/b or the depletion of HuR decreased ERBB2 expression in the TAMR cells, resulting in the reversal of tamoxifen resistance. In contrast, the inactivation of miR26a/b or forced expression of HuR decreased tamoxifen responsiveness of the parental ER+ breast cancer cells. We further showed that the increase in HuR expression in the TAMR ER+ breast cancer cells is attributable to an increase in the HuR mRNA isoform with shortened 3-UTR, which exhibits increased translational activity. This shortening of the HuR mRNA 3-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells. cell line (MCF7,T47D,MCF7/TAMR ,T47D/TAMR) up-regulated sensitive ERBB2 ERBB2 NA validated 2592 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biol Chem 2017 28637868 miRBase MI0000084 miR-26b miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR In the study, we reported that the ERBB2 expression is regulated at the post-transcriptional level by miR26a/b and the RNA-binding protein human antigen R (HuR), both of which associate with the 3-UTR of the ERBB2 transcripts. We demonstrated that miR26a/b inhibits the translation of ERBB2 mRNA, whereas HuR enhances the stability of the ERBB2 mRNA. In TAMR ER+ breast cancer cells with elevated ERBB2 expression, we observed a decrease in the level of miR26a/b and an increase in the level of HuR. The forced expression of miR26a/b or the depletion of HuR decreased ERBB2 expression in the TAMR cells, resulting in the reversal of tamoxifen resistance. In contrast, the inactivation of miR26a/b or forced expression of HuR decreased tamoxifen responsiveness of the parental ER+ breast cancer cells. We further showed that the increase in HuR expression in the TAMR ER+ breast cancer cells is attributable to an increase in the HuR mRNA isoform with shortened 3-UTR, which exhibits increased translational activity. This shortening of the HuR mRNA 3-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells. cell line (MCF7,T47D,MCF7/TAMR ,T47D/TAMR) up-regulated sensitive ERBB2 ERBB2 NA validated 2593 miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep 2017 28638102 miRBase MIMAT0004779 miR-509-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Since we have already established a cell-based reporter system for identifying EMT-suppressive microRNAs (miRNAs) in the pancreatic cancer cell line Panc1, we performed a function-based screening assay by combining this reporter system and a miRNA library composed of 1,090 miRNAs. As a result, we identified miR-509-5p and miR-1243 as EMT-suppressive miRNAs, although the mechanisms for EMT-suppression induced by these miRNAs have yet to be clarified. Herein, we demonstrated that overexpression of miR-509-5p and miR-1243 increased the expression of E-cadherin through the suppression of EMT-related gene expression and that drug sensitivity increased with a combination of each of these miRNAs and gemcitabine. Moreover, miR-509-5p was associated with worse overall survival in patients with pancreatic cancer and was identified as an independently selected predictor of mortality. cell line (Panc1, KMP3, KP4-4, BxPC3, CFPAC1 and SU.86.86 ) up-regulated sensitive HMGA2 HMGA2 NA validated 2594 miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep 2017 28638102 miRBase MI0006373 miR-1243 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Since we have already established a cell-based reporter system for identifying EMT-suppressive microRNAs (miRNAs) in the pancreatic cancer cell line Panc1, we performed a function-based screening assay by combining this reporter system and a miRNA library composed of 1,090 miRNAs. As a result, we identified miR-509-5p and miR-1243 as EMT-suppressive miRNAs, although the mechanisms for EMT-suppression induced by these miRNAs have yet to be clarified. Herein, we demonstrated that overexpression of miR-509-5p and miR-1243 increased the expression of E-cadherin through the suppression of EMT-related gene expression and that drug sensitivity increased with a combination of each of these miRNAs and gemcitabine. Moreover, miR-509-5p was associated with worse overall survival in patients with pancreatic cancer and was identified as an independently selected predictor of mortality. cell line (Panc1, KMP3, KP4-4, BxPC3, CFPAC1 and SU.86.86 ) up-regulated sensitive SMAD2 and SMAD4 SMAD2 and SMAD4 TGF-Beta signalling pathway validated 2595 MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. Tumour Biol 2017 28639887 miRBase MI0000476/MI0000455 miR-138 miRNA NA TRAIL therapy hepatocellular carcinoma RT-qPCR In this study, to identify potential therapeutic targets for TRAIL-resistant cancer cells, we compared the expression levels of interferon-stimulated gene 15 in TRAIL-sensitive and TRAIL-resistant hepatocellular carcinoma cell lines. Western blot analysis showed that interferon-stimulated gene 15 expression levels were significantly higher in resistant HLCZ01and Huh7 cells than in sensitive LH86 and SMMC-7721 cells. Interferon-stimulated gene 15 knockdown in resistance cells led to TRAIL sensitivity. Conversely, interferon-stimulated gene 15 overexpression in sensitive cells resulted in TRAIL resistance. Our bioinformatics search detected a putative target sequence for microRNA miR-138 in the 3 untranslated region of the interferon-stimulated gene 15. Real-time quantitative polymerase chain reaction analysis demonstrated that miR-138 was significantly downregulated in TRAIL-resistant cells compared to TRAIL-sensitive cells. Forced expression of miR-138 in resistant cells decreased both messenger RNA and protein levels of interferon-stimulated gene 15, and when exposed to TRAIL, activated poly(adenosine diphosphate-ribose) polymerase, indicating sensitization to TRAIL. The results suggested that miR-138 regulates the interferon-stimulated gene 15 expression by directly targeting the 3 untranslated region of interferon-stimulated gene 15 and modulates the sensitivity to TRAIL-induced apoptosis. cell line (Huh7, LH86,HLCZ01,SMMC-7721) up-regulated sensitive ISG15 ISG15 NA validated 2596 Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/Beta-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. Tumour Biol 2017 28639895 miRBase MI0000242/MI0000281 miR-199a miRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR The aim of this study was to investigate the biological function of miR-199a/b on cisplatin resistance in colorectal cancer stem cells and its related mechanisms. Here, ALDHA1+ cells from primary colorectal cancer tissues behaved similar to cancer stem cells and were chemoresistant to cisplatin. The presence of a variable fraction of ALDHA1 was detected in 9 out of 10 colorectal cancer specimens. Significantly, increased miR-199a/b expression was detected in ALDHA1+ colorectal cancer stem cells, accompanied by a downregulation of Gsk3 and an overexpression of catenin and ABCG2. In patient cohort, enhanced miR-199a/b expression in colorectal cancer tissues was associated with cisplatin response and poor patient survival. In addition, 80% of colorectal cancer samples showed lower level of Gsk3 than their adjacent normal counterparts. Furthermore, Gsk3 was the direct target of miR-199a/b. MiR-199a/b regulated Wnt/catenin pathway by targeting Gsk3 in ALDHA1+ colorectal cancer stem cells. By blocking Wnt/catenin pathway, we implied that ABCG2 lies downstream of Wnt/catenin pathway. ABCG2 was further demonstrated to contribute cisplatin resistance in ALDHA1+ colorectal cancer stem cells and can be regulated by miR-199a/b. Thus, our data suggested that upregulation of miR-199a/b in ALDHA1+ colorectal cancer stem cells contributed to cisplatin resistance via Wnt/catenin-ABCG2 signaling, which sheds new light on understanding the mechanism of cisplatin resistance in colorectal cancer stem cells and facilitates the development of potet of potential therapeutics againstainst colorectal cancer. cell line up-regulated resistant GSK3Beta GSK3Beta Wnt/Beta-catenin pathway validated 2597 Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/Beta-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. Tumour Biol 2017 28639895 miRBase MI0000282 miR-199b miRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR The aim of this study was to investigate the biological function of miR-199a/b on cisplatin resistance in colorectal cancer stem cells and its related mechanisms. Here, ALDHA1+ cells from primary colorectal cancer tissues behaved similar to cancer stem cells and were chemoresistant to cisplatin. The presence of a variable fraction of ALDHA1 was detected in 9 out of 10 colorectal cancer specimens. Significantly, increased miR-199a/b expression was detected in ALDHA1+ colorectal cancer stem cells, accompanied by a downregulation of Gsk3 and an overexpression of catenin and ABCG2. In patient cohort, enhanced miR-199a/b expression in colorectal cancer tissues was associated with cisplatin response and poor patient survival. In addition, 80% of colorectal cancer samples showed lower level of Gsk3 than their adjacent normal counterparts. Furthermore, Gsk3 was the direct target of miR-199a/b. MiR-199a/b regulated Wnt/catenin pathway by targeting Gsk3 in ALDHA1+ colorectal cancer stem cells. By blocking Wnt/catenin pathway, we implied that ABCG2 lies downstream of Wnt/catenin pathway. ABCG2 was further demonstrated to contribute cisplatin resistance in ALDHA1+ colorectal cancer stem cells and can be regulated by miR-199a/b. Thus, our data suggested that upregulation of miR-199a/b in ALDHA1+ colorectal cancer stem cells contributed to cisplatin resistance via Wnt/catenin-ABCG2 signaling, which sheds new light on understanding the mechanism of cisplatin resistance in colorectal cancer stem cells and facilitates the development of potet of potential therapeutics againstainst colorectal cancer. cell line up-regulated resistant Gsk3Beta Gsk3Beta Wnt/Beta-catenin pathway validated 2598 Application of miR-182 for Determination of Glucocorticoid-Resistant Patients with Lymphoid Malignancy Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017 28641635 miRBase MI0000272 miR-182 miRNA NA Glucocorticoid lymphoid malignancy qRT-PCR Real-time quantitative PCR(qRT-PCR) was employed to detect the expression of miR-182 in lymphoma patients (68 cases, the specimens indluded bone marrow of 20 cases, and plasma of 48 cases), multiple myeloma patients (24 cases, the specimens included bone marrow of 14 cases and plasma of 10 cases), ALL patients (3 cases, specimen was plasma of 3 cases) and non-lymphotic system disorder patients (18 cases, specimens included bone marrow of 8 cases and plasma of 10 cases). cell line up-regulated resistant NA NA NA validated 2599 MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2 Zhongguo Fei Ai Za Zhi 2017 28641694 miRBase MI0000822 miR-133b miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR Using miRBase and miRNAMap database to sequence comparison miR-133b and PKM2 gene. Using immune magnetic separation method to select the CD133+/CD34+ lung cancer stem cells from A549 cells, and using flow cytometry to detect the purity. The expression of miR-133b mRNA was detected by real-time fluorescence quantitative PCR (qRT-PCR). Cell proliferation was detected by CCK8 assay. 15 ug/mL DDP was treated to cells which was transfected with miR-133b, and apoptosis was detected by flow Cytometry at 0 h, 12 h, 24 h, 72 h. The expression of PKM2 protein was detected by Western blot. cell line (A549) up-regulated sensitive PKM2 PKM2 NA validated 2600 miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-kappaB/XIAP axis. Sci Rep 2017 28646148 miRBase MIMAT0000417 miR-15b-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells cell line (SW620, HCT116, DLD1, and SW1116) up-regulated sensitive NF-kappaB1 and IKK-alpha NF-kappaB1 and IKK-alpha NF-kappaB pathway validated 2601 miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting alphaB-crystallin. Mol Ther 2017 28648665 miRBase MI0003126 miR-491 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR,RT-qPCR In the present study, we investigate the clinical significance of serum miR-491 level and the potential role of miR-491 in OS lung metastasis and chemoresistance. Clinical data show that the level of miR-491 was decreased in serum from OS patients compared with healthy control subjects, and that a decreased serum miR-491 level is correlated with increased metastasis, poor chemoresponse, and lower survival rate in OS patients. In vitro and in vivo experiments show that overexpression of miR-491 suppresses OS cell lung metastasis, whereas it enhances cisplatin (CDDP)-induced tumor growth inhibition and apoptosis. In contrast, inhibition of miR-491 stimulates OS cell lung metastasis and suppresses CDDP-induced tumor growth inhibition and apoptosis. Furthermore, we demonstrate that miR-491 exerts its role by directly targeting alphaB-crystallin (CRYAB) in OS. cell line (MG63, Saos-2, and U2OS ) up-regulated sensitive CRYAB CRYAB NA validated 2602 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol 2017 28653877 miRBase MI0000439 miR-23b miRNA DB00515 (APRD00359) Cisplatin endometrial carcinoma qRT-PCR The role of TUSC7 and miR-23b in endometrial carcinoma cells was detected using quantitative real-time PCR , cell proliferation assay , flow cytometry assay , chemoresistance assay and RNA pull-down assay, etc. tissue and cell line ( ESC, HEC1A) down-regulated sensitive NA NA NA validated 2603 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol 2017 28653877 miRBase MI0000439 miR-23b miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel endometrial carcinoma qRT-PCR The role of TUSC7 and miR-23b in endometrial carcinoma cells was detected using quantitative real-time PCR, cell proliferation assay, flow cytometry assay, chemoresistance assay and RNA pull-down assay, etc. tissue and cell line ( ESC, HEC1A) down-regulated sensitive NA NA NA validated 2604 Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs. Arch Gynecol Obstet 2017 28660502 miRBase MI0005534 miR-891b miRNA NA N-methyl-N-nitro-N-nitrosoguanidine (MNNG) breast cancer RT-qPCR The expression of miR-891b and PARP1 in human breast cancer cells HCC1806 was overexpressed by transfection with their mimics or expressing vector. Then, the transfected cells were exposed to 40 -M N-methyl-N-nitro-N-nitrosoguanidine (MNNG) for 1 h. The correlation between miR-891b and PARP1 was detected by RT-qPCR, western blot, and dual-luciferase reporter assay. Besides, MTT assay and Annexin V assay were done to measure cell proliferation and apoptosis, respectively. cell line ( HCC1806) up-regulated sensitive PARP1 PARP1 NA validated 2605 Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS One 2017 28665983 miRBase MI0000065 let-7d miRNA DB00515 (APRD00359) Cisplatin head and neck squamous cell carcinoma qRT-PCR The aim of this study includes whether different expression levels of let-7d has an influence on chemo- and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models from A to E) were generated with the lentiviral system. Expression levels of pluripotency, chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done with MTT assay. cell line ( FaDu ) up-regulated sensitive NA NA NA validated 2606 Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS One 2017 28665983 miRBase MI0000065 let-7d miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil head and neck squamous cell carcinoma qRT-PCR The aim of this study includes whether different expression levels of let-7d has an influence on chemo- and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models from A to E) were generated with the lentiviral system. Expression levels of pluripotency, chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done with MTT assay. cell line ( FaDu ) up-regulated sensitive NA NA NA validated 2607 Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS One 2017 28665983 miRBase MI0000065 let-7d miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel head and neck squamous cell carcinoma qRT-PCR The aim of this study includes whether different expression levels of let-7d has an influence on chemo- and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models from A to E) were generated with the lentiviral system. Expression levels of pluripotency, chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done with MTT assay. cell line ( FaDu ) up-regulated sensitive NA NA NA validated 2608 Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS One 2017 28665983 miRBase MI0000065 let-7d miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin head and neck squamous cell carcinoma qRT-PCR The aim of this study includes whether different expression levels of let-7d has an influence on chemo- and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models from A to E) were generated with the lentiviral system. Expression levels of pluripotency, chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done with MTT assay. cell line ( FaDu ) up-regulated sensitive NA NA NA validated 2609 MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer. Gene 2017 28669929 miRBase MI0000471 miR-126 miRNA NA TRAIL therapy cervical cancer qRT-PCR In the present study, we established in vitro TRAIL-resistant cervical cancer cell lines through long-term exposure to TRAIL. Interestingly, we observed significant upregulation of c-FLIP in TRAIL-resistant Hela and SiHa cells (Hela-TR and SiHa-TR) compared to their parental Hela and SiHa cells. Although Hela-TR and SiHa-TR cells exhibited low-sensitivity to TRAIL treatment, knockdown of c-FLIP significantly increased the cytotoxicity of TRAIL to them. In contrast to high protein level of c-FLIP, expression of miR-126 was significantly downregulated in Hela-TR and SiHa-TR cells. Results of western blot analysis, luciferase assays and bioinformatics proved that c-FLIP was the target of miR-126. Furthermore, as c-FLIP is the cellular antagonist to caspase-8, transfection with miR-126 promoted the activation of caspase-8 induced by TRAIL. As a result, miR-126 increased the TRAIL-induced apoptosis in Hela-TR and SiHa-TR cells. In addition, miR-126 was also able to increase the cytotoxicity of TNF-alpha and FasL (caspase-8 inducers) to Hela-TR and SiHa-TR. We demonstrate that miR-126 impairs drug resistance to TRAIL, TNF-alpha and FasL through inhibiting the expression of c-FLIP in cervical cancer. cell line ( human cervical cancer cell lines) up-regulated sensitive c-FLIP NA NA validated 2610 Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR-221. Mol Med Rep 2017 28677788 miRBase MI0000298 miR-221 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin oral squamous cell carcinoma RT-qPCR In the present study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to assess miR-221 expression in OSCC cells in response to doxorubicin treatment. In addition, the SCC4 and SCC9 OSCC cell lines were transfected with anti-miR-221 oligonucleotides and cell viability and apoptosis following doxorubicin treatment were evaluated using an MTT assay and Annexin V-fluorescein isothiocyanate/Hoechst double staining, respectively. The mRNA and protein expression levels of tissue inhibitor of metalloproteinase-3 (TIMP3) in anti-miR-221-transfected cells were assessed using RT-qPCR and western blot analysis, respectively. Furthermore, a luciferase reporter assay was performed to investigate whether TIMP3 may be a direct target gene of miR-221. To explore the roles of TIMP3 in miR-221-mediated cell responses, TIMP3 expression was silenced following transfection with TIMP3-targeting small interfering (si)RNA in cells overexpressing miR-221, and cell viability and apoptosis in response to doxorubicin treatment were measured. cell line ( SCC4,SCC9 ) down-regulated sensitive TIMP3 TIMP3 NA validated 2611 MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2017 28678319 miRBase MIMAT0000449 miR-146a-5p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The exosomes were isolated by ExoQuick kit. The exosomal morphology and particle size distribution were evaluated by the transmission electron microscopy and nanoSight assay respectively. Cell proliferation was detected using the MTT assay. NSCLC cells were infected with mimics or inhibitor to overexpress or downregulate miR-146a level. Besides, Quantitative real-time PCR, Western blot analysis, and immunohistochemistry were applied to detect the relative miRNA and protein levels. cell line (A549,A549/DDP) up-regulated resistant Atg12 Atg12 NA validated 2612 miR-340 suppresses tumor growth and enhances chemosensitivity of colorectal cancer by targeting RLIP76. Eur Rev Med Pharmacol Sci 2017 28682430 miRBase MI0000802 miR-340 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The level of miR-340 in CRC cells was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting. CRC cell lines were used as model cell lines and the anti-tumor effect of miR-340 in vitro was examined. The luciferase reporter assay was performed. The level of miR-340 was restored in CRC cells by the usage of the miR-340 mimic. Re-expression of RLIP76 in CRC cells was then constructed. Moreover, the target gene of miR-340 was identified through the experiment of in vivo xenograft model. cell line ( HT-29,HCT116,NCM460 ) up-regulated sensitive RLIP76 RLIP76 NA validated 2613 Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol Int 2017 28685895 miRBase MI0005543 miR-708 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The purpose of this study was to investigate the role of mir-708 in regulating cisplatin sensitivity of ovarian cancer cells. To this end, ovarian cancer cells were transfected with miR-708-expressing plasmids or vector before treatment with different concentrations of cisplatin for 48-h. The 50% inhibitory concentration (IC50 ) value was calculated. Apoptosis was analyzed by measuring caspase-3 activity. The target gene mediating the function of miR-708 was identified. Ectopic expression of miR-708 sensitized SKOV3 and A2780 cells to cisplatin, decreasing the IC50 value by two- to threefold. miR-708 overexpression significantly augmented cisplatin-induced apoptosis in ovarian cancer cells, which was coupled with increased caspase-3 activity by two- to fourfold. Similarly, overexpression of miR-708 increased the sensitivity of cisplatin-resistant SKOV3/DDP and A2780/DDP cells to cisplatin-induced toxicity, reducing the IC50 by three- and fivefold, respectively. Delivery of miR-708 enhanced cisplatin-induced elevation in caspase-3 activity in both cisplatin-resistant and parental ovarian cancer cells. Mechanistically, miR-708 downregulated the expression of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) and suppressed Akt phosphorylation. Silencing of IGF2BP1 markedly blocked the phosphorylation of Akt. Overexpression of IGF2BP1 restored cisplatin resistance and Akt phosphorylation in miR-708-overexpressing ovarian cancer cells. Collectively, miR-708 increases the susceptibility of ovarian cancer cells to cisplatin by targeting IGF2BP1 and inhibiting Akt signaling. cell line ( A2780,SKOV3,A2780/DDP and SKOV3/DDP) up-regulated sensitive IGF2BP1 IGF2BP1 IGF2BP1/Akt pathway validated 2614 GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother 2017 28686971 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. tissue and cell line ( A549, NCI-H1299, H460, SK-MES-1,H157, H358,16HBE) up-regulated resistant PTEN PTEN miR-21/PTEN pathway validated 2615 MiR-503 sensitizes human hepatocellular carcinoma cells to cisplatin by targeting bcl-2 Zhong Nan Da Xue Xue Bao Yi Xue Ban 2017 28690214 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR MiR-503 and bcl-2 mRNA expression levels in hepatocellular carcinoma cells were measured by real-time quantitative (qRT)-PCR; Bcl-protein level was detected by Western blot; miR-503 mimics were transiently transfected to the BEL-7402 cells by liposome transfection; potential target genes of miR-503 were predicted by Bioinformatics software; miR-503 potential targets were validated by dual luciferase activity; and the cell viability was measured by MTT assay. cell line (HL-7702,BEL-7402) up-regulated sensitive bcl-2 bcl-2 NA validated 2616 Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 2017 28714373 miRBase MI0000077 miR-21 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel renal carcinoma qPCR In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. tissue and cell line (HK-2,ACHN, 786-O) down-regulated sensitive PTEN, PDCD4, TIMP3 PTEN, PDCD4, TIMP3 PI3K/Akt pathway validated 2617 Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 2017 28714373 miRBase MI0000077 miR-21 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil renal carcinoma qPCR In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. tissue and cell line (HK-2,ACHN, 786-O) down-regulated sensitive PTEN, PDCD4, TIMP3 PTEN, PDCD4, TIMP3 PI3K/Akt pathway validated 2618 Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 2017 28714373 miRBase MI0000077 miR-21 miRNA DB00526 (APRD00186) Oxaliplatin renal carcinoma qPCR In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. tissue and cell line (HK-2,ACHN, 786-O) down-regulated sensitive PTEN, PDCD4, TIMP3 PTEN, PDCD4, TIMP3 PI3K/Akt pathway validated 2619 Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 2017 28714373 miRBase MI0000077 miR-21 miRNA DB05928 Dovitinib renal carcinoma qPCR In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome. In vitro, miR-21 was also overexpressed in renal carcinoma cell lines compared to HK-2 human proximal tubule epithelial cell line. Moreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy. Finally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression. tissue and cell line (HK-2,ACHN, 786-O) down-regulated sensitive PTEN, PDCD4, TIMP3 PTEN, PDCD4, TIMP3 PI3K/Akt pathway validated 2620 Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02. Onco Targets Ther 2017 28721074 miRBase MI0000100 miR-98 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia RT-PCR Real-time quantitative polymerase chain reaction analyzed the expression difference between miR-98 and E2F1 in leukemia cell lines, K562 and K562/A02. The downstream target gene of miR-98 was predicted by TargetScan; K562/A02 was transiently transfected with miR-98 mimic to upregulate the expression of miR-98; real-time quantitative polymerase chain reaction and Western blot were used to analyze the expression alterations of E2F1; cell counting kit-8 was used to evaluate the influence on K562/A02 proliferation and sensitivity to chemotherapeutic drugs; meanwhile, Western blot was used to analyze the expression of p21, Bax, matrix metalloproteinase 9 and ABCG2 proteins. cell line ( K562,K562/A02 ) up-regulated sensitive E2F1 E2F1 NA validated 2621 miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechnol Lett 2017 28721584 miRBase MI0000268 miR-34a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel glioma qRT-PCR Quantitative real-time PCR analysis showed that miR-34a level was lower, but PD-L1 expression level was higher in glioma tissue specimens compared with normal brain tissues and their expression levels were negatively correlated. Ectopic expression of miR-34a inhibited glioma cell proliferation, promoted cell cycle arrest in G1/S phase and cell apoptosis. Additionally, miR-34a/PD-L1 axis was again confirmed and co-expression of PD-L1 with miR-34a mimics attenuated the effects of miR-34a on cell proliferation and apoptosis in glioma cells. Importantly, PD-L1 overexpression resulted in chemoresistance in glioma cells, this effect was attenuated by miR-34a overexpression. tissue and cell line ( U251,U87-MG, U87-P,) up-regulated sensitive PD-L1 PD-L1 miR-34a/PD-L1 pathway validated 2622 MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anticancer Drugs 2017 28723865 miRBase MIMAT0000680 miR-106b-5p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In this study, we explored the mechanism of microRNA-106b-5p (miR-106b-5p), which is involved in the resistance to cisplatin in the A549 cell line of NSCLC. Quantitative real-time PCR was used to test the expression of miR-106-5p in the A549 and the A549/DDP cell line of NSCLC. The cell counting kit-8 assay was used to detect cell viability. Flow cytometry was used to measure cell cycle and cell apoptosis. Luciferase reporter assays and western blot were performed to confirm whether polycystic kidney disease-2 (PKD2) is a direct target gene of miR-106b-5p. Immunohistochemistry was performed to examine the distribution of PKD2 expression in patients who are sensitive and resistant to cisplatin. The experiments indicated that the expression of miR-106b-5p was significantly decreased in A549/DDP compared with that in A549. MiR-106b-5p affected the tolerance of cells to cisplatin by negatively regulating PKD2. Upregulation of miR-106b-5p or downregulation of PKD2 expression can cause A549/DDP cells to become considerably more sensitive to cisplatin. The results showed that miR-106b-5p enhanced the sensitivity of A549/DDP cells to cisplatin by targeting the expression of PKD2. cell line ( A549) down-regulated resistant PKD2 PKD2 NA validated 2623 Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res 2017 28743276 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR In this work, a negative correlation between DDR1 and a tumor suppressor miRNA, miR-199a-3p, was observed in ovarian cancer tissues. Furthermore, in vitro experimental results confirmed that miR-199a-3p decreased the expression of DDR1 via targeting the 3UTR of DDR1 mRNA. To explore the mechanisms for miR-199a-3p silence in ovarian cancer, the methylation status of the miR-199a promoter was analyzed in ovarian epithelial or cancer cells by methylation-specific PCR and bisulphite sequencing. As expected, the miR-199a promoter was hypermethylated in ovarian cancer cells but not in normal ovarianepithelial cells. Interestingly, knockdown of DNA methyltransferase 3A (DNMT3A) notably increased miR-199a-3p level and then attenuated the expression of DDR1 in ovarian cancer cells, which suggested that DNMT3A was responsible for the miR-199a promoter hypermethylation. Phenotype experiments showed that overexpression of miR-199a-3p significantly impaired the migratory, invasive, and tumorigenic capabilities of ovarian cancer cells as well as enhanced cisplatin resistance through inhibiting DDR1 expression. cell line (SKOV3,HO-8910,IOSE386) up-regulated resistant DDR1 DDR1 miR-199a/DDR1 pathway validated 2624 A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients Biosci Rep 2017 28765596 miRBase MIMAT0015073 miR-3190-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The role of miR-3190-5p in colorectal cancer cells was detected by quantitative real-time PCR, western blot analysis,and MTT assay.etc. cell line ( CHO,HCT-116) up-regulated sensitive NA NA NA validated 2625 miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep 2017 28765915 miRBase MI0000095 miR-93 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In the present study, the expression differences of miR-93 between paired breast cancer tissues confirmed it is involved in the progression of breast cancer. Such a difference was also observed in doxorubicin-resistant and -sensitive cells. Overexpressed miR-93 in sensitive cells revealed increases in cellular proliferation and the expression levels of drug-resistant-related genes, and a decrease in sensitivity to doxorubicin. This demonstrated the relationship between miR-93 and breast cancer drug resistance. Simultaneously, EMT was confirmed in miR-93 overexpressing sensitive cells. This indicated the triadic relationship among miR-93, EMT and drug resistance in breast cancer. We applied the Dual-luciferase Reporter assay to expose the direct interaction between miR-93 and PTEN, which suggested that miR-93 contributes to inducing EMT and drug resistance of breast cancer cells by targeting PTEN. tissue and cell line (MCF-7,MCF-7/ADR) up-regulated resistant PTEN PTEN NA validated 2626 Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog 2017 28767179 miRBase MI0000810 miR-135b miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The study was to explore whether miR-135b and miR-182 modulated 5-FU chemoresistance of CRC by targeting ST6GALNAC2 via PI3K/AKT pathway. MiR-135b and miR-182 were found to be up-regulated in CRC tissues and 5-FU resistant CRC cell lines. Forced miR-135b and miR-182 expression also affected ST6GALNAC2 levels. Using reporter-gene assay, ST6GALNAC2 was identified as direct target of miR-135b and miR-182, while ST6GALNAC2 expression exhibited patterns opposite to that of miR-135b and miR-182 in CRC samples and cell lines. Interestingly, up-regulation of miR-135b or miR-182 increased drug resistance and proliferation, but decreased apoptosis in 5-FU resistant CRC cell lines. Suppression of these miRNAs implicated an inverse function, while altered expression of ST6GALNAC2 mediated CRC progression upon transfection with miR-135b/-182 mimic or inhibitor. Furthermore, miR-135b and miR-182 were clarified to regulate the activity of phosphoinositide-3 kinase (PI3K)/AKT pathway. Inhibition of the PI3K/AKT pathway enhanced the chemosensitivity to 5-FU in HCT-8/5-FU and LoVo/5-FU. Taken together, miR-135b and miR-182 may reverse the resistance to 5-FU in CRC cells by targeting ST6GALNAC2 via PI3K/AKT pathway, which render potential chemotherapy targets for the treatment of CRC. cell line (HCT-8,HCT-8/5-FU) up-regulated resistant ST6GALNAC2 ST6GALNAC2 PI3K/AKT pathway validated 2627 Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog 2017 28767179 miRBase MI0000272 miR-182 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The study was to explore whether miR-135b and miR-182 modulated 5-FU chemoresistance of CRC by targeting ST6GALNAC2 via PI3K/AKT pathway. MiR-135b and miR-182 were found to be up-regulated in CRC tissues and 5-FU resistant CRC cell lines. Forced miR-135b and miR-182 expression also affected ST6GALNAC2 levels. Using reporter-gene assay, ST6GALNAC2 was identified as direct target of miR-135b and miR-182, while ST6GALNAC2 expression exhibited patterns opposite to that of miR-135b and miR-182 in CRC samples and cell lines. Interestingly, up-regulation of miR-135b or miR-182 increased drug resistance and proliferation, but decreased apoptosis in 5-FU resistant CRC cell lines. Suppression of these miRNAs implicated an inverse function, while altered expression of ST6GALNAC2 mediated CRC progression upon transfection with miR-135b/-182 mimic or inhibitor. Furthermore, miR-135b and miR-182 were clarified to regulate the activity of phosphoinositide-3 kinase (PI3K)/AKT pathway. Inhibition of the PI3K/AKT pathway enhanced the chemosensitivity to 5-FU in HCT-8/5-FU and LoVo/5-FU. Taken together, miR-135b and miR-182 may reverse the resistance to 5-FU in CRC cells by targeting ST6GALNAC2 via PI3K/AKT pathway, which render potential chemotherapy targets for the treatment of CRC. cell line (HCT-8,HCT-8/5-FU) up-regulated resistant ST6GALNAC2 ST6GALNAC2 PI3K/AKT pathway validated 2628 miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Lett 2017 28789414 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The present study was performed to analyze the association between microRNA-21 and cisplatin resistance in epithelial ovarian cancer (EOC) SKOV3 and SKOV3/DDP cells. In this experiment, the resistance of SKOV3 and SKOV3/DDP cells to cisplatin was evaluated using the MTT assay. Reverse transcription-quantitative polymerase chain reaction analysis was used to assess miRNA-21 levels and phosphatase and tensin homolog (PTEN) mRNA levels. Western blotting was used to assess PTEN protein levels. miRNA-21 mimics or inhibitors were transfected into SKOV3 and SKOV3/DDP cells. Prior to transfection, higher expression levels of miRNA-21 were observed in SKOV3/DDP cells compared with SKOV3 cells. Following transfection with miRNA-21 mimics, SKOV3 cells demonstrated increased sensitivity to cisplatin compared with negative control cells. Following transfection with the miRNA-21 inhibitor, SKOV3/DDP cells demonstrated decreased sensitivity to cisplatin compared with negative control cells. Furthermore, PTEN mRNA expression levels in SKOV3 cells transfected with miRNA-21 mimics was significantly lower compared with negative control cells. These results suggested that miRNA-21 may regulate cisplatin resistance by negatively targeting PTEN in EOC. cell line (SKOV3, SKOV3/DDP ) up-regulated resistant PTEN PTEN PTEN/PI3K/Akt signaling pathway validated 2629 Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells Iran J Basic Med Sci 2017 28804605 miRBase MI0000077 miR-21 miRNA DB11672 Curcumin breast cancer RT-PCR we have used different methods such as MTT, apoptosis, cell cycle analysis, transwell migration assay and RT-PCR to find out more. cell line (MCF7, SKBR3 and MDA-MB231) up-regulated resistant NA NA NA validated 2630 LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep 2017 28831025 miRBase MI0000735 miR-29c miRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (U251, U373, LN229, U118, and LN229) up-regulated sensitive NA NA DNA mismatch repair pathway validated 2631 MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood) 2017 28836853 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil gastric adenocarcinoma RT-PCR Since miR-31 is a pleomorphic molecule, we evaluated the miR-31/RhoA axis in inducing the malignant phenotype of gastric cancer cells MKN-45. Also, the clinicopathological significance of RhoA was investigated in a well-defined collection of gastric carcinomas which were embedded in tissue microarray blocks. Induction of miR-31 in MKN-45 followed by suppression of RhoA expression resulted in increased sensitivity to 5-fluorouracil, inhibition of cell proliferation, and invasion compared to the control groups. Immunohistochemical analysis in gastric adenocarcinoma patients samples showed significantly higher expression of RhoA in diffuse versus intestinal subtype tumors ( P=0.009), poorly differentiated versus well and moderately differentiated tumors ( P=0.03) and the presence of vascular invasion versus the absence of vascular invasion ( P=0.04). Our findings suggest a critical role for miR-31, as a tumor suppressor gene, in gastric cancer tumorigenesis by targeting the RhoA. Impact statement Gastric cancer ranks as the third leading cause of cancer-associated deaths worldwide. The RhoA gene encodes a small GTPase protein of Rho family (RhoA) that its dysregulation is associated with cell motility and invasion. A strong line of evidence supports the regulation of RhoA by a number of miRs, including miR-31 in tumors. Our findings revealed that miR-31 is involved in gastric cancer tumorigenesis as a tumor suppressor gene. Through down-regulation of RhoA, miR-31 decreased cell proliferation, migration, and invasion in gastric cancer cells. In addition, induction of miR-31 increased sensitivity to 5-FU. cell line (MKN-45,293T) up-regulated sensitive RhoA RhoA NA validated 2632 MicroRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway. Oncol Rep 2017 28849187 miRBase MI0000294/MI0000295 miR-218 miRNA DB00515 (APRD00359) Cisplatin oral cancer qRT-PCR In the present study, we demonstrated that microRNA-218 (miR-218) was significantly upregulated in cisplatin-resistant oral cancer cells. The results of cell viability and apoptosis assay showed that ectopic expression of miR-218 induced cell survival and resistance to cisplatin, whereas suppression of miR-218 caused apoptosis and enhanced sensitivity to cisplatin. Moreover, we identified PPP2R5A as a new direct target of miR-218 by using the dual luciferase reporter assay. Overexpression of miR-218 led to inhibition of PPP2R5A expression, whereas knockdown of miR-218 increased PPP2R5A levels. Introduction of PPP2R5A abrogated miR-218-mediated cell survival and drug resistance. Furthermore, suppression of miR-218 or PPP2R5A significantly promoted or reduced cisplatin-induced apoptosis, respectively. Finally, PPP2R5A overexpression or Beta-catenin knockdown inhibited miR-218-mediated Wnt activation and partially restored cell sensitivity. Our data revealed a molecular link between miR-218 and PPP2R5A/Wnt signaling and implicates miR-218 as a potential target for oral cancer therapy. cell line (UM1, UM2, Cal27, MD1386Ln,SCC9, SCC15,SCC25,Tca8113) up-regulated resistant PPP2R5A PPP2R5A PPP2R5A/Wnt signaling pathway validated 2633 Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). J Exp Clin Cancer Res 2017 28859669 miRBase MI0003132 miR-493 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR,RT-PCR Real-time quantitative PCR (qRT-PCR) and In situ hybridization (ISH) were used to analyze the expression of miR-493 in lung cancer cell lines and tumor tissue, respectively. Bisulfite sequencing PCR (BSP) was used to exam the promoter CpG Island of miR-493. The effect of miR-493 on chemosensitivity was evaluated by cell viability assays, apoptosis assays and in vivo experiment. The DNA damage was measured by Gamma-H2AX immunofluorescence. Luciferase reporter assay was used to assess the target genes of miR-493. Expression of target proteins and downstream molecules were analyzed by Western blot. cell line (H1975, A549, H1299, H460,A549/DDP) up-regulated sensitive TCRP1 TCRP1 AKT pathway validated 2634 MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res 2017 28861147 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin cervical cancer RT-PCR We detected the differential expression of miR-214 in 19 cases cervical cancer tissues and normal tissues as well as 4 cervical cancer cells and one normal cervical cells by Real-time PCR. Then, wound healing assay, transwell invasion assay and MTT were used to detect the effects of migration, invasion and sensitivity to cisplatin of cervical cancer when miR-214 was overexpressed. Western blot, immunofluorescence and Flow Cytometry were used to detect the mechanism of migration, invasion and sensitivity to cisplatin. Next, bioinformatics analysis was used to find the target of miR-214. Through the luciferase reporter assay, Real-time PCR and western blot, we confirmed the binding relationship of miR-214 and FOXM1. In cervical cancer tissues, the expression of FOXM1 was detected by western blot and Immunohistochemistry. We also knocked down FOXM1 in cervical cancer cells, wound healing assay, transwell invasion assay and MTT were performed to detect the migration, invasion and sensitivity to cisplatin abilities of FOXM1. Western blot and Flow Cytometry were used to detect the mechanism of migration, invasion and sensitivity to cisplatin by FOXM1. Finally, we performed rescue expriments to confirm the function relationship between miR-214 and FOXM1. cell line (CaSki, SiHa, C33A and Hela) up-regulated sensitive FOXM1 FOXM1 NA validated 2635 microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). Am J Transl Res 2017 28861151 miRBase MI0000284 miR-204 miRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-qPCR In this study, analysis using miRNA microarray showed that miR-204 is downregulated in chemoresistant PC tissues with respect to its expression in chemosensitive PC tissues and benign prostatic hyperplasia tissues. Microarray results were validated via qPCR. The changes in miR-204 expression levels were also observed in vitro. Forced overexpression of miR-204 evidently attenuated docetaxel chemoresistance and promoted apoptosis in PC-3-R cells, whereas miR-204 knockdown effectively reduced docetaxel-induced cell death and inhibited cell apoptosis. Mechanistically, miR-204 directly targets the 3-untranslated region of zinc-finger E-box-binding homeobox 1 (ZEB1) and inhibits its protein expression via translational repression. Furthermore, suppression of ZEB1 could effectively improve miR-204 deficiency-triggered chemoresistance in PC cells. cell line (PECs,PC-3,PC-3-R) up-regulated sensitive ZEB1 ZEB1 ZEB1 pathway validated 2636 MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells. Cell Cycle 2017 28898169 miRBase MI0000084 miR-26b miRNA DB00853 (APRD00557) Temozolomide glioma RT-qPCR In the study,we investigated the relationship between mir-26b and temozolomide resistance in gliomas.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. wound healing assay, transwell invasion assay and MTT were used to detect the effects of migration, invasion and sensitivity to temozolomide of glioma when miR-26b was overexpressed. Western blot were used to detect the mechanism of migration, invasion and sensitivity to temozolomide MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SNB19, SNB19 TR, T98G and T98G TR) up-regulated sensitive Wee1 WEE1 NA validated 2637 MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma. Int J Mol Med 2017 28901390 miRBase MI0000449 miR-132 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In this study, we found that tumor suppressor candidate 3 (TUSC3) was downregulated in temozolomide-resistant U87MG cells (U87MG-res cells) and its restoration sensitized U87MG-res cells to temozolomide. TUSC3 was able to inhibit the formation of GIC phenotypes in the U87MG-res cells. The overexpression of microRNA (miR)-132 inhibited TUSC3 protein expression in the U87MG cells. However, its overexpression did not degrade TUSC3 mRNA expression in the cells. miR-132 was upregulated in the U87MG-res cells and its overexpression induced temozolomide resistance and the formation of cancer stem cell phenotypes in the U87MG cells. cell line (U87MG, U87MG-res) up-regulated resistant TUSC3 TUSC3 NA validated 2638 Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. Oncol Rep 2017 28901474 miRBase MI0000079 miR-23a miRNA DB00530 (APRD00951) Erlotinib lung cancer RT-qPCR In the present study, we isolated cancer stem cells (CSCs) from the PC9 NSCLC cell line. We then observed that the PC9 CSCs showed significant resistance to erlotinib compared with the PC9 non-CSCs. Erlotinib failed to suppress the phosphorylation of PI3K and AKT in PC9 CSCs, although the EGFR was inhibited sufficiently. Mechanically, we observed aberrant upregulation of microRNA-23a (miR-23a) and downregulation of PTEN in PC9 CSCs compared to PC9 non-CSCs. Luciferase reporter assays proved that PTEN was the target of miR-23a in PC9 CSCs. Furthermore, knockdown of miR-23a enhanced the antitumor effect of erlotinib by increasing the expression of PTEN. In addition, transfection with miR-23a inhibitors promoted the erlotinib-dependent inhibition of PI3K/AKT pathway, thus, suppressing the proliferation and inducing apoptosis in PC9 CSCs. These results propose that upregulation of miR-23a is a potential mechanism associated with resistance to EGFR-TKIs in lung cancer stem cells. Inhibition of miR-23a serves as a novel therapeutic strategy to eliminate the EGFR-TKIs resistance of lung cancer stem cells. cell line (PC9) down-regulated sensitive PTEN PTEN PTEN/PI3K/Akt pathway validated 2639 miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin. Exp Cell Res 2017 28928082 miRBase MIMAT0000763 miR-338-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR In the study, three types of human colon cancer cell lines, HT29 (mutant p53), HCT116 (wild-type p53), and HCT116 p53-/- (deficient p53), were treated with 5-FU. We showed that expression of miR-338-3p was correlated with apoptosis and 5-FU resistance in colon cancer cells. Ectopic expression of miR-338-3p conferred resistance to 5-FU in HCT116 cells. Further experiments indicated that miR-338-3p mediated 5-FU resistance through down-regulation of mTOR expression. Moreover, inhibition of miR-338-3p in HT29 and HCT116 p53-/- cells increased their sensitivity to 5-FU treatment. Furthermore, we detected autophagy changes in our experiment because mTOR was known prominently regulating autophagy and the competition between autophagy and apoptosis in response to 5-FU was a mechanism influencing 5-FU sensitivity. Our results reveal a critical and novel role of miR-338-3p in the correlation of 5-FU resistance with p53 status. Moreover, the miR-338-3p inhibitor has the potential to overcome 5-FU resistance in p53 mutant colon cancer cells. cell line (HT29,HCT116,HCT116 p53-/-) down-regulated sensitive mTOR mTOR miR-338-3pmTOR-autophagy pathway validated 2640 miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. J Exp Clin Cancer Res 2017 28938919 miRBase MIMAT0000074 miR-19b-3p miRNA DB00526 (APRD00186) Oxaliplatin colon cancer qRT-PCR A characteristic microRNA-target network of colon cancer was explored using IPA. Then the clinical significance of miR-19b-3p was evaluated in 211 colon cancer patients. The roles of miR-19b-3p and its candidate target gene, SMAD4, in colon cancer progression were examined both in vitro and in vivo. cell line ( SW620, LoVo, HCT 116, SW480, Caco-2, HT-29, RKO, DLD1,NCM460) up-regulated resistant SMAD4 SMAD4 NA validated 2641 miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep 2017 28939896 miRBase MI0000681 miR-155 miRNA DB01169 (APRD00171) Arsenic trioxide lung cancer RT-qPCR In this study, we identified a high level of expression of miR-155 in a human lung adenocarcinoma A549R cell line that is highly resistant to ATO. We showed that the high level of miR-155 was associated with increased levels of cell survival, colony formation, cell migration and decreased cellular apoptosis, and this was mediated by high levels of Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1) and a high ratio of Bcl-2/Bax. Overexpression of the miR-155 mimic in A549R cells resulted in increased levels of colony formation and cell migration as well as reduced apoptosis along with increased Nrf2, NQO1 and HO-1. In contrast, silencing of miR-155 expression with its inhibitor in the cells, significantly decreased the cellular levels of Nrf2, NQO1 and HO-1 as well as the ratio of Bcl-2/Bax. This subsequently reduced the level of colony formation and cell migration facilitating ATO-induced apoptosis. Our results indicate that miR-155 mediated ATO resistance by upregulating the Nrf2 signaling pathway, but downregulating cellular apoptosis in lung cancer cells. cell line ( A549,A549R ) up-regulated resistant NA NA Nrf2 signaling pathway validated 2642 CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. Cell Physiol Biochem 2017 28954272 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR we employed qRT-PCR and western blot to examine the expression level of CXCR4, let-7a and HMGA2. In addition, we used MTT assay to detect cell proliferation and transwell assay to measure migration and invasiveness. The expression level of epithelial marker E-cadherin and mesenthymal marker N-cadherin was detected by western blot. The apoptosis was determined using annexin V-FITC/PI apoptosis detection kit by flow cytometry cell line (HPDE6-C7, Panc-1,BxPc3) up-regulated sensitive NA NA CXCR4/let-7a/HMGA2 pathway validated 2643 miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1. Cancer Chemother Pharmacol 2017 28956120 miRBase MI0000271 miR-181c miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR qRT-PCR was conducted to examine the expression of miR-181c in NSCLC tissues, and parental and cisplatin (DDP)-resistant NSCLC cells. MTT assay and flow cytometry were performed to detect the survival rate and apoptosis in NSCLC cells. Luciferase reporter assay was performed to confirm the potential target of miR-181c. Xenograft tumor experiment was applied to confirm the effect of miR-181c on DDP sensitivity of DDP-resistant NSCLC cells in vivo. cell line ( A549, H1299,A549/DDP,H1299/DDP ) up-regulated resistant WIF1 WIF1 Wnt/Beta-catenin pathway validated 2644 LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle 2017 28961027 miRBase MI0000434 let-7i miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR This study aimed to observe the expression of LncRNA XIST in LAD and to evaluate its biologic role and clinical significance in the resistance of LAD cells to cisplatin. LncRNA XIST expression was markedly increased in cisplatin-resistant A549/DDP cells compared with parental A549 cells as shown by qRT-PCR. LncRNA XIST overexpression in A549 cells increased their chemosensitivity to cisplatin both in vitro and in vivo by protecting cells from apoptosis and promoting cell proliferation. By contrast, LncRNA XIST knockdown in A549/DDP cells decreased the chemoresistance. We revealed that XIST functioned as competing endogenous RNA to repress let-7i, which controlled its down-stream target BAG-1. We proposed that XIST was responsible for cisplatin resistance of LAD cells and XIST exerted its function through the let-7i/BAG-1 axis. Our findings suggested that lncRNA XIST may be a new marker of poor response to cisplatin and could be a potential therapeutic target for LAD chemotherapy. cell line (LAD,A549,A549/DDP) up-regulated sensitive NA NA NA validated 2645 MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett 2017 28965855 miRBase MIMAT0000243 miR-148a-3p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR In this study, we performed integrated analysis of TCGA data from microRNAs (miRNAs) expression matrix of GC patients who received CDDP-based chemotherapy with GEO dataset which contains differential miRNAs expression profiles in CDDP-resistant and -sensitive cell lines. We identified miR-148a-3p downregulation as a key step involved in CDDP resistance. Using a cohort consisting 105 GC patients who received CDDP-based therapy, we found that miR-148a-3p downregulation was associated with a decrease in patients disease-free survival (DFS, P = 0.0077). A series of experiment data demonstrated that: 1) miR-148a-3p was downregulated in CDDP-resistant GC cell lines; 2) miR-148a-3p reconstitution sensitized CDDP-resistant cells to CDDP treatment through promoting mitochondrial fission and decreasing AKAP1 expression level; 3) AKAP1 played a novel role in CDDP resistance by inhibiting P53-mediated DRP1 dephosphorylation; 4) miR-148a-3p reconstitution in CDDP-resistant cells inhibits the cyto-protective autophagy by suppressing RAB12 expression and mTOR1 activation. Taken together, our study demonstrates that miR-148a-3p could be a promising prognostic marker or therapeutic candidate for overcoming CDDP resistance in GC. tissue and cell line (BGC823, SGC7901,BGC823CDDP, SGC7901CDDP) down-regulated resistant AKAP1 and RAB12 AKAP1 and RAB12 NA validated 2646 Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer. Cell Physiol Biochem 2017 28977798 miRBase MIMAT0000087 miR-30a-5p miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR We analyzed the levels of Beclin-1 in etoposide/cisplatin (EP) -resistant and -sensitive cell lines, as well as the relationship between Beclin-1 and patients chemosensitivity. The function of Beclin-1 in chemoresistant SCLC cells in vitro was measured by MTT, WB, colony formation and flow cytometric analysis. Further rescue experiment was performed after co-transfected with siBeclin-1 and miR-30a mimics or inhibitor. tissue and cell line ( H446, Letp,VP16/DDP) up-regulated sensitive NA NA NA validated 2647 Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer. Cell Physiol Biochem 2017 28977798 miRBase MIMAT0000087 miR-30a-5p miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR We analyzed the levels of Beclin-1 in etoposide/cisplatin (EP) -resistant and -sensitive cell lines, as well as the relationship between Beclin-1 and patients chemosensitivity. The function of Beclin-1 in chemoresistant SCLC cells in vitro was measured by MTT, WB, colony formation and flow cytometric analysis. Further rescue experiment was performed after co-transfected with siBeclin-1 and miR-30a mimics or inhibitor. tissue and cell line ( H446, Letp,VP16/DDP) up-regulated sensitive NA NA NA validated 2648 MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am J Cancer Res 2017 28979809 miRBase MI0000114 miR-107 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The aim of this study is to elucidate whether and how miR-107 participates in the modulation of paclitaxel sensitivity in non small cell lung cancer (NSCLC). By qRT-PCR, we found that miR-107 is significantly down-regulated in paclitaxel-resistant A549/Taxol cells compared with corresponding paclitaxel-sensitive counterparts. Overexpression of miR-107 suppresses paclitaxel resistance of A549/Taxol cells through directly inhibiting Bcl-w. Overexpression of miR-107 promotes apoptosis and inhibits proliferation and mobility of A549/Taxol cells under treatment with paclitaxel in vitro. Moreover, miR-107 inhibits in vivo paclitaxel resistance in xenograft model. MiR-107/Bcl-w axis regulates paclitaxel chemoresistance through PI3K-Akt pathway. Our results suggest that up-regulation of miR-107 resensitizes paclitaxel-resistant NSCLC cells by targeting Bcl-w, which reveals a potential mechanism of miR-107 in reversing drug resistance. cell line (A549,HEK 293T) up-regulated sensitive Bcl-w Bcl-w PI3K-Akt pathway validated 2649 miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis. Cell Mol Biol (Noisy-le-grand) 2017 28980925 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma PCR In this study, we report miR-214 contributes to cisplatin resistance in osteosarcoma cells. Overexpression of miR-214 decreased the cisplatin sensitivity. By establishing an osteosarcoma cisplatin resistant cell line, we find miR-214 is significantly upregulated in cisplatin resistant cells. Moreover, we show miR-214 promotes anaerobic glycolysis rates of osteosarcoma cells but suppresses mitochondrial oxidative phosphorylation. Consistently, cisplatin resistant cells exhibit upregulated glycolysis but decreased mitochondrial oxidative phosphorylation, a phenotype called Warburg effect. Finally, we demonstrate inhibition of glycolysis by either glycolysis inhibitor or miR-214 inhibition significantly re-sensitizes cisplatin resistant osteosarcoma cells. cell line up-regulated resistant NA NA NA validated 2650 Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis 2017 28981108 miRBase MI0001729 miR-451 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR In this study, we aimed to investigate the biological role and molecular mechanisms of miR-451 in drug resistance in breast cancer cell lines and in xenograft model. We show that miR-451 is decreased in human breast cancer specimens and in paclitaxel-resistant (PR) cells. Ectopic expression of miR-451 could inhibit the cell migration and invasion, promoted apoptosis, induced cell-cycle arrest Furthermore, tyrosine3-monooxygenase/tryptophan5-monooxygenase activation protein zeta (YWHAZ) was identified as a direct target of miR-451. Remarkably, the expression of YWHAZ is inversely correlated with the level of miR-451 in human breast cancer samples. Co-treatment with miR-451 mimics and YWHAZ-siRNA significantly enhanced YWHAZ knockdown in both SKBR3/PR and MCF-7/PR cells Moreover, miR-451 markedly inhibited expression of Beta-catenin via YWHAZ and subsequently inhibited downstream gene cyclin D1, c-Myc expression. The results of xenograft model in vivo showed that intratumor injection of miR-451 agomir induced a tumor-suppressive effect in SKBR3/PR drug-resistant xenograft model. Taken together, our findings suggested that miR-451 might be considered as important and potential target in paclitaxel-resistant breast cancer treatment. cell line (MCF-7, SKBR3, MCF-7/PR and SKBR3/PR) up-regulated sensitive YWHAZ YWHAZ Beta-catenin signaling pathway validated 2651 MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro. Biochem Biophys Res Commun 2017 28986256 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR In the study, we found that K562 cell proliferation was largely suppressed when it was stably transfected with miR-7. In accordance with that, apoptosis was also significantly upregulated in miR-7 stably-transfected K562 cells. Moreover, we found that miR-7-overexpressed K562 cells were far more sensitive to imatinib than controls. Further investigations showed that the ABL1 was a direct target of miR-7. Expression level of BCR-ABL and the activity of its downstream PI3K/AKT pathway were significantly reduced in miR-7-transfected cells. Taken together, our results showed that miR-7 inhibited proliferation and promoted apoptosis in K562 cells, and miR-7 might help to sensitize them to imatinib through BCR-ABL/PI3K/AKT signaling in chronic myeloid leukemia. cell line ( K562 ) up-regulated sensitive ABL1 ABL1 CR-ABL/PI3K/AKT signaling validated 2652 LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther 2017 29020498 miRBase MIMAT0000425 miR-130a-3p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR qRT-PCR was performed to detect the expression levels of CCAT, miR-130a-3p, or sex-determining region Y-box 4 (SOX4) mRNA. Luciferase reporter assay, RNA immunoprecipitation (RIP), and qRT-PCR analysis were carried out to explore the potential targets of CCAT1 or miR-130a-3p. Effect of CCAT1, miR-130a-3p, or SOX4 on IC50 value of DDP and ATP binding cassette subfamily G member 2 (ABCG2) level in NSCLC cells were determined by cell counting kits-8 (CCK-8) assay and western blot, respectively. cell line (BEAS-2B, A549,H1299,A549/DDP) down-regulated resistant SOX4 SOX4 NA validated 2653 Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep 2017 29039607 miRBase MIMAT0004911 miR-874-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR In the present study, we reported that miR-874-3p was markedly downregulated in CRC tissues compared with that in adjacent normal colorectal epithelial tissues. Upregulation of miR-874-3p attenuated the chemoresistance of CRC cells to 5-fluorouracil (5-FU) in vitro and in vivo. Conversely, inhibition of miR-874-3p yielded an opposite effect. Furthermore, our results demonstrated that miR-874-3p directly inhibited the expression of transcriptional co-activators YAP and TAZ of the Hippo signaling pathway, resulting in the inactivation of the TEAD transcription. cell line (HCT116, SW480, CRC) up-regulated sensitive YAP and TAZ YAP and TAZ Hippo signaling pathway validated 2654 miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis. Cell Death Dis 2017 29048402 miRBase MI0016056 miR-3656 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR In the study, through miRNA profiling of gemcitabine-resistant (GR) and parental PANC-1 cell lines, we found a consistent reduction of miR-3656 in GR PANC-1 cells. miR-3656 overexpression enhanced the antitumor effect of gemcitabine, whereas silencing of miR-3656 resulted in the opposite effect. By performing mechanistic studies using both in vitro and in vivo models, we found that miR-3656 could target RHOF, a member of the Rho subfamily of small GTPases, and regulate the EMT process. Moreover, enforced EMT progression via TWIST1 overexpression compromised the chemotherapy-enhancing effects of miR-3656. Finally, we found significantly lower levels of miR-3656 and higher levels of RHOF in PC tissues compared with adjacent noncancerous pancreatic tissues, and this was also associated with poor PC patients prognosis. cell line (HPDE6-C7, HPNE Capan-2, HPAC, SW1990, PANC-1, CFPAC-1, BXPC-3, ASPC-1, PATU-8988 ) up-regulated sensitive RHOF RHOF EMT pathway validated 2655 miR-146b-5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. Oncol Rep 2017 29048680 miRBase MIMAT0002809 miR-146b-5p miRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-PCR In the present study, we successfully generated U87 and U251-TR cells, and found that miR-146b-5p was downregulated in TR cells. Overexpression of miR-146b-5p restored sensitivity of U87/U251-TR cells to TMZ by targeting tumor necrosis factor receptor-associated factor 6 (TRAF6). The levels of TRAF6 were inversely related to miR-146b-5p levels, and overexpression of TRAF6 in miR-146b-5p OE cells enhanced the resistance against TMZ. Moreover, temozolomide-resistant GBM cells had a higher level of phosphorylated protein kinase B (AKT) and P65. Overexpression of miR-146b-5p or TRAF6 knockdown significantly decreased the level of p-AKT and p-p65. Collectively, our data demonstrated that miR-146b-5p, as a tumor suppressor, mediated temozolomide resistance in GBM cells through negatively regulating TRAF6 expression, indicating that miR-146b-5p and its targeted genes would be potential therapeutic targets for glioma therapy. cell line (U87-MG,U251-MG) up-regulated sensitive TRAF6 TRAF6 AKT and NF-kappaB pathway validated 2656 MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2. Sci Rep 2017 29051585 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR,RT-qPCR In the study, our data showed that miR-200c, which is downregulated in osteosarcoma tissues, drives chemosensitivity to cisplatin in osteosarcoma. We demonstrated that AKT2 is a direct target of miR-200c, Spearmans rank correlation analysis showed that the expression levels of AKT2 and miR-200c in 35 pairs of osteosarcoma specimens were inversely correlated. Moreover, miR-200c inhibited cell proliferation and cell migration. cell line (HOS, U-2OS, Saos-2, MG-63,NHOst) down-regulated sensitive AKT2 AKT2 NA validated 2657 miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomark 2017 29060932 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR Osteosarcoma U2OS cells were transfected with miR-34a mimics for 48 h, then the cells were treated with 3.0 um cisplatin for 24 h. Using siRNA targeting c-Myc and Bim to examine the relation between miR-34a, c-Myc and Bim expression exposure to cisplatin on cisplatin-induced apoptosis. cell line (U2OS ) up-regulated sensitive NA NA c-Myc and Bim pathway validated 2658 Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. Cell Physiol Biochem 2017 29073615 miRBase MIMAT0000436 miR-144-3p miRNA DB01268 (DB07417) Sunitinib clear cell renal cell carcinoma RT-qPCR Gain and loss of function approaches were used to investigate the cell proliferation, cycle distribution, clonogenicity, migration, invasion, chemosensitivity of miR-144-3p in vitro. The xenograft model was used to assess the effects of miR-144-3p overexpression on tumorigenesis. Bioinformatics analysis and dual-luciferase reporter assay were used to indentify AT-rich interactive domain 1A (ARID1A) as a direct target gene of miR-144-3p. Quantitative RT-PCR, Western blotting, and immunohistochemical (IHC) staining were used to explore ARID1A expression level of the mRNA and protein. cell line ( 786-O,SN12-PM6) up-regulated resistant ARID1A ARID1A NA validated 2659 Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2. Oncotarget 2017 29108284 miRBase MI0000084 miR-26b miRNA DB00515 (APRD00359) Cisplatin laryngeal cancer qRT-PCR In the present study, we constantly exposed the laryngeal cancer cell line Hep-2 with cisplatin to establish a cisplatin-resistant laryngeal cancer cell model (Hep-2/R). We found that Hep-2/R cells exhibited obvious resistance to cisplatin compared to the Hep-2 cells. However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R. Mechanically, miR-26b in Hep-2/R decreased the expression of ATF2, and thus inhibiting the phosphorylation of ATF2 and formation of cellular ATF2-c-Jun complex induced by cisplatin. As the results, Hep-2/R cells failed to overexpress the Bcl-xl which is a key anti-apoptotic protein under the cisplatin treatment. Therefore, overexpression of miR-26b was found to be able to promote mitochondrial apoptosis induced by cisplatin. cell line (Hep-2,Hep-2/R) up-regulated sensitive ATF2 ATF2 NA validated 2660 MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. Oncol Lett 2017 29113252 miRBase MI0000082 miR-25 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The present study aimed to investigate the potential role of miR-25 in the cisplatin sensitivity of GC cells. The expression level of miR-25 was significantly upregulated in the cisplatin-resistant GC cell line SGC-7901/DDP compared with the SGC-7901 parental cell line. Overexpression of miR-25 significantly enhanced cell cycle progression and decreased the sensitivity of SGC-7901 cells to cisplatin, whereas inhibition of miR-25 in the SGC-7901/DDP cisplatin-resistant cells resulted in cell cycle arrest at the G0/G1 phase and significantly increased drug sensitivity. Furthermore, the tumor suppressor forkhead box O3a (FOXO3a) was identified as a direct target gene of miR-25 by luciferase assay and western blot analysis, and was shown to mediate the drug-resistance phenotype of GC cells. These findings suggest that upregulation of miR-25 is important for GC cells to establish a cisplatin-resistant phenotype via a FOXO3a-dependent mechanism. cell line ( SGC-7901, SGC-7901/DDP) up-regulated resistant FOXO3a FOXO3a NA validated 2661 MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. Cancer Cell Int 2017 29118673 miRBase MIMAT0000075 miR-20a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR Based on the CCK8 experiments, we performed an RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells (a multi-chemosensitive OS cell line G-292 and a multi-chemoresistant OS cell line SJSA-1) to detect the levels of miR-20a-5p. We predicted Homo sapiens syndecan 2 (SDC2) as one of the target genes of miR-20a-5p via several websites, which was further validated by detecting their expression of both mRNA and protein level in both the miR-20a-5p-mimic transfected G-292 and miR-20a-5p-antagomiR transfected SJSA-1 cells. The involvement of SDC2 with OS chemoresistance was checked by siRNA-mediated repression or overexpression of SDC2 gene. Cell viability was assessed by CCK8 assay. cell line (G-292,SJSA-1 ) down-regulated resistant SDC2 SDC2 NA validated 2662 MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. Cancer Cell Int 2017 29118673 miRBase MIMAT0000075 miR-20a-5p miRNA DB00773 (APRD00239) Etoposide osteosarcoma qRT-PCR Based on the CCK8 experiments, we performed an RNA-seq-based miR-omic analysis of osteosarcoma (OS) cells (a multi-chemosensitive OS cell line G-292 and a multi-chemoresistant OS cell line SJSA-1) to detect the levels of miR-20a-5p. We predicted Homo sapiens syndecan 2 (SDC2) as one of the target genes of miR-20a-5p via several websites, which was further validated by detecting their expression of both mRNA and protein level in both the miR-20a-5p-mimic transfected G-292 and miR-20a-5p-antagomiR transfected SJSA-1 cells. The involvement of SDC2 with OS chemoresistance was checked by siRNA-mediated repression or overexpression of SDC2 gene. Cell viability was assessed by CCK8 assay. cell line (G-292,SJSA-1 ) down-regulated resistant SDC2 SDC2 NA validated 2663 Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep 2017 29130102 miRBase MI0000071 miR-17 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qPCR The role of lncRNA-XISTand NSCLC cells was detected using real-time polymerase chain reaction (qPCR), western blot and cell viability assay,etc. tissue and cell line (A549 and H1299 ) up-regulated sensitive ATG7 ATG7 lncRNA-XIST/miR-17/autophagy validated 2664 miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep 2017 29152656 miRBase MI0000542 miR-320a miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The present study performed gain- and loss-of-function analyses by transfecting cells with mimics or inhibitors and subsequently performing colony formation, proliferation and cisplatin-sensitivity assays. Additionally, in vivo xenograft models were also performed. Bioinformatics algorithms, luciferase reporter activity assay and western blotting were used to predict the potential target of miR-320a. Additionally, the effect of knockdown or overexpression of ADAM metallopeptidase domain 10 (ADAM10) on cell growth and chemosensitivity was examined. The expression of miR-320a and ADAM10 was also determined in primary tumors. The present study revealed that the expression of miR-320a was reduced in GC cells and ectopic miR-320a expression significantly inhibited cell growth in vitro and in vivo and enhanced the sensitivity of GC cells to cisplatin. ADAM10 was a direct target of miR-320a in GC. Knockdown of ADAM10 attenuated the proliferative ability of GC cells, and increased the sensitivity of GC cells to cisplatin. The upregulated ADAM10 accelerated cell growth rate and reduced the cisplatin-sensitivity of cells. Clinically, a significantly negative correlation was identified between the expression of miR-320a and mRNA levels of ADAM10 in tumors. The findings of the present study suggested that miR-320a may function as a tumor suppressor in GC progression and potential therapeutic strategies for GC may be based on the miR-320a/ADAM10 axis. cell line (SGC-7901, AGS, BGC-823 and MGC-803) up-regulated sensitive ADAM10 ADAM10 NA validated 2665 Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017 29162158 miRBase MIMAT0000418 miR-23b-3p miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR ncRNA expression levels in gastric cancer (GC) cells was detected by quantitative real-time PCR (qPCR). MALAT1 shRNAs and overexpression vector were transfected into GC cells to down-regulate or up-regulate MALAT1 expression. In vitro and in vivo assays were performed to investigate the functional role of MALAT1 in autophagy associated chemoresistance. cell line (SGC7901, BGC823,SGC7901/VCR) down-regulated resistant MALAT1 MALAT1 NA validated 2666 Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017 29162158 miRBase MIMAT0000418 miR-23b-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR ncRNA expression levels in gastric cancer (GC) cells was detected by quantitative real-time PCR (qPCR). MALAT1 shRNAs and overexpression vector were transfected into GC cells to down-regulate or up-regulate MALAT1 expression. In vitro and in vivo assays were performed to investigate the functional role of MALAT1 in autophagy associated chemoresistance. cell line (SGC7901, BGC823,SGC7901/VCR) down-regulated resistant MALAT1 MALAT1 NA validated 2667 MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer. Biosci Rep 2017 29162879 miRBase MI0000749 miR-30e miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR In this study, we found that miR-30e was significantly downregulated in tumor tissues of breast cancer (BC) patients and cell lines, and overexpression of miR-30e inhibited cell proliferation, migration and invasion. To understand the potential mechanism of miR-30e in inhibiting tumor growth, we showed that miR-30e blocked the activation of AKT and ERK1/2 pathways, and the expression of HIF-1alpha and VEGF via directly targeting IRS1. Moreover, miR-30e regulates cell proliferation, migration, invasion and increases chemosensitivity of MDA-MB-231 cells to paclitaxel by inhibiting its target IRS1. MiR-30e also inhibited tumor growth and suppressed expression of IRS1, AKT, ERK1/2 and HIF-1alpha in mouse xenograft tumors. To test the clinical relevance of these results, we used 40 pairs of BC tissues and adjacent normal tissues, analyzed the levels of miR-30e and IRS1 expression in these tissues, and found that miR-30e levels were significantly inversely correlated with IRS1 levels in these BC tissues, suggesting the important implication of our findings in translational application for BC diagnostics and treatment in the future. cell line ( HEK293T,MCF-7, MDA-MB-231,MCF10A) up-regulated sensitive IRS1 IRS1 AKT and ERK1/2 pathway validated 2668 MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway. Oncotarget 2017 29163776 miRBase MI0016748 miR-1268b miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR Selected from miRNA microarray and confirmed by real-time quantitative PCR (RT-qPCR), miR-1268b was found to be significantly upregulated in drug sensitive and ERBB2 negative tissues, as well as in breast cancer patients with low clinical stage. And miR-1268b had a higher expression in chemosensitive breast cancer cell lines, compared with the chemoresistant cell line. Moreover, the results revealed that miR-1268b induced breast cancer cell apoptosis and increased cell chemosensitivity. ERBB2 was demonstrated to be the target gene of miR-1268b by dual-luciferase reporter assays, western blot, and immunocytochemistry. Furthermore, PI3KCA, AKT, BCL2 in the ERBB2-PI3K-AKT signaling pathway were found to be downstream effectors of miR-1268b. In conclusion, miR-1268b increased chemosensitivity, at least in part, via modulation of PI3K-AKT pathway by targeting ERBB2. cell line (MDA-MB-231, MDA-MB-468, MDA-MB-453 SKBR3, MCF-7,MCF-7/ADM) up-regulated sensitive ERBB2 ERBB2 PI3K-AKT pathway validated 2669 The effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance. Eur Rev Med Pharmacol Sci 2017 29164556 miRBase MI0000301 miR-224 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin colorectal cancer qRT-PCR Dual luciferase gene reporter assay demonstrated the regulatory relationship between miR-224 and GSK-3Beta. Expression of miR-224, GSK-3Beta, Beta-catenin, and Survivin was measured in normal colon epithelium NCM460, CRC cell line SW480, and drug-resistant SW480/ADM cell line. Flow cytometry measured apoptosis under ADM with an IC50 concentration of SW480 cells, followed by CCK-8 analysis of cell proliferation. SW480/ADM cells were treated with miR-224 inhibitor and/or pSicoR-GSK-3Beta, followed by analysis of the expressions of GSK-3Beta, Beta-catenin and Survivin, cell apoptosis, and cell proliferation by EdU staining. cell line ( NCM460,SW480,SW480/ADM) up-regulated resistant GSK-3Beta GSK-3Beta Wnt/Beta-catenin pathway validated 2670 miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Pharmacogenomics 2017 29173002 miRBase MIMAT0002881 miR-509-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The roles of miR-509-3p in cellular apoptosis were assessed through MTT and DAPI assays. The confirmation of the regulation of BCL2 family members by miR-509-3p was investigated by luciferase reporter assay, western blot, quantitative real-time PCR and rescue experiments. cell line ( HEK-293T,SKOV3 and OVCAR3 ) up-regulated sensitive BCL2 and BCL2L2 BCL2 and BCL2L2 NA validated 2671 Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. Cell Physiol Biochem 2017 29216623 miRBase MI0006381 miR-1246 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR The expression levels of endogenous and exosomal miRNAs were examined by real time PCR, and the expression level of the target protein was detected by western blot. Scanning electron and confocal microscopy were used to characterize exosomes and to study their uptake and transfer. Luciferase reporter plasmids and its mutant were used to confirm direct targeting. Furthermore, the functional significance of exosomal miR-1246 was estimated by invasion assay and cell viability assay. cell line (MCF-7, MDA-MB-231,MCF-10A,HMLE) up-regulated resistant CCNG2 CCNG2 NA validated 2672 Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. Cell Physiol Biochem 2017 29216623 miRBase MI0006381 miR-1246 miRNA DB00445 (APRD00361) epirubicin breast cancer qRT-PCR The expression levels of endogenous and exosomal miRNAs were examined by real time PCR, and the expression level of the target protein was detected by western blot. Scanning electron and confocal microscopy were used to characterize exosomes and to study their uptake and transfer. Luciferase reporter plasmids and its mutant were used to confirm direct targeting. Furthermore, the functional significance of exosomal miR-1246 was estimated by invasion assay and cell viability assay. cell line (MCF-7, MDA-MB-231,MCF-10A,HMLE) up-regulated resistant CCNG2 CCNG2 NA validated 2673 Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. Cell Physiol Biochem 2017 29216623 miRBase MI0006381 miR-1246 miRNA DB00441 (APRD00201) Gemcitabine breast cancer qRT-PCR The expression levels of endogenous and exosomal miRNAs were examined by real time PCR, and the expression level of the target protein was detected by western blot. Scanning electron and confocal microscopy were used to characterize exosomes and to study their uptake and transfer. Luciferase reporter plasmids and its mutant were used to confirm direct targeting. Furthermore, the functional significance of exosomal miR-1246 was estimated by invasion assay and cell viability assay. cell line (MCF-7, MDA-MB-231,MCF-10A,HMLE) up-regulated resistant CCNG2 CCNG2 NA validated 2674 Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel. J Exp Clin Cancer Res 2017 29216925 miRBase MIMAT0004614 miR-193a-5p miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth. cell line (LNCap, PC3, DU145,T24, UM-UC-3,RWPE-1) down-regulated sensitive Bach2 Bach2 miR-193a-5p-Bach2-HO-1 pathway validated 2675 MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4. Am J Transl Res 2017 29218103 miRBase MI0001641 miR-429 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In the present study, we are aimed to examine whether microRNA-429 was involved in mediating the chemo-resistance of pancreatic cancer cells to gemcitabine. Firstly, a gemcitabine-resistant pancreatic cancer cell line (SW1990/GZ) derived from cell line (SW1990) was constructed and found to possess a decreased expression of miR-429 when it is compared to the original cell line. Ectopic expression of miR-429 in SW1990/GZ increased the cellular sensibility to the treatment of gemcitabine, which is coincided with increased expression of PDCD4. As a tumor suppressor, we found that PDCD4 knockdown in SW1990/GZ cells increased its own chemo-resistance to GZ, which indicates PDCD4 also play a regulative role on the GZ-resistance in the pancreatic cancer. To further confirm the function of miR-429 and PDCD4 in gemcitabine-resistant pancreatic cancer, a xenograft nude mouse model was utilized to examine whether miR-429 can restore treatment response of gemcitabine in gemcitabine-resistant xenografts, while protein levels of PDCD4 were up-regulated. Together with those results, these findings collectively provided that miR-429 could enhancer GZ sensitivity via regulation of PDCD4 expression in pancreatic cancer cells, which may offer a novel therapeutic target for the chemotherapy resistance in pancreatic cancer. cell line (SW1990) up-regulated sensitive PDCD4 PDCD4 NA validated 2676 MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. Eur Rev Med Pharmacol Sci 2017 29228450 miRBase MI0000077 miR-21 miRNA DB00262 (APRD00006) Carmustine glioma RT-PCR BCNU-sensitive cells (SWOZ2 cells) were transfected with miR-21 agomir and negative control, and BCNU-resistance cells (SWOZ2-BCNU cells) were transfected with miR-21 antagomir and negative control. The Real-time fluorescence quantitative PCR was used to detect and compare the levels of miR-21expression between SWOZ2-BCNU and SWOZ2 cells. The drug sensitivity of these cells to BCNU was determined by Cell Counting Kit-8 (CCK-8) assay. The protein expression of Spry2 was detected by Western blotting. cell line (SWOZ2,SWOZ2-BCNU) up-regulated resistant Spry2 Spry2 NA validated 2677 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0000722 miR-370-3p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2678 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0000722 miR-370-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2679 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0000736 miR-381-3p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2680 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0000736 miR-381-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2681 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0001639 miR-409-3p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2682 MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J 2017 29242506 miRBase MIMAT0001639 miR-409-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma qRT-PCR To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs. Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling. Expression data suggested activation of these pathways during disease progression, and functional analyses validated that miR-370-3p, miR-381-3p, and miR-409-3p downregulate genes on the PI, MAPK, and BCR signaling pathways, and enhance chemosensitivity of DLBCL cells in vitro. High expression of selected target genes, that is, PIP5K1 and IMPA1, was found to be associated with poor survival in two independent cohorts of chemoimmunotherapy-treated patients (n-=-92 and n-=-233). Taken together, our results demonstrate that differentially expressed miRNAs contribute to disease progression by regulating key cell survival pathways and by mediating chemosensitivity, thus representing potential novel therapeutic targets. cell line (SU-DHL-4 ) up-regulated sensitive NA NA NA validated 2683 MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6. Cell Physiol Biochem 2017 29258115 miRBase MIMAT0000242 miR-129-5p miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR Quantitative RT-PCR (qRT-PCR) was used to determine the expression levels of miR-129-5p and its potential target genes. The effects of miR-129-5p on cell responses to trastuzumab were analyzed by CCK-8 and flow cytometry assays in Her-2-positive breast cancer cells (SKBR-3 and JIMT-1). Bio-informatics analyses were performed to predict target genes of miR-129-5p, and luciferase assays were carried out to confirm the binding of miR-129-5p and rpS6. cell line (SKBR3,JIMT-1) up-regulated sensitive Rps6 RpS6 PI3K/Akt/mTOR pathway validated 2684 miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res 2017 29258605 miRBase MI0000111/MI0000112 miR-105 miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR The miRNA array profiles of 1299 breast cancer patients were collected from the Metabric database and subjected to analysis of the altered miRNAs between TNBC and non-TNBC. In Student¡¯s t-test and Kaplan-Meier analysis, four upregulated miRNAs correlated with poor survival in TNBC but not in non-TNBC. Four miRNAs were manipulated in multiple cell lines to investigate their functional role in carcinogenesis. From these results, we studied miR-105 and miR-93-3p in greater detail. The level of miR-105 and miR-93-3p were evaluated in 25 breast cancer tumor tissues. In addition, the diagnostic utility of circulating miR-105 and miR-93-3p were examined in 12 normal and 118 breast cancer plasma samples by ROC curve construction. cell line (MCF 10A,MB-361, MCF-7, BT-483, AU565, SkBR3,MB-231,Hs578T, HCC1599, HCC1806, HCC1937, BT-549, DU4475,HCC70,MB-231,293 T ) up-regulated resistant SFRP1 SFRP1 Wnt/Beta-catenin pathway validated 2685 miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res 2017 29258605 miRBase MIMAT0004509 miR-93-3p miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR The miRNA array profiles of 1299 breast cancer patients were collected from the Metabric database and subjected to analysis of the altered miRNAs between TNBC and non-TNBC. In Student¡¯s t-test and Kaplan-Meier analysis, four upregulated miRNAs correlated with poor survival in TNBC but not in non-TNBC. Four miRNAs were manipulated in multiple cell lines to investigate their functional role in carcinogenesis. From these results, we studied miR-105 and miR-93-3p in greater detail. The level of miR-105 and miR-93-3p were evaluated in 25 breast cancer tumor tissues. In addition, the diagnostic utility of circulating miR-105 and miR-93-3p were examined in 12 normal and 118 breast cancer plasma samples by ROC curve construction. cell line (MCF 10A,MB-361, MCF-7, BT-483, AU565, SkBR3,MB-231,Hs578T, HCC1599, HCC1806, HCC1937, BT-549, DU4475,HCC70,MB-231,293 T ) up-regulated resistant SFRP1 SFRP1 Wnt/Beta-catenin pathway validated 2686 Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget 2017 29262633 miRBase MI0005569 miR-216b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In the present study, we focused on miR-216b to investigate whether miR-216b determined sensitivity of NSCLC cells to cisplatin. We observed that expression level of miR-216b was significantly decreased in NSCLC cell lines when they were under the cisplatin treatment. However, restore of miR-216b by transfecting with its mimics was found to increase the cytotoxicity of cisplatin to NSCLC cells. Studies on mechanisms elucidated that miR-216b targeted c-Jun in NSCLC. Overexpression of miR-216b can suppress the cisplatin-induced upregulation of c-Jun. As the downstream, overexpression of Bcl-xl induced by c-Jun/ATF2 heterodimers was inhibited in miR-216b transfected NSCLC cells. Since Bcl-xl is a key anti-apoptotic protein, we found that sensitivity of NSCLC cells to cisplatin-induced apoptosis was significantly increased because of the overexpression of miR-216b. cell line (A549 and PC9) up-regulated sensitive c-Jun c-Jun c-Jun/Bcl-xl pathway validated 2687 MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget 2017 29299167 miRBase MI0000447/MI0000727 miR-128 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qRT-PCR In the study, we showed that CSCs have significantly higher expression levels of BMI-1, MUC1-C, stemness proteins, signaling factors, and higher malignancy compared with normal tumor cells. After transfection with miR-128, the BMI-1 and MUC1-C levels in CSCs were suppressed. When miR-128 was stably expressed in PTX-resistant lung cancer stem cells, the cells showed decreased proliferation, metastasis, self-renewal, migration, invasive ability, clonogenicity, and tumorigenicity in vitro and in vivo and increased apoptosis compared with miR-NC (negative control) CSCs. Furthermore, miR-128 effectively decreased the levels of Beta-catenin and intracellular signaling pathway-related factors in CSCs. MiR-128 also decreased the luciferase activity of MUC1 reporter constructs and reduced the levels of transmembrane MUC1-C and BMI-1. These results suggested miR-128 as an attractive therapeutic strategy for PTX-resistant lung cancer via inhibition of BMI-1 and MUC1-C. cell line (A549,A549/PTX) up-regulated sensitive MUC1-C and BMI-1 MUC1 and BMI1 PI3K/AKT pathway validated 2688 MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1. Oncotarget 2017 29416616 miRBase MI0003941 miR-761 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In our study, we indicated that overexpression of miR-761 promoted the sensitivity of colorectal cancer cells to 5-Fluorouracil (5-FU). miR-761 expression was downregulated in colorectal cancer cell lines and tissues. miR-761 expression was lower in patients with low grade than in patients with high grade. In additon, we showed that elevated expression of miR-761 suppressed colorectal cancer cell proliferation, cell cycle, colony formation and cell invasion. We identified that FOXM1 was a direct target gene of miR-761 in colorectal cancer cell. FOXM1 expression was upregulated in colorectal cancer tissues compare to the adjacent non-tumor tissues. MiR-761 expression was negatively associated with the expression of FOXM1 in colorectal cancer tissues. Elevated expression of FOXM1 suppressed the sensitivity of miR-761-overexpressing HT29 cells to 5-FU. We also indicated that FOXM1 overexpression promoted cell proliferation, cycle and invasion of miR-761-overexpressing HT29 cells. These data suggested that miR-761 played a tumor suppressor miRNA in colorectal cancer progression and reduced miR-761 expression might be a major mechanism for 5-FU resistance in colorectal cancer cell. cell line (HT29, SW480, SW620,DLD-1,FHC) up-regulated sensitive FOXM1 FOXM1 NA validated 2689 The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. Oncotarget 2017 29416757 miRBase MI0000446/MI0000470 miR-125b miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR In this study, the potential function of miR-125b on DDP resistance in gastric cancer cells was investigated. Sixteen miRNAs significantly differential expressed in gastric tumor tissues and adjacent tissues were characterized and their corresponding putative target genes were also screened. MiR-125b was selected as our focus for its evident down-regulated expression among candidate genes. Real-time polymerase chain reaction assay indicated that miR-125b was significantly down-regulated in gastric cancer tissues and various cell lines. HER2 was identified as a target gene of miR-125b by dual luciferase reporter assay and Western blot. Moreover, miR-125b overexpression inhibited not only the proliferation, migration, and invasion abilities of HGC-27 and MGC-803 cells, but also in vivo tumor growth of MGC-803 cells by an intratumoral delivery approach. Notably, we observed up-regulated miR-125b contributed to the chemosensitivity of DDP in HGC-27 and MGC-803 cells at different concentrations and also possessed sensibilization for DDP at different times. MiR-125b expression was found to be related to lymph node metastasis, HER2 expression and overall survival of patients through correlation analysis. cell line (GES-1, 293TN,HGC-27, MGC-803, AGS, N87, MKN-45, SGC-7901, BGC-823) up-regulated sensitive HER2 HER2 NA validated 2690 MicroRNA-326 sensitizes human glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway. Cancer Biol Ther 2018 27819521 miRBase MI0000808 miR-326 miRNA DB11672 Curcumin glioblastoma RT-PCR Expressions of miR-326 was detected human glioblastoma tissue and cell lines by RT-PCR. Cell migration was detected by transwell migration and invasion assay. The targeting protein of miR-524-5p was identified by luciferase reporter assay and western blot cell line (U87 and U251) up-regulated sensitive SMO SMO SHH/GLI1 signaling pathway validated 2691 The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. Pathol Oncol Res 2018 28411308 miRBase MI0000650 miR-200c miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we examined the effect of inhibition of miR-200c on the sensitivity of HCT-116 cells to 5-FU. HCT-116 cells were transfected with LNA-anti- miR-200c for 48 h. mRNA expression of miR-200c was investigated by qRT-PCR. The protein expression of phosphatase and tensin homolog (PTEN) and E-cadherin were evaluated by western blotting. Annexin V/ PI staining and caspase 3 activity were used to detect apoptosis. LNA-anti-miR-200c inhibited the miR-200c expression in the transfected cells compared with that in the control group. LNA-anti-miR-200c suppressed the expression of PTEN and E-cadherin independent of the presence of the chemotherapeutic drug 5-FU. LNA-anti-miR-200c reduced the 5-FU-induced apoptosis and caspase 3 activity. cell line ( HCT-116 ) up-regulated sensitive E-cadherin and PTEN E-cadherin and PTEN NA validated 2692 Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Oncol Res 2018 28477403 miRBase MI0000077 miR-21 miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR The role of miR-21 in pancreatic cancer cells was detected using cell Invasion Assay, enzyme-linked immunosorbent assay, histology and immunostaining, qRT-PCR and animal model,etc. cell line ( Panc02) up-regulated sensitive PDCD4 PDCD4 NA validated 2693 MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer. Pathol Oncol Res 2018 28667493 miRBase MI0000070 miR-16-1 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR This study aimed to investigate the regulatory roles and molecular mechanism of miR-16-1 to the chemosensitivity to adriamycin in GC. In this study, the expression of miR-16-1 and FUBP1 was down-regulated and up-regulated respectively in adriamycin-resistant GC tissues and cell lines, and represented a negative relationship between them. MiR-16-1 could silence FUBP1 directly and specifically, FUBP1 was a target gene of miR-16-1. Silence of FUBP1 inhibited the half maximal inhibitory concentration (IC50) of SGC7901/AR cell line to adriamycin, chemosensitivity enhanced significantly. Moreover, FUBP1 silence in SGC7901/AR cell line also inhibited proliferation and invasion, and advanced cell apoptosis. To sum up, the expression of miR-16-1 was positively related with the chemosensitivity of GC to adriamycin, and miR-16-1 could targeted silence FUBP1 to advance the chemosensitivity to adriamycin in GC, which might be a novel potential therapeutic target for GC. cell line ( SGC7901 ) up-regulated sensitive FUBP1 FUBP1 NA validated 2694 MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Int J Cancer 2018 28905994 miRBase MIMAT0000761 miR-324-5p miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-PCR In the study, we found the expression of miR-324-5p was decreased in MM, especially in del(17p) MM. In contrast, the expression of hedgehog (Hh) signaling components was elevated, indicating a correlation between miR-324-5p and Hh signaling in MM. Hh signaling is important for the pathogenesis of MM and maintenance of MM stem cell compartment. Indeed, overexpression of miR-324-5p significantly decreased Hh signaling components Smo and Gli1, and functionally reduced cell growth, survival as well as stem cell compartment in MM. Moreover, miR-324-5p potentiated the anti-MM efficacy of bortezomib through regulating the activities of multidrug-resistance proteins and the expression of Bcl-2 family genes. Consistent results were obtained in vivo. Finally, miR-324-5p overcame the protective effect of bone marrow stromal cells on MM cells. cell line (RPMI8226, ARH-77, U266,NCI-H929,OPM2) up-regulated sensitive NA NA Hedgehog pathway validated 2695 Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. Oncol Res 2018 28950928 miRBase MI0000262 miR-147 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR The present study demonstrated that miR-147 was significantly upregulated in gastric cancer tissues and cell lines. Downregulation of miR-147 decreased cell proliferation and enhanced the chemosensitivity of gastric cancer cells to 5-fluorouracil (5-FU) through the cell apoptosis pathway. In addition, phosphatase and tensin homolog (PTEN) was mechanically identified as the direct target of miR-147 in gastric cancer. PTEN knockdown reversed the effects of miR-147 downregulation on the proliferation, chemosensitivity, and 5-FU-induced apoptosis of gastric cancer cells. Moreover, miR-147 regulated the PI3K/AKT signaling pathway in gastric cancer by targeting PTEN. In conclusion, miR-147 suppressed the proliferation and enhanced the chemosensitivity of gastric cancer cells to 5-FU by promoting cell apoptosis through directly targeting PTEN and regulating the PI3K/AKT signaling pathway. cell line (AGS, SGC-7901,MKN-45, BGC-823, and MGC-803) down-regulated sensitive PTEN PTEN PI3K/AKT signaling pathway validated 2696 miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. Cell Signal 2018 28982601 miRBase MI0005569 miR-216b miRNA DB08881 (DB05238) Vemurafenib melanoma RT-PCR Autophagy maintains cells survival in many stressful conditions including starvation, growth factor deprivation and misfolded protein accumulation. Additionally, autophagic survival mechanisms are used by transformed tumor cells to inhibit cell death, limit drug effectiveness and possibly generate drug resistance. However, the mechanism of how cells utilize autophagy during drug resistance is not fully understood. Here, we demonstrate that miR-216b plays an important role in alleviating drug resistance by regulating autophagy in melanoma. We show that miR-216b attenuates autophagy by directly targeting three key autophagy genes Beclin-1, UVRAG and ATG5. Overexpression of these genes from miRNA immune cDNA constructs rescue autophagic activity in the presence of miR-216b. Antagomir-mediated inactivation of endogenous miR-216b led to an increase of Beclin-1, UVRAG, ATG5, and subsequent autophagic activity. More importantly, we have discovered that BRAF(V600E) inhibitor vemurafenib suppresses miR-216b activity, which in turn activates autophagy to generate drug resistance in both BRAFi-sensitive and -resistant cells. Strikingly, ectopic expression of miR-216b increases the efficacy of vemurafenib both in vitro and in vivo. Taken together, these data indicate that miR-216b regulates autophagy by suppressing three key autophagy genes, and enhances the antitumor activity of vemurafenib in BRAF(V600E) melanoma cells. cell line (A375, A375-R, G-361, G-361-R) up-regulated sensitive Beclin-1, UVRAG and ATG5 Beclin-1, UVRAG and ATG5 the autophagy pathway validated 2697 Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors. Neuro Oncol 2018 29036598 miRBase MIMAT0000271 miR-214-3p miRNA DB00515 (APRD00359) Cisplatin pediatric intracranial nongerminomatous malignant germ cell tumors RT-qPCR We performed methylation and hydroxymethylation DNA immunoprecipitation sequencing, mRNA expression microarray, and small RNA sequencing (smRNA-seq) to determine methylation-regulated genes, including microRNAs (miRNAs). cell line ( HEK293T ) up-regulated resistant BCL2L11 BCL2L11 NA validated 2698 MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1 Gene 2018 29054762 miRBase MI0000268 miR-34a miRNA NA Luteolin stomach cancer qRT-PCR In this study, we explored the roles of miR-34a and the effects of luteolin on GC cells as well as the underlying mechanism of miR-34a in mediating the susceptibility of GC cell to luteolin. Retrospectively study revealed that miR-34a expression was downregulated in human primary GC tissues compared with non-tumor tissues and low miR-34a expression was associated with a significantly shorter overall survival and disease-free survival. MiR-34a overexpression could inhibit GC cells and induce G1 phase arrest via p53/p21 and MAPK /ERK pathways. Luteolin decreased viability of GC cells in a dose-dependent manner. Meanwhile, miR-34a was found to be markedly upregulated in GC cells induced by luteolin and decreased miR-34a level was found in the artificial luteolin-resistant GC cells. Upregulation of miR-34a in luteolin-resistant GC cell could enhance the sensibility of GC cells to luteolin. On the other hand, miR-34a inhibitor could partly counter the anticancer effect of luteolin. In a further assay, we also found that targeting miR-34a could mediate the susceptibility of mouse xenografts to luteolin. Subsequent study found that HK1 was a direct target of miR-34a and downregulated HK1 mRNA or protein levels were presented after miRNA-34a overexpression in GC cells. Moreover, HK1 protein levels was decreased after luteolin treatment and partly restored when co-treated with luteolin and miR-34a inhibitor. Downregulation of HK1 in luteolin-resistant GC cell could increase the cells sensitivity to luteolin. Therefore, our findings firstly suggested that miR-34a could modulate the susceptibility of gastric cancer cell to luteolin via targeting HK1, potentially benefiting GC patients treatment in the future. cell line (AGS,BGC23,SGC7901) up-regulated sensitive HK1 HK1 p53/p21 and MAPK/ERK pathways validated 2699 MicroRNA-103 confers the resistance to long-treatment of adriamycin to human leukemia cells by regulation of COP1. J Cell Biochem 2018 29058777 miRBase MI0000109 miR-103 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin leukemia qRT-PCR Different concentrations of ADR were used to induce K562 and KASUMI-1 cells, and miR-103 mimic, inhibitor were transfected into K562 and KASUMI-1 cells. Cell viability and proliferation were determined by trypan blue staining and MTT assays for evaluating K562 and KASUMI-1 cells drug resistance. The relationship of miR-103 and COP1, Trib1, and C/EBPalpha were analyzed by qRT-PCR and Western blot. Cell proliferation, viability were detected again. Besides, the expressions of main factors of cell cycle and PI3K/AKT signal pathway were analyzed by Western blot. cell line ( K562, KASUMI-1) up-regulated resistant COP1 COP1 PI3K/AKT signal pathway validated 2700 MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study. J Cell Biochem 2018 29058784 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin melanoma qRT-PCR This study explored Cisplatin resistance effect of microRNA-21 (miR-21) antisense oligonucleotide (AS-ODN) in human melanoma A375 cell. AS-ODN was transfected in melanoma A375 cells and Cisplatin-resistant cell line A375/CDDP, and divided into the AS-ODN, nonsense oligonucleotide (NS-ODN) and normal groups. Cell ultrastructure changes were observed through transmission electron microscope. MiR-21 AS-ODN could be tested cell growth effect in different time periods by trypan blue exclusion. MiR-21 mRNA expression change was detected by quantitative fluorescence PCR. Cell apoptosis, cycle distribution and miR-21 AS-ODN effect on proliferation and Cisplatin sensitivity were tested by flow cytometry, MTT assay, TUNEL, and Clonogenic assay. Cell apoptosis was observed after transfection 24h with the AS-ODN group, while the NS-ODN and normal group cells had no apoptotic symptoms; Compared with the normal group, the AS-ODN group began to show obvious cell growth inhibition effect after transfection 24h lasting 72h (all P<0.05), but the NS-ODN group had no significant difference (P>0.05). miR-21 mRNA expression in the AS-ODN group was obviously decreased with rising apoptosis rate (all P<0.05) and there was no significant difference in the NS-ODN group (P>0.05). MiR-21 AS-ODN could remarkably increase A375 cell and A375/CDDP cell sensitivity to Cisplatin (P<0.05), while A375 cell sensitivity to Cisplatin between the NS-ODN group and the normal group had no difference. MiR-21 AS-ODN decreased IC50 and increased Cisplatin sensitivity for A375 cells and A375/CDDP cells, which would be a new target of melanoma treatment. cell line (A375,A375/CDDP) up-regulated sensitive SMAD7 SMAD7 NA validated 2701 Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma. Mol Carcinog 2018 29068478 miRBase MI0003134 miR-494 miRNA DB09298 Silybin osteosarcoma qPCR In the study, we firstly studied the roles of MMP-9 in OS and revealed that silence of MMP-9 inhibited OS cell proliferation as determined by MTT assay and colony formation assay. Secondly, we conducted TUNEL assay and confirmed loss of functions of MMP-9 induced OS cell apoptosis. Next, we used lentivector packaging method to overexpress MMP-9 and found that overexpression of MMP-9 promoted OS cell migration. Fourthly, the results of luciferase assay showed that MMP-9 was targeted by hsa-miR-494, which inhibited OS. Fifthly, we revealed that the levels of hsa-miR-494 were upregulated by the drug silybin which inhibited OS. Finally, we revealed that silybin inhibited OS cell viability by altering the protein levels of Beta-catenin and Runt-related transcription factor 2 (RUNX2) as determined by western blot and immunocytochemistry (ICC). cell line (MG-63) up-regulated sensitive MMP-9 MMP-9 NA validated 2702 MicroRNA-195 desensitizes HCT116 human colon cancer cells to 5-fluorouracil. Cancer Lett 2018 29080751 miRBase MI0000489 miR-195 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR The objective of this study was to investigate whether microRNAs might play a role in the acquisition of resistance. Human colorectal cancer HCT-116 cell lines were transduced with a lentivirus library containing 578 precursor microRNAs (miRNAs) to establish cell lines resistant to 5-fluorouracil (5-FU). Specific miRNAs were identified from four different resistant clones and a miR-195-expressing resistant clone (HCT-116-lenti-miR-195) was further investigated. The HCT-116-lenti-miR-195 cells showed resistant phenotype. These cells grew faster after 5-FU treatment compared to control cells (HCT-116-lenti-control). Check point kinase 1 (CHK1) and G2 check point kinase WEE1 were found to be direct targets of miR-195. Downregulation of miR-195 sensitized HCT-116 cells after 5-FU treatment. Our results demonstrate that miR-195 can promote acquisition of drug resistance to 5-FU. cell line (HCT-116,) up-regulated resistant WEE1 and CHK1 WEE1 and CHK1 NA validated 2703 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/Beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol 2018 29080815 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of HOTAIR and miR-34a in gastric cancer cells was detected using MTT assay, quantitative real-time PCR, Dual-luciferase report assay, RIP assay, caspase-3 activity detection and Western blot , etc. tissue and cell line (SGC7901,MGC803,GES1,SGC7901/DDP) up-regulated sensitive NA NA PI3K/Akt and Wnt/Beta-catenin signaling pathway validated 2704 Effect of microRNA-128 on cisplatin resistance of glioma SHG-44 cells by targeting JAG1. J Cell Biochem 2018 29091297 miRBase MI0000447/MI0000727 miR-128 miRNA DB00515 (APRD00359) Cisplatin glioma qRT-PCR This current study intends to investigate the effect of microRNA-128 (miR-128) on cisplatin (DDP) resistance in glioma SHG-44 cells. SHG-44/DDP cells were transfected with miR-128 antisense oligonucleotide (ASO) and assigned into blank, resistance, NC, anti-miR-128, miR-128 mimic, si-JAG1, and anti-miR-128-+-si-JAG1 groups. qRT-PCR and Western blotting were employed for determining expression of miR-128, JAG1, Bax and Bcl-2. MTT assay, Giemsa staining, and flow cytometry were applied to detect DDP resistance, cellular morphology, and cell cycle, respectively. JAG1 is targeted and negatively regulated by miR-128. In in vitro experiments, compared with the blank group, the rest groups exhibited declined miR-28 and Bax expression, lowered cell inhibition rate and apoptosis rate, but elevated JAG1 and Bcl-2 expression with cells arrested in the S phase. Compared with the resistance group, the anti-miR-128 group showed decreasedBax expression along with a lowered cell inhibition rate and apoptosis rate, but increased JAG1 and Bcl-2 expression with reduced cells arrested in the S phase; while the miR-128 mimic group showed an opposite trend; the si-JAG1 group showed decreased Bcl-2 expression and reduced cells in the S phase. In in vivo experiments, compared with the resistance group, the tumor growth rate, tumor volume, and weight as well as JAG1 expression accelerated in the anti-miR-128 group; whereas the miR-128 mimic and si-JAG1 groups exhibited an opposite trend. Our findings demonstrated that miR-128 ASO transfection might down-regulate the expression of miR-128 in SHG-44/DDP and up-regulate the DDP resistance in SHG-44/DDP cells, providing a potential treatment target for glioma. cell line (SHG-44,SHG-44/DDP ) up-regulated sensitive JAG1 JAG1 NA validated 2705 microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73. Biomed Pharmacother 2018 29091904 miRBase MI0000807 miR-323 miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR In the present study, we sought to determine the function of miR-323 in prostate cancer cell growth and response to docetaxel. The effects of miR-323 overexpression on prostate cancer cell proliferation, colony formation, and tumorigenesis were examined. We also investigated the impact of miR-323 knockdown on cell cycle progression and apoptosis. Ectopic expression of miR-323 promoted cell proliferation and colony formation in vitro and xenograft tumor growth in vivo. Depletion of miR-323 arrested PC-3 prostate cancer cells at the G0/G1 phase and caused significant apoptosis, which was coupled with increased expression of p21 and cleavage of caspase-9 and caspase-3 and reduced expression of cyclin D1. Compared to PC-3 parental cells, docetaxel-resistant PC-3-DR cells had 5.6-fold higher levels of miR-323. Overexpression of miR-323 increased the 50% inhibitory concentration (IC50) value for docetaxel in PC-3 cells, while silencing of miR-323 exerted an opposite effect on PC-3-DR cells. Mechanistically, miR-323 repressed the expression of p73 in prostate cancer cells. Knockdown of p73 augmented cell proliferation and colony formation and blunted sensitivity to docetaxel in PC-3 cells. In addition, overexpression of p73 significantly suppressed cell proliferation and induced apoptosis and docetaxel sensitivity in PC-3-DR cells. cell line (s PC-3, DU145 ) up-regulated resistant p73 p73 NA validated 2706 miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed Pharmacother 2018 29102917 miRBase MI0000440 miR-27b miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR In this study, we found that miR-27b and miR-34a were significantly downregulated in docetaxel-resistant PCa cells. Gain-of-function experiments showed that overexpression of miR-27b or miR-34a enhanced docetaxel sensitivity and inhibited EMT in docetaxel-resistant PCa cells. Moreover, miR-27b and miR-34a was demonstrated to directly target ZEB1 and suppress ZEB1 expression. Loss-of-function analysis disclosed that ZEB1 knockdown enhanced docetaxel sensitivity and suppressed EMT in docetaxel-resistant PCa cells. Rescue experiments presented that ZEB1 overexpression abolished the effects of miR-27b or miR-34a overexpression on docetaxel sensitivity and EMT in docetaxel-resistant PCa cells. Finally, Tumor xenograft assay confirmed the contribution of miR-27b and miR-34a in improving docetaxel sensitivity in PCa in vivo. In summary, miR-27b and miR-34a overexpression enhanced docetaxel sensitivity of PCa partly through inhibiting EMT by targeting ZEB1, providing new insights into the molecular mechanism of miR-27b and miR-34a in modulating docetaxel resistance and potential therapy targets in advanced PCa. tissue and cell line ( HEK-293,PC3,DU-145,PrEC,PC3-DR and DU-145-DR) up-regulated sensitive ZEB1 ZEB1 NA validated 2707 miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed Pharmacother 2018 29102917 miRBase MI0000268 miR-34a miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR In this study, we found that miR-27b and miR-34a were significantly downregulated in docetaxel-resistant PCa cells. Gain-of-function experiments showed that overexpression of miR-27b or miR-34a enhanced docetaxel sensitivity and inhibited EMT in docetaxel-resistant PCa cells. Moreover, miR-27b and miR-34a was demonstrated to directly target ZEB1 and suppress ZEB1 expression. Loss-of-function analysis disclosed that ZEB1 knockdown enhanced docetaxel sensitivity and suppressed EMT in docetaxel-resistant PCa cells. Rescue experiments presented that ZEB1 overexpression abolished the effects of miR-27b or miR-34a overexpression on docetaxel sensitivity and EMT in docetaxel-resistant PCa cells. Finally, Tumor xenograft assay confirmed the contribution of miR-27b and miR-34a in improving docetaxel sensitivity in PCa in vivo. In summary, miR-27b and miR-34a overexpression enhanced docetaxel sensitivity of PCa partly through inhibiting EMT by targeting ZEB1, providing new insights into the molecular mechanism of miR-27b and miR-34a in modulating docetaxel resistance and potential therapy targets in advanced PCa. tissue and cell line ( HEK-293,PC3,DU-145,PrEC,PC3-DR and DU-145-DR) up-regulated sensitive ZEB1 ZEB1 NA validated 2708 Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother 2018 29112934 miRBase MIMAT0000258 miR-181c-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR mRNA levels of GAS5, miR-181c-5p and Hippo pathway related genes were detected by quantitative real-time PCR (qRT-PCR). Protein levels of MDR-1, MST1, YAP and TAZ were measured by western blot. Cell viability was detected by MTT assay. The combination between GAS5 and miR-181c-5p was confirmed by RNA pull-down and RNA immunoprecipitation (RIP) assay. We also established pancreatic cancer-bearing mice model and analyzed tumor volumes. cell line (SW1990,PATU8988, SW1990/GEM, PATU8988/5-FU,PANC-1) down-regulated sensitive NA NA Hippo signaling pathway validated 2709 MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res 2018 29115164 miRBase MI0000783 miR-375 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-PCR Serum samples were obtained from 95 patients with osteosarcoma and 95 healthy individuals. miR-375 expression was detected by real-time polymerase chain reaction. The associations of serum miR-375 expression with the patients¡¯ clinicopathological characteristics and prognosis were then evaluated. Receiver operating characteristic curve analysis was performed to obtain the potential value of serum miR-375 as a biomarker for osteosarcoma diagnosis and chemosensitivity prediction. tissue down-regulated resistant NA NA NA validated 2710 MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res 2018 29115164 miRBase MI0000783 miR-375 miRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-PCR Serum samples were obtained from 95 patients with osteosarcoma and 95 healthy individuals. miR-375 expression was detected by real-time polymerase chain reaction. The associations of serum miR-375 expression with the patients¡¯ clinicopathological characteristics and prognosis were then evaluated. Receiver operating characteristic curve analysis was performed to obtain the potential value of serum miR-375 as a biomarker for osteosarcoma diagnosis and chemosensitivity prediction. tissue down-regulated resistant NA NA NA validated 2711 The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep 2018 29115526 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HCT116,LoVo,LoVo/5-FU,HCT116/5-FU) down-regulated resistant ABCB9 ABCB9 NA validated 2712 Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Biomed Pharmacother 2018 29136760 miRBase MIMAT0004614 miR-193a-5p miRNA DB00853 (APRD00557) Temozolomide glioma qPCR Glioma and the adjacent non-cancerous tissues from 32 patients were collected. The expressions of CASC2 and miR-193a-5p were determined by PCR, and their correlation was analyzed. The correlation between CASC2 expression and the clinical characteristics of patients was also studied. Glioma cells were treated with TMZ to acquire the TMZ-resistant cell lines in which the expressions of CASC2, miR-193a-5p, and mTOR were measured. The regulatory roles of CASC2, miR-193a-5p, and mTOR were defined through the loss of function and luciferase reporter assays. Autophagy was inhibited by autophagy inhibitor 3-MA, CASC2 and mTOR overexpression, or miR-193a-5p inhibitor, and the effect of which on cell viability, apoptosis, and migration of TMZ-resistant glioma cells was evaluated. cell line ( U257 and U87) down-regulated sensitive mTOR mTOR NA validated 2713 MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. Mol Carcinog 2018 29144562 miRBase MI0019116 miR-5100 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR In the study, we demonstrated that miR-5100 was significantly up-regulated in CD44+ CD133+ lung cancer stem cells (LCSCs) compared with non-CSCs. Additionally, over-expression of miR-5100 increased CSC properties, cell growth, and tumor sphere formation in lung cancer cell line A549 or H1299, and that miR-5100 inhibitor significantly increased sensitivity of LCSCs to cisplatin in vitro. Surprisingly, the combination with miR-5100 inhibitor significantly decreased the IC50 of LCSCs to cisplatin. Furthermore, miR-5100 increased CSC properties and cisplatin resistance by inhibiting Rab6, a direct target gene of miR-5100. We demonstrated that miR-5100 overexpression increases the cisplatin resistance of the LCSCs through the mitochondrial apoptosis pathway. In conclusion, our results suggest that miR-5100 increases the cisplatin resistance of the LCSCs by inhibiting the Rab6. This study provides novel insight into the regulation of LCSCs by miRNA. cell line (A549,H1299) up-regulated resistant Rab6 Rab6 mitochondrial apoptosis pathway validated 2714 Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun 2018 29170124 miRBase MI0000650 miR-200c miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by transwell invasion assay.Xenograft in vivo assay was uesd to test the role of LUCAT1 . cell line (MG-63, U2OS, HOS and SAOS-2, hFOB) up-regulated resistant ABCB1 ABCB1 LUCAT1/miR-200c/ABCB1 pathway validated 2715 Overexpressed miR-128a enhances chemoradiotherapy to laryngeal cancer cells and its correlation with BMI1. Future Oncol 2018 29186980 miRBase MI0000447 miR-128a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel laryngeal cancer RT-PCR Hep-2 and AMC-HN-8 cell lines were cultured. MiR-128a was upregulated utilizing lentiviral transfection. Through radiotherapy and chemotherapy assays, the function of miR-128a on chemoradiotherapy was evaluated. The correlation of miR-128a with BMI1 was identified by performing real-time PCR. cell line ( Hep-2,AMC-HN8) up-regulated sensitive BMI1 BMI1 NA validated 2716 Overexpressed miR-128a enhances chemoradiotherapy to laryngeal cancer cells and its correlation with BMI1. Future Oncol 2018 29186980 miRBase MI0000447 miR-128a miRNA DB00515 (APRD00359) Cisplatin laryngeal cancer RT-PCR Hep-2 and AMC-HN-8 cell lines were cultured. MiR-128a was upregulated utilizing lentiviral transfection. Through radiotherapy and chemotherapy assays, the function of miR-128a on chemoradiotherapy was evaluated. The correlation of miR-128a with BMI1 was identified by performing real-time PCR. cell line ( Hep-2,AMC-HN8) up-regulated sensitive BMI1 BMI1 NA validated 2717 Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. Biochem Biophys Res Commun 2018 29191657 miRBase MI0003941 miR-761 miRNA DB06589 Pazopanib synovial sarcoma RT-PCR The objective of our study was to elucidate the role of secreted miRNAs to better understand the regulatory network underlying pazopanib-resistance in synovial sarcoma cells. We performed a comprehensive analysis of secreted miRNA abundance in pazopanib treated/untreated synovial sarcoma cells from four different cell lines (SYO-1, HS-SYII, 1273/99, and YaFuSS) using microarray technology, and discovered miR-761 in EVs as a potential biomarker of pazopanib-resistance in synovial sarcoma. Furthermore, we showed that miR-761 putatively targeted three proteins, thyroid hormone receptor interactor 6 (TRIP6), lamin A/C (LMNA), and NAD-dependent protein deacetylase sirtuin-3 (SIRT3). Knockdown of any of these proteins was shown in previous studies to confer increased resistance to chemotherapeutic agents. Our findings provide new insight into the potential role of miR-761, an EV-secreted miRNA from synovial sarcoma cells, making it a potential candidate for use in sarcoma therapy in the future. cell line (SYO-1, HS-SYII, 1273/99, and YaFuSS) up-regulated resistant TRIP6, LMNA, and SIRT3 TRIP6, LMNA, and SIRT3 NA validated 2718 Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling. Cancer Lett 2018 29196128 miRBase MIMAT0004799 miR-589-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR In the study, we report that miR-589-5p is elevated in HCC tissues, which is caused by recurrent gains. Overexpression of miR-589-5p correlates with poor overall and relapse-free survival in HCC patients. Upregulating miR-589-5p enhances spheroid formation ability, fraction of CD133 positive and side population cells, expression of cancer stem cell factors and the mitochondrial potential, and represses the apoptosis induced by doxorubicin in vitro and tumorigenicity in vivo in HCC cells; conversely, silencing miR-589-5p yields an opposite effect. Our findings further demonstrate miR-589-5p promotes the cancer stem cell characteristics and chemoresistance via targeting multiple negative regulators of STAT3 signaling pathway, including SOCS2, SOCS5, PTPN1 and PTPN11, leading to constitutive activation of STAT3 signaling. tissue and cell line ( L02) up-regulated resistant SOCS2, SOCS5, PTPN1 and PTPN11 SOCS2, SOCS5, PTPN1 and PTPN11 STAT3 signaling pathway validated 2719 MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J Urol 2018 29204706 miRBase MI0000242/MI0000281 miR-199a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer RT-PCR MiR-199a expressions in human prostate cancer tissues and cell lines were investigated with real-time PCR (RT-PCR). MiR-199a was ectopically overexpressed in PC3 cells, and resistance to paclitaxel (PTX) was evaluated consequently. The interaction between miR-199a and the oncogene Yamaguchi sarcoma viral homolog 1 (YES1) was assessed after miR-199a overexpression. YES1 was ectopically overexpressed, followed by evaluation of PTX resistance. The efficacy of miR-199a as a therapeutic agent was also investigated in vivo. cell line (PC3, PC3/TRX) down-regulated resistant YES1 YES1 NA validated 2720 LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol 2018 29205703 miRBase MI0000487 miR-193a miRNA DB01234 (APRD00674) Dexamethasone multiple myeloma qPCR The expression levels of miRNA were determined by quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (RPMI8226, JJN-3, U266, ANBL6, OPM-2, MM1S, MM1R) up-regulated sensitive MCL1 MCL1 miR-193a/MCL1 pathway validated 2721 A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition. Acta Pharmacol Sin 2018 29219949 miRBase MI0000650 miR-200c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qPCR The role of miR-200c in human lung cancer A549 cells was detected using qPCR, wound-healing assay,transwell invasion assay, cytotoxicity assay, immunofluorescence staining, and flow cytometry analysis,etc. cell line ( A549, A549/TAX,) down-regulated sensitive NA NA NA validated 2722 miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res 2018 29229605 miRBase MIMAT0000265 miR-204-5p miRNA DB08881 (DB05238) Vemurafenib melanoma RT-qPCR We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-na-ve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth in vivo Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.Significance: Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes. cell line (A375,A375-VR) up-regulated resistant NA NA NA validated 2723 miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res 2018 29229605 miRBase MIMAT0000268 miR-211-5p miRNA DB08881 (DB05238) Vemurafenib melanoma RT-qPCR We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-na-ve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth in vivo Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.Significance: Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes. cell line (A375,A375-VR) up-regulated resistant NA NA NA validated 2724 Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression. Cancer Biol Ther 2018 29261027 miRBase MI0000478 miR-149 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel malignant mesothelioma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (MSTO-211H,A-375, A549,H69,H69AR) up-regulated resistant NA NA NA validated 2725 MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. Biochem Biophys Res Commun 2018 29269300 miRBase MI0000289/MI0000269 miR-181a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The role of miR-181a in human cancer cells was detected using quantitative RT-PCR,CCK-8, western blot analysis,miRNA microarray,transwell assay,luciferase reporter assay, and immunohistochemistry,etc. cell line ( PC9, PC9GR, H1975 and A549 ) up-regulated resistant GAS7 GAS7 AKT/ERK pathway validated 2726 microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-kappaB signaling. Biomed Pharmacother 2018 29287202 miRBase MI0000789 miR-381 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR In this study, we investigated the role of miR-381 in proliferation, tumorigenesis, and cisplatin resistance of NSCLC cells. The effects of miR-381 overexpression on proliferation, tumorigenesis, cell cycle progression, and cisplatin sensitivity were examined. Overexpression of miR-381 significantly inhibited cell proliferation and colony formation in vitro and tumorigenesis in vivo. Ectopic expression of miR-381 arrested NSCLC cells at G0/G1 phase, which was accompanied by increased expression of p21 and p27 and decreased expression of cyclin D1 and CDK4. Compared to A549 parental cells, cisplatin-resistant equivalents (A549/CDDP) had reduced levels of miR-381. miR-381 re-sensitized A549/CDDP cells to cisplatin and potentiated cisplatin-induced apoptosis. Mechanistically, miR-381 interfered with the activation of nuclear factor (NF)-kappaB through repression of inhibitor of differentiation 1 (ID1). Co-expression of ID1 reversed the suppression of proliferation and enhancement of cisplatin cytotoxicity by miR-381. Taken together, miR-381 can induce growth suppression and chemosensitization in NSCLC, largely through inactivation of NF-kappaB via downregulation of ID1. Restoration of miR-381 represents a potential therapeutic strategy for NSCLC. cell line (A549,A549/CDDP, NCI-H460) up-regulated sensitive ID1 ID1 NF-kappaB pathway validated 2727 Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16. Oncol Res 2018 29295721 miRBase NA miR-135 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The study aimed to explore the functional role of microRNA (miR)-135 in the sensitivity to gefitinib of NSCLC cells. Expression of miR-135 in normal cells and NSCLC cells was assessed, followed by the effects of abnormally expressed miR-135 on cell viability, migration, invasion, apoptosis, sensitivity to gefitinib, and the expression levels of adhesion molecules and programmed death ligand 1 (PD-L1) in H1650 and H1975 cells. Next, the possible target gene of miR-135 was screened and verified. Finally, the potential involvement of the JAK/STAT signaling pathway was investigated. Expression of miR-135 was upregulated in NSCLC cells, and miR-135 silencing repressed cell viability, migration, and invasion, but increased cell apoptosis and sensitivity to gefitinib. E-cadherin and Beta-catenin were significantly upregulated, but PD-L1 was downregulated by the silencing of miR-135. Subsequently, tripartite-motif (TRIM) 16 was screened and verified to be a target gene of miR-135, and miR-135 suppression was shown to function through upregulation of TRIM16 expression. Phosphorylated levels of the key kinases in the JAK/STAT pathway were reduced by silencing miR-135 by targeting TRIM16. In conclusion, miR-135 acted as a tumor promoter, and its suppression could improve sensitivity to gefitinib by targeting TRIM16 and inhibition of the JAK/STAT pathway. cell line ( WI-38, A549, H1650, H1975, H157,and H4006) up-regulated sensitive TRIM16 TRIM16 JAK/STAT signaling pathway validated 2728 The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis 2018 29305580 miRBase MI0003134 miR-494 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qPCR, RT-sqPCR In the study, we identified miR-494 upregulation in a subgroup of human and rat HCCs with stem cell-like characteristics, as well as multiple epigenetic mechanisms involved in its aberrant expression in HCC cell lines and patients. Moreover, we identified p27, puma and pten among miR-494 targets, contributing to speed up cell cycle progression, enhance survival potential in stressful conditions and increase invasive and clonogenic capabilities. MiR-494 overexpression increased sorafenib resistance via mTOR pathway activation in HCC cell lines and, in line, high miR-494 levels associated with decreased sorafenib response in two HCC animal models. A sorafenib-combined anti-miR-494-based strategy revealed an enhanced anti-tumor potential with respect to sorafenib-only treatment in our HCC rat model. In conclusion, our findings suggested miR-494 as a possible therapeutic target as well as a candidate biomarker for patient stratification in advanced HCC. cell line up-regulated resistant p27, pten, and puma p27, pten, and puma mTOR signaling pathway validated 2729 MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 2018 29323124 miRBase MI0005118 miR-770 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In this study, we aimed to determine the role of miR-770 in the regulation of chemo-resistance and metastasis of TNBC. Clinically, miR-770 was highly expressed in chemo-sensitive tissues and predicted a better prognosis of TNBC. Functionally, ectopic expression of miR-770 suppressed the doxorubicin-resistance of TNBC cell lines via regulation of apoptosis and tumor microenvironment, which was mediated by exosomes. Moreover, miR-770 overexpression inhibited the migration and invasion. Rescue of STMN1 could partly reverse the effect of miR-770 in TNBC behaviors. Furthermore, we also demonstrated that overexpression of miR-770 inhibited DOX resistance and metastasis in vivo. Taken together, our results proved that miR-770 could suppress the doxorubicin-resistance and metastasis of TNBC cells, which broaden our insights into the underlying mechanisms in chemo-resistance and metastasis, and provided a new prognostic marker for TNBC cells. cell line (MDA-MB-231 and MDA-MB-468) up-regulated sensitive STMN1 STMN1 NA validated 2730 Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Arch Gynecol Obstet 2018 29327155 miRBase MI0003188 miR-503 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR To investigate the relationship between miR-503 expression and the sensitivity of ovarian cancer cells to cisplatin, the cells were transfected with miR-503 mimics/inhibitors. The relative expression of miR-503 RNA and its targeted gene PI3K mRNA were detected by real-time PCR (RT-PCR). Western blot was used to measure relevant protein levels. Flow cytometry and CCK-8 assay were used to analyze cell proliferation and apoptosis. cell line (SKOV3,SKOV3/DDP) down-regulated resistant PI3K PI3K PI3K/AKT signaling pathway validated 2731 miR-378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRBeta and c-Raf. Mol Med Rep 2018 29328399 miRBase MI0000786 miR-378a miRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer RT-qPCR The present study investigated the link between microRNA-378a (miR-378a) expression and the sensitivity of hepatocellular carcinoma (HCC) and hepatoblastoma (HB) cancers to sorafenib therapy. miR-378a expression was determined in liver tissue samples from healthy candidates and patients with liver cancer using the reverse transcription-quantitative polymerase chain reaction. The antitumor effects of miR-378a alone and in combination with sorafenib were investigated in the HB cell line HepG2 and the HCC cell line SMMC-7721 with methyl thiazoyl tetrazolium, colony formation, flow cytometry and Transwell migration assays. The underlying mechanisms were investigated using western blot analysis. miR-378a expression was decreased in tissue samples from patients with liver cancer. HCC and HB cell line proliferation and invasion ability was inhibited by miR-378a. The combination of miR-378a and sorafenib provided the greatest inhibition. Western blot indicated that mitogen activated protein kinase signaling pathway proteins, vascular endothelial growth factor receptor, platelet derived growth factor receptor Beta, Raf-1 proto-oncogene, serine/threonine kinase and matrix metallopeptidase 2 were regulated by miR-378a alone and to a greater extent when combined with sorafenib. cell line (HepG2 and SMMC-7721) down-regulated sensitive VEGFR, PDGFRBeta and c-Raf VEGFR, PDGFRBeta and c-Raf NA validated 2732 miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Int J Mol Med 2018 29328427 miRBase MI0000822 miR-133b miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-qPCR The objective of the present study was to explore the role of miR-133b and its mechanism in the regulation of cisplatin resistance and tumor progression in cisplatin-resistant non-small cell lung cancer (NSCLC) cells. Reverse transcription-quantitative polymerase chain reaction and western blot assays of the cisplatin-resistant cell lines A549/DPP and H1299/DDP displayed the reduced expression of miR-133b and increased expression of glutathione-S-transferase P1 (GSTP1) in the resistant cells compared with the respective parental cell lines A549 and H1299. Cell Counting kit-8, flow cytometry, colony formation and Transwell migration assays indicated that the overexpression of miR-133b increased the chemosensitivity to cisplatin and attenuated the proliferation and migration capacities of the cisplatin-resistant NSCLC cell lines in vitro. A dual-luciferase reporter assay demonstrated that miR-133b negatively regulated the expression of GSTP1 by targeting its 3-untranslated region. In addition, the knockdown of GSTP1 by transfection with small interfering RNA exerted similar effects on cell chemosensitivity, proliferation and migration as did ectopic miR-133b expression, in addition to the upregulation of Bax and downregulation of Bcl-2, survivin and matrix metalloproteinase expression. In conclusion, the present study findings provide the insights that miR-133b reduces cisplatin resistance and its overexpression contributes to the suppression of the malignant growth and aggressiveness of cisplatin-resistant NSCLC cells by targeting GSTP1. This could potentially be exploited as a novel therapeutic strategy for the reversal of cisplatin resistance. cell line (A549, H1299,A549/DDP,H1299/DDP) up-regulated sensitive GSTP1 GSTP1 NA validated 2733 Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis. Int J Mol Med 2018 29328428 miRBase MI0003662 miR-647 miRNA DB00541 (APRD00495) Vincristine stomach cancer RT-qPCR The expression of miR-647 in GC tissues and SGC7901/VCR cell line (drug resistance to vincristine) was detected by qRT-PCR. The effect of overexpression of miR-647 on drug resistance was evaluated by measuring the half maximal inhibitory concentration (IC50) value of SGC-7901/VCR to vincristine and tumor growth in vivo. Moreover, drug-induced cell apoptosis and cell cycle were evaluated by flow cytometry, as well as the ability of cell migration and invasiveness detected by wound healing and transwell assay. Furthermore, underlying targets of miR-647 were predicted by TargetScan and MicroRNA; meanwhile, the expression of ANK2, FAK, MMP2, MMP12,CD44,SNAIL1 were observed by qRT-PCR and western blot analysis. The present study established that the expression levels of miR-647 were downregulated in GC tissues from patients with metastasis and in the vincristine-resistant SGC7901 (SGC-7901/VCR) GC cell line. The IC50 value for vincristine was significantly decreased, whereas the proportion of cells in G0/G1 phase and the drug-induced apoptotic rate were significantly increased following upregulation of miR-647. Furthermore, the results demonstrated that miR-647 overexpression led to decreased migration and invasion of SGC-7901/VCR cells. Overexpression of miR-647 was also demonstrated to sensitize tumors to chemotherapy in vivo. In addition, miR-647 overexpression was able to reduce the expression levels of ankyrin-B, focal adhesion kinase, matrix metalloproteinase (MMP)2, MMP12, cluster of differentiation 44 and snail family transcriptional repressor 1. tissue and cell line (SGC7901,SGC7901/VCR) up-regulated sensitive NA NA NA validated 2734 miR-214 reduces cisplatin resistance by targeting netrin-1 in bladder cancer cells. Int J Mol Med 2018 29328435 miRBase MI0000290 miR-214 miRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-qPCR The present study aimed to clarify the biological function of miR-214 and potential mechanisms in chemoresistance of bladder cancer cells. Reverse transcription-quantitative polymerase chain reaction demonstrated that miR-214 was downregulated in bladder cancer tissues compared with the level in normal tissues. miR-214 was downregulated in bladder cancer cell lines compared with the level in the normal cell line SV-HUC-1. miR-214 mimics were transfected into T24 and J82 cell lines to restore its expression. The results indicated that miR-214 mimic inhibited proliferation and invasion in these cell lines. In addition, miR-214 mimic reduced cisplatin resistance in T24 and J82 cells, indicated by the inhibition of cell viability and upregulation of cell apoptosis. Western blotting demonstrated that miR-214 mimic was able to upregulate cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP), while downregulate caspase-3 and PARP expression, and AKT phosphorylation. Using prediction software, it was revealed that the netrin-1 oncoprotein is on the target list of miR-214. miR-214 also downregulated netrin-1 protein and mRNA expression levels in the T24 and J82 cell lines. Luciferase reporter assays demonstrated that netrin-1 acted as a direct target of miR-214. A negative correlation between netrin-1 and miR-214 expression in bladder cancer tissues was also observed. In addition, cisplatin treatment could induce netrin-1 protein expression in bladder cancer cells and miR-214 mimic partly blocked this phenomenon. Netrin-1 plasmid transfection inhibited cisplatin-induced apoptosis, upregulated AKT phosphorylation, and downregulated caspase-3 and PARP cleavage. Netrin-1 was restored in cells transfected with miR-214 mimic using plasmid transfection. Netrin-1 transfection restored AKT phosphorylation and blocked caspase/PARP cleavage in the T24 and J82 cell lines. In conclusion, the present study demonstrated that miR-214 is downregulated in bladder cancer tissues and cell lines. miR-214 reduces chemoresistance by targeting netrin-1 in bladder cancer cell lines. cell line (SV-HUC-1, RT-4, J82 and T24 ) up-regulated sensitive netrin-1 netrin-1 NA validated 2735 MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer 2018 29329575 miRBase MI0000737 miR-200a miRNA DB00441 (APRD00201) Gemcitabine breast cancer qRT-PCR Breast cancer cells transfected with mimic or inhibitor for miR-200a was assayed for chemoresistance in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR) in breast cancer patients treated with preoperative chemotherapy. Luciferase assays, cell proliferation assay were performed to identify the targets of miR-200a and the mechanism by which it promotes treatment resistance. Survival analysis was used to evaluate the prognosis value of miR-200a. cell line (MDA-MB-23,MDA-MB-436,MDA-MB-453,BT-549,ZR-75-1,ZR-75-30,T47D,MCF-7,SK-BR-3,MCF-10A) down-regulated sensitive TP53INP1 and YAP1 TP53INP1 and YAP1 NA validated 2736 Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep 2018 29339789 miRBase MI0000681 miR-155 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer PCR In this study, we reported the relevance of miR-155 upregulation in chemoresistant cells associated with EMT. Notably, we found miR-155 induction in exosomes isolated from CSCs and resistant cells, followed by resistant cells¡¯ exosome transfer to the recipient sensitive cells. Functionally, miR-155 mimic assay showed an enrichment in miR-155 from exosome concomitant with miR-155 exosome transfer to breast cancer cells. In parallel to these effects, we also observed EMT change in miR-155 transfected cells. The chemoresistance phenotype transfer to sensitive cells and the migration capability was analyzed by MTT and scratch assays and our results suggest that exosomes may intermediate resistance and migration capacity to sensitive cells partly through exosome transfer of miR-155. cell line (MCF-7 and MDA-MB-231 ) up-regulated resistant NA NA NA validated 2737 Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep 2018 29339789 miRBase MI0000681 miR-155 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer PCR In this study, we reported the relevance of miR-155 upregulation in chemoresistant cells associated with EMT. Notably, we found miR-155 induction in exosomes isolated from CSCs and resistant cells, followed by resistant cells¡¯ exosome transfer to the recipient sensitive cells. Functionally, miR-155 mimic assay showed an enrichment in miR-155 from exosome concomitant with miR-155 exosome transfer to breast cancer cells. In parallel to these effects, we also observed EMT change in miR-155 transfected cells. The chemoresistance phenotype transfer to sensitive cells and the migration capability was analyzed by MTT and scratch assays and our results suggest that exosomes may intermediate resistance and migration capacity to sensitive cells partly through exosome transfer of miR-155. cell line (MCF-7 and MDA-MB-231 ) up-regulated resistant NA NA NA validated 2738 miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling. Biomed Pharmacother 2018 29353201 miRBase MI0000284 miR-204 miRNA DB00002 (BTD00071, BIOD00071) Cetuximab head and neck squamous cell carcinoma qRT-PCR This study aims to investigate the roles of miR-204 in tumor angiogenesis of head and neck squamous cell carcinoma (HNSCC). Here, we found that miR-204 level was reduced in HNSCC tissues relative to that in normal adjacent tissues. Overexpression of miR-204 promoted tumor angiogenesis in HNSCC cells. Mechanistically, JAK2 was identified as a direct target of miR-204, and miR-204 overexpression blocked JAK2/STAT3 pathway. Moreover, overexpression of JAK2 attenuated the inhibition of miR-204 on tumor angiogenesis of HNSCC. Furthermore, overexpression of miR-204 enhanced sensitivity of cetuximab in HNSCC cells, this effect was attenuated by JAK2 overexpression too. Importantly, JAK2 expression was negatively correlated with miR-204 level in HNSCC tissues. Therefore, miR-204 acts as a tumor suppressor by blocking JAK2/STAT3 pathway in HNSCC cells. cell line (5-8 F and 5-8 F-CT) up-regulated sensitive JAK2 JAK2 JAK2/STAT3 pathway validated 2739 miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA. Cancer Biomark 2018 29355113 miRBase MI0000268 miR-34 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-PCR In our study, we examined whether overexpression of miR-34 could sensitize gemcitabine -mediated apoptosis in human pancreatic cancer PANC-1 cells. We found that miR-34 markedly induced gemcitabine -mediated apoptosis in PANC-1 cells. miR-34 induced down-regulation of Slug expression and upregulation of p53 up-regulated modulator of apoptosis (PUMA) expression. The over-expression of Slug or downregulation of PUMA by Slug cDNA or PUMA siRNA transfection markedly blocked miR-34-induced gemcitabine sensitization. Furthermore, miR-34 induced PUMA expression by downregulation of Slug. Taken together, our study demonstrates that miR-34 enhances sensitization against gemcitabine-mediated apoptosis through the down-regulation of Slug expression, and up-regulation of Slug-dependent PUMA expression. cell line (ATCC CRL-1469) up-regulated sensitive NA NA Slug-PUMA pathway validated 2740 miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling. DNA Cell Biol 2018 29364705 miRBase MIMAT0003330 miR-654-5p miRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma RT-PCR This study was aimed at clarifying the effect of miR-654-5p on progression of OSCC. miR-654-5p promoted proliferation, metastasis, and chemoresistance of OSCC in vitro and in vivo. Consistently, miR-654-5p was upregulated in late-stage OSCC and was correlated with poor prognosis of OSCC patients. Furthermore, miR-654-5p was mechanistically verified to target Grb-2-related adaptor protein (GRAP), accompanied by the activation of Ras/MAPK signaling and the facilitation of epithelial-mesenchymal transition in OSCC cells. GRAP was downregulated in T1-2 stage versus T3-4 stage head and neck squamous cell carcinoma (HNSC) and was negatively correlated with tumor-node-metastases (TNM) stage in HNSC patients based on The Cancer Genome Atlas (TCGA) analysis. In addition, GRAP was positively correlated with good prognosis in HNSC patients. Our findings suggest that the miR-654-5p/GRAP/Ras/Erk signaling pathway in OSCC cells might contribute to the underlying mechanism through which miR-654-5p participates in the regulation of OSCC progression. miR-654-5p, as a potential biomarker for the clinical diagnosis and prognosis of OSCC, may be an effective anticancer target for the treatment of OSCC. cell line (Tca-8113 and CAL-27) down-regulated resistant GRAP GRAP Ras/MAPK Signaling validated 2741 miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling. DNA Cell Biol 2018 29364705 miRBase MIMAT0003330 miR-654-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil oral squamous cell carcinoma RT-PCR This study was aimed at clarifying the effect of miR-654-5p on progression of OSCC. miR-654-5p promoted proliferation, metastasis, and chemoresistance of OSCC in vitro and in vivo. Consistently, miR-654-5p was upregulated in late-stage OSCC and was correlated with poor prognosis of OSCC patients. Furthermore, miR-654-5p was mechanistically verified to target Grb-2-related adaptor protein (GRAP), accompanied by the activation of Ras/MAPK signaling and the facilitation of epithelial-mesenchymal transition in OSCC cells. GRAP was downregulated in T1-2 stage versus T3-4 stage head and neck squamous cell carcinoma (HNSC) and was negatively correlated with tumor-node-metastases (TNM) stage in HNSC patients based on The Cancer Genome Atlas (TCGA) analysis. In addition, GRAP was positively correlated with good prognosis in HNSC patients. Our findings suggest that the miR-654-5p/GRAP/Ras/Erk signaling pathway in OSCC cells might contribute to the underlying mechanism through which miR-654-5p participates in the regulation of OSCC progression. miR-654-5p, as a potential biomarker for the clinical diagnosis and prognosis of OSCC, may be an effective anticancer target for the treatment of OSCC. cell line (Tca-8113 and CAL-27) down-regulated resistant GRAP GRAP Ras/MAPK Signaling validated 2742 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 miRBase MI0000292 miR-216a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma RT-qPCR The role of HOTTIP and miR-216a in small cell lung cancer cells was detected using RT-qPCR, western blot analysis , IHC staining analysis , immunofluorescence analysis , in vitro chemosensitivity assay , apoptosis analysis , luciferase reporter assay and RNA immunoprecipitation (RIP) assay,etc. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive NA NA NA validated 2743 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 miRBase MI0000292 miR-216a miRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma RT-qPCR The role of HOTTIP and miR-216a in small cell lung cancer cells was detected using RT-qPCR, western blot analysis , IHC staining analysis , immunofluorescence analysis , in vitro chemosensitivity assay , apoptosis analysis , luciferase reporter assay and RNA immunoprecipitation (RIP) assay,etc. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive NA NA NA validated 2744 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 miRBase MI0000292 miR-216a miRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma RT-qPCR The role of HOTTIP and miR-216a in small cell lung cancer cells was detected using RT-qPCR, western blot analysis , IHC staining analysis , immunofluorescence analysis , in vitro chemosensitivity assay , apoptosis analysis , luciferase reporter assay and RNA immunoprecipitation (RIP) assay,etc. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive NA NA NA validated 2745 Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma. Indian J Clin Biochem 2018 29371766 miRBase MI0000442 miR-122 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma qRT-PCR The present study investigated whether restoration of miR-122 in HCC cells could alter the cell cycle distribution and the expression of multidrug resistance (MDR)-related genes (ABCB1, ABCC1, ABCG2 and ABCF2). After overexpression of miR-122 in HepG2 cells treated or untreated with doxorubicin doses, total RNAs and protein extracts were isolated for application of QRT-PCR and western blotting techniques. Moreover, cell cycle distribution was monitored by flow cytometry. Our results revealed that, the over expression of miR-122 in HepG2 cells treated or untreated with doxorubicin could modulate the sensitivity of cells to chemotherapeutic drug through downregulation of MDR-related genes, ABCB1 and ABCF2. Interpretation of cell cycle distribution revealed that, the anti-proliferative effect of miR-122 is associated with the accumulation of cells in G0/G1 phase. Moreover, treatment with miR-122 and doxorubicin resulted in high percentage of HCC cells in G0/G1 phase. Taken together, our findings revealed that, overexpression of miR-122 inhibited HCC cell growth by inducing cell cycle arrest and this arrest is associated with down-regulation of MDR-related genes. cell line (HepG2) up-regulated sensitive ABCB1,ABCF2 ABCB1,ABCF2 NA validated 2746 miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med 2018 29375703 miRBase NA miR-30 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-sqPCR In the present study, the expression of miR-30a and its effects in cisplatin (CDDP)-resistant human gastric cancer cells were investigated. A CDDP-resistant variant of the SGC-7901 cell line (SGC-7901/CDDP) was established by exposing the cells to gradually increasing drug concentrations, and miR-30a expression was detected by reverse transcription-semi quantitative polymerase chain reaction (RT-sqPCR). To examine the effect of miR-30a expression in the SGC-7901/CDDP cells, miR30a mimics or negative control miRNA were transfected into the cells, and a Cell Counting Kit-8 assay was performed to analyze the chemosensitivity of the different cell groups. RT-sqPCR and western blot analysis were also used to measure MDR1 mRNA and P-glycoprotein expression, and the light chain (LC)3-II/LC3-I ratio. Furthermore, apoptosis induced by the chemotherapeutic CDDP in the different groups was assessed using flow cytometry. The results demonstrated that low expression of miR-30a was associated with chemoresistance in gastric cancer cells, and in the chemoresistant cell line SGC7901/CDDP, CDDP-induced apoptosis was weakened. Additionally, it was demonstrated that the LC3-II/LC3-I ratio was elevated in SGC7901/CDDP cells compared with chemosensitive SGC7901 cells (P<0.001), which could be attenuated by upregulating miR-30a expression (P<0.001 vs. SGC7901/CDDP control cells). These results suggested that autophagy may contribute to drug resistance in gastric cancer cells, and that the reduction of LC3-II in response to miR-30a overexpression may inhibit chemoresistance-associated autophagy in gastric cancer cells. cell line (SGC-7901) down-regulated resistant NA NA NA validated 2747 miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1. Oncol Res 2018 29386087 miRBase MI0000452/MI0000453 miR-135a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The aim of the present study was to reveal the role of miR-135a in gefitinib resistance of NSCLC cells. Human NSCLC cell lines, NCI-H1650 and NCI-H1975, were transfected with miR-135a mimic/inhibitor or miR-135a inhibitor plus pEX-RAC1 (a RAC1-expressing vector). The effects of miR-135a and RAC1 expression on cell viability, apoptosis, migration, and invasion were then detected. The transfected cells were exposed to 0-20 uM gefitinib, and cell viability was then detected at 48 h posttreatment. Western blot analysis was performed to detect the expression changes of main factors in the PI3K/AKT pathway. miR-135a overexpression promoted viability, migration, and invasion, but inhibited apoptosis of NCI-H1650 and NCI-H1975 cells. Cell viability was significantly reduced by gefitinib, and the LC50 values of gefitinib in NCI-H1650 and NCI-H1795 cells were 0.845 and 0.667 uM, respectively. miR-135a overexpression could increase cell viability even under high concentrations of gefitinib. Rac1 was not predicted as a target of miR-135a, while miR-135a could upregulate the expression of RAC1. miR-135a promoted cell growth and metastasis and activated the PI3K/AKT signaling pathway via a RAC1-dependent manner. To conclude, this study demonstrated that miR-135a confers NSCLC cell resistance to gefitinib via upregulation of RAC1. Therapies designed to downregulate miR-135a may help NSCLC patients to overcome gefitinib resistance. cell line ( NCI-H1650 and NCI-H1795 ) up-regulated resistant NA NA PI3K/AKT signaling pathway validated 2748 miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med 2018 29393355 miRBase MIMAT0000076 miR-21-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer RT-qPCR The present study investigated the roles of microRNA (miR)-21-5p in the doxorubicin (DOX) resistance of GC cells and the underlying mechanisms. miR-21-5p expression levels were identified to be inversely correlated with two well-known tumor suppressor genes, phosphatase and tensin homologue and tissue inhibitor of matrix metalloproteinases 3, and were upregulated in GC cell lines in proportion to their degree of resistance. Suppressing miR-21-5p expression partially sensitized SGC7901/DOX cells to DOX, suggesting that knockdown of miR-21-5p expression may be used as a therapeutic strategy to improve GC cell resistance. Importantly, increased miR-21-5p expression levels at diagnosis were correlated with clinicopathological characteristics including advanced stage and poor prognosis, further implying that a relapse of GC may be a consequence of miR-21-5p upregulation, thus providing evidence for the potential utility of miR-21-5p antagonism to sensitize GC cells to DOX chemotherapy. cell line (SGC7901,HEK-293T,SGC7901/DOX,) down-regulated sensitive PTEN and TIMP3 PTEN and TIMP3 NA validated 2749 miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway. Int J Oncol 2018 29393390 miRBase MIMAT0000450 miR-149-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR In this study, we report that miR-149-5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. Furthermore, the silencing of miR-149-5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin in vitro and in vivo. Conversely, the upregulation of miR-149-5p aggravated chemoresistance in ovarian cancer cells. Our results further revealed that miR-149-5p directly targeted the core kinase components of the Hippo signaling pathway, STE20-like kinase (MST)1 and protein salvador homolog 1 (SAV1), resulting in the inactivation of TEA domain (TEAD) transcription. On the whole, our findings reveal a novel mechanism of of action miR-149-5p in inducing chemotherapeutic resistance in ovarian cancer, indicating that miR-149-5p may serve as a chemotherapeutic response indicator and a potential therapeutic target in ovarian cancer. cell line (TOV-21G, A2780, OVCAR-3, Caov-3, ES-2, HO-8910 and SK-OV-3) up-regulated resistant MST1 and SAV1 MST1 and SAV1 Hippo signaling pathway validated 2750 Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug. PLoS One 2018 29394261 miRBase MI0000069 miR-15a miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR In the study, we have shown that knock-down of BMI1 increases the expression of tumor-suppressivemiRNAs. Elevated levels of expression of miR-200a, miR-200b, miR-15a, miR-429, miR-203 were observed upon knock-down of BMI1. Up-regulation of these miRNAsleads to down-regulation ofPRC1 group of proteins i.e. BMI1, RING1A, RING1B and Ub-H2A. Interestingly, overexpression of miR-200a, miR-200b and miR-15aalso produced decreased BMI1 and Ub-H2A protein expression in the CD44+ Cancer Stem Cellpopulation of MDAMB-231cells. Also,elevating the levels of BMI1 regulated miRNAspromoted Mesenchymal to Epithelial transition by regulating the expression of N-Cadherin, Vimentin, Beta-Catenin, Zeb, Snail thereby resulting in decreased invasion, migration and proliferation. Here, we also report that miR-200a, miR-200b, miR-203 accretes the sensitivity of MDAMB-231 cells to the histone deacetylase inhibitor (HDACi) SAHA and miR-15a sensitized breast cancer cells to the chemotherapeutic drug cisplatin leading to apoptosis. These findings suggest that modulatingspecific miRNAs may serve as a therapeutic approach for the treatment of breast cancer cell line (BT549, MDAMB-231, BT549, MDAMB-231) up-regulated sensitive BMI1 BMI1 NA validated 2751 Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Cancer Chemother Pharmacol 2018 29397407 miRBase MI0000266 miR-10a miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression of TUSC7 was detected by quantitative real-time PCR. CCK-8 assay was used to detect cell proliferation ability and chemosensitivity. Flow cytometry were used to detect cell cycle and cell apoptosis. The expression of MDR1 protein was examined by western blot. RNA pull-down assay was applied to confirm the specific combination between TUSC7 and miR-10a. cell line ( U87TR ) up-regulated resistant NA NA NA validated 2752 MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib. Oncol Lett 2018 29399158 miRBase MI0000651/ MI0000437 miR-1 miRNA DB00317 (APRD00997, DB07998) Gefitinib esophageal squamous cell carcinoma RT-qPCR The present study investigated the role of miR-1 and its association with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit (PIK3CA) in the pathophysiology of esophageal squamous cell carcinoma (ESCC), and analyzed the effects of miR-1 inhibitor or mimics on sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitors, the alterations of cell cycle distribution and apoptosis in ESCC cells. Compared with normal tissues, the level of miR-1 expression was significantly lower and PIK3CA expression was higher in ESCC tissues. The level of miR-1 expression was also inversely associated with the level of PIK3CA mRNA expression. Low miR-1 and high PIK3CA expression levels were strongly associated with lymph node metastasis, and the level of miR-1 expression was negatively associated with clinical Tumor-Node-Metastasis stage. Furthermore, exogenous expression of miR-1 inhibited growth, arrested cell cycle in the G1 phase and increased apoptosis in ESCC cells, whereas it decreased PIK3CA protein expression levels. Furthermore, overexpression of miR-1 increased the sensitivity of ESCC cells to the anticancer drug, gefitinib. A possible mechanism for this increased sensitivity to gefitinib may be inactivation of the PIK3CA signaling pathway. cell line (TE-1) up-regulated sensitive NA NA PI3K/Akt/survivin signaling pathway validated 2753 Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun 2018 29408336 miRBase MI0000072 miR-18a miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR The role of UCA1and miR-18a in breast cancer cells was detected using qRT-PCR, western blot analysis, CCK-8 assay, Biotin-RNA pull-down assay, apoptosis assay and matrigel invasion analysis,etc. cell line ( SKBR-3) up-regulated sensitive YAP1 YAP1 NA validated 2754 miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis 2018 29416005 miRBase MIMAT0000419 miR-27b-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR By a system approach, we identified that microRNA-27b-3p (miR-27b), a miRNA deleted in breast cancer tissues and cell lines, has a master role in sensitizing breast cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Mechanistic analysis indicated that miR-27b enhanced responses to PTX by directly targeting CBLB and GRB2 to inactivate both PI3K/Akt and MAPK/Erk signaling pathways. Further, miR-27b was identified as a promising molecular biomarker in chemoresistance, clinicopathological features, and prognosis for breast cancer patients. tissue and cell line (Bads-200,BCap37) up-regulated sensitive CBLB,GRB2 CBLB,GRB2 PI3K/Akt and MAPK/Erk signaling pathway validated 2755 MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. Gene 2018 29427737 miRBase MIMAT0000250 miR-139-5p miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma qPCR The aim of this study was to investigate the ability of miR-139-5p to influence the cisplatin resistance, apoptosis, invasion and migration in NPC cells through the regulation of the EMT. We investigated these processes in parental HNE1 and cisplatin-resistant HNE1/DDP cells transfected with miR-139-5p inhibitors and mimics, respectively. Our results suggest that the upregulation of miR-139-5p expression inhibits proliferation, invasion, migration and EMT in human NPC cells. In addition, we found that miR-139-5p expression levels and DDP-induced apoptosis positively correlate in NPC cells. In conclusion, our results demonstrate that miR-139-5p can regulate the migration, invasion and DDP resistance in human NPC by modulating the EMT. The regulation of miR-139-5p levels might be a new approach to reverse EMT and DDP resistance and counteract metastasis and chemotherapy resistance in human NPC. cell line up-regulated sensitive NA NA NA validated 2756 miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem Biophys Res Commun 2018 29432736 miRBase MI0000300 miR-223 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qPCR In the present study, miR-223 expression was down-regulated in OS tissues and cell lines; miR-223 overexpression enhanced the cellular effects of cisplatin (CDDP) on OS cell lines. Through binding to the HSPA1A 3UTR, miR-223 could regulate Hsp70 protein levels and downstream JNK/JUN signaling pathway, thus modulating OS cell apoptosis through Hsp70 under CDDP stress. Finally, JUN, a downstream transcription factor of JNK signaling, could bind to the promoter region of miR-223 to promote its transcription. In summary, miR-223, Hsp70 and downstream JNK/JUN formed a feedback loop to modulate the chemoresistance of OS to CDDP. cell line (Saos2, U2OS, HOS, MG63,SJSA-1, SK-ES-1,hFOB) up-regulated sensitive Hsp70 Hsp70 JNK signaling pathway validated 2757 miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett 2018 29434858 miRBase MI0000446/MI0000470 miR-125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR MircroRNAs (miRNAs) are considered as essential regulators in the tumorigenesis and chemoresistance of multiple cancer types. In the present study, it was demonstrated that the expression levels of miR-125b were significantly downregulated in the tissues of patients with breast cancer (BC), as well as the BC cell lines in vitro. To study the association between chemoresistance and miR-125b in BC, doxorubicin (DOX)-resistant MCF-7 (MCF-7/R) cells were established, and gain- and loss-of-function experiments were performed. It was demonstrated that the overexpression of miR-125b increased the sensitivity of MCF-7/R cells to DOX. Furthermore, it was revealed that the sensitization of miR-125b mimics to DOX-induced cell death was regulated by the hematopoietic cell-specific protein 1-associated protein X-1 (HAX-1) vector and HAX-1 small interfering RNA. These results emphasized the notable function of miR-125b and its target of HAX-1 in regulating DOX-resistance. In addition, it was demonstrated that the miR-125b mimics promoted the loss of the mitochondrial membrane potential and the generation of reactive oxygen species induced by DOX treatment in MCF-7/R cells. These data suggest that the miR-125b-HAX-1-mitochondria pathway has a notable function in the treatment of DOX-resistant BC cells, which may provide a novel target for the chemotherapy of BC. cell line (MCF-7, MDA-MB-231, T-47D,MCF-10A) up-regulated sensitive HAX-1 HAX-1 miR-125b/HAX-1 signaling pathway validated 2758 miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol Rep 2018 29436681 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The aim of the present study was to investigate the function and mechanism of miR-199a-3p in the CDDP resistance in ovarian cancer. We found that miR-199a-3p was significantly downregulated in chemoresistant ovarian cancer tissues, as well as CDDP-resistant SKOV3/CDDP cells, compared to chemosensitive carcinomas and SKOV3 cells. Restoration of miR-199a-3p in SKOV3/CDDP cells reduced cell proliferation, G1 phase cell cycle arrest, cell invasion, and increased cell apoptosis, resulting in enhanced CDDP sensitivity, while miR-199a-3p inhibition resulted in the opposite effects. Luciferase reporter assay showed that integrin Beta8 (ITGB8), one of the integrins that is involved in the regulation of cell cycle and motility, was a direct target of miR-199a-3p. Overexpression of miR-199a-3p downregulated ITGB8 expression via binding to its 3-UTR. In addition, overexpression of ITGB8 restored CDDP resistance inhibited by miR-199a-3p. Moreover, orthotopic ovarian cancer mouse model showed that miR-199a-3p enhanced CDDP sensitivity of ovarian cancer in vivo. Therefore, our results indicate that miR-199a-3p enhances CDDP sensitivity of ovarian cancer cells through downregulating ITGB8 expression, and miR-199a-3p may serve as a therapeutic target for the treatment of ovarian cancer patients with CDDP-resistance. cell line (SKOV3,SKOV3/CDDP) up-regulated sensitive ITGB8 ITGB8 NA validated 2759 Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance. Cancer Sci 2018 29450946 miRBase MI0000076 miR-20a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The present study revealed that LRIG1 was overexpressed in chemosensitive GC tissues and decreased expression of LRIG1 predicted poor survival in GC patients. We observed that upregulation of LRIG1 enhanced chemosensitivity in GC cells. Interestingly, miR-20a, which was overexpressed in GC MDR cell lines and tissues, was identified to regulate LRIG1 expression by directly targeting its 3 untranslated region. We also found that inhibition of miR-20a suppressed GC MDR, and upregulation showed opposite effects. Moreover, we demonstrated that the miR-20a/LRIG1 axis regulated GC cell MDR through epidermal growth factor receptor (EGFR)-mediated PI3K/AKT and MAPK/ERK signaling pathways. Finally, LRIG1 expression in human GC tissues is inversely correlated with miR-20a and EGFR. cell line (SGC7901,SGC7901/VCR and SGC7901/ADR ) up-regulated resistant LRIG1 LRIG1 PI3K/AKT and MAPK/ERK signaling pathway validated 2760 Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance. Cancer Sci 2018 29450946 miRBase MI0000076 miR-20a miRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The present study revealed that LRIG1 was overexpressed in chemosensitive GC tissues and decreased expression of LRIG1 predicted poor survival in GC patients. We observed that upregulation of LRIG1 enhanced chemosensitivity in GC cells. Interestingly, miR-20a, which was overexpressed in GC MDR cell lines and tissues, was identified to regulate LRIG1 expression by directly targeting its 3 untranslated region. We also found that inhibition of miR-20a suppressed GC MDR, and upregulation showed opposite effects. Moreover, we demonstrated that the miR-20a/LRIG1 axis regulated GC cell MDR through epidermal growth factor receptor (EGFR)-mediated PI3K/AKT and MAPK/ERK signaling pathways. Finally, LRIG1 expression in human GC tissues is inversely correlated with miR-20a and EGFR. cell line (SGC7901,SGC7901/VCR and SGC7901/ADR ) up-regulated resistant LRIG1 LRIG1 PI3K/AKT and MAPK/ERK signaling pathway validated 2761 MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochem Biophys Res Commun 2018 29452092 miRBase MI0003644 miR-630 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The current study aimed to investigate the role of miR-630 in chemoresistant epithelial ovarian cancer. MiR-630 expression levels were detected in ovarian cancer cell line SKOV3 and paclitaxel-resistant SKOV3 (SKOV3-TR) via microarray and qRT-PCR. MiR-630 inhibitors and negative controls were transfected into SKOV3 and SKOV3-TR cells. Wound healing, invasion, chemosensitivity, and cell apoptosis assays were performed to determine proliferation and migration rates. Chemoresistant patient-derived xenograft (PDX) models were established and utilized to verify the effect of miR-630 on chemoresistant ovarian cancer. Inhibition of miR-630 decreased cell proliferation and enhanced the sensitivity of SKOV3-TR and SKOV3 cells to paclitaxel. In the chemosensitivity assay, we observed that the miR-630 inhibitor exhibited a synergistic effect with paclitaxel on SKOV3-TR cells. Inhibition was correlated with enhanced expression of apoptosis-related proteins. APAF-1 was predicted to be a potential target of miR-630. An in vivo PDX study showed that the miR-630 inhibitor sensitized chemoresistant ovarian cancer to paclitaxel. Thus, miR-630 inhibitor sensitizes chemoresistant epithelial ovarian cancer to chemotherapy by enhancing apoptosis. Our findings suggest that miR-630 might be a potential therapeutic target for chemotherapy-resistant ovarian cancer. cell line (SKOV3,SKOV3-TR) down-regulated sensitive APAF-1 APAF-1 NA validated 2762 MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. Cancer Med 2018 29473317 miRBase MI0003649 miR-634 miRNA DB00853 (APRD00557) Temozolomide glioma qPCR we aim to investigate the biological function of miR-634 and the possible mechanisms in glioma. In this study, we found that miR-634 was downregulated in glioma tissues compared with normal brain tissues, and its expression was associated with tumor size and WHO grade. Importantly, glioma patients with low miR-634 expression showed a shorter survival time than patients which had high expression of miR-634. This study also showed that miR-634 was decreased in temozolomide-resistant glioma cells, and restoration of miR-634 could sensitize the resistant cells to temozolomide by targeting CYR61 through Raf-ERK signaling. Our study provides a potential target for overcome drug resistance in glioma. cell line ( U251 and U87 ) down-regulated resistant CYR61 CYR61 Raf-ERK signaling pathway validated 2763 miR-519b-3p promotes responsiveness to preoperative chemoradiotherapy in rectal cancer patients by targeting ARID4B. Gene 2018 29477868 miRBase MIMAT0002837 miR-519b-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR In the study, we showed that the expression of miR-519b-3p was correlated with the responsiveness to preoperative chemoradiotherapy (pCRT) in patients with LARC. We found that miR-519b-3p was highly expressed in responsive LARC samples. And we showed that miR-519b-3p may serve as a novel predictive marker by ROC analysis. In addition, overexpression of miR-519b-3p enhanced responsiveness to chemoradiation in vitro. Mechanistically, we found that miR-519b-3p directly bond to the 3 UTR of ARID4B mRNA whose expression was inversely correlated with miR-519b-3p expression. Finally, we performed functional experiments and showed that miR-519b-3p was directly involved in response to pCRT in rectal cancer patients in an ARID4B-dependent way. cell line ( HCT116 and SW480) up-regulated sensitive ARID4B ARID4B NA validated 2764 Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer Med 2018 29479863 miRBase MI0000103/MI0000739 miR-101 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The role of MALAT1 in glioblastoma cells was detected using qRT-PCR, in situ hybridization analysis, western blot, MTT assay, colony formation assay, Flow cytometric analysis, TUNEL assay, Dual-luciferase reporter assay, Tumor formation assay in a nude mouse model, etc. cell line (U251,U251/TMZ) up-regulated sensitive MALAT1 MALAT1 NA validated 2765 miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling. Int J Oncol 2018 29484434 miRBase MIMAT0000091 miR-33a-5p miRNA NA Celastrol lung adenocarcinoma RT-qPCR The role of miR-34a in diffuse large B-cell lymphoma was detected by western blot analysis,transwell cell migration assays,luciferase reporter assay,flow cytometry,and Xenografts in mice.etc. tissue and cell line (LTEP-a-2 and A549) up-regulated sensitive mTOR mTOR mTOR signaling pathway validated 2766 miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep 2018 29484437 miRBase NA miR-181 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The aim of the present study was to investigate the effect of miR-181 on cisplatin-resistant non-small cell lung cancer (NSCLC). In patients with cisplatin-resistant NSCLC, miR-181 expression was found to be markedly decreased. In addition, in the cisplatin-resistant human lung adenocarcinoma cell line A549/DDP, miR-181 downregulation promoted cell growth and metastasis and inhibited cell apoptosis, whereas miR-181 overexpression exerted the opposite effects. Furthermore, miR-181 downregulation suppressed LC3 and ATG5 protein expression in A549/DDP cells through suppression of the PTEN/PI3K/AKT/mTOR pathway, whereas miR-181 overexpression recovered LC3 and ATG5 protein expression by promoting PTEN/PI3K/AKT/mTOR signaling. In turn, PTEN inhibitors reduced the anticancer effects of miR-181 overexpression on A549/DDP cell growth via the regulation of autophagy through the PI3K/AKT/mTOR pathway. cell line (A549/DDP) down-regulated resistant NA NA PTEN/PI3K/AKT pathway validated 2767 miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1. Anticancer Drugs 2018 29494357 miRBase MI0000802 miR-340 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma PCR The purpose of this study was to elucidate the role of miR-340 in chemoresistance of OS. Plasmid construction and transfection, miRNA arrays, PCR analyses, and western blot analysis, as well as MTT, apoptosis, and luciferase assays were carried out in MG-63 cells and MG-63/cisplatin (DDP)-resistant cells. The results showed that miR-340 was downregulated in OS tissues and drug-resistant OS cells. Moreover, a negative correlation was observed between miR-340 and ZEB1 expression in OS tissues. Forced expression of miR-340 in drug-resistant OS cells significantly reduced multidrug resistance-1 and P-gp expression. Overexpression of miR-340 enhanced sensitivity to DDP by inhibiting viability and promoting apoptosis. The luciferase assay and western blot analysis identified ZEB1 as a direct target of miR-340, and miR-340 negatively regulated ZEB1 expression. Ectopic expression of ZEB1 reversed the effects of miR-340 on P-gp expression, cell viability, and apoptosis. miR-340 alleviated chemoresistance of OS cells by targeting ZEB1. Our results indicate that targeting miR-340 may be a potential therapeutic approach to treat drug-resistant OS. tissue and cell line (MG-63,d MG-63/DDP ) down-regulated resistant ZEB1 ZEB1 NA validated 2768 MicroRNA-29a Functions as a Tumor Suppressor and Increases Cisplatin Sensitivity by Targeting NRAS in Lung Cancer. Technol Cancer Res Treat 2018 29495918 miRBase MI0000087 miR-29a miRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR MicroRNAs have been reported to play an important role in diverse biological processes and progression of various cancers. MicroRNA-29a has been observed to be downregulated in human lung cancer tissues, but the function of microRNA-29a in lung cancer has not been well investigated. In this study, we demonstrated that the expression levels of microRNA-29a were significantly downregulated in 38 pairs of lung cancer tissues when compared to adjacent normal tissues. Overexpression of microRNA-29a inhibited the activity of cell proliferation and colony formation of lung cancer cells, H1299 and A549. Furthermore, microRNA-29a targeted NRAS proto-oncogene in lung cancer cells. In human clinical specimens, NRAS proto-oncogene was highly expressed in human lung cancer tissues compared to normal tissues. More interestingly, microRNA-29a also sensitizes lung cancer cells to cisplatin via its target, NRAS proto-oncogene. Thus, our results in this study demonstrated that microRNA-29a acted as a tumor suppressor microRNA, which indicated potential application of microRNAs for the treatment of human lung cancer in the future. cell line (H1299,A549,HEK293 T ) up-regulated sensitive NRAS NRAS PI3K/AKT signaling pathway validated 2769 MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer. Oncol Res 2018 29495973 miRBase MI0003637 miR-623 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR In this study, miRNA-623 (miR-623) expression was downregulated in GC tissues and cell lines. Functional analysis showed that the restored miR-623 expression could inhibit the proliferation of GC cells and enhance their chemosensitivity to 5-FU via the cell apoptosis pathway. Cyclin D1 (CCND1) was identified as a direct target gene of miR-623 in GC. The overexpressed CCND1 in GC tissues was negatively correlated with miR-623 level. The recovered CCND1 expression counteracted the effects of miR-623 on GC cell proliferation, chemosensitivity, and 5-FU-induced apoptosis. Thus, our results suggest that miR-623 might function as a tumor suppressor in GC and could be a promising therapeutic target for patients with GC, especially those with chemotherapeutic resistance. cell line (MKN-45, SGC-7901, BGC823,MGC-803, GES-1) up-regulated sensitive CCND1 CCND1 NA validated 2770 Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ. Mol Ther Nucleic Acids 2018 29499934 miRBase MIMAT0004784 miR-455-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qPCR In the study, we observed by qPCR that miR-455-3p was significantly decreased in pancreatic cancer tissues and cell lines. We then confirmed that the inhibition of miR-455-3p increased cell proliferation and gemcitabine resistance of pancreatic cancer, whereas forced overexpression of miR-455-3p had the opposite effect. Furthermore, we demonstrated that TAZ, which is associated with drug resistance of pancreatic cancer, is a new direct downstream target of miR-455-3p. Our present study suggests that miR-455-3p contributes to cell proliferation and drug resistance in pancreatic cancer cells via targeting TAZ. cell line (PANC-1, MIAPaCa-2, HPDE6c7, and HEK293T) down-regulated resistant TAZ TAZ NA validated 2771 Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. Cancer Biol Ther 2018 29504819 miRBase MI0000460 miR-144 miRNA DB00515 (APRD00359) Cisplatin anaplastic thyroid carcinoma qRT-PCR Thyroid cancer cells ARO, TPC1 and normal thyroid cells HT-ori3 were used in this research. Expressions of miR-144 and TGF-alpha were uncovered by western blot and qRT-PCR. Expressions of autophagy-related protein LC3 II and apoptosis-related protein Caspase-3 and PARP were explored by western blot and immunofluorescence. Cell viability was detected by MTT assay and apoptosis condition was revealed by flow cytometric analysis and TUNEL staining. Dual-luciferase reporter assay was employed to verify the target relationship. Tissue sections were detected by IHC. Xenograft assay was conducted to further verify conclusions in vivo. cell line (ARO, TPC1,HTori3) up-regulated sensitive TGF-alpha TGF-alpha NA validated 2772 A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics 2018 29507618 miRBase MI0003644 miR-630 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma RT-PCR Manipulation of miR-630 and its targeted gene YAP1 and/or combination of inhibitor treatments was performed to explore whether low miR-630 could confer TKI resistance due to de-targeting YAP1, and this could decrease proapoptotic protein Bad expression through the miR-630/YAP1/ERK feedback loop. A retrospective study was conducted to examine whether the expression of miR-630 and YAP1 could be associated with TKI therapeutic response in patients with lung adenocarcinoma. cell line (PC9, PC9GR and CL97 ) down-regulated resistant YAP1 YAP1 miR-630/YAP1/ERK validated 2773 MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene 2018 29518547 miRBase MIMAT0000280 miR-223-3p miRNA DB01248 (APRD00932) Docetaxel prostate cancer qrt-PCR In our present study, we found that miR-223-3p was up-regulated in PCa cell lines (C4-2, LNCap, PC3, DU-145). Transfection with miR-223-3p inhibitor increased chemo-sensitivity to docetaxel and cell apoptosis rate in PCa cells compared with docetaxel-+-miR-223-3p mock group, especially in DU-145 cells which were more resistant to docetaxel. Bioinformatics study and luciferase reporter assay indicated that FOXO3 was a target of miR-223-3p and the results from western blot suggested that FOXO3 was negatively regulated by miR-223-3p. Further study revealed that up-regulation of FOXO3 by transfection with pCMV-FOXO3 decreased the IC50 values of docetaxel and increased cell apoptosis rate compared with docetaxel-+-pCMV-vector group, suggesting that overexpressed FOXO3 suppressed cell survival and sensitized PCa cells to docetaxel. Moreover, siRNA-mediated knockdown of FOXO3 abolished the effects of miR-223-3p inhibitor on chemo-sensitivity and apoptosis in PCa cells by increasing chemoresistance and decreasing cell apoptosis rate. Finally, the in vivo experiments showed that miR-223-3p inhibitor sensitized prostatic cancer mouse model to docetaxel by increasing the expression of FOXO3. cell lines (C4-2, LNCap, PC3, DU-145) down-regulated resistant FOXO3 FOXO3 NA validated 2774 Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res 2018 29530052 miRBase MIMAT0000090 miR-32-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma RT-PCR We detected the expression of miR-32-5p and PTEN in the multidrug-resistant cell line (Bel/5-FU) and the sensitive cell line (Bel7402), HCC and para-carcinoma liver tissues through real-time PCR. Dual-luciferase reporter assay verified PTEN is the target of miR-32-5p. Exosomes from sensitive and multidrug resistant cell line were obtained and confirmed through ultracentrifuge and Nano Analyzer. Gain- and loss-of-function experiments, rescue experiments, a PI3K/Akt pathway inhibitor, an exosome biogenesis inhibitor, and nude mice xenograft models were used to determine the underlying mechanisms of miR-32-5p and PTEN, as well as exosomal miR-32-5p in inducing multidrug resistance in vitro and in vivo. cell line (Bel7402,Bel/5-FU,HEK-293T, SMCC-7721, HepG2, Hep3B, and MHCC97H ) up-regulated resistant PTEN PTEN PI3K/Akt pathway validated 2775 LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018 29530057 miRBase MI0000301 miR-224 miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR TUSC7, miR-224 and DESC1 expressions in ESCC tissues and cells were detected by qRT-PCR. Protein level of DESC1, EGFR and p-AKT were observed by Western blot. Overall survival was calculated using the Kaplan-Meier method. Dual-luciferase reporter gene assay and RIP assay were used to comfirm TUSC7 binding to miR-224, and miR-224 binding to DESC1. Cell proliferation, apoptosis, and colony formation was detected by MTT, Flow Cytometry and Colony formation assays. cell line (TE-13, KYSE140, EC9706, KYSE30,Het-1A) down-regulated sensitive DESC1 DESC1 DESC1/EGFR/AKT pathway validated 2776 LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018 29530057 miRBase MI0000301 miR-224 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma qRT-PCR TUSC7, miR-224 and DESC1 expressions in ESCC tissues and cells were detected by qRT-PCR. Protein level of DESC1, EGFR and p-AKT were observed by Western blot. Overall survival was calculated using the Kaplan-Meier method. Dual-luciferase reporter gene assay and RIP assay were used to comfirm TUSC7 binding to miR-224, and miR-224 binding to DESC1. Cell proliferation, apoptosis, and colony formation was detected by MTT, Flow Cytometry and Colony formation assays. cell line (TE-13, KYSE140, EC9706, KYSE30,Het-1A) down-regulated sensitive DESC1 DESC1 DESC1/EGFR/AKT pathway validated 2777 Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol Lett 2018 29541229 miRBase MIMAT0000070 miR-17-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qPCR The role of miR-17-5p in gastric cancer cells was detected by miRNA microarray analysis,qPCR, luciferase activity assay,and western blot analysis.etc. cell line (SGC7901,SGC7901/DDP) down-regulated sensitive p21 p21 NA validated 2778 miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. Arch Biochem Biophys 2018 29550144 miRBase MIMAT0000074 miR-19b-3p miRNA DB11805 Saracatinib breast cancer RT-PCR In this study, we established a Src inhibitor saracatinib-resistant breast cancer cell line (SK-BR-3/SI) for the first time. Microarray data and qRT-PCR results showed that miR-19b-3p expression was downregulated in saracatinib-resistant cells compared with saracatinib-sensitive cells. Downregulation of miR-19b-3p remarkably increased the IC50 value of saracatinib, and promoted cell migration. Further studies found that miR-19b-3p reduced PIK3CA expression by directly targeting PIK3CA gene and the resistance of Src inhibitor might be associated with activation of PI3K/Akt pathway after downregulation of miR-19b-3p. Moreover, we demonstrated that PI3K inhibitor LY294002 could reverse saracatinib resistance in saracatinib-resistant cells, which deserved further preclinical and clinical evaluation of dual inhibition of Src and PI3K in breast cancer. cell line ( MDA-MB-231, SK-BR-3, BT-474 and MCF-7) up-regulated sensitive PIK3CA PIK3CA PI3K/Akt pathway validated 2779 MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3. Oncol Lett 2018 29552117 miRBase MI0000681 miR-155 miRNA DB00515 (APRD00359) Cisplatin colon cancer RT-qPCR To investigate the effect of microRNA (miR)-155 on colon cancer chemoresistance to cisplatine and its mechanism. Reverse transcription quantitative polymerase chain reaction was used to measure the levels of miR-155 and forkhead box O3 (FOXO3) in colon cancer specimens and cell lines. Overexpression of miR-155 and miR-155 inhibitor were transfected into colon cancer cell lines to investigate its role of chemoresistance to cisplatin in colon cancer. MTS assays were used to analyse cell viability in vitro. In vivo tumor formation assays were performed in C57BL/6 wild type and miR-155 knockout mice (miR-155-/-). A luciferase reporter assay was used to measure the translation of FOXO3. Additionally, the expression of FOXO3 was detected by western blot analysis. It was identified that miR-155 was markedly upregulated in colon cancer tissue and cell lines. Overexpression of miR-155 enhanced colon cancer cell chemoresistance to cisplatin in vitro and tumorigenesis in vivo. In addition, overexpression of miR-155 was associated with decreased levels of FOXO3, primarily through inhibiting the expression of FOXO3 to increase colon cancer resistanec to cisplatin. The present study demonstrated that miR-155 increased colon cancer drug resistance and decreased FOXO3 expression in vivo and in vitro. This may provide a novel method for the treatment of drug-resistant colon cancer. cell line (HT29 and SW620) up-regulated resistant FOXO3 FOXO3 NA validated 2780 Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2. Biosci Rep 2018 29559564 miRBase MI0003130 miR-202 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-PCR In the present study, we aimed to investigate the roles of miR-202 in the regulation of imatinib sensitivity in CML cell lines and the possible mechanisms involved in this process. We found miR-202 was down-regulated in seven CML cell lines by quantitative reverse-transcription PCR (qRT-PCR) analysis. Overexpression of miR-202 significantly suppressed proliferation rates of CML cells. By establishing imatinib resistant cell lines originating from K562 and KU812 cells, we observed expressions of miR-202 were down-regulated by imatinib treatments and imatinib resistant CML cell lines exhibited lower level of miR-202 On the contrary, imatinib resistant CML cell lines displayed up-regulated glycolysis rate than sensitive cells with the evidence that glucose uptake, lactate production, and key glycolysis enzymes were elevated in imatinib resistant cells. Importantly, the imatinib resistant CML cell lines were more sensitive to glucose starvation and glycolysis inhibitors. In addition, we identified Hexokinase 2 (HK2) as a direct target of miR-202 in CML cell lines. Overexpression of miR-202 sensitized imatinib resistant CML through the miR-202-mediated glycolysis inhibition by targetting HK2. Finally, we provided the clinical relevance that miR-202 was down-regulated in CML patients and patients with lower miR-202 expression displayed higher HK2 expression. The present study will provide new aspects on the miRNA-modulated tyrosine kinase inhibitor (TKI) sensitivity in CML, contributing to the development of new therapeutic anticancer drugs. cell line (K562, KU812,EM2, EM3, LAMA 84, KCL-22, and HL-60 ) up-regulated sensitive HK2 HK2 NA validated 2781 miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol 2018 29561664 miRBase MI0000268 miR-34a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR This study aimed to explore the roles of miRNA-34a (miR-34a) in ovarian cancer (OC) cells and uncover possible mechanisms. The proliferation of OC cells was measured with an MTT assay and soft agar colony formation assay. TargetScan analysis, real-time PCR, and a luciferase reporter assay were used to demonstrate the downstream target of miR-34a in OC cells. HDAC1 expression levels were detected by immunoblot analysis. miR-34a inhibited the proliferation of SKOV3 and OVCA433 cells and enhanced cisplatin sensitivity in cisplatin-resistant SKOV3cp cells. The results of TargetScan analysis, real-time PCR, and luciferase reporter assay confirmed that miR-34a downregulated HDAC1 expression by directly targeting the 3-UTR of HDAC1 mRNA. The overexpression of HDAC1 decreased cisplatin sensitivity and promoted proliferation in OC cells. MTT assay and soft agar colony formation assay showed that HDAC1 overexpression blocked the suppressive effects of miR-34a on SKOV3 cell proliferation. In addition, treatment with the miR-34a mimic partially recovered the cisplatin sensitivity of SKOV3cp cells, whereas HDAC1 overexpression blocked the above phenomena caused by treatment with the miR-34a mimic. miR-34a exhibited suppressive effects on OC cells via directly binding and downregulating HDAC1 expression, which subsequently decreased the resistance to cisplatin and suppressed proliferation in OC cells. cell line (SKOV3,OVCA433,SKOV3cp) up-regulated sensitive HDAC1 HDAC1 NA validated 2782 Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma. Eur Rev Med Pharmacol Sci 2018 29565481 miRBase MI0000785 miR-377 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR Tumor tissues from chemoresistant and control OS patients were subjected to Real-time polymerase chain reaction (PCR) to assess miR-377 expression. The effect and mechanism of miR-377 on cisplatin resistance were assessed using Cell Counting Kit (CCK) 8, flow cytometry, Western blot, and luciferase assays in cisplatin-resistant OS cells lines. cell line (MG-63/CDDP, Saos-2/CDDP,MG-63 and Saos-2 ) down-regulated resistant XIAP XIAP NA validated 2783 MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. Eur Rev Med Pharmacol Sci 2018 29565492 miRBase MI0003581 miR-574 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR Quantitative Real-time poly chain reaction (qRT-PCR) was employed to detect the expression level of miR-574 in breast cancer Dox-resistant MCF-7/Adr cell line and parental MCF-7 cell line. Using miR-574 mimics and inhibitors, miR-574 level was up- or down- regulated. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was handled to detect the IC50, and flow cytometric analysis was employed to measure the apoptosis and cell circle. Dual-luciferase and Western-blot experiments were applied to verify the direct target gene of miR-574. cell line (MCF-7,MCF-7/Adr) up-regulated resistant SMAD4 SMAD4 NA validated 2784 LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther 2018 29565706 miRBase MIMAT0000062 let-7a-5p miRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR In this study, the expressions of NEAT1, let-72-5p and Rsf-1 mRNA were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of NEAT1 and let-72-5p on cell proliferation and cisplatin resistance of NPC cells were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and 5-ethynyl-20-deoxyuridine (EdU) assay. Western blot analysis was performed to detect the protein levels of Rsf-1, Ras, p-Raf1, Raf1, p-MEK1, MEK1, p-ERK1/2 and ERK1/2. Xenograft tumor assay was done to elucidate the role of NEAT1 involved in NPC tumor growth in vivo. cell line (HK-1,CNE-1, CNE-2) up-regulated sensitive Rsf-1 NA Ras-MAPK pathway validated 2785 MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kappaB signaling pathway in breast cancer. Biomed Pharmacother 2018 29567542 miRBase MI0000449 miR-132 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of miR-132/-212 (miR-132 and miR-212) in doxorubicin (DOX)-resistant and -sensitive breast cancer tumors and cells. The function of miR-132/-212 in drug resistance was investigated in vitro (MTT assay, TUNEL assay, fluorescence, immunohistochemistry, luciferase reporter assay, Western blotting). We found that miR-132/-212 were commonly overexpressed in DOX-resistant breast cancer tumors and cells. Silenced miR-132/-212 expression induced DOX accumulation in MCF-7/ADR cells, while overexpression of miR-132/-212 led to breast cancer resistance protein (BCRP)-based DOX efflux in MCF-7 cells. Further study showed that up-regulation of miR-132/-212 in MCF-7/ADR cells suppressed the expression of PTEN, a target gene of miR-132/-212, which activated AKT phosphorylation and the NF-kB pathway and led to increased BCRP expression. Down-regulation of miR-132/-212 sensitized MCF-7/ADR cells to DOX. Mechanistic investigations suggested that miR-132/-212 enhancement was a result of NF-kappaB-mediated transactivation of the pri-miR-132/-212 gene. cell line (MCF-7,MCF-7/ADR) up-regulated resistant PTEN PTEN PTEN-AKT/NF-kappaB signaling pathway validated 2786 MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kappaB signaling pathway in breast cancer. Biomed Pharmacother 2018 29567542 miRBase MI0000288 miR-212 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of miR-132/-212 (miR-132 and miR-212) in doxorubicin (DOX)-resistant and -sensitive breast cancer tumors and cells. The function of miR-132/-212 in drug resistance was investigated in vitro (MTT assay, TUNEL assay, fluorescence, immunohistochemistry, luciferase reporter assay, Western blotting). We found that miR-132/-212 were commonly overexpressed in DOX-resistant breast cancer tumors and cells. Silenced miR-132/-212 expression induced DOX accumulation in MCF-7/ADR cells, while overexpression of miR-132/-212 led to breast cancer resistance protein (BCRP)-based DOX efflux in MCF-7 cells. Further study showed that up-regulation of miR-132/-212 in MCF-7/ADR cells suppressed the expression of PTEN, a target gene of miR-132/-212, which activated AKT phosphorylation and the NF-kB pathway and led to increased BCRP expression. Down-regulation of miR-132/-212 sensitized MCF-7/ADR cells to DOX. Mechanistic investigations suggested that miR-132/-212 enhancement was a result of NF-kappaB-mediated transactivation of the pri-miR-132/-212 gene. cell line (MCF-7,MCF-7/ADR) up-regulated resistant PTEN PTEN PTEN-AKT/NF-kappaB signaling pathway validated 2787 MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Oncotarget 2018 29568392 miRBase MI0003644 miR-630 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR This retrospective study enrolled 114 surgically resected patients with NSCLC who experienced tumor relapse and underwent cisplatin-based chemotherapy. The aim was to examine the possible association between miR-630 (and its targeting of Bcl-2 expression) and the response to cisplatin-based chemotherapy. Patients with tumors expressing low miR-630, high Bcl-2, and a combination of both were more likely than their counterparts to show unfavorable responses to cisplatin-based chemotherapy. Kaplan-Meier and Cox regression analysis indicated that low miR-630, high Bcl-2, and a combination of both may independently predict poor overall survival and short relapse-free survival in patients with NSCLC. Six types of NSCLC cells were collected to determine the inhibitory concentration of cisplatin yielding 50% viability (IC50) by the MTT assay. The IC50 value for cisplatin was negatively correlated with miR-630 expression levels among these cell types, except for A549 cells. Mechanistically, low miR-630 expression conferred cisplatin resistance and colony formation by de-targeting Bcl-2 in NSCLC cells. We therefore suggest that low miR-630, high Bcl-2, and a combination of both may potentially predict an unfavorable chemotherapeutic response and poor outcome in patients with NSCLC. cell line down-regulated resistant Bcl-2 Bcl-2 NA validated 2788 MicroRNA-22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells. Mol Med Rep 2018 29568877 miRBase MI0000078 miR-22 miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR In the present study, a total of 7 patients with OS and 7 healthy volunteers were recruited. Reverse transcription-quantitative polymerase chain reaction and ELISA were performed to determine the expression of miRNAs and mRNAs in the serum of participants. Furthermore, the biological function of miR-22 and S100A11 was examined in MG-63 cells using Cell Counting Kit-8 assays, Transwell migration assays and western blot analysis to determine the effects on cell proliferation, migration and protein expression, respectively, while MG-63 cell sensitivity to cisplatin was assessed by measuring cell viability following cisplatin treatment and calculating the half maximal inhibitory concentration (IC50). Additionally, the association between miR-22 and S100 calcium-binding protein A11 (S100A11) was validated using a luciferase reporter assay. The results demonstrated that miR-22 expression was significantly reduced in patients with OS and the MG-63 OS cell line, compared with healthy volunteers and the normal osteoblast hFOB 1.19 cell line, respectively, while the expression of S100A11 was negatively associated with miR-22 levels in the MG-63 cell line. Furthermore, overexpression of miR-22 inhibited the proliferation and migratory ability of MG-63 cells, and increased the sensitivity of MG-63 cells to cisplatin treatment; however, overexpression of S100A11 partially attenuated the alterations in proliferation, migratory ability and chemosensitivity that were induced by miR-22 overexpression. In addition, it was confirmed that S100A11 is a direct target gene of miR-22 in MG-63 cells. cell line (MG-63) up-regulated sensitive S100A11 S100A11 NA validated 2789 MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer 2018 29571988 miRBase MI0000234 miR-192 miRNA DB00773 (APRD00239) Etoposide lung squamous cell carcinoma RT-qPCR MiRNA expression profile was analysed in 10 non-small cell lung cancer (NSCLC) cell lines using RT-qPCR. H520 and H1703 cells were transfected with miRNA inhibitors (anti-miR-192, -192* and -662) for functional studies. Chemoresistance to cisplatin and etoposide was evaluated using MTT colorimetric assay. H520 cells were subjected to 3D soft-agar colony formation assay and H1703 cells to wound healing assay. Whole transcriptome analysis was used to assess the effect of miR-192 and miR-662 inhibition on gene expression. cell line (H520 and H1703) down-regulated sensitive NA NA NA validated 2790 MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer 2018 29571988 miRBase MI0003670 miR-662 miRNA DB00773 (APRD00239) Etoposide lung squamous cell carcinoma RT-qPCR MiRNA expression profile was analysed in 10 non-small cell lung cancer (NSCLC) cell lines using RT-qPCR. H520 and H1703 cells were transfected with miRNA inhibitors (anti-miR-192, -192* and -662) for functional studies. Chemoresistance to cisplatin and etoposide was evaluated using MTT colorimetric assay. H520 cells were subjected to 3D soft-agar colony formation assay and H1703 cells to wound healing assay. Whole transcriptome analysis was used to assess the effect of miR-192 and miR-662 inhibition on gene expression. cell line (H520 and H1703) down-regulated sensitive NA NA NA validated 2791 MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci 2018 29575368 miRBase MIMAT0004927 miR-708-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR The role of miR-708-3p was deteced by RT-qPCR, Luciferase reporter assay, Western blot and immunohistochemistry assays, MTT assay and apoptotic cell detection, Invasion assay, and animal experiments. cell line (MCF-10A, MCF-7, MDA-MB-468 and MDA-MB-231) up-regulated sensitive ZEB1, CDH2 and vimentin NA NA validated 2792 Let-7c restores radiosensitivity and chemosensitivity and impairs stemness in oral cancer cells through inhibiting interleukin-8. J Oral Pathol Med 2018 29582468 miRBase MI0000064 Let-7c miRNA DB00515 (APRD00359) Cisplatin oral cancer qRT-PCR In this study, phenotypical behaviors and the radio/chemoresistance were examined subsequent to overexpression of let-7c. In addition, the expression of let-7c in cancer stem cells (CSCs) was evaluated and the effect of let-7c on stemness characteristics was assessed. Also, luciferase activity assays were performed to test whether interleukin (IL)-8 was a putative target of let-7c. tissue and cell line(SAS, GNM) up-regulated sensitive NA NA NA validated 2793 TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. Cell Biosci 2018 29588850 miRBase MI0000072 miR-18a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR qRT-PCR analysis was used to detect the expression of TP53TG1, miR-18a and PTEN mRNA in NSCLC tissues and cells. Western blot analysis was performed to determine the protein level of PTEN and cleaved caspase-3. Cell viability and IC50 value were measured by MTT assay. Cell apoptosis was confirmed by flow cytometry assay. Subcellular fractionation assay was used to identify the subcellular location of TP53TG1. Dual-luciferase reporter assay, RNA pull down assay and RNA immunoprecipitation assay were carried out to verify the interaction between TP53TG1 and miR-18a. Xenografts in nude mice were established to verify the effect of TP53TG1 on cisplatin sensitivity of NSCLC cells in vivo. tissue and cell line (A549,A549/DDP) down-regulated sensitive PTEN PTEN miR-18a/PTEN pathway validated 2794 The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis. Biosci Rep 2018 29592872 miRBase MI0000785 miR-377 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qRT-PCR The role of SNHG5 in lung adenocarcinoma cells was detected using quantitative real-time PCR, cell proliferation assay, cell apoptosis analysis, Luciferase reporter assay and western blotting assay, etc. tissue and cell line (PC9,A549,PC9GR,A549GR) down-regulated sensitive CASP1,SNHG5 CASP1,SNHG5 miR-377/CASP1 validated 2795 MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B. Cancer Chemother Pharmacol 2018 29594361 miRBase MI0000261 miR-139 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression of miR-139 in cisplatin-sensitive (n=23) and cisplatin-resistant (n=14) ovarian cancer tissues and cell lines (CAOV-3 and SNU119) was determined using real-time PCR assays; its effect on ovarian cancer cell chemoresistance to different concentrations of cisplatin was then assessed by measuring the cell viability using MTT assays. Next, miR-139 binding to the 3UTR of ATP7A/B was confirmed using luciferase reporter gene assays. Finally, the combined effect of miR-139 and ATP7A/B on the chemoresistance of ovarian cancer cell was assessed. cell line (CAOV-3 and SNU119) up-regulated sensitive ATP7A/B ATP7A/B NA validated 2796 MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2018 29615098 miRBase MIMAT0000253 miR-10a-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR The effects of miR-10a-5p on biological behaviors were analyzed. MiR-10a-5p and TFAP2C levels in tissues were detected, and the clinical value was evaluated. cell line (AsPC-1, BxPC-3, MiaPaCa-2, PANC-1, Su86.86,T3M4,293A ) up-regulated resistant TFAP2C TFAP2C NA validated 2797 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB11616 Pirarubicin bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2798 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2799 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2800 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB00445 (APRD00361) Epirubicin hydrochloride bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2801 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB12385 10-hydroxycamptothecin bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2802 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2803 miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep 2018 29620229 miRBase MIMAT0000077 miR-22-3p miRNA DB00441 (APRD00201) Gemcitabine bladder cancer qRT-PCR In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. cell line ( 5637,T24,m-Uc-3, J82,H-bc) up-regulated resistant NET1 NET1 NA validated 2804 miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther 2018 29636622 miRBase MI0000490 miR-206 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-PCR To indentify the role of miR-206 in 5-FU resistance, the expression of miR-206 was examined by real-time polymerase chain reaction (RT-PCR) in 5-FU-resistant (FR) CRC (HCT116/FR and RKO/FR) and their parental cell lines. miR-206 mimic was transfected to 5-FU-FR CRC, and the 5-FU sensitivity was detected by MTS and flow cytometry. Using miRNA target prediction software, we found that miR-206 could target the 3 untranslated region (3UTR) sequence of Bcl-2. cell line (HCT116 and RKO ) down-regulated resistant Bcl-2 Bcl-2 NA validated 2805 MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells. BMC Cancer 2018 29642855 miRBase MIMAT0000087 miR-30a-5p miRNA DB00515 (APRD00359) Cisplatin melanoma RT-qPCR After cisplatin (DDP) resistant melanoma cells (M8/DDP and SK-Mel-19/DDP) were established in-vitro, high-throughput screening of differentially expressed miRNAs between resistant cells and parental cells were performed. cell line (M8, M8/DDP, SK-Mel-19, SK-Mel-19/DDP,HEK293T) up-regulated resistant IGF1R IGF1R AKT/P53 pathway validated 2806 MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/Beta-catenin pathway. Cell Biochem Funct 2018 29653464 miRBase MI0000748 miR-130b miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The role of miR-130b was deteced by qRT-PCR, Western-blotting assay, apoptosis analysis, Luciferase reporter analysis, and Xenografts. cell line ( A549, H446,A549/CR and H446/CR) up-regulated resistant PTEN PTEN Wnt/Beta-catenin pathway validated 2807 Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma. Biosci Rep 2018 29654165 miRBase MI0000743 miR-34c miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of miRNA were determined by qRT-PCR .The CCK-8 assay was used to monitor the growth of the cells .Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Tumor model was used to test the role of lncRNA NEAT1 and miR-34c . cell line (MG63, 143B, HOS,Saos2,hFOB1.19 ) up-regulated sensitive NA BCL-2 and CCND1 BCL-2 and cyclin D1 pathway validated 2808 let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep 2018 29658612 miRBase MIMAT0004484 let-7d-3p miRNA DB00958 (APRD00466) Carboplatin ovarian cancer qRT-PCR In the present study, we analyzed the expression of three members of the let-7 family (let-7a-3p, let-7d-3p and let-7f), which remains largely uncharacterized in ovarian cancer tissues. We also investigated the function of let-7d-3p in the apoptosis and sensitization to chemotherapy in ovarian cancer cells. Our data from stem-loop quantitative RT-PCR showed that expression of let-7a-3p and let-7d-3p, but not let-7f, was significantly (P<0.04) upregulated in ovarian tumors relative to that noted in normal ovarian tissues. Markedly, an increased expression of let-7d-3p (also known as let-7d-3*) was associated with positive response to carboplatin/paclitaxel treatment in ovarian cancer patients. To investigate the biological relevance of let-7d-3p, we knocked down its expression in SKOV-3 ovarian cancer cell line using antagomiRs. Loss of function analysis showed that inhibition of let-7d-3p significantly (P<0.05) impaired cell proliferation and activated apoptosis. In contrast, scratch/wound healing and Transwell chamber assays showed that migration and invasion abilities were not affected in the let-7d-3p-deficient SKOV-3 cancer cells. Notably, Annexin V assays showed a significant (P<0.05) increase in cell death of cancer cells treated with the let-7d-3p inhibitor plus carboplatin indicating a synergistic effect of the drug with antagomiR therapy. Gene ontology classification of predicted targets of let-7d-3p identified a number of genes involved in cellular pathways associated with therapy resistance such as ABC transporters, HIF-1, RAS and ErbB signaling. In summary, our findings showed that inhibition of let-7d-3 activates apoptosis and that its upregulation is associated with a positive response of ovarian cancer patients to carboplatin/paclitaxel chemotherapy. cell line (SKOV-3) up-regulated sensitive NA NA NA validated 2809 let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep 2018 29658612 miRBase MIMAT0004484 let-7d-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR In the present study, we analyzed the expression of three members of the let-7 family (let-7a-3p, let-7d-3p and let-7f), which remains largely uncharacterized in ovarian cancer tissues. We also investigated the function of let-7d-3p in the apoptosis and sensitization to chemotherapy in ovarian cancer cells. Our data from stem-loop quantitative RT-PCR showed that expression of let-7a-3p and let-7d-3p, but not let-7f, was significantly (P<0.04) upregulated in ovarian tumors relative to that noted in normal ovarian tissues. Markedly, an increased expression of let-7d-3p (also known as let-7d-3*) was associated with positive response to carboplatin/paclitaxel treatment in ovarian cancer patients. To investigate the biological relevance of let-7d-3p, we knocked down its expression in SKOV-3 ovarian cancer cell line using antagomiRs. Loss of function analysis showed that inhibition of let-7d-3p significantly (P<0.05) impaired cell proliferation and activated apoptosis. In contrast, scratch/wound healing and Transwell chamber assays showed that migration and invasion abilities were not affected in the let-7d-3p-deficient SKOV-3 cancer cells. Notably, Annexin V assays showed a significant (P<0.05) increase in cell death of cancer cells treated with the let-7d-3p inhibitor plus carboplatin indicating a synergistic effect of the drug with antagomiR therapy. Gene ontology classification of predicted targets of let-7d-3p identified a number of genes involved in cellular pathways associated with therapy resistance such as ABC transporters, HIF-1, RAS and ErbB signaling. In summary, our findings showed that inhibition of let-7d-3 activates apoptosis and that its upregulation is associated with a positive response of ovarian cancer patients to carboplatin/paclitaxel chemotherapy. cell line (SKOV-3) up-regulated sensitive NA NA NA validated 2810 Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway. J Cell Biochem 2018 29663500 miRBase MI0000469 miR-125a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (QRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HS-5,HL60/ADR)) up-regulated sensitive HK2 HK2 microRNA-125a/hexokinase 2 pathway validated 2811 MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. Biomed Pharmacother 2018 29665645 miRBase MI0000489 miR-195 miRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR In our study, the lower expression of miR-195 was appeared in DOC-resistant PC cells (DU145/DOC) rather than DOC-sensitive DU145 cells. The up-regulation of miR-195 lowered the IC50 of DOC, facilitated the apoptosis and inhibited the colony formation ability in DU145/DOC cells. Moreover, we also found that miR-195 had the binding site with clusterin (CLU) by the online TargetScan database mining. Luciferase tests revealed that miR-195 binds to the 3-UTR of CLU. MiR-195 overexpression decreased the amassment of CLU in DU145/DOC cells. Knockdown of CLU diminished the IC50 of DOC and enhanced the apoptosis of DU145/DOC cells, which was consistent with the influence of miR-195 on DOC-induced cell apoptosis. Taken together, our results illuminated that miR-195 improved the sensitivity of resistant PC cells to DOC by suppressing CLU. Hence, miR-195 may be a potentially promising molecular target for drug resistance of PC. cell line (DU145,DU145/DOC) down-regulated resistant CLU CLU NA validated 2812 Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 2018 29674277 miRBase MI0000459 miR-143 miRNA DB00441 (APRD00201) Gemcitabine bladder cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell invasion assay. Xenograft tumor model was used to test the role of FOXD2-AS1 and miR-143 . cell line (T24, 5637) down-regulated sensitive NA ABCC3 FOXD2-AS1/miR-143/ABCC3 validated 2813 miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. Biochem Biophys Res Commun 2018 29678577 miRBase MIMAT0002175 miR-485-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR In the present study, we demonstrated that overexpression of miR-485-5p suppresses breast cancer progression and enhances chemosensitivity both in vitro and in vivo. Further study demonstrated that miR-485-5p directly targeted the 3-untranslated region of survivin and overexpression of survivin overcomes the miR-485-5p induced effects on breast cancer. In conclusion, our study identified that miR-485-5p suppresses cancer progression and enhances the chemosensitivity by targeting survivin. Targeting survivin by miR-485-5p may provide a potential approach to reverse chemosensitivity in breast cancer cells. cell line (MDA-MB-231, MDA-MB-468, MCF7,MDA-MB-231) up-regulated sensitive survivin survivin NA validated 2814 miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. Biochem Biophys Res Commun 2018 29678577 miRBase MIMAT0002175 miR-485-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR In the present study, we demonstrated that overexpression of miR-485-5p suppresses breast cancer progression and enhances chemosensitivity both in vitro and in vivo. Further study demonstrated that miR-485-5p directly targeted the 3-untranslated region of survivin and overexpression of survivin overcomes the miR-485-5p induced effects on breast cancer. In conclusion, our study identified that miR-485-5p suppresses cancer progression and enhances the chemosensitivity by targeting survivin. Targeting survivin by miR-485-5p may provide a potential approach to reverse chemosensitivity in breast cancer cells. cell line (MDA-MB-231, MDA-MB-468, MCF7,MDA-MB-231) up-regulated sensitive survivin survivin NA validated 2815 Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Thorac Cancer 2018 29697201 miRBase MI0006444 miR-1307 miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR MiRNA expression was detected in human breast cancer cell lines MCF-7 and MDA-MB-468 via real time PCR; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide, cell viability, colony formation, and luciferase reporter gene assays; Western blot; and immunohistochemistry. cell line (MCF-7 and MDA-MB-468 ) up-regulated sensitive Mdm4 Mdm4 NA validated 2816 MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin (Shanghai) 2018 29701752 miRBase MI0000300 miR-223 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colorectal cancer qRT-PCR The aim of the current study was to evaluate the role of miR-223/FBXW7 pathway in chemosensitivity in different CRC cell lines and to investigate the relevant underlying mechanisms. We found that high levels of FBXW7 expression were associated with increased doxorubicin sensitivity in different CRC cell lines, and FBXW7 was regulated by miR-223. Overexpression of miR-223 decreased FBXW7 expression and the sensitivity of CRC cells to doxorubicin, while suppression of miR-223 had the opposite effect. Moreover, epithelial-mesenchymal transition (EMT) was proved to be regulated by miR-223/FBXW7 pathway and involved in the drug resistance. In conclusion, miR-223/FBXW7 axis regulates doxorubicin sensitivity through EMT in CRC, which may lead to the development of individualized treatment in clinical practice. cell line (HT-29, SW480, SW620, and LoVo) down-regulated resistant FBXW7 FBXW7 miR-223/FBXW7 pathway validated 2817 miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett 2018 29702190 miRBase MI0000477 miR-146a miRNA DB00515 (APRD00359) Cisplatin lung cancer qPCR In the study, we investigated CHOP expression in tumor tissues form 69 lung cancer patients, finding that deficient CHOP expression is associated with poor prognosis. Cisplatin-resistant lung cancer cells exhibited lower expression of CHOP compared to that in sensitive lung cancer cells, and silencing or augmenting CHOP expression enhanced or impaired cisplatin resistance, respectively. Mechanistic investigations revealed that CHOP is directly associated with the regulation of autophagy or apoptosis-regulatory genes including LC3-II, death receptor 5 (DR5), and telomere repeat-binding factor 3. Notably, CHOP was identified as a target of miR-146a, and increased miR-146a expression in lung cancer cells was suggested to be responsible for CHOP mRNA down-regulation. Further, animal models confirmed that abnormally expressed miR-146a in lung cancer cells does not affect growth, but rather alters chemotherapy sensitivity. cell line (A549, H446, A549/CDDP, H446/CDDP) up-regulated sensitive CHOP CHOP NA validated 2818 Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett 2018 29702194 miRBase MI0000443/MI0000444/MI0000445 miR-124a miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qPCR In this study, we found that hsa-miR-124a was downregulated during spheroid formation of the NSCLC cell lines SPC-A1 and NCI-H1650 and NSCLC tissues compared with normal lung cells and tissues. Patients with lower hsa-miR-124a expression had shorter overall survival (OS) and progression free survival (PFS). Moreover, ubiquitin-specific protease 14 (USP14) was confirmed to be a direct target of hsa-miR-124a. Furthermore, concomitant low hsa-miR-124a expression and high USP14 expression were correlated with a shorter median OS and PFS in NSCLC patients. Cellular functional analysis verified that the tumor suppressor hsa-miR-124a negatively regulated cell growth and self-renewal, and promoted apoptosis and gefitinib sensitivity of lung cancer stem cells by suppressing its target gene USP14. Our results provide the first evidence that USP14 is a direct target of hsa-miR-124a, and that hsa-miR-124a inhibits stemness and enhances the gefitinib sensitivity of NSCLC cells by targeting USP14. Thus, hsa-miR-124a and USP14 may be useful as tumor biomarkers for the diagnosis and treatment of NSCLC. cell line (SPC-A1 and NCI-H1650) up-regulated sensitive USP14 USP14 NA validated 2819 Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother 2018 29710482 miRBase MI0000760 miR-361 miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell invasion assay. In vivo tumor xenograft model was used to test the role of miR-361 and BLACAT1 . tissue and cell line s (BGC-823, SGC-7901, MGC-803, GES-1) down-regulated resistant BLACAT1 and ABCB1 BLACAT1 and ABCB1 BLACAT1/miR-361/ABCB1 pathway validated 2820 Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin Beta3. Oncogene 2018 29717264 miRBase MIMAT0002173 miR-483-3p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR The aim of this study was to understand the roles of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we reported the evidence of miR-483-3p silencing and epithelial-to-mesenchymal transition (EMT) phenotype in both in vitro and in vivo EGFR-mutant NSCLC models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p efficiently increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation and promoting apoptosis. Moreover, miR-483-3p reversed EMT and inhibited migration, invasion, and metastasis of gefitinib-resistant lung cancer cells. Mechanistically, miR-483-3p directly targeted integrin Beta3, and thus repressed downstream FAK/Erk signaling pathway. Furthermore, the silencing of miR-483-3p in gefitinib-resistant lung cancer cells was due to hypermethylation of its own promoter. cell line (HCC827, H1975, A549, H292, H1299) up-regulated sensitive Integrin Beta3 NA FAK/Erk signaling validated 2821 Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Am J Physiol Cell Physiol 2018 29719173 miRBase MIMAT0000250 miR-139-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The present study aims at investigating the effects of microRNA-139-5p (miR-139-5p) on cisplatin resistance of ovarian cancer (OC) with involvement of ring finger protein 2 (RNF2) and the mitogen-activated protein kinase (MAPK) signaling pathway. OC tissues were obtained from 66 primary OC patients. The cisplatin-sensitive A2780 and cisplatin-resistant A2780/DDP cell lines were collected for construction of RNF2 silencing and overexpressed plasmids. Cell vitality and apoptosis were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and annexin V-FITC/propidium iodide double-staining, respectively. Next, expression of RNF2, extracellular signal-related kinase, and p38 was determined by quantitative reverse transcription-quantitative polymerase chain reaction and Western blot analysis. Finally, the volume of xenograft tumors in BALB/c nude mice was detected. RNF2 and miR-139-5p were identified to be involved in OC. In addition, MAPK activation and RNF2 were related to cisplatin resistance of OC. miR-139-5p was downregulated in cisplatin-resistant OC tissues, and miR-139-5p overexpression could inhibit cell vitality, reduce cisplatin resistance, and promote apoptosis of OC cells. Furthermore, miR-139-5p combined with MAPK inhibitors more obviously reduced cisplatin resistance of OC. Taken together, this study demonstrated that miR-139-5p overexpression combined with inactivation of the MAPK signaling pathway can reverse the cisplatin resistance of OC by suppressing RNF2. cell line (A2780,A2780/DDP) up-regulated sensitive RNF2 RNF2 MAPK signaling pathway validated 2822 MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol 2018 29726011 miRBase MI0003190 miR-505 miRNA DB00563 (APRD00353) Methotrexate colorectal cancer qRT-PCR Microarray was used to select differentially expressed miRNAs. QRT-PCR and western blot were performed to assess miR-505 and RASSF8 mRNA levels in MTX-sensitive and MTX-resistant CRC tissues and cells. Cell viability, propagation and apoptosis were confirmed by MTT, colony formation assays and flow cytometry. Transwell and wound healing assays were conducted on cancerous cells to determine cell metastasis. The target relationship between miR-505 and RASSF8 was validated using dual-luciferase reporter gene assay. cell line (SW480, SW620, LS174T) up-regulated resistant RASSF8 RASSF8 NA validated 2823 MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics 2018 29752546 miRBase MI0003198 miR-514 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The relation of miR-514 expression with prognosis in ovarian cancer patients was analyzed based on GSE73584 datasets. The regulation of miR-514 on proliferation and cisplatin chemosensitivity of ovarian cells was examined by MTT assay, colony-formation assay and soft-agar colony-formation assay. Dual luciferase assay was performed to detect the direct interaction of miR-514 with its downstream targets. Immunobloting and qRT-PCR were performed for target gene expression analysis. Low expression of miR-514 was related to poor prognosis in ovarian cancer patients. MiR-514 repressed proliferation and decreased cisplatin chemosensitivity in ovarian cancer cells by targeting ATP binding cassette subfamily. MiR-514 is of clinically significance in ovarian cancer by attenuating proliferation of ovarian cancer cells and decreasing chemoresistance of cisplatin by targeting ATP binding cassette subfamily. cell line up-regulated resistant ATP binding cassette subfamily NA NA validated 2824 MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol 2018 29767234 miRBase MIMAT0000443 miR-125a-5p miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma RT-qPCR The role of miR-125a-5p was deteced by RT-qPCR, Western blot analysis, CCK-8 assay, Cell apoptosis assay, Would healing assay, Cell invasion assay, Plasmid construction and luciferase reporter assay. tissue and cell line (ESCC ) up-regulated sensitive STAT3 STAT3 STAT3 signaling pathway validated 2825 miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer. Exp Cell Res 2018 29772221 miRBase MI0000745 miR-301a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-PCR Hypoxia is a hallmark of pancreatic cancer (PC) and is associated with gemcitabine resistance. However, the mechanisms underlying hypoxia-induced gemcitabine resistance in PC remain greatly unknown. Our previous work showed that miR-301a, a hypoxia-sensitive miRNA, is involved in PC metastasis under hypoxia via regulation of its target gene P63. Here, we showed that miR-301a was upregulated in a NF-kappaB independent manner and promoted gemcitabine resistance under hypoxic conditions in vitro. In addition, TAp63, a member of the P63 family, reversed hypoxia-induced gemcitabine resistance by promoting degradation of HIF-1alpha. Furthermore,we proved that TAp63 was a functional downstream target of miR-301a and mediated the biological properties of miR-301a in PC. Taken together, these findings indicate that miR-301a exerts as a critical regulator involved in hypoxia-induced gemcitabine resistance in PC and may have potentials to be a therapeutic target for PC patients. cell line (MIA PaCa-2, BxPC-3, Panc-1, HPAF-II,SW1990, AsPC-1 and HEK 293T) up-regulated resistant TAp63 TAp63 NA validated 2826 UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun 2018 29777711 miRBase MI0000252/MI0000473 miR-129 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis.fuciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SKOV3, HeyA-8,SKOV3/PTX and HeyA-8/PTX) down-regulated sensitive ABCB1 ABCB1 UCA1/miR-129/ABCB1 validated 2827 Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer. Mol Cancer Res 2018 29784669 miRBase MI0003124 miR-489 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The current study identifies autophagy as a novel pathway targeted by miR-489 and reports Unc-51 like autophagy activating kinase 1 (ULK1) and lysosomal protein transmembrane 4 Beta (LAPTM4B) to be direct targets of miR-489. Furthermore, the data demonstrate autophagy inhibition and LAPTM4B downregulation as a major mechanism responsible for miR-489-mediated doxorubicin sensitization. Finally, miR-489 and LAPTM4B levels were inversely correlated in human tumor clinical specimens, and more importantly, miR-489 expression levels predict overall survival in patients with 8q22 amplification (the region in which LAPTM4B resides).Implications: These findings expand the understanding of miR-489-mediated tumor suppression and chemosensitization in and suggest a strategy for using miR-489 as a therapeutic sensitizer in a defined subgroup of resistant breast cancer patients cell line (T47D) up-regulated sensitive ULK1 and LAMTM4B ULK1 and LAMTM4B NA validated 2828 miR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer. Int J Mol Med 2018 29786108 miRBase MI0003134 miR-494 miRNA DB01259 (DB02584) Lapatinib stomach cancer qRT-PCR The aim of the present study was to explore the effects of miR-494 and FGFR2 in regulation of cancer-initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2-positive gastric cancer. Western blot analysis was used to identify that the expression of fibroblast growth factor receptor 2 (FGFR2), a receptor tyrosine kinase, was upregulated in gastric cancer tissues. Formation of cancer initiating cells (CICs) and resistance to lapatinib were determined using sphere growth assay and MTT assay, respectively. The overexpression of FGFR2 promoted the generation of cancer-initiating cells (CICs) and resistance to lapatinib in HER2-positive gastric cancer YCC1 cells. In addition, it was observed that overexpression of microRNA (miR)-494 downregulated the protein expression of FGFR2, inhibited the formation of CICs and reversed lapatinib resistance in YCC1-F cells (HER2-positive, FGFR2 overexpressing and lapatinib-resistant gastric cancer cells). Therefore, it was concluded that miR-494 inhibited the CIC phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2-positive gastric cancer. cell line (YCC1-F) up-regulated sensitive FGFR2 FGFR2 NA validated 2829 microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. Arch Biochem Biophys 2018 29802821 miRBase MIMAT0000242 miR-129-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR By qRT-PCR assay, we revealed that the expression of miR-129-5p was significantly decreased in breast cancer tissues and Adriamycin-resistant breast cancer cells (MDA-MB-231/ADR, MCF-7/ADR). CCK-8, colony formation, wound healing, Transwell invasion, and flow cytometric profiles were examined to determine the influence of miR-129-5p on Adriamycin-resistant breast cancer in vitro. The upregulation of miR-129-5p decreased the IC50 concentration of Adriamycin and invasion and promoted the apoptosis of MDA-MB-231/ADR cells in the presence of Adriamycin, whereas the upregulation of SOX2 reversed these effects. A luciferase reporter assay confirmed the binding of miR-129-5p to the 3'UTR of SOX2. Collectively, it was suggested that miR-129-5p suppresses Adriamycin resistance in breast cancer by directly targeting SOX2. tissue and cell line (MDA-MB-231, MCF-7,MDA-MB-231/ADR,MCF-7/ADR) up-regulated sensitive SOX2 SOX2 NA validated 2830 MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy. Cell Physiol Biochem 2018 29807360 miRBase MI0000735 miR-29c miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR We employed qRT-PCR, western blot and immunofluorescence to examine the expression level of miR-29c, USP22 and autophagy relative protein. In addition, we used MTT assay to detect cell proliferation and transwell assay to measure migration and invasiveness. The apoptosis was determined using annexin V-FITC/PI apoptosis detection kit by flow cytometry. Luciferase reporter assays confirmed the relationship between USP22 and miR-29c. cell line (PANC-1) up-regulated sensitive USP22 USP22 NA validated 2831 MicroRNA-663b mediates TAM resistance in breast cancer by modulating TP73 expression. Mol Med Rep 2018 29845295 miRBase MI0006336 miR-663b miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR The aim of the present study was to investigate the role of miRNA-663b in TAM resistance in breast cancer.The expression levels of miRNA were determined byReverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( MCF7,MCF7/TAM) up-regulated resistant TP73 TP73 NA validated 2832 MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy. Cell Biol Int 2018 29851226 miRBase MI0000651/ MI0000437 miR-1 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR In the present study, RT-qPCR assay revealed that microRNA-1 (miR-1) expression was downregulated in DDP resistant NSCLC tissues and cells. Western blot assay presented a remarkable increase of LC3B-II/LC3B-I ratio and a notable decline of p62 level in DDP resistant NSCLC cells, while these effects were weakened by miR-1. GFP-LC3 puncta experiment showed that ectopic expression of miR-1 induced a noticeable downregulation of GFP-LC3 positive cell percentage in DDP resistant NSCLC cells. Bioinformatical analysis and luciferase assay revealed that autophagy related 3 (ATG3) was a target of miR-1. Also, Western blot and RT-qPCR assays manifested that ATG3 was highly expressed in DDP resistant NSCLC tissues and cells. Additionally, miR-1 inhibited ATG3 expression and ATG3 upregulation abolished miR-1-meidated autophagy inhibition in DDP resistant NSCLC cells. Cell Counting Kit-8 (CCK-8) assay showed that the half maximal inhibitory concentration (IC50 ) of cisplatin (DDP) was reduced in miR-1-enforced DDP resistant NSCLC cells, but was restored following the overexpression of ATG3. Flow cytometry experiments further showed that miR-1 overexpression induced a significant upregulation of apoptotic rate and ATG3 restoration weakened miR-1-induced apoptosis in DDP resistant NSCLC cells. Collectively, our study validated that miR-1 overexpression improved DDP sensitivity of NSCLC cells by inhibiting ATG3-mediated autophagy, providing a potential therapeutic target for easing chemoresistance of anti-tumor drugs. cell line (A549, H1299, A549/DDP and H1299/DDP) up-regulated sensitive ATG3 ATG3 NA validated 2833 Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. Int J Biol Macromol 2018 29852230 miRBase MIMAT0000461 miR-195-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In the present study, we found that miR-195-5p expression was significantly decreased as compared to paired, tumor-adjacent normal colorectal tissues. We demonstrated that miR-195-5p inhibited the stem-like capacity of CRC cells. We established 5-FU-resistant SW620 and HT-29 cell lines and performed a variety of functional assays following exposure to miR-195-5p and anti-miR-195-5p. In 5-FU-resistant cells, expression of miR-195-5p, P-gp and ABCG2 was decreased. MiR-195-5p significantly increased cancer cell apoptosis and decreased tumor sphere formation. In order to determine the mechanism by which miR-195-5p reduced CRC cell stemness and chemoresistance, we first identified potential targets of miR-195-5p. The 3 UTR of Notch signaling proteins Notch2 and RBPJ, which are essential genes in CRC cell stemness and chemoresistance, possessed double putative binding sites of miR-195-5p. qRT-PCR and western blot assays demonstrated significant decreases in Notch2 and RBPJ when CRC cell lines were exposed to miR-195-5p and significant increases when exposed to anti-miR-195-5p. These findings indicate that miR-195-5p has the potential to improve standard therapeutic approaches to CRC. tissue and cell line (SW480, SW620, HT-29, and HCT-160) up-regulated sensitive Notch2 and RBPJ Notch2 and RBPJ Notch signaling pathway validated 2834 miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. Biomed Pharmacother 2018 29864913 miRBase MI0000252/MI0000473 miR-129 miRNA DB00531 (APRD00408) Cytoxan neuroblastoma RT-qPCR The expression levels of miRNA were determined byReverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( NBSD, SK-N-SH, SK-SY-5Y, SK-N-AS, IMR-32, Neuro-2a, BEM17,NB1, Kelly and NB-1643) up-regulated sensitive MYO10 MYO10 NA validated 2835 MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer 2018 29866054 miRBase MIMAT0000232 miR-199a-3p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR We performed the qRT-PCR, western blot and the luciferase reporter assays to test whether Adenylate Kinase 4 (AK4) is the target of miR-199a-3p. Up- or down-regulation of miR-199a-3p and/or the AK4 gene was done to detect their roles in OS multi-drug resistance using drug resistance profiling assays. We further predicted the putative signal pathway involved in the miR-199a-3p-mediated OS drug-resistance. cell line (G-292,U2OS, MNNG/HOS) up-regulated resistant AK4 AK4 NF-kappaB pathway validated 2836 MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer 2018 29866054 miRBase MIMAT0000232 miR-199a-3p miRNA DB00958 (APRD00466) Carboplatin osteosarcoma qRT-PCR We performed the qRT-PCR, western blot and the luciferase reporter assays to test whether Adenylate Kinase 4 (AK4) is the target of miR-199a-3p. Up- or down-regulation of miR-199a-3p and/or the AK4 gene was done to detect their roles in OS multi-drug resistance using drug resistance profiling assays. We further predicted the putative signal pathway involved in the miR-199a-3p-mediated OS drug-resistance. cell line (G-292,U2OS, MNNG/HOS) up-regulated resistant AK4 AK4 NF-kappaB pathway validated 2837 MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer 2018 29866054 miRBase MIMAT0000232 miR-199a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR We performed the qRT-PCR, western blot and the luciferase reporter assays to test whether Adenylate Kinase 4 (AK4) is the target of miR-199a-3p. Up- or down-regulation of miR-199a-3p and/or the AK4 gene was done to detect their roles in OS multi-drug resistance using drug resistance profiling assays. We further predicted the putative signal pathway involved in the miR-199a-3p-mediated OS drug-resistance. cell line (G-292,U2OS, MNNG/HOS) up-regulated resistant AK4 AK4 NF-kappaB pathway validated 2838 Negative Regulation of PTEN by MicroRNA-221 and Its Association with Drug Resistance and Cellular Senescence in Lung Cancer Cells. Biomed Res Int 2018 29876362 miRBase MI0000298 miR-221 miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR The expression levels of miR-221 in different lung cancer cell lines H226, H1299, and A549 were measured. H1299 and A549 cell lines were transfected to overexpress and downexpress miR-221, and cell viability and cell senescence were determined. The PTEN/Akt pathway was then examined by real-time polymerase chain reaction and Western blot analysis. cell line (A549) up-regulated resistant PTEN PTEN PTEN/Akt pathway validated 2839 miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol 2018 29876787 miRBase MI0006405 miR-1268a miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR We conducted RNA sequencing (RNA-seq) for GBM cells treated continuously with TMZ 1 or 2 week or not. Bioinformatic analysis was used to predict targets of these altered miRNAs. Subsequently, we studied the potential role of miR-1268a in TMZ-resistance of GBM cells. cell line (U87 and LN229) up-regulated sensitive ABCC1 ABCC1 NA validated 2840 microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chem Biol Interact 2018 29890129 miRBase MIMAT0000231 miR-199a-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR Higher protective autophagy was identified in IM-resistant K562 (K562R) cells. Inhibition of autophagy by the inhibitors, chloroquine and 3-methyladenine, enhanced IMs efficacy in K562R cells. In addition, microRNA (miR)-199a/b-5p were downregulated in K562R cells compared to parent cells. Overexpression of miR-199a/b-5p reduced autophagy and induced cell apoptosis, resulting in enhanced IMs efficacy in K562R cells. Moreover, expression levels of the Wingless-type MMTV integration site family member 2 (WNT2), a positive regulator of autophagy, were significantly higher in K562R cells, and it was validated as a direct target gene of miR-199a/b-5p. Overexpressions of miR-199a/b-5p inhibited WNT2 downstream signaling. Furthermore, overexpression and knockdown of WNT2 influenced autophagy formation and CML drug sensitivity to IM. Overexpression of WNT2 could also reverse miR-199a/b-5p-enhanced IM efficacy in K562R cells. These results emphasized that miR-199a/b-5p inhibited autophagy via repressing WNT2 signaling and might provide novel therapeutic strategies for future IM-resistant CML therapy and drug development. cell line (K562, K562R, KU812, and KU812R) up-regulated sensitive WNT2 WNT2 WNT2-mediated Beta-catenin signaling pathway validated 2841 microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chem Biol Interact 2018 29890129 miRBase MIMAT0000263 miR-199b-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR Higher protective autophagy was identified in IM-resistant K562 (K562R) cells. Inhibition of autophagy by the inhibitors, chloroquine and 3-methyladenine, enhanced IMs efficacy in K562R cells. In addition, microRNA (miR)-199a/b-5p were downregulated in K562R cells compared to parent cells. Overexpression of miR-199a/b-5p reduced autophagy and induced cell apoptosis, resulting in enhanced IMs efficacy in K562R cells. Moreover, expression levels of the Wingless-type MMTV integration site family member 2 (WNT2), a positive regulator of autophagy, were significantly higher in K562R cells, and it was validated as a direct target gene of miR-199a/b-5p. Overexpressions of miR-199a/b-5p inhibited WNT2 downstream signaling. Furthermore, overexpression and knockdown of WNT2 influenced autophagy formation and CML drug sensitivity to IM. Overexpression of WNT2 could also reverse miR-199a/b-5p-enhanced IM efficacy in K562R cells. These results emphasized that miR-199a/b-5p inhibited autophagy via repressing WNT2 signaling and might provide novel therapeutic strategies for future IM-resistant CML therapy and drug development. cell line (K562, K562R, KU812, and KU812R) up-regulated sensitive WNT2 WNT2 WNT2-mediated Beta-catenin signaling pathway validated 2842 Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1. Cancer Biomark 2018 29914005 miRBase MI0000087 miR-29a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol nasopharyngeal carcinoma qRT-PCR This study aims to investigate the role of miR-29a in regulating STAT3, as well as in Taxol resistance of nasopharyngeal carcinoma CNE-1 cells. Dual luciferase reporter gene assay showed a regulatory relationship between miR-29a and STAT3. Rhodamine 123 repository in CNE-1 and CNE1/Taxol drug resistant cells was measured together with the expression of miR-29a, STAT3, and p-STAT3. Flow cytometry was used to measure cell apoptosis and PCNA expression under Taxol treatment. CNE-1/Taxol cells were treated with miR-29a mimic and or si-STAT3, followed by measuring the expression of miR-29a, STAT3, and p-STAT3 and cell apoptosis. CCK-8 assay was performed to evaluate cell proliferation. MiR-29a inhibited STAT3 expression. Significantly lower Rhodamine 123 repository, miR-29a expression and apoptosis and higher expression of STAT3, p-STAT3 and PCNA were observed in CNE-2/ Taxol cells than those in CNE-1 cells. Transfection of miR-29a mimic and/or si-STAT3 decreased STAT3, p-STAT3 and PCNA expression, inhibited proliferation and promoted cell apoptosis. MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression. cell line ( CNE-1, NP69) down-regulated resistant STAT3 STAT3 NA validated 2843 miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma. Basic Clin Pharmacol Toxicol 2018 29924913 miRBase MIMAT0000419 miR-27b-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin anaplastic thyroid cancer RT-PCR The role of miR-27b-3p in the human anaplastic thyroid cancer cells was detected by CCK-8, real-time PCR, western blot analysis,dual-luciferase reporter assay,and ELISA. cell line (SW1736 and 8305C) down-regulated sensitive PPARGamma PPARGamma NA validated 2844 Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-kappaB signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun 2018 29935185 miRBase MI0000070/MI0000115 miR-16 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel hepatocellular carcinoma qRT-PCR The aim of this study was to investigate whether miR-16 is participated in chemoresistance in HCC and shed light on the underlying molecular mechanisms. The findings of the current study discover that miR-16 is down-regulated in HCC tissue and cell lines. The results demonstrate that the inhibition of miR-16 renders resistance to paclitaxel in vitro and in vivo by targeting IKBKB via NF-kappaB signaling pathway, suggesting that miR-16 may be a meaningful therapeutic potential to overcome drug resistance in HCC. cell line (s SMMC-7721, PLC,BEL-7402, BEL-7404, HepG2, HCCLM3,LO2) down-regulated resistant IKBKB IKBKB NF-kappaB signaling pathway validated 2845 Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. Cell Physiol Biochem 2018 29940566 miRBase MI0000284 miR-204 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR The expression of miR-204 was detected in clinical tumor samples and GC cell lines by real time PCR. Tumor cells growth, invasion, and migration were measured by MTT assay, wound healing assay, and transwell invasion assay, respectively. Western blot method was used to detect the protein levels of indicated genes. Luciferase reporter assay was performed to validate the target gene of miR-204. The in vivo role of miR-204 was measured using a xenograft mouse model of GC. cell line ( GES-1,i.e., AGS, SGC-7901, MKN-45, MGC-803,and BGC-823) up-regulated sensitive TGFBR2 TGFBR2 TGF-Beta signalling pathway validated 2846 Knockdown of MiR-20a Enhances Sensitivity of Colorectal Cancer Cells to Cisplatin by Increasing ASK1 Expression. Cell Physiol Biochem 2018 29940575 miRBase MI0000076 miR-20a miRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR MTT assays were performed to determine the viability of HT29, SW480, and LoVo cells. Quantitative real time polymerase chain reaction (qRT-PCR) was performed to examine the expression of miR-20a in these cell lines. Regulation of the miR-20a/ASK1 axis was confirmed by western blotting and luciferase reporter assays. After treatment with miR-20a inhibitor (anti-miR-20a) and cisplatin, production of reactive oxygen species (ROS), mitochondrial membrane potential, and apoptosis were measured by flow cytometry. Activation of ASK1, Bcl-xl, JNK, and caspase-9, -7, and -3 was detected by western blotting. cell line ( HT29, SW480) down-regulated sensitive ASK1 ASK1 ROS/ASK1/JNK pathway validated 2847 MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance. Eur Rev Med Pharmacol Sci 2018 29949147 miRBase MI0000283 miR-203 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin prostate cancer PCR Dual luciferase assay confirmed the targeted relationship between miR-203 and MEK1. MiR-203, MEK1, p-ERK1/2, and B cell lymphoma 2 (Bcl-2) expressions were compared in normal prostate epithelial cells PrEC, prostate cancer cells PC-3M, and drug resistance cells PC-3M/ADM. PC-3M, PC-3M/ADM cell apoptosis and proliferation were detected by using flow cytometry under ADM treatment at IC50 concentration of PC-3M cells. PC-3M cells were cultured in vitro and divided into four groups, including microRNA-normal control (miR-NC), miR-203 mimic, small interfere NC (si-NC), and si-MEK1. cell line ( PC-3M, PC-3M/ADM ) up-regulated sensitive MEK1 MEK1 ERK/MAPK signaling pathway validated 2848 Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. Cancer Biol Med 2018 29951339 miRBase MI0000113 miR-106a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR Eighty-five NSCLC patients, who completed four cycles of gemcitabine and cisplatin chemotherapy, volunteered for this study and their serum samples were collected. Serum samples from 60 healthy subjects were used as controls. Real-time quantitative polymerase chain reaction (real-time qPCR) was used to quantify the level of miR-106a in the serum. Demographic and survival data of these patients were collected for the analysis. tissue down-regulated sensitive NA NA NA validated 2849 Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. Cancer Biol Med 2018 29951339 miRBase MI0000113 miR-106a miRNA DB00441 (APRD00201) Gemcitabine lung non-small cell carcinoma RT-qPCR Eighty-five NSCLC patients, who completed four cycles of gemcitabine and cisplatin chemotherapy, volunteered for this study and their serum samples were collected. Serum samples from 60 healthy subjects were used as controls. Real-time quantitative polymerase chain reaction (real-time qPCR) was used to quantify the level of miR-106a in the serum. Demographic and survival data of these patients were collected for the analysis. tissue down-regulated sensitive NA NA NA validated 2850 MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol 2018 29953965 miRBase MI0000071 miR-17 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR Microarray analysis revealed that aberrant expressed microRNA-17 (miR-17) and DEDD were identified in GC. DEDD has been found to act as an endogenous suppressor of tumor growth and metastasis through epithelial-mesenchymal transition (EMT) process. However, the role of miRNA-17 (miR-17) has not been clearly evaluated in GC, thereby a series of in vitro experiments were performed in this study. The levels of miR-17 and DEDD in GC tissues from patients diagnosed with GC and in five GC cell lines (SGC-7901, MKN-45, HGC-27, BGC823, and AGS) were detected. It was found that miR-17 up-regulated and DEDD down-regulated in GC, and SGC-7901 and AGS cells were adopted for the in vitro cell experiments, in which the expression of miR-17 or DEDD was regulated by transfection. DEDD was validated to be a target gene of miR-17. Inhibition of miR-17 impaired EMT in GC cells. In addition, transwell assay and scratch test results revealed that inhibition of miR-17 hindered GC cell invasion and migration. Moreover, inhibition of miR-17 reduced resistance to cisplatin- or 5-Fu in GC cells and induced cisplatin- or 5-Fu-treated GC cell apoptosis, which evaluated by using CCK-8 and flow cytometry assays. From the short review above, the key findings emerge that inhibition of miR-17 may have tumor suppressive effects on GC and enhance its chemosensitivity by promoting DEDD, highlighting a novel target for GC therapy. cell line (GES-1,AGS, BGC823, HGC27,MKN45, SGC7901) down-regulated sensitive DEDD DEDD NA validated 2851 MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol 2018 29953965 miRBase MI0000071 miR-17 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR Microarray analysis revealed that aberrant expressed microRNA-17 (miR-17) and DEDD were identified in GC. DEDD has been found to act as an endogenous suppressor of tumor growth and metastasis through epithelial-mesenchymal transition (EMT) process. However, the role of miRNA-17 (miR-17) has not been clearly evaluated in GC, thereby a series of in vitro experiments were performed in this study. The levels of miR-17 and DEDD in GC tissues from patients diagnosed with GC and in five GC cell lines (SGC-7901, MKN-45, HGC-27, BGC823, and AGS) were detected. It was found that miR-17 up-regulated and DEDD down-regulated in GC, and SGC-7901 and AGS cells were adopted for the in vitro cell experiments, in which the expression of miR-17 or DEDD was regulated by transfection. DEDD was validated to be a target gene of miR-17. Inhibition of miR-17 impaired EMT in GC cells. In addition, transwell assay and scratch test results revealed that inhibition of miR-17 hindered GC cell invasion and migration. Moreover, inhibition of miR-17 reduced resistance to cisplatin- or 5-Fu in GC cells and induced cisplatin- or 5-Fu-treated GC cell apoptosis, which evaluated by using CCK-8 and flow cytometry assays. From the short review above, the key findings emerge that inhibition of miR-17 may have tumor suppressive effects on GC and enhance its chemosensitivity by promoting DEDD, highlighting a novel target for GC therapy. cell line (GES-1,AGS, BGC823, HGC27,MKN45, SGC7901) down-regulated sensitive DEDD DEDD NA validated 2852 miR-195-5p regulates multi-drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep 2018 29956811 miRBase MIMAT0000461 miR-195-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR In the present study, the effect of miR-195-5p in regulating the MDR of GC cells was investigated. Reverse transcription quantitative-polymerase chain reaction was used to analyze the levels of miR-195-5p in GC cells. Western blot analysis was performed to analyze the protein levels of ZNF139, P-gp, BCL-2 and MRP1. The chemosensitivity of GC cells was determined by MTT. The results showed that the expression of miR-195-5p was decreased in poorly differentiated GC tissues with a higher chemosensitivity. The overexpression of miR-195-5p promoted the chemosensitivity of GC cells. Bioinformatics analysis indicated that Zing finger 139 (ZNF139) was a target of miR-195-5p. miR-195-5p negatively regulated the expression of ZNF139 by binding to its 3-untranslated region. The silencing of ZNF139 promoted the chemosensitivity of GC cells, and the downregulation of ZNF139 reversed the effect of miR-195-5p inhibitor on the chemosensitivity of GC cells. In conclusion, miR-195-5p regulated the MDR of GC cells via targeting ZNF139. cell line (MKN28,MKN74) up-regulated sensitive ZNF139 ZNF139 NA validated 2853 miR-195-5p regulates multi-drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep 2018 29956811 miRBase MIMAT0000461 miR-195-5p miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer RT-qPCR In the present study, the effect of miR-195-5p in regulating the MDR of GC cells was investigated. Reverse transcription quantitative-polymerase chain reaction was used to analyze the levels of miR-195-5p in GC cells. Western blot analysis was performed to analyze the protein levels of ZNF139, P-gp, BCL-2 and MRP1. The chemosensitivity of GC cells was determined by MTT. The results showed that the expression of miR-195-5p was decreased in poorly differentiated GC tissues with a higher chemosensitivity. The overexpression of miR-195-5p promoted the chemosensitivity of GC cells. Bioinformatics analysis indicated that Zing finger 139 (ZNF139) was a target of miR-195-5p. miR-195-5p negatively regulated the expression of ZNF139 by binding to its 3-untranslated region. The silencing of ZNF139 promoted the chemosensitivity of GC cells, and the downregulation of ZNF139 reversed the effect of miR-195-5p inhibitor on the chemosensitivity of GC cells. In conclusion, miR-195-5p regulated the MDR of GC cells via targeting ZNF139. cell line (MKN28,MKN74) up-regulated sensitive ZNF139 ZNF139 NA validated 2854 Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun 2018 29966655 miRBase MIMAT0000252 miR-7-5p miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Cell migration was detected by transwell migration . tissue and cell line (SMMC-7721, Huh7, SK-Hep-1, HepG2,Lo-2) down-regulated resistant ABCC1 ABCC1 NA validated 2855 Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother 2018 29966970 miRBase MI0000811 miR-148b miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma RT-PCR The expression patterns of miR-148b, HDAC6, and Ezrin were detected in CHOP-resistant clinical specimens and a DLBCL cell line. miR-148b, HDAC6, and Ezrin in DLBCL cells were manipulated by cell transfection to explore the functional correlation between them. Cell viability was determined using a CCK-8 assay. cell line ( CRL2631) down-regulated resistant Ezrin NA NA validated 2856 Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother 2018 29966970 miRBase MI0000811 miR-148b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma RT-PCR The expression patterns of miR-148b, HDAC6, and Ezrin were detected in CHOP-resistant clinical specimens and a DLBCL cell line. miR-148b, HDAC6, and Ezrin in DLBCL cells were manipulated by cell transfection to explore the functional correlation between them. Cell viability was determined using a CCK-8 assay. cell line ( CRL2631) down-regulated resistant Ezrin NA NA validated 2857 Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother 2018 29966970 miRBase MI0000811 miR-148b miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma RT-PCR The expression patterns of miR-148b, HDAC6, and Ezrin were detected in CHOP-resistant clinical specimens and a DLBCL cell line. miR-148b, HDAC6, and Ezrin in DLBCL cells were manipulated by cell transfection to explore the functional correlation between them. Cell viability was determined using a CCK-8 assay. cell line ( CRL2631) down-regulated resistant Ezrin NA NA validated 2858 Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother 2018 29966970 miRBase MI0000811 miR-148b miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma RT-PCR The expression patterns of miR-148b, HDAC6, and Ezrin were detected in CHOP-resistant clinical specimens and a DLBCL cell line. miR-148b, HDAC6, and Ezrin in DLBCL cells were manipulated by cell transfection to explore the functional correlation between them. Cell viability was determined using a CCK-8 assay. cell line ( CRL2631) down-regulated resistant Ezrin NA NA validated 2859 Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. Biomed Res Int 2018 29967774 miRBase MIMAT0003322 miR-652-3p miRNA DB00541 (APRD00495) Vincristine acute lymphocytic leukemia qRT-PCR MicroRNAs (miRNAs) expression profiles were screened in plasma samples from pediatric patients with acute lymphoblastic leukemia (ALL) and healthy controls, using qRT-PCR-based TaqMan low-density miRNA arrays. MiR-652-3p (a circulating miRNA) was downregulated in new diagnosis (ND) patients compared with healthy controls. The levels of miR652-3p were restored in complete remission (CR) but were downregulated again in disease relapse (RE). The expression pattern of miR-652-3p was validated in bone marrow (BM) samples from other pediatric ALL patients. MiR-652-3p was significantly upregulated in BM when the patients (n=86) achieved CR, as compared with the matched ND samples (p<0.001). Moreover, the miR-652-3p levels in BM decreased again in two patients at RE. In addition, the lymphoblastic leukemia cell lines Reh and RS4:11 were found to have lower levels of miR-625-3p than the normal B-cell line. Overexpression of miR-652-3p using agomir increased the sensitivity to vincristine and cytarabine (all p<0.05) and promoted apoptosis (both p<0.05) in Reh and RS4:11 cells. In conclusion, the results suggested that a low level of miR-652-3p might be involved in the pathogenesis of pediatric ALL. Overexpression of miR-652-3p might suppress lymphoblastic leukemia cells, promoting apoptosis and increasing sensitivity to chemotherapeutic drugs. cell line (TEL/AML1+ Reh and MLL/AF4+ RS4:11 ) up-regulated sensitive NA NA NA validated 2860 Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. Biomed Res Int 2018 29967774 miRBase MIMAT0003322 miR-652-3p miRNA DB00987 (APRD00499) Cytarabine acute lymphocytic leukemia qRT-PCR MicroRNAs (miRNAs) expression profiles were screened in plasma samples from pediatric patients with acute lymphoblastic leukemia (ALL) and healthy controls, using qRT-PCR-based TaqMan low-density miRNA arrays. MiR-652-3p (a circulating miRNA) was downregulated in new diagnosis (ND) patients compared with healthy controls. The levels of miR652-3p were restored in complete remission (CR) but were downregulated again in disease relapse (RE). The expression pattern of miR-652-3p was validated in bone marrow (BM) samples from other pediatric ALL patients. MiR-652-3p was significantly upregulated in BM when the patients (n=86) achieved CR, as compared with the matched ND samples (p<0.001). Moreover, the miR-652-3p levels in BM decreased again in two patients at RE. In addition, the lymphoblastic leukemia cell lines Reh and RS4:11 were found to have lower levels of miR-625-3p than the normal B-cell line. Overexpression of miR-652-3p using agomir increased the sensitivity to vincristine and cytarabine (all p<0.05) and promoted apoptosis (both p<0.05) in Reh and RS4:11 cells. In conclusion, the results suggested that a low level of miR-652-3p might be involved in the pathogenesis of pediatric ALL. Overexpression of miR-652-3p might suppress lymphoblastic leukemia cells, promoting apoptosis and increasing sensitivity to chemotherapeutic drugs. cell line (TEL/AML1+ Reh and MLL/AF4+ RS4:11 ) up-regulated sensitive NA NA NA validated 2861 MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway. J Biochem Mol Toxicol 2018 29968951 miRBase MI0005567 miR-760 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-qPCR In this study, we found that miR-760 was decreased in HCC cell lines, and doxorubicin (Dox) treatment significantly decreased miR-760 expression in HCC cells. Overexpression of miR-760 sensitized HCC cells to Dox-induced cytotoxicity and apoptosis, whereas miR-760 inhibition showed the opposite effects. Notch1 was predicted as a target gene of miR-760. miR-760 negatively regulated Notch1 expression and Notch1/Hes1 signaling. Overexpression of miR-760 increased PTEN expression and decreased the phosphorylation of Akt. Activation of Notch signaling significantly reversed the inhibitory effect of miR-760 on Dox-resistance and abrogated the effect of miR-760 on the PTEN/Akt signaling pathway in HCC cells. Overall, our results demonstrate that miR-760 inhibits Dox-resistance in HCC cells through inhibiting Notch1 and promoting PTEN expression. cell line (Huh-7, HepG2, SMMC-7221, HL-7702) up-regulated sensitive Notch1 Notch1 Notch1/Hes1-PTEN/Akt Signaling Pathway validated 2862 The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. Biochem Biophys Res Commun 2018 29969627 miRBase MI0000089 miR-31 miRNA DB00851 (APRD00331) Dacarbazine melanoma qRT-PCR Our previous study revealed a miR-31-SOX10 axis that regulated tumor growth and resistance to chemotherapy of melanoma. Up-regulation of SOX10 and down-regulation of miR-31 were found in melanoma tissues. SOX10 was further identified as a target of miR-31. Overexpression of SOX10 dramatically promoted melanoma cell proliferation and chemotherapy resistance both in vitro and in vivo. While enforced miR-31 expression suppressed cell growth and enhanced the chemosensitivity of melanoma cells, the re-expression of SOX10 rescued these effects by activating PI3K/AKT signaling pathway. In conclusion, our results demonstrated that SOX10 acted as an oncogene and was negatively regulated by miR-31, which supports the potential therapeutic strategy against melanoma by targeting the miR-31-SOX10 axis. tissue and cell line ( A375, A2058, SKMEL13, HT144, SKMEL5, A875, SKMEL1, M21and 293T) up-regulated sensitive SOX10 SOX10 PI3K/AKT signaling pathway validated 2863 miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1. Cell Physiol Biochem 2018 29975932 miRBase MI0000102 miR-100 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR We established cisplatin-resistant BC models in MDA-MB-231 and MCF-7 BC cell lines through long-term exposure to cisplatin. Quantitative reverse transcription PCR was used to examine the expression of microRNA (miR)-100. MTT cell viability assays were performed to determine cell viability. Regulation of hematopoietic cell-specific protein 1-associated protein X-l (HAX-1) targeted by miR-100 was confirmed by western blotting and luciferase reporter assays. The mitochondrial membrane potential and apoptosis were measured by flow cytometry. Release of cytochrome c from the mitochondria into the cytoplasm, HAX-1 expression, and activation of caspase-9 and caspase-3 were detected by western blotting. cell line (MDA-MB-231 and MCF-7) up-regulated sensitive HAX-1 HAX-1 the mitochondrial pathway validated 2864 MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1. Biomed Res Int 2018 29984257 miRBase MI0000093/MI0000094 miR-92a miRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle and apoptosis were assessed by flow cytometry with PI and PI/Annexin-V stain, respectively. The expression of proteins was examined by western blot. qPCR was used to detect the expression of RNA. Cell migration was assayed with transwell assay. cell line (MG63, HOS, and hFOB) up-regulated sensitive Notch1 Notch1 Notch1 signaling pathway validated 2865 miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Biomed Pharmacother 2018 29990840 miRBase MIMAT0004602 miR-125a-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR We used qRT-PCR to detect miR-125a-3p expression in two PDAC cell lines. And we measured cell viability and apoptosis by MTT assay and flow cytometry, respectively. Scratch wound healing assay and transwell invasion assay were used to test the effects of miR-125a-3p and Fyn on cell EMT process. In addition, we validated the interaction of miR-125a-3p and Fyn by dual luciferase reporter assay. qRT-PCR and western blot were used to detect the mRNA and protein expressions of E-cadhrein, N-cadhrein, Snail and Fyn. cell line ( PATU8988 T, PANC-1) up-regulated sensitive Fyn Fyn NA validated 2866 Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. J Med Chem 2018 29993250 miRBase MI0000077 miR-21 miRNA DB01030 (APRD00687) Topotecan renal cell carcinoma qRT-PCR Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a >10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction. cell line (HeLa,NIH 3T3,A498,MIA PaCa-2,A172,HCT-116,U-87,MCF-7,d PC-3) down-regulated sensitive PDCD4 PDCD4 NA validated 2867 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 miRBase MI0000242/MI0000281 miR-199a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) up-regulated sensitive MRP1 MRP1 miR-199a/MRP1 validated 2868 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 miRBase MI0000242/MI0000281 miR-199a miRNA DB00541 (APRD00495) Vincristine breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) up-regulated sensitive MRP1 MRP1 miR-199a/MRP1 validated 2869 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 miRBase MI0000242/MI0000281 miR-199a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) up-regulated sensitive MRP1 MRP1 miR-199a/MRP1 validated 2870 MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis. Cell Physiol Biochem 2018 30001529 miRBase MI0000268 miR-34a miRNA DB00445 (APRD00361) epirubicin Bladder Cancer qRT-PCR In this study, real-time quantitative polymerase chain reaction (PCR) was used to analyze the expression of miR-34a in bladder cancer cell line BIU87 and its EPI chemoresistant cell line BIU87/ADR. The miR-34a profiles in bladder cancer tissues were obtained from The Cancer Genome Atlas database. The effect of miR-34a on chemosensitivity was evaluated by cell viability assays, colony formation assays, and in vivo experimentation. Apoptosis and the cell cycle were examined by flow cytometry. A luciferase reporter assay was used to assess the target genes of miR-34a. Western blot and qPCR were used to analyze the expression of target proteins and downstream molecules. cell line (BIU87 and BIU87/ADR ) up-regulated sensitive TCF1 and LEF1 TCF1 and LEF1 Wnt/Beta-catenin pathway validated 2871 Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway. Pharmazie 2018 30001772 miRBase MI0016786 miR-4443 miRNA DB00445 (APRD00361) epirubicin lung non-small cell carcinoma qRT-PCR We aimed to elucidate the roles and regulatory mechanism of miR-4443 in regulating the resistance of non-small cell lung cancer (NSCLC) cells to epirubicin (EPI). Fifty-four advanced NSCLC patients were classified as insensitive or sensitive according to patients responses following EPI-based chemotherapy and then the expression of miR-4443 was determined. The EPI-resistant H1299 cells were collected and transfected with miR-4443 mimics, whereas parental H1299 cells were transfected with miR-4443 inhibitors. The inhibition of growth (IC50), cell cycle or apoptosis of different transfected groups were investigated. Additionally, the potential target of miR-3188 was identified and verified by luciferase reporter assay. Besides, the regulatory relationship between miR-3188 and JAK2/STAT3 pathway was explored. cell line ( H1299) up-regulated resistant INPP4A INPP4A JAK2/STAT3 pathway validated 2872 miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). Med Sci Monit 2018 30011263 miRBase MI0000113 miR-106a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR Cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Gene expression levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). Protein expression levels were evaluated by Western blot. TargetScan was used for the prediction of binding sites for miRNA in mRNAs. The interaction between mRNA 3'UTR and miRNA was verified by dual luciferase reporter assay. Tissue samples were obtained from 33 CRC patients who received surgery at Xingtai People's Hospital. cell line (HCT116/SW620 ) up-regulated resistant DUSP2 DUSP2 NA validated 2873 microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Biomed Pharmacother 2018 30021351 miRBase MIMAT0000073 miR-19a-3p miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma RT-qPCR In this study, miR-19a-3p was noted to be upregulated in HCC specimens and cell lines. Aberrant expression of miR-19a-3p stimulated HCC cell metastasis, and phosphatase and tensin homolog (PTEN) was shown to be a direct target of miR-19a-3p. miR-19a-3p-mediated HCC metastasis was reversed by restoration of PTEN or could be imitated by silencing of PTEN. Modulation of miR-19a-3p also altered expression of phosphorylated Akt, a downstream mediator of PTEN. Moreover, aberrant expression of miR-19a-3p induced sorafenib resistance by regulating the PTEN/Akt pathway. In conclusion, ectopic expression of miR-19a-3p contributes to HCC metastasis and chemoresistance by modulating PTEN expression and the PTEN-dependent pathways. cell line (L02,PLC/PRF/5, BEL-7402, Hep3B and HepG2) up-regulated resistant PTEN PTEN PTEN/Akt pathway validated 2874 MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells. Biomed Pharmacother 2018 30021382 miRBase MIMAT0000726 miR-373-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic carcinoma qRT-PCR R software was applied for analyzing differentially expressed genes (DEGs) in cell samples. The potential biological pathway was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, based on R software. The gemcitabine-resistance PC cells were screened out using MTT assay, and they were applied in the next experiments. MiR-373-3p and CCND2 expression in GEM-PANC-1 cells were measured by qRT-PCR. After transfection, the expression of CCND2 protein was examined via western blot assay. Cells viability and apoptosis were confirmed by MTT proliferation assay and Flow cytometry, whereas cells migration and invasion were analyzed by transwell assay. The targeting relationship between miR-373-3p and CCND2 was identified by dual-luciferase reporter assay. cell line (Panc-1,GEM-PANC-1) up-regulated sensitive CCND2 CCND2 NA validated 2875 MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep 2018 30037365 miRBase MI0000764 miR-363 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR In this study, it was indicated that miR-363 downregulation was significantly correlated with EOC carcinogenesis and cisplatin resistance. Moreover, miR-363 overexpression could resensitise cisplatin-resistant EOC cells to cisplatin treatment both in vitro and in vivo. In addition, data revealed that EMT inducer Snail was significantly upregulated in cisplatin-resistant EOC cell lines and EOC patients and was a functional target of miR-363 in EOC cells. Furthermore, snail overexpression could significantly attenuate miR-363-suppressed cisplatin resistance of EOC cells, suggesting that miR-363-regulated cisplatin resistance is mediated by snail-induced EMT in EOC cells. Taken together, findings suggest that miR-363 may be a biomarker for predicting responsiveness to cisplatin-based chemotherapy and a potential therapeutic target in EOC. cell line (OV2008, A2780s,C13, A2780cp) down-regulated resistant snail Snail NA validated 2876 BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica 2018 30049824 miRBase MI0000479 miR-150 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR In this study, we placed these findings into the broader context of the MYC/miR-150/MYB/miR-155/PU.1 oncogenic network. We propose that up-regulated MYC and miR-155 in CD34+ leukemic stem and progenitor cells, in concert with BCR-ABL1, impair the molecular mechanisms of myeloid differentiation associated with low miR-150 and PU.1 levels. We revealed that MYC directly occupied the -11.7 kb and -0.35 kb regulatory regions in the MIR150 gene. MYC occupancy was markedly increased through BCR-ABL1 activity, causing inhibition of MIR150 gene expression in CML CD34+ and CD34- cells. Furthermore, we found an association between reduced miR-150 levels in CML blast cells and their resistance to tyrosine kinase inhibitors (TKIs). Although TKIs successfully disrupted BCR-ABL1 kinase activity in proliferating CML cells, this treatment did not efficiently target quiescent leukemic stem cells. The study presents new evidence regarding the MYC/miR-150/MYB/miR-155/PU.1 leukemic network established by aberrant BCR-ABL1 activity. The key connecting nodes of this network may serve as potential druggable targets to overcome resistance of CML stem and progenitor cells. cell line (K562, MEG-01, KCL-22,HL-60 and KG-1) down-regulated resistant NA NA NA validated 2877 STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance. Biosci Rep 2018 30061175 miRBase MI0000292 miR-216a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR In the study, we aim to explore the role and mechanism of miR-216a in the cisplatin resistance of ovarian cancer. The effects of miR-216a overexpression and inhibition on ovarian cell proliferation, colony formation, and cisplatin resistance were investigated by MTT assay and soft agar colony formation assay. Bioinformatics analyses using TargetScan and rVista, qPCR, and luciferase assay were also used to explore and verify downstream effectors and regulators of miR-216a Proliferation, colony formation, and cisplatin resistance of ovarian cancer cells are promoted by miR-216a overexpression but inhibited by miR-216a inhibition. PTEN is a direct target of miR-216a and PTEN expression antagonizes the tumor-promoting function of miR-216a STAT3 is a regulator of miR-216a, and PTEN is also regulated by STAT3. miR-216a up-regulation is associated with cisplatin resistance in ovarian cancer and this effect is mediated by PTEN. STAT3 is a regulator of miR-216a Strategies that inhibit miR-216a is a potential strategy for overcoming the cisplatin resistance in ovarian cancer. cell line (SKOV3 and OVCA433) up-regulated resistant PTEN PTEN NA validated 2878 Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway. Biosci Rep 2018 30061180 miRBase MIMAT0002890 miR-299-5p miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In the study, we report a role for miR-299-5p in GBM. The level of miR-299-5p expression was detected in glioma specimens and cell lines by qRT-PCR. Luciferase reporter assays and Western blots were performed to verify GOLPH3 as a direct target of miR-299-5p. In vitro cell proliferation, invasion, cell cycle distribution, and apoptosis were assessed to determine whether or not miR-299-5p knockdown sensitized GBM cells to temozolomide (TMZ). We demonstrated that miR-299-5p levels were up-regulated in the GBM groups compared with the normal control group. The highest expression of miR-129-5p occurred in the highest GBM stage. miR-299-5p knockdown significantly inhibited the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway. We also showed that miR-299-5p knockdown enhanced sensitivity of GBM cells to TMZ both in vitro and in vivo by inhibiting cell proliferation and invasion and promoting apoptosis. In addition, we demonstrated that GOLPH3 is a novel functional target of miR-299-5p GOLPH3 regulates the MAPK/ERK axis under miR-299-5p regulation. cell line (SNB19, LN308, T98G, A172, and U251) down-regulated resistant GOLPH3 GOLPH3 MAPK/ERK signaling pathway validated 2879 Ultrasound-targeted microbubble destruction-mediated miR-205 enhances cisplatin cytotoxicity in prostate cancer cells. Mol Med Rep 2018 30066866 miRBase MI0000285 miR-205 miRNA DB00515 (APRD00359) Cisplatin prostate cancer RT-qPCR The aim of the present study was to investigate the potential roles of UTMD-mediated miRNA (miR)-205 delivery in the development of prostate cancer (PCa). In the present study, miR-205 expression was examined by reverse transcription-quantitative polymerase chain reaction assay. miR-205 mimics were transfected into PC-3 cells using the UTMD method, and the PC-3 cells were also treated with cisplatin. Cell proliferation, apoptosis, migration and invasion abilities were detected using Cell Counting kit-8, flow cytometry, wound healing and Transwell assays, respectively. In addition, the protein expression levels of caspase-9, cleaved-caspase 9, cytochrome c (cytoc), epithelial (E)-cadherin, matrix metalloproteinase-9 (MMP-9), phosphorylated (p)-extracellular signal-regulated kinase (ERK) and ERK were measured by western blot analysis. cell line (RWPE-1,VCaP, LNCaP, PC-3, and DU145) down-regulated sensitive NA NA ERK pathway validated 2880 A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Int J Oncol 2018 30066905 miRBase MI0000083/MI0000750 miR-26a miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR The expression levels of miR-26a in ER-positive breast cancer were detected by reverse transcription-quantitative polymerase chain reaction. E2F transcription factor 7 (E2F7) and MYC proto-oncogene, bHLH transcription factor (MYC) levels were detected by western blotting. The present study demonstrated that miR-26a expression was reduced in ER-positive breast cancer compared with in normal breast tissues, whereas E2F7 expression was significantly elevated. Furthermore, an inverse correlation between miR-26a and E2F7 expression was detected in ER-positive breast cancer. The results indicated that miR-26a directly inhibited E2F7 expression through translational inhibition and indirectly inhibited MYC expression partly via E2F7 repression. E2F7, in turn, decreased miR-26a expression via MYC-induced transcriptional inhibition of miRNAs. Furthermore, transfection with miR-26a mimics increased the expression of its host genes (CTD small phosphatase like and CTD small phosphatase 2), whereas ectopic E2F7 expression abrogated the effects of miR-26a. These findings indicated that miR-26a and E2F7 may form a double-negative feedback loop, resulting in downregulation of miR-26a and upregulation of E2F7 in ER-positive breast cancer. Both miR-26a knockdown and E2F7 overexpression conferred resistance to TAM in MCF-7 cells. Conversely, miR-26a overexpression and E2F7 silencing resensitized MCF-7 resistant cells to TAM. These findings revealed that a feedback loop between miR-26a and E2F7 may promote TAM resistance in ER-positive breast cancer. cell line ( MCF-7,T47D, BT474, SKBR3, MDA-MB-231, Hs578T,MCF-10A) down-regulated resistant E2F7 E2F7 NA validated 2881 Knockdown of miR-935 increases paclitaxel sensitivity via regulation of SOX7 in non-small-cell lung cancer. Mol Med Rep 2018 30066948 miRBase MI0005757 miR-935 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma PCR In the present study, the inhibition of microRNA (miR)-935 increased the expression of SOX7 at the mRNA and protein levels in A549 cells. The luciferase reporter assay verified that miR-935 could directly bind to the 3untranslated region of SOX7 mRNA to suppress its expression in A549 cells. In addition, the inhibition of miR-935 enhanced the anticancer effect of paclitaxel, i.e., induced cell growth arrest and apoptosis in A549 cells. It was further observed that the inhibition of miR-935 decreased the B cell lymphoma (Bcl)-2 and phosphorylated-RAC-alpha serine/threonine-protein kinase (AKT) protein levels and increased the Bcl-2 associated X, apoptosis regulator protein levels, without affecting the AKT levels in the presence of paclitaxel within A549 cells. The findings of the present study validate miR-935 as a predictor of paclitaxel sensitivity in NSCLC. cell line (A549) down-regulated sensitive SOX7 SOX7 NA validated 2882 Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1. Cell Physiol Biochem 2018 30071508 miRBase MI0000810 miR-135b miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR QRT-PCR analysis was performed to detect the expression of miR-135b in CRC patients serum and CRC cell lines. MTT assays were used to evaluate the effect of anti-miR-135b on oxaliplatin-induced cell death in CRC cell lines. Western blot, flow cytometry and luciferase reporter assays were performed to evaluate the potential mechanism and pathway of anti-miR-135b-promoted apoptosis in oxaliplatin-treated CRC cells. cell line ( HT29, SW620 and SW480) down-regulated sensitive FOXO1 FOXO1 FOXO1 pathway validated 2883 Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Biomed Pharmacother 2018 30086458 miRBase MIMAT0000092 miR-92a-3p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The main objective of our study was to find potential miR-92a-3p regulating pathways involved in tamoxifen resistance and to construct their regulatory network using bioinformatics. Four gene expression profiles were retrieved from GEO database and the GEO2R tool was used for analysis. GSE41922 and GSE42072 were applied to investigate aberrant miR-92a-3p expression in breast cancer serum and tissue. We found that miR-92a-3p expression was higher in breast cancer serum or tissue than in healthy volunteer serum or adjacent normal tissue, and high expression of miR-92a-3p could predict poor prognosis of breast cancer patients. In our qRT-PCR validation, we found that miR-92a-3p was upregulated in tamoxifen-resistant cells. MiR-92a-3p might play a role in tamoxifen resistance. In order to find the relationship between miR-92a-3p and some key genes and their potential molecular mechanisms in tamoxifen-resistant cells. The microarray data GSE26459 and GSE28267 were analyzed to determine the differentially expressed genes (DEGs) or miRNAs (DEMs). Furthermore, the related long non-coding RNAs (lncRNAs) were screened with starBase v2.0. Finally,microRNA.org,miRDB, targetminer and targetscan were applied to predict the targets of miR-92a-3p. Through analysis, we find that miR-92a-3p may be used as a potential biomarker for early detection of cancer and monitoring the efficacy of endocrine therapy. cell line (MCF-7) up-regulated resistant NA NA NA predicted 2884 Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother 2018 30098551 miRBase MI0000239 miR-197 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The role of miR-197 and TUG1 in triple negative breast cancer cells was detected using qRT-PCR, cell viability assay , bioinformatic analysis , dual luciferase reporter assay , western blot and TOP flash/FOPflash assay ,etc. tissue and cell line (MCF10 A,MCF7, T47D,MDA-MB-231 and BT549) up-regulated sensitive NLK NLK Wnt pathway validated 2885 LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci 2018 30099826 miRBase MIMAT0003885 miR-454-3p miRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration assays . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549, H157,HEK-293T) down-regulated resistant Stat3 STAT3 NA validated 2886 Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett 2018 30102952 miRBase MI0000809 miR-151a miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM). Whether exosomal transfer of miRNAs derived from TMZ-resistant GBM cells could confer TMZ resistance remains to be determined. qPCR was used to determine miR-151a expression in two TMZ-resistant GBM cell lines. The direct targets of miR-151a were identified by microarray assays, bioinformatics and further RNA chromatin immunoprecipitation (RNA-ChIP) assay. We characterized exosomes from TMZ-resistant cell lines, serum and cerebrospinal fluid (CSF) and determined the effect of exosomes from TMZ-resistant cells on recipient GBM cells. miR-151a loss drove the acquisition of TMZ resistance. Restored miR-151a expression sensitized TMZ-resistant GBM cells via inhibiting XRCC4-mediated DNA repair. TMZ-resistant GBM cells conferred TMZ chemoresistance to recipient TMZ-sensitive cells in an exosomal miR-151a loss-dependent manner. Restoration of exosomal miR-151a from donor TMZ-resistant cells abolished the chemoresistance dissemination that was directed by donor TMZ-resistant cells. CSF-derived exosomes contained miRNA signatures reflective of the underlying chemoresistant status of GBMs in terms of miR-151a expression levels. Exosomal miR-151a is not only essentially a less-invasive liquid biopsy that might predict chemotherapy response, but also represents a promising therapeutic target for therapy-refractory GBMs. cell line (U87, U251, T98G, LN229 and A172 ) down-regulated resistant XRCC4 XRCC4 NA validated 2887 miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine 2018 30111512 miRBase MIMAT0003258 miR-590-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin hepatocellular carcinoma RT-qPCR In this study, real-time PCR and western blotting were used to identify the expression profile of key components of Hippo signaling pathway between chemoresistant and chemosensitive HCC cell lines. In vitro and in vivo loss- and gain-of-function studies were performed to reveal the effects and related mechanism of microRNA-590-5p/YAP1 axis in the chemoresistant phenotype of HCC cells. tissue and cell line (HepG2, Huh7,HepG2/ADR and Huh7/ADR ) up-regulated resistant YAP1 YAP1 Hippo signaling pathway validated 2888 miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol Nephrol 2018 30117016 miRBase MIMAT0000242 miR-129-5p miRNA DB00441 (APRD00201) Gemcitabine bladder cancer qRT-PCR The IC50 for gemcitabine in 20 bladder cancer cells was first profiled from Genomics of Drug Sensitivity in Cancer. miR-129-5p level and gene mRNA expression were detected using quantitative real-time PCR (qRT-PCR). Cell viability, apoptosis, and gene protein level were assessed by MTT, flow cytometry, and Western blot, respectively. Regulatory relationship between Wnt5a and miR-129-5p was determined using luciferase reporter assay. cell line (UM-UC-3 and SW780) down-regulated resistant Wnt5a Wnt5a NA validated 2889 miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother 2018 30119173 miRBase MI0003514 miR-539 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR In this study, we found that miR-539 was significantly downregulated in DDP-resistant cell lines (A549/DDP and H1299/DDP). Overexpression of miR-539 enhanced the sensitivity of DDP-resistant NSCLC cells to DDP by suppressing cell proliferation, causing cell cycle arrest, inducing apoptosis, repressing invasion and migration. Whereas, downregulation of miR-539 inhibited the sensitivity of parental NSCLC cells to DDP by promoting cell proliferation and decreasing DDP-induced apoptosis. Furthermore, the luciferase report assay identified doublecortin-like kinase 1 (DCLK1) was a direct target of miR-539. Knockdown of DCLK1 mimicked the function of miR-539-mediated cell chemosensitivity in DDP-resistant NSCLC cells, while restoration of DCLK1 reversed the effect of miR-539 overexpression. We also found that P13-K/AKT/mTOR signaling pathway was also involved in miR-539/DCLK1 axis -mediated chemosensitivity in DDP-resistant NSCLC cells. Additionally, the downregulation of miR-539 was closely correlated with severe clinicopathological parameters including the upregulation of DCLK1, chemosensitivity to DDP, and tumor aggressiveness in NSCLC patients. In conclusion, miR-539 increased the chemosensitivity to DDP in NSCLC cells by directly targeting DCLK1, which might provide potential biomarkers for DDP-resistant NSCLC therapy. cell line ( A549,A549/DDP,H1299,H1299/DDP) down-regulated resistant DCLK1 DCLK1 P13?K/AKT/mTOR signaling pathway validated 2890 MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother 2018 30119207 miRBase MI0006356 miR-1294 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The expression of miR-1294 in OC tissues (n=30) and cell lines was measured by qRT-PCR. Cell transfection was carried out to establish miR-1294 overexpression or knockdown. MTT and clone formation assays were performed to examine proliferation in OC cells. Additionally, wound healing and tumor invasion assays were used to investigate cell migration and invasion, respectively. Finally, the expression of epithelial-to-mesenchymal transition (EMT)-associated proteins was measured in OC cells by western blot. cell line ( SKOV3) up-regulated sensitive IGF1R IGF1R NA validated 2891 Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother 2018 30119236 miRBase MI0000457 miR-141 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (NCM460,SW480, HT29, HCT116,HT29/OXA and HCT116/OXA) down-regulated sensitive PDCD4 PDCD4 NA validated 2892 Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother 2018 30119255 miRBase MI0000542 miR-320a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Fuantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells .Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell lines (MG-63, U2OS, HOS,SAOS-2, hFOB) down-regulated resistant MCL1 MCL1 NA validated 2893 lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141 Cell Commun Signal 2018 30119680 miRBase MI0000457 miR-141 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR Cell proliferation assays, western blot analysis, qRT-PCR, the dual-luciferase reporter assay and RNA immunoprecipitation were performed to investigate the mechanisms by which KRAL mediates 5-fluorouracil resistance in HCC cell lines. cell line (HepG2,SMMC-7721) down-regulated sensitive NA NA Nrf2 signaling pathway validated 2894 Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14. Cell Physiol Biochem 2018 30121664 miRBase MIMAT0000431 miR-140-5p miRNA DB01042 (APRD00118) Melphalan multiple myeloma RT-PCR Plasmids that could interfere with the expression of linc00515 and ATG14 were loaded into myeloma cells, which were cultured with melphalan. MTT assay and flow cytometry analysis were utilized to investigate the effect of linc00515, miR-140-5p and ATG14 on the resistance of myeloma cells. QRT-PCR was used to determine the levels of mRNAs. Western blot was utilized to explore the level of ATG14 and autophagy-related proteins. Dual luciferase assay was utilized to explore the targeting relationship between linc00515, miR-140-5p and ATG14. GFP LC3 fluorescence assay was conducted to study the autophagy of cells. cell line (LP1 and KMS11) up-regulated sensitive ATG14 ATG14 NA validated 2895 MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1. Thorac Cancer 2018 30126075 miRBase MI0005564 miR-873 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR MiRanda and Targetscan websites were used to predict the target gene of miR-873 in NSCLC. Luciferase activity was examined using a dual luciferase reporter gene assay kit. The viability, tube formation, and proliferation of cells were analyzed by cell counting kit-8, angiogenic analysis, and flow cytometry, respectively. The levels of miR-873 and GLI1 were evaluated using quantitative real-time PCR and Western blot assays. cell line (BEAS-2B,PC9,PC9/GR) down-regulated resistant GLI1 GLI1 NA validated 2896 LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. Biosci Rep 2018 30126852 miRBase MI0000069 miR-15a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Fuciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .TUNEL staining was used to detect apoptotic cell death.Tumor model was used to test the role of LINC00473 and miR-15a . tissue and cell line( HCT116,HCT116/ Taxol, SW620 and LoVo) up-regulated sensitive NA NA NA validated 2897 The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 2018 30146342 miRBase MI0003135 miR-495 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR In this study, we found that miR-495 was significantly downregulated in lung cancer tissue specimens. This study aimed to elucidate the functions, direct target genes, and molecular mechanisms of miR-495 in lung cancer. miR-495 downregulated its substrate UBE2C through direct interaction with UBE2C 32- untranslated region. UBE2C is a proto-oncogene activated in lung cancer; however, its role in chemotherapeutic resistance is unclear. Herein, UBE2C expression levels were higher in DDP-resistant NSCLC cells; this was associated with the proliferation, invasion, and DDP resistance in induced cisplatin-resistant NSCLC cells. Furthermore, epithelialmesenchymal transitions (EMT) contributed to DDP resistance. Moreover, UBE2C knockdown downregulated vimentin. In contrast, E-cadherin was upregulated. Importantly, miR-495 and UBE2C were associated with cisplatin resistance. We attempted to evaluate their effects on cell proliferation and cisplatin resistance. We also performed EMT, cell migration, and invasion assays in DDP-resistant NSCLC cells overexpressing miR-495 and under-expressing UBE2C. Furthermore, in silico assays coupled with western blotting and luciferase assays revealed that UBE2C directly binds to the 52-UTR of the drug-resistance genes ABCG2 and ERCC1. Furthermore, miR-495 downregulated ABCG2 and ERCC1 via regulation of UBE2C. Together, the present results indicate that the miR495-UBE2C-ABCG2/ERCC1 axis reverses DDP resistance via downregulation of anti-drug genes and reducing EMT in DDP-resistant NSCLC cells. cell line (A549, H1299, Calu6, H520,HBEC-3KT) down-regulated resistant UBE2C UBE2C NA validated 2898 MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit 2018 30147110 miRBase MI0003135 miR-495 miRNA DB00305 (APRD00284) Mitomycin stomach cancer RT-qPCR After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2, and mTOR was determined by RT-qPCR and Western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay and apoptosis was assessed by flow cytometry. tissue up-regulated sensitive ERBB2 ERBB2 mTOR signaling pathway validated 2899 MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit 2018 30147110 miRBase MI0003135 miR-495 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-qPCR After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2, and mTOR was determined by RT-qPCR and Western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay and apoptosis was assessed by flow cytometry. tissue up-regulated sensitive ERBB2 ERBB2 mTOR signaling pathway validated 2900 MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit 2018 30147110 miRBase MI0003135 miR-495 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-qPCR After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2, and mTOR was determined by RT-qPCR and Western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay and apoptosis was assessed by flow cytometry. tissue up-regulated sensitive ERBB2 ERBB2 mTOR signaling pathway validated 2901 MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). Med Sci Monit 2018 30147110 miRBase MI0003135 miR-495 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2, and mTOR was determined by RT-qPCR and Western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay and apoptosis was assessed by flow cytometry. tissue up-regulated sensitive ERBB2 ERBB2 mTOR signaling pathway validated 2902 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA BCHE miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 2903 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA ADAM2 miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 2904 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA NKAIN3 miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 2905 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA ANKRD1 miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 2906 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA KRTAP13-2 miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 2907 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 miRBase NA IP6K3 miRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 2908 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. Medicine (Baltimore) 2018 30170406 miRBase NA miR-17-92 miRNA DB00526 (APRD00186) Oxaliplatin stomach cancer PCR This study aimed to determine the role of plasma miR-17-92 cluster level in predicting chemoresistance in patients with gastric cancer (GC) undergoing oxaliplatin/capecitabine (XELOX) chemotherapy.Patients recently diagnosed with advanced GC were chosen as participants based on the inclusion criteria. The plasma levels of miR-17-5p, miR-18a, miR-19a/b, miR-20a, and miR-92-1 (miR-17-92 cluster) were determined through quantitative RT-PCR of blood samples from GC patients and healthy volunteers. All the patients received XELOX chemotherapy, and the effectiveness of the chemotherapy was evaluated.The miR-17-92 plasma level was increased in advanced GC patients and decreased after XELOX chemotherapy. Moreover, the miR-17-92 cluster level was associated with chemotherapy response but not with chemotherapy-related toxicity. The miR-17-92 cluster plasma level was decreased in chemosensitive patients, but not in chemoresistant patients, after chemotherapy. The sensitivity and specificity of the combined detection of the miR-17-92 cluster in patients with advanced GC were 100% each.The results suggest that the miR-17-92 plasma level is associated with the progression of advanced GC and effectiveness of XELOX chemotherapy. tissue and cell line down-regulated sensitive NA NA NA validated 2909 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. Medicine (Baltimore) 2018 30170406 miRBase NA miR-17-92 miRNA DB01101 (APRD00203) Capecitabine stomach cancer PCR This study aimed to determine the role of plasma miR-17-92 cluster level in predicting chemoresistance in patients with gastric cancer (GC) undergoing oxaliplatin/capecitabine (XELOX) chemotherapy.Patients recently diagnosed with advanced GC were chosen as participants based on the inclusion criteria. The plasma levels of miR-17-5p, miR-18a, miR-19a/b, miR-20a, and miR-92-1 (miR-17-92 cluster) were determined through quantitative RT-PCR of blood samples from GC patients and healthy volunteers. All the patients received XELOX chemotherapy, and the effectiveness of the chemotherapy was evaluated.The miR-17-92 plasma level was increased in advanced GC patients and decreased after XELOX chemotherapy. Moreover, the miR-17-92 cluster level was associated with chemotherapy response but not with chemotherapy-related toxicity. The miR-17-92 cluster plasma level was decreased in chemosensitive patients, but not in chemoresistant patients, after chemotherapy. The sensitivity and specificity of the combined detection of the miR-17-92 cluster in patients with advanced GC were 100% each.The results suggest that the miR-17-92 plasma level is associated with the progression of advanced GC and effectiveness of XELOX chemotherapy. tissue and cell line down-regulated sensitive NA NA NA validated 2910 MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2. Biomed Res Int 2018 30175116 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR We determined the role of microRNA (miR)-9 in regulating cisplatin chemoresistance in nonsmall cell lung cancer (NSCLC) cells. miR-9 and eukaryotic translation initiation factor 5A2 (eIF5A2) levels were examined by reverse transcription-quantitative PCR. Cell Counting Kit-8 and the 5-ethynyl-2-deoxyuridine (EdU) assay were used to determine the effects of miR-9 mimic or inhibitor on NSCLC cell proliferation and viability, respectively. Bioinformatics was used to analyze the relationship between miR-9 and eIF5A2. Flow cytometry was used to analyze the percentage of apoptotic cells. miR-9 mimic enhanced cisplatin sensitivity, while miR-9 inhibitor produced the opposite result. eIF5A2 was identified as a potential target of miR-9, where miR-9 regulated eIF5A2 expression at mRNA and protein level. miR-9 mimic decreased the expression of eIF5A2 mRNA and protein, while miR-9 inhibitor increased eIF5A2 expression. eIF5A2 knockdown resolved the effects of miR-9 mimic or inhibitor on cisplatin sensitivity. miR-9 may be a potential biomarker for enhancing cisplatin sensitivity by regulating eIF5A2 in NSCLC cells. cell lines (A549, NCI-H358, and NCI-H1299) up-regulated sensitive EIF5A2 EIF5A2 NA validated 2911 miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells. J Immunol Res 2018 30175154 miRBase MI0000268 miR-34a miRNA DB00526 (APRD00186) Oxaliplatin colon cancer RT-qPCR In the study, we report for the first time that miR-34a expression was significantly downregulated in clinical CCa samples from oxaliplatin-resistant patients and in experimentally established multidrug-resistant CCa cells. By using histoculture drug response assay, we further confirmed that clinical CCa samples with lower miR-34a expression appeared to be more resistant to chemotherapy. Functionally, ectopic expression of exogenous miR-34a resensitized multidrug-resistant HCT-8/OR cells to oxaliplatin treatment, whereas miR-34a inhibition augmented the oxaliplatin resistance in chemosensitive HCT-8 cells. Mechanistically, miR-34a positively regulated the mRNA stability of the ornithine decarboxylase antizyme 2 (OAZ2) by directly targeting its three prime untranslated region (3UTR). Consequently, suppression of the expression of miR-34a/OAZ2 signaling by chemotherapeutic agents significantly enhanced the activation of MDR-associated ATP-binding cassette (ABC) transporters and antiapoptosis pathways, thus leading to MDR development in CCa cells. Collectively, our combined analysis reveals a critical role of miR-34a/OAZ2 cascade in conferring a proper cellular response to CCa chemotherapy. tissue and cell line (HCT-8, HCT-116, and SW-480) down-regulated resistant OAZ2 OAZ2 NA validated 2912 MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer. Technol Cancer Res Treat 2018 30176759 miRBase MI0000824 miR-325 miRNA DB00515 (APRD00359) Cisplatin bladder cancer qPCR Human microRNA-325 expression was probed by quantitative real-time polymerase chain reaction in both in vitro bladder cancer cell lines and in vivo bladder carcinoma tissues retrieved from patients with cancer. The prognostic potential of human microRNA-325 in predicting postoperative overall survival of patients with bladder cancer was estimated. Endogenous human microRNA-325 was overexpressed by lentiviral transduction in bladder cancer cell lines, T24 and 5637 cells. The tumor regulatory effects of human microRNA-325 upregulation on T24 and 5637 cells were evaluated both in vitro and in vivo. cell line (T24, RT4, 5637, HT-1376, J82, UM-UC-3, and TCCSUP) up-regulated sensitive NA NA NA validated 2913 miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. Exp Hematol 2018 30195077 miRBase MI0000293 miR-217 miRNA DB01254 Dasatinib chronic myeloid leukemia qPCR In this study, we observed an increased level of AGR2 in TKI-resistant CML cells. Silence of AGR2 in dasatinib-resistant K562 (K562DR) cells led to restored sensitivity to dasatinib both in vitro and in vivo. Exposure to dasatinib induced upregulation of AGR2 in K562 cells, which indicated a probable treatment-related drug resistance. We further investigated the potential interaction between microRNA (miRNA) and AGR2 in K562DR cells and found that downregulation of miR-217 was associated with overexpression of AGR2 in K562DR cells. Luciferase reporter assay identified that miR-217 negatively regulated expression of AGR2 through binding the 3-untranslated region of AGR2. Hypermethylation of the CpG island on the promoter region of the MIR217 gene is a probable reason for the downregulation of miR-217 in dasatinib-treated K562 cells. Forced expression of miR-217 led to decreased expression of AGR2 as well as compromised TKI-resistant potential of K562DR cells. Similarly, overexpression of miR-217 resensitized K562DR cells to dasatinib treatment in a murine xenograft transplantation model. TKI treatment-induced drug resistance is correlated with a decrease of miR-217 and upregulation of AGR2. The miR-217/AGR2 interaction might be a potential therapeutic target in treating CML patients with TKI resistance. tissue and cell line (K562, KCL22 and KU812) up-regulated sensitive AGR2 AGR2 miR-217/AGR2 pathway validated 2914 The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a. Mol Ther Nucleic Acids 2018 30195778 miRBase MI0001444 miR-422a miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer RT-qPCR The expression levels of miRNA were determined by Real-Time qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration .Human tumor-bearing nude mice was used to test the role of D63785 and miR-422a . tissue and cell lines (GES-1, SGC7901, MGC803, BGC823, NCI-N87,HEK293 and HEK293T) up-regulated sensitive MEF2D MEF2D miR-422a-MEF2D signaling pathway validated 2915 Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep 2018 30213983 miRBase MI0000069 miR-15a miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-PCR The aim of this study was to investigate the basis of etoposide-resistance in neuroblastoma. To this end, a MYCN-amplified neuroblastoma cell line (HTLA-230) was treated with increasing etoposide concentrations and an etoposide-resistant cell line (HTLA-ER) was obtained. HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio. While both cell populations shared a homozygous TP53 mutation encoding a partially-functioning protein, a mono-allelic deletion of 13q14.3 locus, where the P53 inducible miRNAs 15a/16-1 are located, and the consequent miRNA down-regulation were detected only in HTLA-ER cells. This event correlated with BMI-1 oncoprotein up-regulation which caused a decrease in p16 tumor suppressor content and a metabolic adaptation of HTLA-ER cells. These results, taken collectively, highlight the role of miRNAs 15a/16-1 as markers of chemoresistance. cell line (HTLA-230,HTLA-ER) down-regulated resistant NA NA NA validated 2916 Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep 2018 30213983 miRBase MI0000070 miR-16-1 miRNA DB00773 (APRD00239) Etoposide neuroblastoma RT-PCR The aim of this study was to investigate the basis of etoposide-resistance in neuroblastoma. To this end, a MYCN-amplified neuroblastoma cell line (HTLA-230) was treated with increasing etoposide concentrations and an etoposide-resistant cell line (HTLA-ER) was obtained. HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio. While both cell populations shared a homozygous TP53 mutation encoding a partially-functioning protein, a mono-allelic deletion of 13q14.3 locus, where the P53 inducible miRNAs 15a/16-1 are located, and the consequent miRNA down-regulation were detected only in HTLA-ER cells. This event correlated with BMI-1 oncoprotein up-regulation which caused a decrease in p16 tumor suppressor content and a metabolic adaptation of HTLA-ER cells. These results, taken collectively, highlight the role of miRNAs 15a/16-1 as markers of chemoresistance. cell line (HTLA-230,HTLA-ER) down-regulated resistant NA NA NA validated 2917 MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. Med Sci Monit 2018 30219819 miRBase MIMAT0000252 miR-7-5p miRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression levels of miR-7-5p were detected in cisplatin-resistant cervical cancer cells, HeLa, and SiHa cells (HPV16-positive), and in clinical tissue samples, using miR-7-5p inhibition and a luciferase reporter assay. Fifteen paired cervical cancer tissue samples and adjacent normal cervical tissues were obtained from 15 patients who underwent surgery for cervical cancer. Western blot and flow cytometry were used to investigate cell apoptosis. The expression of mir-7-5p was detected by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) cell line up-regulated resistant BCL2 and PARP-1 BCL2 and PARP-1 NA validated 2918 miR-501-3p sensitizes glioma cells to cisplatin by targeting MYCN. Mol Med Rep 2018 30221699 miRBase MIMAT0004774 miR-501-3p miRNA DB00515 (APRD00359) Cisplatin glioma RT-PCR In the present study, it was revealed that miR-501-3p expression was decreased in glioma tissues and further underexpressed in cisplatin-resistant glioma cells compared with wild-type (WT) glioma cells. Furthermore, cisplatin treatment inhibited the level of miR-501-3p in a time-dependent way. Ectopic expression of miR-501-3p suppressed glioma cell growth and invasion, but increased cisplatin-resistant glioma cell apoptosis. Furthermore, miR-501-3p sensitized glioma cells to cisplatin-induced proliferation arrest and death. Mechanistically, it was demonstrated that miR-501-3p targeted MYCN in glioma cells. In addition, it was revealed that miR-501-3p inhibited MYCN expression by a luciferase reporter assay and reverse transcription-quantitative polymerase chain reaction. Notably, restoration of MYCN reversed the effects of miR-501-3p in cisplatin-resistant glioma cells. In conclusion, these results suggested that miR-501-3p may serve a promising marker for cisplatin resistance. cell line up-regulated sensitive MYCN MYCN NA validated 2919 miRNA-328 overexpression confers cisplatin resistance in non-small cell lung cancer via targeting of PTEN. Mol Med Rep 2018 30221716 miRBase MI0000804 miR-328 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR In the present study, reverse transcription-quantitative polymerase chain reaction analysis revealed a significant increase in miR-328 and a significant decrease in phosphatase and tensin homolog (PTEN) mRNA expression levels within tumor tissues from patients with cisplatin-resistant NSCLC compared with those of cisplatin-sensitive NSCLC patients. In addition, there was a negative correlation between PTEN mRNA and the miR-328 expression levels. In addition, higher miR-328 expression levels, and lower PTEN mRNA and protein expression levels, were detected in cisplatin-resistant A549 (A549rCDDP) cells when compared with in their parental cells. A549rCDDP cells demonstrated significantly higher cell viability compared with A549 cells following treatment with all concentrations of cisplatin tested (2, 4, 6 and 8 -M). Additionally, transfection of miR-328 inhibitor significantly increased PTEN mRNA and protein expression levels. Furthermore, the present study predicted and confirmed PTEN, a well-known tumor suppressor, as a direct target of miR-328 in NSCLC cells via the online tool MiRanda and a dual luciferase assay, respectively. Cell viability assay and flow cytometry analysis demonstrated that inhibition of miR-328 also induced cellular apoptosis and decreased cell proliferation in A549rCDDP cells treated with cisplatin. In conclusion, these results suggested that abnormal expression of miR-328 may contribute to cisplatin resistance in NSCLC, and may be considered to be a novel therapeutic target and indicator for the treatment and prognosis of patients with NSCLC treated with cisplatin-based chemotherapy. cell line ( A549,A549rCDDP ) up-regulated sensitive PTEN PTEN NA validated 2920 MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS. Technol Cancer Res Treat 2018 30231694 miRBase NA miR-19b-5p miRNA DB00515 (APRD00359) Cisplatin Nasopharyngeal Carcinoma qRT-PCR In our study, these results demonstrated that microRNA-19b-5p was significantly downregulated in 37 pairs of nasopharyngeal carcinoma tissues when compared to normal tissues. Enforced expression of microRNA-19b-5p inhibited activity of cell proliferation and cell migration of nasopharyngeal carcinoma cancer cells, CNE1 and HNE1. Furthermore, microRNA-19b-5p targeted KRAS proto-oncogene, GTPase in cancer cells. In human clinical specimens, KRAS was higher expressed in cancer tissues when compared with normal tissues, which was inversely correlated with the expression of microRNA-19b-5p. More interestingly, microRNA-19b-5p sensitizes CNE1 cells to cisplatin by inhibiting its target KRAS. Finally, microRNA-19b-5p inhibits tumorigenesis in vivo. Thus, our results investigated that microRNA-19b-5p functioned as a tumor suppressor and indicated its potential application for the treatment of human nasopharyngeal carcinoma in future. cell line ( HEK293T ) up-regulated sensitive KRAS KRAS NA validated 2921 Chemo-resistance of A172 glioblastoma cells is controlled by miR-1271-regulated Bcl-2. Biomed Pharmacother 2018 30248541 miRBase MI0003814 miR-1271 miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In this study, we aimed to explore the regulation role of miR-1271 on the development of GBM. We found that miR-1271 was a Bcl-2-targeting miRNA, and the levels of miR-1271was decreased in samples from patients with GBM, compared with those from corresponding normal tissue samples. On the other hand, the levels of miR-1271 were inversely related to the levels of Bcl-2, which have been significantly increased in GBM samples. The overall survival was poorer in patients with low levels of miR-1271, compared to those with high levels of miR-1271. In vitro, the chemo-resistant cell survival mediated with Bcl-2 was inhibited by overexpression of miR-1271 and was enhanced by depletion of miR-1271. Thus, the chemo-resistance of GBM cells may be promoted after suppressing miR-1271 through cell survival mediated with Bcl-2. The prognosis of patients with GBM receiving chemotherapy may be improved by overexpressing miR-1271 in cancerous cells. cell line (A172) up-regulated sensitive Bcl-2 Bcl-2 NA validated 2922 Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib. Neoplasma 2018 30249101 miRBase MIMAT0000085 miR-28-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor NA Microarray datasets under the accession number of GSE63159 and GSE45901 were downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed miRNAs (DEMs) that are related to imatinib resistance were identified. GO function and KEGG pathway enrichment analyses were performed, and lncRNA-miRNA-target gene regulatory networks were constructed. Finally, the critical miRNAs and their target genes that are related to imatinib resistance or sensitivity were identified. NA up-regulated resistant NA NA NA predicted 2923 Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib. Neoplasma 2018 30249101 miRBase MIMAT0000443 miR-125a-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor NA Microarray datasets under the accession number of GSE63159 and GSE45901 were downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed miRNAs (DEMs) that are related to imatinib resistance were identified. GO function and KEGG pathway enrichment analyses were performed, and lncRNA-miRNA-target gene regulatory networks were constructed. Finally, the critical miRNAs and their target genes that are related to imatinib resistance or sensitivity were identified. NA up-regulated resistant NA NA NA predicted 2924 miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2. Biomed Pharmacother 2018 30257357 miRBase MIMAT0000732 miR-378a-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR MiR-378a-3p has been reported to sensitize breast cancer cells to chemotherapy. Here, we hypothesized that miR-378a-3p is a potential chemosensitizer in ovarian cancer. Firstly, miR-378a-3p was uncovered to down-regulated in ovarian cancer tissues and cell lines through using qRT-PCR analysis and northern blot analysis. According to the result of Kaplan Meier analysis, low expression of miR-378a-3p is closely associated with unfavorable prognosis of ovarian cancer patients. Subsequently, gain-of function assays indicated that miR-378a-3p suppressed cell proliferation and promoted cell apoptosis. Moreover, miR-378a-3p was found to enhance cisplatin sensitivity of ovarian cancer cells. Mechanism investigations suggested that MAPK1 and GRB2 are two targets of miR-378a-3p. Finally, rescue assays revealed that MAPK1 and GRB2 can reverse the effects of miR-378a-3p on chemosensitivity of ovarian cancer cells. In conclusion, miR-378a-3p enhanced the sensitivity of ovarian cancer cells to cisplatin through targeting MAPK1 and GRB2. tissue and cell line (OVCAR3, SKOV3 and HEK293T ) up-regulated sensitive MAPK1 and GRB2 MAPK1 and GRB2 NA validated 2925 MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother 2018 30257412 miRBase MI0006431 miR-1284 miRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The levels of miR-1284 in different tissues and cell lines were detected through using qRT-PCR analysis. Kaplan Meier analysis was utilized to analyze the influence of miR-1284 expression on the overall survival rate of cervical cancer patients. The biological effects of miR-1284 on the progression and chemosensitivity of cervical cancer were tested through conducting functional assays. Mechanism investigations were used to prove the binding relation between miR-1284 and HMGB1. Rescue assays were applied to demonstrate the effects of miR-1284-HMGB1 axis on chemosensitivity of cervical cancer cells. tissue and cell line (MS751, HeLa, SiHa, C33 A,ECS) up-regulated sensitive HMGB1 HMGB1 NA validated 2926 miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. Eur J Pharmacol 2018 30266665 miRBase MI0000789 miR-381 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In this study, we found that miR-381 expression was down-regulated in DOX-resistant breast cancer cells. miR-381 overexpression increased DOX sensitivity and enhanced DOX-induced apoptosis in breast cancer cells. Moreover, miR-381 could directly target FYN to suppress its expression. Additionally, FYN knockdown displayed similar effect on DOX sensitivity as miR-381 up-regulation. Furthermore, FYN overexpression partly reversed miR-381-induced sensitivity to DOX. Finally, enforced expression of miR-381 also improved DOX sensitivity of breast cancer cells in vivo. In summary, miR-381 inactivated MAPK signaling by down-regulating FYN, thereby promoting the chemosensitization of breast cancer cells to DOX. Therefore, miR-381/FYN/MAPK pathway may be applied as a novel target to overcome DOX resistance in breast cancer patients. cell line (MCF-7, MDA-MB-231,MCF/DOX and MDA-MB-231 ) down-regulated resistant FYN FYN MAPK signaling pathway validated 2927 Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncol Rep 2018 30272330 miRBase MIMAT0000617 miR-200c-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR The aim of the present study was to investigate the role and mechanism of action of miR-200c-3p in the resistance of breast cancer to paclitaxel. It was observed that miR-200c-3p expression, as determined by reverse transcription-quantitative polymerase chain reaction analysis, was significantly downregulated in paclitaxel-resistant MCF-7/Tax cells compared with parental MCF-7 cells. Overexpression of miR-200c-3p increased the chemosensitivity to paclitaxel and enhanced apoptosis in MCF-7/Tax cells, whereas the downregulation of miR-200c-3p exerted the opposite effect. In addition, upregulation of miR-200c-3p in MCF-7/Tax cells suppressed the expression of sex-determining region Y-box 2 (SOX2) at the mRNA and protein levels. Dual-luciferase reporter assay demonstrated that SOX2 is a target of miR-200c-3p in MCF-7/Tax cells. Moreover, knockdown of SOX2 expression increased chemosensitivity to paclitaxel and upregulated miR-200c-3p expression in MCF-7/Tax cells. cell line (MCF-7,MCF-7/Tax) down-regulated resistant SOX2 SOX2 NA validated 2928 Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo. J Breast Cancer 2018 30275853 miRBase MIMAT0000435 miRNA-143-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR We established a hypodermic tumor nude mice model using paclitaxel-resistant TNBC cells. We expressed ectopic hsa-miRNA-143-3p under the control of a breast cancer-specific human mammaglobin promoter that guided the efficient expression of exogenous hsa-miRNA-143-3p only in breast cancer cells. Thereafter, we overexpressed hsa-miRNA-143-3p in xenografts using a recombinant virus system and quantified the expression of hsa-miRNA-143-3p, CIAPIN1 protein, and proteins encoded by related functional genes by western blot. cell line (BT-20, MDA-MB-231, MCF7, SKBr-3, Lovo, HepG2A549, 293T, and MRC-5 ) down-regulated resistant CIAPIN1 CIAPIN1 NA validated 2929 miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Cell Physiol Biochem 2018 30278449 miRBase MI0001648 miR-449a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR Tamoxifen sensitivity was validated by using Cell Counting Kit-8 in tamoxifen-sensitive breast cancer cells (MCF-7, T47D) and tamoxifen-resistant cells (MCF-7/TAM, T47D/ TAM). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of miR-449a in tamoxifen-sensitive/-resistant cells and patient serums. Dual-luciferase assay was used to identify the binding of miR-449a and predicted gene ADAM22. The expression level of ADAM22 was determined by qRT-PCR and western blotting in miR-449a +/- breast cancer cells. Subsequently, rescue experiments were carried out to identify the function of ADAM22 in miR-449a-reduced tamoxifen resistance. Finally, Gene ontology (GO) and Protein-protein interaction analyses were performed to evaluate the potential mechanisms of ADAM22 in regulating tamoxifen resistance. cell line (MCF-7, T47D) down-regulated resistant ADAM22 ADAM22 NA validated 2930 ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer. Biosci Rep 2018 30279206 miRBase MI0000060/MI0000061/MI0000062 Let-7a miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR . Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Transwell was selected to test the invasive ability of the cells . A wound healing assay was performed to examine the capacity of cell migration. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line (LOVO, HCT116, HT29, RKO, SW480 ) down-regulated resistant NA NA NA validated 2931 MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Cell Physiol Biochem 2018 30282072 miRBase MI0000268 miR-34a miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer qRT-PCR We used data from The Cancer Genome Atlas to compare miR-34a expression levels in prostate cancer (PC) tissues with normal prostate tissues. The effects of miR-34a inhibition and overexpression on PC proliferation were evaluated in vitro via Cell Counting Kit-8 (CCK-8) proliferation, colony formation, apoptosis, and cell-cycle assays. A luciferase reporter assay was employed to identify the interactions between miR-34a and specific target genes. To determine the effects of up-regulation of miR-34a on tumor growth and chemo-resistance in vivo, we injected PC cells overexpressing miR-34a into nude mice subcutaneously and evaluated the rate of tumor growth during paclitaxel treatment. We examined changes in the expression levels of miR-34a target genes JAG1 and Notch1 and their downstream genes via miR-34a transfection by quantitative reverse transcription PCR (qRT-PCR) and western blot assay. cell lines (PC-3 and PC-3PR) up-regulated sensitive JAG1 and Notch1 JAG1 and Notch1 Notch1 signaling pathway validated 2932 miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int J Oncol 2018 30320370 miRBase MI0005532 miR-874 miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR In the present study, the precise roles and underlying mechanisms of miR-874 in MDR were investigated in GC. The overexpression of miR-874 reversed cancer cell drug resistance in vitro. According to reporter gene and western blot assays, Autophagy-related 16-like 1 (ATG16 L1) was identified as a direct target of miR-874. ATG16L1 was also demonstrated to be positively associated with autophagy. Reducing the expression of ATG16L1 and inhibiting the occurrence of autophagy sensitized GC cells to chemotherapy. Thus, the miR-874/ATG16L1/autophagy regulatory loop was demonstrated to serve an important role in MDR in GC. Furthermore, miR-874 may be used as a prognostic factor in GC. Overall, miR-874 could inhibit autophagy and sensitize GC cells to chemotherapy via the target gene ATG16L1, highlighting the potential clinical application of miR-874 in chemotherapeutic resistance. tissue and cell line ( SGC7901,BGC823, SGC7901) up-regulated sensitive ATG16L1 ATG16L1 NA validated 2933 Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Mol Oncol 2018 30341811 miRBase MIMAT0005871 miR-1207-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The role of PVT1 and miR1207 in pancreatic cancer cells was detected using qRT-PCR, cell proliferation, apoptosis and cell cycle analysis, PC cell-engrafted tumor mouse model, etc. cell line (293T,MIA PaCa-2, Su.86.86, Capan-1, PANC-1, SW1990, BxPC-3 and AsPC-1) up-regulated sensitive SRC SRC NA validated 2934 Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Mol Oncol 2018 30341811 miRBase MIMAT0005872 miR-1207-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The role of PVT1 and miR1207 in pancreatic cancer cells was detected using qRT-PCR, cell proliferation, apoptosis and cell cycle analysis, PC cell-engrafted tumor mouse model, etc. cell line (293T,MIA PaCa-2, Su.86.86, Capan-1, PANC-1, SW1990, BxPC-3 and AsPC-1) up-regulated sensitive RhoA RhoA NA validated 2935 LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Biochem Biophys Res Commun 2018 30366670 miRBase MI0000804 miR-328 miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR Recombinant virus construction and infection was performed to overexpress or knockdown the expression of MALAT1. Dual luciferase reporter assay was applied to vetify the interaction between MALAT1 and miR-328. The cell viability and cell cycle were analyzed by CCK-8 assay and flow cytometry, respectively. Quantitative real time PCR and western blotting assays were used to measure the expression of genes and proteins. cell line (K562 and KG-1) down-regulated resistant NA NA NA validated 2936 Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother 2018 30372881 miRBase MI0000073 miR-19a miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) . Luciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( BGC823, SGC7901,BGC823/DDP and SGC7901/DDP) tissue and cell line ( GES-1,BGC823, SGC7901,BGC823/DDP and SGC7901/DDP) down-regulated sensitive CASC2 CASC2 NA validated 2937 MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS. Technol Cancer Res Treat 2018 30384806 miRBase MI0000078 miR-22 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR In our study, these results demonstrated that microRNA-22 expression levels were significantly reduced in 40 pairs of human breast cancer tissues when compared to normal tissues. Enforced expression of microRNA-22 inhibited activity of cell proliferation and cell migration in breast cancer cells. Furthermore, microRNA-22 targeted NRAS proto-oncogene, GTPase (NRAS) in breast cancer cells. The expression levels of NRAS in human clinical specimens were higher in breast cancer tissues when compared to normal tissues. Moreover, microRNA-22 sensitized breast cancer cells to paclitaxel by regulation of NRAS. Our results then demonstrated that microRNA-22 functioned as a tumor suppressor microRNA and indicated potential application for the diagnosis and treatment of cancer in the future. tissue and cell line ( MCF7, MDM231 and HEK293T) up-regulated sensitive NRAS NRAS NA validated 2938 lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer. Mol Ther Nucleic Acids 2018 30388621 miRBase MI0000298 miR-221 miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (HPDE6-C7,PANC-1, AsPC-1, Capan-2, SW1990, and BXPC-3 ) up-regulated resistant NA SOCS3 miR-221/SOCS3 pathway validated 2939 MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide. Anticancer Res 2018 30396951 miRBase MI0000114 miR-107 miRNA DB13063 Parthenolide lung non-small cell carcinoma RT-qPCR The effects of miR-107 on cell proliferation and target gene expression were studied. Combinatorial effects of miR-107 and parthenolide were evaluated. cell line (A549) up-regulated sensitive IKBKG IKBKG NA validated 2940 MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma. J Exp Clin Cancer Res 2018 30400960 miRBase MIMAT0000089 miR-31-5p miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma RT-qPCR MiR-31-5p and PARP1 in HCC tissues were tested by RT-PCR and histological analysis, respectively. Next, clonogenic assay and western blot were used to detect miR-31-5p and PARP1 to modulate sensitivity to OXA-based chemotherapy. The distribution of OXA in the nuclear and intracellular was detected by ICP-MS. Coimmunoprecipitation was used to characterize the protein-protein interaction between PARP1 and ABCB9. A xenograft nude mouse model was used to examine the in vivo effects of miR-31-5p. cell line (LO2,MIHA, Hep3B, Huh7) down-regulated sensitive PARP1 PARP1 NA validated 2941 Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. Cancer Med 2018 30430771 miRBase MIMAT0000680 miR-106b-5p miRNA DB00515 (APRD00359) Cisplatin seminoma qRT-PCR In this study, using microarray analysis, we found that long non-coding RNA H19 was upregulated while miRNA-106b-5p was downregulated in an established cisplatin-resistant TCam-2 cell line. Moreover, H19 acts as a miRNA-106b-5p sponge and thus impairs the function of miRNA-106b-5p on its target gene, TDRG1. Based on these findings, we propose that H19 promotes the expression of TDRG1 by sequestering miRNA-106b-5p and uses this mechanism to facilitate cell survival in cisplatin-based chemotherapeutic conditions. tissue and cell line ( TCam-2) down-regulated resistant TDRG1 TDRG1 PI3K/Akt/mTOR signaling pathway validated 2942 Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Cell Physiol Biochem 2018 30439707 miRBase MIMAT0000250 miR-139-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR Cisplatin-resistant SKOV3 and A2780 ovarian cancer cell lines (SKOV3-R and A2780-R, respectively) were established by long-term exposure to cisplatin. MTT assays were performed to evaluate the viability of SKOV3, SKOV3-R, A2780, and A2780-R cells. Quantitative PCR was used to examine the expression of miR-139-5p in these cell lines. The regulatory mechanism was confirmed by western blot analysis and luciferase reporter assays. After treatment with miR-139-5p and cisplatin, mitochondrial membrane potential and apoptosis were measured by using flow cytometry. Interaction with c-Jun and activating transcription factor 2 (ATF2) was evaluated by co-immunoprecipitation. Expression of B-cell lymphoma-extra large (Bcl-xl) and activation of caspase-9 and caspase-3 were detected by western blotting. cell line (SKOV3 and A2780) up-regulated sensitive C-Jun c-Jun c-Jun/Bcl-xl pathway validated 2943 Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1. Cell Physiol Biochem 2018 30439718 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colorectal cancer qRT-PCR The expressions of XIST, miR-124, serum and glucocorticoid-inducible kinase 1 (SGK1) mRNA in DOX-resistant CRC tissues and cells were detected by qRT-PCR or western blot analysis. DOX sensitivity was assessed by detecting IC50 value of DOX, the protein levels of P-glycoprotein (P-gp) and glutathione S-transferase-Pi (GST-Pi) and apoptosis. The interactions between XIST, miR-124 and SGK1 were confirmed by luciferase reporter assay, qRT-PCR and western blot. Xenograft tumor assay was used to verify the role of XIST in DOX resistance in CRC in vivo. tissue and cell line (HCT116,LoVo) up-regulated resistant SGK1 SGK1 NA validated 2944 Mechanism of miR-221 contributes to gefitinib resistance in PC-9 cells Zhonghua Yi Xue Za Zhi 2018 30440142 miRBase MI0000298 miR-221 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer PCR PC-9 cells were transfected with LV-NC and LV-miR-221 to establish cell stabilizing strains (PC-9/NC and PC-9/miR-221), then they were used to detect the relative expression of miR-221 and apoptotic protease activating factor-1 (APAF-1) mRNA by real-time fluorescence quantitative PCR (qRT-PCR). The effects of gefitinib (0-4 umol/L) on the growth and proliferation of cell stabilizing strains were detected by CCK-8 Assay. After gefitinib treatment, cell apoptosis was detected by Flow Cytometry Assays. The expression of epidermal growth factor receptor (EGFR), phosphorylated epidermal growth factor receptor (p-EGFR), APAF-1 and cleaved cysteinyl aspartate specific proteinase-3 (Cleaved-caspase-3) were detected by Western blot. Dual-Luciferase Reporter Assay was used to evaluate the relationship between APAF-1 and miR-221 cell line (PC-9/NC,PC-9/miR-221) up-regulated resistant APAF-1 APAF-1 NA validated 2945 Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer Biochem Biophys Res Commun 2018 30458987 miRBase MI0000290 miR-214 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR Our objective was to investigate whether exosomes derived from gefitinib resistant non-small cell lung cancer cells could confer resistance to its recipient cells. Exosomes were successfully isolated by ultracentrifugation and exosomes morphologies and sizes were determined by transmission electron microscopy and dynamic light scattering analysis. Fluorescent PKH-67 labeled exosomes derived from PC-9GR cells could be taken up and internalized by PC-9 cells. CCK8 measurement showed that PC-9GR-derived exosomes could confer gefitinib resistance in PC-9 cells. MiRNA-214 was upregulated in gefitinib resistant PC-9GR cells and its derived exosomes by qPCR analysis. Inhibition of exosomal miR-214 with antagomir reversed gefitinib resistance conferred by PC-9GR-derived exosomes in vitro, which was confirmed by flow cytometry analysis and westernblot of apoptotic protein (caspase-3, caspase-3 cleaved, bax) and anti-apoptotic protein (bcl-2). Finally, exosomes enriched with miR-214 antagomir was further confirmed to reverse gefitinib resistance in vivo. Our results are the first to show that exosomes derived from gefitinib-resistant PC-9GR cells could transfer resistance to its recipient sensitive PC-9 cells, which might be mediated by exosomal transfer of miR-214. cell line (PC-9, PC-9GR) up-regulated resistant NA NA NA validated 2946 MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells. Exp Cell Res 2018 30463687 miRBase MI0000100 miR-98 miRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR The present study aims to investigate the expression, biological roles and potential mechanisms of miR-98 in human bladder cancer. We found that miR-98 was upregulated in bladder urothelial carcinoma tissues compared with adjacent normal tissues. In addition, miR-98 expression was higher in bladder cancer cell lines than in uroepithelial cell line SV-HUC-1. Functional studies revealed that miR-98 mimic promoted proliferation of T24 cells while miR-98 inhibitor inhibited proliferation of BIU-87 cells. Moreover, miR-98 mimic increased cisplatin/doxorubicin resistance and inhibited apoptosis in T24 cells, while miR-98 inhibitor decreased chemoresistance and facilitated apoptosis in BIU-87 cells. Further experiments using MitoTracker and JC-1 staining showed that miR-98 could regulate mitochondrial fission/fusion balance and mitochondrial membrane potential. Western blot showed that miR-98 upregulated cyclin D1, p-Drp1 and Drp1. Using luciferase reporter assay, we demonstrated that LASS2 acted as a direct target of miR-98. LASS2 overexpression induced mitochondrial fusion and downregulated mitochondrial potential, with decreased p-Drp1 status. Additionally, LASS2 siRNA abrogated the effects of miR-98 mimic on Drp1phosphorylation and chemoresistance. We also found a negative correlation between LASS2 and miR-98 in bladder cancer tissues. In conclusion, our study demonstrates that miR-98 targets LASS2 and regulates bladder cancer chemoresistance through modulation of mitochondrial function. cell line (SV-HUC-1, J82, T24, 5637, RT4, BIU-87) up-regulated resistant LASS2 LASS2 NA validated 2947 MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells. Exp Cell Res 2018 30463687 miRBase MI0000100 miR-98 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin bladder cancer qRT-PCR The present study aims to investigate the expression, biological roles and potential mechanisms of miR-98 in human bladder cancer. We found that miR-98 was upregulated in bladder urothelial carcinoma tissues compared with adjacent normal tissues. In addition, miR-98 expression was higher in bladder cancer cell lines than in uroepithelial cell line SV-HUC-1. Functional studies revealed that miR-98 mimic promoted proliferation of T24 cells while miR-98 inhibitor inhibited proliferation of BIU-87 cells. Moreover, miR-98 mimic increased cisplatin/doxorubicin resistance and inhibited apoptosis in T24 cells, while miR-98 inhibitor decreased chemoresistance and facilitated apoptosis in BIU-87 cells. Further experiments using MitoTracker and JC-1 staining showed that miR-98 could regulate mitochondrial fission/fusion balance and mitochondrial membrane potential. Western blot showed that miR-98 upregulated cyclin D1, p-Drp1 and Drp1. Using luciferase reporter assay, we demonstrated that LASS2 acted as a direct target of miR-98. LASS2 overexpression induced mitochondrial fusion and downregulated mitochondrial potential, with decreased p-Drp1 status. Additionally, LASS2 siRNA abrogated the effects of miR-98 mimic on Drp1phosphorylation and chemoresistance. We also found a negative correlation between LASS2 and miR-98 in bladder cancer tissues. In conclusion, our study demonstrates that miR-98 targets LASS2 and regulates bladder cancer chemoresistance through modulation of mitochondrial function. cell line (SV-HUC-1, J82, T24, 5637, RT4, BIU-87) up-regulated resistant LASS2 LASS2 NA validated 2948 Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis. Cell Physiol Biochem 2018 30466095 miRBase MIMAT0002846 miR-520c-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR Quantitative real-time PCR was used to detect HOXA-AS2 expression in the BM samples and ADR cell lines, U/A and T/A cells. Furthermore, the effects of HOXA-AS2 silencing on cell proliferation and apoptosis were assessed in vitro by CCK8 and flow cytometry, and on tumor growth in vivo. Furthermore, bioinformatics online programs predicted and luciferase reporter assay were used to validate the association of HOXA-AS2 and miR-520c-3p in AML. cell line (U937 and THP-1) down-regulated resistant S100A4 S100A4 miR-520c3p/S100A4 pathway validated 2949 miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther 2018 30470250 miRBase MI0000270/MI0000683 miR-181b miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR Cancer stem cell (CSC)-like properties were tested by a cell proliferation assay and flow cytometry; miR-181b expression was measured by real-time PCR; and Notch2 and related proteins were detected by Western blotting and immunohistochemistry. A mouse xenograft model was also established. cell line (H1650, H1299, A549, and A549/DDP) up-regulated sensitive Notch2 Notch2 Notch2/Hes1 signalling pathway validated 2950 Down-Regulation of MiR-125b Reverses Drug Resistance of Doxorubicin-Resistant Leukemia Cells Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 30501692 miRBase MI0000446/MI0000470 miR125b miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin leukemia PR-qPCR The expression levels of miR125b in doxorubicine drug-sensitive and doxorubicine drug-resistant leukemia cell lines.HL-60, K562 and HL-60/Dox, the K562/Dox were detected by using RT-qPCR; the up-regulation or inhibition of miR-1256 expression in HL-60/Dox were performed by electroporation transfection, then the viability of cells treated with doxorubicine of different concentration was detected by CCK-8 method, the proliferation inhibition curve of cells was drawed, and the IC50 was calculated. cell line (HL-60, K562 and HL-60/Dox) down-regulated sensitive NA NA NA validated 2951 Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma Sci Rep 2018 30510209 miRBase MIMAT0000425 miR-130a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR The current study investigated the role of different expression levels of miR-130a-3p and miR-148a-3p on drug resistance and tumor biology in four esophageal squamous cell carcinoma cell lines.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assays through flow cytometry. cell line (KYSE-70, KYSE-140, KYSE-270 and KYSE-410) up-regulated/down-regulated sensitive Bcl-2,XIAP Bcl-2,XIAP p53-dependent apoptosis-pathway validated 2952 Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma Sci Rep 2018 30510209 miRBase MIMAT0000243 miR-148a-3p miRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR The current study investigated the role of different expression levels of miR-130a-3p and miR-148a-3p on drug resistance and tumor biology in four esophageal squamous cell carcinoma cell lines.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assays through flow cytometry. cell line (KYSE-70, KYSE-140, KYSE-270 and KYSE-410) up-regulated/down-regulated sensitive Bcl-2,Bim Bcl-2,Bim p53-dependent apoptosis-pathway validated 2953 Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma Sci Rep 2018 30510209 miRBase MIMAT0000425 miR-130a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma qRT-PCR The current study investigated the role of different expression levels of miR-130a-3p and miR-148a-3p on drug resistance and tumor biology in four esophageal squamous cell carcinoma cell lines.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assays through flow cytometry. cell line (KYSE-70, KYSE-140, KYSE-270 and KYSE-410) up-regulated/down-regulated sensitive Bcl-2,XIAP Bcl-2,XIAP p53-dependent apoptosis-pathway validated 2954 Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma Sci Rep 2018 30510209 miRBase MIMAT0000243 miR-148a-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma qRT-PCR The current study investigated the role of different expression levels of miR-130a-3p and miR-148a-3p on drug resistance and tumor biology in four esophageal squamous cell carcinoma cell lines.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Apoptosis assays through flow cytometry. cell line (KYSE-70, KYSE-140, KYSE-270 and KYSE-410) up-regulated/down-regulated sensitive Bcl-2,Bim Bcl-2,Bim p53-dependent apoptosis-pathway validated 2955 miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma. Med Sci Monit 2018 30518744 miRBase MI0000087 miR-29a miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR Two MTX-resistant osteosarcoma cell lines, MG-63/MTX and U2OS/MTX, were generated by continuous exposure to stepwise increasing concentrations of MTX. miR-29abc, COL3A1, and MCL1 mRNA expression levels were determined using quantitative real-time PCR (qRT-PCR). Protein expression levels of COL3A1 and MCL1 were detected by Western blot. Cell viability, IC50 value, and cell apoptosis were assessed by CCK-8 assay and flow cytometry, respectively. The target relationship between the miR-29 family and COL3A1 or MCL1 was confirmed by luciferase reporter assay. cell line (MG-63, U2OS,MG-63/MTX,U2OS/MTX ) up-regulated sensitive COL3A1 and MCL1 COL3A1 and MCL1 NA validated 2956 miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma. Med Sci Monit 2018 30518744 miRBase MI0000105/MI0000107 miR-29b miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR Two MTX-resistant osteosarcoma cell lines, MG-63/MTX and U2OS/MTX, were generated by continuous exposure to stepwise increasing concentrations of MTX. miR-29abc, COL3A1, and MCL1 mRNA expression levels were determined using quantitative real-time PCR (qRT-PCR). Protein expression levels of COL3A1 and MCL1 were detected by Western blot. Cell viability, IC50 value, and cell apoptosis were assessed by CCK-8 assay and flow cytometry, respectively. The target relationship between the miR-29 family and COL3A1 or MCL1 was confirmed by luciferase reporter assay. cell line (MG-63, U2OS,MG-63/MTX,U2OS/MTX ) up-regulated sensitive COL3A1 and MCL1 COL3A1 and MCL1 NA validated 2957 miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma. Med Sci Monit 2018 30518744 miRBase MI0000735 miR-29c miRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR Two MTX-resistant osteosarcoma cell lines, MG-63/MTX and U2OS/MTX, were generated by continuous exposure to stepwise increasing concentrations of MTX. miR-29abc, COL3A1, and MCL1 mRNA expression levels were determined using quantitative real-time PCR (qRT-PCR). Protein expression levels of COL3A1 and MCL1 were detected by Western blot. Cell viability, IC50 value, and cell apoptosis were assessed by CCK-8 assay and flow cytometry, respectively. The target relationship between the miR-29 family and COL3A1 or MCL1 was confirmed by luciferase reporter assay. cell line (MG-63, U2OS,MG-63/MTX,U2OS/MTX ) up-regulated sensitive COL3A1 and MCL1 COL3A1 and MCL1 NA validated 2958 LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Med Sci Monit 2018 30521500 miRBase MI0000474 miR-134 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel epithelial ovarian cancer RT-PCR We analyzed aberrantly expressed lncRNAs in chemoresistant EOC cells by microarray and confirmed LINC01118 expression by real-time PCR. The paclitaxel sensitivity alternation was analyzed by MTS, flow cytometry, and Transwell assay, while wound healing assays were performed to assess apoptosis, migration, and invasion in vitro. The interaction between LINC01118 and miR-134 was confirmed by luciferase assay. tissue and cell line ( SKOV3-TR30, SKOV3-TR30, A2780,SKOV3-DDP, COC1/DDP ) down-regulated resistant ABCC1 ABCC1 NA validated 2959 miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway. Cell Physiol Biochem 2018 30522099 miRBase MI0003130 miR-202 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR Quantitative reverse transcriptase real-time PCR analysis was performed to examine the expression of miR-202. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed to evaluate the sensitivity of cisplatin against NSCLC cells. The miR-202/KRas axis was confirmed by western blot and luciferase reporter assays. Cell apoptosis was measured by flow cytometry. KRas expression, MEK1/2 and ERK1/2 phosphorylation, and activation of caspase-9 and caspase-3 were detected by western blot. cell line (NCI-H441 and A549) up-regulated sensitive KRas KRas Ras/MAPK Pathway validated 2960 miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity. Cell Physiol Biochem 2018 30522111 miRBase MI0000442 miR-122 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The expression of miR-122 in CRC cells was examined by quantitative reverse transcriptase real-time PCR. The cytotoxicity of oxaliplatin against CRC cells was evaluated by Cell Counting Kit-8 assays. Mitochondrial membrane potentials and cell apoptotic rates were measured by flow cytometry. Cellular protein expression and interactions were detected by western blot and co-immunoprecipitation. cell line (SW480,HT29,SW480/OR, HT29/OR ) up-regulated sensitive XIAP XIAP XIAP/caspases pathway validated 2961 Increased miR-142 and decreased DJ-1 enhance the sensitivity of pancreatic cancer cell to adriamycin. Eur Rev Med Pharmacol Sci 2018 30536312 miRBase MIMAT0000433 miR-142-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin pancreatic cancer qRT-PCR Dual luciferase assay was performed to assess the targeted relationship between miR-142 and DJ-1. MiR-142, DJ-1, and PTEN expressions in SW1990 cells and drug-resistant SW1990/ADM cells were compared. SW1990/ADM cells were divided into five groups, including mimic-NC, miR-142 mimic, small interfere normal control (si-NC), si-DJ-1, and miR-142 mimic + si-DJ-1 groups. DJ-1, PTEN, phosphorylated-AKT (p-AKT), and Survivin expressions were tested. Cell apoptosis was determined by flow cytometry. Cell proliferation was evaluated by EdU staining. cell line (SW1990,SW1990/ADM) up-regulated sensitive DJ-1 DJ-1 PI3K/AKT signaling pathway validated 2962 miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin. Cell Physiol Biochem 2018 30537730 miRBase MI0003134 miR-494 miRNA NA TRAIL therapy stomach cancer qRT-PCR Expression of miR-494 in gastric cancer tissues and cell lines was detected by quantitative reverse transcriptase real time PCR (qRT-PCR) analysis. Effect of miR-494 on regulating the TRAIL sensitivity to gastric cancer cell lines was evaluated by MTT assays. Bioinformatics and luciferase reporter assays were used to confirm the regulation of miR-494 on survivin. Mitochondrial apoptosis pathway in gastric cancer cells was tested by western blot and flow cytometry analysis. cell line (BGC-823 and MGC-803) up-regulated sensitive survivin survivin RAIL-DR4/ DR5 pathway validated 2963 Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor. J Biosci 2018 30541960 miRBase MIMAT0005450 miR-518e-5p miRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor PCR In the study, we analyzed serum miRNA expression profiles to identify specific serum miRNAs that could be used as early diagnostic markers. Candidate miRNAs were validated using Taqman quantitative PCR with serum samples from secondary imatinibresistant GIST patients (n = 39), imatinib-sensitive GIST patients (n = 37), and healthy controls (n = 28). Serum miR- 518e-5p and miR-548e levels were higher in secondary imatinib-resistant GIST than imatinib-sensitive GIST patients or healthy controls (P less than 0.0001). However, ROC analysis indicated that only miR-518e-5p could distinguish imatinibresistant GIST. To discriminate imatinib-resistant from imatinib-sensitive GIST patients, the AUC for serum miR-518e-5p was 0.9938, with 99.8% sensitivity and 82.1% specificity. Serum miR-518e-5p could also discriminate imatinib-resistant GIST patients from healthy controls with 99.9% sensitivity and 97.4% specificity. These data indicate that serum miR-518e- 5p is a potentially promising non-invasive biomarker for early detection and diagnosis of secondary imatinib-resistant GIST. Serum up-regulated resistant NA NA NA predicted 2964 miR-144-3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. Oncol Rep 2018 30542710 miRBase MIMAT0000436 miR-144-3p miRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR In this study, the response of mir-144-3p to cisplatin in lung cancer was studied.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( A549, H1299, HepG2, MCF-7, HeLa and Cos-7 ) down-regulated resistant Nrf2 Nrf2 Nrf2 signaling pathway validated 2965 Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. Ann Clin Lab Sci 2018 30610041 miRBase MI0001150 miR-196b miRNA DB00853 (APRD00557) Temozolomide glioma qPCR In the present study, we explored the effects of miR-196b expression on glioma cells and characterized the relationship between miR-196b expression and the PI3K/AKT signaling pathway. We found that downregulation of miR-196b decreased the proliferation of U87 and U251 glioma cells. When anti-miR-196b and radiotherapy were used together, cellular proliferation decreased, whereas apoptosis and caspase 3/7activity, an indicator of apoptosis, increased. Meanwhile, downregulation of miR-196b remarkably inhibited glioma cell growth and colony formation when concurrent with temozolomide administration. Further studies demonstrated that neither upregulation nor downregulation of miR-196b markedly changed the protein expression levels of downstream molecules in the PI3K/AKT signaling pathway in cellular experiments. Therefore, whether miR-196b plays a role by activating the PI3K/AKT signaling pathway has not yet been determined. Together, our findings indicate that downregulation of miR-196b increased glioma cell sensitivity to temozolomide chemotherapy and radiotherapy and may be a valuable target when treating malignant gliomas. cell line (U87 and U251) down-regulated sensitive NA NA PI3K/AKT pathway validated 2966 Differential expression of serum miRNAs in patients with advanced non-small cell lung cancer treated by gifitinib before and after acquiring drug resistance Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 30643043 miRBase MI0000077 miR-21 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-PCR A total of 4 patients with advanced NSCLC from Affiliated Hospital of Yueyang Vocational Technical College, who acquired drug resistance during gefitinib therapy from June 2013 to June 2015, were enrolled. Serum samples were collected before treatment and after acquiring drug resistance. MicroRNA (miRNA) microarray was used to assess the levels and compositions of miRNAs in serum. Real-time RT-PCR was used to validate the results of miRNAs with significant differences in expression. The candidate miRNAs inhibitors and mimics were transfected into lung cancer cells by liposome, and the sensitivity of lung cancer cells to gifitinib was detected serum up-regulated resistant PTEN, PDCD4 NA PI3K/Akt pathway predicted 2967 MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D. Cell Mol Biol (Noisy-le-grand) 2018 30672438 miRBase MI0003134 miR-494 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer RT-PCR In this study, we explored investigate the target gene of miR-494 and its roles in chemoresistance of gastric cancer. We found that miR-494 was significantly down-regulated in gastric cancer cells lines compared to the normal gastric epithelial cell line. Exogenous overexpression of miR-494 increased the chemosensitivity of gastric cancer cells to doxorubicin. Moreover, miR-494 expression was reduced in a doxorubicin-resistant gastric cancer cells (AGS/dox) compared with the parental cells. MTT assay showed that AGS/dox cells exhibited an elevated viability compared with the parental cells. Enforced expression of miR-494 inhibited AGS/dox cell viability and colony formation ability. In addition, we demonstrated that elevated expression of miR-494 inhibited the mRNA and protein expression of phosphodiesterases 4D (PDE4D) in gastric cancer cell. Luciferase assay showed that miR-494 directly targeted the 3UTR region of PDE4D. Furthermore, restoration of PDE4D recovered the chemoresistance in miR-494-overexpressed gastric cancer cells. Taken together, this study demonstrated that miR-494 enhanced doxorubicin sensitivity via regulation of PDE4D expression, suggesting a novel therapeutic strategy for anti-chemoresistance in gastric cancer. cell line down-regulated resistant PDE4D PDE4D NA validated 2968 miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther 2019 29925897 miRBase MI0000272 miR-182 miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-PCR The purpose of the current study was to investigate the function of miR-182 in trastuzumab resistance in breast cancer cells. The results showed that both breast cancer SKBR3 trastuzumab-resistant cells (SKBR3/TR) and BT474 trastuzumab-resistant cells (BT474/TR) were associated with miR-182 downregulation compared with their parental cells. Ectopic expression of the miR-182 mimic inhibited trastuzumab resistance, decreasing the invasion and migration of these trastuzumab-resistant cells. However, the miR-182 inhibitor increased trastuzumab resistance, cell invasion, and migration in the parental cells. In addition, MET is a directly targeted gene of miR-182 in breast cancer cells. MET knockdown showed an inhibitory effect of trastuzumab resistance on trastuzumab-resistant cells. In contrast, MET overexpression in SKBR3 cells produced an effect that promotes resistance to trastuzumab. Moreover, we revealed that overexpression of miR-182 reduced trastuzumab resistance in trastuzumab-resistant cells due in part to MET/PI3K/AKT/mTOR signaling pathway inactivation. Furthermore, miR-182 could also sensitize SKBR3/TR cells to trastuzumab in vivo. cell line (SKBR3,BT474) down-regulated resistant MET MET MET/PI3K/AKT/mTOR signaling pathway validated 2969 Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. FASEB J 2019 29985646 miRBase MIMAT0000758 miR-135b-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of miR-135b-5p in human gastric cancer cells was detected by qRT-PCR, western blot analysis,and luciferase reporter assay.etc. cell line ( SNU1 and SNU601) up-regulated resistant KLF4 KLF4 NF-kappaB pathway validated 2970 miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 2019 30166592 miRBase MI0000454 miR-137 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR Using RNA sequence analysis (RNA-seq), for the first time we find that miR-137 level is extremely low in cisplatin resistant ovarian cancer cells, correlating with higher levels of c-Myc and EZH2 expression. Further analyses indicate that in resistant cells c-Myc enhances the expression of EZH2 by directly suppressing miR-137 that targets EZH2 mRNA, and increased expression of EZH2 activates cellular survival pathways, resulting in the resistance to cisplatin. Inhibition of c-Myc-miR-137-EZH2 pathway re-sensitizes resistant cells to cisplatin. Both in vivo and in vitro analyses indicate that cisplatin treatment activates c-Myc-miR-137-EZH2 pathway. Importantly, elevated c-Myc-miR-137-EZH2 pathway in resistant cells is sustained by dual oxidase maturation factor 1 (DUOXA1)-mediated production of reactive oxygen species (ROS). Significantly, clinical studies further confirm the activated c-Myc-miR-137-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients. Thus, our studies elucidate a novel role of miR-137 in regulating c-Myc-EZH2 axis that is crucial to the regulation of cisplatin resistance in ovarian cancer. cell line (PEO1 or PEO4) down-regulated resistant EZH2 EZH2 c-Myc-miR-137-EZH2 pathway validated 2971 HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer. Mol Genet Genomics 2019 30196354 miRBase MI0000476/MI0000455 miR-138 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR Quantitative real-time PCR (RT-PCR) was employed to assess the level of miR-138 in gefitinib-sensitive PC9 cells and gefitinib-resistant PC9GR cells. Bioinformatic algorithms (TargetScan) and rVISTA 2.0 were used to predict binding sites on miR-138 and its target genes. MiR-138 inhibited cell proliferation of PC9 and A549 cells. In PC9GR cells, miR-138 expression was inhibited. Gefitinib treatment negatively regulated miR-138 in PC9 cells. Transfection of PC9GR cells with miR-138 mimics significantly reduced cell viability. MiR-138 was directly regulated by Homeobox A4 (HOXA4) via an HOXA4-binding site on the promoter region. TargetScan predicted numerous miR-138 target genes and EGFR was found to be the functional downstream effector of miR-138. We demonstrated that miR-138 is regulated by HOXA4 and exerts its functions via inhibiting EGFR expression in NSCLC cells. cell line ( PC9 and A549) down-regulated resistant EGFR EGFR NA validated 2972 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000097 miR-99a-5p miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2973 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000097 miR-99a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2974 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000097 miR-99a-5p miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2975 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000097 miR-99a-5p miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2976 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000097 miR-99a-5p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2977 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000423 miR-125b-5p miRNA DB00531 (APRD00408) Cyclophosphamide diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells.The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2978 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000423 miR-125b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells.The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2979 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000423 miR-125b-5p miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells.The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2980 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000423 miR-125b-5p miRNA DB00635 (APRD00340) Prednisone diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells.The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2981 Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019 30211623 miRBase MIMAT0000423 miR-125b-5p miRNA DB00073 (BTD00014, BIOD00014) Rituximab diffuse large B-cell lymphoma qRT-PCR Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells.The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. cell line (SU-DHL-2 ) up-regulated resistant NA NA NA validated 2982 Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. J Cell Physiol 2019 30221354 miRBase MIMAT0000447 miR-134-5p miRNA DB00515 (APRD00359) Cisplatin cervical cancer RT-qPCR The role of NCK1-AS1 in cervical cancer cells was detected using dual-luciferase reporter gene assay, RNA pull-down assay, RNA immunoprecipitation (IP) assay,RT-qPCR, western blot, CCK-8 assay, immunofluorescence assay and flow cytometry,etc. cell line up-regulated sensitive MSH2 MSH2 NA validated 2983 MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells. Anticancer Drugs 2019 30273182 miRBase MI0000489 miR-195 miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR In the study,we found that miR-195 expression was significantly decreased in TMZ-resistant glioma cells induced with TMZ and correlated to the resistance index negatively. Also, the exogenous expression of miR-195 reversed TMZ resistance and induced the apoptosis of TMZ-resistant glioblastoma cells. Further bioinformatics analysis showed cyclin E1 (CCNE1) was a potential target gene of miR-195. Knockdown of CCNE1 partially reversed the effect of decreased miR-195 on TMZ resistance. The data from The Cancer Genome Atlas - Cancer Genome further suggested that hsa-miR-195 could negatively regulate the expression of CCNE1 in glioma. In conclusion, miR-195 reverses the resistance to TMZ by targeting CCNE1 in glioma cells and it could act as a potential target for treatment in glioma with TMZ resistance. cell line ( U251MG ) down-regulated resistant CCNE1 CCNE1 NA validated 2984 LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/Beta-catenin pathway. Gene 2019 30300682 miRBase MIMAT0004692 miR-340-5p miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR In our present study, we firstly detected miR-340-5p expression in breast cancer cell lines and found lower expression of miR-340-5p in breast cancer cell lines (MCF-7, MDA-MB-231, BT-549, ZR-75-1) through qRT-PCR. Overexpressed miR-340-5p inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. Through bioinformatic prediction, we found that LGR5 was a potential target of miR-340-5p. LGR5 was highly expressed in breast cancer cells. Relative expression of LGR5 was negatively regulated by miR-340-5p. Knockdown of LGR5 also inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. Moreover, knockdown of LGR5 decreased the expression of Beta-catenin, c-myc, Survivin. The activation of Wnt/Beta-catenin pathway contracted the effects of LGR5 siRNA, indicating that LGR5 siRNA inhibited cell proliferation and drug resistance with induced apoptosis via suppressing Wnt/Beta-catenin signaling pathway in breast cancer. cell lines (MCF-7, MDA-MB-231, BT-549, ZR-75-1) up-regulated sensitive LGR5 LGR5 Wnt/Beta-catenin pathway validated 2985 Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol 2019 30352127 miRBase MI0000077 miR-21 miRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression levels of miRNA were determined by quantitative real-time polymerase chain reaction and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell migration and invasion assay. TUNEL staining was used to detect apoptotic cell death. cell line down-regulated sensitive TIMP3 and PDCD4 TIMP3 and PDCD4 STAT3 signaling pathway validated 2986 Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p. Int J Oncol 2019 30365045 miRBase MIMAT0000646 miR-155-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer RT-qPCR In the present study, a paclitaxel-resistant gastric cancer cell line (MGC-803R) was generated with a morphological phenotype of epithelial-to-mesenchymal transition (EMT) and increased expression levels of microRNA (miR)-155-5p. MGC-803R cell-derived exosomes were effectively taken up by paclitaxel-sensitive MGC-803S cells, which exhibited EMT and chemoresistance phenotypes. miR-155-5p was enriched in MGC-803R exosomes and could be delivered into MGC-803S cells. miR-155-5p overexpression in MGC-803S cells via transfection with mimics resulted in similar phenotypic effects as treatment with MGC-803R exosome and increased miR-155-5p content in MGC-803S exosomes, which then capable of inducing the malignant phenotype in the sensitive cells. GATA binding protein 3 (GATA3) and tumor protein p53-inducible nuclear protein 1 (TP53INP1) were identified as targets of miR-155-5p. Exosomal miR-155-5p inhibited these targets by directly targeting their 3 untranslated regions. Knockdown of miR-155-5p was observed to reverse the EMT and chemoresistant phenotypes of MGC-803R cells, potentially via GATA3 and TP53INP1 upregulation, which inhibited MGC-803R-exosomes from inducing the malignant phenotype. These results demonstrated that exosomal delivery of miR-155-5p may induce EMT and chemoresistant phenotypes from paclitaxel-resistant gastric cancer cells to the sensitive cells, which may be mediated by GATA3 and TP53INP1 suppression. cell line (MGC-803,MGC-803R) up-regulated sensitive GATA3 and TP53INP1 GATA3 and TP53INP1 NA validated 2987 miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med 2019 30365062 miRBase MI0000483 miR-186 miRNA DB00515 (APRD00359) Cisplatin glioblastoma RT-PCR In this study, using western blot analysis, we found that Yin Yang 1 (YY1) expression was increased in cisplatin-resistant glioblastoma U87MG cells (U87MG-CR). We observed that the silencing of YY1 sensitized the U87MG-CR cells to cisplatin and that the overexpression of YY1 promoted the resistance of LN-229 glioblastoma cells to cisplatin, as shown by MTT assay. Using sphere formation assay, we also found that the silencing of YY1 inhibited the formation of the glioblastoma-initiating cell (GIC) phenotype in the U87MG-CR cells. In addition, the results of RT-qPCR revealed that miR-186 expression was decreased in U87MG-CR cells. Using RT-PCR and western blot analysis, we observed that overexpression of miR-186 inhibited YY1 expression in U87MG-CR cells. The overexpression of miR-186 also reversed cisplatin resistance and the formation of the GIC phenotype in glioblastoma cells. On the whole, the findings of this study demonstrate that miR-186 reverses cisplatin resistance and inhibits the formation of the GIC phenotype by degrading YY1 in glioblastoma. cell line (U87MG,U87MG-CR) up-regulated sensitive YY1 YY1 NA validated 2988 LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol 2019 30365113 miRBase MI0000441 miR-30b miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells. cell line ( HGC-27, 293T, AGS) up-regulated sensitive ATG5 ATG5 NA validated 2989 LncRNA BLACAT1 is involved in chemoresistance of non-small cell lung cancer cells by regulating autophagy. Int J Oncol 2019 30387831 miRBase MI0000071 miR-17 miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The aim of the present study was to determine the effect of the long non-coding RNA (lncRNA) bladder cancer-associated transcript 1 (BLACAT1) in chemoresistance of non-small cell lung cancer (NSCLC) cells. Expression of lncRNA BLACAT1, microRNA (miR)-17, autophagy-related protein 7 (ATG7), multidrug-resistance protein 1 (MRP1), and the autophagy-associated proteins light chain 3 (LC3)-II/LC3-I and Beclin 1 were detected using the reverse transcription-quantitative polymerase chain reaction and western blot analysis. Cell viability was determined using an MTT assay. The interaction between BLACAT1 and miR-17 was determined using RNA immunoprecipitation and RNA pull-down assays. A cisplatin (DDP)-resistant NSCLC cell A549/DDP xenograft model in nude mice was established to investigate the effect of BLACAT1 on the chemoresistance of NSCLC cells cell line (A549, H1299, A549/DDP and H1299/DDP) down-regulated resistant ATG7 ATG7 miR-17/ATG7 signaling pathway validated 2990 miR-34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE-A/p53 signaling. Int J Oncol 2019 30387834 miRBase MI0000268 miR-34a miRNA DB00958 (APRD00466) Carboplatin retinoblastoma RT-qPCR The present study aimed to explore the combined role of microRNA (miR)-34a, melanoma antigen-A (MAGE-A) and p53 in altering the chemosensitivity of retinoblastoma (RB) cells. Human RB and adjacent tumor tissues, as well as human RB cell lines (HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) were used. In addition, four chemotherapeutic drugs, including carboplatin, etoposide, Adriamycin and vincristine, were used to treat the cell lines, in order to evaluate the sensitivity of RB cells. Furthermore, miR-34a expression was detected by reverse transcription-quantitative polymerase chain reaction, and western blotting was implemented to quantify expression levels of MAGE-A and p53. A luciferase reporter gene assay was used to validate the targeted association between miR-34a and MAGE-A. The results indicated that SO-Rb50 cells exhibited the highest resistance to carboplatin, Adriamycin and vincristine (P<0.05), whereas HXO-Rb44 cells revealed the highest inhibition rate in response to etoposide (P<0.05) out of the four cell lines. Furthermore, reduced miR-34a expression and increased MAGE-A expression significantly elevated the survival rate and viability of SO-Rb50 cells following drug treatment (all P<0.05). miR-34a was also demonstrated to directly target MAGE-A, thereby significantly promoting the viability of RB cells and depressing apoptosis (P<0.05). p53, which was subjected to modulation by miR-34a and MAGE-A, also significantly reduced the proliferation rate of RB cells (P<0.05). In conclusion, the miR-34a/MAGE-A/p53 axis may be conducive to enhancing the efficacies of chemotherapeutic treatments for RB. tissue and cell line ( HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) up-regulated sensitive MAGE-A NA MAGE-A/p53 signaling validated 2991 miR-34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE-A/p53 signaling. Int J Oncol 2019 30387834 miRBase MI0000268 miR-34a miRNA DB00773 (APRD00239) Etoposide retinoblastoma RT-qPCR The present study aimed to explore the combined role of microRNA (miR)-34a, melanoma antigen-A (MAGE-A) and p53 in altering the chemosensitivity of retinoblastoma (RB) cells. Human RB and adjacent tumor tissues, as well as human RB cell lines (HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) were used. In addition, four chemotherapeutic drugs, including carboplatin, etoposide, Adriamycin and vincristine, were used to treat the cell lines, in order to evaluate the sensitivity of RB cells. Furthermore, miR-34a expression was detected by reverse transcription-quantitative polymerase chain reaction, and western blotting was implemented to quantify expression levels of MAGE-A and p53. A luciferase reporter gene assay was used to validate the targeted association between miR-34a and MAGE-A. The results indicated that SO-Rb50 cells exhibited the highest resistance to carboplatin, Adriamycin and vincristine (P<0.05), whereas HXO-Rb44 cells revealed the highest inhibition rate in response to etoposide (P<0.05) out of the four cell lines. Furthermore, reduced miR-34a expression and increased MAGE-A expression significantly elevated the survival rate and viability of SO-Rb50 cells following drug treatment (all P<0.05). miR-34a was also demonstrated to directly target MAGE-A, thereby significantly promoting the viability of RB cells and depressing apoptosis (P<0.05). p53, which was subjected to modulation by miR-34a and MAGE-A, also significantly reduced the proliferation rate of RB cells (P<0.05). In conclusion, the miR-34a/MAGE-A/p53 axis may be conducive to enhancing the efficacies of chemotherapeutic treatments for RB. tissue and cell line ( HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) up-regulated sensitive MAGE-A NA MAGE-A/p53 signaling validated 2992 miR-34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE-A/p53 signaling. Int J Oncol 2019 30387834 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin retinoblastoma RT-qPCR The present study aimed to explore the combined role of microRNA (miR)-34a, melanoma antigen-A (MAGE-A) and p53 in altering the chemosensitivity of retinoblastoma (RB) cells. Human RB and adjacent tumor tissues, as well as human RB cell lines (HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) were used. In addition, four chemotherapeutic drugs, including carboplatin, etoposide, Adriamycin and vincristine, were used to treat the cell lines, in order to evaluate the sensitivity of RB cells. Furthermore, miR-34a expression was detected by reverse transcription-quantitative polymerase chain reaction, and western blotting was implemented to quantify expression levels of MAGE-A and p53. A luciferase reporter gene assay was used to validate the targeted association between miR-34a and MAGE-A. The results indicated that SO-Rb50 cells exhibited the highest resistance to carboplatin, Adriamycin and vincristine (P<0.05), whereas HXO-Rb44 cells revealed the highest inhibition rate in response to etoposide (P<0.05) out of the four cell lines. Furthermore, reduced miR-34a expression and increased MAGE-A expression significantly elevated the survival rate and viability of SO-Rb50 cells following drug treatment (all P<0.05). miR-34a was also demonstrated to directly target MAGE-A, thereby significantly promoting the viability of RB cells and depressing apoptosis (P<0.05). p53, which was subjected to modulation by miR-34a and MAGE-A, also significantly reduced the proliferation rate of RB cells (P<0.05). In conclusion, the miR-34a/MAGE-A/p53 axis may be conducive to enhancing the efficacies of chemotherapeutic treatments for RB. tissue and cell line ( HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) up-regulated sensitive MAGE-A NA MAGE-A/p53 signaling validated 2993 miR-34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE-A/p53 signaling. Int J Oncol 2019 30387834 miRBase MI0000268 miR-34a miRNA DB00541 (APRD00495) Vincristine retinoblastoma RT-qPCR The present study aimed to explore the combined role of microRNA (miR)-34a, melanoma antigen-A (MAGE-A) and p53 in altering the chemosensitivity of retinoblastoma (RB) cells. Human RB and adjacent tumor tissues, as well as human RB cell lines (HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) were used. In addition, four chemotherapeutic drugs, including carboplatin, etoposide, Adriamycin and vincristine, were used to treat the cell lines, in order to evaluate the sensitivity of RB cells. Furthermore, miR-34a expression was detected by reverse transcription-quantitative polymerase chain reaction, and western blotting was implemented to quantify expression levels of MAGE-A and p53. A luciferase reporter gene assay was used to validate the targeted association between miR-34a and MAGE-A. The results indicated that SO-Rb50 cells exhibited the highest resistance to carboplatin, Adriamycin and vincristine (P<0.05), whereas HXO-Rb44 cells revealed the highest inhibition rate in response to etoposide (P<0.05) out of the four cell lines. Furthermore, reduced miR-34a expression and increased MAGE-A expression significantly elevated the survival rate and viability of SO-Rb50 cells following drug treatment (all P<0.05). miR-34a was also demonstrated to directly target MAGE-A, thereby significantly promoting the viability of RB cells and depressing apoptosis (P<0.05). p53, which was subjected to modulation by miR-34a and MAGE-A, also significantly reduced the proliferation rate of RB cells (P<0.05). In conclusion, the miR-34a/MAGE-A/p53 axis may be conducive to enhancing the efficacies of chemotherapeutic treatments for RB. tissue and cell line ( HXO-Rb44, SO-Rb50, Y79 and WERI-Rb-1) up-regulated sensitive MAGE-A NA MAGE-A/p53 signaling validated 2994 CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol 2019 30395908 miRBase MIMAT0026480 miR-153-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia qRT-PCR In this study, we established a doxorubicin (ADM)-resistant THP-1 AML cell line (THP-1/ADM). A high-throughput microarray was used to identify circRNA expression profiles of THP-1/ADM cells and naive THP-1 cells. The identified potential functional circRNA molecule was further validated in THP-1/ADM cells and bone marrow (BM) specimens from 42 AML patients. The interactions with target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were also explored. As a result, 49 circRNAs that are significantly differentially expressed between THP-1/ADM and THP-1 cells were identified. Of these circRNAs, downregulation of circPAN3 by small interfering RNA significantly restored ADM sensitivity of THP-1/ADM cells. Furthermore, BM samples from patients with refractory and recurrent AML showed increased expression of circPAN3. A detailed circRNA/miRNA/mRNA interaction network was predicated for this circRNA. Subsequent mechanistic experiments showed that downregulation of circPAN3 could decrease the expression of X-linked inhibitor of apoptosis protein (XIAP), but this effect was counteracted by miR-153-3p or miR-183-5p specific inhibitors. Luciferase experiments further demonstrated that these molecules are involved in the circPAN3 regulatory network. Our results revealed that circPAN3 may be a key mediator for chemoresistance of AML cells, which may depend on the circPAN3-miR-153-5p/miR-183-5p-XIAP axis. tissue and cell line (THP-1) down-regulated resistant XIAP XIAP NA validated 2995 CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol 2019 30395908 miRBase MIMAT0000261 miR-183-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia qRT-PCR In this study, we established a doxorubicin (ADM)-resistant THP-1 AML cell line (THP-1/ADM). A high-throughput microarray was used to identify circRNA expression profiles of THP-1/ADM cells and naive THP-1 cells. The identified potential functional circRNA molecule was further validated in THP-1/ADM cells and bone marrow (BM) specimens from 42 AML patients. The interactions with target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were also explored. As a result, 49 circRNAs that are significantly differentially expressed between THP-1/ADM and THP-1 cells were identified. Of these circRNAs, downregulation of circPAN3 by small interfering RNA significantly restored ADM sensitivity of THP-1/ADM cells. Furthermore, BM samples from patients with refractory and recurrent AML showed increased expression of circPAN3. A detailed circRNA/miRNA/mRNA interaction network was predicated for this circRNA. Subsequent mechanistic experiments showed that downregulation of circPAN3 could decrease the expression of X-linked inhibitor of apoptosis protein (XIAP), but this effect was counteracted by miR-153-3p or miR-183-5p specific inhibitors. Luciferase experiments further demonstrated that these molecules are involved in the circPAN3 regulatory network. Our results revealed that circPAN3 may be a key mediator for chemoresistance of AML cells, which may depend on the circPAN3-miR-153-5p/miR-183-5p-XIAP axis. tissue and cell line (THP-1) down-regulated resistant XIAP XIAP NA validated 2996 Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27. Biomed Pharmacother 2019 30399596 miRBase MIMAT0000738 miR-383-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The aim of theses present study was to explore the role of miR-383-5p in the proliferation and chemosensitivity of ovarian cancer cells. MiR-383-5p expression was down-regulated while the expression of TRIM27 was up-regulated in ovarian cancer tissues and cell lines. We came up with the hypothesis that miR-383-5p might be involved in the tumor progression and chemoresistance of ovarian cancer through targeting TRIM27. Bioinformatics study and Luciferase reporter assay indicated that TRIM27 was a target of miR-383-5p and negatively regulated by miR-383-5p in ovarian cancer cells. Up-regulation of miR-383-5p was found to suppress cell proliferation and decrease Ki67 and PCNA expression in ovarian cancer cells (OVCAR3, A2780), suggesting that overexpressed miR-383-5p inhibited cell proliferation of ovarian cancer cells. In addition, up-regulation of miR-383-5p decreased the IC50 value of ovarian cancer cells to paclitaxel and increased cell apoptosis rate under the treatment of paclitaxel, indicating that overexpressed miR-383-5p enhanced chemosensitivity in ovarian cancer cells. However, overexpressed TRIM27 by pcDNA3.1-TRIM27 transfection counteracted the inhibitory effect of miR-383-5p on cell proliferation and chemoresistance in ovarian cancer cells. In vivo experiments also revealed that tumor growth could be inhibited by miR-383-5p mimic. Taken together, this present study found that miR-383-5p was lowly expressed while TRIM27 was highly expressed in ovarian cancer. Up-regulation of miR-383-5p inhibited cell proliferation, tumor growth and enhanced chemosensitivity of ovarian cancer cells through suppressing TRIM27 expression. Therefore, miR-383-5p/TRIM27 axis may be the potential target for the treatment of ovarian cancer. cell line ( SKOV3, A2780, OVCAR-3, Caov-3,) up-regulated sensitive TRIM27 TRIM27 PI3K/AKT pathway validated 2997 miR-509-3p enhances platinum drug sensitivity in ovarian cancer. Gene 2019 30408550 miRBase MIMAT0002881 miR-509-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR Our study aims on identifying role of miRNAs in drug-resistance of platinum in ovarian cancer. In present study, we compared the expression profiles of miRNAs between three pairs of platinum-resistant and platinum-sensitive ovarian tissues and found that miR-509-3p was significantly down-regulated in cisplatin-resistant ovarian cancer tissues. The different expression of miR-509-3p was further determined by RT-qPCR analyses of tissue samples from groups of 20 patients with cisplatin-sensitive ovarian cancer and 7 patients with cisplatin-resistant ovarian cancer. Functional studies demonstrated that miR-509-3p inhibitor decreased cell response to cisplatin (CDDP) and promoted cell survival in SKOV3 ovarian cancer cells. Furthermore, we found gene expression level of Golgi phosphoprotein-3 (GOLPH3) and wntless Wnt ligand secretion mediator (WLS) were regulated by miR-509-3p. The direct bindings of miR-509-3p to GOLPH3 and WLS genes were confirmed by dual-luciferase reporter assay. And the negative correlation between their expression levels in SKOV3 cells was further verified with RT-qPCR. cell line (HEK-293A,SKOV3) down-regulated resistant GOLPH3 and WLS GOLPH3 and WLS NA validated 2998 MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Breast 2019 30415143 miRBase MI0000085 miRNA-27a miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR Tamoxifen resistant cells were generated by molecular evolution with six cycles of tamoxifen treatment. MCF7 and T47D luminal A breast cancer cell lines were either treated with miR-27a mimics, or ER-signaling was modulated ectopically. The changes were analyzed with RT-qPCR, western blotting and transcriptional activity ERE-reporter assays. Moreover, the response to SERM treatments (tamoxifen, endoxifen and toremifen) was investigated by cell viability and apoptosis measurements. An in silico analysis of survival data from the METABRIC study was performed in order to assess the prognostic value of miR-27a for response to SERM treatment. cell line (MCF7,TAM6) up-regulated sensitive NA NA NA validated 2999 miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1 Cell Biol Int 2019 30444043 miRBase MI0000789 miR-381 miRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR In the present study, we aimed to investigate the functional role of miR-381 in cisplatin (DDP) resistance of breast cancer and discover the underlying molecular mechanism. The expression levels of miR-381 and MDR1 were detected by quantitative real-time PCR (qRT-PCR) and Western blot analysis in breast cancer tissues and cell lines. The DDP sensitivity and cell apoptosis of breast cancer cells were determined by MTT assay and flow cytometric analysis, respectively. The relationship between miR-381 and MDR1 was explored by target prediction and luciferase reporter analysis. tissue and cell line (MCF-10A, MCF-7,MDA-MB-231,MCF-7/DDP and MDA-MB-231/DDP ) up-regulated sensitive MDR1 MDR1 NA validated 3000 Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell 2019 30462844 miRBase MIMAT0004959 miR-216b-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer RT-PCR To characterise Linc00518 expression in prostate cancer and elucidate the potential mechanistic involvement in paclitaxel resistance, the relative expression of Linc00518 and miR-216b-5p was determined by real-time PCR. The regulatory effect of miR-216b-5p on either Linc00518 or GATA6 was interrogated with luciferase reporter assay. The endogenous GATA6 protein was analysed by Western blotting. The cell viability was measured by MTT assay and IC50 of paclitaxel was calculated through cell counting cell line (LNCap, DU145, PC3,DU145/PR and PC3/PR ) down-regulated resistant GATA6 GATA6 NA validated 3001 Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci 2019 30485589 miRBase MIMAT0000459 miR-193a-3p miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR The purpose of the present study was to examine the mechanism of miRNA-mediated chemoresistance to cisplatin in CD44-positive gastric cancer stem cells. We sorted gastric cancer cells according to level of CD44 expression by FACS and analyzed their miRNA expression profiles by microarray analysis. We found that miR-193a-3p was significantly upregulated in CD44(+) cells compared with CD44(-) cells. Moreover, SRSF2 of miR-193a-3p target gene was downregulated in CD44(+) cells. We studied the modulation of Bcl-X and caspase 9 mRNA splicing by SRSF2 and found that more pro-apoptotic variants of these genes were generated. We also found that downstream anti-apoptotic genes such as Bcl-2 were upregulated, whereas pro-apoptotic genes such as Bax and cytochrome C were downregulated in CD44(+) cells compared to CD44(-) cells. In addition, we found that an elevated level of miR-193a-3p triggered the development of cisplatin resistance in CD44(+) cells. Inhibition of miR-193a-3p in CD44(+) cells increased SRSF2 expression and also altered the levels of multiple apoptotic genes. Furthermore, inhibition of miR-193a-3p reduced cell viability and increased the number of apoptotic cells. Therefore, miR-193a-3p may be implicated in the development of cisplatin resistance through regulation of the mitochondrial apoptosis pathway. cell line (MKN45,AGS,KATO III) up-regulated resistant SRSF2 SRSF2 the mitochondrial pathway validated 3002 Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys Res Commun 2019 30509491 miRBase MI0006276 miR-1183 miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR we identified hsa_circ_0004015 was upregulated in NSCLC tissues, and was associated with the poor overall survival rate of NSCLC patients. Knockdown of hsa_circ_0004015 significantly decreased cell viability, proliferation, and invasion, whereas overexpression exhibited opposed effects in vivo and in vitro. Furthermore, hsa_circ_0004015 could enhance the resistance of HCC827 to gefitinib. In mechanism, hsa_circ_0004015 acted as a sponge for miR-1183, and PDPK1 was revealed to be target gene of miR-1183. Subsequently, functional assays illustrated that the oncogenic effects of hsa_circ_0004015 was attributed to the regulation of miR-1183/PDPK1 axis. In conclusion, circ_0016760/miR-1183/PDPK1 signaling pathway might play vital roles in the tumorigenesis of NSCLC. tissue and cell line ( A549, H1975,H358, H1299, HCC827,16HBE,HCC827I/R ) up-regulated resistant PDPK1 PDPK1 miR-1183/PDPK1 signaling pathway validated 3003 MicroRNA-29a enhances cisplatin sensitivity in non-small cell lung cancer through the regulation of REV3L. Mol Med Rep 2019 30535450 miRBase MI0000087 miR-29a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.Cell viability was determined by Cell Counting Kit-8. cell lines (A549 and H1650, and 293 ) up-regulated sensitive REV3L REV3L NA validated 3004 MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Int J Mol Med 2019 30535471 miRBase MI0003138 miR-497 miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-PCR In the present study, miRNA and protein expression levels were detected by reverse transcription-quantitative polymerase chain reaction and western blot analyses, respectively. The cell proliferation and viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and plate clonality assays, and the cell growth cycle was measured with a flow cytometer. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end-labeling, Annexin V and caspase-3 activity assays were performed to examine the cell apoptotic rates. cell line up-regulated sensitive Bcl-2 Bcl-2 NA validated 3005 miR-138-5p modulates the expression of excision repair cross-complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin. Oncol Rep 2019 30535472 miRBase MIMAT0000430 miR-138-5p miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR In the present study, the expression and regulatory mechanisms of miR-138-5p were investigated in the gastric cancer cell line SGC7901 and its cisplatin-resistant derivative SGC7901/DDP. Gene microarray and reverse transcription-quantitative polymerase chain reaction analyses revealed that miR-138-5p was expressed at significantly lower levels in SGC7901/DDP compared with SGC7901 cells. Using computational predictive algorithms, two proteins involved in the nuclear excision repair pathway were identified, excision repair cross-complementing (ERCC)1 and ERCC4, as putative miR-138-5p target genes. Western blot analysis confirmed that ERCC1 and ERCC4 expression levels were inversely proportional to miR-138-5p levels in SGC7901 and SGC7901/DDP cells. Furthermore, ERCC1 and ERCC4 were upregulated in SGC7901 cells expressing miR-138-5p-targeting short hairpin RNA and, conversely, downregulated in SGC7901/DDP cells overexpressing miR-138-5p, confirming that this miRNA regulates ERCC protein levels. Notably, miR-138-5p silencing enhanced the cisplatin resistance of SGC7901 cells, while miR-138-5p overexpression partially reversed the cisplatin resistance of SGC7901/DDP cells. cell line (SGC7901,SGC7901/DDP) down-regulated resistant ERCC1,ERCC4 ERCC1,ERCC4 NER pathway validated 3006 MicroRNA-506-3p reverses gefitinib resistance in non-small cell lung cancer by targeting Yes-associated protein 1. Mol Med Rep 2019 30535506 miRBase MIMAT0002878 miR-506-3p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The aim of the present study was to determine the role and underlying molecular mechanism of miR-506-3p in the regulation of gefitinib sensitivity in NSCLC. A gefitinib-resistant PC-9 (PC-9GR) cell line was established, and reduced miR-506-3p expression was observed in PC-9GR cells as compared with that in parental cells. The results of cell cytotoxicity and cell apoptosis assays indicated that PC-9GR cells were more sensitive to gefitinib following the transfection with an miR-506-3p mimic, while transfection with an miR-506-3p antagonist reduced the sensitivity of PC-9GR cells to gefitinib. It was further revealed that Yes-associated protein 1 (YAP1) was directly suppressed by miR-506-3p in PC-9GR cells. The elevated sensitivity of PC-9GR cells to gefitinib following transfection with the miR-506-3p mimic was counteracted by the overexpression of YAP1. Furthermore, an inverse correlation between the miR-506-3p and YAP1 mRNA levels was detected in lung adenocarcinoma specimens. cell line (PC-9GR) up-regulated sensitive YAP1 YAP1 NA validated 3007 The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Int J Biol Macromol 2019 30537505 miRBase MI0000271 miR-181c miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR In this study, we found that a particular miRNA species, miR-181c, was significantly low-expressed in breast cancer cell line MCF-7 which developed chemoresistance towards doxorubicin (Adriamycin, ADR, subclone renamed as MCF-7/ADR) than in the wild-type MCF-7 cells. Induced overexpression of miR-181c significantly inhibited cell proliferation, reversed the chemoresistance towards doxorubicin, and reduced the growth of resistant breast cancer xenograft tumors in vitro and in vivo. Using a bioinformatics approach, we also identified osteopontin (OPN) as a direct target of miR-181c. In contrast to low miR-181c expression in MCF-7/ADR cells, OPN showed a reversely high expression in resistant MCF-7/ADR cells. Our results suggest that miR-181c may regulate chemosensitivity and chemoresistance by downregulating OPN, resulting in enhanced p53-dependent transactivation and apoptosis in resistant breast cancer cells. cell line (MCF-7, MCF-7/ADR) up-regulated sensitive OPN NA p53 signaling pathway validated 3008 miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/Beta-catenin pathway. Exp Mol Pathol 2019 30539797 miRBase MI0000442 miR-122 miRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR We used qRT-PCR to measure expressions of miR-122, Beta-catenin and MDR1 in four HCC cell lines. And we assessed the effects of miR-122 or Beta-catenin on cell viability and apoptosis upon oxaliplatin (OXA) treatment by MTT assay and flow cytometry. In addition, we validated the interactions of miR-122/Beta-catenin and Beta-catenin/MDR1 by dual luciferase reporter assay and chromatin immunoprecipitation (ChIP). Western blotting was used to determine the protein levels of Beta-catenin, Wnt1 and MDR1. In the end, we verified the anti-tumor effect of miR-122 in vivo by using mouse tumor xenograft model. cell lines (HepG2, Bel-7402, SMMC-7721,Huh-7,WRL-68) up-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 3009 TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother 2019 30551433 miRBase MI0000268 miR-34a miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR The expression levels of miRNA were determined by quantitative real-time PCR (qRT-PCR) .Fuciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.ChIP experiments were performed using Magna RIP RNA-Binding Protein Immunoprecipitation Kit .Animal experiments was used to test the role of TUG1 andmiR-34a . tissue and cell line (HS-5, HL60 ) down-regulated resistant NA NA NA validated 3010 MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. Biomed Pharmacother 2019 30551476 miRBase MIMAT0000257 miR-181b-5p miRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The aim of this study was to explore the molecular mechanism of miR-181b-5p and its target gene on modulating TMZ chemosensitivity in glioma cells. The enhanced chemosensitivity effect of miR-181b-5p to TMZ in glioma cells U87MG and U251 was detected by MTT method. Dual luciferase reporter assay, quantitative real-time PCR (qRT-PCR) and Western blotting were performed to demonstrate that miR-181b-5p directly targets Bcl-2 to reduce the expression. Transwell and Flow cytometry assays showed that combination of miR-181b-5p and TMZ exerted stronger effects on inhibiting U87MG cells proliferation, migration and invasion as well as promoting apoptosis and S phase arrest than miR-181b-5p and TMZ alone. The same tendency was observed in the upregulation of apoptosis-related protein Bax and downregulation of cycle-related proteins CyclinD1 and CDK4. In vivo experiments indicated that miR-181b-5p could enhance the tumor-suppressive effect of TMZ cell line (U87MG and U251 ) up-regulated sensitive Bcl-2 Bcl-2 NA validated 3011 MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating Beta-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed Pharmacother 2019 30551544 miRBase MI0000253 miR-148a miRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR In this study, we used cisplatin to selectively enrich cisplatin-resistant CRC cells from SW480 cell line, and these selected cisplatin-resistant SW480 cells were with significantly enhanced expression of stem cell markers and increased chemoresistance. MicroRNA (miRNA) array and qRT-PCR assay identified the down-regulation of miR-148a in cisplatin-resistant SW480 cells. Overexpression of miR-148a suppressed expression of stem cell markers, inhibited sphere formation, invasion and migration, induced apoptosis, and reduced chemo-resistance in cisplatin-resistant SW480 cells. Bioinformatics prediction and luciferase reporter assay revealed that WNT10b was a downstream target of miR-148a, and overexpression of miR-148a suppressed WNT10b expression and Beta-catenin signaling activities. Enforced expression WNT10b attenuated the effects of miR-148a on cisplatin-resistant SW480 cells sphere formation, invasion and migration. Further study showed that overexpression of miR-148a also suppressed in vivo tumor growth, and WNT10b expression and Beta-catenin signaling activities in tumor tissues were suppressed by miR-148a overexpression. In the clinical samples, miR-184a was found to be down-regulated in CRC tissues, down-regulation of miR-148a predicted poor prognosis in CRC patients. cell line (SW480) up-regulated sensitive WNT10b WNT10b Beta-catenin signaling pathway validated 3012 Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. Mol Carcinog 2019 30556928 miRBase MI0000447/MI0000727 miR-128 miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR the differentially expressed lncRNAs were screened based on microarray analysis. The expression of linc00161, miR-128 and MAPK1 in ovarian cancer-resistant tissues and cells was tested qRT-PCR, whereas MAPK1 protein expression was examined via western blot in the ovarian cancer resistant cells. The targeted relationship between miR-128 and linc00161 as well as the relationship between miR-128 and MAPK1 were testified by Dual luciferase gene reporter assay. The influence of miR-128 and MAPK1 on the proliferation of ovarian cancer-resistant cells was demonstrated by CCK-8 and colony formation assay. The effect of linc00161 on ovarian cancer was demonstrated by xenograft tumor model in vivo. tissue and cell line ( SKOV3, SKOV3/DDP,CoC1,CoC1/DDP ) down-regulated resistant MAPK1 MAPK1 MAPK signaling pathway validated 3013 miRNA-106a Promotes Breast Cancer Cell Proliferation, Clonogenicity, Migration, and Invasion Through Inhibiting Apoptosis and Chemosensitivity. DNA Cell Biol 2019 30570350 miRBase MIMAT0004517 miR-106a-3p miRNA DB00515 (APRD00359) Cisplatin breast cancer RT-PCR To explore the effect of miR-106a in breast cancer cell behavior and sensitivity to chemotherapeutic agents. Tumor tissue and adjacent normal tissue were derived from 40 breast cancer patients, and miR-106a expression was measured by reverse transcription-qPCR. Breast cancer cells, MDA-MB-231 and MCF-7, were treated with miRNA-106a mimic (MM) or miRNA-106a inhibitor (MI) and negative controls. Cell proliferation was measured by MTT assay. Clonogenicity was measured by colony-forming assay. Cell migration and invasion ability were measured by scratch test and transwell assay, respectively. Apoptosis was determined by flow cytometry, and chemosensitivity to cisplatin was measured by MTT assay. Finally, protein expression of p53, Bax, Bcl-2, RUNX3, and ABCG2 was quantified by western blot. cell line (MDA-MB-231 and MCF-7) up-regulated resistant RUNX3 and ABCG2 RUNX3 and ABCG2 NA validated 3014 MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res 2019 30586549 miRBase MIMAT0000252 miR-7-5p miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In this study, we used RNA sequencing and high-throughput screening techniques, which revealed that miR-7-5p is significantly downregulated in TMZ resistant LN229 cells (LN229/TMZ-R) compared to control cells (LN229), and low miR-7-5p expression was correlated with recurrence in GBM patients. Ectopic overexpression of miR-7-5p sensitized LN229/TMZ-R cells to TMZ and suppressed the stemness of glioblastoma stem cells (GSCs). Further experiments demonstrated that miR-7-5p exerts its role by directly targeting the 3-untranslated region of Yin Yang 1 (YY1). cell line ( LN229) up-regulated sensitive YY1 YY1 NA validated 3015 Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p. DNA Cell Biol 2019 30601026 miRBase MIMAT0003886 miR-769-5p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined byquantitative PCR and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by invasion assay.Tumor xenograft in vivo model was used to the role of ncRNA . tissue and cell line (H460, A549, SK-MES-1, H1299 ) up-regulated resistant EGFR EGFR NA validated 3016 Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. J Pharm Pharmacol 2019 30604411 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00530 (APRD00951) Erlotinib pancreatic cancer qRT-PCR Human pancreatic cell lines Capan-1 and BXPC-3 were cultured with different concentrations of erlotinib (0, 10, 50, and 100 um) for 48 h. The relative cell viability and apoptosis was detected using MTT assays and flow cytometry apoptosis analysis, respectively. Transfection of pcDNA-EphA2, si-EphA2 and miR-124 mimic/inhibitor was used to modulate the intracellular level of EphA2 and miR-124. The interaction between miR-124 and the 3UTR of EphA2 was explored using dual luciferase reporter assay cell line (Capan-1,BXPC-3,) up-regulated sensitive EphA2 EphA2 NA validated 3017 Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer Mol Cancer 2019 30621694 miRBase MI0000446/MI0000470 miR-125b miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR Trastuzumab-resistant SKBR-3-TR and BT474-TR cell lines were established by grafting SKBR-3 and BT474 cells into mouse models and subjected to trastuzumab treatment. LncRNA microarray followed by quantitative reverse transcription PCR (qRT-PCR) was carried out to verify the differentially expressed lncRNAs. Western blotting, bioinformatics analysis, immunofluorescence assay and immunoprecipitation assays (ChIP and RIP) were performed to identify the involvement and functional interactions between H3K27 acetylation and terminal differentiation-induced non-coding RNA (TINCR) or between TINCR and its downstream genes including miR-125b, HER-2 and Snail-1. In addition, a series of in vitro and in vivo assays were performed to assess the functions of TINCR. cell line (SKBR-3, BT474,MCF-10A) down-regulated resistant Snail-1 Snail-1 miR-125b-HER-2/Snail-1 pathway validated 3018 Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol 2019 30628514 miRBase MI0003648 miR-633 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR In this study, we investigated the role of miR-633, an oncogenic miRNA, in gastric cancer chemoresistance.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL assay to detect cell apoptosis. cell line (SGC7901,SGC7901/DDP,GES-1,MGC-803,BGC-823, AGS, NCI-N87) up-regulated resistant FADD FADD NA validated 3019 Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol 2019 30628514 miRBase MI0003648 miR-633 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR In this study, we investigated the role of miR-633, an oncogenic miRNA, in gastric cancer chemoresistance.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. TUNEL assay to detect cell apoptosis. cell line (SGC7901,SGC7901/DDP,GES-1,MGC-803,BGC-823, AGS, NCI-N87) up-regulated resistant FADD FADD NA validated 3020 MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Int J Oncol 2019 30628651 miRBase MI0000342 miR-200b miRNA DB00441 (APRD00201) Gemcitabine pancreatic carcinoma RT-PCR The aim of this study was to examine the potential role of miRNA (miR)-200b and miR-301 in predicting the chemo-responses to treatment for pancreatic carcinoma.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell lines (Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45) up-regulated sensitive NA NA NA validated 3021 MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. Int J Oncol 2019 30628651 miRBase MI0000745 miR-301 miRNA DB00441 (APRD00201) Gemcitabine pancreatic carcinoma RT-PCR The aim of this study was to examine the potential role of miRNA (miR)-200b and miR-301 in predicting the chemo-responses to treatment for pancreatic carcinoma.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell lines (Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45) up-regulated resistant NA NA NA validated 3022 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive SEPW1 SEPW1 NA validated 3023 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 miRBase MI0000813 miR-324 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive SEPW1 SEPW1 NA validated 3024 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 miRBase MI0000263/MI0000264/ MI0000265 miR-7 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive SEPW1 SEPW1 NA validated 3025 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 miRBase MI0000813 miR-324 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive SEPW1 SEPW1 NA validated 3026 miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol 2019 30639456 miRBase MIMAT0000433 miR-142-5p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The purpose of this study was to identify microRNAs (miRNAs) that bind to the 3 untranslated region (3UTR) of XIAP and have a role in chemoresistance in ovarian cancer. Using in silico analysis and literature review, a panel of miRNAs dysregulated in chemoresistant ovarian cancer was generated from hundreds of miRNAs that were predicted to target the XIAP 3UTR. Using a dual luciferase reporter assay and cellular co-transfection of a miRNA expression vector and a luciferase reporter fused to the XIAP 3UTR cognate miRNA binding site, we identified three miRNAs of which miR-142-5p had the greatest inhibitory effect. We found that overexpression of miR-142-5p suppressed XIAP expression by binding to its 3UTR in OVCAR3 and SKOV3 cells. Using a chemosensitivity assay, we found that in OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells, overexpression or inhibition of miR-142-5p increased or suppressed their sensitivities to cisplatin respectively. In contrast, introducing XIAP without a 3UTR counteracted the effect of overexpressed miR-142-5p on cisplatin-induced apoptosis in OVCAR3 ovarian cancer cells. Furthermore, we found a negative correlation between miR-142-5p expression and XIAP protein levels in clinical samples from patients with EOC. Using clinical and miRNA expression data of more than 200 ovarian cancer patients treated with platinum-based chemotherapy from The Cancer Genome Atlas (TCGA) database, we found ovarian cancer patients with higher expression levels of miR-142-5p had longer median progression-free survival as compared to patients with lower miR-142-5p levels. We demonstrated that miR-142-5p also targeted four other anti-apoptotic genes, baculoviral IAP repeat-containing 3 (BIRC3), B-cell lymphoma-2 (BCL2), BCL2 like 2 (BCL2L2), and myeloid cell leukemia sequence 1 (MCL1) specifically. Transcriptome sequencing shed light on the essential apoptosis-related pathway in which miR-142-5p may be involved. cell line (HEK-293T,OVCAR3,SKOV3) up-regulated sensitive XIAP BIRC3, BCL2, BCL2L2, MCL1, and XIAP NA validated 3027 Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol 2019 30642385 miRBase MI0000238/MI0000279 miR-196a miRNA DB00515 (APRD00359) Cisplatin head and neck cancer RT-PCR Focusing on CAFs as stromal drivers of chemoresistance, we aimed to investigate the mechanism underlying CAF-mediated cisplatin resistance in HNC.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SCC-4, SCC-9, SCC-25, CAL 27, 293T, HN4, HN6, HN30) up-regulated resistant CDKN1B and ING5 CDKN1B and ING5 NA validated 3028 miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol Lett 2019 30655858 miRBase MIMAT0005871 miR-1207-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol triple-receptor negative breast cancer RT-qPCR The present study first evaluated the expression levels of microRNA (miR)-1207-5p in human normal breast epithelial MCF-10A cells and TNBC cell lines (MDA-MB-231, MDA-MB-436 and MDA-MB-453). The results revealed that the highest miR-1207-5p level was in MDA-MB-231, which suggested an oncogenic role of miR-1207-5p in TNBC. Therefore, MDA-MB-231 served as the present studys research model in subsequent experiments. The mRNAs that functioned as tumor suppressor factors for miR-1207-5p were then determined. Leucine zipper tumor suppressor gene 1 (LZTS1), which was predicted by TargetScan 6.2 and was supported by the results of a dual luciferase assay, was identified as a target of miR-1207-5p. AntagomiR-1207-5p increased LZTS1 mRNA and protein expressions, enhanced cell growth arrest and cell apoptosis induced by Taxol in MDA-MB-231 cells. Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression. Finally, miR-1207-5p expression was significantly increased, while LZTS1 expression was significantly decreased, in TNBC tissues when compared with normal adjacent tissues, and there was a negative correlation between miR-1207-5p and LZTS1 expression. In addition, there was a notable elevation in the expression of miR-1207-5p and a reduction in the expression of LZTS1 in the Taxol non-responsive TNBC tissues when compared with the Taxol-responsive TNBC tissues. cell line (MCF-10A,MDA-MB-231, MDA-MB-436, MDA-MB-453 ) up-regulated resistant LZTS1 LZTS1 NA validated 3029 MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci 2019 30657558 miRBase MI0000490 miR-206 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Dual-Luciferase reporter gene assay confirmed targeted regulation between miR-206 and MAPK3. DDP resistant cell line BGC823/DDP and SGC7901/DDP were generated for comparing miR-206 and MAPK3 expression against parental cells using quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot, followed by flow cytometry measuring apoptosis. Drug-resistant cells were transfected with miR-206 mimic for measuring MAPK3 and phosphorylated MAPK3 (p-MAPK3) expression. Flow cytometry and EdU were employed for measuring cell apoptosis and proliferation. cell line (BGC823/DDP and SGC7901/DDP) down-regulated resistant MAPK3 MAPK3 MAPK2 signaling pathway validated 3030 Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma. Gene 2019 30658067 miRBase MIMAT0000681 miR-29c-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel endometrial carcinoma qPCR First, we found that KDM5B expression significantly higher in EC tissues and cell lines. The elevated KDM5B expression was associated with high pathological grade and low PTX sensitivity. The functional role of KDM5B in PTX-resistant Ishikawa-R and HEC1A-R cells were examined by gene silencing experiments. cell line ( T HECs,HEC-1A) up-regulated sensitive KDM5B KDM5B miR-125a-5p-Bcl2/MRP4 pathway validated 3031 miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer. J Exp Clin Cancer Res 2019 30658681 miRBase MI0000486 miR-190 miRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-qPCR The effect of miR-190 on breast cancer anti-estrogen sensitivity was investigated both in vitro and in vivo. The protein expression levels and localization were analyzed by western blotting and immunofluorescence, respectively. Chromatin immunoprecipitation and dual-luciferase reporter assays were used to validate the regulation of the zinc-finger E-box binding homeobox 1/ ERalpha-miR-190-SRY-related high mobility group box 9 (ZEB1/ERalpha-miR-190-SOX9) axis. cell lines ( MCF7, T47D, MDA-MB-453, MDA-MB-468, MDA-MB-231, and MDA-MB-435) up-regulated sensitive SOX9 SOX9 Wnt/Beta-catenin pathway validated 3032 lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 2019 30661902 miRBase MI0000462 miR-152 miRNA DB00441 (APRD00201) Gemcitabine osteosarcoma qRT-PCR We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot. cell line ( MG63,293 T, MG63/DOX) down-regulated resistant NA NA c-MET/PI3K/AKT pathway validated 3033 lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 2019 30661902 miRBase MI0000462 miR-152 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot. cell line ( MG63,293 T, MG63/DOX) down-regulated resistant NA NA c-MET/PI3K/AKT pathway validated 3034 miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2. J Exp Clin Cancer Res 2019 30665445 miRBase MIMAT0000758 miR-135b-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qPCR In this study, expression levels of AGR2 and miR-135b-5p were analyzed in different breast cancer cell lines as well as in clinical breast cancer tissues. The in vitro and in vivo functional effect of AGR2 and miR-135b-5p were also investigated. A luciferase reporter assay was applied to confirm the interaction between miR-135b-5p and AGR2 mRNA. cell line (ATCC HTB-22,ATCC HTB-26) up-regulated sensitive AGR2 AGR2 NA validated 3035 Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition. Onco Targets Ther 2019 30666128 miRBase MIMAT0003247 miR-582-5p miRNA DB00877 (APRD00178, DB02439) Rapamycin bladder cancer qRT-PCR Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. tissue and cell line (SV-HUC-1, HT-1376, T24, J82, 5637, EJ ) up-regulated resistant ATG7 ATG7 NA validated 3036 miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol Lett 2019 30675199 miRBase MI0000342 miR-200b miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The aim of the present study was to investigate the key miRNAs involved in modulating drug resistance in ovarian cancer cells.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HIOSE-80 and MCC-3) down-regulated resistant DNMT3A,DNMT3B,DNMT1 DNMT3A,DNMT3B,DNMT1 NA validated 3037 miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol Lett 2019 30675199 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The aim of the present study was to investigate the key miRNAs involved in modulating drug resistance in ovarian cancer cells.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HIOSE-80 and MCC-3) down-regulated resistant DNMT3A,DNMT3B,DNMT1 DNMT3A,DNMT3B,DNMT1 NA validated 3038 MicroRNA-31 triggers G2/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zeste homolog 2 (ZH2). Arch Biochem Biophys 2019 30677405 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The study was designed to investigate the tumor suppressive role of miR-31 via regulation of zeste homolog 2 (ZH2). It was found that miR-31 is significantly downregulated in GC cell lines. Overexpression of miR-31 causes significant (P<0.05) decrease in the viability and colony formation via initiation of G2/M cell cycle arrest of the AGS cancer cells. Moreover, miR-31 overexpression also enhanced the chemosensitivity of miR-31 to the anticancer drug 5-fluorouracil. In silico analysis together with dual luciferase reporter assay indicated zeste homolog 2 (ZH2) to be the potential target of miR-31 in AGS cells. Investigation of ZH2 expression in GC cell lines showed it to be significantly (P<0.05) upregulated. Nonetheless, overexpression of miR-31 in AGS cells resulted in the suppression of ZH2 expression. Additionally, silencing of ZH2 in the AGS cells also caused inhibition of AGS cell proliferation and colony formation via G2/M arrest. Moreover, overexpression of ZH2 could at least partially reverse the tumor suppressive effects of miR-31 indicating direct involvement of ZH2 in the miR-31 mediated inhibitory effects on AGS cell proliferation. Finally, miR-31 overexpression caused significant (P<0.05) inhibition of the migration and invasion of the AGS gastric cancer cells. The overexpression of miR-31 also caused downregulation of mesenchymal markers (Vimentin and N-cadherin) and upregulation of epithelial marker (E-cadherin) protein expression was in AGS cells. It is therefore concluded that miR-31 acts as a tumor suppressor and may prove essential in the treatment of GC. cell line (GES-1,AGS, SNU-1, SNU-5, SNU16) up-regulated sensitive ZH2 ZH2 NA validated 3039 Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratisl Lek Listy 2019 30685990 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil gastric adenocarcinoma qRT-PCR In the current study, parental MKN-45, MKN-45-control vector, and MKN-45-miR-31 populations were compared in terms of cell cycle transitions, migration, cell invasion, and proliferation. In addition, downstream targets of miR-31, including E2F6, and SMUG1 were examined using Real-time RT-PCR and western blotting. MKN-45-miR-31 showed an increased sensitivity to 5-FU, decreased migration and cell invasion compared to the control groups (p = 0.0001, p = 0.01 and p = 0.01, respectively). There was a significant increase in the percentage of cells in G1/pre-G1 phase in MKN-45-miR-31 relative to the control groups (p = 0.001). Induction of miR-31 expression in MKN-45 caused a significant reduction of E2F6 and SMUG1 genes. Our findings indicated that induction of miR-31 expression could increase drug sensitivity, and diminish tumor cell migration and invasion of gastric cancer cells. cell line (AGS,MKN-45,HEK 293) up-regulated sensitive E2F6, and SMUG1 E2F6, and SMUG1 NA validated 3040 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000754 miR-337-3p miRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3041 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000264 miR-203a-3p miRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3042 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000754 miR-337-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3043 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000264 miR-203a-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3044 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000754 miR-337-3p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3045 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000264 miR-203a-3p miRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3046 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000754 miR-337-3p miRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3047 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 miRBase MIMAT0000264 miR-203a-3p miRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3048 MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. J Clin Med 2019 30717317 miRBase MI0000442 miR-122 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma RT-PCR we assessed the relationship between miR-122 and SerpinB3 and their influence on cell phenotype and sorafenib resistance in HCC. A bioinformatics analysis identified SerpinB3 among hypothetical miR-122 targets. In SerpinB3-overexpressing HepG2 cells, miR-122 transfection decreased SerpinB3 mRNA and protein levels, whereas miR-122 inhibition increased SerpinB3 expression. Luciferase assay demonstrated the interaction between miR-122 and SerpinB3 mRNA. In an HCC rat model, high miR-122 levels were associated with negative SerpinB3 expression, while low miR-122 levels correlated with SerpinB3 positivity. A negative correlation between miR-122 and SerpinB3 or stem cell markers was found in HCC patients. Anti-miR-122 transfection increased cell viability in sorafenib-treated Huh-7 cells, while miR-122 overexpression increased sorafenib sensitivity in treated cells, but not in those overexpressing SerpinB3. In conclusion, we demonstrated that miR-122 targets SerpinB3, and its low levels are associated with SerpinB3 positivity and a stem-like phenotype in HCC. cell line (HepG2, Hep3B, Huh7 ) up-regulated sensitive SerpinB3 SerpinB3 NA validated 3049 Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. J Exp Clin Cancer Res 2019 30728036 miRBase MIMAT0004613 miR-188-3p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The effects of overexpression and knockdown of LINC00346 on the proliferation, cell cycle progression, apoptosis, and gemcitabine resistance were investigated. Bioinformatic analysis, luciferase reporter assay, and RNA immunoprecipitation assay were performed to search for potential microRNAs (miRs) that can interact with LINC00346. cell lines (PANC-1, MIA PaCa-2, Capan-1, and BxPC-3) down-regulated resistant BRD4 BRD4 NA validated 3050 LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis 2019 30728351 miRBase MIMAT0000100 miR-29b-3p miRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-qPCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. Xenograft model in nude mice was used to test the role of ncRNA cell line ( H929, U266, 8226) down-regulated resistant MCL-1 MCL-1 NA validated 3051 miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis. Int J Biol Sci 2019 30745844 miRBase MI0000466/MI0000467/MI0000468 miR-9 miRNA DB00694 (APRD00521) Daunorubicin acute myeloid leukemia qRT-PCR We explored the potential role of miR-9 in Dnr resistance in AML cells and its mechanism of action.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. cell line (HL-60, KG-1, THP-1 and Kasumi-1 ) up-regulated sensitive EIF5A2 EIF5A2 NA validated 3052 Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res 2019 30770776 miRBase MI0000300 miR-223 miRNA DB12257 Platinum epithelial ovarian cancer qRT-PCR The miRNA levels were detected by qRT-PCR. Protein levels of HIF-1alpha, CD163 and PTEN-PI3K/AKT pathway were assessed by Western blot (WB) and Immunohistochemistry (IHC). Exosomes were isolated, and then confirmed by Transmission electron microscopy (TEM), Nanoparticle Tracking Analysis (NTA) and WB. Internalization of macrophages-secreted exosomes in EOC cells was detected by Confocal microscope. Subsequently, Dual-luciferase reporter assay verified PTEN was the target of miR-223. Gain- and loss-of-function experiments, rescue experiments, and SKOV3 xenograft models were performed to uncover the underlying mechanisms of miR-223 and PTEN-PI3K/AKT pathway, as well as the exosomal miR-223 in inducing multidrug resistance in vitro and in vivo. tissue and cell line (A2780,MCF-7, MBA-MD-231,Hela) up-regulated resistant PTEN PTEN PI3K/AKT pathway validated 3053 MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death Dis 2019 30770779 miRBase MI0000088 miR-30a miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR we delineated the miRNA expression profile and key signaling pathways associated with gemcitabine response. Furthermore, we confirmed that miR-30a, one node of this network, regulated cellular response to gemcitabine through SNAI1-IRS1-AKT pathway. MiR-30a directly targeted SNAI1, which activates AKT and ERK through regulating IRS1 in vitro and in vivo. Clinically, miR-30a is downregulated in pancreatic cancer tissue and associated with overall patient survival. We also identified miR-30a as an AKT-FOXO3a-regulated gene that forms a feedback loop. cell line (PANC-1, SW1990, and BxPC-3 ) up-regulated sensitive SNAI1 and IRS1 SNAI1 and IRS1 SNAI1/IRS1/AKT pathway validated 3054 Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression. Oncotarget 2019 30774764 miRBase MIMAT0000460 miR-194-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR In this study, we identified microRNAs (miRNA) that regulate paclitaxel resistance and tested their potential utility as therapeutic targets. Paclitaxel-resistant cell lines were established using two EOC cell lines: SKVO3ip1 and HeyA8. miRNA PCR arrays showed that miR-194-5p was downregulated in paclitaxel-resistant cells. Forced expression of miR-194-5p resensitized resistant cells to paclitaxel. Conversely, miR-194-5p inhibition induced paclitaxel resistance in parental cells. In silico analysis and luciferase reporter assay revealed that MDM2 is a direct target of miR-194-5p. MDM2 was upregulated in paclitaxel resistant cells compared with parental cells. MDM2 inhibition also resensitized resistant cells to paclitaxel and forced MDM2 induced paclitaxel resistance in parental cells. miR-194-5p induced p21 upregulation and G1 phase arrest in resistant cells by downregulating MDM2. Furthermore, a public database showed that high MDM2 expression was associated with a shorter progression-free survival in EOC patients treated with paclitaxel. Collectively, our results show that restoring miR-194-5p expression resensitizes EOCs to paclitaxel, and this may be exploited as a therapeutic option. cell line ( SKOV3ip1) down-regulated resistant MDM2 MDM2 NA validated 3055 MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep 2019 30777929 miRBase MIMAT0000075 miR-20a-5p miRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR MTT assay and Western blot analysis revealed that long-time gemcitabine treatment in PC cells induced drug resistance and RRM2 increase, and silence of RRM2 blocked gemcitabine resistance. Among the predicted eight RRM2-related microRNAs, the expression of miR-20a-5p showed the most significant discrepancy between gemcitabine-resistant cells and parental cells. Furthermore, the Dual-Luciferase reporter gene assay indicated that miR-20a-5p directly targeted RRM2 3UTR, thus inhibited expression of RRM2 and overcame gemcitabine resistance of PC cells. Retrospective study suggested that plasma miR-20a-5p level was correlated with gemcitabine resistance in PC patient. ROC curve showed that miR-20a-5p abundant level might predict gemcitabine resistance with an AUC of 89% (P<0.0001). Additionally, the PFS of patients with high and low expression levels miR-20a-5p was 2.8 and 4.5 months (P<0.001), respectively. cell line ( MIA-PaCa2,HEK293) up-regulated sensitive RRM2 RRM2 NA validated 3056 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit 2019 30778022 miRBase MIMAT0004676 miR-34b-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel Bladder Cancer qRT-PCR This research compared the multidrug-sensitive (5637) BCa cell line and the multidrug-resistant (EJ) BCa cell line. We found that CCND2 (G1/S-specific cyclin-D2) and P2RY1 (purinergic receptor P2Y1) were the targets of miR-34b-3p, as further validated by qRT-PCR (quantitative real-time polymerase chain reaction) and western blot analysis. cell line ( 5637,EJ) up-regulated sensitive CCND2 and P2RY1 CCND2 and P2RY1 NA validated 3057 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit 2019 30778022 miRBase MIMAT0004676 miR-34b-3p miRNA DB11616 Pirarubicin Bladder Cancer qRT-PCR This research compared the multidrug-sensitive (5637) BCa cell line and the multidrug-resistant (EJ) BCa cell line. We found that CCND2 (G1/S-specific cyclin-D2) and P2RY1 (purinergic receptor P2Y1) were the targets of miR-34b-3p, as further validated by qRT-PCR (quantitative real-time polymerase chain reaction) and western blot analysis. cell line ( 5637,EJ) up-regulated sensitive CCND2 and P2RY1 CCND2 and P2RY1 NA validated 3058 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit 2019 30778022 miRBase MIMAT0004676 miR-34b-3p miRNA DB00445 (APRD00361) Epirubicin hydrochloride Bladder Cancer qRT-PCR This research compared the multidrug-sensitive (5637) BCa cell line and the multidrug-resistant (EJ) BCa cell line. We found that CCND2 (G1/S-specific cyclin-D2) and P2RY1 (purinergic receptor P2Y1) were the targets of miR-34b-3p, as further validated by qRT-PCR (quantitative real-time polymerase chain reaction) and western blot analysis. cell line ( 5637,EJ) up-regulated sensitive CCND2 and P2RY1 CCND2 and P2RY1 NA validated 3059 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit 2019 30778022 miRBase MIMAT0004676 miR-34b-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin Bladder Cancer qRT-PCR This research compared the multidrug-sensitive (5637) BCa cell line and the multidrug-resistant (EJ) BCa cell line. We found that CCND2 (G1/S-specific cyclin-D2) and P2RY1 (purinergic receptor P2Y1) were the targets of miR-34b-3p, as further validated by qRT-PCR (quantitative real-time polymerase chain reaction) and western blot analysis. cell line ( 5637,EJ) up-regulated sensitive CCND2 and P2RY1 CCND2 and P2RY1 NA validated 3060 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit 2019 30778022 miRBase MIMAT0004676 miR-34b-3p miRNA DB00515 (APRD00359) Cisplatin Bladder Cancer qRT-PCR This research compared the multidrug-sensitive (5637) BCa cell line and the multidrug-resistant (EJ) BCa cell line. We found that CCND2 (G1/S-specific cyclin-D2) and P2RY1 (purinergic receptor P2Y1) were the targets of miR-34b-3p, as further validated by qRT-PCR (quantitative real-time polymerase chain reaction) and western blot analysis. cell line ( 5637,EJ) up-regulated sensitive CCND2 and P2RY1 CCND2 and P2RY1 NA validated 3061 miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1. Exp Cell Res 2019 30779921 miRBase MI0000735 miR-29c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharyngeal cancer qRT-PCR We assessed the effects of miR-29c, an miRNA identified in a genome-wide study of Taxol resistance, on genes associated with resistance in NPC cells. We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin Beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells. Further investigations using a TUNEL assay and BAX/BCL-2 ratio, found that overexpression of miR-29c and knockdown of ITGB1 can resensitize drug-resistant NPC cells to Taxol and promote apoptosis. In addition, a dual-luciferase reporter assay indicated that ITGB1 is the target of miR-29c. Furthermore, silencing miR-29c markedly increased Taxol-resistant NPC tumor growth in a nude mouse xenograft model while knockdown of ITGB1 reversed this result. Overall, these data demonstrate that miR-29c regulates resistance to Taxol in NPC by targeting ITGB1. cell line (SUNE-1 and C666-1 cells) up-regulated sensitive ITGB1 ITGB1 NA validated 3062 A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing Beta5-integrin/c-met signaling pathway. J Exp Clin Cancer Res 2019 30782177 miRBase NA miR-365-3p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil oral squamous cell carcinoma RT-PCR Upregulation of keratin 16 (KRT16) was found by comparing isogenic pairs of low and high invasive human OSCC lines via microarray analysis. OSCC cells with ectopic expression or silencing of KRT16 were used to scrutinize functional roles and associated molecular mechanisms. tissue and cell line (OC-3, CGHNC9, and C9-IV3) up-regulated sensitive EHF EHF Beta5-integrin/c-met signaling pathway validated 3063 Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother 2019 30784927 miRBase MI0000284 miR-204 miRNA DB00515 (APRD00359) Cisplatin glioma qRT-PCR The expression levels of miRNA were determined by Quantitative real-time PCR (qRT-PCR) . Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The activities of caspase-3 and caspase-9 in U87 and U251 cells were detected by a colorimetric assay kit . Tumor xenograft formation assay was used to test the role of miR-miR-204 . tissue and cell line (U87, U251,U373 and SNB19) up-regulated sensitive NA NA NA validated 3064 Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technol Cancer Res Treat 2019 30786836 miRBase MI0000737 miR-200a miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR Fourteen candidate microRNAs were chosen from the literature, and their plasma levels were measured by quantitative polymerase chain reaction (PCR). Forty metastatic breast cancer patients were chosen as the training groups. The potential significant microRNAs were validated in another 103 plasma samples. peripheral blood up-regulated resistant NA NA NA predicted 3065 Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technol Cancer Res Treat 2019 30786836 miRBase MI0000286 miR-210 miRNA DB01248 (APRD00932) Docetaxel breast cancer qRT-PCR Fourteen candidate microRNAs were chosen from the literature, and their plasma levels were measured by quantitative polymerase chain reaction (PCR). Forty metastatic breast cancer patients were chosen as the training groups. The potential significant microRNAs were validated in another 103 plasma samples. peripheral blood up-regulated resistant NA NA NA predicted 3066 Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Am J Transl Res 2019 30788003 miRBase MI0003672 miR-663a miRNA DB12387 OSI-027 pancreatic ductal adenocarcinoma RT-PCR, qRT-PCR In the present study, we examined the molecular basis for the effective combination of OSI-027 and gemcitabine (GEM). Firstly, we identified a specific miRNA expression profile in PDAC cells after treatment with either of these drugs. We found that miR-663a was significantly upregulated after treatment with GEM and downregulated after OSI-027 treatment. With combination of the two drugs, miR-663a level was lower than the GEM group, but higher than the OSI-027 group. Real-time quantitative PCR confirmed these observations. To further establish the role of miR-663a in OSI-027 and GEM resistance in pancreatic cancer, we transfected PDAC cells with miR-663a mimic or miR-663a inhibitor. Cell viability and proliferation assays showed that miR-663a mimic enhanced drug sensitivity, while inhibitor promoted drug resistance. Moreover, we found that the combined effect of OSI-027 and GEM disappeared after inhibiting miR-663a. Our study clearly demonstrates that GEM upregulates miR-663a, thereby promoting the sensitivity of pancreatic cancer cells to OSI-027. Our study suggests that miR-663a expression may be a useful indicator of the potential for chemoresistance and provides a potential new therapeutic target to avert chemoresistance in PDAC. cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2) up-regulated sensitive NA NA NA validated 3067 Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Am J Transl Res 2019 30788003 miRBase MI0003672 miR-663a miRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma RT-PCR, qRT-PCR In the present study, we examined the molecular basis for the effective combination of OSI-027 and gemcitabine (GEM). Firstly, we identified a specific miRNA expression profile in PDAC cells after treatment with either of these drugs. We found that miR-663a was significantly upregulated after treatment with GEM and downregulated after OSI-027 treatment. With combination of the two drugs, miR-663a level was lower than the GEM group, but higher than the OSI-027 group. Real-time quantitative PCR confirmed these observations. To further establish the role of miR-663a in OSI-027 and GEM resistance in pancreatic cancer, we transfected PDAC cells with miR-663a mimic or miR-663a inhibitor. Cell viability and proliferation assays showed that miR-663a mimic enhanced drug sensitivity, while inhibitor promoted drug resistance. Moreover, we found that the combined effect of OSI-027 and GEM disappeared after inhibiting miR-663a. Our study clearly demonstrates that GEM upregulates miR-663a, thereby promoting the sensitivity of pancreatic cancer cells to OSI-027. Our study suggests that miR-663a expression may be a useful indicator of the potential for chemoresistance and provides a potential new therapeutic target to avert chemoresistance in PDAC. cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2) up-regulated sensitive NA NA NA validated 3068 miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochem Biophys Res Commun 2019 30791979 miRBase MIMAT0000098 miR-100-5p miRNA DB08865 (DB08700) Crizotinib EML4-ALK positive NSCLC NA In this study we sought to explore a possible involvement of microRNAs (miRNAs) in conferring resistance to ALK TKIs in ALK TKI-refractory NSCLC cell lines. We subjected our ALK TKI-refractory cancer cells along with parental cancer cells to systematic miRNA expression arrays. Furthermore, ALK TKI-refractory cancer cells were exposed to a synthetic miRNA inhibitory Locked Nucleic Acid (LNA)-library in the presence of ALK TKIs Crizotinib or Lorlatinib. The outcome of the combined approaches uncovered miR-100-5p to confer resistance to Crizotinib and Lorlatinib in EML4-ALK NSCLC cells and to be a potential therapeutic target in drug resistance. cell line (DFCI032, NCI-H2228,) up-regulated resistant NA NA NA validated 3069 miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochem Biophys Res Commun 2019 30791979 miRBase MIMAT0000098 miR-100-5p miRNA DB12130 Lorlatinib EML4-ALK positive NSCLC NA In this study we sought to explore a possible involvement of microRNAs (miRNAs) in conferring resistance to ALK TKIs in ALK TKI-refractory NSCLC cell lines. We subjected our ALK TKI-refractory cancer cells along with parental cancer cells to systematic miRNA expression arrays. Furthermore, ALK TKI-refractory cancer cells were exposed to a synthetic miRNA inhibitory Locked Nucleic Acid (LNA)-library in the presence of ALK TKIs Crizotinib or Lorlatinib. The outcome of the combined approaches uncovered miR-100-5p to confer resistance to Crizotinib and Lorlatinib in EML4-ALK NSCLC cells and to be a potential therapeutic target in drug resistance. cell line (DFCI032, NCI-H2228,) up-regulated resistant NA NA NA validated 3070 MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. J Cell Mol Med 2019 30801960 miRBase MI0000791 miR-383 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma RT-PCR In the present study, RT-PCR and western blotting were used to identify the expression profile of miR-383 and eukaryotic translation initiation factor 5A2 (EIF5A2). The bioinformatics website Targetscan was used to predict the target genes of miR-383. In vitro and in vivo loss- and gain-of-function studies were performed to reveal the effects and potential mechanism of the miR-383/EIF5A2 axis in chemoresistance of HCC cells. The expression level of miR-383 correlated negatively with doxorubicin (Dox) sensitivity. Overexpression of miR-383 promoted HCC cells to undergo Dox-induced cytotoxicity and apoptosis, whereas miR-383 knockdown had the opposite effects. EIF5A2 was predicted as a target gene of miR-383. EIF5A2 knockdown sensitized HCC cells to Dox. Moreover, miR-383 inhibition-mediated HCC Dox resistance could be reversed by silencing EIF5A2. Finally, we demonstrated that miR-383 inhibition could enhance Dox sensitivity by targeting EIF5A2 in vivo. The results indicated that miR-383 inhibited Dox resistance in HCC cells by targeting EIF5A2. Targeting the miR-383/EIF5A2 axis might help to alleviate the chemoresistance of HCC cells. cell line (Huh-7, HepG2, SUN-387 and SUN-449) down-regulated sensitive EIF5A2 EIF5A2 NA validated 3071 microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells. Open Med (Wars) 2019 30805558 miRBase MIMAT0005591 miR-1236-3p miRNA DB00515 (APRD00359) Cisplatin lung cancer PR-qPCR In this study, we found that the expression level of miR-1236-3p was significantly decreased in lung cancer tissues and A549 cell line. In addition, the half maximal inhibitory concentration (IC50) of DDP in A549 cells was significantly lower than that in A549/DDP cells, while the expression level of miR-1236-3p was prominently down-regulated in A549/DDP cells. Combining the online tool TargetScan and a dual-luciferase reporter assay, tumor protein, translationally-controlled 1 (TPT1) was proved to be the direct target gene of miR-1236-3p. The MTT and flow cytometry assays demonstrated that up-regulation of miR-1236-3p could markedly inhibit A549/DDP cell proliferation but promote apoptosis, which could be significantly reversed by pcDNA3.1-TPT1 plasmids. Finally, we further demonstrated that miR-1235-3p could restrain the expression levels of TPT1, Pim-3, phosphate-Bcl-2-associated death promoter (p-BAD) and B-cell lymphoma-extra large (Bcl-XL) in A549/DDP cells, while the inhibition could be reversed by pcDNA3.1-TPT1 as well. In a word, our study demonstrated that miR-1236-3p could reverse DDP resistance by modulation of TPT1 gene and inhibition of Pim-3 signaling pathway in lung cancer cells. cell line (BESA-2B,A549) down-regulated resistant TPT1 TPT1 pim-3 signaling pathway validated 3072 Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Genet Test Mol Biomarkers 2019 30807260 miRBase MIMAT0000422 miR-124-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR The expression of the ABCC4 protein and miR-124-3p were detected, respectively, by immunohistochemical staining and quantitative real-time polymerase chain reaction in breast cancer tumor tissue, MCF-7 and MCF-7-ADR cell lines. Suppression of ABCC4 expression and miR-124-3p overexpression were performed in MCF-7-ADR cell lines. Western blot assays were used to detect expression of ABCC4 and permeability glycoprotein 1/multi-drug resistance protein 1 (P-gp) in cells. Cell Counting Kit-8, flow cytometry, transwell, and scratch assays were conducted to detect cell proliferation, cell cycle, invasion, and migration of cells. tissue and cell line (MCF-7 and MCF-7-ADR ) up-regulated sensitive NA NA NA validated 3073 Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin. Med Sci Monit 2019 30821276 miRBase MI0000287 miR-211 miRNA DB00515 (APRD00359) Cisplatin melanoma qRT-PCR We used qRT-PCR to test miR-211 expression. Cell viability assay and mouse xenograft assay were performed to examine the role of miR-211 on the sensitivity of melanoma cells to cisplatin. The epigenetic modification of miR-211 promoter was assess by DNA methylation analysis and DAC treatment. RESULTS In this study, decreased miR-211 expression was detected. Bisulfite sequencing PCR showed that DNA hypermethylation contributed to the downregulation of miR-211 in melanoma tissues. In melanoma cells, overexpressed 211 could enhance the anticancer effect of cisplatin and restoration of miR-211 rendered susceptibility to cisplatin in cisplatin-resistant cells. And the same result was showed in vivo by mouse xenograft assay. What is more, DAC treatment could increase miR-211 expression and EZH2 expression was increased in cisplatin-resistant cells. MiR-211 could be transcriptionally repressed by EZH2 mediated promoter methylation. cell line (A375 and SK-MEL-28) down-regulated resistant NA NA NA validated 3074 Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci 2019 30840279 miRBase MIMAT0004593 miR-130a-5p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR TAM-resistant BC cell lines were first verified. Subsequently, cell proliferation and apoptosis were detected using cell counting kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine (EdU) assay and flow cytometry, respectively. Protein levels of ABCB1, ABCC1, and ABCG2 in TAM-treated MCF-7 and MCF-7R cells were determined by Western blot. ADAMTS9-AS2 expression in BC tissues, para-cancerous tissues, as well as MCF-7 and MCF-7R cells, was accessed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between ADAMTS9-AS2 expression with pathological grade and tumor size of BC was explored. Chromatin fractionation was conducted to elucidate the subcellular distribution of ADAMTS9-AS2. The binding condition between ADAMTS9-AS2 and microRNA-130a-5p, as well as microRNA-130a-5p and PTEN, was verified by the dual-luciferase reporter gene assay. Furthermore, regulatory effects of ADAMTS9-AS2, microRNA-130a-5p, and PTEN on the proliferation and apoptosis of MCF-7R cells were determined. tissue and cell line ( MCF-7R ) up-regulated sensitive PTEN PTEN NA validated 3075 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 miRBase MIMAT0000227 miR-197-3p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549,H1299,H460,SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant p120-ctn p120-ctn NA validated 3076 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 miRBase MIMAT0000227 miR-197-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549,H1299,H460,SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant p120-ctn p120-ctn NA validated 3077 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 miRBase MIMAT0000227 miR-197-3p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549,H1299,H460,SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant p120-ctn p120-ctn NA validated 3078 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 miRBase MIMAT0000227 miR-197-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The expression levels of miRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells .Mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549,H1299,H460,SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant p120-ctn p120-ctn NA validated 3079 Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway. Biosci Rep 2019 30842340 miRBase MI0005565 miR-543 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR This study investigated whether the down-regulation of miR-543 expression enhanced 5-fluorouracil (5-FU)-induced apoptosis in HCT8/FU colon cancer cells. In our study, qRT-PCR revealed that miR-543 expression was up-regulated in the HCT8/FU colon cancer cell line compared with that of HCT8 colon cancer cell line. An miR-543 inhibitor or mimic was transfected, followed by MTT assay to detect 5-FU sensitivity in HCT8 and HCT8/FU cell lines, which showed that IC50 of 5-FU was positively correlated with miR-543 expression. Further studies showed that miR-543 enhanced drug resistance by down-regulating the expression of phosphatase and tensin homolog (PTEN), which negatively regulates protein kinase B (AKT) activation. Additionally, an elevated expression of PTEN reversed the chemoresistance of miR-543-overexpressing HCT8 cells to 5-FU. These results indicate that miR-543 might be a target to increase the sensitivity of CRC cells to 5-FU through the PTEN/PI3K/AKT pathway. cell line ( HCT8 and HCT8/FU ) down-regulated sensitive PTEN PTEN PTEN/PI3K/AKT pathway validated 3080 MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3. J Gastroenterol Hepatol 2019 30843262 miRBase MIMAT0004925 miR-876-3p miRNA DB00515 (APRD00359) Cisplatin stomach cancer qPCR Cell viability was analyzed via CCK-8 and colony formation assay. Stem cell-like properties were examined via spheroid colony formation assay. mRNA abundance of key genes was analyzed via quantitative polymerase chain reaction. Protein level of TMED3 and stem cell markers was examined by western blot. TargetScan, luciferase, and biotin-miRNA pulldown assay were used to identify miR-876-3ps target. cell lines (MGC-803, AGS, BGC-823, SGC-7901, MKN-45, N87, HGC-27,GES-1) down-regulated resistant TMED3 TMED3 NA validated 3081 MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer. Gene 2019 30878390 miRBase MIMAT0004658 miR-155-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR To investigate the relationship and mechanism between mir-155-3p and taxol resistance in human breast cancer.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Then test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs . Finally, the relevant targets were discussed. cell line (MCF-7, SKBR-3, and MDA-MB-231 ) down-regulated resistant MYD88 MYD88 NA validated 3082 MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression. Am J Transl Res 2019 30899388 miRBase MI0003626 miR-613 miRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression of miR-613 and Sex-determining region Y (SRY)-box 9 (SOX9) in GC tissues and cell lines was detected by using qRT-PCR. Cell migration and viability were measured by the wound healing assay and CCK-8 assays. Western blot and dual-luciferase reporter were done to identify the target gene of miR-613. tissue and cell line ( MGC-803, HGC-27, HGC-27,SGC-7901,GES-1 ) down-regulated resistant SOX9 SOX9 NA validated 3083 miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. Exp Cell Res 2019 30904483 miRBase MI0015999 miR-3609 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qPCR In the present study, we discovered a novel microRNA, miR3609, that influences the malignancy of breast cancer. Our results showed miR-3609 expression was lower in resistant breast cancer cells than in sensitive breast cancer cells (MCF-7), while PD-L1 expression was higher in resistant breast cancer cells than in sensitive breast cancer cells. Co-transfection of a miR-3609 plasmid with a luciferase construct containing the PD-L1 3-untranslated region suppressed luciferase activity. Transfection of a miR-3609 mimic markedly suppressed PD-L1 protein expression in MDA-MB-231 and MDA-MB-468 cells in a dose-dependent manner and increased the sensitivity of MCF7/ADR cells to adriamycin, whereas transfection of a miR-3609 inhibitor enhanced PD-L1 protein expression in HBL-100 and MCF-7 cells. In addition, knockdown of PD-L1 by siRNA restored the sensitivity of MCF7/ADR cells to adriamycin. Mice injected with breast cancer cells stably overexpressing miR3609 survived markedly longer and had fewer tumors than mice injected with control miRNA (miR-sc)-transfected cells. Treatment with a CD8+ blocking antibody (anti-CD8) eliminated these effects, suggesting that CD8+ T cells are required for the efficacy of miR3609 in breast cancer. Further, low miR-3609 expression and high PD-L1 expression were correlated with poor prognosis in breast cancer patients. Therefore, restoration of miR-3609 expression may sensitize breast cancer to adriamycin by blocking PD-L1 expression. cell line (MCF-7,MCF-7/ADR, MDA-MB-231, and MDA-MB-468) down-regulated resistant PD-L1 PD-L1 NA validated 3084 Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother 2019 30904818 miRBase MI0000490 miR-206 miRNA DB00451 (APRD00235, EXPT02993) Euthyrox papillary thyroid carcinoma qRT-PCR qRT-PCR was conducted to examine the expression of miR-206 in PTC tissues, parental and TPC-1/euthyrox. The CCK-8 assay, EdU assay and flow cytometry were performed to test cells viability, proliferation and apoptosis, respectively. Luciferase reporter assay was used to confirm the potential target of miR-206. Western blotting analysis was performed to evaluate the expressions of related-proteins. cell line (Nthy-ori3-1,TPC-1,TPC-1/euthyrox) down-regulated resistant MAP4K3 MAP4K3 p38 and JNK signaling pathway validated 3085 MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27. Cell Mol Biol Lett 2019 30915129 miRBase MI0000290 miR-214 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer qRT-PCR In this study, we investigated the expression and mechanism of mir-214 in 5-fu resistant colon cancer cells.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HT-29 and LoVo) up-regulated sensitive Hsp27 Hsp27 NA validated 3086 MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene 2019 30917930 miRBase MIMAT0003239 miR-574-3p miRNA DB00515 (APRD00359) Cisplatin gastric carcinoma qPCR We investigated the mechanism via which miR-574-3p regulated cancer cell migration and invasion to determine the relationship between epithelial mesenchymal transition (EMT) and drug resistance. The expression levels of miRNA were determined by Transient transfection and quantitative real-time PCR (qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (e SGC7901, AGS, BGC823, MGC803, HGC27, HEK293T) up-regulated sensitive ZEB1 ZEB1 NA validated 3087 microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Oncologist 2019 30918109 miRBase MI0001721 miR-431 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin adrenocortical carcinoma RT-PCR Samples from primary ACC tumors of 10 Stage IV patients were examined for differentially expressed miRNAs between a sensitive and resistant cohort. Candidate microRNAs were restored via transfection in two functional ACC cell lines. Gain of function and effects on apoptosis and cell cycle were assessed. cell line up-regulated sensitive ZEB1 ZEB2 NA validated 3088 microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Oncologist 2019 30918109 miRBase MI0001721 miR-431 miRNA DB00648 (APRD00494) Mitotane breast adenocarcinoma RT-PCR Samples from primary ACC tumors of 10 Stage IV patients were examined for differentially expressed miRNAs between a sensitive and resistant cohort. Candidate microRNAs were restored via transfection in two functional ACC cell lines. Gain of function and effects on apoptosis and cell cycle were assessed. cell line up-regulated sensitive ZEB1 ZEB2 NA validated 3089 Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol 2019 30937906 miRBase MI0000816 miR-335 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qPCR HCC cell lines and tumor tissue were quantified for NEAT1 expression by quantitative polymerase chain reaction (qPCR). Following shRNA (short hairpin RNA) knockdown of NEAT1, cell viability, apoptosis, and related protein expression were measured after drug treatment. The downstream target of NEAT1, including miR-335 and c-Met was studied using a combination of luciferase binding assay, gene knockdown/overexpression, western blot analysis, and cell viability/apoptosis assay. Cancer cells with NEAT1 knockdown were transplanted onto nude mice for in vivo tumorigenesis assay. cell line (HepG2, Bel7404) up-regulated sensitive c-Met c-Met c-Met-Akt signaling pathway validated 3090 miR-210-3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3. Mol Med Rep 2019 30957179 miRBase MIMAT0000267 miR-210-3p miRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-PCR The potential role of microRNA (miR)-210-3p in carcinogenesis and the cisplatin sensitivity of ovarian cancer were evaluated in the present study. The relative expression levels of miR-210-3p in cisplatin-sensitive SKOV-3 cells and cisplatin-resistant SKOV-3/DDP cells were determined using reverse transcription-quantitative polymerase chain reaction analysis. miR-210-3p mimics and inhibitors were transfected into SKOV-3/DDP cells. Cell Counting Kit-8, scratch and Transwell invasion assays and flow cytometry were conducted to evaluate the role of miR-210-3p in ovarian cancer cells. A luciferase reporter assay was used to verify the association between miR-210-3p and E2F transcription factor 3 (E2F3). Drug sensitivity was evaluated by treating the cells with cisplatin. cell line (SKOV-3,SKOV-3/DDP) up-regulated sensitive E2F3 E2F3 NA validated 3091 MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Adv 2019 30967394 miRBase MI0000681 miR-155 miRNA DB00541 (APRD00495) Vincristine diffuse large B-cell lymphoma RT-qPCR The purpose of the present study was to investigate microRNA (miRNA) involvement in vincristine resistance in DLBCL, which was pursued by functional in vitro analysis in DLBCL cell lines and by outcome analysis of patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Differential miRNA expression analysis identified miR-155 as highly expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones. Ectopic upregulation of miR-155 sensitized germinal-center B-cell-like (GCB)-DLBCL cell lines to vincristine, and consistently, reduction and knockout of miR-155 induced vincristine resistance, documenting that miR-155 functionally induces vincristine sensitivity. Target gene analysis identified miR-155 as inversely correlated with Wee1, supporting Wee1 as a target of miR-155 in DLBCL. Chemical inhibition of Wee1 sensitized GCB cells to vincristine, suggesting that miR-155 controls vincristine response through Wee1. Outcome analysis in clinical cohorts of DLBCL revealed that high miR-155 expression level was significantly associated with superior survival for R-CHOP-treated patients of the GCB subclass, independent of international prognostic index, challenging the commonly accepted perception of miR-155 as an oncomiR. However, miR-155 did not provide prognostic information when analyzing the entire DLBCL cohort or activated B-cell-like classified patients. cell line(SU-DHL-5, OCI-Ly7) up-regulated sensitive Wee1 WEE1 NA validated 3092 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0004597 miR-140-3p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3093 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0004597 miR-140-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3094 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0004597 miR-140-3p miRNA DB00515 (APRD00359) Cisplatin chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3095 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0000646 miR-155-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3096 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0000646 miR-155-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3097 Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol 2019 30980798 miRBase MIMAT0000646 miR-155-5p miRNA DB00515 (APRD00359) Cisplatin chordoma qRT-PCR We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity. cell line up-regulated resistant PTEN PTEN PI3K-Akt-mTOR signaling pathway validated 3098 miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/Beta-catenin signaling via targeting SOX2. Life Sci 2019 30980849 miRBase MIMAT0000445 miR-126-3p miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR qRT-PCR analysis was used to measure the expressions of miR-126-3p and SOX2 mRNA in GBM tissues and cells. Cell viability, colony forming ability and apoptosis were detected to evaluate the effect of miR-126-3p or SOX2 on TMZ resistance. Luciferase reporter experiments were applied to identify the target genes of miR-126-3p. Western blot analysis was performed to determine the protein levels associated with Wnt/Beta-catenin signaling. TOP/FOP Flash assays were conducted to determine the effects of miR-126-3p or SOX2 on Wnt/B-catenin signaling. tissue and cell line (U87 and U251) up-regulated sensitive SOX2 SOX2 Wnt/Beta-catenin pathway validated 3099 MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. Oncol Res 2019 30982490 miRBase MI0000284 miR-204 miRNA DB01169 (APRD00171) Arsenic trioxide acute myeloid leukemia RT-qPCR In this study, the mechanism of mir-204 in acute myeloid leukemia and arsenic trioxide was studied.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line up-regulated sensitive BIRC6 BIRC6 NA validated 3100 MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother 2019 30999114 miRBase MIMAT0000276 miR-219a-5p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR In the study, using quantitative real time PCR analysis, we observed that miR-219a-5p was down-regulated in responding tumor tissues compared with that in non-responding tumor tissues from NSCLC patients received DDP-based chemotherapy. Consistently, miR-219a-5p expression was lower in cisplatin (DDP)-resistant NSCLC cell lines (A549-R and SPC-A1-R) than that in corresponding parental cells (A549 and SPC-A1). Gain of-function assay showed ectopic expression of miR-219a-5p reversed DDP chemoresistance of NSCLC cells in vitro and in vivo. Using bioinformatics prediction and dual-luciferase reporter assays, we identified the FGF9 gene as a novel direct target of miR-219a-5p. Moreover, restoration of FGF9 expression reversed the miR-219a-5p-mediated chemosensitivity. In conclusion, this study demonstrated miR-219a-5p plays a crucial role in the development of acquired drug resistance to DDP in NSCLC cells by targeting FGF9 and might be a therapeutic target for DDP resistance in clinical practice. tissue and cell lines (A549 and SPC-A1,A549-R and SPC-A1-R) down-regulated resistant FGF9 FGF9 NA validated 3101 Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. PLoS One 2019 31009516 miRBase MIMAT0003948 miR-770-5p miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab her2-receptor positive breast cancer qRT-PCR This study aimed to find drug-responsive miRNAs, and explore their anticancer activities in HER2+ breast cancer cells and regulatory role in the trastuzumab response. qRT-PCR-array analysis was performed with effective concentrations of tamoxifen and trastuzumab treated BT-474, SK-BR-3 and MCF-7 cells. Motility and invasion analyses were performed with wound healing and xCELLigence impedance-based assays respectively. Viability of cells following mimic transfection and drug treatment was assessed by WST-1 assay. Western blot analysis was used to assess miR-770-5p regulation of proteins and their phosphorylated forms. The clinical relevance of miR-770-5p was examined by TCGA data analysis. cell lines (BT-474, SK-BR-3, MCF-7) up-regulated sensitive HER2 HER2 HER2 signaling pathway validated 3102 MicroRNA-27a regulates the proliferation, chemosensitivity and invasion of human ovarian cancer cell lines by targeting Cullin 5. Arch Biochem Biophys 2019 31047870 miRBase MI0000085 miR-27a miRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The study was undertaken to unveil the therapeutic implications of miR-27a in ovarian cancer.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (Caov-4, SK-OV-3, OVACAR-3,UWB1.289,SV40, DoTc24510, GH329 and UACC-3247 ) up-regulated resistant CUL5 CUL5 NA validated 3103 MicroRNA-27a regulates the proliferation, chemosensitivity and invasion of human ovarian cancer cell lines by targeting Cullin 5. Arch Biochem Biophys 2019 31047870 miRBase MI0000085 miR-27a miRNA DB01248 (APRD00932) Docetaxel ovarian cancer qRT-PCR The study was undertaken to unveil the therapeutic implications of miR-27a in ovarian cancer.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (Caov-4, SK-OV-3, OVACAR-3,UWB1.289,SV40, DoTc24510, GH329 and UACC-3247 ) up-regulated resistant CUL5 CUL5 NA validated 3104 LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci 2019 31047896 miRBase MI0000735 miR-29c miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR RT-qPCR was performed to detect the expressions of LINC00511, miR-29c, and cyclin dependent kinase 6 (CDK6) in breast cancer tissues and cells. Pearson correlation analysis was used to analyze the correlation between miR-29c, CDK6 and LINC00511 expression in breast cancer tissues. The interactions between LINC00511, CDK6 and miR-29c were explored by luciferase reporter assay, RT-qPCR and western blot. MTT assay and flow cytometry analysis were applied to evaluate paclitaxel cytotoxicity. cell line (MDA-MB-231, MCF-7, Hs-578T, and T47D) down-regulated sensitive CDK6 CDK6 NA validated 3105 LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2019 31053148 miRBase MI0000077 miR-21 miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR Sorafenib-resistant HCC (SR-HCC) cells were generated and their sorafenib-resistant properties were confirmed by cell viability and apoptosis assays. Potential lncRNAs were screened by using multiple bioinformatics analyses and databases. The expression of genes and proteins was detected by qRT-PCR, Western blot and in situ hybridization. Gene silencing was achieved by specific siRNA or lncRNA Smart Silencer. The effects of anti-SNHG1 were evaluated in vitro and in experimental animals by using quantitative measures of cell proliferation, apoptosis and autophagy. The binding sites of miR-21 and SNHG1 were predicted by using the RNAhybrid algorithm and their interaction was verified by luciferase assays. cell line (HepG2,Huh7,SR-HCC ) up-regulated resistant NA NA AKT pathway validated 3106 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 miRBase MIMAT0004752 miR-20b-3p miRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The role of Lnc-TALC in glioblastoma cells was detected using microarray analysis,coding potential analysis, cell apoptosis analysis, CCK-8 assay, colony formation assay, 5-Ethynyl-2'-deoxyuridine (EdU)assay, western blot, PCR, luciferase reporter assay and Xenograft model in vivo, etc. cell line (LN229, U251, 551W, HG7,229R, 251R, 551WR, and HG7R) down-regulated resistant MET MET c-MET Signaling Pathway validated 3107 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000065 let-7d-5p miRNA DB12200 (DB06026) Tivantinib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3108 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000072 miR-18a-5p miRNA DB12200 (DB06026) Tivantinib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3109 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MI0003652 miR-637 miRNA DB12200 (DB06026) Tivantinib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3110 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000062 let-7a-5p miRNA DB00188 (APRD00828, DB07475) Bortezomib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3111 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004561 miR-187-5p miRNA DB01248 (APRD00932) Docetaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3112 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MI0003594 miR-586 miRNA DB01248 (APRD00932) Docetaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3113 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004517 miR-106a-3p miRNA DB01248 (APRD00932) Docetaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3114 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000763 miR-338-3p miRNA DB01248 (APRD00932) Docetaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3115 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004595 miR-135a-3p miRNA NA JNJ-707 breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3116 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004768 miR-497-3p miRNA DB01204 (APRD00371) Mitoxantrone breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3117 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MI0003655 miR-640 miRNA DB01204 (APRD00371) Mitoxantrone breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3118 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000099 miR-101-3p miRNA DB01204 (APRD00371) Mitoxantrone breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3119 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0002868 miR-522-3p miRNA DB01204 (APRD00371) Mitoxantrone breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3120 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004592 miR-125b-1-3p miRNA DB01204 (APRD00371) Mitoxantrone breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3121 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004517 miR-106a-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3122 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004561 miR-187-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3123 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0002868 miR-522-3p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3124 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MI0003594 miR-586 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3125 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0003220 miR-556-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3126 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004611 miR-185-3p miRNA DB06603 Panobinostat breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3127 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000084 miR-27a-3p miRNA DB12985 Quisinostat breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3128 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000259 miR-182-5p miRNA DB12027 Serdemetan breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3129 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000078 miR-23a-3p miRNA DB00877 (APRD00178, DB02439) Sirolimus breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3130 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004799 miR-589-5p miRNA DB01268 (DB07417) Sunitinib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated sensitive NA NA NA predicted 3131 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MI0003594 miR-586 miRNA DB04960 Tipifarnib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3132 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0004810 miR-629-5p miRNA DB04960 Tipifarnib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3133 MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS One 2019 31063487 miRBase MIMAT0000259 miR-182-5p miRNA DB07232 Veliparib breast cancer NA To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. cell line up-regulated resistant NA NA NA predicted 3134 miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene 2019 31075412 miRBase MI0003626 miR-613 miRNA DB00515 (APRD00359) Cisplatin liver cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( Huh7 and HCCLM3 ) down-regulated resistant SOX9 SOX9 SOX9 pathway validated 3135 miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene 2019 31075412 miRBase MI0003626 miR-613 miRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line ( Huh7 and HCCLM3 ) down-regulated resistant SOX9 SOX9 SOX9 pathway validated 3136 miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin. Exp Ther Med 2019 31086572 miRBase MI0003814 miR-1271 miRNA DB00515 (APRD00359) Cisplatin colorectal cancer RT-qPCR To investigate the drug resistance mechanism of mir-1271 in colorectal cancer.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (SW480 ) down-regulated resistant mTOR mTOR NA validated 3137 MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy. Hum Mol Genet 2019 31087038 miRBase MI0000460 miR-144 miRNA DB08809 Dichloroacetate glioblastoma qRT-PCR In this work, we hypothesized that gene therapy based on modulation of a miRNA with aberrant expression in glioblastoma and predicted to target crucial metabolic enzymes might impair tumor cell metabolism. We found that the increase of miR-144 levels, shown to be downregulated in U87 and DBTRG human glioblastoma cell lines, as well as in glioblastoma tumor samples, promoted the downregulation of mRNA of enzymes involved in bioenergetic pathways, with consequent alterations in cell metabolism, impairment of migratory capacity, and sensitization of DBTRG cells to a chemotherapeutic drug, the dichloroacetate. cell line (U87) down-regulated resistant PDK1, TIGAR, IDH1 and IDH2 PDK1, TIGAR, IDH1 and IDH2 NA validated 3138 The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. J Cell Biochem 2019 31087707 miRBase MIMAT0000432 miR-141-3p miRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qPCR Microarray analysis was performed to screen microRNAs that are differentially expressed in wild type and trastuzumab-resistant (TR) breast cancer cell lines. TargetScan helped predict the target gene of miR-141-3p. The regulatory relationship was confirmed through a luciferase reporter assay, quantitative reverse transcriptase polymerase chain reaction, and Western blot analysis. The MTT assay, transwell invasion assay, and wound scratch assay were performed to measure the proliferative, invasive, and migratory ability of breast cancer cells, respectively. Tumor cell xenografts in nude mice were conducted to observe the effect of miR-141-3p on trastuzumab resistance in breast cancer cells in vivo. The enzyme-linked immunosorbent assay was used to detect protein secretion. tissue and cell line (MDA-MB-231, SKBR3, HEK-293T ) down-regulated resistant CDK8 CDK8 miRNA-141-3p/CDK8 pathway validated 3139 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0000076 miR-21-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3140 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0000076 miR-21-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3141 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MI0006381 miR-1246 miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3142 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MI0006381 miR-1246 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3143 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0022942 miR-1229-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3144 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0022942 miR-1229-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3145 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0000095 miR-96-5p miRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3146 A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol 2019 31089750 miRBase MIMAT0000095 miR-96-5p miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Based on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily. cell line (HCT116, SW480, and HCT-8) up-regulated resistant NA NA NA validated 3147 MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am J Cancer Res 2019 31106002 miRBase MI0005566 miR-374b miRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR The critical goal of the present study was to understand sorafenib resistance in HCC cells and to uncover multiple targets that may overcome this problem. The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HEK293T,Hep3B, HepG2, HCCLM3) down-regulated resistant PKM2 PKM2 PKM2-mediated glycolysis pathway validated 3148 Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. J Cell Physiol 2019 31111480 miRBase MI0000073 miR-19a miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR This study aimed to investigate the potential role of lncRNA-AC078883.3 in the development of chemoresistance against cisplatin. Real-time PCR, Western blot analysis, Immunohistochemistry (IHC) assay, bioinformatic analysis, and luciferase assay were collaboratively used to establish the lncRNA-AC078883.3/miR-19a/PTEN/AKT pathway. Also, the effect of cisplatin on cell proliferation was observed via an MTT assay. Furthermore, Cox regression and Kaplan-Meier analyses were used to study whether lncRNA-AC078883.3 is involved in the survival of NSCLC. cell line(A549 and H460) up-regulated resistant PTEN PTEN PTEN/Akt pathway validated 3149 microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019 31113460 miRBase MIMAT0004958 miR-301b-3p miRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR Microarray analysis was performed to screen the differentially expressed lncRNA associated with NSCLC and its potential mechanism. The lncRNA MBNL1-AS1 expression was quantified in 56 paired NSCLC and adjacent normal tissue samples. In an attempt to outline the function of lncRNA MBNL1-AS1 in NSCLC and to identify the interaction among lncRNA MBNL1-AS1, microRNA-301b-3p (miR-301b-3p) and TGFBR2, ectopic expression, depletion, and reporter assay experiments were conducted to detect CSC proliferation, migration, invasion, drug resistance, and sphere formation in NSCLC. cell line (A549, H1299, and SK-MES-1) down-regulated sensitive TGFBR2 TGFBR2 TGF-Beta signalling pathway validated 3150 microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019 31113460 miRBase MIMAT0004958 miR-301b-3p miRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR Microarray analysis was performed to screen the differentially expressed lncRNA associated with NSCLC and its potential mechanism. The lncRNA MBNL1-AS1 expression was quantified in 56 paired NSCLC and adjacent normal tissue samples. In an attempt to outline the function of lncRNA MBNL1-AS1 in NSCLC and to identify the interaction among lncRNA MBNL1-AS1, microRNA-301b-3p (miR-301b-3p) and TGFBR2, ectopic expression, depletion, and reporter assay experiments were conducted to detect CSC proliferation, migration, invasion, drug resistance, and sphere formation in NSCLC. cell line (A549, H1299, and SK-MES-1) down-regulated sensitive TGFBR2 TGFBR2 TGF-Beta signalling pathway validated 3151 Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis. J Cell Physiol 2019 31131448 miRBase MIMAT0003393 miR-425-5p miRNA DB00515 (APRD00359) Cisplatin laryngeal carcinoma RT-PCR In this study, LINC-PINT expression in normal and tumor tissues were studied. Using a bioinformatic approach, microRNA (miRNA) targets of LINC-PINT and gene targets of the miRNA were determined. The impact of LINC-PINT on cell proliferation and chemoresistance was determined. Further through a set of silencing and re-expression studies phenotype rescue was studied. cell line (Hep-2) down-regulated sensitive PTCH1 PTCH1 Hedgehog pathway validated 3152 circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther 2019 31153828 miRBase MIMAT0000259 miR-182-5p miRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of hsa_circ_0004015 in non-small cell lung cancer cells was detected using quantitative real-time PCR (RT-PCR) assay, plasmid construction and dual luciferase activity assay,etc. cell line(MCF7,T47D and HEK293T) up-regulated resistant FOXO3a FOXO3a NA validated 3153 Induced miR-31 by 5-FU exposure contributes to the resistance in colorectal tumors Cancer Sci 2019 31162779 miRBase MI0000089 miR-31 miRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal tumors qRT-PCR The aim of this study is to determine and analyze the drug resistance-related miRNA in colorectal cancer. We established four types of 5-FU resistant colon cancer cell line in vitro and in vivo. We then analyzed miRNA expression profile by miRNA array in these 4 cell lines, and identified the drug resistance-related miRNAs. We examined the expression levels of the identified miRNA in 112 colorectal tumor samples from the patients. We identified possible 12 miRNAs to be involved in 5-FU resistance by miRNA arrays. We then examined the relationship between miR-31, which was most promising among them, and drug resistance. The ectopic expression of mimic miR-31 showed a significant 5-FU resistance in the parental DLD-1 cells, while anti-miR-31 caused significantly growth inhibition in DLD/F cells that is 5-FU resistant colon cancer cell line DLD-1 under exposure of 5-FU. When we exposed high dose of 5-FU to parent or 5-FU resistant cells, the expression levels of miR-31 were raised higher than those of controls. Notably, the expression levels of miR-31 were positively correlated with the grade of clinical stages of colorectal tumors. The protein expression levels of factor inhibiting hypoxia-inducible factor 1 (FHI-1) were downregulated by transfection of mimic miR-31 into DLD-1 cells. cell line (DLD-1 and SW480) up-regulated resistant FIH-1 FIH-1 NA validated 3154 LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life 2019 31188543 miRBase MIMAT0000062 miR-let-7a-5p miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin prostate cancer qRT-PCR Microarray analysis was conducted to determine differentially expressed lncRNAs and mRNAs. Gene Set Enrichment analysis was implemented for verification of dys-regulated signaling pathways between DU-145 cells and doxorubicin-resistant prostate cancer DU-145 cells. Relative expression of lncRNA LOXL1-AS1 in doxorubicin-resistant prostate cancer DU-145 cells was analyzed by qRT-PCR. CCK-8 assay and flow cytometry analysis were employed to detect cell proliferation and apoptosis, respectively. Cell migration was performed by transwell assay. Furthermore, targeted relationships between lncRNA LOXL1-AS1 and miR-let-7a-5p, as well as miR-let-7a-5p and EGFR were predicted using bioinformatics analysis and validated by dual-luciferase reporter gene assay. Besides, tumor xenograft assay was utilized for verification of the roles of LOXL1-AS1 in PCa progression in vivo. cell line (DU-145,s DU-145/DOX) up-regulated resistant EGFR EGFR NA validated 3155 miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma. Oncology 2019 31195398 miRBase MI0000748 miR-130b miRNA DB01268 (DB07417) Sunitinib renal cell carcinoma qRT-PCR The expression of miR-130b in 32 RCC tissues and their corresponding normal kidney tissues was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). We performed a 4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assay in RCC cell lines transfected with miR-130b inhibitor or miR-130b mimics. We evaluated the relationship between miR-130b and PTEN and also analyzed the effect of miR-130b on sunitinib resistance. tissue and cell line (Caki-1- sr ) up-regulated resistant NA NA NA validated 3156 miR-107 Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel. Open Med (Wars) 2019 31206033 miRBase MI0000114 miR-107 miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR The study aimed to lucubrate the underlying mechanisms of miR-107 in regulating the sensitivity of breast cancer cells to PTX.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (MCF-7 ) up-regulated sensitive TPD52 TPD52 Wnt/Beta-catenin pathway validated 3157 MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2. J Cell Biochem 2019 31222822 miRBase MI0003646 miR-33b miRNA DB00694 (APRD00521) Daunorubicin acute myeloid leukemia qRT-PCR In this study, we aimed to study the effect of miR-33b in regulating sensitivity to daunorubicin (DNR) in acute myelocytic leukemia (AML). We used quantitative real-time polymerase chain reaction and Cell Counting Kit-8 assay to detect the level of miR-33b and cell viability. Cell apoptosis and the expression of eIF5A-2 and MCL-1 protein were detected by flow cytometry analysis and Western Blot analysis, respectively cell line up-regulated sensitive eIF5A-2 EIF5A-2 NA validated 3158 miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. J Exp Clin Cancer Res 2019 31227006 miRBase MIMAT0000445 miR-126-3p miRNA DB08912 Dabrafenib melanoma qRT-PCR miRNA expression in two BRAF-mutant melanoma cell lines and their dabrafenib-resistant sublines was determined using Affymetrix GeneChip- miRNA 3.1 microarrays and/or qRT-PCR. The effects of miR-126-3p re-expression on proliferation, apoptosis, cell cycle, ERK1/2 and AKT phosphorylation, dabrafenib sensitivity, invasiveness and VEGF-A secretion were evaluated in the dabrafenib-resistant sublines using MTT assays, flow cytometry, immunoblotting, invasion assays in Boyden chambers and ELISA. ADAM9, PIK3R2, MMP7 and CXCR4 expression in the sensitive and dabrafenib-resistant cells was determined by immunoblotting. Small RNA interference was performed to investigate the consequence of VEGFA or ADAM9 silencing on proliferation, invasiveness or dabrafenib sensitivity of the resistant sublines. Long-term proliferation assays were carried out in dabrafenib-sensitive cells to assess the effects of enforced miR-126-3p expression or ADAM9 silencing on resistance development. VEGF-A serum levels in melanoma patients treated with BRAFi or BRAFi+MEKi were evaluated at baseline (T0), after two months of treatment (T2) and at progression (TP) by ELISA. cell line (A375 and SK-Mel28) down-regulated resistant ADAM9 and VEGF-A ADAM9 and VEGF-A NA validated 3159 Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD. Exp Ther Med 2019 31258693 miRBase MI0003634 miR-620 miRNA DB00441 (APRD00201) Gemcitabine triple-receptor negative breast cancer RT-qPCR Between December 2011 and December 2014, 36 TNBC samples were obtained from Liaocheng Peoples Hospital. Three gemcitabine-resistant MDA-MB-231 cell lines (MDA-MB-231rGEM1, MDA-MB-231rGEM2 and MDA-MB-231rGEM3) were obtained by exposure of MDA-MB-231 cells to increasing concentrations of gemcitabine for >12 months. Reverse transcription-quantitative polymerase chain reaction was performed to detect the expression levels of specific genes, including microRNA (miR)-620, ATP-binding cassette sub-family B member 1 (ABCB1), ABCC10, cytidine monophosphate kinase, deoxycytidine monophosphate deaminase (DCTD), nucleoside diphosphate kinase 1 (NME1), ribonucleoside-diphosphate reductase large subunit (RRM1) and RRMB2. Western blot analysis was performed to assess the protein expression levels of DCTD. Furthermore, cell proliferation was assessed using a Cell Counting Kit-8 assay and cell apoptosis was detected using an Annexin V/Dead Cell Apoptosis kit. Interactions between miR-620 and DCTD were predicted using TargetScan and detected with the dual luciferase reporter assay. cell line(MDA-MB-231, BT549) up-regulated resistant DCTD DCTD NA validated 3160 Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun 2019 31262449 miRBase MI0000072 miR-18a miRNA NA oncolytic vaccinia virus colorectal cancer RT-PCR The role of UCA1 in colorectal cancer cells was detected using Real-time PCR, Plaque formation assays, virus binding and entry assays, GTPase activation assays, etc. cell line (CaCo2, LoVo, HT29, SW480,COLO205, HCT116, T84) down-regulated sensitive NA NA NA validated 3161 Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun 2019 31262449 miRBase MI0000272 miR-182 miRNA NA oncolytic vaccinia virus colorectal cancer RT-PCR The role of UCA1 in colorectal cancer cells was detected using Real-time PCR, Plaque formation assays, virus binding and entry assays, GTPase activation assays, etc. cell line (CaCo2, LoVo, HT29, SW480,COLO205, HCT116, T84) down-regulated sensitive NA NA NA validated 3162 miR-1 reverses multidrug resistance in gastric cancer cells via downregulation of sorcin through promoting the accumulation of intracellular drugs and apoptosis of cells. Int J Oncol 2019 31268161 miRBase MI0000651/ MI0000437 miR-1 miRNA DB00541 (APRD00495) Vincristine stomach cancer RT-qPCR To investigate the molecular mechanism of MDR, the roles of microRNA (miR)-1 were studied in GC. Reverse transcription-quantitative polymerase chain reaction and western blotting were used to investigate the expression levels of miR-1 and sorcin in SGC7901/ADM and SGC7901/VCR cell lines. The effect of miR-1 on the half maximal inhibitory concentration (IC50), cell apoptosis rates and drug accumulation was uncovered by MTT assay and flow cytometric analysis. Furthermore, dual-luciferase assay and western blotting were used to determine the target of miR-1 in GC polymerase chain reaction and western blotting were used to investigate the expression levels of miR-1 and sorcin in SGC7901/ADM and SGC7901/VCR cell lines. The effect of miR-1 on the half maximal inhibitory concentration (IC50), cell apoptosis rates and drug accumulation was uncovered by MTT assay and flow cytometric analysis. Furthermore, dual-luciferase assay and western blotting were used to determine the target of miR-1 in GC. It was demonstrated that miR-1 was highly downregulated in MDR GC cell lines, including SGC7901/ADM and SGC7901/VCR. Overexpression of miR-1 in MDR GC cells decreased IC50, but increased the cell apoptosis rates and promoted the drug accumulation in cancer cells. Dual-luciferase activity assay indicated that sorcin was the target of miR-1 in GC. In addition, overexpression of sorcin could partially reverse the effect of miR-1 in MDR GC cells.. cell line (SGC7901,SGC7901/VCR, SGC7901/ADM) down-regulated resistant sorcin NA NA validated 3163 miR-1 reverses multidrug resistance in gastric cancer cells via downregulation of sorcin through promoting the accumulation of intracellular drugs and apoptosis of cells. Int J Oncol 2019 31268161 miRBase MI0000651/ MI0000437 miR-1 miRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-qPCR To investigate the molecular mechanism of MDR, the roles of microRNA (miR)-1 were studied in GC. Reverse transcription-quantitative polymerase chain reaction and western blotting were used to investigate the expression levels of miR-1 and sorcin in SGC7901/ADM and SGC7901/VCR cell lines. The effect of miR-1 on the half maximal inhibitory concentration (IC50), cell apoptosis rates and drug accumulation was uncovered by MTT assay and flow cytometric analysis. Furthermore, dual-luciferase assay and western blotting were used to determine the target of miR-1 in GC polymerase chain reaction and western blotting were used to investigate the expression levels of miR-1 and sorcin in SGC7901/ADM and SGC7901/VCR cell lines. The effect of miR-1 on the half maximal inhibitory concentration (IC50), cell apoptosis rates and drug accumulation was uncovered by MTT assay and flow cytometric analysis. Furthermore, dual-luciferase assay and western blotting were used to determine the target of miR-1 in GC. It was demonstrated that miR-1 was highly downregulated in MDR GC cell lines, including SGC7901/ADM and SGC7901/VCR. Overexpression of miR-1 in MDR GC cells decreased IC50, but increased the cell apoptosis rates and promoted the drug accumulation in cancer cells. Dual-luciferase activity assay indicated that sorcin was the target of miR-1 in GC. In addition, overexpression of sorcin could partially reverse the effect of miR-1 in MDR GC cells.. cell line (SGC7901,SGC7901/VCR , SGC7901/ADM) down-regulated resistant sorcin NA NA validated 3164 MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep 2019 31273056 miRBase MI0000299 miR-222 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR The aim of the present study was to find the relationship between miR-222 and DOX resistance. We found that miR-222 was highly expressed in patients serum and DOX-resistant cell line MCF-7-R and that miR-222 could promote proliferation and migration of breast cancer cells. Our results also showed that inhibition of miR-222 in MCF-7-R significantly increased Bcl-2 interacting mediator (Bim) expression both in mRNA and protein levels by using quantitative real-time PCR (qRT-PCR) and Western blot. MTT and flow cytometry suggested that lower expressed miR-222 enhanced apoptosis and decreased IC50 of MCF-7-R cells. Conversely, in MCF-7 cells transfected with miR-222 mimics, up-regulation of miR-222 was associated with decreased Bim level accompanied by less apoptosis and higher IC50 Moreover, miR-222 inhibitors reversed DOX resistance via miR-222-Bim-caspase pathway. cell line (MCF7) up-regulated resistant Bim Bim Bim pathway validated 3165 MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. Sci Rep 2019 31278310 miRBase MI0000290 miR-214 miRNA DB09053 Ibrutinib prostate cancer RT-qPCR In the present study, we investigated the role of miR-214 on prostate cancer cell survival/migration/invasion, cell cycle regulation.The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. and apoptosis. cell line(PC3, DU145, and LNCaP) up-regulated sensitive PTK6 PTK6 NA validated 3166 MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene 2019 31278368 miRBase MIMAT0003330 miR-654-5p miRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR-654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer. cell line (SKOV3, OAW42, 59M, OAW28, OVCAR4, TOV112, OV90, A2780, A2780cis, BIN67,IGROV1, IOSE-503, IOSE-385 and HEK293T) down-regulated resistant CDCP1 and PLAGL2 CDCP1 and PLAGL2 MYC, WNT and AKT pathways validated 3167 MiR-124 Reversed the Doxorubicin Resistance of Breast Cancer Stem Cells Through STAT3/HIF-1 Signaling Pathways. Cell Cycle 2019 31286834 miRBase MI0000443/MI0000444/MI0000445 miR-124 miRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR To understand the inner mechanism of drug resistance in breast cancer and look for remedy methods, we referred to bioinformatic analysis and predicted that signal transducer and activator of transcription 3 (STAT3) and miR-124 was overexpressed in MCF7-R cells (MCF7 cells resistant to DOX) compared with MCF cells. Expression levels of RNA and protein were separately determined by qRT-PCR and western blot. Dual luciferase assay was performed to verify the targeting relationship between STAT3 and miR-124. Optical density (OD) values and apoptotic rates of cells were respectively determined via MTT assays and flow cytometric analysis. Cell invasion was detected to verify drug resistance. cell line (MCF7) up-regulated sensitive STAT3 STAT3 STAT3/HIF-1 signaling pathways validated 3168 MicroRNA-200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER-ERCC3/4 pathway. Oncol Lett 2019 31289483 miRBase MI0000650 miR-200c miRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The present study aimed to investigate the molecular mechanism underlying the ability of miR-200c-3p to reverse drug resistance in a SGC7901/DDP GC cell line, particularly its effects on the ERCC excision repair 3, TFIIH core complex helicase subunit (ERCC3) and ERCC excision repair 4, endonuclease catalytic subunit (ERCC4) proteins in the nucleotide excision repair (NER) pathway. Reverse transcription-quantitative polymerase chain reaction demonstrated that miR-200c-3p expression in cisplatin-resistant SGC7901/DDP cells was lower than in parental SGC7901 cells, whereas the protein expression levels of ERCC3 and ERCC4 in these cells were higher by western blot analysis. In SGC7901/DDP-derived miR-200c-3p overexpressing cells, ERCC3 expression, ERCC4 expression and cisplatin resistance were decreased compared with in parental SGC7901/DDP cells and SGC7901/DDP-derived vector control cells. In SGC7901-derived miR-200c-3p knockdown cells, ERCC3 expression, ERCC4 expression and cisplatin resistance were increased compared with in parental SGC7901 cells and SGC7901-derived vector control cells. In conclusion, overexpression of miR-200c-3p may reverse drug resistance in the SGC7901/DDP GC cell line via downregulation of ERCC3 and ERCC4, which suggested this may be part of a mechanism involving the NER pathway. cell line (SGC7901/DDP, SGC7901) down-regulated resistant ERCC3 and ERCC4 ERCC3 and ERCC4 NER pathway validated 3169 Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncol Lett 2019 31289540 miRBase MI0000440 miR-27b miRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma RT-qPCR The clinical tissues of 34 patients with OSCC-resistant cancer and 28 patients with cisplatin-sensitive OSCC in Nanjing General Hospital were collected. The expression levels of miR-27b and Frizzled-7 (FZD7) in cancer tissues were detected by reverse transcription-quantitative polymerase chain reation (RT-qPCR). After a certain gradient of cisplatin was used to induce stable acquired resistance of OSCC cell line Tca8113/CDDP, a dose of miR-27b was added to construct a cell line overexpressing miR-27b in the drug-resistant cell line. The effect of cisplatin on the proliferation of drug-resistant OSCC cells was detected by colony formation assay. In addition, the scratch test and Transwell formation assay was performed to examine the effect of cisplatin drug stimulation on proliferation and migration of Tca8113/CDDP. Flow cytometry and Hoechst 33258 staining were used to detect the effect of miR-27b on apoptosis of OSCC-resistant cells after cisplatin chemotherapy tissue and cell line (Tca8113/CDDP ) down-regulated resistant NA NA FZD7 signaling pathway validated 3170 H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 1996 8674037 Ensembl ENSG00000130600 H19 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin leukemia RT-PCR,Northern blot The role of H19 in Atypical Multidrug-resistant cells was detected using Southern and Northern blot analysis, RT-PCR and Gene database analysis. etc. cell line (MCF-7,MCF-7/AdrVp,NCI-HI688,HL-60,HL-60/Vinc,HL60/Adr, UMCC-1,UMCC-1/VP) up-regulated resistant NA NA NA validated 3171 H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 1996 8674037 Ensembl ENSG00000130600 H19 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR,Northern blot The role of H19 in Atypical Multidrug-resistant cells was detected using Southern and Northern blot analysis, RT-PCR and Gene database analysis. etc. cell line (MCF-7,MCF-7/AdrVp,NCI-HI688,HL-60,HL-60/Vinc,HL60/Adr, UMCC-1,UMCC-1/VP) up-regulated resistant NA NA NA validated 3172 H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 1996 8674037 Ensembl ENSG00000130600 H19 lncRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma RT-PCR,Northern blot The role of H19 in Atypical Multidrug-resistant cells was detected using Southern and Northern blot analysis, RT-PCR and Gene database analysis. etc. cell line (MCF-7,MCF-7/AdrVp,NCI-HI688,HL-60,HL-60/Vinc,HL60/Adr, UMCC-1,UMCC-1/VP) up-regulated resistant NA NA NA validated 3173 H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 1996 8674037 Ensembl ENSG00000130600 H19 lncRNA DB00661 (APRD00335) Verapamil breast cancer RT-PCR,Northern blot The role of H19 in Atypical Multidrug-resistant cells was detected using Southern and Northern blot analysis, RT-PCR and Gene database analysis .etc. cell line (MCF-7,MCF-7/AdrVp,NCI-HI688,HL-60,HL-60/Vinc,HL60/Adr, UMCC-1,UMCC-1/VP) up-regulated resistant NA NA NA validated 3174 H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 1996 8674037 Ensembl ENSG00000130600 H19 lncRNA DB00541 (APRD00495) Vincristine leukemia RT-PCR,Northern blot The role of H19 in Atypical Multidrug-resistant cells was detected using Southern and Northern blot analysis, RT-PCR and Gene database analysis. etc. cell line (MCF-7,MCF-7/AdrVp,NCI-HI688,HL-60,HL-60/Vinc,HL60/Adr, UMCC-1,UMCC-1/VP) up-regulated resistant NA NA NA validated 3175 Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006 16569192 RefSeq NR_002769.1 PCGEM1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin prostate cancer Northern blot The expression levels of lncrna were determined by Northern blot and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (LNCaP) up-regulated resistant NA NA NA validated 3176 Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 2007 17297456 Ensembl ENSG00000130600 H19 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma Northern blot The expression levels of lincRNA were determined by Northern-blot and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lincRNAs. cell line (HepG2, R-HepG2) up-regulated resistant NA NA NA validated 3177 Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer 2010 20859285 RefSeq NR_024049.1 BCAR4 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival (PFS) and clinical benefit in patients with oestrogen receptor (ERalpha)-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease. In a separate cohort of patients with lymph node-negative, ERalpha-positive cancer, and not receiving systemic adjuvant therapy, BCAR4 levels were evaluated for association with distant metastasis-free survival (MFS). The function of BCAR4 was studied with immunoblotting and RNA interference in a cell model. cell line (ZR-75-1 ) up-regulated resistant NA NA ERBB2 and ERBB3 signalling validated 3178 Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun 2011 21316338 Ensembl ENSG00000249859 PVT1 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer PCR Using a genome-wide and piggyBac transposon-based genetic screening platform, we identified the relationship between PVT1 and gemcitabine in human pancreatic cancer ASPC-1 cells . Luciferase activity assay was used to verify the target genes of lincRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lincRNAs . cell line (ASPC-1) down-regulated sensitive NA NA NA validated 3179 Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients. J Cancer Sci Ther 2011 23543869 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin sarcoma RT-PCR Expression of MTDH protein or HOTAIR was detected by Western blotting or qRT-PCR, respectively, in primary and metastatic sarcoma patient tissue samples. tissue down-regulated sensitive NA NA NA validated 3180 Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients. J Cancer Sci Ther 2011 23543869 Ensembl ENSG00000228630 HOTAIR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin sarcoma RT-PCR Expression of MTDH protein or HOTAIR was detected by Western blotting or qRT-PCR, respectively, in primary and metastatic sarcoma patient tissue samples. tissue down-regulated sensitive NA NA NA validated 3181 Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 2012 22576688 Ensembl ENSG00000214049 UCA1a lncRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR The role of UCA1a in bladder cancer cells was detected using RT-PCR, MTT assay, cell motility and invasion assay, microarray analysis and tumorigenesis assay,etc. tissue and cell line ( BLZ-211, 5637 and UM-UC-2) up-regulated resistant NA NA NA validated 3182 BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer 2012 22892392 RefSeq NR_024049.1 BCAR4 lncRNA DB01259 (DB02584) Lapatinib breast cancer RT-PCR Proliferation assays were applied to determine the effect of BCAR4 expression on lapatinib treatment. Changes in cell signalling were quantified with reverse-phase protein microarrays. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) of ERBB2 and BCAR4 was performed in 1418 primary breast cancers. Combined BCAR4 and ERBB2 mRNA levels were evaluated for association with progression-free survival (PFS) in 293 oestrogen receptor-alpha(ER)-positive patients receiving tamoxifen as first-line monotherapy for recurrent disease. cell line (ZR-75-1, MCF7) up-regulated sensitive NA NA NA validated 3183 BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer 2012 22892392 RefSeq NR_024049.1 BCAR4 lncRNA DB01259 (DB02584) Lapatinib breast cancer RT-PCR Proliferation assays were applied to determine the effect of BCAR4 expression on lapatinib treatment. Changes in cell signalling were quantified with reverse-phase protein microarrays. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) of ERBB2 and BCAR4 was performed in 1418 primary breast cancers. Combined BCAR4 and ERBB2 mRNA levels were evaluated for association with progression-free survival (PFS) in 293 oestrogen receptor-alpha(ER)-positive patients receiving tamoxifen as first-line monotherapy for recurrent disease. cell line (ZR-75-1, MCF7) up-regulated sensitive NA NA NA validated 3184 Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013 23676682 Ensembl ENSG00000234741 GAS5 lncRNA NA Nutlin-3a prostate cancer Real time RT-PCR The role of GAS5 in prostate cancer cells was detected using real time RT-PCR, plasmid DNA transfection, RNA interference by siRNA, fluorescence microscopy assay,etc. cell line (22Rv1 and PC-3) down-regulated resistant NA NA NA validated 3185 Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013 23676682 Ensembl ENSG00000234741 GAS5 lncRNA DB01248 (APRD00932) Docetaxel prostate cancer Real time RT-PCR The role of GAS5 in prostate cancer cells was detected using real time RT-PCR, plasmid DNA transfection, RNA interference by siRNA, fluorescence microscopy assay,etc. cell line (22Rv1 and PC-3) down-regulated resistant NA NA NA validated 3186 Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013 23676682 Ensembl ENSG00000234741 GAS5 lncRNA DB01204 (APRD00371) Mitoxantrone prostate cancer Real time RT-PCR The role of GAS5 in prostate cancer cells was detected using real time RT-PCR, plasmid DNA transfection, RNA interference by siRNA, fluorescence microscopy assay,etc. cell line (22Rv1 and PC-3) down-regulated resistant NA NA NA validated 3187 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl NA lncRNA AK126698 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3188 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl NA lncRNA AK123263 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3189 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl NA lncRNA CES1P1-001 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3190 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl NA RP3-508I15.14 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3191 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl ENSG00000182165 TP53TG1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3192 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl NA AC090952.4.1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) down-regulated resistant NA NA NA validated 3193 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 UCSC uc003bgl.1 uc003bgl.1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) up-regulated resistant NA NA NA validated 3194 The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013 23741487 Ensembl ENSG00000231814 LINC00210 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR,Realtime RT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line (A549,A549/CDDP ) up-regulated resistant NA NA NA validated 3195 Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One 2013 23936419 Ensembl ENSG00000228630 HOTAIR lncRNA DB01645 (EXPT01582) Genistein prostate cancer qRT-PCR Microarray expression profiling of mRNAs, lncRNA and miRNA was undertaken in A549 cells and cisplatin resistant A549/CDDP cells. Differentially expressed mRNAs, lncRNAs and miRNAs, verified by realtime RT-PCR, were subjected to pathway analysis. Expression of NKD2 and Beta-catenin was assessed by realtime RT-PCR and western blot analysis. The effect of lncRNA AK126698 on cisplatin induced apoptosis was investigated by annexin-V/PI flow cytometry. cell line ( LNCaP, PC3, DU145,RWPE-1) down-regulated sensitive miR-34a NA NA validated 3196 The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res 2013 24141629 Ensembl ENSG00000229807 Xist lncRNA DB12565 (DB05921) Abexinostat breast cancer qRT-PCR We evaluated the effect of the HDACi compound abexinostat on CSCs from 16 breast cancer cell lines (BCL) using ALDEFLUOR assay and tumorsphere formation. We performed gene expression profiling to identify biomarkers predicting drug response to abexinostat. Then, we used patient-derived xenograft (PDX) to confirm, in vivo, abexinostat treatment effect on breast CSCs according to the identified biomarkers. cell line (BCLs) up-regulated resistant NA NA NA validated 3197 The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage. Mol Cancer 2013 24168400 Ensembl NA ERIC lncRNA DB00773 (APRD00239) Etoposide osteosarcoma real-time RT-PCR The role of ERIC in osteosarcoma cells was detected using Real-Time RT- PCR, western blotting, transfection/infection procedures, fluorescence-activated cell sorting analysis and RNA Seq analysis,etc. cell line (U2OS,SAOS-2 ) down-regulated sensitive NA NA NA validated 3198 A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 2014 24184505 Ensembl NA lncRNA-BX537613 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-PCR The role of ARA in cancer cells was detected using real-time PCR, siRNA transfection and Sulforhodamine B (SRB) assays, cell cycle and apoptosis analysis, migration assays, etc. cell line (MCF-7,HepG2,MCF-7/ADR,HepG2/ADR) up-regulated sensitive NA NA NA validated 3199 A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 2014 24184505 Ensembl NA lncRNA-BX537613 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin liver cancer RT-PCR The role of ARA in cancer cells was detected using real-time PCR, siRNA transfection and Sulforhodamine B (SRB) assays, cell cycle and apoptosis analysis, migration assays, etc. cell line (MCF-7,HepG2,MCF-7/ADR,HepG2/ADR) up-regulated sensitive NA NA NA validated 3200 PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014 24473064 Ensembl ENSG00000253438 PCAT-1 lncRNA DB09074 (DB05940) Olaparib prostate cancer qPCR The role of PCAT-1 in prostate cancer cells was detected using luciferase assays, immunoblot analysis, Xenograft assays and I-SceI homologous recombination assay,etc. cell line (PC3,PCAT-1, LNCAP,LNCaP, Du145,RWPE) up-regulated sensitive NA NA NA validated 3201 PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014 24473064 Ensembl ENSG00000253438 PCAT-1 lncRNA DB07232 Veliparib prostate cancer qPCR The role of PCAT-1 in prostate cancer cells was detected using luciferase assays, immunoblot analysis, Xenograft assays and I-SceI homologous recombination assay,etc. cell line (PC3,PCAT-1, LNCAP,LNCaP, Du145,RWPE) up-regulated sensitive NA NA NA validated 3202 Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk 2014 24703244 Ensembl ENSG00000234741 GAS5 lncRNA DB00877 (APRD00178, DB02439) Rapamycin mantle cell lymphoma RT-PCR We downregulated endogenous GAS5 in mantle cell lymphoma cell lines using RNA interference before treatment with several rapalogues. The effect of GAS5 downregulation was monitored by 3 independent analyses of cell viability, DNA synthesis, and colony-forming ability. cell line (Jeko-1,Z-138 ) down-regulated resistant NA NA mTOR signaling pathway validated 3203 Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk 2014 24703244 Ensembl ENSG00000234741 GAS5 lncRNA DB00877 (APRD00178, DB02439) Sirolimus mantle cell lymphoma RT-PCR We downregulated endogenous GAS5 in mantle cell lymphoma cell lines using RNA interference before treatment with several rapalogues. The effect of GAS5 downregulation was monitored by 3 independent analyses of cell viability, DNA synthesis, and colony-forming ability. cell line (Jeko-1,Z-138 ) down-regulated resistant NA NA mTOR signaling pathway validated 3204 Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk 2014 24703244 Ensembl ENSG00000234741 GAS5 lncRNA DB06287 Temsirolimus mantle cell lymphoma RT-PCR We downregulated endogenous GAS5 in mantle cell lymphoma cell lines using RNA interference before treatment with several rapalogues. The effect of GAS5 downregulation was monitored by 3 independent analyses of cell viability, DNA synthesis, and colony-forming ability. cell line (Jeko-1,Z-138 ) down-regulated resistant NA NA mTOR signaling pathway validated 3205 Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res 2014 24874432 Ensembl ENSG00000147852 linc-VLDLR lncRNA DB00398 (APRD01304, DB07438) Sorafenib Hepatocellular cancer RT-PCR The expression levels of lncRNA were determined by Real-time PCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( HepG2, Hep3B, PLC/PRF-5 and Huh-7 ) up-regulated resistant NA NA NA validated 3206 Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res 2014 24874432 Ensembl ENSG00000147852 linc-VLDLR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin Hepatocellular cancer RT-PCR The expression levels of lncRNA were determined by Real-time PCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( HepG2, Hep3B, PLC/PRF-5 and Huh-7 ) up-regulated resistant NA NA NA validated 3207 Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res 2014 24874432 Ensembl ENSG00000147852 linc-VLDLR lncRNA DB04690 Camptothecin Hepatocellular cancer RT-PCR The expression levels of lncRNA were determined by Real-time PCR and those of protein were by Western blot analysis. MTS assay was used to test cell proliferation . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( HepG2, Hep3B, PLC/PRF-5 and Huh-7 ) up-regulated resistant NA NA NA validated 3208 Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 2014 24926545 Ensembl ENSG00000249859 PVT1 lncRNA DB00515 (APRD00359) Cisplatin malignant pleural mesothelioma qRT-PCR We used small interfering RNA (siRNA)-mediated knockdown in MPM cell lines to determine the effect of C-MYC and PVT1 abrogation on MPM cells undergoing apoptosis, proliferation, and cisplatin sensitivity. We also characterized the expression of microRNAs spanning the PVT1 region in MPM cell lines. Copy number analysis was measured by quantitative polymerase chain reaction and fluorescence in situ hybridization. cell line (H2452, MET-5A, H2052, H28,MSTO-211H,HCT-4012, Meso, HP3, HP5, HP7, HP9 and HP10) down-regulated sensitive NA NA NA validated 3209 Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol 2014 24958102 Ensembl NA lncRNA MRUL lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .Fluorescence intensity assay for intracellular ADR. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR,SGC7901/ADR) down-regulated sensitive ABCB1 ABCB1 NA validated 3210 Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol 2014 24958102 Ensembl NA lncRNA MRUL lncRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .Fluorescence intensity assay for intracellular ADR. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SGC7901,SGC7901/VCR,SGC7901/ADR) down-regulated sensitive ABCB1 ABCB1 NA validated 3211 A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells 2014 25078450 RefSeq NR_004435.1 snaR lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colon cancer RT-qPCR The expression levels of lncRNA were determined RT-qPCR . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SNU-C4,SNU-C5,SNU-C4R,SNU-C5R,HCT-116) down-regulated resistant NA NA NA validated 3212 Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med 2014 25169763 Ensembl ENSG00000243197 LOC285194 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma qRT-PCR The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection or from those who received surgical resection alone . The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed. tissue and cell line (KYSE30, KYSE 70, KYSE 150, KYSE510, Eca109, Het-1A) down-regulated resistant NA NA NA validated 3213 Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med 2014 25169763 Ensembl ENSG00000243197 LOC285194 lncRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection or from those who received surgical resection alone. The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed. tissue and cell line (KYSE30, KYSE 70, KYSE 150, KYSE510, Eca109, Het-1A) down-regulated resistant NA NA NA validated 3214 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000583748 AC022596.6 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3215 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000425692 AC022596.6 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3216 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000584612 KRT16P2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3217 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000581210 KRT16P1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3218 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000579062 KRT16P2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3219 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 RefSeq ENST00000395675 FOXO3B lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3220 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000446115 RP11-439L18.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3221 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 RefSeq NR_024538 GSTM4 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3222 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000458343 KRT42P lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3223 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000555300 RP11-104E19.1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3224 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000583364 AC015818.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3225 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000578693 AC006050.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3226 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000412143 PSORS1C3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3227 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000326333 KRT17P2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3228 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000579363 AC022596.2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3229 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000420566 AC006050.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3230 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000554221 LINC00520 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3231 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000560054 RP11-499F3.2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line down-regulated sensitive NA NA NA predicted 3232 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 RefSeq NR_026892 AFAP1-AS1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3233 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000566942 RP11-284N8.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3234 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000562112 NAPSB lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3235 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000567369 CTA-363E6.2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3236 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000579713 RP11-403A21.2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3237 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000565118 ABCC6P1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3238 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000450920 SRGAP3-AS2 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3239 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 UCSC TCONS_00003617 XLOC_001406 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3240 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000433329 HBBP1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3241 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 UCSC uc010jub.1 AK293020 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3242 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000562490 RP11-102F4.3 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3243 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000564038 RP11-1223D19.1 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3244 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 Ensembl ENST00000466677 RP4-555L14.5 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3245 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 RefSeq NR_024344 LOC283174 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3246 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 RefSeq NR_038386 LOC728537 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3247 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 UCSC uc022cjh.1 IGL@ lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3248 Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One 2014 25250788 UCSC uc001lku.1 AK125699 lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma qPCR Differentially expressed lncRNAs and mRNA were identified using microarray profiling of tumors with partial response (PR) vs. with progressive disease (PD) from advanced lung squamous cell carcinoma patients treated with cisplatin based chemotherapy and validated by quantitative real-time PCR (qPCR). Furthermore, the expression of AC006050.3-003 was assessed in another 60 tumor samples. tissue and cell line up-regulated sensitive NA NA NA predicted 3249 Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther 2014 25258543 Ensembl ENSG00000249859 PVT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer qPCR First, we used lncRNA microarrays to conduct a preliminary screening for candidate lncRNAs of gastric cancer biomarkers in both human gastric cancer tissues and in two gastric cancer cell lines, SGC7901 cells and paclitaxel-resistant SGC7901 cells. The lncRNA plasma-cytoma variant translocation 1 (PVT1) was found to exhibit higher expression in both gastric cancer tissues and the SGC7901 paclitaxel-resistant cell line. Quantitative polymerase chain reaction was used for large-scale analysis in a large number of human gastric cancer tissues to verify the involvement of PVT1 in development of gastric cancer. The relationships between PVT1 expression and clinical features were also analyzed. tissue and cell line (SGC7901 ) up-regulated resistant NA NA NA predicted 3250 LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer 2014 25496320 Ensembl NA LEIGC lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil gastric carcinoma qRT-PCR The differential expression of lncRNAs in gastric cancer and paired non-cancerous tissues were identified by microarray and validated using quantitative real-time PCR. Gastric samples from patients with gastric cancer were further analyzed for levels of a specifically downregulated lncRNA (termed as LEIGC). cell line (MGC-803, AGS, SGC-7901) up-regulated sensitive NA NA NA validated 3251 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl ENST00000507437 RNPS1P1-201 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) up-regulated resistant NA NA NA predicted 3252 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl ENST00000508827 LINC01303-201 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) up-regulated resistant NA NA NA predicted 3253 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 RefSeq NR_026685 NA lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) up-regulated resistant NA NA NA predicted 3254 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl NA BC087858 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) up-regulated resistant NA NA NA predicted 3255 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl ENST00000381279 AL390205.1-201 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) down-regulated resistant NA NA NA predicted 3256 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl ENST00000418077 RPL23P11-201 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) down-regulated resistant NA NA NA predicted 3257 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl NA BG188549 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) down-regulated resistant NA NA NA predicted 3258 Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015 25482516 Ensembl NA BE244504 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR In the study, EGFR-TKIs sensitive and resistant human lung cancer cells were analyzed by lncRNA microarray . The expression levels of lncRNA were determined by qRT-PCR . The CCK-8 assay was used to monitor the growth of the cells . cell line (PC9,H1975, H1299, A549,PC9/R) down-regulated resistant NA NA NA predicted 3259 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate 2015 25650269 Ensembl ENSG00000234741 GAS5 lncRNA DB12774 AZD8055 prostate cancer qRT-PCR The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. cell line ( 22Rv1, LNCaP, PC-3,DU 145) up-regulated sensitive NA NA NA validated 3260 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate 2015 25650269 Ensembl ENSG00000234741 GAS5 lncRNA DB11651 BEZ235 prostate cancer qRT-PCR The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. cell line ( 22Rv1, LNCaP, PC-3,DU 145) up-regulated sensitive NA NA NA validated 3261 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate 2015 25650269 Ensembl ENSG00000234741 GAS5 lncRNA DB01590 Everolimus prostate cancer qRT-PCR The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. cell line ( 22Rv1, LNCaP, PC-3,DU 145) up-regulated sensitive NA NA NA validated 3262 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate 2015 25650269 Ensembl ENSG00000234741 GAS5 lncRNA DB00877 (APRD00178, DB02439) Sirolimus prostate cancer qRT-PCR The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. cell line ( 22Rv1, LNCaP, PC-3,DU 145) up-regulated sensitive NA NA NA validated 3263 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate 2015 25650269 Ensembl ENSG00000234741 GAS5 lncRNA DB06287 Temsirolimus prostate cancer qRT-PCR The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. cell line ( 22Rv1, LNCaP, PC-3,DU 145) up-regulated sensitive NA NA NA validated 3264 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 LNCipedia lnc-ZNF532-3:1 Lnc-ZNF532 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3265 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl NA CR619813 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3266 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000514487 AC008443.5-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3267 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000441966 DDX6P1-205 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3268 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000457739 RARRES2P3-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3269 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000430203 NA lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3270 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000419190 ELF3-AS1-202 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3271 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000512634 AC019163.1-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3272 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000419694 AP000221.1-203 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3273 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000514084 OR5H7P-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3274 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl BC063868 NA lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3275 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000449714 AC007364.1-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3276 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000511385 AC097652.1 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3277 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl NA AF086204 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3278 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000414485 CYCSP33-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3279 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 UCSC uc.255 NA lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3280 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000443851 AC112653.1-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3281 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl BC036409.1 BC036409 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3282 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000505494 AC084048.1-201 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3283 Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anticancer Drugs 2015 25763542 Ensembl NA lncRNA AK022798 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis.The CCK-8 assay was used to monitor the growth of the cells . Choice of a differentially expressed gene list using a volcano plot and heat map analysis . cell line (SGC7901, BGC823,SGC7901/DDP, BGC823/DDP) up-regulated resistant NA NA NA validated 3284 HOTAIR is a potential target for the treatment of cisplatin resistant ovarian cancer. Mol Med Rep 2015 25824616 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer RT-qPCR The expression levels of lncRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) . CCK-8 test was used for evaluation of cell proliferation and cell survival rates. Cell migration was detected by invasion assay. cell line (SKOV-3,SKOV-3CDDP/R) up-regulated resistant NA NA NA validated 3285 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC uc010vzg.1 uc010vzg.1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3286 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC TCONS_00026506 TCONS_00026506 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3287 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC TCONS_00029808 TCONS_00029808 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3288 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC TCONS_00018504 TCONS_00018504 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3289 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000424436 AL031846.1-202 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3290 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC TCONS_00006911 TCONS_00006911 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3291 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000439517 CASC2-204 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3292 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000566764 AC092338.1-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3293 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 UCSC TCONS_00008533 TCONS_00008533 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3294 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000538640 AC009509.2-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) up-regulated resistant NA NA NA predicted 3295 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000468960 TRRAP-207 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3296 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 RefSeq NR_038990 EHHADH-AS1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3297 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000534068 LINC02726-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3298 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000507398 AC008413.2-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3299 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000515310 HAND2-AS1-232 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3300 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000415104 NA lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3301 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000518633 AC135166.1-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3302 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000509136 AC097716.1-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3303 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000512210 AC124854.1-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3304 Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Asian Pac J Cancer Prev 2015 25921151 Ensembl ENST00000504419 LINC02214-201 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR A 5-FU-based concurrent CRR cell model was established using human CRC cell line HCT116. Microarray expression profiling of lncRNAs and mRNAs was undertaken in parental HCT116 and 5-FU-based CRR cell lines. cell line (HCT116, CRR-HCT116) down-regulated resistant NA NA NA predicted 3305 The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol 2015 25925741 Ensembl ENSG00000234741 GAS5 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qRT-PCR To investigate the expression of growth arrest-specific 5 (GAS5) in lung adenocarcinoma, we performed real-time reverse-transcriptase polymerase chain reaction. The correlation between GAS5 expression levels and the samples clinicopathological features was also analyzed. Primary resistance to EGFR-TKIs was identified in the human lung adenocarcinoma cell line A549. Plasmid vectors were used to overexpress GAS5 in A549 cells. MTT (3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide) colony formation assays and EdU (5-ethynyl-2-deoxyuridine) assays were used to assess cell proliferation, and flow-cytometric analysis was used to evaluate the apoptosis rate. The expression levels of our target proteins, namely, EGFR, p-EGFR, ERK, p-ERK, Akt, p-Akt, IGF-1R (insulin-like growth factor 1 receptor), and p-IGF-1R, were analyzed by western blotting. A549 cells transfected with pcDNA-GAS5 were injected into nude mice. The transplanted mice were treated with gefitinib to study the effect of GAS5 on the resistance to EGFR-TKIs in vivo. cell line (A549, H1299, H1975, HCC827,HBE) up-regulated sensitive IGF-1R IGF-1R EGFR pathway validated 3306 Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun 2015 25956062 Ensembl ENSG00000249859 PVT1 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR In this study, the mRNA levels of PVT1 in gastric cancer tissues of cisplatin-resistant patients and two kinds of cisplatin-resistant cells BGC823/DDP and SGC7901/DDP were detected by qRT-PCR. The influence of PVT1 knockdown or overexpression on anticancer drug resistance was assessed by measuring the cytotoxicity of cisplatin and the rate of apoptosis detected by CCK-8 assay and flow cytometry, respectively. Further, we investigated the expression levels of MDR1, MRP, mTOR and HIF-1alpha by qRT-PCR and western blotting. cell line (BGC823,SGC7901,BGC823/DDP and SGC7901/DDP) up-regulated resistant NA NA NA validated 3307 The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. PLoS One 2015 25992654 Ensembl ENSG00000214548 MEG3 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. lncRNA microarray was used to test the lncrna expression in different cell lines . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549,A549/DDP) down-regulated resistant NA NA NA validated 3308 Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol 2015 26097562 Ensembl ENSG00000249859 PVT1 lncRNA DB00958 (APRD00466) Carboplatin ovarian cancer qRT-PCR The role of PVT1 in ovarian cancer cells was detected using LncRNA profiling, cell proliferation assay, RNA interference and qRT-PCR assay, etc. cell line (3AO) up-regulated sensitive NA NA NA validated 3309 Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol 2015 26097562 Ensembl ENSG00000249859 PVT1 lncRNA DB01248 (APRD00932) Docetaxel ovarian cancer qRT-PCR The role of PVT1 in ovarian cancer cells was detected using LncRNA profiling, cell proliferation assay, RNA interference and qRT-PCR assay, etc. cell line (3AO) up-regulated sensitive NA NA NA validated 3310 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000132819 RBM38 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3311 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000161960 EIF4A1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3312 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000233122 CTAGE7P lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3313 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000270123.2 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3314 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000122952 ZWINT lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3315 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000078070 MCCC1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3316 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000114770 ABCC5 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3317 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000128604 IRF5 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3318 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000113013 HSPA9 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3319 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000168826 ZBTB49 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3320 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000113758 DBN1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3321 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000175556 LONRF3 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3322 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000196387 ZNF140 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3323 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000089157 RPLP0 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3324 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000114841 DNAH1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3325 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000100479 POLE2 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3326 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000125089 SH3TC1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3327 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000261098 AP000766.1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3328 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000173039 RELA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3329 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000176715 ACSF3 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3330 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000105072 C19orf44 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3331 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000105486 LIG1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3332 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000140474 ULK3 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3333 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000087157 PGS1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3334 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAG000474 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3335 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000105499 PLA2G4C lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3336 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000160352 ZNF714 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3337 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAG006731 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3338 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAG013992 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3339 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAT022136 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3340 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAT079374 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3341 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000103248 MTHFSD lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3342 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 NONCODE NONHSAT022142 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3343 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000012048 BRCA1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3344 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000264549 SNORD95 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3345 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000243701 LINC00883 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3346 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000245532 NEAT1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3347 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000104976 SNAPC2 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3348 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000105717 PBX4 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3349 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 LNCipedia LOC100506844 lnc-CTDSP2-2:11 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3350 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 LNCipedia LOC257358 NA lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) down-regulated resistant NA NA NA predicted 3351 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000052723 SIKE1 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3352 Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing. Gene 2015 26164760 Ensembl ENSG00000196247 ZNF107 lncRNA DB00541 (APRD00495) Vincristine colon cancer PCR A cDNA library of HCT-8 VCR-resistant colon cancer cell was established through PCR amplification. Using HiSeq 2500 sequencing and bioinformatic methods, we identified lncRNAs showing different expression levels in drug-resistant and non-resistant cells, and constructed expression profiles of the lncRNA differences. The pretreatment of data was quality controlled using FastQC software. Transcription of lncRNA was calculated using Fragments Per Kilobase of transcript per Million fragments mapped (FPKM). To reveal the potential functions of these lncRNAs, we applied GO analysis to study the differentially expressed lncRNAs. cell line (HCT-8,HCT-8/VCR ) up-regulated resistant NA NA NA predicted 3353 Fentanyl inhibits the invasion and migration of colorectal cancer cells via inhibiting the negative regulation of Ets-1 on BANCR. Biochem Biophys Res Commun 2015 26296467 Ensembl ENSG00000278910 BANCR lncRNA DB00813 (APRD00347, DB05853, DB06055, DB06220, DB05564) Fentanyl colorectal cancer RT-PCR The expression levels of Ets-1 and BANCR were first detected in fentanyl-treated CRC cells. The interaction between Ets-1 and BANCR promoter was verified with chromatin immunoprecipitation assays, as well as corresponding acetylation of histones. The regulation of Ets-1 on BANCR expression was confirmed through luciferase assays and RT-PCR analysis. And, cell clone formation, cell migration and invasion were observed to evaluate the anti-tumor effects of fentanyl. Ets-1 overexpression or co-overexpression with BANCR was further performed by plasmids transfection to show the regulatory role of Ets-1 in fentanyl-induced mechanism. cell line ( LOVO and SW480 ) up-regulated sensitive NA NA NA validated 3354 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 RefSeq NR_073012 PRSS21 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3355 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000563280 FOXC2-AS1-201 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3356 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 RefSeq NR_026880 MGC12916 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3357 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000525893 AC138230.1-201 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3358 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC TCONS_00029064 TCONS_00029064 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3359 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC uc010lgv.1 uc010lgv.1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3360 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000553559 SNHG10-202 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3361 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000555866 SNHG10-204 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3362 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC uc003txt.3 uc003txt.3 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3363 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC TCONS_00023486 TCONS_00023486 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) up-regulated resistant NA NA NA predicted 3364 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 RefSeq NR_036444 FENDRR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3365 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC uc003lrn.1 uc003lrn.1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3366 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000440570 MIR503HG-202 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3367 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000415000 LRRC52-AS1-201 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3368 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000476909 LINC00595-207 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3369 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 RefSeq NR_040001 LINC01116 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3370 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000457390 LINC02802-204 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3371 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 Ensembl ENST00000567054 MT1CP-201 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3372 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 RefSeq NR_073080 PHLDA3 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3373 Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. Int J Clin Exp Pathol 2015 26464619 UCSC uc002sts.4 uc002sts.4 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) . MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. lncRNA microarray was used to test the lncrna expression in different cell lines .GO analysis is a functional analysis associating differentially expressed mRNAs with GO categories. Pathway analysis for differentially expressed mRNAs was provided, based on the latest KEGG database cell line (MG63,MG63/DXR) down-regulated resistant NA NA NA predicted 3374 HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med 2015 26497652 Ensembl ENSG00000228630 HOTAIR lncRNA DB00958 (APRD00466) Carboplatin ovarian cancer RT-PCR We analyzed HOTAIR expression and associated surrogate DNA methylation (DNAme) in 134 primary ovarian cancer cases (63 received carboplatin, 55 received cisplatin and 16 no chemotherapy). We validated our findings by HOTAIR expression and DNAme analysis in a multicentre setting of five additional sets, encompassing 946 ovarian cancers. Chemo-sensitivity has been assessed in cell culture experiments. cell line ( SKOV3IP ) up-regulated resistant NA NA NA validated 3375 Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun 2015 26523512 Ensembl ENSG00000228630 HOTAIR lncRNA DB00818 (APRD01201, EXPT02558, DB05893) Propofol cervical cancer RT-qPCR In vitro, the different concentrations of propofol were co-incubated with cervical cancer cell lines, including Hela, Caski and C-33A cells respectively. The pcDNA-HOTAIR plasmid was transfected into cells after the treatment of 10 ug/ml propofol. The cell viability and apoptosis were detected by MTT assay and TUNEL method. In vivo, propofol was injected into mice of transplantation tumor with Caski cells or with pcDNA-HOTAIR treated Caski cells. cell line (HeLa, Caski and C33A ) down-regulated sensitive NA NA mTOR signaling pathway validated 3376 Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med 2015 26884974 Ensembl ENSG00000249859 PVT1 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The expression levels of lncRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The CCK-8 assay was used to monitor the growth of the cells . cell line (SKOV-3/DDP,A2780/DDP,A2780) up-regulated resistant NA NA apoptotic pathway validated 3377 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000472323 ZBTB20-AS4 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) up-regulated resistant NA NA NA predicted 3378 Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 2015 25755691 Ensembl ENST00000514420 TMPRSS11BNL-206 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR In this study, gemcitabine-resistant pancreatic cancer cell line SWl990/GZ was obtained by treating parental cell line SWl990 in vitro . Then, we test the different express of lncRNA between SWl990 and SWl990/GZ by lncRNA microarray . Finally, Gene Ontology analysis and Pathway analysis revealed that differential expression mRNA involved in significant biological regulatory function and some genes may be particular to pancreatic cancer chemotherapy resistance. Quantitative real time PCR confirmed the changes of the role of lncRNA . cell line (SW1990,SW1990/GZ) down-regulated resistant NA NA NA predicted 3379 LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 2016 26364613 Ensembl ENSG00000228630 HOTAIR lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The role of HOTAIR in breast cancer cells was detected using qPCR, western blotting, Chromosome conformation capture (3C) assay, RNA pulldown assay,RNA immunoprecipitation (RIP), Immunofluoresent staining,Gene expression microarray and data analysis, cell proliferation and clonogenic assay, etc. cell line (MCF7 and T47D ) up-regulated resistant NA NA ER signaling validated 3380 A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. Tumour Biol 2016 26408180 Ensembl ENSG00000260944 ODRUL lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The role of ODRUL in osteosarcoma cells was detected microarray expression analysis, CCK-8, cell apoptosis assay, cell cycle assay, qRT-PCR, migration assay and invasion assay,etc. cell line ( MG63, SaoS2,U-2OS,MG63/DXR, KH-OS,KHOS/DXR ) up-regulated resistant ABCB1 ABCB1 NA validated 3381 Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol 2016 26781446 Ensembl ENSG00000228630 HOTAIR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin bladder transitional cell carcinoma qRT-PCR The expression of HOTAIR was detected by quantitative real-time PCR. Overall survival rate was calculated by Kaplan-Meier method with the log-rank test for comparisons. MTT assay was used to detect cell proliferation ability and chemosensitivity. Dual-color flow cytometric method was used to detect cell apoptosis. cell line (TCC T24,J82,SV-HUC-1) up-regulated resistant NA NA NA validated 3382 Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 2016 27034004 Ensembl ENSG00000234741 GAS5 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR The role of GAS5 in breast cancer cells was detected using microarray analysis, Immunohistochemistry and scoring system, MTT assay, colony formation assay, qRT-PCR assay, western blot assay and animal studies, etc. cell line (SKBR-3,SKBR-3/Tr) down-regulated resistant PTEN PTEN mTOR signaling pathway validated 3383 LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 2016 27046651 Ensembl ENSG00000214049 UCA1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR,Northern blot The expression levels of miRNA were determined by qRT-PCR and Northern blotting. Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. RIP assay was used to determines target information cell line (HEK-293T, HCT8, HCT116, HT29, LoVo, SW480) up-regulated resistant miR-204-5p NA NA validated 3384 The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Sci Rep 2016 27193186 Ensembl ENSG00000130600 H19 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR The role of H19 in high-grade serous ovarian cancer cells was detected using clonogenic assay, RNA-Sequencing data analysis, RNA extraction, cDNA Synthesis and qRT-PCR analysis, mutation analysis, nude mouse model, western blotting,etc. cell line ( A2780-DR ) down-regulated sensitive NA NA NA validated 3385 The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One 2016 27232880 Ensembl ENSG00000249859 PVT1 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer qPCR The role of PVT1 in cervical cancer cells was detected using qPCR, RNA fluorescent in situ hybridization (FISH) and immunocytochemistry, cell proliferation assay, cell death and apoptosis assays, cell migration and invasion assays,western blotting and RNA immunoprecipitation,etc. cell line (SiHa,HeLa,DoTc2 4510) down-regulated sensitive NA NA NA validated 3386 Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. Oncotarget 2016 27270310 Ensembl ENSG00000266835 lncRNA RP11-838N2.4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. TUNEL staining was used to detect apoptotic cell death . cell line (U87,U251,U87TR and U251TR ) up-regulated sensitive miR-10a NA NA validated 3387 NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget 2016 27270317 Ensembl ENSG00000245532 NEAT1 lncRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR In this study, we found that EGCG upregulated CTR1 and increased platinum accumulation in NSCLC (A549, H460 and H1299) cells, cDDP-resistant A549 cells and a nude mouse xenograft model. Cisplatin-induced inhibition of cell growth was enhanced by EGCG treatment in vitro and in vivo. MicroRNA hsa-mir-98-5p appears to suppress CTR1 gene expression, while long non-coding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) appears to enhance it. Bioinformatics analysis showed that hsa-mir-98-5p has specific complementary binding sites for NEAT1. In addition, hsa-mir-98-5p was predicted to be a putative CTR1 target. NEAT1 may act as a competing endogenous lncRNA to upregulate EGCG-induced CTR1 by sponging hsa-mir-98-5p in NSCLC. cell line ( A549,H460,H1299,A549/cDDP ) up-regulated sensitive NA NA NA validated 3388 GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells. Eur Rev Med Pharmacol Sci 2016 27338051 Ensembl ENSG00000234741 GAS5 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR GAS5 expression in cancerous and adjacent normal tissues from 15 NSCLC patients received neoadjuvant chemotherapy and the following surgery were measured using qRT-PCR analysis. GAS5 gain-and-loss study was performed using A549 and A549/DDP cells as an in-vitro model to investigate the effect of GAS5 on autophagy and cisplatin sensitivity. cell line (A549,A549/DDP) down-regulated resistant NA NA NA validated 3389 Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. J Biol Chem 2016 27342777 Ensembl ENSG00000246985 SOCS2-AS1 lncRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR The role of SOCS2-AS1 in prostate cancer cells was detected using qRT-PCR, ChIP assay, RIP assay, MTS assay, cell proliferation assay, western blotting, migration assay, microarray analysis and TUNEL assay, etc. cell line (LNCaP,VCaP,LTAD) down-regulated sensitive TNFSF10 TNFSF10 NA validated 3390 Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. Onco Targets Ther 2016 27366087 Ensembl ENSG00000130600 H19 lncRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( U87 and U251) down-regulated sensitive NA NA NA validated 3391 miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1. Tumour Biol 2016 27460077 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Animal studies was used to test the role of miR-326 . cell line (A549,A549/CDDP) down-regulated sensitive NA NA miR-326/SP1 pathway validated 3392 Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumour Biol 2016 27553025 Ensembl ENSG00000234771 SLC25A25-AS1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The role of SLC25A25-AS1 in colorectal cancer cells was detected using MTT assay, western blot, In vitro proliferation and drug sensitivity assay, etc. cell line (HCT-116 and HT-29) down-regulated resistant NA NA Erk and p38 signaling pathway validated 3393 Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumour Biol 2016 27553025 Ensembl ENSG00000234771 SLC25A25-AS1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colorectal cancer RT-qPCR The role of SLC25A25-AS1 in colorectal cancer cells was detected using MTT assay, western blot, In vitro proliferation and drug sensitivity assay, etc. cell line (HCT-116 and HT-29) down-regulated resistant NA NA Erk and p38 signaling pathway validated 3394 Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget 2016 27566568 RefSeq NR_108049.1 CCAT1 lncRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The expression levels of miRNA were determined by Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Cell migration was detected by transwell migration and invasion assay. cell line (SPC-A1, H1299,SPC-A1/DTX and H1299/DTX) up-regulated resistant Let-7c NA NA validated 3395 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 2016 27591936 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin bladder cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell vitality assay and Apoptosis assay sed to test the drug-resistant phenotype changes in cancer cells. cell line (5637, UMUC-2,5637 ) down-regulated resistant miR-196a-5p NA NA validated 3396 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 2016 27591936 Ensembl ENSG00000214049 UCA1 lncRNA DB00441 (APRD00201) Gemcitabine bladder cancer RT-PCR The expression levels of miRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell vitality assay and Apoptosis assay sed to test the drug-resistant phenotype changes in cancer cells. cell line (5637, UMUC-2,5637 ) down-regulated resistant miR-196a-5p NA NA validated 3397 Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. Cancer Lett 2016 27609068 Ensembl ENSG00000226935 LINC00161 lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR The expression levels of miRNA were determined by Real-time RT-PCR and RT-PCR, those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells.LC-MS/MS analysis was used to protein identification and quantitation cell line ( MG-63, U2OS) up-regulated sensitive miR-645 IFIT2 NA validated 3398 Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1alpha feedback regulatory loop. Tumour Biol 2016 27629141 Ensembl ENSG00000214049 UCA1 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of miRNA were determined by qRT-PCR and those of protein were by Western blot analysis. The putative microRNA (miRNA) binding sites in UCA1 was predicted by using PITA and RNAhybrid . Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line ( MCF-7, BT474, LCC2, and LCC9) up-regulated resistant NA NA NA validated 3399 The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol 2016 27686228 Ensembl ENSG00000214049 UCA1 lncRNA DB01248 (APRD00932) Docetaxel prostate cancer qRT-PCR QRT-PCR was performed to detect UCA1, miR-204 and Sirt1 mRNA expression. Western blot assay was performed to assess Sirt1, P-gp and caspase-3 expression. The regulative effect of UCA1/miR-204/Sirt1 axis on docetaxel sensitivity of prostate cancer cells was examined by measurement of docetaxel IC50, dictation of cleaved caspase-3 and flow cytometric analysis of cell apoptosis. cell line ( PNT2, LNCaP, 22RV1, 22RV1/DR) up-regulated sensitive NA NA UCA1/miR-204/Sirt1 validated 3400 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 Ensembl ENSG00000214049 UCA1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) up-regulated resistant miR-27b NA NA validated 3401 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) up-regulated resistant miR-27b NA NA validated 3402 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b Med Sci Monit 2016 27694794 Ensembl ENSG00000214049 UCA1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The microarray data of dysregulated lncRNAs in gastric cancer tissues was retrieved in the GEO dataset. QRT-PCR analysis was performed to assess UCA1 expression based on 28 paired cancerous and peritumoral normal tissues. The human gastric cancer cell line SGC-7901, and SGC-7901 derived Adriamycin (doxorubicin) resistant SGC-7901/ADR, cisplatin resistant SGC-7901/DDP, and 5-FU resistant SGC-7901/FU cells were used as in vitro cell models to assess the effect of UCA1 and miR-27b on MDR. tissue and cell line (SGC-7901,SGC-7901/ADR,SGC-7901/DDP,SGC-7901/FU) up-regulated resistant miR-27b NA NA validated 3403 Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway Med Sci Monit 2016 27765938 Ensembl ENSG00000214049 UCA1 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR Tamoxifen sensitive MCF-7 cells were transfected for UCA1 overexpression, while tamoxifen resistant LCC2 and LCC9 cells were transfected with UCA siRNA for UCA1 knockdown. qRT-PCR was performed to analyze UCA1 expression. CCK-8 assay, immunofluorescence staining of cleaved caspase-9, and flow cytometric analysis of Annexin V/PI staining were used to assess tamoxifen sensitivity. Western blot analysis was performed to detect p-AKT and p-mTOR expression. cell line (MCF-7) up-regulated resistant NA NA mTOR signaling pathway validated 3404 Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. Cancer Chemother Pharmacol 2016 27785603 Ensembl ENSG00000258609 Linc-ROR lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR Pancreatic cancer cell lines PANC-1 and MIAPaCa-2 cells were used as in vitro model. Autophagy was assessed by western blot of LC3 I/II and observation GFP-LC3 puncta. Cell viability was examined using CCK-8 assay. Cell apoptosis was examined by flow cytometric analysis of Annexin V/PI staining. QRT-PCR, RNA fluorescence in situ hybridization and dual luciferase assay were used to study the expression and the binding between linc-ROR and miR-124. cell line ( PANC-1 and MIAPaCa-2 ) up-regulated resistant NA NA NA validated 3405 LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016 27845892 Ensembl ENSG00000130600 H19 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Chromatin immunoprecipitation (ChIP) assays were performed using the ChIP assay kit . cell line (MCF-7,ZR-75-1,MCF-7R and ZR-75-1R ) up-regulated resistant BIK and NOXA BIK and NOXA NA validated 3406 LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016 27845892 Ensembl ENSG00000130600 H19 lncRNA DB00445 (APRD00361) epirubicin breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Chromatin immunoprecipitation (ChIP) assays were performed using the ChIP assay kit . cell line (MCF-7,ZR-75-1,MCF-7R and ZR-75-1R ) up-regulated resistant BIK and NOXA BIK and NOXA NA validated 3407 LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016 27845892 Ensembl ENSG00000130600 H19 lncRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Chromatin immunoprecipitation (ChIP) assays were performed using the ChIP assay kit . cell line (MCF-7,ZR-75-1,MCF-7R and ZR-75-1R ) up-regulated resistant BIK and NOXA BIK and NOXA NA validated 3408 Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients. J Thorac Dis 2016 28066612 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qPCR Tissue samples were collected from NSCLC patients, and total RNA was isolated for assessment of HOTAIR expression and drug resistance status. MTT assays, tumor sphere formation assays, and western blot were performed to cytologically determine the relationship between HOTAIR expression and cisplatin resistance, as well as to elucidate the potential molecular mechanism involved. cell line (A459,A549/CDDP) up-regulated resistant NA NA NA validated 3409 Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett 2016 28105167 Ensembl ENSG00000224818 RP11-134G8.8 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qPCR Reannotation and identification of differentially expressed lncRNAs were performed using the microarray data set GSE38122 in the Gene Expression Omnibus database. The role of lncrna in HepG2 cells was detected using qPCR, cell cycle analysis, Immunofluorescence and microscopic analysis, etc. cell line (HepG2) up-regulated resistant NA NA p53 signaling pathway validated 3410 Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett 2016 28105167 Ensembl ENSG00000260912 RP11-363E7.4 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qPCR Reannotation and identification of differentially expressed lncRNAs were performed using the microarray data set GSE38122 in the Gene Expression Omnibus database. The role of lncrna in HepG2 cells was detected using qPCR, cell cycle analysis, Immunofluorescence and microscopic analysis, etc. cell line (HepG2) up-regulated resistant NA NA p53 signaling pathway validated 3411 Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett 2016 28105167 NONCODE NONHSAT055585.2 RP1-193H18.2 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qPCR Reannotation and identification of differentially expressed lncRNAs were performed using the microarray data set GSE38122 in the Gene Expression Omnibus database. The role of lncrna in HepG2 cells was detected using qPCR, cell cycle analysis, Immunofluorescence and microscopic analysis, etc. cell line (HepG2) up-regulated sensitive NA NA p53 signaling pathway validated 3412 Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer. J Med Biochem 2016 28356873 Ensembl ENSG00000285219 HULC lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR We obtained GC tissue samples from 42 GC patients and detected the expression level of HULC in the plasma and tissues via qRT-PCR. The relationship between HULC expression and survival rate was confirmed by Kaplan-Meier survival analysis. We verified the expression of HULC in GC cell lines via qRT-PCR, and the function of HULC was detected via flow cytometry assay and CCK-8 assay. cell line (GES-1,MGC-803 and MKN-45 ) up-regulated sensitive NA NA NA validated 3413 Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer. J Med Biochem 2016 28356873 Ensembl ENSG00000285219 HULC lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR We obtained GC tissue samples from 42 GC patients and detected the expression level of HULC in the plasma and tissues via qRT-PCR. The relationship between HULC expression and survival rate was confirmed by Kaplan-Meier survival analysis. We verified the expression of HULC in GC cell lines via qRT-PCR, and the function of HULC was detected via flow cytometry assay and CCK-8 assay. cell line (GES-1,MGC-803 and MKN-45 ) up-regulated sensitive NA NA NA validated 3414 Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer. J Med Biochem 2016 28356873 Ensembl ENSG00000285219 HULC lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer qRT-PCR We obtained GC tissue samples from 42 GC patients and detected the expression level of HULC in the plasma and tissues via qRT-PCR. The relationship between HULC expression and survival rate was confirmed by Kaplan-Meier survival analysis. We verified the expression of HULC in GC cell lines via qRT-PCR, and the function of HULC was detected via flow cytometry assay and CCK-8 assay. cell line (GES-1,MGC-803 and MKN-45 ) up-regulated sensitive NA NA NA validated 3415 The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene 2017 27530352 Ensembl ENST00000520944 SNHG6-003 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of SNHG6-003 in hepatocellular carcinoma cells was detected using tissue microarray, The Cancer Genome Atlas (TCGA) project database, Oncomine database and bioinformatics analysis, CCK-8, EdU and in vivo tumor growth assays, etc. cell line (BEL-7402, SMMC-7721, MHCC-97H, SK-Hep-1, Huh7,HCC-LM3) up-regulated resistant miR-26a/b TAK1 p38 pathway validated 3416 The role of long non-coding RNA HOTAIR in the progression and development of laryngeal squamous cell carcinoma interacting with EZH2. Acta Otolaryngol 2017 27542077 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin laryngeal squamous cell carcinoma qRT-PCR Quantitative real time-PCR (qPCR) was conducted to measure the expression of HOTAIR and EZH2 in tissue samples. Clinicopathological features were collected and statistically analyzed combining with the expression of HOTAIR and EZH2. The variance of EZH2 with down-regulating HOTAIR was measured by qPCR. CCK-8 proliferation test was conducted to detect the proliferation feature in LSCC cells. After cultured with a series of cis-platinum concentrations for 24h, cell viability was detected using CCK-8 assay, and the inhibition rates were calculated. cell line down-regulated sensitive NA NA NA validated 3417 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_003605 ZFAS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3418 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000584934 AL135905.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3419 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_000029 RPL23AP7 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3420 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000458247 SLC25A38P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3421 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000422205 TMEM14DP-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3422 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000461972 FAM228B-202 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3423 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000444980 COX6CP2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3424 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_026761 LINC00467 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3425 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_036659 ZFAS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3426 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000422137 OR2AM1P-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3427 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000416146 AC017078.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3428 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000502774 WDR45P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3429 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc003xcr.3 uc003xcr.3 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3430 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc002jdy.1 uc002jdy.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3431 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc003vhn.1 uc003vhn.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3432 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc010czc.3 uc010czc.3 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3433 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc021rgk.1 uc021rgk.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3434 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc021ufh.1 uc021ufh.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3435 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc001ygz.2 uc001ygz.2 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3436 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc.57 uc.57 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3437 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000515464 MYLK-AS2-202 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3438 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_002578 GAS5 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3439 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000443688 AL354707.1-203 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3440 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000433407 AL590128.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3441 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000467018 RPL39P38-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3442 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000446355 AC002066.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3443 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000392269 RPL9P21-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3444 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000576784 AC145207.3-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3445 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc002jdy.1 uc002jdy.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3446 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000554535 DNAJC8P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3447 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000442889 CAMTA1-DT-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3448 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000519475 SUMO2P16-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3449 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000475062 AC087385.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3450 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000448365 AC078842.2-202 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3451 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_024530 RPL23AP7 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3452 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000561649 AC120498.4-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3453 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc003vhn.1 uc003vhn.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3454 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_003038 SNHG5 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3455 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000550947 AC034102.6-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3456 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000504145 AF117829.1-207 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3457 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_003606 ZFAS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3458 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000475925 RPL30P6-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3459 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000460497 AC079193.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3460 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_027401 FAM223A lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3461 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000448842 AC125238.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3462 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00014652 TCONS_00014652 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3463 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000557989 AC022613.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3464 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_033928 LOC389641 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3465 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000421965 AC006159.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3466 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_015377 PAX8-AS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3467 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000422817 AL031733.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3468 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000533528 RAB30-DT-206 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3469 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000538113 AC008011.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3470 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000461109 RPL31P57-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3471 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000540066 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3472 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_003581 ATP8B5P lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3473 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000425698 LINC01136-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3474 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000432727 Z98752.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3475 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00026294 TCONS_00026294 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3476 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000436709 Z82188.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3477 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000433233 AC007563.3-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) up-regulated resistant NA NA NA predicted 3478 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_045121 DGCR5 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3479 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00028472 TCONS_00028472 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3480 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000318333 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3481 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000416673 RPL23AP7-202 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3482 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000423223 SVIL-AS1-203 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3483 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000563660 MAN2C1-217 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3484 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000552169 SETP7-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3485 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000404856 DDX18P3-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3486 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000542064 LINC02747-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3487 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000415349 KRT18P39-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3488 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000427492 AL512656.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3489 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl AK091357 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3490 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000436229 RPL23AP19-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3491 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000446295 NUS1P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3492 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000320232 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3493 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_002612 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3494 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000565374 AC009117.2-204 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3495 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000441270 AL121917.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3496 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000407916 AC006971.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3497 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00014883 TCONS_00014883 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3498 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_046273 LOC729683 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3499 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00027767 TCONS_00027767 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3500 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc010czc.3 uc010czc.3 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3501 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000492507 RPL23AP73-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3502 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000579595 AP001020.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3503 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000509173 AC109481.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3504 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc021rgk.1 uc021rgk.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3505 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000558620 AC092079.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3506 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00028253 TCONS_00028253 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3507 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000504656 AC021087.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3508 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000272567 AL078621.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3509 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000562082 AL513534.2-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3510 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_073453 LINC00601 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3511 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC TCONS_00004466 TCONS_00004466 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3512 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000491601 RPL23AP75-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3513 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc021ufh.1 uc021ufh.1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3514 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000463581 AC112771.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3515 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl AK055628 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3516 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000404566 BOLA2P3-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3517 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 UCSC uc001ygz.2 uc001ygz.2 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3518 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_046375 MRVI1-AS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3519 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000435260 AC046176.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3520 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000503999 HNRNPA1P44-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3521 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000532714 NA lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3522 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000492365 AP002982.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3523 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000571486 NDUFA3P6-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3524 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_004436 SNAR-A2 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3525 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000455730 LDHBP1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3526 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000557078 PPIAP6-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3527 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000418335 AC008063.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3528 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000529841 AP001781.1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3529 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_024399 SNAI3-AS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3530 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000438347 CCND3P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3531 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000535200 PXN-AS1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3532 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_028415 LINC00942 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3533 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 RefSeq NR_015454 MAFG-DT lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3534 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000433871 CIDECP1-205 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3535 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000325243 CBX3P1-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3536 Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene 2017 27729273 Ensembl ENST00000484463 RPL38P3-201 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR Microarray analysis was used to identify lncRNAs and mRNAs that were expressed abnormally in oxaliplatin resistant HCC .The expression levels of lncRNA were determined by qRT-PCR . cell line (MHCC97H,MHCC97H-OXA) down-regulated resistant NA NA NA predicted 3537 lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells. DNA Cell Biol 2017 27854515 Ensembl ENSG00000214049 UCA1 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-PCR In the present study, long noncoding RNA (lncRNA) UCA1 was identified as an important modulator of MDR1 by a model system of leukemia cell lines with a gradual increase of MDR1 expression and IM resistance. Overexpression of UCA1 increased MDR1 expression to promote IM resistance of CML cells. Furthermore, for the first time, we demonstrated that UCA1 functions as a competitive endogenous (ceRNA) of MDR1 through completely binding the common miR-16. cell line (K562,K562/IM,K562/IM-R) up-regulated resistant miR-16 NA NA validated 3538 Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol 2017 27878359 Ensembl ENSG00000234741 GAS5 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin bladder transitional cell carcinoma qRT-PCR The expression of GAS5 was detected by quantitative real-time PCR. Statistical analysis was used to determine the relationship between GAS5 expression and clinical features and the prognostic value of GAS5 for disease free survival. MTT assay was used to detect cell proliferation ability and chemosensitivity. Dual-color flow cytometric method was used to detect cell apoptosis. The expression of Bcl-2 protein was examined by western blot. tissue and cell line (T24, J82) up-regulated resistant NA NA NA validated 3539 H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/Beta-catenin pathway. Exp Cell Res 2017 27919747 Ensembl ENSG00000130600 H19 lncRNA DB00563 (APRD00353) Methotrexate colorectal cancer qRT-PCR The role of H19 in colorectal cancer cells was detected using MTT assay, colony formation assays, qRT-PCR, western blotting, RNA oligoribonucleotides and cell transfections, etc. tissue and cell line (HT-29) up-regulated resistant NA NA Wnt/Beta-catenin pathway validated 3540 A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration. Oncotarget 2017 27980230 Ensembl ENSG00000226659 lncRNA RP11-137H2.4 lncRNA DB00860 (APRD00197) Prednisolone acute lymphocytic leukemia RT-qPCR The role of lncRNA in childhood acute lymphoblastic leukemia cells was detected using RT-qPCR, vector particle production and transduction, proliferation, apoptosis, and drug response assays, cell migration assay, gene expression and ontology analyses,etc. cell line (Reh,NALM-6) down-regulated sensitive NA NA NRAS/BRAF/NF-kappaB MAPK pathway predicted 3541 A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration. Oncotarget 2017 27980230 Ensembl ENSG00000226659 lncRNA RP11-137H2.4 lncRNA DB04690 Camptothecin acute lymphocytic leukemia RT-qPCR The role of lncRNA in childhood acute lymphoblastic leukemia cells was detected using RT-qPCR, vector particle production and transduction, proliferation, apoptosis, and drug response assays, cell migration assay, gene expression and ontology analyses,etc. cell line (Reh,NALM-6) down-regulated sensitive NA NA NRAS/BRAF/NF-kappaB MAPK pathway predicted 3542 Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother Pharmacol 2017 28063065 Ensembl ENSG00000258609 lncRNA-ROR lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR Breast epithelial (MCF10A), breast cancer (MCF7), and natural tamoxifen-resistant breast cancer (MDA-MB-231) cell lines were selected, and the relative lncRNA-ROR expressions were detected using quantitative real-time polymerase chain reaction (qRT-PCR). In vitro induction of TR5 cell line was performed. There were six groups: MCF7, MCF7/TR5, MDA-MB-231, MCF7-ROR, MCF7/TR5 ROR-siRNA, and the MDA-MB-231 ROR-siRNA groups. CCK-8 assay was conducted to assess the changes in drug resistance of each group. The expression of the epithelial mesenchymal transition (EMT) marker was detected using Western blotting. Transwell was selected to test the invasive ability of the cells. Expressions of microRNA-205 (miR-205) and ZEB1/2 were detected using qRT-PCR . cell line (MCF7, MCF7/TR5, MDA-MB-231, MCF7-ROR, MCF7/TR5 ROR-siRNA, and the MDA-MB-231) down-regulated sensitive miR-205 NA NA validated 3543 MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 Mol Cancer Ther 2017 28069878 Ensembl ENSG00000251562 MALAT1 lncRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer RT-PCR, qRT-PCR The role of MALAT1 in colorectal cancer cells was detected using quantitative real-time PCR and RT-qPCR, cell viability assay, immunofluorescence analysis and western blot,etc. cell line (HT29, SW480, SW620,FHC) down-regulated sensitive NA NA NA validated 3544 LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget 2017 28086241 LNCipedia lnc-SLC6A9-5:2 lnc-SLC6A9-5:2 lncRNA NA 131I papillary thyroid carcinoma qRT-PCR The role of SLC6A9-5:2 in papillary thyroid carcinoma cells was detected using qRT-PCR, western blot analysis, cell proliferation assay, lncRNA microarray assay, luciferase reporter assay,Immunofluorescence and confocal laser scanning microscopy (CLSM),etc. tissue and cell line down-regulated resistant NA NA SLC6A9-PARP-1 pathway validated 3545 LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. J Cell Biochem 2017 28121023 Ensembl ENSG00000177640 CASC2 lncRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (U251, U373, SNB19, U118 and LN229) up-regulated sensitive miR-181a NPTEN PTEN Pathway validated 3546 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 UCSC TCONS_00003617 TCONS_00003617 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3547 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000424251 AC003659.1-201 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3548 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000446495 BX119904.2-201 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3549 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000547898 AC079600.3-201 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3550 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000555539 LINC02274-201 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3551 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 UCSC UC002rlw.3 UC002rlw.3 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3552 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 UCSC TCONS_00006578 TCONS_00006578 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3553 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000424410 FAM230B-205 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3554 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 RefSeq NR_028308 BABAM2-AS1 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3555 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 UCSC TCONS_00003974 TCONS_00003974 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) up-regulated resistant NA NA NA predicted 3556 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000449694 AP003774.1-203 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3557 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 RefSeq NR_038435 HOXD-AS2 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3558 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 UCSC TCONS_00021730 TCONS_00021730 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3559 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000457645 NA lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3560 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000511064 AC073475.1-202 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3561 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000558952 CRNDE-205 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3562 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000400178 MIR99AHG-201 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3563 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 RefSeq NR_046438 MEIS1-AS3 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3564 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000458468 NA lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3565 Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res 2017 28128423 Ensembl ENST00000422352 LINC00658-203 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qPCR An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. cell line (A2780, CP70, SKOV3, and SKOV3/DDP) down-regulated resistant NA NA NA predicted 3566 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 Ensembl ENSG00000285219 HULC lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR ,western blot, SiRNA assay , dual-luciferase reporter assay , confocal microscopy , Co-IP assay and Xenograft tumor assay in nude mice , etc. tissue and cell line up-regulated resistant NA NA NA validated 3567 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 Ensembl ENSG00000285219 HULC lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR ,western blot, SiRNA assay , dual-luciferase reporter assay , confocal microscopy , Co-IP assay and Xenograft tumor assay in nude mice , etc. tissue and cell line up-regulated resistant NA NA NA validated 3568 LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 2017 28166203 Ensembl ENSG00000285219 HULC lncRNA DB11616 Pirarubicin hepatocellular carcinoma qRT-PCR The role of HULC in liver cancer cells was detected using qRT-PCR ,western blot, SiRNA assay , dual-luciferase reporter assay , confocal microscopy , Co-IP assay and Xenograft tumor assay in nude mice , etc. tissue and cell line up-regulated resistant NA NA NA validated 3569 MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 2017 28187000 Ensembl ENSG00000251562 MALAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-qPCR By using the HiSeq sequencing and bioinformatics methods, we identified lncRNAs showing different expression levels in TMZ-resistant and non-resistant patients. RT-qPCR was then performed in tissues and serum samples . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line (U87 and U251) up-regulated resistant miR-203 NA miR-203-TS pathway validated 3570 MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 2017 28187000 Ensembl ENSG00000251562 MALAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma RT-qPCR The expression levels of lncRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . cell line ( U87 and U251) down-regulated sensitive miR-203 NA miR-203-TS pathway validated 3571 H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells. Neoplasia 2017 28189050 Ensembl ENSG00000130600 H19 lncRNA DB11094 1,25(OH)2D3 colon cancer qRT-PCR The expression levels of miRNA were determined by Quantitative Real-Time PCR (qRT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HT-29, DLD-1) up-regulated resistant miR-675-5p VDR Wnt/Beta-catenin pathway validated 3572 LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. Biomol Ther (Seoul) 2017 28190319 Ensembl ENSG00000214548 MEG3 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia RT-qPCR The expression levels of lncRNA were determined by real-time quantitative PCR and those of protein were by Western blot analysis. Lciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells . cell line ( K562 ) up-regulated sensitive miR-21 NA NA validated 3573 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis 2017 28252643 Ensembl ENSG00000234741 GAS5 lncRNA NA 2-O-Methylmagnolol melanoma qRT-PCR The role of GAS5 in cancer cells was detected using SRB colorimetric assay, flow cytometric analysis, DNA microarray analysis, western blotting, Annexin V-FITC and propidium iodide staining assay, IHC and hematoxylin eosin staining, etc. tissue and cell line (A375,A431) up-regulated sensitive NA NA NA validated 3574 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis 2017 28252643 Ensembl ENSG00000234741 GAS5 lncRNA NA 2-O-Methylmagnolol squamous cell carcinoma qRT-PCR The role of GAS5 in cancer cells was detected using SRB colorimetric assay, flow cytometric analysis, DNA microarray analysis, western blotting, Annexin V-FITC and propidium iodide staining assay, IHC and hematoxylin eosin staining, etc. tissue and cell line (A375,A431) up-regulated sensitive NA NA NA validated 3575 LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target 2017 28296507 Ensembl ENSG00000249859 PVT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer qRT-PCR The role of PVT1and miR-195 in cervical cancer cells was detected using bioinformatics analysis, qRT-PCR analysis, CCK-8 analysis, RNA pull-down assay, dual luciferase assay, western blot analysis and flow cytometric analysis, etc. cell line (HPV-16-positive CaSki and SiHa) up-regulated sensitive miR-195 Smad3 NA validated 3576 TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun 2017 28302487 Ensembl ENSG00000253352 TUG1 lncRNA DB00563 (APRD00353) Methotrexate colorectal cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HT-29-P/HT-29-R,HCT-8) down-regulated sensitive miR-186 NA NA validated 3577 Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett 2017 28323030 Ensembl ENSG00000260944 FOXC2-AS1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The role of FOXC2-AS1 in osteosarcoma cells was detected using CCK-8 assay, colony formation assay, qRT-PCR analyses, western blotting analysis, Xenograft transplantation and RNase protection assay,etc. cell line (MG63, SaoS2, HOS,KH-OS,KH-OS/DXR,U2-OS/DXR) up-regulated resistant FOXC2 FOXC2 NA validated 3578 LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle 2017 28358263 RefSeq NR_108049.1 CCAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharynx cancer qRT-PCR qRT-PCR was used for testing the expression of CCAT1, miR-181a and CPEB2 in tumor tissues and NPC cancers. NPC cells were transfected with siRNAs to suppress the mRNA level of CCAT1 in NPC cells. MTT assays and flow cytometry analysis were used to assess the sensitivity of paclitaxel in NPC cells. Luciferase reporter assays were used to examine the interaction of CCAT1 or CPEB2 to miR-181a. cell line (CNE1 and CNE2 ) down-regulated sensitive miR-181a NA CCAT1/miR-181a/CPEB2 validated 3579 LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle 2017 28358263 RefSeq NR_108049.1 CCAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel nasopharynx cancer qRT-PCR This study aimed to investigate whether long non-coding RNA CCAT1 was involved in Paclitaxel resistance in nasopharyngeal carcinoma (NPC). qRT-PCR was used for testing the expression of CCAT1, miR-181a and CPEB2 in tumor tissues and NPC cancers. NPC cells were transfected with siRNAs to suppress the mRNA level of CCAT1 in NPC cells. MTT assays and flow cytometry analysis were used to assess the sensitivity of paclitaxel in NPC cells. Luciferase reporter assays were used to examine the interaction of CCAT1 or CPEB2 to miR-181a. cell line (CNE1 and CNE2) up-regulated resistant miR-181a NA CCAT1/miR-181a/CPEB2 validated 3580 Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. Oncotarget 2017 28388536 Ensembl ENSG00000258609 ROR lncRNA DB01248 (APRD00932) Docetaxel lung adenocarcinoma qRT-PCR The role of ROR in lung adenocarcinoma cells was detected using lncRNA microarray analysis, qRT-PCR,luciferase reporter assay, in vitro chemosensitivity assay, colony formation assay, flow cytometric analysis, cell migration and invasion assays, xenograft transplantation assays, TUNEL assay, western bolt analysis and antibodies, etc. cell line (SPC-A1,H1299,SPC-A1/DTX and H1299/DTX) down-regulated sensitive miR-145 NA epithelial mesenchymal transition pathway validated 3581 The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells. Oncotarget 2017 28402932 Ensembl ENSG00000240498 ANRIL lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell migration . cell line (A549,A549/Taxol) up-regulated resistant Bcl-2 Bcl-2 NA validated 3582 Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer. Cancer Biother Radiopharm 2017 28414550 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The role of NEAT1 in gastric cancer cells was detected using real time quantitative PCR, MTT assay, cell Invasion assay and apoptosis detection, etc. cell line (SGC7901, SGC7901/ADR) up-regulated resistant NA NA NA validated 3583 Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget 2017 28415557 Ensembl ENSG00000253603 CTA lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The expression levels of miRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line ( Saos-2, U-2OS, MG-63, MG-63/DOX) up-regulated sensitive miR-210 NA NA validated 3584 Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a Beijing Da Xue Xue Bao Yi Xue Ban 2017 28416841 Ensembl ENSG00000214049 UCA1 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR qRT-PCR was performed to detect UCA1 and miR-18a expression in breast cancer cells. Dual luciferase assay was performed to detect the binding between miR-18a and UCA1 3UTR. Tamoxifen sensitive MCF-7 cells were transfected with UCA1 expression vector or miR-18a inhibitors. Tamoxifen resistant LCC9 and BT474 cells were transfected with UCA1 siRNA or miR-18a mimics. CCK-8 assay was performed to detect cell viability. Soft agar assay was performed to assess cell colony formation. Flow cytometric analysis was performed to check cell cycle distribution. cell line ( BT-474) up-regulated resistant miR-18a NA NA validated 3585 Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway. Oncotarget 2017 28427191 NONCODE NONHSAT054511.2 RP11-708H21.4 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In the study, through next generation RNA sequencing and experimental validations, we determined the expression status of RP11-708H21.4 in colorectal cancer (CRC) and explored its clinical significance and biological functions in CRC. Differentially expressed lncRNAs from CRC samples and corresponding normal mucosa tissues was screened through RNA sequencing, and RP11-708H21.4 was selected for further experimental validation. The expression levels of RP11-708H21.4 in CRC tissues and cell lines were determined using qRT-PCR. Also, the relationship between the clinicopathological features and RP11-708H21.4 expression was analyzed. Cell viability was examined by CCK-8 and colony assays; cell migration and invasion were detected by transwell assays; cell cycle and cell apoptosis were analyzed by flow cytometry. The chemosensitivity of CRC cells to 5-Fluorouracil (5-FU) was also determined using CCK-8 assay. CRC xenograft tumor models were established to determine the biological functions of RP11-708H21.4 in vivo. Levels of cell cycle-related proteins and AKT/mTOR pathway-related proteins were detected by western blot assay. cell line ( HeLa) up-regulated sensitive NA NA AKT/mTOR pathway validated 3586 The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. J Biol Chem 2017 28476883 Ensembl ENSG00000228630 HOTAIR lncRNA NA TRAIL therapy pancreatic cancer qRT-PCR The role of HOTAIR in pancreatic cancer cells was detected using quantitative real-time PCR, western blot analysis, lentiviral constructs, analysis of apoptosis, chromatin immunoprecipitation (ChIP) assay,etc. cell line (MiaPaCa-2, BxPC3, Suit2, and PANC-1 ) up-regulated resistant NA NA NA validated 3587 Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys 2017 28495512 Ensembl ENSG00000177640 CASC2 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer RT-PCR The role of CASC2 in cervical cancer cells was detected using real-time PCR, western blot,MTT assay and BrdU incorporation assay, etc. tissue and cell line (SiHa, Me180, HCE1, HeLa and CaSki) up-regulated sensitive miR-21 PTEN PTEN pathway validated 3588 Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. Biochim Biophys Acta Mol Cell Res 2017 28499919 LNCipedia LINC01828:24 AC023115.3 lncRNA DB00515 (APRD00359) Cisplatin glioblastoma qRT-PCR The role of AC023115.3 and miR-26a in malignant glioma cells was detected using western blot, microarray and computational analysis, dual-luciferase reporter assay, MTT assay, RIP assay,Real-time RT-PCR and RT-PCR, fluorescence microscopy and transmission electron microscopy,etc. cell line (U87MG, U251MG) up-regulated sensitive NA NA miR-26a-GSK3Beta-Mcl1 pathway validated 3589 Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett 2017 28529576 Ensembl ENSG00000171889 MIR31HG lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR PC9 and PC9-R cells were treated with gefitinib and, after 48 h, proliferation and apoptosis were analyzed using a Cell Counting Kit-8 (CCK-8) assay and flow cytometry. Microarray expression profiling of lncRNAs was undertaken in both PC9 and PC9-R cells, and the expression profiles were verified by reverse transcription quantitative-polymerase chain reaction. cell line (PC9 and PC9-R) up-regulated resistant NA NA EGFR/PI3K/AKT signaling pathway validated 3590 Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer. Tumour Biol 2017 28635401 Ensembl ENSG00000258609 ROR lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. TUNEL staining was used to detect apoptotic cell death. Tumor formation in nude mice was used to test the role of ROR . cell line (MCF7, BT474, MDA-MB-435, and MDA-MB-231) down-regulated sensitive NA NA NA validated 3591 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol 2017 28653877 Ensembl ENSG00000243197 TUSC7 lncRNA DB00515 (APRD00359) Cisplatin endometrial carcinoma qRT-PCR The role of TUSC7 and miR-23b in endometrial carcinoma cells was detected using quantitative real-time PCR , cell proliferation assay , flow cytometry assay , chemoresistance assay and RNA pull-down assay , etc. tissue and cell line ( ESC, HEC1A) up-regulated sensitive miR-23b NA NA validated 3592 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol 2017 28653877 Ensembl ENSG00000243197 TUSC7 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel endometrial carcinoma qRT-PCR The role of TUSC7 and miR-23b in endometrial carcinoma cells was detected using quantitative real-time PCR , cell proliferation assay , flow cytometry assay , chemoresistance assay and RNA pull-down assay , etc. tissue and cell line ( ESC, HEC1A) up-regulated sensitive miR-23b NA NA validated 3593 Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Cell Physiol Biochem 2017 28668966 Ensembl ENSG00000251562 MALAT1 lncRNA DB00853 (APRD00557) Temozolomide Glioblastoma RT-PCR The glioblastoma cell lines U251 and U87 were exposed to increasing concentrations of TMZ to generate TMZ-resistant colonies (the U251/TMZ and U87/TMZ cell lines). The expression levels of MALAT1 and proteins related to epithelial-mesenchymal transition (EMT) were detected by real-time PCR and western blot, respectively. After the transfection of si-MALAT1 or pcDNA-MALAT1, cell viability, mRNA expression of MDR-associated proteins (MDR1, MRP5 and LRP1), and protein expression of EMT related proteins (ZEB1, Snail and SLUG) were evaluated. cell line (U251,U87,U251/TMZ and U87/TMZ) up-regulated resistant ZEB1 ZEB1 NA validated 3594 Long non-coding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells. Mol Med Rep 2017 28677749 Ensembl ENSG00000214548 MEG3 lncRNA DB00515 (APRD00359) Cisplatin glioma RT-qPCR To investigate the role of MEG3, the mRNA levels of MEG3 under cisplatin treatment were investigated by reverse transcription-quantitative polymerase chain reaction, and the cell viability and apoptosis were examined by MTT assay, and flow cytometry analysis and western blotting, respectively. cell line (U87) up-regulated sensitive NA NA NA validated 3595 Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Eur Rev Med Pharmacol Sci 2017 28678322 Ensembl ENSG00000230061 TRPM2-AS lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression level of lncRNA TRPM2-AS was identified by using qRT-PCR assay. The apoptosis rate and the alteration of the cell cycle were detected by the flow cytometric analysis. Cell Counting Kit-8 assay (CCK8) was utilized for detecting chemo-sensitivity of the cisplatin-resistant A549/DDP cells. The p53 and p66shc protein levels were detected by Western blotting assay. cell line (A549,A549/DDP) down-regulated sensitive NA NA p53-p66shc pathway validated 3596 GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother 2017 28686971 Ensembl ENSG00000234741 GAS5 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR The expression levels of lncRNA were determined by Real-time PCR and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Soft agar assays were performed to determine the in vitro tumorigenicity of the cells. tissue and cell line ( A549, NCI-H1299, H460, SK-MES-1,H157, H358,16HBE) down-regulated resistant NA NA miR-21/PTEN pathway validated 3597 The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol 2017 28720546 Ensembl ENSG00000245532 NEAT1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration and invasion assay. cell line (MCF-7,MDA-MB-231, T-47-D and ZR-75-1) down-regulated sensitive miR-211 HMGA2 NA validated 3598 Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol Lett 2017 28721581 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin endometrial cancer RT-PCR The role of HOTAIR in endometrial cancer cells was detected using LncRNA profiling, CCK-8 assay, cell apoptosis assay and western blotting,etc. cell line down-regulated sensitive Beclin-1, MDR, and P-gp Beclin-1, MDR, and P-gp NA validated 3599 LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis. Mol Ther 2017 28750740 Ensembl ENSG00000260944 ODRUL lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma PCR The expression levels of lncRNA were determined by PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. The CCK-8 assay was used to monitor the growth of the cells. A wound healing assay was performed to examine the capacity of cell migration. Xenograft transplantation was used to test the role of ODRUL . cell line (SaoS2, HOS, U2-OS, MG63, and 143B) up-regulated resistant miR-3182 MMP2 NA validated 3600 Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway. Oncol Rep 2017 28791407 Ensembl ENSG00000214548 MEG3 lncRNA DB00853 (APRD00557) Temozolomide glioma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. The CCK-8 assay was used to monitor the growth of the cells . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Glioma xenografts was used to the role of MEG3 . cell line (U-251 and M059J) up-regulated sensitive miR-93 NA PI3K/AKT pathway validated 3601 LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep 2017 28831025 Ensembl ENSG00000229807 XIST lncRNA DB00853 (APRD00557) Temozolomide glioma RT-PCR The expression levels of lncRNA were determined by Real-time PCR and those of protein were by Western blot analysis. Fuciferase activity assay was used to verify the target genes of miRNAs.MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. tissue and cell line (U251, U373, LN229, U118, and LN229) down-regulated sensitive miR-29c NA DNA mismatch repair pathway validated 3602 Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway. Cell Physiol Biochem 2017 28848149 Ensembl ENSG00000130600 H19 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the relative expression of H19 and miR-675 in normal (GES-1) and gastric cancer cell lines (SGC-7901, SGC-7901/DDP) as well as in tumor tissues. Gain and loss of function approaches were carried out to investigate the potential roles of H19/miR-675 in cell proliferation and apoptosis. Moreover, Fas associated via death domain (FADD) was validated to be the target of miR-675 via luciferase reporter assay. Western blotting was used to evaluate the protein expression of related signaling pathway. cell line ( SGC-7901,SGC-7901/DDP, GES-1) up-regulated resistant miR-675 Fas FADD/Caspase 8/Caspase 3 Signaling Pathway validated 3603 LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res 2017 28861326 Ensembl ENSG00000203875 SNHG5 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (K562,K562-R) up-regulated resistant miR-205-5p ABCC2 NA validated 3604 Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat Med 2017 28920960 Ensembl ENSG00000224057 EGFR-AS1 lncRNA NA TKIs squamous cell carcinoma Northern blot The role of EGFR-AS1 insquamous cell carcinomar cells was detected using Northern blots, the cancer genome atlas analysis, in vivo locked nucleic acid treatment. etc. cell line (NCC-HN19, NCC-HN64, NCC-HN1 and NCC-HN43) down-regulated sensitive NA NA NA validated 3605 CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. Cell Physiol Biochem 2017 28954272 Ensembl ENSG00000121966 CXCR4 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR we employed qRT-PCR and western blot to examine the expression level of CXCR4, let-7a and HMGA2. In addition, we used MTT assay to detect cell proliferation and transwell assay to measure migration and invasiveness. The expression level of epithelial marker E-cadherin and mesenthymal marker N-cadherin was detected by western blot. The apoptosis was determined using annexin V-FITC/PI apoptosis detection kit by flow cytometry cell line (HPDE6-C7, Panc-1,BxPc3) down-regulated sensitive HMGA2 HMGA2 CXCR4/let-7a/HMGA2 pathway validated 3606 LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle 2017 28961027 Ensembl ENSG00000229807 XIST lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. TUNEL staining was used to detect apoptotic cell death. cell line (A549) up-regulated resistant NA NA NA validated 3607 LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther 2017 29020498 RefSeq NR_108049.1 CCAT1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR qRT-PCR was performed to detect the expression levels of CCAT, miR-130a-3p, or sex-determining region Y-box 4 (SOX4) mRNA. Luciferase reporter assay, RNA immunoprecipitation (RIP), and qRT-PCR analysis were carried out to explore the potential targets of CCAT1 or miR-130a-3p. Effect of CCAT1, miR-130a-3p, or SOX4 on IC50 value of DDP and ATP binding cassette subfamily G member 2 (ABCG2) level in NSCLC cells were determined by cell counting kits-8 (CCK-8) assay and western blot, respectively. cell line (BEAS-2B, A549,H1299,A549/DDP) up-regulated resistant miR-130a-3p SOX4 NA validated 3608 lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/Beta-catenin signaling. Nat Med 2017 29035371 Ensembl ENSG00000255248 MIR100HG lncRNA DB00002 (BTD00071, BIOD00071) Cetuximab colorectal cancer qRT-PCR The role of MIR100HG in colorectal cancer cells was detected using RNA-Seq analysis,Small RNA-Seq analysis, quantitative RT-PCR, western blot analysis,luciferase reporter assays, Electrophoretic mobility shift assay, fluorescence in situ hybridization (FISH) assays,etc. cell line (NCI-H508, Caco-2, SW403, SW948, HT29, SK-CO-1, DLD-1, SW480, SW837, SW48, SW620, LoVo, COLO205, T84, LS174T, NCI-H716, HCT8, HCT15, SW1116, RKO, COLO320DM, HuTu80, LS123, and HCT116) up-regulated resistant miR-125b GATA6 Wnt/Beta-catenin pathway validated 3609 Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer 2017 29041978 Ensembl ENSG00000258609 ROR lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR In this study, we profiled lncRNA expression against a focused group of lncRNAs selected from lncRNA database. CRISPR/Cas9 was employed to knockout (KO) linc-RoR in MCF-7 cells, while rescue experiments were carried out to re-express linc-RoR in KO cells. Colony formation and MTT assays were used to examine the role of linc-RoR in estrogen-independent growth and tamoxifen resistance. Western blot and qRT-PCR were used to determine the change of protein and lncRNA levels, respectively. The expression of DUSP7 in clinical specimens was downloaded from Oncomine ( www.oncomine.org ) and the dataset from Kaplan-Meier Plotter ( http://kmplot.com ) was used to analyze the clinical outcomes in relation to DUSP7. cell line (MCF-7) up-regulated resistant NA NA MAPK/ERK signaling pathway validated 3610 Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis 2017 29048549 Ensembl ENSG00000249859 PVT1 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Animal experiments was used to test the role of PVT1 . cell line (BxPC3, MiaPaCa2,PDAC) down-regulated sensitive NA NA NA validated 3611 Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer. Mol Med Rep 2017 29067469 Ensembl ENST00000605570.1 AK001796 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to monitor the differences in the expression of AK001796 in cisplatin-resistant (A549/DDP) cells and parental A549 cells. Cellular sensitivity to cisplatin and cell viability were examined using an MTT assay. Cell apoptosis and cell cycle distribution were measured using flow cytometry. The expression levels of cell cycle proteins cyclin C (CCNC), baculoviral IAP repeat containing 5 (BIRC5), cyclin-dependent kinase 1 (CDK1) and G2 and S phase-expressed 1 (GTSE1) were assessed using RT-qPCR and western blot analyses. cell line (A549,A549/DDP) up-regulated resistant NA NA NA validated 3612 LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. Oncotarget 2017 29069754 Ensembl ENSG00000268388 FENDRR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The role of FENDRR in osteosarcoma cells was detected using drug-resistance assay, colony formation assay, qRT-PCR, cell cycle and apoptosis analysis, western blot analysis, bioinformatics analysis, in vivo tumor xenograft model, etc. cell line (MG63,SaoS2,HOS,MG63/DXR,KH-OS/DXR,U2-OS/DXR) down-regulated resistant ABCB1 and ABCC1 ABCB1 and ABCC1 NA validated 3613 Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget 2017 29113297 Ensembl ENSG00000223949 ROR1-AS1 lncRNA DB01234 (APRD00674) Dexamethasone mantle cell lymphoma qRT-PCR The role of ROR1-AS1 in mantle cell lymphoma cells was detected using cell proliferation assay, RNA-immunoprecipitation (RNA-IP),RT-PCR and quantitative RT-PCR, etc. cell line (Mino, Granta, JVM2, Z138,HEK-293T ) up-regulated resistant NA NA NA validated 3614 Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget 2017 29113297 Ensembl ENSG00000223949 ROR1-AS1 lncRNA DB09053 Ibrutinib mantle cell lymphoma qRT-PCR The role of ROR1-AS1 in mantle cell lymphoma cells was detected using cell proliferation assay, RNA-immunoprecipitation (RNA-IP),RT-PCR and quantitative RT-PCR, etc. cell line (Mino, Granta, JVM2, Z138,HEK-293T ) up-regulated resistant NA NA NA validated 3615 LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther 2017 29123412 Ensembl ENSG00000214548 MEG3 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression of MEG3, miR-21-5p, and sex-determining region Y-box 7 (SOX7) in NSCLC tissues or cells was examined by quantitative real-time polymerase chain reaction (qRT-PCR). 3-(4,5-Dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), flow cytometry, and caspase-3 activity analysis were applied to assess the DDP sensitivity of NSCLC cells. The interaction between MEG3, miR-21-5p, and SOX7 was explored by luciferase reporter assay, RNA immunoprecipitation (RIP) assay, qRT-PCR, and Western blot. Mouse NSCLC transplanted tumor was established to verify the functional role of MEG3 in DDP resistance in vivo. cell line (A549, H1299,A549-DDP and H1299-DDP) up-regulated sensitive miR-21-5p SOX7 NA validated 3616 LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med 2017 29125238 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma RT-qPCR UCA1 expression in tumor tissues and cells was tested by qRT-PCR. MTT, flow cytometry and caspase-3 activity analysis were explored to evaluate the CDDP sensitivity in OSCC cells. Western blot analysis was used to measure BCL2, Bax and SF1 protein expression. Luciferase reporter assay was conducted to investigate the molecular relationship between UCA1, miR-184, and SF1. Nude mice model was used to confirm the functional role of UCA1 in CDDP resistance in vivo. tissue and cell line ( Tca8113, TSCCA, CAL-27, SCC-9,Tca8113-CDDP,TSCCA-CDDP) up-regulated resistant miR-184 SF1 NA validated 3617 Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep 2017 29130102 Ensembl ENSG00000229807 XIST lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qPCR The role of lncRNA-XIST in NSCLC cells was detected using real-time polymerase chain reaction (qPCR), western blot and cell viability assay,etc. tissue and cell line (A549 and H1299 ) down-regulated sensitive miR-17 ATG7 lncRNA-XIST/miR-17/autophagy validated 3618 Huaier Extract Inhibits Breast Cancer Progression Through a LncRNA-H19/MiR-675-5p Pathway. Cell Physiol Biochem 2017 29145193 Ensembl ENSG00000130600 H19 lncRNA NA Huaier extract breast cancer qRT-PCR Microarray profiling was performed to identify the candidate lncRNAs affected by Huaier extract. Quantitative realtime PCR (qPCR) was used to evaluate the transfection efficiency and the influence of Huaier extract on H19 expression. The effect of Huaier extract on the cell viability was examined by MTT. Moreover, the rates of apoptotic cells were detected using flow-cytometric analysis. Western blot analysis was applied to show the protein levels of CBL. cell line (MDA-MB-231, MDA-MB-468 and MCF7) down-regulated sensitive miR-675-5p CBL LncRNA-H19/MiR675-5p Pathway validated 3619 Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017 29162158 Ensembl ENSG00000251562 MALAT1 lncRNA DB00541 (APRD00495) Vincristine stomach cancer qRT-PCR lncRNA expression levels in gastric cancer (GC) cells was detected by quantitative real-time PCR (qPCR). MALAT1 shRNAs and overexpression vector were transfected into GC cells to down-regulate or up-regulate MALAT1 expression. In vitro and in vivo assays were performed to investigate the functional role of MALAT1 in autophagy associated chemoresistance. cell line (SGC7901, BGC823,SGC7901/VCR) down-regulated sensitive miR-23b-3p NA NA validated 3620 Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017 29162158 Ensembl ENSG00000251562 MALAT1 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR ncRNA expression levels in gastric cancer (GC) cells was detected by quantitative real-time PCR (qPCR). MALAT1 shRNAs and overexpression vector were transfected into GC cells to down-regulate or up-regulate MALAT1 expression. In vitro and in vivo assays were performed to investigate the functional role of MALAT1 in autophagy associated chemoresistance. cell line (SGC7901, BGC823,SGC7901/VCR) up-regulated resistant miR-23b-3p NA NA validated 3621 Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017 29162158 Ensembl ENSG00000251562 MALAT1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR ncRNA expression levels in gastric cancer (GC) cells was detected by quantitative real-time PCR (qPCR). MALAT1 shRNAs and overexpression vector were transfected into GC cells to down-regulate or up-regulate MALAT1 expression. In vitro and in vivo assays were performed to investigate the functional role of MALAT1 in autophagy associated chemoresistance. cell line (SGC7901, BGC823,SGC7901/VCR) up-regulated resistant miR-23b-3p NA NA validated 3622 Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep 2017 29176691 Ensembl ENSG00000240498 ANRIL lncRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma qRT-PCR The expression levels of lncRNA were determined by Reverse transcription and real-time quantitative PCR . Those of protein were by Western blot analysis. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line (OSCC3, SCC4, HSC3,CAL27,A2780) up-regulated resistant NA NA caspase-3-dependent apoptotic pathway validated 3623 Shikonin reduces tamoxifen resistance through long non-coding RNA uc.57. Oncotarget 2017 29179465 UCSC uc.57 uc.57 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. The CCK-8 assay was used to monitor the growth of the cells .Tumor xenograft and tumorigenicity assay was used to test the role of uc.57 . tissue and cell line (MCF-7,MCF-7R) up-regulated sensitive BCL11A BCL11A PI3K/AKT and MAPK signaling pathways validated 3624 Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis 2017 29180678 Ensembl ENSG00000222041 LINC00152 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-PCR The expression levels of lncRNA were determined by RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. The CCK-8 assay was used to monitor the growth of the cells . Cell migration was detected by transwell migration and invasion assay. Xenograft tumor assay was used to test the role of LINC00152 . cell line (HCT8, HT29, LoVo, HCT116, SW480, and SW620) up-regulated resistant miR-139-5p NOTCH1 miR-139-5p/NOTCH1 pathway validated 3625 LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther 2017 29180871 Ensembl ENSG00000245532 NEAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expressions of NEAT1 and miR-194 in ovarian cancer tissues and cells were estimated by quantitative real-time polymerase chain reaction (qRT-PCR). MTT, flow cytometry, and Western blot assays were used to assess the effect of NEAT1 on PTX resistance in PTX-resistant ovarian cancer cells. Luciferase reporter assay was applied to examine the association between NEAT1, zinc finger E-box-binding homeobox 1 (ZEB1) and miR-194. Xenograft tumor model was established to confirm the biological role of NEAT1 in PTX resistance of ovarian cancer in vivo. cell line (SKOV3, HeyA-8,SKOV3/PTX, HeyA-8/PTX ) up-regulated resistant miR-194 ZEB1 NA validated 3626 LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 2017 29190892 Ensembl ENSG00000130600 H19 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer quantitative real-time RT-PCR The role of H19 in breast cancer cells was detected using cell viability assay, microarray analysis, quantitative real-time RT-PCR, western blot analysis, etc. cell line (MCF-7,MCF-7/Dox400, MCF-7/Dox800, MCF-7/Dox1600,MCF-7/Con400, MCF-7/Con800 and MCF-7/Con1600) up-regulated resistant NA NA cullin4A-MDR1 pathway validated 3627 LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 2017 29190892 Ensembl ENSG00000130600 H19 lncRNA DB00445 (APRD00361) epirubicin breast cancer quantitative real-time RT-PCR The role of H19 in breast cancer cells was detected using cell viability assay, microarray analysis, quantitative real-time RT-PCR, western blot analysis, etc. cell line (MCF-7,MCF-7/Dox400, MCF-7/Dox800, MCF-7/Dox1600,MCF-7/Con400, MCF-7/Con800 and MCF-7/Con1600) up-regulated resistant NA NA cullin4A-MDR1 pathway validated 3628 LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 2017 29190892 Ensembl ENSG00000130600 H19 lncRNA DB11616 Pirarubicin breast cancer quantitative real-time RT-PCR The role of H19 in breast cancer cells was detected using cell viability assay, microarray analysis, quantitative real-time RT-PCR, western blot analysis, etc. cell line (MCF-7,MCF-7/Dox400, MCF-7/Dox800, MCF-7/Dox1600,MCF-7/Con400, MCF-7/Con800 and MCF-7/Con1600) up-regulated resistant NA NA cullin4A-MDR1 pathway validated 3629 LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 2017 29190892 Ensembl ENSG00000130600 H19 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer quantitative real-time RT-PCR The role of H19 in breast cancer cells was detected using cell viability assay, microarray analysis, quantitative real-time RT-PCR, western blot analysis, etc. cell line (MCF-7,MCF-7/Dox400, MCF-7/Dox800, MCF-7/Dox1600,MCF-7/Con400, MCF-7/Con800 and MCF-7/Con1600) up-regulated resistant NA NA cullin4A-MDR1 pathway validated 3630 Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR. Exp Ther Med 2017 29201179 Ensembl ENSG00000228630 HOTAIR lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-qPCR The role of HOTAIR in pancreatic cancer stem-like cells was detected using RT-qPCR, transwell migration assay, serial replating experiments,CKK-8 assay and flow cytometric analysis,etc. cell line (Panc-1) up-regulated resistant NA NA NA validated 3631 Reciprocal regulation of DGCR5 and miR-320a affects the cellular malignant phenotype and 5-FU response in pancreatic ductal adenocarcinoma. Oncotarget 2017 29207609 Ensembl ENSG00000237517 DGCR5 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic ductal adenocarcinoma qRT-PCR The role of DGCR5 and miR-320a in pancreatic ductal adenocarcinoma cells was detected qRT-PCR, cell proliferation and colony formation assay, transwell migration and invasion assay, etc. cell line up-regulated sensitive miR-320a PDCD4 NA validated 3632 Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget 2017 29228625 Ensembl ENSG00000225383 SFTA1P lncRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma real-time RT-PCR The role of SFTA1P in lung squamous cell carcinoma cells was detected using real-time RT-PCR, drug sensitivity assay, EdU incorporation assay, flow cytometry assay and western blot analysis,etc. cell line (NCl-H226, SK-MES-1, NCl-H1299, A549, A549-DDP,HBE) up-regulated sensitive hnRNP-U GADD45A NA validated 3633 Effect and mechanism of long noncoding RNAs HOTAIR on occurrence and development of gastric cancer. J Cell Biochem 2017 29236333 Ensembl ENSG00000228630 HOTAIR lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR We investigated the lncRNA expression level in GC tissues and normal gastric mucosa tissues by lncRNA chips analysis. The expression of lncRNA HOTAIR was detected by quantitative real time polymerase chain reaction (qRT-PCR). The relationship between HOTAIR expression level and prognosis was investigated by analyzing clinical samples. The influence of HOTAIR downregulation on GC cell proliferation, chemosensitivity, apoptosis, and invasion were determined by bromodeoxyuridine (BrdU) incorporation assay, flow cytometry analysis, and transwell assay. Tumor xenograft model was developed to study the influence of downregulated HOTAIR on tumor growth and metastasis. cell line ( BGC-823 and MKN-45) down-regulated sensitive NA NA NA validated 3634 Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway. Oncol Lett 2017 29250186 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma RT-qPCR The expression levels of lncRNA were determined by RT-qPCR and those of protein were by Western blot analysis. Cell migration was detected by transwell migration and invasion assay. The CCK-8 assay was used to monitor the growth of the cells . cell line (Huh7) down-regulated sensitive NA NA STAT3/ABCB1 signaling pathway validated 3635 Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells Zhejiang Da Xue Xue Bao Yi Xue Ban 2017 29256224 Ensembl NA RP11-770J1.3 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression of lncRNA RP11-770J1.3 and TMEM25 in human breast cancer MCF-7(paclitaxel sensitive) and MCF-7/PR(paclitaxel resistant) cells were detected by quantitative RT-PCR. The synthetic interfering fragments of lncRNA RP11-770J1.3 and TMEM25 were transfected into MCF-7/PR cells. Sulforhodamine B assay was used to detect the sensitivity of MCF-7/PR cells to paclitaxel after interference of lncRNA RP11-770J1.3 and TMEM25. The expression of multidrug-resistance genes and proteins were detected by qRT-PCR and Western blot, respectively. cell line (MCF-7,MCF-7/PR) down-regulated sensitive MRP, BCRP, BCRP, and MDR/p-gp MRP, BCRP, BCRP, and MDR/p-gp NA validated 3636 Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells Zhejiang Da Xue Xue Bao Yi Xue Ban 2017 29256224 Ensembl ENSG00000149582 TMEM25 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The expression of lncRNA RP11-770J1.3 and TMEM25 in human breast cancer MCF-7(paclitaxel sensitive) and MCF-7/PR(paclitaxel resistant) cells were detected by quantitative RT-PCR. The synthetic interfering fragments of lncRNA RP11-770J1.3 and TMEM25 were transfected into MCF-7/PR cells. Sulforhodamine B assay was used to detect the sensitivity of MCF-7/PR cells to paclitaxel after interference of lncRNA RP11-770J1.3 and TMEM25. The expression of multidrug-resistance genes and proteins were detected by qRT-PCR and Western blot, respectively. cell line (MCF-7,MCF-7/PR) down-regulated sensitive MRP, BCRP, BCRP, and MDR/p-gp MRP, BCRP, BCRP, and MDR/p-gp NA validated 3637 Long non-coding RNA LINC00261 sensitizes human colon cancer cells to cisplatin therapy. Braz J Med Biol Res 2017 29267503 Ensembl ENSG00000259974 LINC00261 lncRNA DB00515 (APRD00359) Cisplatin colon cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration and invasion assay. tissue and cell line ( HCT116, HCT8, HT29, SW480,FHC) up-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 3638 Overexpression of HOTTIP promotes proliferation and drug resistance of lung adenocarcinoma by regulating AKT signaling pathway. Eur Rev Med Pharmacol Sci 2017 29272003 Ensembl ENSG00000243766 HOTTIP lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung adenocarcinoma qRT-PCR Differentially expressed lncRNAs in normal lung tissues and lung adenocarcinoma tissues were analyzed in The Cancer Genome Atlas (TCGA) database, followed by analysis of differential lncRNAs in treated sensitive and insensitive groups. HOTTIP was found to be highly expressed in lung adenocarcinoma tissues and in drug-resistant tissues. Next, the expression of HOTTIP in clinical samples and its relation to clinical data were analyzed. Then, we examined the effect of HOTTIP in lung adenocarcinoma by detecting changes in cell proliferation and drug resistance after overexpression and interference with HOTTIP. cell line (A549,A549/PA,16HBE) up-regulated resistant NA NA AKT pathway validated 3639 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000099251 HSD17B7P2 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3640 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA RP11-443P15.2 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3641 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000173559 NABP1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3642 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000113456 RAD1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3643 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA RP11-327I22.2 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3644 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000215559 ANKRD20A11P lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3645 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000166863 TAC3 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3646 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000196072 BLOC1S2 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3647 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000099725 PRKY lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3648 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA AL583842.6 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3649 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA RP11-551L14.1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3650 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA LOC100132774 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3651 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl NA RP11-551L14.1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3652 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000261279 ULK4P1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3653 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000168393 DTYMK lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) down-regulated resistant NA NA NA predicted 3654 Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma. Biomed Res Int 2017 29279851 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qPCR We used a high-throughput microarray to compare the lncRNA and mRNA expression profiles in cisplatin resistance cell A549/DDP and cisplatin sensitive cell A549. Several candidate cisplatin resistance-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. cell line (A549, NCI-H1299,A549/DDP) up-regulated resistant NA NA NA predicted 3655 Silence of Long Noncoding RNA NEAT1 Inhibits Malignant Biological Behaviors and Chemotherapy Resistance in Gastric Cancer. Pathol Oncol Res 2018 28401449 Ensembl ENSG00000245532 NEAT1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin stomach cancer RT-qPCR The role of NEAT1 in gastric cancer cells was detected using real time quantitative PCR, MTT assay and cell invasion assay, etc. cell line (SGC7901,GES-1,SGC7901/ADR) down-regulated sensitive NA NA NA validated 3656 High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Lab Invest 2018 29035381 Ensembl ENSG00000106031 HOXA13 lncRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR The role of HOXA13 in hepatocellular carcinomas cells was detected qRT-PCR, migration assay, soft agar colony assay, proliferation assay, and In vitro sorafenib exposure, etc. cell line ( SNU-449 and HepG2) up-regulated resistant NA NA NA validated 3657 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/Beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol 2018 29080815 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of HOTAIR in gastric cancer cells was detected using quantitative real-time PCR, dual-luciferase report assay, RNA immunoprecipitation (RIP) assay, Caspase-3 activity detection, western blotting, Animals and treatment, etc. cell line (SGC7901,MGC803,GES1,SGC7901/DDP,MGC803/DDP) down-regulated sensitive miR-34a NA PI3K/Akt and Wnt/Beta-catenin signaling pathway validated 3658 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/Beta-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol 2018 29080815 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The role of HOTAIR and miR-34a in gastric cancer cells was detected using MTT assay, quantitative real-time PCR, Dual-luciferase report assay, RIP assay, caspase-3 activity detection and western blot , etc. tissue and cell line (SGC7901,MGC803,GES1,SGC7901/DDP) up-regulated sensitive miR-34a NA PI3K/Akt and Wnt/Beta-catenin signaling pathway validated 3659 Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother 2018 29112934 Ensembl ENSG00000234741 GAS5 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic cancer qRT-PCR mRNA levels of GAS5, miR-181c-5p and Hippo pathway related genes were detected by quantitative real-time PCR (qRT-PCR). Protein levels of MDR-1, MST1, YAP and TAZ were measured by western blot. Cell viability was detected by MTT assay. The combination between GAS5 and miR-181c-5p was confirmed by RNA pull-down and RNA immunoprecipitation (RIP) assay. We also established pancreatic cancer-bearing mice model and analyzed tumor volumes. cell line (SW1990,PATU8988, SW1990/GEM, PATU8988/5-FU,PANC-1) down-regulated resistant miR-181c-5p NA Hippo signaling pathway validated 3660 The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep 2018 29115526 Ensembl ENST00000547547 RP11-611E13.3-001 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HCT116, LoVo,LoVo/5-FU,HCT116/5-FU) up-regulated sensitive miR-31 NA NA validated 3661 The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep 2018 29115526 Ensembl ENST00000547547 RP11-611E13.3-001 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (HCT116,LoVo,LoVo/5-FU,HCT116/5-FU) down-regulated resistant miR-31 NA NA validated 3662 Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Biomed Pharmacother 2018 29136760 Ensembl ENSG00000177640 CASC2 lncRNA DB00853 (APRD00557) Temozolomide glioma qPCR Glioma and the adjacent non-cancerous tissues from 32 patients were collected. The expressions of CASC2 and miR-193a-5p were determined by PCR, and their correlation was analyzed. The correlation between CASC2 expression and the clinical characteristics of patients was also studied. Glioma cells were treated with TMZ to acquire the TMZ-resistant cell lines in which the expressions of CASC2, miR-193a-5p, and mTOR were measured. The regulatory roles of CASC2, miR-193a-5p, and mTOR were defined through the loss of function and luciferase reporter assays. Autophagy was inhibited by autophagy inhibitor 3-MA, CASC2 and mTOR overexpression, or miR-193a-5p inhibitor, and the effect of which on cell viability, apoptosis, and migration of TMZ-resistant glioma cells was evaluated. cell line ( U257,U87, U257TR, U87TR) up-regulated sensitive miR-193a-5p mTOR NA validated 3663 Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer. Biomed Pharmacother 2018 29136952 Ensembl ENSG00000237872 POU5F1P4 lncRNA DB00002 (BTD00071, BIOD00071) Cetuximab colorectal cancer qPCR o gain insights into the functions of long non-coding RNA (lncRNA) in cetuximab resistance, we used a lncRNA-mining approach to distinguish lncRNA specific probes in Affymetrix HG-U133A 2.0 arrays. Then we performed lncRNA expression profiling in a cetuximab treated mCRC cohort from Gene Expression Ominus (GEO). The potential lncRNAs were further validated in acquired cetuximab resistant cell lines and clinical samples of our hospital. The functions and associated pathways of the prognostic lncRNA were predicted by GO and KEGG analyses. cell line (Caco2, NCI-H508) down-regulated resistant NA NA NA validated 3664 Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun 2018 29170124 Ensembl ENSG00000248323 LUCAT1 lncRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . Cell migration was detected by transwell invasion assay. Xenograft in vivo assay was uesd to test the role of LUCAT1 . cell line (MG-63, U2OS, HOS and SAOS-2, hFOB) up-regulated resistant miR-200c ABCB1 LUCAT1/miR-200c/ABCB1 pathway validated 3665 Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. Int J Biochem Cell Biol 2018 29175387 Ensembl NA BDLNR lncRNA NA Baicalein cervical cancer qRT-PCR The role of BDLNR in cervical cancer cells was detected using qRT-PCR, Glo cell viability assays, in vitro TdT-mediated dUTP nick end labeling (TUNEL) assays, transwell assays, animals assays and baicalein treatment, RNA pull-down assay, RNA immunoprecipitation (RIP) assays, Chromatin immunoprecipitation (ChIP) assays, western blot, etc. cell line (HeLa, SiHa, ME-180, and Caski) up-regulated sensitive NA NA PI3K/Akt pathway validated 3666 Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 2018 29202181 Ensembl ENSG00000251562 MALAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The role of MALAT1 in glioblastoma cells was detected using proliferation assay, wound-healing assay, antibody array, quantitative RT-PCR assay, flow cytometry assay, colony-formation assay and XTT assays, etc. cell line (U87, T98G,LN-18,U87-luc2,U87R) down-regulated sensitive NA NA NA validated 3667 LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol 2018 29205703 Ensembl ENSG00000245532 NEAT1 lncRNA DB01234 (APRD00674) Dexamethasone multiple myeloma qPCR The expression levels of lncRNA were determined by quantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (RPMI8226, JJN-3, U266, ANBL6, OPM-2, MM1S, MM1R) down-regulated sensitive NA MCL1 miR-193a/MCL1 pathway validated 3668 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000527239 CTD-2589M5.4 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) up-regulated resistant NA NA NA predicted 3669 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000442532 RP13-766D20.2 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2781/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) up-regulated resistant NA NA NA predicted 3670 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000435731 SDHAP1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2782/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) up-regulated resistant NA NA NA predicted 3671 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000433161 HAR1A lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2783/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) up-regulated resistant NA NA NA predicted 3672 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000568177 RP11-600F24.7 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2784/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) up-regulated resistant NA NA NA predicted 3673 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000429829 XIST lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2785/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3674 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000583962 CCDC144NL-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2786/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3675 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000585445 ZNF667-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2787/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3676 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000556667 SLC25A21-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2788/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3677 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000419368 RFPL1S lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2789/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3678 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000417533 RP11-262H14.5 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2790/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3679 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000552334 PWAR6 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2791/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3680 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000470236 NCK1-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2792/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3681 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000514260 EPHA5-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2793/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3682 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000359941 TP53TG1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2794/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3683 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000607933 DUXAP8 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2795/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3684 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000623772 C17orf82 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2796/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3685 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000455414 RP11-432J24.5 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2797/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3686 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000557993 OIP5-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2798/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3687 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000607166 ZEB1-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2799/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3688 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000561521 LINC00662 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2800/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3689 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000453317 JPX lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2801/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3690 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000553596 ARHGAP5-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2802/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3691 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000452942 ENTPD1-AS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2803/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3692 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000414002 SNHG5 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2804/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3693 Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol 2018 29219179 Ensembl ENST00000500741 NRAV lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2805/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A2780,SW-2/DDP, SW-2/EPI,A2780/PTX) down-regulated resistant NA NA NA predicted 3694 Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther 2018 29293402 Ensembl ENSG00000223784 LINP1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2806/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (MDA-MB-231, MDA-MB-468, MCF7,MDA-MB-231/5FU and MDA-MB-231/DOX) up-regulated resistant NA NA NA validated 3695 Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther 2018 29293402 Ensembl ENSG00000223784 LINP1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil breast cancer qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2807/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (MDA-MB-231, MDA-MB-468, MCF7,MDA-MB-231/5FU and MDA-MB-231/DOX) up-regulated resistant NA NA NA validated 3696 LncRNA PCAT-1 promotes tumour growth and chemoresistance of oesophageal cancer to cisplatin. Cell Biochem Funct 2018 29314203 Ensembl ENSG00000253438 PCAT-1 lncRNA DB00515 (APRD00359) Cisplatin oesophageal cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2808/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (KYSE30, KYSE450, and Eca109) down-regulated sensitive NA NA NA validated 3697 Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. Oncol Rep 2018 29328401 Ensembl ENSG00000214548 MEG3 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-qPCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2809/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. tissue and cell line (SW 1990, COLO357, MIA PaCa-2, T3M4, AsPC-1, BxPC-3, CAPAN-1 and PANC-1) down-regulated resistant NA NA NA validated 3698 Chronic oxymatrine treatment induces resistance and epithelial-mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells. Oncol Rep 2018 29328404 Ensembl ENSG00000251562 MALAT1 lncRNA NA Oxymatrine colorectal cancer RT-qPCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2810/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (HT29 and SW480) up-regulated resistant NA NA NA validated 3699 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 Ensembl ENSG00000243766 HOTTIP lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma RT-qPCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2811/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive miR-216a NA NA validated 3700 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 Ensembl ENSG00000243766 HOTTIP lncRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma RT-qPCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2812/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive miR-216a NA NA validated 3701 Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis 2018 29367594 Ensembl ENSG00000243766 HOTTIP lncRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma RT-qPCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2813/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. tissue and cell line (H69, H69AR, H446, H446AR SCLC,NCI-H446,H446AR) up-regulated sensitive miR-216a NA NA validated 3702 Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Cancer Chemother Pharmacol 2018 29397407 Ensembl ENSG00000243197 TUSC7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2814/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line ( U87TR ) down-regulated resistant miR-10a NA NA validated 3703 Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun 2018 29408336 Ensembl ENSG00000214049 UCA1 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2815/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line ( SKBR-3) down-regulated sensitive NA NA NA validated 3704 Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res 2018 29423000 Ensembl ENSG00000249859 PVT1 lncRNA DB00515 (APRD00359) Cisplatin colorectal cancer qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2816/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. tissue and cell line (HT29, SW480, HCT116, RKO, LoVo, NCM460) up-regulated resistant NA NA intrinsic apoptotic pathway validated 3705 Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/Beta-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem 2018 29424266 Ensembl ENSG00000177410 ZFAS1 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2817/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (SGC7901) down-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 3706 Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/Beta-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem 2018 29424266 Ensembl ENSG00000177410 ZFAS1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel stomach cancer RT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2818/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (SGC7901) down-regulated sensitive NA NA Wnt/Beta-catenin pathway validated 3707 Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun 2018 29470986 Ensembl ENSG00000228630 HOTAIR lncRNA DB08865 (DB08700) Crizotinib lung non-small cell carcinoma qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2819/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (A549, H460, H1299, NCI-H460, HCC-827,HBEC) down-regulated sensitive ULK1 ULK1 ULK1 pathway validated 3708 Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma. Cancer Med 2018 29479863 Ensembl ENSG00000251562 MALAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR In order to discover different expressions of lncRNA , we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2820/PTX . The expression levels of lncRNA were determined by Real-time PCR . BLAST is used to select the sequence that were complementary or similarity to the differentially expressed lncRNA sequence using the human mRNA database . Then, RNAplex was used to calculate the complementary energy between two sequences . TFurthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs'targets. cell line (U251,U251/TMZ) down-regulated sensitive NA NA NA validated 3709 Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-kappaB signaling. Chem Biol Interact 2018 29481769 Ensembl ENSG00000278709 NKILA lncRNA NA Baicalein hepatocellular carcinoma qRT-PCR The role of NKILA in hepatocellular carcinoma cells was detected using qRT-PCR, Glo cell viability assays, TUNEL assays, Transwell migration assays, western blot and Luciferase reporter assays , etc. tissue and cell line (QSG-7701,SMMC-7721, Hep3B, HCCLM3 and HepG2) up-regulated sensitive NA NA NF-kappaB pathway validated 3710 LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother 2018 29505924 Ensembl ENSG00000251562 MALAT1 lncRNA DB00515 (APRD00359) Cisplatin lung cancer qRT-PCR Human lung cancer cell line A549 and the DDP-resistant cell line A549/DDP were used. Cell transfection was performed to establish A549/MALAT1 and A549/DDP/shMALAT1 cells. The qRT-PCR analysis was performed to detect lncRNA-MALAT1 level. Cell viability, colony formation assay, apoptosis analysis, western blot analysis, immunohistochemistry, and animal study were carried out. cell line (A549,A549/DDP) up-regulated resistant NA NA NA validated 3711 LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018 29530057 Ensembl ENSG00000243197 TUSC7 lncRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR TUSC7, miR-224 and DESC1 expressions in ESCC tissues and cells were detected by qRT-PCR. Protein level of DESC1, EGFR and p-AKT were observed by Western blot. Overall survival was calculated using the Kaplan-Meier method. Dual-luciferase reporter gene assay and RIP assay were used to comfirm TUSC7 binding to miR-224, and miR-224 binding to DESC1. Cell proliferation, apoptosis, and colony formation was detected by MTT, Flow Cytometry and Colony formation assays. cell line (TE-13, KYSE140, EC9706, KYSE30,Het-1A) up-regulated sensitive NA NA DESC1/EGFR/AKT pathway validated 3712 LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018 29530057 Ensembl ENSG00000243197 TUSC7 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal squamous cell carcinoma qRT-PCR TUSC7, miR-224 and DESC1 expressions in ESCC tissues and cells were detected by qRT-PCR. Protein level of DESC1, EGFR and p-AKT were observed by Western blot. Overall survival was calculated using the Kaplan-Meier method. Dual-luciferase reporter gene assay and RIP assay were used to comfirm TUSC7 binding to miR-224, and miR-224 binding to DESC1. Cell proliferation, apoptosis, and colony formation was detected by MTT, Flow Cytometry and Colony formation assays. cell line (TE-13, KYSE140, EC9706, KYSE30,Het-1A) up-regulated sensitive NA NA DESC1/EGFR/AKT pathway validated 3713 LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther 2018 29561707 Ensembl ENSG00000259104 PTCSC3 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin anaplastic thyroid cancer qRT-PCR Expression of RNA and protein was analyzed by qRT-PCR and western blot, respectively. Flow cytometry was used to analyze the expression rate of CD133+ cells. The endogenous expression of related genes was modulated by recombinant plasmids and cell transfection. Combination condition and interaction between PTCSC3 and STAT3 were determined by RIP and RNA pull-down assay, respectively. MTT assay was performed to detect cytotoxicity. Chromatin immunoprecipitation was conducted to identify interactions between STAT3 and DNA promoter of INO80. cell line (8505C,FTC 238,FTC 133) up-regulated sensitive STAT3 INO80 STAT3/INO80 pathway validated 3714 LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther 2018 29565706 Ensembl ENSG00000245532 NEAT1 lncRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-qPCR In this study, the expressions of NEAT1, let-72-5p and Rsf-1 mRNA were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of NEAT1 and let-72-5p on cell proliferation and cisplatin resistance of NPC cells were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and 5-ethynyl-20-deoxyuridine (EdU) assay. Western blot analysis was performed to detect the protein levels of Rsf-1, Ras, p-Raf1, Raf1, p-MEK1, MEK1, p-ERK1/2 and ERK1/2. Xenograft tumor assay was done to elucidate the role of NEAT1 involved in NPC tumor growth in vivo. cell line (HK-1,CNE-1, CNE-2) down-regulated sensitive let-7a-5p NA Ras-MAPK pathway validated 3715 TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. Cell Biosci 2018 29588850 Ensembl ENSG00000182165 TP53TG1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR qRT-PCR analysis was used to detect the expression of TP53TG1, miR-18a and PTEN mRNA in NSCLC tissues and cells. Western blot analysis was performed to determine the protein level of PTEN and cleaved caspase-3. Cell viability and IC50 value were measured by MTT assay. Cell apoptosis was confirmed by flow cytometry assay. Subcellular fractionation assay was used to identify the subcellular location of TP53TG1. Dual-luciferase reporter assay, RNA pull down assay and RNA immunoprecipitation assay were carried out to verify the interaction between TP53TG1 and miR-18a. Xenografts in nude mice were established to verify the effect of TP53TG1 on cisplatin sensitivity of NSCLC cells in vivo. tissue and cell line (A549,A549/DDP) up-regulated sensitive NA NA miR-18a/PTEN pathway validated 3716 The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis. Biosci Rep 2018 29592872 Ensembl ENSG00000203875 SNHG5 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung adenocarcinoma qRT-PCR The role of SNHG5 in lung adenocarcinoma cells was detected using quantitative real-time PCR, cell proliferation assay, cell apoptosis analysis, Luciferase reporter assay and western blotting assay, etc. tissue and cell line (PC9,A549,PC9GR,A549GR) up-regulated sensitive miR-377 CASP1 miR-377/CASP1 validated 3717 LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol Med. 2018 29602203 Ensembl ENSG00000237187 NR2F1-AS1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The role of lncRNA NR2F1-AS1 in hepatocellular carcinoma cells was detected using microarray analysis, quantitative real-time PCR, CCK-8 assay, transwell invasion and migration assay, Dual-luciferase reporter assay, Western blot and Xenograft nude mice assay, etc. cell line (Huh7,HepG2,Lo-2) up-regulated resistant miR-363 ABCC1 NR2F1-AS1/miR-363/ABCC1 pathway validated 3718 Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma. Biosci Rep 2018 29654165 Ensembl ENSG00000245532 NEAT1 lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR .The CCK-8 assay was used to monitor the growth of the cells .Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Tumor model was used to test the role of lncRNA NEAT1 and miR-34c cell line (MG63, 143B, HOS,Saos2,hFOB1.19 ) up-regulated resistant NA NA BCL-2 and cyclin D1 pathway validated 3719 Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway. J Cell Biochem 2018 29663500 Ensembl ENSG00000214049 UCA1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR (QRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. cell line (HS-5,HL60/ADR) down-regulated sensitive miR-125a HK2 microRNA-125a/hexokinase 2 pathway validated 3720 Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 2018 29674277 Ensembl ENSG00000237424 FOXD2-AS1 lncRNA DB00441 (APRD00201) Gemcitabine bladder cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell invasion assay.Xenograft tumor model was used to test the role of FOXD2-AS1 and miR-143 . cell line (T24, 5637) up-regulated sensitive miR-143 ABCC3 FOXD2-AS1/miR-143/ABCC3 validated 3721 Knockdown of long non-coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep 2018 29693171 Ensembl ENSG00000249859 PVT1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The role of PVT1 in colorectal cancer cells was detected using cell transfection and cytotoxicity assay, western blotting and RT-qPCR, etc. tissue and cell line ( HCT-8 and HCT-116 ) up-regulated resistant NA NA NA validated 3722 Chemotherapy-Induced Long Non-coding RNA 1 Promotes Metastasis and Chemo-Resistance of TSCC via the Wnt/Beta-Catenin Signaling Pathway. Mol Ther 2018 29699939 Ensembl NA CILA1 lncRNA DB00515 (APRD00359) Cisplatin tongue squamous cell carcinoma qRT-PCR The role of CILA1 in tongue squamous cell carcinoma cells was detected using cell viability, Proliferation assay, apoptosis assay, lncRNA Microarray and qRT-PCR, western blot analysis and Immunofluorescence Staining, boyden chamber assay and Tumor Xenografts,etc. cell line (CAL27 and SCC9) up-regulated resistant NA NA Wnt/Beta-catenin pathway validated 3723 Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKalpha/NF-kappaB pathway. Biochem Biophys Res Commun 2018 29702091 Ensembl ENSG00000251562 MALAT1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil liver cancer RT-qPCR The role of MALAT1 in liver cancer cells was detected using Real-time quantitative PCR, western blot analysis, colony formation assay, migration and invasion assays, CCK-8 analysis and EdU analysis, flow cytometry analysis and tumorigenic nude mice, etc. cell line (Hep3B, HepG2, Huh7,SMMC7721, MHCC97-L, HCCLM3,Bel7402, L02 and NCTC1469) down-regulated sensitive NA NA IKKalpha/NF-kappaB pathway validated 3724 Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother 2018 29710482 Ensembl ENSG00000281406 BLACAT1 lncRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell invasion assay. In vivo tumor xenograft model was used to test the role of miR-361 and BLACAT1 . tissue and cell line s (BGC-823, SGC-7901, MGC-803, GES-1) up-regulated resistant miR-361 ABCB1 BLACAT1/miR-361/ABCB1 pathway validated 3725 A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer. Int J Oncol 2018 29749482 Ensembl ENST00000426122 RNF144A-AS1 lncRNA DB12257 Platinum ovarian cancer NA In order to study the role of long non-coding RNAs in predicting platinum-based chemoresistance in patients with high-grade serous ovarian carcinoma, a=7-lncRNA signature was developed by analyzing 561 microarrays and 136 specimens from RNA-sequencing obtained from online databases. Then, in vitro experiments was used to test the result . NA down-regulated resistant NA NA NA predicted 3726 A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer. Int J Oncol 2018 29749482 Ensembl ENST00000434796 GAS5 lncRNA DB12257 Platinum ovarian cancer NA In order to study the role of long non-coding RNAs in predicting platinum-based chemoresistance in patients with high-grade serous ovarian carcinoma, a=7-lncRNA signature was developed by analyzing 561 microarrays and 136 specimens from RNA-sequencing obtained from online databases. Then, in vitro experiments was used to test the result . NA down-regulated resistant NA NA NA predicted 3727 A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer. Int J Oncol 2018 29749482 Ensembl ENST00000455503 RP11-126K1.6 lncRNA DB12257 Platinum ovarian cancer NA In order to study the role of long non-coding RNAs in predicting platinum-based chemoresistance in patients with high-grade serous ovarian carcinoma, a=7-lncRNA signature was developed by analyzing 561 microarrays and 136 specimens from RNA-sequencing obtained from online databases. Then, in vitro experiments was used to test the result . NA up-regulated resistant NA NA NA predicted 3728 A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer. Int J Oncol 2018 29749482 Ensembl ENST00000567832 RP11-439E19.10 lncRNA DB12257 Platinum ovarian cancer NA In order to study the role of long non-coding RNAs in predicting platinum-based chemoresistance in patients with high-grade serous ovarian carcinoma, a=7-lncRNA signature was developed by analyzing 561 microarrays and 136 specimens from RNA-sequencing obtained from online databases. Then, in vitro experiments was used to test the result . NA up-regulated resistant NA NA NA predicted 3729 A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer. Int J Oncol 2018 29749482 Ensembl ENST00000603915 RP11-348N5.7 lncRNA DB12257 Platinum ovarian cancer NA In order to study the role of long non-coding RNAs in predicting platinum-based chemoresistance in patients with high-grade serous ovarian carcinoma, a=7-lncRNA signature was developed by analyzing 561 microarrays and 136 specimens from RNA-sequencing obtained from online databases. Then, in vitro experiments was used to test the result . NA up-regulated resistant NA NA NA predicted 3730 UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochem Biophys Res Commun 2018 29777711 Ensembl ENSG00000214049 UCA1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (SKOV3, HeyA-8,SKOV3/PTX and HeyA-8/PTX) up-regulated resistant miR-129 ABCB1 UCA1/miR-129/ABCB1 validated 3731 The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. Exp Ther Med 2018 29805510 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin lung cancer RT-PCR The role of lncRNA-HOTAIR in non-small cell lung cancer cells was detected using RT-PCR, CCK-8 assay and western blot analysis, etc. tissue and cell line (NCI-H1299) down-regulated sensitive NA NA Wnt pathway validated 3732 Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer. Int J Oncol 2018 29845246 Ensembl ENSG00000266835 RP11-838N2.4 lncRNA DB00530 (APRD00951) Erlotinib lung non-small cell carcinoma RT-qPCR The role of lncRNA RP11-838N2.4 in non-small cell lung cancer cells was detected using RT-qPCR, microarray analysis, bioinformatics analysis, CCK8 assay, fluorescence in situ hybridization analysis and western blot analysis, etc. tissue and cell line (HCC827 and HCC4006) up-regulated resistant NA NA NA validated 3733 LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. Biochimie 2018 29959065 Ensembl ENSG00000226856 THOR lncRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma qRT-PCR The role of lncRNA THOR in nasopharyngeal carcinoma cells was detected using MTT assay, transwell migration assay, qRT-PCR, western blotting, RIP assay, luciferase reporter assay, Immunofluorescent assay, in vivo tumorigenic assay, etc. tissue and cell line (FaDu, SCC25, HN30, HN4, SCC4, Cal27, HN13 and HN12) up-regulated resistant YAP NA Hippo signaling pathway validated 3734 LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. J Pharmacol Sci. 2018 29960845 Ensembl ENSG00000253352 TUG1 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR The expression of TUG1 was defined by qRT-PCR. The apoptotic cells were detected by flow cytometry assay. The cell migration and invasion were measured by scratch assay and Transwell assay. The level of ERK pathway was detected using Western blot. cell line (PANC-1, PANC-28, BXPC3, and SW1990) up-regulated resistant NA NA ERK pathway validated 3735 Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun 2018 29966655 Ensembl ENSG00000269821 KCNQ1OT1 lncRNA DB00526 (APRD00186) Oxaliplatin hepatocellular carcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis.Fuciferase activity assay was used to verify the target genes of miRNAs.The CCK-8 assay was used to monitor the growth of the cells .Cell migration was detected by transwell migration . tissue and cell line (SMMC-7721, Huh7, SK-Hep-1, HepG2,Lo-2) up-regulated resistant miR-7-5p,ABCC1 ABCC1 NA validated 3736 Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. Biomed Pharmacother 2018 29966979 Ensembl ENSG00000212766 EWSAT1 lncRNA NA Calycosin nasopharyngeal carcinoma qPCR The role of EWSAT1 in nasopharyngeal carcinoma cells was detected using CCK-8 assay, BrdU assay, qPCR, western blot analysis and Mouse xenograft tumor model, etc. cell line (CNE1, CNE2, and C666-1) up-regulated resistant NA NA TRAF6-related pathways validated 3737 Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. Cancer Lett 2018 29969658 Ensembl ENSG00000234741 GAS5 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR A microarray of lncRNAs was screened in tamoxifen-resistant MCF-7R cells and the parental, non-resistant MCF-7-cells. The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell assay. Subcutaneous xenograft mouse model was used to test the role of lncRNA GAS5 . cell line (MCF-7,MCF-7R) up-regulated sensitive miR-222 PTEN AKT/mTOR pathway validated 3738 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 Ensembl ENSG00000183674 Linc00518 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) down-regulated sensitive miR-199a MRP1 miR-199a/MRP1 validated 3739 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 Ensembl ENSG00000183674 Linc00518 lncRNA DB00541 (APRD00495) Vincristine breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) down-regulated sensitive miR-199a MRP1 miR-199a/MRP1 validated 3740 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell Physiol Biochem 2018 30001527 Ensembl ENSG00000183674 Linc00518 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR Expressions of linc00518, miR-199a and MRP1 were evaluated by RT-qPCR or western blot. IC50 values of adriamycin (ADR), vincristine (VCR) and paclitaxel (PTX) were determined by XTT assays and cell apoptosis was assessed by flow cytometry. Luciferase reporter and RIP assays were employed to detect the interaction of linc00518, miR-199a and MRP-1. cell line ( MCF-10A, MCF-7,MCF-7/ADR) down-regulated sensitive miR-199a MRP1 miR-199a/MRP1 validated 3741 Curcumin inhibits proliferation and enhances apoptosis in A549 cells by downregulating lncRNA UCA1. Pharmazie 2018 30001775 Ensembl ENSG00000214049 UCA1 lncRNA DB11672 Curcumin lung cancer qRT-PCR Different concentrations of curcumin were exposed to A549 cells for 24 h and cell viability was measured by CCK-8 assay. The expression of UCA1 was overexpressed in A549 cells by transfection with pEX-UCA1. Cell proliferation was determined by BrdU staining and assessing the expression of CyclinD1 using western blot and RT-PCR assay. Apoptotic cells were measured by flow cytometry assay. Western blot was performed to assess the expression of apoptosis-related, Wnt and mTOR pathways-related factors. cell line (A549) up-regulated resistant NA NA Wnt and mTOR pathway validated 3742 Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer. Int J Oncol 2018 30015837 Ensembl ENSG00000224078 lncRNA-SNHG14 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-qPCR Trastuzumab-resistant cell lines were established by continuously grafting HER2+ SKBR-3 and BT474 cells into trastuzumab-containing culture medium.Tn lncRNA microarray assay followed by reverse transcription-quantitative polymerase chain reaction analysis to identify that the different express of ncRNA in cell lines .Functional experimentation demonstrated that knockdown of lncRNA-SNHG14 potently promoted trastuzumab-induced cytotoxicity.The Signal Transduction Reporter Array indicated that lncRNA-SNHG14 may promote the effect of trastuzumab by targeting the apoptosis regulator Bcl-2 (Bcl-2)/apoptosis regulator BAX (Bax) signaling pathway. cell line ( SKBR-3 and BT474) up-regulated resistant NA NA Bcl-2/Bax apoptosis signaling pathway validated 3743 HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer Sci 2018 30047193 Ensembl ENSG00000228630 HOTAIR lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer qRT-PCR The expression levels of lncRNA were determined by Reverse transcription and quantitative real-time polymerase chain reaction . Those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Orthotopic nude mouse model and treatment was used to test the role of HOTAIR . cell line (95C, 95D and YTMLC-90) up-regulated resistant NA NA EMT and the Beta-catenin pathway validated 3744 Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res 2018 30049286 Ensembl ENSG00000152931 PART1 lncRNA DB00317 (APRD00997, DB07998) Gefitinib esophageal squamous cell carcinoma RT-qPCR Gefitinib-resistant cell lines were established by continuously grafting TE1 and KYSE-450 cells into gefitinib-containing culture medium. LncRNA microarray assay followed by RT-qPCR were used to verify the differential expression of lncRNA Prostate Androgen-Regulated Transcript 1 (PART1) between gefitinib resistant and parental cell lines. RNA fluorescence in situ hybridization (FISH) was used to investigate whether extracellular PART1 could be incorporated into exosomes and transmitted to recipient cells. Subsequently, a series of in vitro assays and a xenograft tumor model were used to observe the functions of lncRNA PART1 in ESCC cells. A signal transduction reporter array, bioinformatics analysis, western blotting, and immunofluorescence were carried out to verify the regulation of PART1 and its downstream Bcl-2 signaling pathway. cell line (TE1, TE6, TE8, TTn, and KYSE-450) up-regulated resistant miR-129 Bcl-2 miR-129/Bcl-2 pathway validated 3745 RNA interference of long noncoding RNA HOTAIR suppresses autophagy and promotes apoptosis and sensitivity to cisplatin in oral squamous cell carcinoma. J Oral Pathol Med 2018 30053324 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma qRT-PCR HOTAIR expression in OSCC cells was knocked down by small RNA interference. Transmission electron microscope, Western blot, and flow cytometry assay were used to detect the level of autophagy and apoptosis. OSCC cells were medicated with cisplatin, and median lethal dose (LD50) was performed to evaluate the effect on chemosensitivity of HOTAIR. cell line (KB,CAL-27) down-regulated sensitive NA NA NA validated 3746 LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci 2018 30070323 Ensembl ENSG00000248092 NNT-AS1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR Fluorescence quantitative Real-time polymerase chain reaction (qRT-PCR) was used to detect the expression levels of lncRNA NNT-AS1 in NSCLC cell lines (A549 and SPCA-1) and DDP-resistant cell lines (A549/DDP and SPCA-1/DDP). Corresponding plasmids of si-NTT-AS1 and si-NC were conducted. Then, methyl thiazolyl tetrazolium (MTT) assay was applied to detect the changes in half inhibition concentration (IC50) values of DDP in A549/DDP and SPCA-1/DDP cells after interference in lncRNA NNT-AS1 expression. Clone formation assay and flow cytometry were employed to detect the changes in proliferation, cycle and apoptosis of A549/DDP and SPCA-1/DDP cells caused by si-NNT-AS1. Protein expressions of molecular markers in mitogen-activated protein kinase (MAPK)/Slug signaling pathway after interference in lncRNA NNT-AS1 expression was detected by Western blotting. The differential expressions of lncRNA NNT-AS1 in 10 pairs of drug-resistant and non-resistant tissues were detected by qRT-PCR. cell line (A549, SPCA-1,A549/DDP and SPCA-1/DDP) up-regulated resistant NA NA MAPK/Slug pathway validated 3747 Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol 2018 30076870 Ensembl ENSG00000251562 MALAT1 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The role of MALAT1 in non-small cell lung cancer cells was detected using qRT-PCR, cell viability assay and colony forming assay, Annexin V-FITC/PI apoptosis analysis, western blot analysis, Terminal deoxynucleotidyl transferase dUTP nick and labeling (TUNEL) assay,etc. cell line (PC-9,PC-9-ZD) down-regulated sensitive NA NA STAT3 signaling pathway validated 3748 Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics 2018 30083271 Ensembl ENSG00000130600 H19 lncRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The AOM/DSS-induced colitis-associated cancer (CAC) mouse model was established, and RNA sequencing was performed. Small interfering RNA (siRNA) sequences were used to knock down H19. Cell apoptosis was measured by flow cytometry. SW480 cells with H19 stably knocked down were used to establish a xenograft model. The indicated protein levels in xenograft tumor tissues were confirmed by immunohistochemistry assay, and cell apoptosis was analyzed by TUNEL apoptosis assay. RNA-FISH and immunofluorescence assays were performed to assess the expression of H19 in tumor stroma and cancer nests. The AldeRed ALDH detection assay was performed to detect intracellular aldehyde dehydrogenase (ALDH) enzyme activity. Isolated exosomes were identified by transmission electron microscopy, nanoparticle tracking and Western blotting. tissue and cell line (HCT116 and SW480) up-regulated resistant miR-141 NA Beta-catenin signaling pathway validated 3749 LncRNA GACAT3 acts as a competing endogenous RNA of HMGA1 and alleviates cucurbitacin B-induced apoptosis of gastric cancer cells. Gene 2018 30098426 Ensembl ENSG00000236289 GACAT3 lncRNA NA Cucurbitacin B stomach cancer qRT-PCR The role of GACAT3 in gastric cancer cells was detected using quantitative RT-PCR, cell proliferation assay and flow cytometry analysis, western blot analysis and dual luciferase assay, etc. cell line (BGC-823 and SGC-7901) up-regulated resistant NA NA NA validated 3750 Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother 2018 30098551 Ensembl ENSG00000253352 TUG1 lncRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR The role of miR-197 and TUG1 in triple negative breast cancer cells was detected using qRT-PCR, Cell viability assay, bioinformatic analysis, dual luciferase reporter assay, western blot and TOPflash/FOPflash assay,etc. tissue and cell line (MCF10 A,MCF7, T47D,(MDA-MB-231 and BT549) down-regulated sensitive miR-197 NLK Wnt pathway validated 3751 LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci 2018 30099826 Ensembl ENSG00000240990 HOXA11-AS lncRNA DB00515 (APRD00359) Cisplatin lung adenocarcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative RT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Cell migration was detected by transwell migration assays . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (A549, H157,HEK-293T) up-regulated resistant miR-454-3p STAT3 NA validated 3752 Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin-resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med 2018 30106089 Ensembl ENSG00000249395 CASC9 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR The expression of CASC9 in breast cancer tissues and cell lines, in addition to drug-resistant breast cancer cells (MCF-7/DOX), was detected by reverse transcription-quantitative polymerase chain reaction. Subsequently, MCF-7/DOX cells were transfected with the silencing vector pS-CASC9, containing enhancer of zeste homolog 2 (EZH2), multidrug resistance protein 1 (MDR1) or control small interfering (si)RNAs. The viability, apoptosis, migration and invasion of the transfected cells were assessed via an MTT assay, flow cytometry and a Transwell assay, respectively. The expression levels of apoptosis-associated proteins (apoptosis regulator Bcl-2, apoptosis regulator BAX, caspase-3 and caspase-9) were determined by western blotting. An RNA pull-down assay was performed to identify CASC9-binding candidates. In addition, the expression levels of the MDR1 gene and its encoded protein, P-glycoprotein, were detected. cell line (MCF-7/DOX) up-regulated resistant NA NA NA validated 3753 Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother 2018 30119236 Ensembl ENSG00000214548 MEG3 lncRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR In the present study, we aimed to identify the role of MEG3 in oxaliplatin-resistant colorectal cancer (CRC) and its potential mechanisms. MEG3 was down-regulated in oxaliplatin-resistant CRC tissues and cell lines. Low MEG3 expression was correlated with poor prognosis of CRC patients. Overexpression of MEG3 improved oxaliplatin sensitivity of HT29/OXA and HCT116/OXA cells. MEG3 suppressed miR-141 expression in HCT116/OXA cells. Moreover, MEG3 elevated PDCD4 expression through targeting miR-141, acting as a competing endogenous RNA (ceRNA). miR-141 inhibition or PDCD4 up-regulation could mimic the functional role in oxaliplatin resistance, which was counteracted by overexpression of MEG3. cell line (NCM460,(SW480, HT29, HCT116,HT29/OXA and HCT116/OXA) up-regulated sensitive miR-141 PDCD4 NA validated 3754 Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother 2018 30119255 Ensembl ENSG00000197989 SNHG12 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR In present study, we explored the function and underlying mechanism of SNHG12 on doxorubicin resistance in osteosarcoma. High expression of SNHG12 was associated with doxorubicin resistance and a poor overall survival in osteosarcoma. Furthermore, doxorubicin-resistant cells revealed a higher expression of SNHG12 compared with doxorubicin-sensitive cells. Moreover, dual luciferase reporter and RNA immunoprecipitation assays revealed that miR-320a targeted to SNHG12. Besides, knockdown of SNHG12 contributed to the upregulation of miR-320a and improved the sensitivity of doxorubicin. Additionally, miR-320a inhibited the expression of Myeloid cell leukemia 1 (MCL1). Finally, the results indicated that SNHG12 mediated doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. cell lines (MG-63, U2OS, HOS,SAOS-2, hFOB) up-regulated resistant miR-320a MCL1 NA validated 3755 lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141 Cell Commun Signal 2018 30119680 Ensembl ENST000004977918 KRAL lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma qRT-PCR Cell proliferation assays, western blot analysis, qRT-PCR, the dual-luciferase reporter assay and RNA immunoprecipitation were performed to investigate the mechanisms by which KRAL mediates 5-fluorouracil resistance in HCC cell lines. cell line (HepG2,SMMC-7721) up-regulated sensitive NA NA Nrf2 signaling pathway validated 3756 Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14. Cell Physiol Biochem 2018 30121664 RefSeq NR_024092.1 LINC00515 lncRNA DB01042 (APRD00118) Melphalan multiple myeloma RT-PCR Plasmids that could interfere with the expression of linc00515 and ATG14 were loaded into myeloma cells, which were cultured with melphalan. MTT assay and flow cytometry analysis were utilized to investigate the effect of linc00515, miR-140-5p and ATG14 on the resistance of myeloma cells. QRT-PCR was used to determine the levels of mRNAs. Western blot was utilized to explore the level of ATG14 and autophagy-related proteins. Dual luciferase assay was utilized to explore the targeting relationship between linc00515, miR-140-5p and ATG14. GFP LC3 fluorescence assay was conducted to study the autophagy of cells. cell line (LP1 and KMS11) up-regulated resistant miR-140-5p ATG14 NA validated 3757 LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. Biosci Rep 2018 30126852 RefSeq NR_026860.1 LINC00473 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol colorectal cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . TUNEL staining was used to detect apoptotic cell death. Tumor model was used to test the role of LINC00473 and miR-15a . tissue and cell line( HCT116,HCT116/ Taxol, SW620 and LoVo) down-regulated sensitive miR-15a NA NA validated 3758 The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells. Mol Cancer 2018 30153828 Ensembl ENSG00000245532 NEAT1 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of lncRNA NEAT1 in chronic myeloid leukemia cells was detected using RNA-seq data analysis, qRT-PCR and ChIP assay, etc. cell line down-regulated sensitive NA NA NA validated 3759 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 Ensembl ENSG00000235026 DPP10-AS1 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 3760 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 Ensembl NA G058502 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 3761 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 RefSeq NR_027378.1 UG0898H09 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) up-regulated resistant NA NA NA predicted 3762 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 Ensembl NA G090385 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 3763 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 Ensembl ENSG00000235899 LINC01564 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 3764 Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles Zhonghua Nan Ke Xue 2018 30156069 Ensembl ENSG00000259277 RP13-126C7.1 lncRNA DB08899 (DB05094) Enzalutamide prostate cancer PCR Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 umol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray. cell line (LNCAP, C4-2B,LNCAP-ENZA, C4-2B-ENZA) down-regulated resistant NA NA NA predicted 3765 SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res 2018 30157918 Ensembl ENSG00000255737 AGAP2-AS1 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-qPCR Trastuzumab-resistant SKBR-3 and BT474 cells were obtained by continuous culture with 5 mg/mL trastuzumab for 6 months. RT-qPCR assay was used to determine the expression of AGAP2-AS1 in tissues and cells. RNA fluorescence in situ hybridization was used to investigate the subcellular location of AGAP2-AS1 in breast cancer cells. Bioinformatic analysis, chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), western blotting, and immunofluorescence were carried out to verify the regulatory interaction of AGAP2-AS1, CREB-binding protein (CBP), and MyD88. In addition, a series of in vitro assays and a xenograft tumor model were used to analyze the functions of AGAP2-AS1 in breast cancer cells. cell line (SKBR-3 and BT474) up-regulated resistant MyD88 MyD88 NF-kappaB pathway validated 3766 Long non-coding RNA 00607 as a tumor suppressor by modulating NF-kappaB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis 2018 30169594 Ensembl ENSG00000235770 LINC00607 lncRNA NA Interferon-alpha hepatocellular carcinoma Real-time RT-PCR The role of lncRNA 00607 in hepatocellular carcinoma cells was detected using western blot, Real-time RT-PCR analysis, proliferation assay, RNA FISH analysis, Xenograft tumor growth in nude mice, ChIP assay, etc. tissue and cell line (MHCC97H, HCCLM3, PLC, Hep3B, HepG2 and 7721 ) up-regulated sensitive NA NA NF-kappaB p65/p53 signaling validated 3767 Long non-coding RNA 00607 as a tumor suppressor by modulating NF-kappaB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis 2018 30169594 Ensembl ENSG00000235770 LINC00607 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil hepatocellular carcinoma Real-time RT-PCR The role of lncRNA 00607 in hepatocellular carcinoma cells was detected using western blot, Real-time RT-PCR analysis, proliferation assay, RNA FISH analysis, Xenograft tumor growth in nude mice, ChIP assay, etc. tissue and cell line (MHCC97H, HCCLM3, PLC, Hep3B, HepG2 and 7721 ) up-regulated sensitive NA NA NF-kappaB p65/p53 signaling validated 3768 Long non-coding RNA 00607 as a tumor suppressor by modulating NF-kappaB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis 2018 30169594 Ensembl ENSG00000235770 LINC00607 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin hepatocellular carcinoma Real-time RT-PCR The role of lncRNA 00607 in hepatocellular carcinoma cells was detected using western blot, Real-time RT-PCR analysis, proliferation assay, RNA FISH analysis, Xenograft tumor growth in nude mice, ChIP assay, etc. tissue and cell line (MHCC97H, HCCLM3, PLC, Hep3B, HepG2 and 7721 ) up-regulated sensitive NA NA NF-kappaB p65/p53 signaling validated 3769 Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation. Biochem Biophys Res Commun 2018 30173893 Ensembl ENSG00000214548 MEG3 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung cancer qPCR 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were performed to determine cell proliferation. Quantitative polymerase chain reaction was used to determine the levels of MEG3 expressions. Western blot and immunofluorescence were used to detect protein levels. Small interfering RNA or pCDNA-MEG3 transfection was used to downregulate or upregulate MEG3 expression. Dichlorof luorescein diacetate was used to detect intracellular reactive oxygen species. Flow cytometry was used to analyze apoptosis. cell line (A549) up-regulated sensitive NA NA MEG3-P53 pathway validated 3770 The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a. Mol Ther Nucleic Acids 2018 30195778 Ensembl NA D63785 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin stomach cancer RT-qPCR The expression levels of lncRNA were determined by Real-Time qPCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. Cell migration was detected by transwell migration .Human tumor-bearing nude mice was used to test the role of D63785 and miR-422a . tissue and cell lines (GES-1, SGC7901, MGC803, BGC823, NCI-N87,HEK293 and HEK293T) down-regulated sensitive miR-422a MEF2D miR-422a-MEF2D signaling pathway validated 3771 Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol 2018 30244121 Ensembl ENSG00000130600 H19 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer qRT-PCR The role of H19 in triple-negative breast cancer cells was detected using qRT-PCR, MTT assay, apoptosis analysis, western blot and immunohistochemistry, etc. cell line (MDA-MB-453, MDA-MB-157, MDA-MB-231,Hs578Bst, MCF-10A,MDA-MB-231/PTX) down-regulated sensitive NA NA AKT pathway validated 3772 Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways. Int J Oncol 2018 30272271 Ensembl ENSG00000214049 CUDR lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil pancreatic ductal adenocarcinoma RT-qPCR The role of CUDR in pancreatic ductal adenocarcinoma cells was detected using RT-qPCR, LncRNA microarrays and analysis, MTT proliferation assay, wound-healing assay, Transwell migration and invasion assays, Cell cycle and apoptosis analyses, immunofluorescence analyses, western blotting and subcutaneous xenograft transplantation, etc. tissue and cell line ( Panc-1 ) up-regulated resistant NA NA AKT and ERK pathway validated 3773 ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer. Biosci Rep 2018 30279206 Ensembl ENSG00000240498 ANRIL lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR The expression levels of lncRNA were determined by qRT-PCR . Luciferase activity assay was used to verify the target genes of ncRNAs. The CCK-8 assay was used to monitor the growth of the cells .Transwell was selected to test the invasive ability of the cells . A wound healing assay was performed to examine the capacity of cell migration. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line (LOVO, HCT116, HT29, RKO, SW480 ) up-regulated resistant Let-7a NA NA validated 3774 Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Mol Oncol 2018 30341811 Ensembl ENSG00000249859 PVT1 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The role of PVT1 and miR1207 in pancreatic cancer cells was detected using qRT-PCR, cell proliferation, apoptosis and cell cycle analysis, PC cell Xengrafted tumor mouse model, etc. cell line (293T,MIA PaCa-2, Su.86.86, Capan-1, PANC-1, SW1990, BxPC-3 and AsPC-1) down-regulated sensitive NA NA NA validated 3775 Downregulation of long noncoding RNA PVT1 attenuates paclitaxel resistance in glioma cells. Cancer Biomark 2018 30347597 Ensembl ENSG00000249859 PVT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel glioma qRT-PCR The paclitaxel-resistant glioma cells SHG-44 RE was obtained through screening the SHG 44 cells that were cultured in medium containing a certain concentration of paclitaxel. Cell survival of SHG 44 RE and SHG 44 cells under the treatment of paclitaxel was detected by MTT assay. The aberrant expressed lncRNAs were screened out with microarray analysis. Further qRT-PCR was utilized to validate the expression of lncRNA PVT1 in the two cells. After manipulating the expression of PVT1, cell viability and apoptosis were measured by MTT and flow cytometry respectively. cell line (SHG-44,SHG-44 RE) down-regulated sensitive NA NA NA validated 3776 LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Biochem Biophys Res Commun 2018 30366670 Ensembl ENSG00000251562 MALAT1 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR Recombinant virus construction and infection was performed to overexpress or knockdown the expression of MALAT1. Dual luciferase reporter assay was applied to vetify the interaction between MALAT1 and miR-328. The cell viability and cell cycle were analyzed by CCK-8 assay and flow cytometry, respectively. Quantitative real time PCR and western blotting assays were used to measure the expression of genes and proteins. cell line (K562 and KG-1) down-regulated sensitive miR-328 NA NA validated 3777 Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother 2018 30372881 Ensembl ENSG00000177640 CASC2 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time PCR (qRT-PCR) . Fuciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. tissue and cell line ( BGC823, SGC7901,BGC823/DDP and SGC7901/DDP) down-regulated resistant miR-19a CASC2 NA validated 3778 Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int 2018 30377411 Ensembl ENSG00000214049 UCA1 lncRNA DB00002 (BTD00071, BIOD00071) Cetuximab colorectal cancer qRT-PCR First, acquired cetuximab-resistant cell lines were generated, and UCA1 expressions in these cells and their exosomes were compared. We also systematically evaluate the stability of exosomal UCA1. Thereafter, the predictive value of exosomal UCA1 in CRC patients treated with cetuximab was evaluated. Finally, through cell apoptosis assays and immunofluorescence staining, we analyzed the role of UCA1-containing exosomes in conferring cetuximab resistance. cell line (Caco2,Caco2-CS,Caco2-CR) up-regulated resistant NA NA NA validated 3779 lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer. Mol Ther Nucleic Acids 2018 30388621 Ensembl ENSG00000234741 GAS5 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer RT-PCR The expression levels of lncRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. cell line (HPDE6-C7,PANC-1, AsPC-1, Capan-2, SW1990, and BXPC-3 ) up-regulated sensitive miR-221 SOCS3 miR-221/SOCS3 pathway validated 3780 Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. Cancer Med 2018 30430771 Ensembl ENSG00000130600 H19 lncRNA DB00515 (APRD00359) Cisplatin seminoma qRT-PCR In this study, using microarray analysis, we found that long non-coding RNA H19 was upregulated while miRNA-106b-5p was downregulated in an established cisplatin-resistant TCam-2 cell line. Moreover, H19 acts as a miRNA-106b-5p sponge and thus impairs the function of miRNA-106b-5p on its target gene, TDRG1. Based on these findings, we propose that H19 promotes the expression of TDRG1 by sequestering miRNA-106b-5p and uses this mechanism to facilitate cell survival in cisplatin-based chemotherapeutic conditions. tissue and cell line ( TCam-2) up-regulated resistant miRNA-106b-5p TDRG1 PI3K/Akt/mTOR signaling pathway validated 3781 Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1. Cell Physiol Biochem 2018 30439718 Ensembl ENSG00000229807 XIST lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin colorectal cancer qRT-PCR The expressions of XIST, miR-124, serum and glucocorticoid-inducible kinase 1 (SGK1) mRNA in DOX-resistant CRC tissues and cells were detected by qRT-PCR or western blot analysis. DOX sensitivity was assessed by detecting IC50 value of DOX, the protein levels of P-glycoprotein (P-gp) and glutathione S-transferase-Pi (GST-Pi) and apoptosis. The interactions between XIST, miR-124 and SGK1 were confirmed by luciferase reporter assay, qRT-PCR and western blot. Xenograft tumor assay was used to verify the role of XIST in DOX resistance in CRC in vivo. tissue and cell line (HCT116,LoVo) down-regulated resistant miR-124 SGK1 NA validated 3782 Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway. J Cell Biochem 2018 30444026 Ensembl ENSG00000088340 FER1L4 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel ovarian cancer qRT-PCR In the study, we examined the expression level of FER1L4 in human ovarian epithelial cell lines IOSE80 and HOSEpiC and human ovarian cancer cell lines OVCAR-3, Caov-3, and SKOV3 through RNA isolation and quantitative polymerase chain reaction (qRT-PCR). SKOV3 cell lines were treated with PTX. The cell survival rate and apoptosis rate of SKOV3 and SKOV3-PR at different PTX dose levels were evaluated. Next, qRT-PCR was performed to detect the expression of FER1L4 in SKOV3 and SKOV3-PR cell lines. SKOV3-PR cell lines were transfected with pcDNA3.1 as the control group (SKOV3-PR/pcDNA3.1) or pcDNA3.1-FER1L4 to upregulate the expression level of FER1L4 (SKOV3-PR/pcDNA3.1-FER1L4). The level of cell survival, apoptosis, and colony formation were compared between the two groups using MTT, flow cytometry analysis, and colony formation assay. To reveal the molecular mechanism, we measured the relative protein phosphorylation level of ERK and MAPK in SKOV3, SKOV3-PR, SKOV3-PR/pcDNA3.1, and SKOV3-PR/pcDNA3.1-FER1L4 groups using an enzyme-linked immunosorbent assay. The effects of SB203580 (a p38 MAPK inhibitor) on PTX were also investigated to reveal the function of the MAPK pathway on the PTX tolerance of SKOV3. cell line (SKOV3,SKOV3-PR) up-regulated sensitive NA NA MAPK signaling pathway validated 3783 Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis. Cell Physiol Biochem 2018 30466095 Ensembl ENSG00000253552 Hoxa-AS2 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR Quantitative real-time PCR was used to detect HOXA-AS2 expression in the BM samples and ADR cell lines, U/A and T/A cells. Furthermore, the effects of HOXA-AS2 silencing on cell proliferation and apoptosis were assessed in vitro by CCK8 and flow cytometry, and on tumor growth in vivo. Furthermore, bioinformatics online programs predicted and luciferase reporter assay were used to validate the association of HOXA-AS2 and miR-520c-3p in AML. cell line (U937 and THP-1) up-regulated resistant iR-520c-3p S100A4 miR-520c3p/S100A4 pathway validated 3784 Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. Cell Physiol Biochem 2018 30481766 LNCipedia linc-LEPROTL1-6 XLOC_006753 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The expression levels of XLOC_006753 in GC patients and MDR GC cell lines (SGC-7901/5-FU and SGC-7901/DDP cell line) were assessed by qRT-PCR. Statistical analyses were conducted to determine the relationship between XLOC_006753 expression and clinical features and to assess the prognostic value of XLOC_006753 for overall survival and progression-free survival. Then, a CCK-8 assay was used to detect cell proliferation ability and chemosensitivity. Flow cytometry was used to detect cell cycle and cell apoptosis. A wound-healing assay and transwell assay were used to detect cell migration. The expression of markers for MDR, G1/S transition, epithelial-mesenchymal transition (EMT) and PI3K/ AKT/mTOR signaling pathway were examined by western blot. cell line (SGC-7901/5-FU and SGC-7901/DDP) up-regulated resistant NA NA PI3K/AKT/mTOR Signaling Pathway validated 3785 Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. Cell Physiol Biochem 2018 30481766 LNCipedia linc-LEPROTL1-6 XLOC_006753 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR The expression levels of XLOC_006753 in GC patients and MDR GC cell lines (SGC-7901/5-FU and SGC-7901/DDP cell line) were assessed by qRT-PCR. Statistical analyses were conducted to determine the relationship between XLOC_006753 expression and clinical features and to assess the prognostic value of XLOC_006753 for overall survival and progression-free survival. Then, a CCK-8 assay was used to detect cell proliferation ability and chemosensitivity. Flow cytometry was used to detect cell cycle and cell apoptosis. A wound-healing assay and transwell assay were used to detect cell migration. The expression of markers for MDR, G1/S transition, epithelial-mesenchymal transition (EMT) and PI3K/ AKT/mTOR signaling pathway were examined by western blot. cell line (SGC-7901/5-FU and SGC-7901/DDP) up-regulated resistant NA NA PI3K/AKT/mTOR Signaling Pathway validated 3786 Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cell Physiol Biochem 2018 30497079 Ensembl ENSG00000130600 H19 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer NA Here we utilized established ETR cell models; the Tamoxifen (Tam)-resistant LCC2 and the Fulvestrant and Tam cross-resistant LCC9 cells. Gain and loss of H19 function were achieved through lentiviral transduction as well as pharmacological inhibitors of the Notch and c-Met receptor signaling pathways. The effects of altered H19 expression on cell viability and ETR were assessed using three-dimensional (3D) organoid cultures and 2D co-cultures with low passage tumour-associated fbroblasts (TAFs). cell line ( LCC2,LCC9, T-47D ) down-regulated sensitive NA NA NA validated 3787 Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cell Physiol Biochem 2018 30497079 Ensembl ENSG00000130600 H19 lncRNA DB00947 (APRD00654) Fulvestrant breast cancer NA Here we utilized established ETR cell models; the Tamoxifen (Tam)-resistant LCC2 and the Fulvestrant and Tam cross-resistant LCC9 cells. Gain and loss of H19 function were achieved through lentiviral transduction as well as pharmacological inhibitors of the Notch and c-Met receptor signaling pathways. The effects of altered H19 expression on cell viability and ETR were assessed using three-dimensional (3D) organoid cultures and 2D co-cultures with low passage tumour-associated fbroblasts (TAFs). cell line ( LCC2,LCC9, T-47D ) down-regulated sensitive NA NA NA validated 3788 Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. Onco Targets Ther 2018 30519041 Ensembl ENSG00000130600 H19 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qPCR Quantitative polymerase chain reaction (qPCR) was utilized for comparison of lncRNA H19 expression level in breast cancers with different stages. qPCR and Western blotting were used to detect gene and protein, respectively. tissue and cell line (MCF-7, SK-BR-3,MCF-7-R, SK-BR-3-R) down-regulated sensitive NA NA Wnt pathway validated 3789 CX-3543 Promotes Cell Apoptosis through Downregulation of CCAT1 in Colon Cancer Cells. Biomed Res Int 2018 30519593 RefSeq NR_108049.1 CCAT1 lncRNA DB06638 CX-3543 colon cancer RT-qPCR Semiquantitative PCR was used to detect the relative expression of CCAT1 in colon cancer (CC) tissues and HT29 cell lines. Real-time PCR (RT-PCR) was also used to investigate the expression of CCAT1 and c-Myc after HT29 cells being treated by CX3543 for 24 h. Cell apoptosis assay and cell proliferation assay were conducted in HT29 cells after being treated by CX3543. tissue and cell line (HT29 ) down-regulated sensitive NA NA NA validated 3790 LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Med Sci Monit 2018 30521500 Ensembl ENSG00000222005 LINC01118 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel epithelial ovarian cancer RT-PCR We analyzed aberrantly expressed lncRNAs in chemoresistant EOC cells by microarray and confirmed LINC01118 expression by real-time PCR. The paclitaxel sensitivity alternation was analyzed by MTS, flow cytometry, and Transwell assay, while wound healing assays were performed to assess apoptosis, migration, and invasion in vitro. The interaction between LINC01118 and miR-134 was confirmed by luciferase assay. tissue and cell line (SKOV3-TR30, SKOV3-TR30, A2780,SKOV3-DDP, COC1/DDP) up-regulated resistant miR-134 ABCC1 NA validated 3791 Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer. Oncol Rep 2018 30542738 Ensembl ENSG00000130600 H19 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR The role of H19 in non-small cell lung cancer cells was detected using Transmission electron microscopy, RT-qPCR,TUNEL assay, CCK-8 assay and western blotting, etc. cell line (HCC827 and HCC4006) down-regulated sensitive NA NA NA validated 3792 MEG3 affects the progression and chemoresistance of T-cell lymphoblastic lymphoma by suppressing epithelial-mesenchymal transition via the PI3K/mTOR pathway. J Cell Biochem 2018 30556337 Ensembl ENSG00000214548 MEG3 lncRNA DB00515 (APRD00359) Cisplatin precursor T-lymphoblastic lymphoma/leukemia qRT-PCR The role of MEG3 in T-cell lymphoblastic lymphoma cells was detected using quantitative real-time PCR, wound healing assay, invasion and migration assays, western blot analysis and Jurkat cells xenograft model, etc. cell line (Jurkat and SUP-T1) up-regulated sensitive NA NA PI3K/mTOR pathway validated 3793 MEG3 affects the progression and chemoresistance of T-cell lymphoblastic lymphoma by suppressing epithelial-mesenchymal transition via the PI3K/mTOR pathway. J Cell Biochem 2018 30556337 Ensembl ENSG00000214548 MEG3 lncRNA DB00531 (APRD00408) Cyclophosphamide precursor T-lymphoblastic lymphoma/leukemia qRT-PCR The role of MEG3 in T-cell lymphoblastic lymphoma cells was detected using quantitative real-time PCR, wound healing assay, invasion and migration assays, western blot analysis and Jurkat cells xenograft model, etc. cell line (Jurkat and SUP-T1) up-regulated sensitive NA NA PI3K/mTOR pathway validated 3794 H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR. Ann Transl Med 2018 30596070 Ensembl ENSG00000228630 HOTAIR lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung small cell carcinoma qRT-PCR The levels of EZH2 and H3K27me3 were identified in SCLC tissues by immunohistochemical (IHC) staining and in SCLC multidrug-resistant cells by Western blotting. Cell counting kit-8 (CCK-8) and flow cytometry were used to detect and analyze the biological function of H3K27me3. Then, we assessed the role of HOTAIR in the regulation of EZH2 and H3K27me3 by using lentivirus and small interfering RNA. Further, bisulfite sequencing PCR was conducted to detect the methylation levels of HOXA1 DNA. Finally, Western blotting was performed to examine the regulatory role of H3K27me3 in controlling HOTAIR expression in SCLC. cell line (NCI-H69, NCI-H446,NCI-H69AR ) up-regulated resistant NA NA NA validated 3795 H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR. Ann Transl Med 2018 30596070 Ensembl ENSG00000228630 HOTAIR lncRNA DB00515 (APRD00359) Cisplatin lung small cell carcinoma qRT-PCR The levels of EZH2 and H3K27me3 were identified in SCLC tissues by immunohistochemical (IHC) staining and in SCLC multidrug-resistant cells by Western blotting. Cell counting kit-8 (CCK-8) and flow cytometry were used to detect and analyze the biological function of H3K27me3. Then, we assessed the role of HOTAIR in the regulation of EZH2 and H3K27me3 by using lentivirus and small interfering RNA. Further, bisulfite sequencing PCR was conducted to detect the methylation levels of HOXA1 DNA. Finally, Western blotting was performed to examine the regulatory role of H3K27me3 in controlling HOTAIR expression in SCLC. cell line (NCI-H69, NCI-H446,NCI-H69AR ) up-regulated resistant NA NA NA validated 3796 H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the lncRNA HOTAIR. Ann Transl Med 2018 30596070 Ensembl ENSG00000228630 HOTAIR lncRNA DB00773 (APRD00239) Etoposide lung small cell carcinoma qRT-PCR The levels of EZH2 and H3K27me3 were identified in SCLC tissues by immunohistochemical (IHC) staining and in SCLC multidrug-resistant cells by Western blotting. Cell counting kit-8 (CCK-8) and flow cytometry were used to detect and analyze the biological function of H3K27me3. Then, we assessed the role of HOTAIR in the regulation of EZH2 and H3K27me3 by using lentivirus and small interfering RNA. Further, bisulfite sequencing PCR was conducted to detect the methylation levels of HOXA1 DNA. Finally, Western blotting was performed to examine the regulatory role of H3K27me3 in controlling HOTAIR expression in SCLC. cell line (NCI-H69, NCI-H446,NCI-H69AR ) up-regulated resistant NA NA NA validated 3797 Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel. Arch Biochem Biophys 2019 29373811 Ensembl ENSG00000177640 CASC2 lncRNA DB01248 (APRD00932) Docetaxel prostate cancer RT-PCR The expression levels of lncRNA were determined by Real-time PCR . Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. cell line (LNCap and PC-3) up-regulated sensitive miR-183 NA RTK signaling pathway validated 3798 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl ENST00000412153 NRAL lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) up-regulated resistant miR-340-5p Nrf2 NRAL/miR-340-5p/Nrf2 validated 3799 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 LNCipedia lnc-NR2F1-2:1 XLOC_004474 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) up-regulated resistant NA NA NA predicted 3800 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 GenBank AL590303.1 AL590303.1 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) up-regulated resistant NA NA NA predicted 3801 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 LNCipedia LINC01979:5 LOC101928766 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) up-regulated resistant NA NA NA predicted 3802 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl ENSG00000232685 LINC00442 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) up-regulated resistant NA NA NA predicted 3803 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl ENST00000497718 C3P1-202 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) down-regulated resistant NA NA NA predicted 3804 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl ENST00000370341.3 bA305P22.4 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) down-regulated resistant NA NA NA predicted 3805 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl NA RP5-837M10.4 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) down-regulated resistant NA NA NA predicted 3806 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 Ensembl NA AP001469.9 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) down-regulated resistant NA NA NA predicted 3807 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 2019 30030687 GenBank AC144835.1 AC144835.1 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The role of NRAL in hepatocellular carcinoma cells was detected using microarray assay, qRT-PCR, dual-luciferase reporter assay, RIP assay, CCK-8 assay, apoptosis assay and western blot analysis, etc. cell line (SMMC-7721,HepG2, HepG2/CDDP,SMMC-7721/CDDP,Huh7/CDDP) down-regulated resistant NA NA NA predicted 3808 The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. J Cell Biochem 2019 30216500 Ensembl ENSG00000258667 HIF1A-AS2 lncRNA DB00515 (APRD00359) Cisplatin bladder cancer qRT-PCR The role of HIF1A-AS2 in bladder cancer cells was detected using quantitative real-time polymerase chain reaction, MTT assay, apoptosis analysis, chromatin immunoprecipitation and coimmunoprecipitation, etc. cell line (T24, 5637, and SW780) up-regulated resistant Bax,HMGA1 Bax,HMGA1 NA validated 3809 Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. J Cell Physiol 2019 30221354 RefSeq NR_110176 NCK1-AS1 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer RT-qPCR The role of NCK1-AS1 in cervical cancer cells was detected using dual-luciferase reporter gene assay, RNA pull-down assay, RNA immunoprecipitation (IP) assay,RT-qPCR, western blot, CCK-8 assay, immunofluorescence assay and flow cytometry,etc. cell line down-regulated sensitive miR-134-5p MSH2 NA validated 3810 Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer. FASEB J 2019 30226808 Ensembl ENSG00000259974 LINC00261 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil esophageal cancer qRT-PCR The role of LINC00261 in esophageal cancer cells was detected using luciferase reporter gene assay, RNA immunoprecipitation, Methylation-specific PCR, Colorimetric water-soluble tetrazolium salt 1 assay, 5-Ethynyl-29-deoxyuridine labeling assay, qRT-PCR and western bolt analysis, etc. cell line (KYSE150, Eca109,TE-1,TE-5) up-regulated sensitive DPYD DPYD NA validated 3811 Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol 2019 30352127 Ensembl ENSG00000234741 GAS5 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression levels of lncRNA were determined by quantitative real-time polymerase chain reaction and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Cell migration was detected by transwell migration and invasion assay.TUNEL staining was used to detect apoptotic cell death. cell line down-regulated resistant miR-21 TIMP3 and PDCD4 STAT3 signaling pathway validated 3812 LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol 2019 30365113 Ensembl ENSG00000251562 MALAT1 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-qPCR The expression levels of lncRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. The CCK-8 assay was used to monitor the growth of the cells. cell line ( HGC-27, 293T, AGS) up-regulated resistant miR?30b ATG5 NA validated 3813 LncRNA BLACAT1 is involved in chemoresistance of non-small cell lung cancer cells by regulating autophagy. Int J Oncol 2019 30387831 LNCipedia BLACAT1:9 BLACAT1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The aim of the present study was to determine the effect of the long non-coding RNA (lncRNA) bladder cancer-associated transcript 1 (BLACAT1) in chemoresistance of non-small cell lung cancer (NSCLC) cells. Expression of lncRNA BLACAT1, microRNA (miR)-17, autophagy-related protein 7 (ATG7), multidrug-resistance protein 1 (MRP1), and the autophagy-associated proteins light chain 3 (LC3)-II/LC3-I and Beclin 1 were detected using the reverse transcription-quantitative polymerase chain reaction and western blot analysis. Cell viability was determined using an MTT assay. The interaction between BLACAT1 and miR-17 was determined using RNA immunoprecipitation and RNA pull-down assays. A cisplatin (DDP)-resistant NSCLC cell A549/DDP xenograft model in nude mice was established to investigate the effect of BLACAT1 on the chemoresistance of NSCLC cells cell line (A549, H1299, A549/DDP and H1299/DDP) down-regulated sensitive miR-17 ATG7 miR-17/ATG7 signaling pathway validated 3814 lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene 2019 30391438 Ensembl ENST00000413352.3 lncARSR lncRNA DB00515 (APRD00359) Cisplatin liver cancer RT-PCR The role of lncARSR in liver cancer cells was detected using spheroid formation assay, in vitro limiting dilution assay, in vivo limiting dilution assay, Real-time PCR, western blotting assay, flow-cytometric analysis, apoptosis assay and luciferase reporter assay, etc. cell line (SMMC7721 and HCCLM3) down-regulated sensitive NA NA STAT3 signaling pathway validated 3815 lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene 2019 30391438 Ensembl ENST00000413352.3 lncARSR lncRNA DB00398 (APRD01304, DB07438) Sorafenib liver cancer RT-PCR The role of lncARSR in liver cancer cells was detected using spheroid formation assay, in vitro limiting dilution assay, in vivo limiting dilution assay, Real-time PCR, western blotting assay, flow-cytometric analysis, apoptosis assay and luciferase reporter assay, etc. cell line (SMMC7721 and HCCLM3) down-regulated sensitive NA NA STAT3 signaling pathway validated 3816 Overexpression of lncRNA EGFR-AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non-small cell lung cancer. Int J Oncol 2019 30431074 Ensembl ENSG00000224057 EGFR-AS1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The present study aimed to investigate the effect of lncRNAs on NSCLC resistance to chemotherapy. The relative expression level of epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was quantified by reverse transcription-quantitative polymerase chain reaction analysis in NSCLC tissues, paired adjacent normal tissues, patient plasma and NSCLC cell lines, and its association with prognosis was assessed by multivariate analysis. The biological functions of EGFR-AS1 in NSCLC cells were determined in vitro. It was found that EGFR-AS1 was abnormally upregulated in NSCLC tissues compared with adjacent normal lung tissues. Furthermore, patients with NSCLC with increased expression of EGFR-AS1 had a poor prognosis. EGFR-AS1 knockdown significantly inhibited NSCLC malignancy in vitro, including cell proliferation and chemoresistance. Furthermore, the expression levels of EGFR-AS1 were increased in plasma samples from patients with cisplatin-based chemotherapy resistance. Bioinformatics analysis and a luciferase reporter assay confirmed that EGFR-AS1 mediated cell proliferation and chemoresistance through directly binding to microRNA-223. Therefore, EGFR-AS1 overexpression-induced chemoresistance can contribute to poor prognosis in NSCLC. cell line ( A549, NCI-H460,NCI-H1299, NCI-H358, HCC827, NCI-H292, NCI-H838) up-regulated resistant miR-223 IGF1R IGF1R/AKT/PI3K signaling pathway validated 3817 Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell 2019 30462844 Ensembl ENSG00000183674 Linc00518 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel prostate cancer RT-PCR To characterise Linc00518 expression in prostate cancer and elucidate the potential mechanistic involvement in paclitaxel resistance, the relative expression of Linc00518 and miR-216b-5p was determined by real-time PCR. The regulatory effect of miR-216b-5p on either Linc00518 or GATA6 was interrogated with luciferase reporter assay. The endogenous GATA6 protein was analysed by Western blotting. The cell viability was measured by MTT assay and IC50 of paclitaxel was calculated through cell counting cell line (LNCap, DU145, PC3,DU145/PR and PC3/PR ) up-regulated resistant miR-216b-5p GATA6 NA validated 3818 LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther 2019 30481109 Ensembl ENSG00000147687 TATDN1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression of TATDN1, miR-451 and TRIM66 in NSCLC tissues and cell lines were detected by qRT-PCR or western blot. Immunohistochemistry (IHC) assay was performed for the detection of TATDN1 expression profile. 88 patients who underwent cisplatin treatment were followed up to 60-months for the analysis of survival rate. MTT and Flow cytometry analysis were performed for the assessment of cell survival rate, proliferation and apoptosis. Bioinformatics, Dual-Luciferase reporter were employed to analyze the interaction among TATDN1, miR-451 and TRIM66. Xenograft tumor model was constructed to verify the role of TATDN1 in NSCLC treated with cisplatin (DDP) in vivo. cell line (A549,H157,A549/DDP,H157/DDP) up-regulated resistant miR-451 TRIM66 NA validated 3819 Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATBeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem 2019 30548308 Ensembl ENSG00000247556 OIP5-AS1 lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma qPCR The role of OIP5-AS1 in osteosarcoma cells was detected using qPCR, CCK-8 assays, apoptosis assays, western blot analysis, Tumorigenicity assays in nude mice, Bioinformatics prediction and luciferase reporter assays,etc. cell line (MG63,SaOS2,MG63-CR,SaOS2-CR) up-regulated resistant miR-340-5p LPAATBeta LPAATBeta/PI3K/AKT/mTOR signaling pathway validated 3820 TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. Biomed Pharmacother 2019 30551418 Ensembl ENSG00000253552 HOXA-AS2 lncRNA NA Glucocorticoid acute lymphocytic leukemia qRT-PCR The role of HOXA-AS2 in acute lymphoblastic leukemia cells was detected using quantitative real-time PCR, western blot, chromatin immunoprecipitation assay, Pull-down assay and mass spectrometry, Luciferase reporter assay, CCK-8 assay and cell apoptosis assay,etc. cell line ( CCRF-CEM, Jurkat and CEM/C1) up-regulated resistant HOXA3 HOXA3 HOXA3/EGFR/Ras/Raf/MEK/ERK pathway validated 3821 TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother 2019 30551433 Ensembl ENSG00000253352 TUG1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin acute myeloid leukemia qRT-PCR The expression levels of lncRNA were determined by Fuantitative real-time PCR (qRT-PCR) .Fuciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs.Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic.ChIP experiments were performed using Magna RIP RNA-Binding Protein Immunoprecipitation Kit .Animal experiments was used to test the role of miR-34a and TUG1. tissue and cell line (HS-5, HL60) up-regulated resistant NA NA NA validated 3822 Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. Mol Carcinog 2019 30556928 Ensembl ENSG00000226935 Linc00161 lncRNA DB00515 (APRD00359) Cisplatin ovarian cancer qRT-PCR the differentially expressed lncRNAs were screened based on microarray analysis. The expression of linc00161, miR-128 and MAPK1 in ovarian cancer-resistant tissues and cells was tested qRT-PCR, whereas MAPK1 protein expression was examined via western blot in the ovarian cancer resistant cells. The targeted relationship between miR-128 and linc00161 as well as the relationship between miR-128 and MAPK1 were testified by Dual luciferase gene reporter assay. The influence of miR-128 and MAPK1 on the proliferation of ovarian cancer-resistant cells was demonstrated by CCK-8 and colony formation assay. The effect of linc00161 on ovarian cancer was demonstrated by xenograft tumor model in vivo. tissue and cell line ( SKOV3, SKOV3/DDP,CoC1,CoC1/DDP ) up-regulated resistant miR-128 MAPK1 MAPK signaling pathway validated 3823 Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p. DNA Cell Biol 2019 30601026 Ensembl ENSG00000233532 LINC00460 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined byquantitative PCR and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. The CCK-8 assay was used to monitor the growth of the cells . Cell migration was detected by invasion assay. Tumor xenograft in vivo model was used to the role of ncRNA . tissue and cell line (H460, A549, SK-MES-1, H1299 ) up-regulated resistant miR-769-5p EGFR NA validated 3824 Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract 2019 30606658 Ensembl ENSG00000147852 linc-VLDLR lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin esophageal cancer qRT-PCR The expression of linc-VLDLR and ABCG2 mRNA in 60 cases of esophageal carcinoma tissue, para-carcinoma tissue and the normal esophagus tissue were detected using Fluorescence quantitative reverse transcription polymerase chain reaction (qRT-PCR). Fifty percent inhibiting concentration (IC50) of adriamycin (ADM) to Eca109 cells was detected by MTT assay, after the treatment of different concentrations of adriamycin (ADM) on esophageal squamous cell carcinoma Eca109 cell line for 24h. EVs were extracted from culture medium after the treatment of three concentrations of ADM (setting based on the IC50) on Eca109 cells for 24h. Linc-VLDLR expression in EVs was detected by qRT-PCR. After the treatment of the extracted EVs on virgin Eca109 cells for 48h, then intervening these cells for 24h by different concentrations of ADM, the new values of IC50 were detected by MTT assay. Cell cycle, cell apoptosis and ABCG2 protein expression of these Eca109 cells were detected by flow cytometry (FCM). Linc-VLDLR and ABCG2 mRNA expression in these Eca109 cells were detected by qRT-PCR. cell line (Eca109) up-regulated resistant NA NA NA validated 3825 Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer Mol Cancer 2019 30621694 Ensembl ENSG00000223573 TINCR lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR Trastuzumab-resistant SKBR-3-TR and BT474-TR cell lines were established by grafting SKBR-3 and BT474 cells into mouse models and subjected to trastuzumab treatment. LncRNA microarray followed by quantitative reverse transcription PCR (qRT-PCR) was carried out to verify the differentially expressed lncRNAs. Western blotting, bioinformatics analysis, immunofluorescence assay and immunoprecipitation assays (ChIP and RIP) were performed to identify the involvement and functional interactions between H3K27 acetylation and terminal differentiation-induced non-coding RNA (TINCR) or between TINCR and its downstream genes including miR-125b, HER-2 and Snail-1. In addition, a series of in vitro and in vivo assays were performed to assess the functions of TINCR. cell line (SKBR-3, BT474,MCF-10A) up-regulated resistant NA Snail-1 miR-125b-HER-2/Snail-1 pathway validated 3826 Long non-coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol 2019 30628639 Ensembl ENSG00000214049 UCA1 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer RT-PCR,RT-qPCR The role of UCA1 in breast cancer cells was detected using RT-PCR, WST-1 assay, flow cytometry for cell cycle and apoptosis analysis, RNA immunoprecipitation (RIP) assay, chromatin immunoprecipitation (ChIP) assay and western blot, etc. cell line (MCF-7,T47D,LCC2, LCC9) up-regulated resistant p21 p21 PI3K/AKT signaling pathway validated 3827 Ginsenoside Rg3 inhibits cell growth, migration and invasion in Caco-2 cells by downregulation of lncRNA CCAT1. Exp Mol Pathol 2019 30633886 RefSeq NR_108049.1 CCAT1 lncRNA NA Ginsenoside Rg3 colorectal cancer qRT-PCR CRC tissue was obtained from hospital and Caco-2 cells were purchased. Caco-2 cells were treated with Rg3 and/or transfected with pc- CCAT1 or pcDNA3.1. The group without Rg3 treatment was treated as control. Cell viability, cell apoptosis, cell migration and invasion were detected by Cell Counting Kit-8 assay, flow cytometry and Transwell chamber migration/invasion assay, respectively. The expression of CyclinD1, apoptosis related proteins (p53, Bcl-2, Bax, pro-/Cleaved-Caspase-3), migration and invasion related proteins (MMP-9 and vimentin), and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) related proteins (p/t-PI3K, p/t-AKT) were examined by western blot. The expression of CCAT1 was measured by quantitative real time RCR (qRT-PCR). cell line (Caco-2) down-regulated sensitive NA NA PI3K/AKT signal pathway validated 3828 Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem Biophys Res Commun 2019 30638658 Ensembl NA FAM84B-AS lncRNA DB12257 Platinum stomach cancer qRT-PCR (1) The expression of FAM84B-AS was detected in samples from 228 cases of fresh gastric cancer to analyze its association with clinical data and gastric cancer prognosis. (2) An lncRNA interference cell line model was established and used to study the effects of FAM84B-AS on the malignant biological behaviors of gastric cancer cells and platinum drug resistance at the cellular level. (3) The mechanisms underlying the effect of FAM84B-AS on gastric cancer were investigated using Western blotting. cell line (SGC-7901, MGC-803, MKN-45, AGS,HGC-27,NCIN87,BGC-823 and SGC-7901/DDP) up-regulated sensitive NA NA NA validated 3829 PILAR1, a novel prognostic LncRNA, reveals the presence of a unique subtype of lung adenocarcinoma patients with KEAP1 mutations. Gene 2019 30639423 Ensembl ENSG00000233461 PILAR1 lncRNA DB00773 (APRD00239) Etoposide lung adenocarcinoma RT-PCR The role of PILAR1 in lung adenocarcinoma cells was detected using RNA-sequencing analysis, Differential expression and survival analysis,Characterization of PILAR1 structure and normal and tumour expression analysis, knockdown proliferation and colony formation assay, real-time PCR and microarray analysis, pathway and CIBERSORT analysis, etc. tissue and cell line ( A549 and H1437) down-regulated sensitive NA NA NA predicted 3830 Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells. J Cell Biochem 2019 30652341 Ensembl ENSG00000214049 UCA1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The inhibition rate and IC 50 of DDP were detected in A549 and A549/DDP cells by 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide assay. The expression of lncRNA UCA1 was measured in A549 and A549/DDP cells by quantitative real-time polymerase chain reaction. The expressions of N-cadherin, E-cadherin, vimentin, and Snail were detected in A549 and A549/DDP cells by Western blot analysis. cell line (A549,A549/DDP) down-regulated sensitive NA NA NA validated 3831 lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 2019 30661902 Ensembl ENSG00000249859 PVT1 lncRNA DB00441 (APRD00201) Gemcitabine osteosarcoma qRT-PCR We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot. cell line ( MG63,293 T, MG63/DOX) up-regulated resistant miR-152 NA c-MET/PI3K/AKT pathway validated 3832 lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 2019 30661902 Ensembl ENSG00000249859 PVT1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot. cell line ( MG63,293 T, MG63/DOX) up-regulated resistant miR-152 NA c-MET/PI3K/AKT pathway validated 3833 lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 2019 30661902 Ensembl ENSG00000249859 PVT1 lncRNA DB00441 (APRD00201) Gemcitabine osteosarcoma qRT-PCR We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot. cell line (l MG63, 293 T,e MG63/DOX) up-regulated resistant miR-152 NA c-MET/PI3K/AKT pathway validated 3834 Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition. Onco Targets Ther 2019 30666128 Ensembl ENSG00000214049 UCA1 lncRNA DB00877 (APRD00178, DB02439) Rapamycin bladder cancer qRT-PCR Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot. wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed. tissue and cell line (SV-HUC-1, HT-1376, T24, J82, 5637, EJ ) down-regulated resistant miR-582-5p ATG7 NA validated 3835 Long non-coding RNA highly up-regulated in liver cancer promotes epithelial-to-mesenchymal transition process in oral squamous cell carcinoma. J Cell Mol Med 2019 30677230 Ensembl ENSG00000285219 HULC lncRNA DB00515 (APRD00359) Cisplatin oral squamous cell carcinoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis.The CCK-8 assay was used to monitor the growth of the cells. lncRNA microarray was used to test the lncrna expression in different cell lines . Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. A wound healing assay was performed to examine the capacity of cell migration. cell line (SCC9, SCC15, SCC25,CAL27,HOK) down-regulated sensitive NA NA NA validated 3836 Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis. Med Sci Monit 2019 30681073 Ensembl ENSG00000177640 CASC2 lncRNA DB04115 (EXPT00672) Berberine colorectal cancer RT-qPCR Reverse transcription-quantitative PCR (RT-qPCR) was performed to detect the expression levels of lncRNA CASC2 and Bcl-2 mRNA in colorectal cancer cells. MTT assay was performed to evaluate cell viability. Flow cytometry and TUNEL assay were used to analyze the apoptosis of cancer cells. RNA immunoprecipitation (RIP) assay was done to verify the interaction between lncRNA CASC2 and (AU-binding factor 1) AUF1, or AUF1 and B-cell CLL/lymphoma 2 (Bcl-2). cell line (HT29 and HCT116) up-regulated sensitive Bcl-2 Bcl-2 NA validated 3837 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia NA lnc-DNMT1-2:1 lncRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3838 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia lnc-RPLP0-4:1 lnc-RPLP0-4:1 lncRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3839 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia NA lnc-DNMT1-2:1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3840 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia lnc-RPLP0-4:1 lnc-RPLP0-4:1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3841 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia NA lnc-DNMT1-2:1 lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3842 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia lnc-RPLP0-4:1 lnc-RPLP0-4:1 lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3843 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia NA lnc-DNMT1-2:1 lncRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 3844 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 LNCipedia lnc-RPLP0-4:1 lnc-RPLP0-4:1 lncRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 3845 Propofol suppresses proliferation and migration of papillary thyroid cancer cells by down-regulation of lncRNA ANRIL. Exp Mol Pathol 2019 30703346 Ensembl ENSG00000240498 ANRIL lncRNA DB00818 (APRD01201, EXPT02558, DB05893) Propofol papillary thyroid cancer RT-qPCR Human PTC cell lines TPC-1 and IHH-4 were treated by propofol. ANRIL expression vector (pc-ANRIL) was transfected into TPC-1 cells to overexpress the expression of ANRIL. CCK-8, BrdU assay, transwell assay, flow cytometry and Western blot were performed to evaluate cell proliferation, migration and apoptosis. The expression changes of ANRIL were detected by RT-qPCR. cell line (TPC-1 and IHH-4) up-regulated resistant NA NA Wnt/Beta-catenin and NF-kappaB pathway validated 3846 Long non-coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells. Oncol Rep 2019 30720129 RefSeq NR_026774.1 LINC00239 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia RT-qPCR The role of linc00239 in acute myeloid leukaemia cells was detected using RT-qPCR, CCK-8 assay, colony formation on soft agar, CFSE/PI staining, AnnexinV-FITC/PI staining, TUNEL staining and western blotting, etc. cell line (HL-60,KG-1) up-regulated resistant NA NA PI3K/Akt/mTOR pathway validated 3847 Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. J Exp Clin Cancer Res 2019 30728036 Ensembl ENSG00000255874 linc00346 lncRNA DB00441 (APRD00201) Gemcitabine pancreatic cancer qRT-PCR The effects of overexpression and knockdown of LINC00346 on the proliferation, cell cycle progression, apoptosis, and gemcitabine resistance were investigated. Bioinformatic analysis, luciferase reporter assay, and RNA immunoprecipitation assay were performed to search for potential microRNAs (miRs) that can interact with LINC00346. cell lines (PANC-1, MIA PaCa-2, Capan-1, and BxPC-3) up-regulated resistant miR-188-3p BRD4 NA validated 3848 LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis 2019 30728351 Ensembl ENSG00000130600 H19 lncRNA DB00188 (APRD00828, DB07475) Bortezomib multiple myeloma RT-qPCR The expression levels of lncRNA were determined by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. The CCK-8 assay was used to monitor the growth of the cells. Xenograft model in nude mice was used to test the role of ncRNA cell line ( H929, U266, 8226) up-regulated resistant miR-29b-3p MCL-1 NA validated 3849 Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene 2019 30738960 Ensembl ENSG00000177410 ZFAS1 lncRNA DB00515 (APRD00359) Cisplatin cervical cancer qRT-PCR The expression of ZFAS1 in cervical cancer tissues and cell lines was detected by qRT-PCR. The cervical cancer CaSki and the HeLa cell lines were transfected to be divided into Blank, siR-Control, and siR-ZFAS1 groups. MTT, wound-healing, and transwell assays were used to evaluate cell biological function. Cisplatin with different concentrations was used to treat cells in different transfection groups, and MTT assays were used to detect the cell growth inhibition rate and the half-inhibitory concentration (IC50) of cisplatin was measured. Cell apoptosis was determined by flow cytometry. A xenograft mouse model was used to investigate the effects of siR-ZFAS1 on the chemosensitivity to cisplatin. cell line (HaCaT,CaSki, HeLa and C33A) down-regulated sensitive NA NA NA validated 3850 MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 2019 30742067 Ensembl ENSG00000228598 MACC1-AS1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer qRT-PCR The role of MACC1-AS1 in gastric cancer cells was detected using CPT1 activity assay, animal experiments, bioinformatics analysis, MTT assay, qRT-PCR, western blotting, flow cytometric analysis, Sphere-formation assay and dual-luciferase reporter assay, etc. cell line (AGS,MKN45 ) up-regulated resistant miR-145-5p NA NA validated 3851 MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 2019 30742067 Ensembl ENSG00000228598 MACC1-AS1 lncRNA DB00526 (APRD00186) Oxaliplatin stomach cancer qRT-PCR The role of MACC1-AS1 in gastric cancer cells was detected using CPT1 activity assay, animal experiments, bioinformatics analysis, MTT assay, qRT-PCR, western blotting, flow cytometric analysis, Sphere-formation assay and dual-luciferase reporter assay, etc. cell line (AGS,MKN45 ) up-regulated resistant miR-145-5p NA NA validated 3852 Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro. Pathol Res Pract 2019 30777616 Ensembl ENSG00000240498 ANRIL lncRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR The role of ANRIL in osteosarcoma cells was detected using real-time PCR assay, cell proliferation assay, colony formation assay, dual luciferase reporter assay, apoptosis assay and western blot, etc. cell line (MG-63, U2-OS, Saos-2 and 293 T) down-regulated sensitive miR-125a-5p STAT3 NA validated 3853 NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway. J Drug Target 2019 30782035 Ensembl ENSG00000245532 NEAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined by qRT-PCR and those of protein were by Western blot analysis. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. Animal experiments was used to test the role of NEAT1 . cell line (PC-9, H1573, H1299, A549,BE,A549/PTX) down-regulated sensitive NA NA AKT/mTOR pathway validated 3854 Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother 2019 30784927 Ensembl ENSG00000224189 HOXD-AS1 lncRNA DB00515 (APRD00359) Cisplatin glioma qRT-PCR The expression levels of lncRNA were determined by Quantitative real-time PCR (qRT-PCR) . Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of lncRNAs. Cell migration was detected by transwell migration and invasion assay. Flow Cytometric Assay was used to determine if cells were viable, apoptotic, or necrotic. The activities of caspase-3 and caspase-9 in U87 and U251 cells were detected by a colorimetric assay kit . Tumor xenograft formation assay was used to test the role of miR-204 . tissue and cell line (U87, U251,U373 and SNB19) up-regulated resistant miR-204 NA NA validated 3855 Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/Beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res 2019 30791958 Ensembl ENSG00000246430 LINC00968 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR,Northern blot Breast cancer chip GSE26910 was utilized to identify differential expression in LINC00968 and WNT2. The possible relationship among LINC00968, transcriptional repressor HEY and WNT2 was analyzed and then verified. Effects of LINC00968 on activation of the Wnt2/Beta-catenin signaling pathway was also tested. Drug resistance, colony formation, cell migration, invasion ability and cell apoptosis after transfection were also determined. Furthermore, tumor xenograft in nude mice was performed to test tumor growth and weight in vivo. cell line (HEK-293-T,MCF-7,MCF-7/ADM and KPL-4/ADM) up-regulated sensitive HEY1 WNT2 Wnt2/Beta-catenin signaling pathway validated 3856 Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/Beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res 2019 30791958 Ensembl ENSG00000246430 LINC00968 lncRNA DB00541 (APRD00495) Vincristine breast cancer RT-qPCR,Northern blot Breast cancer chip GSE26910 was utilized to identify differential expression in LINC00968 and WNT2. The possible relationship among LINC00968, transcriptional repressor HEY and WNT2 was analyzed and then verified. Effects of LINC00968 on activation of the Wnt2/Beta-catenin signaling pathway was also tested. Drug resistance, colony formation, cell migration, invasion ability and cell apoptosis after transfection were also determined. Furthermore, tumor xenograft in nude mice was performed to test tumor growth and weight in vivo. cell line (HEK-293-T,MCF-7,MCF-7/ADM and KPL-4/ADM) up-regulated sensitive HEY1 WNT2 Wnt2/Beta-catenin signaling pathway validated 3857 Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/Beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res 2019 30791958 Ensembl ENSG00000246430 LINC00968 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer RT-qPCR,Northern blot Breast cancer chip GSE26910 was utilized to identify differential expression in LINC00968 and WNT2. The possible relationship among LINC00968, transcriptional repressor HEY and WNT2 was analyzed and then verified. Effects of LINC00968 on activation of the Wnt2/Beta-catenin signaling pathway was also tested. Drug resistance, colony formation, cell migration, invasion ability and cell apoptosis after transfection were also determined. Furthermore, tumor xenograft in nude mice was performed to test tumor growth and weight in vivo. cell line (HEK-293-T,MCF-7,MCF-7/ADM and KPL-4/ADM) up-regulated sensitive HEY1 WNT2 Wnt2/Beta-catenin signaling pathway validated 3858 Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther 2019 30799935 RefSeq NR_038269.1 GIHCG lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR Expression of GIHCG was detected by quantitative real time polymerase chain reaction (qRT-PCR) in seven CRC cell lines and 110 CRC tissues. Comparison of clinicopathological characteristics in the high GIHCG expression group and the low GIHCG expression group was performed. The overall survival (OS) and progression-free survival (PFS) of the patients were depicted with Kaplan-Meier test and compared with Log-rank test. Univariate and multivariate analyses were carried out to detect the risk factors for poor OS and PFS. In addition, expression of GIHCG was silenced with siRNAs in LoVo cells and overexpressed with pcDNA3.1-GIHCG vector in SW480 cells, respectively. And the Transwell assay, Matrigel assay, colony formation assay and Cell Counting Kit-8 assay (CCK-8) were performed to investigate the role of GIHCG in the migration, invasion and proliferation of CRC cells. Besides, the role of GIHCG in chemoresistance was also detected. cell line (SW620, HT29, HCT8, HCT116, LoVo, SW480, DLD1,LoVo-5-FU-R, SW480-5-FU-R, LoVo-Oxa-R, and SW480-Oxa-R ) up-regulated resistant NA NA NA validated 3859 Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther 2019 30799935 RefSeq NR_038269.1 GIHCG lncRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR Expression of GIHCG was detected by quantitative real time polymerase chain reaction (qRT-PCR) in seven CRC cell lines and 110 CRC tissues. Comparison of clinicopathological characteristics in the high GIHCG expression group and the low GIHCG expression group was performed. The overall survival (OS) and progression-free survival (PFS) of the patients were depicted with Kaplan-Meier test and compared with Log-rank test. Univariate and multivariate analyses were carried out to detect the risk factors for poor OS and PFS. In addition, expression of GIHCG was silenced with siRNAs in LoVo cells and overexpressed with pcDNA3.1-GIHCG vector in SW480 cells, respectively. And the Transwell assay, Matrigel assay, colony formation assay and Cell Counting Kit-8 assay (CCK-8) were performed to investigate the role of GIHCG in the migration, invasion and proliferation of CRC cells. Besides, the role of GIHCG in chemoresistance was also detected. cell line (SW620, HT29, HCT8, HCT116, LoVo, SW480, DLD1,LoVo-5-FU-R, SW480-5-FU-R, LoVo-Oxa-R, and SW480-Oxa-R ) up-regulated resistant NA NA NA validated 3860 Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci 2019 30840279 RefSeq NR_038264.1 ADAMTS9-AS2 lncRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR TAM-resistant BC cell lines were first verified. Subsequently, cell proliferation and apoptosis were detected using cell counting kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine (EdU) assay and flow cytometry, respectively. Protein levels of ABCB1, ABCC1, and ABCG2 in TAM-treated MCF-7 and MCF-7R cells were determined by Western blot. ADAMTS9-AS2 expression in BC tissues, para-cancerous tissues, as well as MCF-7 and MCF-7R cells, was accessed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between ADAMTS9-AS2 expression with pathological grade and tumor size of BC was explored. Chromatin fractionation was conducted to elucidate the subcellular distribution of ADAMTS9-AS2. The binding condition between ADAMTS9-AS2 and microRNA-130a-5p, as well as microRNA-130a-5p and PTEN, was verified by the dual-luciferase reporter gene assay. Furthermore, regulatory effects of ADAMTS9-AS2, microRNA-130a-5p, and PTEN on the proliferation and apoptosis of MCF-7R cells were determined. tissue and cell line ( MCF-7R ) down-regulated sensitive miR-130a-5p PTEN NA validated 3861 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 Ensembl ENSG00000251562 MALAT1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . mice models was used to test the role of miR-197-3p/p120 Catenin Axis .. cell lines (i.e.A549, H1299, H460, SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant miR-197-3p p120-ctn NA validated 3862 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 Ensembl ENSG00000251562 MALAT1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549, H1299, H460, SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant miR-197-3p p120-ctn NA validated 3863 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 Ensembl ENSG00000251562 MALAT1 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549, H1299, H460, SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant miR-197-3p p120-ctn NA validated 3864 LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Mol Cells 2019 30841025 Ensembl ENSG00000251562 MALAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel lung non-small cell carcinoma qRT-PCR The expression levels of lncRNA were determined by quantitative real time-polymerase chain reaction (qRT-PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of lncRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The CCK-8 assay was used to monitor the growth of the cells . mice models was used to test the role of miR-197-3p/p120 Catenin Axis . cell lines (i.e.A549, H1299, H460, SPC-A-1,i.e. HBE,i.e. SPC-A-1) up-regulated resistant miR-197-3p p120-ctn NA validated 3865 Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway. Int J Oncol 2019 30864686 Ensembl ENST00000501122 lncNEAT1_2 lncRNA DB12700 Solamargine stomach cancer RT-qPCR The role of lncNEAT1_2 in gastric cancer cells was detected using RT-qPCR, cell cycle analysis, Annexin V-fluorescein isothiocyanate (FITC)/PI apoptosis assay, transient transfection assay, tumor xenograft and TUNEL assay, etc. cell line (AGS, BGC823, SGC7901, HGC27 and MGC803) up-regulated sensitive NA NA MAPK signaling pathway validated 3866 LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Mol Ther Nucleic Acids 2019 30889481 Ensembl ENSG00000232677 LINC00665 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR The role of LINC00665 in non-small-cell lung cancer cells was detected using quantitative Real-Time PCR, colony formation assays, flow cytometric analysis, transwell migration assay, tumor formation assay, western blot analysis and RIP assay, etc. cell line (PC9,PC9/GR) up-regulated resistant NA NA PI3K/AKT Pathway validated 3867 Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Med Sci Monit 2019 30893293 Ensembl ENSG00000163597 SNHG16 lncRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR In situ hybridization (ISH) staining was performed to detect the expression level of SNHG16 in HCC tissues and adjacent non-cancerous tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the level of SNHG16 in HCC samples, adjacent non-cancerous tissues and HCC cell lines. Transwell assay was performed to investigate the migration and invasion ability of HCC cells. Cell viability assays were performed to determine the ability of proliferation and sorafenib resistance of HCC cells. cell line (HL-7702,SK-Hep-1, Huh7, Hep3B, and HepG2) down-regulated sensitive NA NA NA validated 3868 Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis 2019 30894512 Ensembl ENSG00000245532 NEAT1 lncRNA DB00515 (APRD00359) Cisplatin breast cancer qRT-PCR We performed lncRNA profiling by the LncRNA Profiler qPCR Array Kit in normal control (NC) and breast cancers (BC) blood samples and further validated in a larger cohort of samples by qRT-PCR. Gene expression level and localization were investigated by qRT-PCR, western blotting, and immunofluorescence staining. Flow cytometric analysis was carried out to detect cancer stem cells. Functional studies were performed both in vitro and in vivo xenograft model. cell line (MDA-MB-231) up-regulated resistant NA NA NA validated 3869 Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis 2019 30894512 Ensembl ENSG00000245532 NEAT1 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol breast cancer qRT-PCR We performed lncRNA profiling by the LncRNA Profiler qPCR Array Kit in normal control (NC) and breast cancers (BC) blood samples and further validated in a larger cohort of samples by qRT-PCR. Gene expression level and localization were investigated by qRT-PCR, western blotting, and immunofluorescence staining. Flow cytometric analysis was carried out to detect cancer stem cells. Functional studies were performed both in vitro and in vivo xenograft model. cell line (MDA-MB-231) up-regulated resistant NA NA NA validated 3870 Increased Expression of Exosomal AGAP2-AS1 (AGAP2 Antisense RNA 1) In Breast Cancer Cells Inhibits Trastuzumab-Induced Cell Cytotoxicity. Med Sci Monit 2019 30910994 RefSeq NR_027032.1 AGAP2-AS1 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer qRT-PCR By culturing HER2-positive SKBR-3 and BT474 cells with transtuzumab-containing medium, we built trastuzumab-resistant cells. Quantitative real-time PCR was used to test the expression of AGAP2-AS1 in the built trastuzumab-resistant cells. Cell viability assay and TUNEL assay were used to test the cell viability and apoptosis in each group. Exosomes were purified from cells cultured in exosomes-depleted FBS and identified by transmission electron microscopy. cell line (SKBR-3, BT474,MCF-10A) down-regulated sensitive NA NA NA validated 3871 Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol 2019 30937906 Ensembl ENSG00000245532 NEAT1 lncRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qPCR HCC cell lines and tumor tissue were quantified for NEAT1 expression by quantitative polymerase chain reaction (qPCR). Following shRNA (short hairpin RNA) knockdown of NEAT1, cell viability, apoptosis, and related protein expression were measured after drug treatment. The downstream target of NEAT1, including miR-335 and c-Met was studied using a combination of luciferase binding assay, gene knockdown/overexpression, western blot analysis, and cell viability/apoptosis assay. Cancer cells with NEAT1 knockdown were transplanted onto nude mice for in vivo tumorigenesis assay. cell line (HepG2, Bel7404) down-regulated sensitive miR-335 c-Met c-Met-Akt signaling pathway validated 3872 Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer 2019 30953511 Ensembl ENST00000425894 GBCDRlnc1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin gallbladder cancer qRT-PCR We established doxorubicin (Dox)-resistant gallbladder cancer cells and used microarray analysis to compare the expression profiles of lncRNAs in Dox-resistant gallbladder cancer cells and their parental cells. Knockdown or exogenous expression of lncRNA combined with in vitro and in vivo assays were performed to prove the functional significance of lncRNA. The effects of lncRNA on autophagy were assessed by stubRFP-sensGFP-LC3 and western blot. We used RNA pull-down and mass spectrometry analysis to identify the target proteins of lncRNA. cell line (NOZ,GBC-SD,NOZ/Dox and GBC-SD/Dox) down-regulated sensitive NA NA GBCDRlnc1/PGK1 pathway validated 3873 Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma J Exp Clin Cancer Res 2019 30992025 Ensembl ENSG00000246273 SBF2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR LncSBF2-AS1 level in TMZ-resistance or TMZ-sensitive GBM tissues and cells were analyzed by qRT-PCR and FISH assays. A series of in vitro assay and xenograft tumor models were performed to observe the effect of lncSBF2-AS1 on TMZ-resistance in GBM. CHIP assay were used to investigate the correlation of SBF2-AS1 and transcription factor zinc finger E-box binding homeobox 1 (ZEB1). Dual-luciferase reporter, RNA immunoprecipitation (RIP), immunofluorescence and western blotting were performed to verify the relation between lncSBF2-AS1, miR-151a-3p and XRCC4. Comet assay and immunoblotting were performed to expound the effect of lncSBF2-AS1 on DNA double-stand break (DSB) repair. A series of in vitro assay and intracranial xenografts tumor model were used to determined the function of exosomal lncSBF2-AS1. cell line (U87, LN229, A172, T98, U251,293T ) up-regulated resistant miR-151a-3p XRCC4 NA validated 3874 Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer 2019 30999914 Ensembl ENSG00000235947 Ai-lncRNA EGOT lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cancer qRT-PCR Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. cell line (HeLa,MCF7, T47D, UACC-812, SK-BR-3, MDA-MB-453, MDA-MB-231, Hs578T, HCC70, BT549, and MDA-MB-468) up-regulated sensitive NA NA NA validated 3875 SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. J Exp Clin Cancer Res 2019 31014355 Ensembl ENSG00000232956 SNHG15 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR We applied RNAseq analysis from patient-derived data with validation in independent cohort of patients. We followed these studies with gene regulation analysis as well as experimental dissection of the role of the identified lncRNA by multiple in vitro and in vivo methods. cell line (DLD1, HCT 116, HT-29, LoVo, LS513, SW620 and T84 ) down-regulated sensitive NA NA NA validated 3876 LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci 2019 31047896 Ensembl ENSG00000227036 LINC00511 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-qPCR RT-qPCR was performed to detect the expressions of LINC00511, miR-29c, and cyclin dependent kinase 6 (CDK6) in breast cancer tissues and cells. Pearson correlation analysis was used to analyze the correlation between miR-29c, CDK6 and LINC00511 expression in breast cancer tissues. The interactions between LINC00511, CDK6 and miR-29c were explored by luciferase reporter assay, RT-qPCR and western blot. MTT assay and flow cytometry analysis were applied to evaluate paclitaxel cytotoxicity. cell line (MDA-MB-231, MCF-7, Hs-578T, and T47D) up-regulated sensitive miR-29c CDK6 NA validated 3877 LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2019 31053148 Ensembl ENSG00000255717 lncRNA SNHG1 lncRNA DB00398 (APRD01304, DB07438) Sorafenib hepatocellular carcinoma qRT-PCR Sorafenib-resistant HCC (SR-HCC) cells were generated and their sorafenib-resistant properties were confirmed by cell viability and apoptosis assays. Potential lncRNAs were screened by using multiple bioinformatics analyses and databases. The expression of genes and proteins was detected by qRT-PCR, Western blot and in situ hybridization. Gene silencing was achieved by specific siRNA or lncRNA Smart Silencer. The effects of anti-SNHG1 were evaluated in vitro and in experimental animals by using quantitative measures of cell proliferation, apoptosis and autophagy. The binding sites of miR-21 and SNHG1 were predicted by using the RNAhybrid algorithm and their interaction was verified by luciferase assays. cell line (HepG2,Huh7,SR-HCC ) up-regulated resistant Akt NA AKT pathway validated 3878 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424980.5 lnc-TALC lncRNA DB00853 (APRD00557) Temozolomide glioblastoma qRT-PCR The role of Lnc-TALC in glioblastoma cells was detected using microarray analysis,coding potential analysis, cell apoptosis analysis, CCK-8 assay, colony formation assay, 5-Ethynyl-2'-deoxyuridine (EdU)assay, western blot, PCR, luciferase reporter assay and Xenograft model in vivo, etc. cell line (LN229, U251, 551W, HG7,229R, 251R, 551WR, and HG7R) up-regulated resistant miR-20b-3p MET c-MET Signaling Pathway validated 3879 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERC1-1:5 lnc-ERC1-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3880 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-15K19.2.1-3:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3881 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SCG3-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3882 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028415 LINC00942 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3883 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036444 FENDRR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3884 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602425 LINC01081-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3885 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT025399 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3886 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000408207 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3887 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HIST1H2BI-1:1 lnc-HIST1H2BI-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3888 Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-Lexpressions in human nasopharyngeal carcinoma HNE1 cells in vitro Nan Fang Yi Ke Da Xue Xue Bao 2019 31068307 Ensembl ENSG00000229807 XIST lncRNA DB00515 (APRD00359) Cisplatin nasopharyngeal carcinoma RT-PCR Realtime PCR was performed to detect the expression of XIST in cisplatin-resistant human nasopharyngeal carcinoma cell line HNE1/DDP. The effects of up-regulation and down-regulation of XIST on DDP resistance, proliferation and apoptosis of HNE1/ DDP cells were assessed using MTT assay, EdU assay and flow cytometry. Western blotting was used to detect the changes in the expressions of programmed cell death 4 (PDCD4) and Fas ligand (Fas-L) proteins in the cells in response to up-regulation or down-regulation of XIST. cell line (HNE1,HNE1/DDP) down-regulated sensitive PDCD4 and Fas-L PDCD4 and Fas-L NA validated 3889 Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation. J Exp Clin Cancer Res 2019 31072375 Ensembl ENSG00000100181 TPTEP1 lncRNA DB00515 (APRD00359) Cisplatin hepatocellular carcinoma qRT-PCR The differential expressions of LncRNAs in HCC cells treated with cisplatinum were determined by RNA-seq. The roles of TPTEP1 in HCC development by applying gene function gain and loss analysis in MHCC97H and QYG-7703 cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR), cell proliferation, colony formation, cell invasion and flow cytometry assays. The underlying mechanism of TPTEP1 sensitizing hepatocellular carcinoma cells to cisplatinum was examined by RNA-pull down, western blotting, subcellular fractionation, RNA immunoprecipitation and dual luciferase reporter assays. The effect of TPTEP1 on tumorigenesis in vivo was performed with a subcutaneous xenograft mouse model of HCC. In addition, TPTEP1 expression was detected in clinical tumor tissue samples by qRT-PCR. cell line (HepG2, SMMC-7721, QGY-7703, Huh-7, MHCC97h, SNU-449 and Sk-hep1, and L02) up-regulated sensitive NA NA IL-6/STAT3 pathway validated 3890 Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. J Cell Physiol 2019 31111480 Ensembl ENSG00000278924 lncRNA-AC078883.3 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-PCR This study aimed to investigate the potential role of lncRNA-AC078883.3 in the development of chemoresistance against cisplatin. Real-time PCR, Western blot analysis, Immunohistochemistry (IHC) assay, bioinformatic analysis, and luciferase assay were collaboratively used to establish the lncRNA-AC078883.3/miR-19a/PTEN/AKT pathway. Also, the effect of cisplatin on cell proliferation was observed via an MTT assay. Furthermore, Cox regression and Kaplan-Meier analyses were used to study whether lncRNA-AC078883.3 is involved in the survival of NSCLC. cell line (A549 and H460) down-regulated resistant miR-19a PTEN PTEN/AKT pathway validated 3891 microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019 31113460 Ensembl ENSG00000229619 MBNL1-AS1 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma RT-qPCR Microarray analysis was performed to screen the differentially expressed lncRNA associated with NSCLC and its potential mechanism. The lncRNA MBNL1-AS1 expression was quantified in 56 paired NSCLC and adjacent normal tissue samples. In an attempt to outline the function of lncRNA MBNL1-AS1 in NSCLC and to identify the interaction among lncRNA MBNL1-AS1, microRNA-301b-3p (miR-301b-3p) and TGFBR2, ectopic expression, depletion, and reporter assay experiments were conducted to detect CSC proliferation, migration, invasion, drug resistance, and sphere formation in NSCLC. cell line (A549, H1299, and SK-MES-1) up-regulated sensitive miR-301b-3p TGFBR2 TGF-Beta signalling pathway validated 3892 microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019 31113460 Ensembl ENSG00000229619 MBNL1-AS1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR Microarray analysis was performed to screen the differentially expressed lncRNA associated with NSCLC and its potential mechanism. The lncRNA MBNL1-AS1 expression was quantified in 56 paired NSCLC and adjacent normal tissue samples. In an attempt to outline the function of lncRNA MBNL1-AS1 in NSCLC and to identify the interaction among lncRNA MBNL1-AS1, microRNA-301b-3p (miR-301b-3p) and TGFBR2, ectopic expression, depletion, and reporter assay experiments were conducted to detect CSC proliferation, migration, invasion, drug resistance, and sphere formation in NSCLC. cell line (A549, H1299, and SK-MES-1) up-regulated sensitive miR-301b-3p TGFBR2 TGF-Beta signalling pathway validated 3893 Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis. J Cell Physiol 2019 31131448 Ensembl ENSG00000231721 LINC-PINT lncRNA DB00515 (APRD00359) Cisplatin laryngeal carcinoma RT-PCR In this study, LINC-PINT expression in normal and tumor tissues were studied. Using a bioinformatic approach, microRNA (miRNA) targets of LINC-PINT and gene targets of the miRNA were determined. The impact of LINC-PINT on cell proliferation and chemoresistance was determined. Further through a set of silencing and re-expression studies phenotype rescue was studied. cell line (HEp-2) down-regulated resistant miR-425-5p PTCH1 Hedgehog pathway validated 3894 LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. Arch Bronconeumol 2019 31133357 Ensembl ENSG00000251562 MALAT1 lncRNA DB00317 (APRD00997, DB07998) Gefitinib lung cancer RT-PCR MALAT1 in A549 and HCC 1299 human lung adenocarcinoma cell lines was silenced by shRNA or overexpressed using plasmid, and the cell viability and cell proliferation were evaluated by MTT assay and soft agar colony formation assay. RNA levels were detected by RT-PCR, and the protein expression was measured by western blot. The binding between MALAT1 and miR-200a was validated by luciferase reporter assays using pSi-Chech 2 vectors. cell line (A549, HCC1299) up-regulated resistant miR-200a ZEB1 NA validated 3895 Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation. Braz J Med Biol Res 2019 31166382 Ensembl ENSG00000229140 CCDC26 lncRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib gastrointestinal stromal tumor RT-qPCR The role of lncRNA CCDC26 in human gastrointestinal stromal tumors cells was detected using CCK-8 assay, EDU assay, flow cytometric analysis, western blot, quantitative real-time PCR and RNA pull-down assay, etc. cell line (GIST-882 and GIST-T1) up-regulated sensitive NA NA NA validated 3896 LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur Rev Med Pharmacol Sci 2019 31173289 Ensembl ENSG00000203875 SNHG5 lncRNA DB00515 (APRD00359) Cisplatin stomach cancer RT-PCR We detected the expressions of SNHG5, apoptosis-specific genes (Bax and Bcl-2) and drug resistance-specific genes (MDR1 and MRP1) in cisplatin-sensitive and cisplatin-resistant GC patients. The expression levels were also detected in cisplatin-resistant GC cell lines (BGC823/DDP, SGC7901/DDP) and GC cell lines (BGC823 and SGC7901). Through the liposome transfection, the regulatory effects of SNHG5 on proliferative potential and apoptosis were examined by cytotoxicity assay and flow cytometry assay, respectively. The protein levels of apoptosis-related genes and drug resistance-related genes influenced by SNHG5 were detected by Western blot. cell line (BGC823, SGC7901,BGC823/DDP, SGC7901/DDP) up-regulated resistant NA NA NA validated 3897 LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci 2019 31180057 Ensembl ENSG00000227036 LINC00511 lncRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel cervical cancer RT-qPCR The role of LINC00511 in cervical cancer cells was detected using RT-qPCR, western blot analysis, CCK-8 assay, TdT-mediated dUTP-biotin nick end-labeling (TUNEL) staining and transwell assay, etc. tissue and cell line (Hela/PTX) down-regulated sensitive NA NA NA validated 3898 Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene 2019 31181314 Ensembl ENSG00000249375 CASC11 lncRNA DB00526 (APRD00186) Oxaliplatin ovarian squamous cell carcinoma qRT-PCR The role of CASC11 in ovarian squamous cell carcinoma cells was detected using qRT-PCR, cell transfection and MTT assay,etc. tissue and cell line (UWB1.289) up-regulated resistant NA NA NA validated 3899 Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene 2019 31181314 Ensembl ENSG00000249375 CASC11 lncRNA NA Tetraplatin ovarian squamous cell carcinoma qRT-PCR The role of CASC11 in ovarian squamous cell carcinoma cells was detected using qRT-PCR, cell transfection and MTT assay, etc. tissue and cell line (UWB1.289) up-regulated resistant NA NA NA validated 3900 Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene 2019 31181314 Ensembl ENSG00000249375 CASC11 lncRNA DB00515 (APRD00359) Cisplatin ovarian squamous cell carcinoma qRT-PCR The role of CASC11 in ovarian squamous cell carcinoma cells was detected using qRT-PCR, cell transfection and MTT assay, etc. tissue and cell line (UWB1.289) up-regulated resistant NA NA NA validated 3901 Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene 2019 31181314 Ensembl ENSG00000249375 CASC11 lncRNA DB00958 (APRD00466) Carboplatin ovarian squamous cell carcinoma qRT-PCR The role of CASC11 in ovarian squamous cell carcinoma cells was detected using qRT-PCR, cell transfection and MTT assay, etc. tissue and cell line (UWB1.289) up-regulated resistant NA NA NA validated 3902 LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life 2019 31188543 Ensembl ENSG00000261801 LOXL1-AS1 lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin prostate cancer qRT-PCR Microarray analysis was conducted to determine differentially expressed lncRNAs and mRNAs. Gene Set Enrichment analysis was implemented for verification of dys-regulated signaling pathways between DU-145 cells and doxorubicin-resistant prostate cancer DU-145 cells. Relative expression of lncRNA LOXL1-AS1 in doxorubicin-resistant prostate cancer DU-145 cells was analyzed by qRT-PCR. CCK-8 assay and flow cytometry analysis were employed to detect cell proliferation and apoptosis, respectively. Cell migration was performed by transwell assay. Furthermore, targeted relationships between lncRNA LOXL1-AS1 and miR-let-7a-5p, as well as miR-let-7a-5p and EGFR were predicted using bioinformatics analysis and validated by dual-luciferase reporter gene assay. Besides, tumor xenograft assay was utilized for verification of the roles of LOXL1-AS1 in PCa progression in vivo. cell line (DU-145,s DU-145/DOX) down-regulated resistant miR-let-7a-5p EGFR NA validated 3903 LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer. J Oncol 2019 31205469 Ensembl ENSG00000249859 PVT1 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil stomach cancer RT-PCR The tumorigenic ability of PVT1 was verified by subcutaneous and orthotopic mouse models. Flow cytometry assay and TdT-mediated dUTP Nick-End Labeling staining were conducted to explore the effects of PVT1 on gastric cancer cell apoptosis. We investigated the relative gene and protein that are involved in apoptosis in real-time PCR and western blot assay. The resistance to 5- Fluorouracil (5-Fu) caused by PVT1 was evaluated using cell viability assay. Then, to confirm the effects of PVT1 on 5-Fu resistance, we conducted the Kaplan-Meier analysis based on three public databases. cell line (SGC-7901) up-regulated resistant BCL2 NA NA validated 3904 LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer. J Cancer 2019 31205562 Ensembl ENSG00000228630 HOTAIR lncRNA DB00675 (APRD00123) Tamoxifen breast cancer NA The role of HOTAIR in triple-negative breast cancers cells was detected using Immunohistochemical analysis and evaluation, RNA in situ hybridization assay. etc. tissue up-regulated resistant NA NA NA validated 3905 Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun 2019 31262449 Ensembl ENSG00000214049 UCA1 lncRNA NA oncolytic vaccinia virus colorectal cancer RT-PCR The role of UCA1 in colorectal cancer cells was detected using Real-time PCR, Plaque formation assays, virus binding and entry assays, GTPase activation assays, etc. cell line (CaCo2, LoVo, HT29, SW480,COLO205, HCT116, T84) up-regulated sensitive miR-18a/miR-182 NA NA validated 3906 Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med 2019 31281438 Ensembl ENSG00000228630 HOTAIR lncRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-qPCR DOXR-MCF-7 cells were transfected with lncRNA-HOTAIR small interfering RNA (siRNA) and control siRNA. Subsequently, MTT and colony formation assays were performed to assess cell proliferation. Cell apoptosis was also evaluated via flow cytometry. In addition, western blotting and reverse transcription-quantitative polymerase chain reaction were performed to detect the expression of caspase-3, B-cell lymphoma 2, Bcl-2-associated X protein, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and mechanistic target of rapamycin (mTOR), and the phosphorylation of PI3K, AKT, and mTOR. cell line (MCF-7,SKBR3,DOXR-MCF-7) down-regulated sensitive NA NA PI3K/AKT/mTOR signaling pathway validated 3907 LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2. Acta Biochim Biophys Sin (Shanghai) 2019 31287493 Ensembl ENSG00000253352 TUG1 lncRNA DB00515 (APRD00359) Cisplatin esophageal squamous cell carcinoma qRT-PCR The role of TUG1 in esophageal squamous cell carcinoma cells was detected using qRT-PCR, MTT assay, cell apoptosis assay, western blot analysis and RNA pull-down assay, etc. cell line ( TE-1,TE-1/DDP) up-regulated resistant Nrf2 Nrf2 NA validated 3908 Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2. Eur Rev Med Pharmacol Sci 2019 31298373 Ensembl ENSG00000248323 LUCAT1 lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was utilized to detect LUCAT1 expression in A549/DDP cells and A549 cells. Then, we conducted cell counting kit-8 (CCK-8) assay and flow cytometric analysis to detect the function of LUCAT1 on the resistance of NSCLC cells to cisplatin. Furthermore, the potential mechanism was explored by mechanism assays. cell line (A549,A549/DDP) up-regulated resistant IGF-2 IGF-2 NA validated 3909 Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non-small cell lung cancer (NSCLC) cells through ERK1/2 and Beta-catenin signaling pathways. Pathol Res Pract 2019 31300295 RefSeq NR_026941.1 CASC2c lncRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma RT-qPCR The expression of CASC2c in NSCLC tissues and cell lines was detected by real-time fluorescence quantitative PCR (RT-qPCR). MTT and Transwell assay were used to determine the proliferation and migration of NSCLC cells in the experimental group and the control group respectively. The drug sensitivity test was used to confirm whether increasing the CASC2c expression level could reverse the resistance of NSCLC cells to the chemotherapy drug cisplatin. The effects of CASC2c on the expression levels of p-ERK1/2 and Beta-catenin were detected by western blot. tissue and cell line (H292, H226, H1975, H460,BEAS-2B ) up-regulated sensitive NA NA ERK1/2 and Beta-catenin signaling pathways validated 3910 Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. J Drug Target 2019 31359792 Ensembl ENSG00000281406 BLACAT1 lncRNA DB08916 Afatinib lung non-small cell carcinoma qRT-PCR The role of BLACAT1 in non-small cell lung cancer cells was detected using MTT assay, colony formation assay, apoptosis analysis, qRT-PCR and western blot analysis, immunohistochemistry, and in vivo study were carried out, etc. cell line (Calu3 and H1975) down-regulated sensitive NA NA STAT3 signaling pathway validated 3911 Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer 2019 31381140 Ensembl NA CCAL lncRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qRT-PCR The role of CCAL in colorectal cancer cells was detected using flow cytometry, quantitative RT-PCR analyses, CCAL RNA copy number analysis, exosome experiments, Co-culture assay, western blot,TOP-flash luciferase assay, CCK8 assay, apoptosis assay and TUNEL assay, etc tissue and cell line ( SW480, HCT116, HEK293T ) up-regulated resistant NA NA Beta-catenin signaling pathway validated 3912 Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res 2019 31391118 Ensembl ENSG00000234741 GAS5 lncRNA DB00515 (APRD00359) Cisplatin epithelial ovarian cancer RT-qPCR The low expression of lncRNA GAS5 in EOC tissues and OC cell lines was determined by microarray analyses and Real-Time qPCR. Flow cytometer assays were used to detect cell cycle and apoptosis of OC cells. CCK8 assay were performed to investigate the DDP sensitivity of OC cells. Western blot was carried out to detect cell growth markers, apoptotic markers, PARP1, E2F4, MAPK pathway protein expression and other protein expression in OC cell lines. The binding of GAS5 and E2F4 were proved by RNA pull-down and RIP assay. The effect of E2F4 on PARP1 were determined by CHIP-qPCR assay and luciferase reporter assay. The effect of lncRNA GAS5 on OC cells was assessed in vitro and in vivo. cell line (HEY, A2780, A2780/DDP, HO8910, HO8910PM, SKOV3, SKOV3/DDP,IOSE) up-regulated sensitive E2F4/PARP1 E2F4/PARP1 MAPK signaling pathway validated 3913 Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle 2019 31416393 Ensembl ENSG00000245694 CRNDE lncRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin liver cancer RT-qPCR First, drug-resistance model (HepG2 and BEL-7402) of human liver cancer cells was established. Then, CRNDE expression in drug-resistant cell lines (HepG2/adriamycin [ADM], BEL-7402/ADM) and parental cell lines (HepG2, BEL-7402) was detected. Furthermore, HepG2/ADM and BEL-7402/ADM cell lines with poor CRNDE expression or miR-33a overexpression was constructed. Next, drug-resistance index was calculated, and cell proliferation, apoptosis, migration, and invasion were detected, respectively. Then, the growth of tumor was observed in nude mice. Finally, the binding relationship between CRNDE and miR-33a and the targeting relationship between miR-33a and HMGA2 were verified. cell line (HepG2,BEL-7402,HepG2/ADM and BEL-7402/ADM) up-regulated resistant miR-33a HMGA2 NA validated 3914 Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle 2019 31416393 Ensembl ENSG00000245694 CRNDE lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil liver cancer RT-qPCR First, drug-resistance model (HepG2 and BEL-7402) of human liver cancer cells was established. Then, CRNDE expression in drug-resistant cell lines (HepG2/adriamycin [ADM], BEL-7402/ADM) and parental cell lines (HepG2, BEL-7402) was detected. Furthermore, HepG2/ADM and BEL-7402/ADM cell lines with poor CRNDE expression or miR-33a overexpression was constructed. Next, drug-resistance index was calculated, and cell proliferation, apoptosis, migration, and invasion were detected, respectively. Then, the growth of tumor was observed in nude mice. Finally, the binding relationship between CRNDE and miR-33a and the targeting relationship between miR-33a and HMGA2 were verified. cell line (HepG2,BEL-7402,HepG2/ADM and BEL-7402/ADM) up-regulated resistant miR-33a HMGA2 NA validated 3915 Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle 2019 31416393 Ensembl ENSG00000245694 CRNDE lncRNA DB00515 (APRD00359) Cisplatin liver cancer RT-qPCR First, drug-resistance model (HepG2 and BEL-7402) of human liver cancer cells was established. Then, CRNDE expression in drug-resistant cell lines (HepG2/adriamycin [ADM], BEL-7402/ADM) and parental cell lines (HepG2, BEL-7402) was detected. Furthermore, HepG2/ADM and BEL-7402/ADM cell lines with poor CRNDE expression or miR-33a overexpression was constructed. Next, drug-resistance index was calculated, and cell proliferation, apoptosis, migration, and invasion were detected, respectively. Then, the growth of tumor was observed in nude mice. Finally, the binding relationship between CRNDE and miR-33a and the targeting relationship between miR-33a and HMGA2 were verified. cell line (HepG2,BEL-7402,HepG2/ADM and BEL-7402/ADM) up-regulated resistant miR-33a HMGA2 NA validated 3916 Long non-coding RNA bladder cancer-associated transcript 2 contributes to disease progression, chemoresistance and poor survival of patients with colorectal cancer. Oncol Lett 2019 31423277 RefSeq NR_038904.1 BLACAT2 lncRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer RT-qPCR The role of BLACAT2 in colorectal cancer cells was detected using RT-qPCR, transwell migration and invasion assays, colony formation assay and MTT assay, etc. cell line (HIEC-6,LOVO, SW620, HCT15, HCT116, SW480 and DLD1) up-regulated resistant NA NA NA validated 3917 Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther 2019 31436255 Ensembl ENSG00000130600 H19 lncRNA DB00072 (BTD00098, BIOD00098) Trastuzumab breast cancer RT-PCR We evaluated trastuzumab sensitivity in breast cancer cell lines, SKBR3, HCC1954, and MDA-MB-231. We also evaluated H19 expression in these cell lines after treatment with different trastuzumab concentrations. Besides, H19 was downregulated to investigate its role in cell viability and trastuzumab sensitivity and a trastuzumab resistance cell line was cultured to verify the effect of H19 in trastuzumab resistance. Forty-eight HER2-positive breast cancer patients treated with trastuzumab in the first-line setting were selected retrospectively to explore the relationship between H19 expression and tumor-node-metastasis (TNM) stage as well as trastuzumab resistance. cell line (SKBR3, HCC1954, and MDA-MB-231) up-regulated resistant NA NA NA validated 3918 Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene 2019 31444414 NONCODE NONHSAT101069.2 NONHSAT101069 lncRNA DB00445 (APRD00361) epirubicin breast cancer qRT-PCR,Northern blot The role of NONHSAT101069 in breast cancer cells was detected using qRT-PCR, western blot, cell migration and invasion assays, CCK-8 assay, luciferase reporter assay, Northern blot and animal assays, etc. cell line (MCF-7, T47D, MDA-MB-231,SUM1315, ZR-75-1,SK-Br-3,MCF-10A,MCF-7/ADR) up-regulated resistant miR-129-5p Twist1 NA validated 3919 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000532168 LINC02762-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3920 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608023 MIR29B2CHG-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3921 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584952 AC055811.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3922 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452675 LINC02541-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3923 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589702 AC008569.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3924 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600280 LINC02614-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3925 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605056 AC104695.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3926 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000414426 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3927 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000548687 AC025569.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3928 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000412321 AL122058.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3929 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CASP5-2:1 lnc-CASP5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3930 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580242 COLEC12-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3931 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GABARAPL1-2:1 lnc-GABARAPL1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3932 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HPSE2-1:1 lnc-HPSE2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3933 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX51-9:1 lnc-DDX51-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3934 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CSNK1A1-1:1 lnc-CSNK1A1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3935 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027256 TREML3P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3936 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TXNDC12-4:1 lnc-TXNDC12-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3937 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000434560 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3938 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002936 TOB2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3939 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KCNE4-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3940 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000479229 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3941 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431083 AC099552.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3942 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033957 LINC00842 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3943 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PSG4-1:1 lnc-PSG4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3944 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033519 MASP1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3945 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPR89B-11:2 lnc-GPR89B-11:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3946 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMARCAL1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3947 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033925 FENDRR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3948 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DCDC5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3949 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM182B-8:10 lnc-FAM182B-8:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3950 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DCDC5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3951 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_111000 LOC101060524 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3952 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIMP4-2:1 lnc-TIMP4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3953 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026713 FAM182A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3954 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PIK3CG-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3955 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033652 MSC-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3956 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000597169 CCDC194-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3957 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HK2-1:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3958 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033878 LINC00944 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3959 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568817 AC104072.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3960 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GLOD4-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3961 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045121 DGCR5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3962 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033888 LOC284344 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3963 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX37-10:24 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3964 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC106017.3.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3965 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI27L1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3966 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621819 AC009878.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3967 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000535153 LINC02282-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3968 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT098097 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3969 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122045 LINC02593 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3970 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CXCL12-4:1 lnc-CXCL12-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3971 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589310 LINC01764-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3972 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000523133 MSC-AS1-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3973 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC009237.1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3974 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIF5C-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3975 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT087996.2 NONHSAT087996 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3976 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110783 LINC01444 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3977 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033774 BASP1P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3978 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT023953 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3979 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580867 LINC01444-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3980 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560727 AC066613.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3981 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036503 PRKCQ-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3982 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_039989 MIR4458HG lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3983 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000562313 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3984 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000515614 LINC00942-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3985 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLEC7A-2:1 lnc-CLEC7A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3986 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033711 TP73-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3987 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612143 AL139384.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3988 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COL6A3-2:1 lnc-COL6A3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3989 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125841 LINC01564 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3990 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000548213 LINC01551-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3991 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000498714 FOXP1-IT1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3992 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026589 WHAMMP2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3993 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMARCAL1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3994 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SRGN-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3995 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027040 ATP6V0E2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3996 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMARCAL1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3997 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ODZ3-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3998 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MGMT-2:1 lnc-MGMT-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 3999 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613389 AC245041.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4000 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLEC2A-3:2 lnc-CLEC2A-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4001 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DHRSX-1:2 lnc-DHRSX-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4002 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ANXA8-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4003 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024045 RAET1K lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4004 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UMODL1-1:2 lnc-UMODL1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4005 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520156 AC027117.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4006 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RUNX2-2:1 lnc-RUNX2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4007 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PSG6-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4008 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PDGFRL-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4009 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MEGF6-4:1 lnc-MEGF6-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4010 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045127 RAET1E-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4011 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCP1B-6:1 lnc-DCP1B-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4012 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001434 HLA-H lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4013 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580268 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4014 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMARCAL1-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4015 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003714 POM121L9P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4016 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000529416 AP000880.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4017 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FABP2-4:1 lnc-FABP2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4018 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104172 TMEM132D-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4019 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033712 TP73-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4020 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598518 IGFL2-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4021 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNMTL1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4022 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPRASP2-1:1 lnc-GPRASP2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4023 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000511928 LINC02600-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4024 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HSFY2-10:1 lnc-HSFY2-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4025 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580756 AP000915.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4026 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRMD4A-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4027 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC167-4:2 lnc-CCDC167-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4028 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026714 FAM182B lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4029 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM123-3:2 lnc-TMEM123-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4030 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582858 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4031 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCP1B-6:2 lnc-DCP1B-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4032 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM188A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4033 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GARNL3-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4034 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX37-10:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4035 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003521 WHAMMP3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4036 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-THNSL1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4037 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610135 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4038 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX37-10:20 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4039 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SSTR2-2:1 lnc-SSTR2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4040 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026915 AADACP1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4041 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf65-10:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4042 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424251 AC003659.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4043 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ULBP2-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4044 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449075 THORLNC-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4045 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033931 LINC01085 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4046 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000533504 AP000880.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4047 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC93-2:4 lnc-CCDC93-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4048 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033752 NMRAL2P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4049 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449819 THORLNC-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4050 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NKX6-2-3:2 lnc-NKX6-2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4051 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC30A10-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4052 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505448 AC104825.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4053 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DEC1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4054 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120335 LOC101928414 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4055 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX51-10:1 lnc-DDX51-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4056 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104173 TMEM132D-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4057 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000440726 LINC02041-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4058 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000412812 AC079630.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4059 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000544499 LINC00944-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4060 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109780 LINC00513 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4061 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583461 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4062 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602761 LINC02577-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4063 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MKI67-2:1 lnc-MKI67-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4064 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLDN1-2:1 lnc-CLDN1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4065 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CYP4F11-1:1 lnc-CYP4F11-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4066 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000528497 LINC02697-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4067 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000540739 TMEM132D-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4068 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC069257.9.1-4:69 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4069 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602900 AP002840.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4070 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MUC4-1:9 lnc-MUC4-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4071 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617667 AC087588.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4072 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036502 PRKCQ-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4073 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424493 AC024560.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4074 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIF5C-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4075 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615979 AC027348.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4076 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026732 LINC01551 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4077 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLEC2A-3:1 lnc-CLEC2A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4078 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT144908 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4079 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624365 AL353597.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4080 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PITRM1-5:1 lnc-PITRM1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4081 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C9orf66-7:1 lnc-C9orf66-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4082 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000588307 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4083 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520646 AC027117.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4084 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000599781 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4085 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHSY1-5:5 lnc-CHSY1-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4086 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000325042 AC073072.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4087 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FGF9-1:2 lnc-FGF9-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4088 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHRS2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4089 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026810 FAM106CP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4090 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC110373.1-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4091 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433673 MAP3K2-DT-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4092 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000486671 TCL6-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4093 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLSTN2-1:1 lnc-CLSTN2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4094 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NIPA1-1:12 lnc-NIPA1-1:12 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4095 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110388 LINC01186 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4096 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000557777 LINC01579-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4097 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103738 SOX9-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4098 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000485282 AC004917.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4099 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000472238 AC121764.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4100 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAF1-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4101 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000527483 EDRF1-DT-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4102 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNHIT6-1:2 lnc-ZNHIT6-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4103 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF716-24:2 lnc-ZNF716-24:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4104 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000453951 LINC01293-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4105 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PSG2-2:1 lnc-PSG2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4106 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC069257.9.1-4:67 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4107 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARRDC3-1:16 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4108 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110840 LOC101927136 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4109 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI27L1-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4110 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614011 AC018695.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4111 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036526 SUGT1P4-STRA6LP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4112 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-USP35-1:14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4113 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COPS4-1:2 lnc-COPS4-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4114 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602695 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4115 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581211 LINC01444-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4116 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026731 LINC01551 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4117 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038996 USP30-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4118 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NYAP2-2:1 lnc-NYAP2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4119 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000455607 AL355312.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4120 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KCNB1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4121 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPTLC1-6:3 lnc-SPTLC1-6:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4122 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT018657.2 NONHSAT018657 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4123 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLCO2B1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4124 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000519068 MSC-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4125 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT017486.2 NONHSAT017486 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4126 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454321 AL137186.2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4127 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MSC-4:1 lnc-MSC-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4128 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C10orf96-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4129 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024583 POM121L8P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4130 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617916 AC005393.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4131 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPSAP58-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4132 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNHIT6-1:4 lnc-ZNHIT6-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4133 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613809 AL139384.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4134 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000599817 IGFL2-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4135 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605044 AL121917.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4136 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109795 LINC01508 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4137 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000416958 AC118754.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4138 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT125277.2 NONHSAT125277 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4139 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT095934.2 NONHSAT095934 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4140 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FSIP1-5:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4141 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605513 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4142 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000515153 AC012625.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4143 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130766 BISPR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4144 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046357 RNF165 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4145 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PCM1-4:4 lnc-PCM1-4:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4146 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618848 AC243829.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4147 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024591 POM121L1P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4148 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602332 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4149 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZDHHC11B-1:1 lnc-ZDHHC11B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4150 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLSTN2-1:2 lnc-CLSTN2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4151 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-METTL19-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4152 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PIWIL4-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4153 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000563933 LINC02555-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4154 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OLR1-1:1 lnc-OLR1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4155 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC092327.1-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4156 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615212 MUC20-OT1-249 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4157 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ADA-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4158 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNHIT6-1:3 lnc-ZNHIT6-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4159 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110292 SNHG31 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4160 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT004347.2 NONHSAT004347 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4161 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024405 LOC730101 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4162 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126334 LOC101927932 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4163 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAF1-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4164 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000576252 AC087392.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4165 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027003 LOC93429 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4166 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422204 AC116366.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4167 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OBFC2A-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4168 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000444114 LINC01638-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4169 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MIPOL1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4170 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GABARAPL1-2:2 lnc-GABARAPL1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4171 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FTSJD2-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4172 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582363 LINC00667-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4173 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KANK1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4174 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000441841 LINC02243-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4175 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000428329 AC007319.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4176 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026576 SAA3P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4177 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZHX3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4178 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SCUBE1-2:1 lnc-SCUBE1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4179 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GBP6-3:1 lnc-GBP6-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4180 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040070 LOXL1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4181 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIMM10-1:1 lnc-TIMM10-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4182 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125792 LINC01291 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4183 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PSG2-4:1 lnc-PSG2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4184 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015440 PRDM16-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4185 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HK2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4186 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037888 STX18-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4187 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SGCE-1:4 lnc-SGCE-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4188 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028044 IGF2-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4189 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CRIPT-4:1 lnc-CRIPT-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4190 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609207 LINC02593-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4191 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARHGAP29-7:1 lnc-ARHGAP29-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4192 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000420508 AP000550.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4193 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCA4-2:1 lnc-ABCA4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4194 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZDHHC2-2:1 lnc-ZDHHC2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4195 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DEC1-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4196 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026913 LY6E-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4197 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CABP4-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4198 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000574560 AC087392.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4199 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AIPL1-1:2 lnc-AIPL1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4200 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-STIM2-10:1 lnc-STIM2-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4201 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARHGEF1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4202 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC89-6:1 lnc-CCDC89-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4203 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTPLB-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4204 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512133 TMEM132D-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4205 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607794 AC004233.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4206 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000571302 AC005736.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4207 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103535 NEXN-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4208 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040091 LOC100506990 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4209 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NTSR1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4210 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLDN1-1:1 lnc-CLDN1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4211 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CALCRL-2:1 lnc-CALCRL-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4212 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF674-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4213 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033939 SCOC-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4214 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI44-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4215 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FGL1-3:8 lnc-FGL1-3:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4216 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SBF2-1:2 lnc-SBF2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4217 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000522244 AC104248.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4218 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046836 HS1BP3-IT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4219 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125365 LINC02595 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4220 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXorf28-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4221 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C8orf47-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4222 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003268 CTAGE10P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4223 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567108 AC109449.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4224 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC112721.1.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4225 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126160 FAM106B lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4226 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BMP7-1:1 lnc-BMP7-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4227 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000586961 AC011476.3-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4228 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602981 AC087203.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4229 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027064 TINCR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4230 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDKN2B-2:2 lnc-CDKN2B-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4231 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616245 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4232 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026791 HCG27 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4233 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SHB-1:1 lnc-SHB-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4234 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC39A11-2:21 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4235 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103859 LINC01082 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4236 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CUL5-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4237 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ITGAX-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4238 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000412872 AL713998.1-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4239 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANKRD27-10:1 lnc-ANKRD27-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4240 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038969 PPP1R26-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4241 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT117917.2 NONHSAT117917 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4242 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600197 MUC20-OT1-238 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4243 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620056 AC243829.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4244 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512647 AC012613.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4245 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610389 AC105105.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4246 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM3B-3:2 lnc-FAM3B-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4247 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024431 ZMIZ1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4248 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZSCAN12-2:1 lnc-ZSCAN12-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4249 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LTBP1-1:1 lnc-LTBP1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4250 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF674-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4251 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT137714 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4252 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503263 AC106795.2-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4253 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT080492.2 NONHSAT080492 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4254 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034096 FTCDNL1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4255 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GLOD4-4:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4256 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612098 MUC20-OT1-248 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4257 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CSF1R-1:1 lnc-CSF1R-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4258 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI27L1-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4259 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454537 AC012501.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4260 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624506 FP236315.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4261 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SOHLH2-3:1 lnc-SOHLH2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4262 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033884 HTATSF1P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4263 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109819 NR2F1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4264 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RBFA-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4265 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606179 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4266 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NBR2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4267 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000528717 AP001830.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4268 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EID3-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4269 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC25A41-3:1 lnc-SLC25A41-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4270 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110226 HECW2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4271 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033298 CCDC163 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4272 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002307 MSX2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4273 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125805 TMEM92-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4274 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415590 SFTA1P-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4275 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C14orf126-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4276 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_105045 LINC01843 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4277 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARHGAP15-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4278 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DEC1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4279 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BAHD1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4280 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOA3-9:2 lnc-NCOA3-9:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4281 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNAJC3-2:1 lnc-DNAJC3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4282 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SNX13-2:6 lnc-SNX13-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4283 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607326 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4284 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT103586.2 NONHSAT103586 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4285 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARRDC3-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4286 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122105 MIR570HG lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4287 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPO11-1:5 lnc-SPO11-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4288 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCRN4L-8:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4289 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GLRX3-13:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4290 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPGR-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4291 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EIF3M-2:11 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4292 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RBM27-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4293 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MKLN1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4294 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_119376 FER1L4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4295 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NPR3-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4296 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028295 LINC00029 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4297 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX37-10:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4298 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_029193 SH3RF3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4299 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PRICKLE2-3:2 lnc-PRICKLE2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4300 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-JPH4-3:1 lnc-JPH4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4301 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-A-5:1 lnc-HLA-A-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4302 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026597 DIRC3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4303 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LIPG-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4304 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HSBP1L1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4305 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000569927 AC114811.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4306 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SGCE-1:1 lnc-SGCE-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4307 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM74-1:2 lnc-TMEM74-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4308 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612806 AC013564.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4309 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109825 NR2F1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4310 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF113B-9:1 lnc-RNF113B-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4311 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-THUMPD1-3:1 lnc-THUMPD1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4312 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110724 LINC01480 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4313 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606841 AC116312.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4314 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDHR4-4:3 lnc-CDHR4-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4315 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120412 LMO7-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4316 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RXFP2-3:1 lnc-RXFP2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4317 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000423466 AC026355.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4318 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000538329 AC092112.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4319 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582591 AP000919.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4320 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KATNB1-1:1 lnc-KATNB1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4321 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000473550 DUBR-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4322 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120549 WT1-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4323 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC073263.1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4324 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568776 AC105411.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4325 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-INTS10-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4326 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-METTL19-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4327 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606778 AC016877.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4328 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624769 AC093535.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4329 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FRMD4A-4:1 lnc-FRMD4A-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4330 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT118258.2 NONHSAT118258 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4331 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM176A-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4332 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT116540.2 NONHSAT116540 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4333 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584608 AC005828.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4334 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TBC1D7-2:1 lnc-TBC1D7-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4335 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606272 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4336 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ERAP2-7:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4337 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C17orf48-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4338 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608615 AP000345.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4339 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514752 SLC7A11-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4340 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054059 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4341 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120592 PRSS23 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4342 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024356 FBLL1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4343 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GGT1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4344 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609975 AC009237.14-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4345 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045484 LOC646626 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4346 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602175 MUC20-OT1-245 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4347 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C6orf106-1:1 lnc-C6orf106-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4348 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000586248 LINC00662-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4349 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433644 FANCC-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4350 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454799 FAM66C-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4351 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DERA-4:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4352 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_111906 LOC100506175 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4353 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LHFPL4-4:1 lnc-LHFPL4-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4354 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT004238.2 NONHSAT004238 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4355 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SCRN3-10:1 lnc-SCRN3-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4356 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR143-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4357 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EIF3A-1:1 lnc-EIF3A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4358 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DMTF1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4359 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000555771 AC005476.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4360 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IMP4-7:1 lnc-IMP4-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4361 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CASP4-1:2 lnc-CASP4-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4362 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NECAB2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4363 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ADIPOR2-3:1 lnc-ADIPOR2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4364 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LTBP1-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4365 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-YLPM1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4366 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103549 LUCAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4367 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC12A8-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4368 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C8orf31-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4369 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619523 AC245041.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4370 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120598 GACAT2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4371 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT017225 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4372 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126004 LINC02762 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4373 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARRDC3-1:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4374 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110611 LINC01752 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4375 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045116 C5orf56 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4376 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POM121L7-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4377 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606434 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4378 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NARG2-7:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4379 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLINT1-3:1 lnc-CLINT1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4380 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAP9-11:1 lnc-MAP9-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4381 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMEM178-1:14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4382 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC2A13-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4383 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C1orf52-2:1 lnc-C1orf52-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4384 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619182 TCL6-213 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4385 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000397551 PAXIP1-AS2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4386 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIGD4-3:1 lnc-TIGD4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4387 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026874 LINC02593 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4388 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034079 CASP17P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4389 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM188A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4390 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624395 Z95114.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4391 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001590 IFITM4P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4392 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000434300 AL390957.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4393 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DKK1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4394 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002727 RFPL1S lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4395 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000501520 AC138904.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4396 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110806 LINC01969 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4397 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608032 AP000919.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4398 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000527511 LINC02762-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4399 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WISP2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4400 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MASTL-3:2 lnc-MASTL-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4401 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT108933.2 NONHSAT108933 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4402 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608412 AC058791.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4403 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT031866 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4404 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT118058.2 NONHSAT118058 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4405 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054054 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4406 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPTLC3-5:1 lnc-SPTLC3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4407 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC22A5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4408 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028301 DUBR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4409 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000513626 LUCAT1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4410 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COPS4-1:1 lnc-COPS4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4411 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SAMD4A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4412 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WSB1-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4413 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NUDCD2-8:1 lnc-NUDCD2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4414 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110326 MAP3K14-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4415 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C16orf53-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4416 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449168 AC096649.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4417 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104644 LINC01204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4418 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033346 BOK-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4419 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDH18-13:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4420 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037176 PSMB8-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4421 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110671 DEPDC1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4422 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605007 AC018638.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4423 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036466 LINC00987 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4424 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_077228 MTHFD2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4425 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRGPRF-6:1 lnc-MRGPRF-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4426 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXorf36-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4427 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037184 NSMCE1-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4428 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027622 LOC100128164 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4429 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NKX2-5-7:1 lnc-NKX2-5-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4430 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOA3-9:5 lnc-NCOA3-9:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4431 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C9orf29-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4432 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUMF2-8:1 lnc-SUMF2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4433 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000395900 WT1-AS-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4434 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_048547 MGST1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4435 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605534 AL121917.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4436 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000444586 AL513210.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4437 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LUC7L3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4438 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503602 AC004803.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4439 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CA4-1:1 lnc-CA4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4440 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C9orf93-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4441 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125775 LURAP1L-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4442 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RLIM-2:24 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4443 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TCF19-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4444 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607057 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4445 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589518 AC008105.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4446 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C8orf42-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4447 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZDHHC2-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4448 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CADM1-7:1 lnc-CADM1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4449 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560197 AC013652.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4450 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-JAKMIP2-1:1 lnc-JAKMIP2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4451 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000483218 AC019068.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4452 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604491 AC097634.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4453 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI27L1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4454 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT033089.2 NONHSAT033089 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4455 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TTC30B-1:6 lnc-TTC30B-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4456 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054092 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4457 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600642 AL137002.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4458 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LAMA4-3:1 lnc-LAMA4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4459 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607586 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4460 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CADM2-6:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4461 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000517833 LY6E-DT-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4462 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000599382 AC245884.8-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4463 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FABP2-2:1 lnc-FABP2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4464 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000517482 AC090192.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4465 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559008 AC016705.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4466 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF135-1:16 lnc-RNF135-1:16 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4467 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SP110-2:1 lnc-SP110-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4468 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000570945 MIR193BHG-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4469 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR143-3:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4470 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033315 BDNF-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4471 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000537616 AC010186.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4472 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000570843 AC108134.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4473 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C9orf102-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4474 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CARD6-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4475 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF705A-3:1 lnc-ZNF705A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4476 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC069257.9.1-4:30 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4477 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454380 AC116366.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4478 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OBFC2A-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4479 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SCARB2-2:5 lnc-SCARB2-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4480 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607837 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4481 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605233 POC1B-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4482 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520185 AC007991.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4483 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609272 FAM106A-212 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4484 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027000 LINC00965 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4485 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RASD1-2:1 lnc-RASD1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4486 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000591892 AL031320.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4487 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000579138 AC005544.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4488 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM172A-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4489 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103852 TAT-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4490 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_108105 CT66 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4491 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120467 LOC101928416 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4492 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TNPO3-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4493 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MED14-5:1 lnc-MED14-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4494 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C4orf34-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4495 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT056405.2 NONHSAT056405 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4496 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000444077 AC017006.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4497 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000529938 LINC02762-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4498 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BEND7-1:3 lnc-BEND7-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4499 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC16A14-3:1 lnc-SLC16A14-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4500 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054078 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4501 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RAG1-5:1 lnc-RAG1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4502 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624364 AP001528.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4503 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104646 LINC02405 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4504 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026659 LOC727896 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4505 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000499322 AC105285.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4506 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618708 MUC20-OT1-251 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4507 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_121212 LINC01507 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4508 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTPRG-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4509 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000440492 LINC02574-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4510 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613779 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4511 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PPP1R12A-3:1 lnc-PPP1R12A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4512 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000601033 AC007785.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4513 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520863 AC108863.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4514 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFI44-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4515 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C17orf51-1:9 lnc-C17orf51-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4516 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GTDC1-25:1 lnc-GTDC1-25:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4517 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033972 LINC02709 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4518 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104643 FLJ32255 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4519 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000450890 ITGB1-DT-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4520 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MUC4-1:8 lnc-MUC4-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4521 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-YARS2-3:1 lnc-YARS2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4522 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AFAP1L1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4523 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000469484 WNT5A-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4524 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612967 C5orf56-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4525 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FARSB-8:2 lnc-FARSB-8:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4526 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CGGBP1-3:1 lnc-CGGBP1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4527 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103548 LUCAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4528 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CORO2A-1:1 lnc-CORO2A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4529 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GBP3-2:1 lnc-GBP3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4530 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM138A-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4531 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MKL2-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4532 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KCNJ5-2:1 lnc-KCNJ5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4533 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ATP6V1G2-DDX39B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4534 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449473 AC093157.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4535 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607679 AL354872.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4536 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110856 LOC101928516 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4537 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054101 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4538 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000473756 LINC00973-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4539 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TLE2-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4540 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000470427 DENND6A-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4541 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DUOXA2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4542 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNK2-7:8 lnc-TNK2-7:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4543 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNAJB9-5:1 lnc-DNAJB9-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4544 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XPO4-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4545 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581471 LINC00667-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4546 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000407772 HCG27-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4547 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ERMAP-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4548 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000535242 AC138466.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4549 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054102 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4550 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568827 AC092338.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4551 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HIRIP3-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4552 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000526642 NAV2-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4553 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RBM45-2:1 lnc-RBM45-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4554 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024125 ATP1A1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4555 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C2CD2L-1:1 lnc-C2CD2L-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4556 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028471 APOOP5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4557 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565689 LOXL1-AS1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4558 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPR155-2:1 lnc-GPR155-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4559 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126057 LINC02520 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4560 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000533672 AP001528.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4561 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000511794 LINC02057-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4562 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM50B-4:1 lnc-TMEM50B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4563 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027082 SFTA1P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4564 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624848 AC016397.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4565 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL353597.1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4566 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000369884 WBP1L-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4567 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FBXO15-3:4 lnc-FBXO15-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4568 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAPK6-12:4 lnc-MAPK6-12:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4569 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000490162 LINC02577-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4570 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT136246 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4571 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028594 ZNF833P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4572 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000506664 LINC00461-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4573 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024126 ATP1A1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4574 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPM1N-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4575 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF8-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4576 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000391000 AL135998.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4577 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FYCO1-3:1 lnc-FYCO1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4578 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015389 LINC00667 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4579 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600062 AC097717.1-243 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4580 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DLC1-2:1 lnc-DLC1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4581 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000494869 AC063952.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4582 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613598 AC002094.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4583 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619983 AC138466.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4584 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCL4L1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4585 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC233263.1-7:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4586 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UGT3A2-1:1 lnc-UGT3A2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4587 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MUC2-1:1 lnc-MUC2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4588 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024399 SNAI3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4589 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606034 AL645608.7-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4590 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM110A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4591 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610252 AC009237.15-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4592 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033947 LIMD1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4593 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SGCE-1:3 lnc-SGCE-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4594 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616851 AC243649.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4595 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KLF15-3:4 lnc-KLF15-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4596 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510240 AC010285.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4597 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VWC2L-1:5 lnc-VWC2L-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4598 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445201 LINC01138-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4599 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623125 AC093908.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4600 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003133 GBP1P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4601 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449486 PAXIP1-AS2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4602 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033867 LOC392232 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4603 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf79-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4604 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM110B-1:9 lnc-FAM110B-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4605 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518552 AC018607.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4606 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565937 AC009065.5-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4607 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000456634 LINC00029-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4608 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF674-1:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4609 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT024013 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4610 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MZT2A-17:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4611 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ISM1-3:1 lnc-ISM1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4612 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000488040 AC092944.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4613 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566535 NSMCE1-DT-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4614 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110473 LINC-PINT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4615 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HCN2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4616 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VAV3-3:1 lnc-VAV3-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4617 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000515895 AC142283.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4618 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RAG1-5:3 lnc-RAG1-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4619 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KB-1507C5.2.1-3:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4620 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HNRNPA1L2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4621 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BMP7-1:3 lnc-BMP7-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4622 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX8-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4623 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AGBL3-1:1 lnc-AGBL3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4624 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000591365 AC008105.3-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4625 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620892 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4626 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103839 FRY-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4627 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDRT1-1:1 lnc-CDRT1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4628 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR143-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4629 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-973F15.1.1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4630 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM5B-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4631 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF470-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4632 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040068 LOXL1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4633 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CNPPD1-1:1 lnc-CNPPD1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4634 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TCL1B-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4635 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-USP9X-8:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4636 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-APIP-1:2 lnc-APIP-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4637 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WDR31-1:2 lnc-WDR31-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4638 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ITPA-2:1 lnc-ITPA-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4639 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581452 DSG1-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4640 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAF1-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4641 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TOM1L2-1:1 lnc-TOM1L2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4642 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608064 AC093726.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4643 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457075 BX284668.5-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4644 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ABHD10-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4645 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNASET2-2:1 lnc-RNASET2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4646 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC069257.9.1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4647 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MYL12B-3:2 lnc-MYL12B-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4648 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073453 LINC00601 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4649 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033709 TP73-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4650 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-INSL4-8:1 lnc-INSL4-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4651 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608943 AC006566.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4652 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC114947.1.1-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4653 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OBFC2A-9:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4654 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026809 FAM106A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4655 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OBFC2A-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4656 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DGCR2-3:1 lnc-DGCR2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4657 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PDGFRB-1:2 lnc-PDGFRB-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4658 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DHX57-6:1 lnc-DHX57-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4659 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000440629 AP001432.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4660 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC2A10-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4661 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPAP2-1:2 lnc-RPAP2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4662 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUMF2-9:1 lnc-SUMF2-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4663 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000427598 KCNK15-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4664 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457233 MUC20-OT1-221 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4665 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GRIK5-1:2 lnc-GRIK5-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4666 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000376617 AC148477.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4667 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NKAIN3-9:1 lnc-NKAIN3-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4668 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ACOT12-5:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4669 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MKLN1-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4670 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NEUROG3-3:1 lnc-NEUROG3-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4671 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTPRG-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4672 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615677 WT1-AS-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4673 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015436 LINC00461 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4674 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000471057 FAM182A-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4675 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623655 ERICD-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4676 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582865 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4677 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MZT2A-1:1 lnc-MZT2A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4678 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000438195 LINC01358-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4679 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SEPT9-1:4 lnc-SEPT9-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4680 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033369 LINC01056 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4681 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ATP10A-8:1 lnc-ATP10A-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4682 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WDR5-2:2 lnc-WDR5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4683 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CATSPER3-5:1 lnc-CATSPER3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4684 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000562763 AC009097.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4685 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000477059 LINC01391-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4686 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-POM121L12-2:2 lnc-POM121L12-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4687 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054060 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4688 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC110373.1-8:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4689 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ST3GAL6-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4690 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000413185 EPCAM-DT-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4691 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ATM-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4692 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000578280 AC004585.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4693 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC45A1-6:1 lnc-SLC45A1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4694 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415144 AL138831.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4695 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C6orf201-2:6 lnc-C6orf201-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4696 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614580 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4697 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000478367 WT1-AS-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4698 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583253 AP005136.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4699 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRIM2-1:1 lnc-TRIM2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4700 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046451 LOC374443 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4701 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561822 PRKCQ-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4702 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DPH5-2:2 lnc-DPH5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4703 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KIAA0930-4:6 lnc-KIAA0930-4:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4704 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038308 LINC01094 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4705 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDH18-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4706 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000426023 AC022034.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4707 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KIF1C-3:1 lnc-KIF1C-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4708 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000525548 AP002433.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4709 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565041 AC005606.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4710 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000574654 AC137056.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4711 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554029 AL359233.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4712 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BCL7C-1:3 lnc-BCL7C-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4713 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415285 AL160153.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4714 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FBXO15-6:3 lnc-FBXO15-6:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4715 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002163 OR7E37P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4716 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PTPN7-2:1 lnc-PTPN7-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4717 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT116907 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4718 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CRHR1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4719 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZFP90-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4720 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-APTX-2:3 lnc-APTX-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4721 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT059510.2 NONHSAT059510 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4722 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT140817.2 NONHSAT140817 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4723 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP001496.1-1:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4724 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BIRC2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4725 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM83A-5:1 lnc-FAM83A-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4726 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERICH1-9:3 lnc-ERICH1-9:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4727 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC112721.1.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4728 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SNX32-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4729 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608737 MUC20-OT1-247 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4730 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SIPA1L1-3:1 lnc-SIPA1L1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4731 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HIST1H2BJ-5:1 lnc-HIST1H2BJ-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4732 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SOD2-3:3 lnc-SOD2-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4733 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000533179 SOX9-AS1-211 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4734 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MFSD8-8:4 lnc-MFSD8-8:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4735 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024402 SNAI3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4736 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF461-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4737 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPATA5-1:2 lnc-SPATA5-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4738 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027178 SNHG29 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4739 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000455309 AC017002.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4740 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000517910 GASAL1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4741 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000448740 DSE-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4742 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EIF4E3-7:1 lnc-EIF4E3-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4743 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-USP14-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4744 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT053955 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4745 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000441568 LINC01747-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4746 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT108292 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4747 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MYNN-8:1 lnc-MYNN-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4748 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNFSF18-1:2 lnc-TNFSF18-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4749 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616826 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4750 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607314 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4751 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PLEKHA5-5:1 lnc-PLEKHA5-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4752 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-VMP1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4753 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDH18-14:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4754 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047479 CCDC200 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4755 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCD3-1:2 lnc-ABCD3-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4756 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581117 AP006565.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4757 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX5-4:1 lnc-DDX5-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4758 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605502 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4759 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HIST1H3D-1:1 lnc-HIST1H3D-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4760 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505978 AC005823.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4761 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TUB-5:1 lnc-TUB-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4762 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000545508 LINC00944-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4763 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RBM11-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4764 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_021492 CHKB-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4765 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VCAN-2:1 lnc-VCAN-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4766 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623796 AL359183.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4767 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002174 CMAHP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4768 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AIM1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4769 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609553 AC096992.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4770 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514145 LINC02021-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4771 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000358234 AC011450.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4772 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000420096 OGFRP1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4773 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028288 TCL6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4774 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX47-3:1 lnc-DDX47-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4775 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CABP4-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4776 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445420 KCNK15-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4777 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC6A20-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4778 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EPN2-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4779 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TPP2-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4780 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120365 TMC3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4781 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CTH-10:1 lnc-CTH-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4782 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRIO-1:1 lnc-TRIO-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4783 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510523 AC105285.1-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4784 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERC2-2:1 lnc-ERC2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4785 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623371 AC099494.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4786 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024476 PAXIP1-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4787 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033864 CYP4F24P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4788 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617238 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4789 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126419 P3H2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4790 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034123 CKMT2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4791 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPUSD2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4792 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP002414.1.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4793 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLIPR1-5:1 lnc-GLIPR1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4794 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AGAP1-3:2 lnc-AGAP1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4795 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-XXYLT1-4:1 lnc-XXYLT1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4796 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000538219 LINC00987-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4797 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LARP1B-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4798 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM208A-1:2 lnc-FAM208A-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4799 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000432045 AC016831.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4800 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT136340 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4801 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HNRNPH1-5:1 lnc-HNRNPH1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4802 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MIPOL1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4803 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANKRD27-9:1 lnc-ANKRD27-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4804 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LRRC58-5:1 lnc-LRRC58-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4805 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028287 GABARAPL3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4806 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ALG9-1:1 lnc-ALG9-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4807 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMAD2-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4808 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF705D-3:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4809 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033343 PSCA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4810 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NMT2-2:2 lnc-NMT2-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4811 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110953 LINC01504 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4812 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPRIN2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4813 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_121649 LINC01391 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4814 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602431 AC125494.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4815 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DNAJB4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4816 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-B3GNT9-2:1 lnc-B3GNT9-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4817 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046101 LINC01545 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4818 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NRP1-2:1 lnc-NRP1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4819 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431981 AL133410.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4820 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RBM27-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4821 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FER1L6-1:2 lnc-FER1L6-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4822 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GUCY1A3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4823 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560419 AF111167.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4824 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SPTLC3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4825 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDC123-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4826 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415026 AP001468.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4827 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000611330 AC010492.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4828 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT076729 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4829 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028138 ATP2B1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4830 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ORMDL3-1:1 lnc-ORMDL3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4831 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF582-5:6 lnc-ZNF582-5:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4832 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624529 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4833 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CEP120-6:1 lnc-CEP120-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4834 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CXCL3-1:1 lnc-CXCL3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4835 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MFAP5-1:1 lnc-MFAP5-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4836 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RBM45-1:1 lnc-RBM45-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4837 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037884 LOC100507053 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4838 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF6-4:1 lnc-RNF6-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4839 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615200 AL049692.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4840 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LRRC58-5:3 lnc-LRRC58-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4841 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNAJB6-3:1 lnc-DNAJB6-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4842 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_123740 RIMKLB lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4843 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000579057 LINC00271-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4844 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110952 LINC01504 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4845 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SYF2-4:2 lnc-SYF2-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4846 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DHRSX-3:1 lnc-DHRSX-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4847 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC110373.1-8:15 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4848 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CARD16-1:1 lnc-CARD16-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4849 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GIMAP5-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4850 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120506 LINC01510 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4851 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT118268 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4852 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC091435.1-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4853 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CAPZA3-3:2 lnc-CAPZA3-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4854 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422542 SNHG26-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4855 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MTRNR2L4-2:1 lnc-MTRNR2L4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4856 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF623-1:1 lnc-ZNF623-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4857 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606160 AL450270.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4858 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046450 LOC374443 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4859 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNAJB12-4:1 lnc-DNAJB12-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4860 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF658-2:2 lnc-ZNF658-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4861 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073180 LIPE-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4862 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLAIN1-6:1 lnc-SLAIN1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4863 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000526906 AC080023.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4864 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027916 AKR1C8P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4865 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IKZF2-3:5 lnc-IKZF2-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4866 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC092327.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4867 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C10orf10-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4868 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNFSF18-2:1 lnc-TNFSF18-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4869 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SORCS2-2:1 lnc-SORCS2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4870 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000478845 AC037198.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4871 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DEC1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4872 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SHC3-6:3 lnc-SHC3-6:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4873 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPL30-4:1 lnc-RPL30-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4874 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110384 PLS3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4875 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110177 NCK1-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4876 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP000974.1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4877 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GCSH-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4878 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PSG6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4879 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614782 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4880 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KLF15-2:5 lnc-KLF15-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4881 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GDA-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4882 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419211 AC015987.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4883 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561746 AP000766.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4884 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000461864 NCK1-DT-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4885 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610021 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4886 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_051988 FBXW10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4887 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PSG4-2:1 lnc-PSG4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4888 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CALM2-2:9 lnc-CALM2-2:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4889 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HIST2H3PS2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4890 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CYB5A-2:1 lnc-CYB5A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4891 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620519 AC092747.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4892 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GCNT6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4893 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMCHD1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4894 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HNRNPA3-1:1 lnc-HNRNPA3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4895 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERICH1-9:4 lnc-ERICH1-9:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4896 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WDR31-1:1 lnc-WDR31-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4897 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000575792 MIR193BHG-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4898 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SFMBT1-1:1 lnc-SFMBT1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4899 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000541749 LINC02387-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4900 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602443 AF131215.7-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4901 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNK2-7:7 lnc-TNK2-7:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4902 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RBCK1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4903 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015378 ZNF674-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4904 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GIMAP6-2:1 lnc-GIMAP6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4905 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPLP1-5:1 lnc-RPLP1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4906 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619353 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4907 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF720-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4908 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024394 LINC00689 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4909 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM106B-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4910 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000538731 LINC02361-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4911 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC069257.9.1-4:29 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4912 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027329 PSMG3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4913 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047507 HOXC13-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4914 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TRIM39-RPP21-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4915 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054103 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4916 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038911 MIF-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4917 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612616 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4918 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT031729.2 NONHSAT031729 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4919 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C10orf28-7:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4920 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457813 AC018685.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4921 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM19A1-3:1 lnc-FAM19A1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4922 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MFSD8-6:1 lnc-MFSD8-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4923 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036569 STAG3L5P-PVRIG2P-PILRB lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4924 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL713998.1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4925 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454253 Z99916.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4926 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602554 AC011450.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4927 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027097 LINC00486 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4928 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054083 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4929 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MZT2A-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4930 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015379 UCA1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4931 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZFP57-7:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4932 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MKL2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4933 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTBP1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4934 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TCL1B-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4935 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560743 AC013652.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4936 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000499459 AC008966.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4937 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM69-1:1 lnc-TMEM69-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4938 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607175 AL021807.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4939 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419832 AC073323.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4940 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622847 AL122023.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4941 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PQLC2-1:1 lnc-PQLC2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4942 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602739 AC009108.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4943 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSC22D2-4:1 lnc-TSC22D2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4944 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_004401 SEC1P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4945 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSHB-2:1 lnc-TSHB-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4946 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000469070 AC092910.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4947 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHX38-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4948 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623752 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4949 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561826 AC092142.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4950 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608162 AP005432.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4951 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPR83-3:1 lnc-GPR83-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4952 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000533697 AP003032.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4953 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CEP89-1:2 lnc-CEP89-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4954 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000599770 AC243960.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4955 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000362361 AC069285.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4956 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015341 SMURF2P1-LRRC37BP1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4957 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KIAA1210-4:1 lnc-KIAA1210-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4958 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SAP30-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4959 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580993 AC008088.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4960 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607876 AL135910.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4961 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503052 AC020661.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4962 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000529127 AC103855.2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4963 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125975 WARS2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4964 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036533 LOC100499489 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4965 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OGFOD1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4966 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC17A5-2:1 lnc-SLC17A5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4967 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRPM1-3:1 lnc-TRPM1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4968 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617006 AC008622.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4969 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLEC2D-8:7 lnc-CLEC2D-8:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4970 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GJE1-3:2 lnc-GJE1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4971 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415536 AC003092.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4972 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERCC6L-2:1 lnc-ERCC6L-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4973 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HSF4-1:1 lnc-HSF4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4974 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PRELID2-1:4 lnc-PRELID2-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4975 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ERAP2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4976 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SDSL-9:1 lnc-SDSL-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4977 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046662 ADIPOQ-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4978 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HOXD13-3:2 lnc-HOXD13-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4979 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000571639 MIR193BHG-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4980 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZHX1-5:1 lnc-ZHX1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4981 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC002365.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4982 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036522 ZNF667-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4983 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552663 LINC02356-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4984 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CD302-2:1 lnc-CD302-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4985 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602488 CCDC18-AS1-224 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4986 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERC1-2:1 lnc-ERC1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4987 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-XRN2-8:1 lnc-XRN2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4988 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLVS1-1:5 lnc-CLVS1-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4989 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TPH2-5:1 lnc-TPH2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4990 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581677 AP000845.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4991 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT135090.2 NONHSAT135090 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4992 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621984 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4993 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CETP-2:1 lnc-CETP-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4994 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLRX-3:1 lnc-GLRX-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4995 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZC3HAV1L-1:1 lnc-ZC3HAV1L-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4996 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DNAL1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4997 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559277 TMC3-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4998 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613210 AC004494.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 4999 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SNX10-6:1 lnc-SNX10-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5000 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDKN3-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5001 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PPP1R13L-2:1 lnc-PPP1R13L-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5002 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_102326 HCG18 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5003 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623999 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5004 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DCBLD1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5005 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037602 LINC01578 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5006 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_044999 OR7E12P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5007 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037875 MAP4K3-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5008 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCAKD-2:1 lnc-DCAKD-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5009 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR51B4-3:2 lnc-OR51B4-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5010 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PAIP1-2:1 lnc-PAIP1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5011 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609315 AL359091.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5012 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ERAP2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5013 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565523 AC023824.5-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5014 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WFDC3-1:1 lnc-WFDC3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5015 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPT2-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5016 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NOC2L-8:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5017 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCDC43-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5018 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT108638 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5019 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034072 SARS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5020 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NUCB2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5021 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120686 LINC01503 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5022 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027501 BCDIN3D-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5023 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620563 AC096708.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5024 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT119334.2 NONHSAT119334 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5025 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454980 AP000695.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5026 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518539 KBTBD11-OT1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5027 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COLEC12-4:3 lnc-COLEC12-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5028 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130742 FAM86EP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5029 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ENPP1-5:3 lnc-ENPP1-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5030 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CLDN16-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5031 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM117B-6:1 lnc-FAM117B-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5032 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026827 LINC00839 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5033 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000495691 AC007952.8-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5034 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CENPJ-1:6 lnc-CENPJ-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5035 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566575 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5036 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF192-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5037 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000548691 AC079598.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5038 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPP1R2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5039 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSC22D2-3:1 lnc-TSC22D2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5040 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AFAP1-2:1 lnc-AFAP1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5041 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002569 SCARNA9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5042 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606796 AL096865.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5043 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MC5R-1:2 lnc-MC5R-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5044 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MEGF10-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5045 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF31-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5046 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024489 LOC100129534 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5047 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445534 AC112715.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5048 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP000350.4.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5049 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IQGAP2-4:1 lnc-IQGAP2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5050 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026955 NRAD1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5051 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CNNM1-3:1 lnc-CNNM1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5052 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BCAT1-3:1 lnc-BCAT1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5053 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHST7-5:1 lnc-CHST7-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5054 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NKD2-3:8 lnc-NKD2-3:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5055 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616774 AC092119.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5056 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620493 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5057 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR143-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5058 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GRB14-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5059 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027425 FAM66D lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5060 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000509548 LINC02512-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5061 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582527 AC132825.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5062 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000573896 SPACA6-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5063 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104462 CENPW lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5064 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCDC144A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5065 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHD2-11:1 lnc-CHD2-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5066 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577218 AC068025.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5067 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000548901 AC011595.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5068 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMEM133-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5069 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609288 AC131235.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5070 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TDO2-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5071 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000625115 CU633904.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5072 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026921 LOC202181 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5073 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624846 CU638689.4-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5074 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000547042 AC005841.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5075 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERI3-1:1 lnc-ERI3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5076 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GCNT6-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5077 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LRRTM1-7:1 lnc-LRRTM1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5078 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C5orf39-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5079 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCT5-15:1 lnc-CCT5-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5080 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PIGZ-1:1 lnc-PIGZ-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5081 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000455986 NKAP-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5082 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000468859 LINC02614-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5083 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ST6GALNAC5-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5084 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577798 COX10-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5085 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT023699 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5086 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MYO18B-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5087 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033969 PLCE1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5088 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPRML-3:15 lnc-RPRML-3:15 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5089 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPS12-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5090 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MTSS1L-1:1 lnc-MTSS1L-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5091 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034089 CCDC18-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5092 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512538 SLC7A11-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5093 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000585780 MAP3K14-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5094 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000511543 FAM13A-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5095 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002779 NUDT9P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5096 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125364 MKLN1-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5097 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CENPW-3:1 lnc-CENPW-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5098 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624610 AC007342.7-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5099 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-STAG1-5:1 lnc-STAG1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5100 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000562696 AC092115.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5101 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623064 AC011466.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5102 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000436672 AL356277.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5103 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FXYD6-2:1 lnc-FXYD6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5104 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAMSTR-1:1 lnc-MAMSTR-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5105 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf14-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5106 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PZP-6:2 lnc-PZP-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5107 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CST7-5:1 lnc-CST7-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5108 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCDC144C-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5109 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000533670 LINC02754-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5110 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036485 SBF2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5111 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C14orf135-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5112 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRPS5-12:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5113 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607350 AL512329.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5114 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BLACE-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5115 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CRCP-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5116 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602790 AC005479.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5117 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608029 AC106052.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5118 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000363024 AC093872.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5119 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FBXO44-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5120 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOA3-23:1 lnc-NCOA3-23:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5121 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SERP1-1:1 lnc-SERP1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5122 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COBLL1-1:1 lnc-COBLL1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5123 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT070320.2 NONHSAT070320 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5124 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RAET1E-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5125 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000387419 MT-TD-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5126 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512978 LINC02100-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5127 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433747 AC073529.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5128 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567614 AC244090.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5129 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027120 HSD52 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5130 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SPRED2-11:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5131 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-STAG1-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5132 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EBF3-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5133 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609514 AL355512.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5134 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IL5-1:2 lnc-IL5-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5135 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000425820 AL138789.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5136 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AHNAK-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5137 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC109486.1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5138 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_105006 LINC01111 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5139 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZBTB17-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5140 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036581 TMEM238L lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5141 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000496842 AC080013.1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5142 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TK2-8:1 lnc-TK2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5143 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028062 PRKY lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5144 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UCN2-2:2 lnc-UCN2-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5145 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623593 AC145098.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5146 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027413 LINC00910 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5147 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM156B-1:1 lnc-FAM156B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5148 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LPAR6-4:1 lnc-LPAR6-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5149 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000530049 AC116021.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5150 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASNS-1:9 lnc-ASNS-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5151 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C15orf54-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5152 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EIF2B5-6:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5153 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC007401.2.1-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5154 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT117915 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5155 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000447430 LINC00513-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5156 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038905 FZD4-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5157 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000479612 LINC00882-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5158 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MUC19-2:1 lnc-MUC19-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5159 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CACNG5-2:1 lnc-CACNG5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5160 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PREX2-2:1 lnc-PREX2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5161 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KB-1980E6.3.1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5162 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000541092 AP000786.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5163 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LEF1-3:6 lnc-LEF1-3:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5164 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000549961 AC084879.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5165 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000522970 AC007991.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5166 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602575 AF131215.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5167 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RAB40B-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5168 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUSD1-2:1 lnc-SUSD1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5169 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000437416 AC096537.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5170 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026835 FLJ37201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5171 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-C-4:1 lnc-HLA-C-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5172 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000458463 Z99756.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5173 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607421 U47924.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5174 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KNTC1-3:1 lnc-KNTC1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5175 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PLSCR2-5:1 lnc-PLSCR2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5176 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605886 AL365181.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5177 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000499900 AC139795.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5178 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DDX60L-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5179 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPATCH8-2:1 lnc-GPATCH8-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5180 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608985 AC097717.1-244 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5181 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANXA11-1:1 lnc-ANXA11-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5182 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DGCR2-1:1 lnc-DGCR2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5183 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C10orf96-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5184 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000458080 Z93930.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5185 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-A-7:2 lnc-HLA-A-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5186 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000591569 BLOC1S3-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5187 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DMGDH-1:3 lnc-DMGDH-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5188 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PSORS1C2-1:2 lnc-PSORS1C2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5189 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCP110-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5190 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HSD17B14-4:1 lnc-HSD17B14-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5191 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM50B-3:1 lnc-TMEM50B-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5192 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109821 NR2F1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5193 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RND3-4:1 lnc-RND3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5194 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT008794 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5195 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF135-1:12 lnc-RNF135-1:12 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5196 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SF3B5-3:1 lnc-SF3B5-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5197 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCDC54-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5198 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CPN1-1:1 lnc-CPN1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5199 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLUD2-14:1 lnc-GLUD2-14:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5200 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000436600 CT66-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5201 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UBE2E3-9:1 lnc-UBE2E3-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5202 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000440326 MYOSLID-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5203 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KAT7-5:1 lnc-KAT7-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5204 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RIBC2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5205 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-STXBP4-1:3 lnc-STXBP4-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5206 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT108241 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5207 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000556035 AL132709.7-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5208 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000458509 TH2LCRR-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5209 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ACADL-1:1 lnc-ACADL-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5210 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WDR27-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5211 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110012 LINC00211 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5212 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577678 AC099850.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5213 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002929 LOC148709 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5214 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000509194 AC093801.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5215 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130107 GHET1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5216 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430416 AC019080.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5217 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HDAC2-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5218 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026675 CRYM-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5219 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPIAL4C-9:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5220 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NFE2L2-1:3 lnc-NFE2L2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5221 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC011497.1-2:11 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5222 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-171N4.2.1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5223 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C15orf60-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5224 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FDXACB1-3:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5225 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DERA-4:2 lnc-DERA-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5226 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040092 LOC100506990 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5227 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf65-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5228 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000537288.1 A2ML1-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5229 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC17-5:1 lnc-CCDC17-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5230 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZFP62-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5231 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619354 AC099521.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5232 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FDXACB1-3:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5233 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606963 AC100814.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5234 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027626 CMAHP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5235 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FRMD6-2:2 lnc-FRMD6-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5236 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026730 TPTE2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5237 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559857 AC090907.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5238 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTD-2117L12.1.1-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5239 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TBXAS1-4:1 lnc-TBXAS1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5240 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PSG2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5241 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000391200 AC087893.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5242 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOA3-5:9 lnc-NCOA3-5:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5243 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TEFM-8:1 lnc-TEFM-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5244 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015360 LINC01184 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5245 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HIATL1-19:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5246 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NIPA1-1:14 lnc-NIPA1-1:14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5247 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000603533 AL161729.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5248 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027995 ANKRD20A9P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5249 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCAKD-1:3 lnc-DCAKD-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5250 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FCHO2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5251 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002806 FAM13A-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5252 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616043 LINC02614-215 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5253 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCUN1D5-5:1 lnc-DCUN1D5-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5254 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037183 SPANXA2-OT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5255 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSC22D2-1:3 lnc-TSC22D2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5256 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000597199 LINC01480-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5257 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TTC30B-4:1 lnc-TTC30B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5258 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DMAP1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5259 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CKS2-3:2 lnc-CKS2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5260 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OSBPL6-2:14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5261 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PRDM4-6:4 lnc-PRDM4-6:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5262 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612219 AC008013.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5263 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622426 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5264 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046268 TGFB2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5265 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GCNT6-5:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5266 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ATP6V1H-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5267 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PDHX-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5268 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-166B2.1.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5269 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM83A-7:1 lnc-FAM83A-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5270 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM49B-9:1 lnc-FAM49B-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5271 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT125967 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5272 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554634 AC005476.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5273 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109822 NR2F1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5274 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618824 AC103691.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5275 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451213 AC093157.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5276 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623222 AL022069.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5277 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612367 AC009163.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5278 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608916 AC073529.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5279 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TDRD3-12:1 lnc-TDRD3-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5280 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NRSN1-5:1 lnc-NRSN1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5281 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PLS1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5282 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026575 GK3P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5283 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-STAG3L4-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5284 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC31A1-1:1 lnc-SLC31A1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5285 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM241-4:1 lnc-TMEM241-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5286 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000442355 AC007952.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5287 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC167-2:1 lnc-CCDC167-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5288 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EDAR-5:1 lnc-EDAR-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5289 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARRDC2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5290 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NUP43-1:1 lnc-NUP43-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5291 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PSMB3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5292 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624087 AC131212.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5293 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM41B-4:1 lnc-TMEM41B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5294 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000427169 LINC02806-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5295 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASNS-1:1 lnc-ASNS-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5296 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC104024.2.1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5297 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518993 AC090152.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5298 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CEP63-4:1 lnc-CEP63-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5299 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000595525 AC004597.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5300 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606660 LINC02609-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5301 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C11orf75-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5302 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CALCOCO2-9:1 lnc-CALCOCO2-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5303 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512754 LINC01085-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5304 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TLR1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5305 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMAD5-9:1 lnc-SMAD5-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5306 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C17orf104-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5307 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARMC1-3:1 lnc-ARMC1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5308 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ACOT12-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5309 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TAB2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5310 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609349 AC012360.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5311 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C16orf62-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5312 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SIRT7-1:3 lnc-SIRT7-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5313 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003028 SNORA25 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5314 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT023638.2 NONHSAT023638 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5315 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604982 AC112220.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5316 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110035 LOC100996671 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5317 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GDF10-3:1 lnc-GDF10-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5318 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FDXACB1-3:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5319 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551187 AC044802.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5320 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000434919 SFTA1P-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5321 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002171 OR7E156P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5322 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000390787 MIR761-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5323 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LINC00293-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5324 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000578929 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5325 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRPS28-3:12 lnc-MRPS28-3:12 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5326 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034132 LINC00939 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5327 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000470348 AC087071.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5328 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LEAP2-4:1 lnc-LEAP2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5329 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR183-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5330 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL137145.1-2:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5331 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110204 CHROMR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5332 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034077 THAP9-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5333 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104147 LOC100996447 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5334 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CXorf38-3:1 lnc-CXorf38-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5335 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EEF1A2-1:3 lnc-EEF1A2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5336 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ACYP2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5337 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617424 AC114778.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5338 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518024 LY6E-DT-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5339 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT116905 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5340 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FNBP4-5:1 lnc-FNBP4-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5341 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CPEB2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5342 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C9orf129-2:1 lnc-C9orf129-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5343 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNP1-5:4 lnc-TNP1-5:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5344 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606279 AC087045.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5345 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BTBD1-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5346 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621471 AC103858.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5347 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002451 ABCA11P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5348 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_023380 CCDC144CP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5349 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000524252 AC100800.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5350 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PRAGMIN.1-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5351 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF699-2:2 lnc-ZNF699-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5352 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PRELID2-1:6 lnc-PRELID2-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5353 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UGDH-1:1 lnc-UGDH-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5354 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AGMAT-5:1 lnc-AGMAT-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5355 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX5-3:2 lnc-DDX5-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5356 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ACSM3-1:3 lnc-ACSM3-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5357 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002147 MYH16 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5358 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FGL1-3:2 lnc-FGL1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5359 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000573315 LINC00514-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5360 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110944 LINC02182 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5361 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM22E-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5362 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000439057 KDM4A-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5363 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000556024 AL121790.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5364 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF259-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5365 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF135-1:11 lnc-RNF135-1:11 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5366 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613067 AC097634.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5367 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AKR1C3-1:1 lnc-AKR1C3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5368 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451762 WDFY3-AS2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5369 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IFITM2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5370 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000436488 AC140481.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5371 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623871 AC148477.7-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5372 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MYL12B-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5373 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608576 AC073529.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5374 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RAG1-4:1 lnc-RAG1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5375 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000487238 AC092944.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5376 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MYO19-1:3 lnc-MYO19-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5377 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SAG-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5378 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110037 LOC100996437 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5379 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_108045 LINC00867 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5380 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM19A1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5381 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT013575 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5382 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM106A-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5383 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003190 USP32P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5384 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000366405 ZPR1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5385 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027424 FAM66E lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5386 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PLEKHA2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5387 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000429315 KIF9-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5388 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FERMT2-4:1 lnc-FERMT2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5389 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C5orf22-7:1 lnc-C5orf22-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5390 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PTCH2-1:1 lnc-PTCH2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5391 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040033 LINC01915 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5392 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622374 AC131025.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5393 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620494 LINC02340-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5394 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000563574 AL135818.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5395 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126038 LRRC37A8P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5396 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ANGPT2-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5397 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C17orf28-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5398 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BDNF-6:1 lnc-BDNF-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5399 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GAPVD1-2:1 lnc-GAPVD1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5400 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CA5B-1:3 lnc-CA5B-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5401 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF572-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5402 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103855 LOC100506258 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5403 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRMPD2-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5404 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PARN-10:1 lnc-PARN-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5405 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNASET2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5406 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PDE4B-1:1 lnc-PDE4B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5407 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNAJC19-5:8 lnc-DNAJC19-5:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5408 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM104A-3:1 lnc-FAM104A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5409 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PML-1:1 lnc-PML-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5410 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622740 LINC01551-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5411 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC114-2:3 lnc-CCDC114-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5412 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR27-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5413 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AATF-2:1 lnc-AATF-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5414 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000563434 AL138756.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5415 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NUS1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5416 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CGA-4:1 lnc-CGA-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5417 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000415338 AC239798.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5418 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RCOR2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5419 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMUB1-1:2 lnc-TMUB1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5420 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDX19B-2:1 lnc-DDX19B-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5421 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZZZ3-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5422 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SEC22A-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5423 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TEX9-2:1 lnc-TEX9-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5424 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PIGY-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5425 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000532890 MIR100HG-218 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5426 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026966 LOC100130691 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5427 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FOXO3-4:1 lnc-FOXO3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5428 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SCIMP-1:7 lnc-SCIMP-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5429 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125377 LOC100288798 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5430 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PLSCR2-5:3 lnc-PLSCR2-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5431 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-UCHL1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5432 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000497961 AC112496.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5433 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038847 LINC00672 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5434 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C17orf69-2:18 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5435 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT054095 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5436 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GTF2E1-1:1 lnc-GTF2E1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5437 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000418546 AC016831.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5438 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC9A7-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5439 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT108567 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5440 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DPP6-6:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5441 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SNAP47-1:3 lnc-SNAP47-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5442 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620737 MUC20-OT1-252 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5443 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTD-2049J23.3.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5444 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PATL2-1:1 lnc-PATL2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5445 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GJA10-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5446 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC091435.1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5447 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000530303 AP000679.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5448 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584431 AP000919.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5449 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FBLN2-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5450 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PENK-2:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5451 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FMO4-3:1 lnc-FMO4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5452 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZRSR2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5453 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BCL10-1:1 lnc-BCL10-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5454 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TXNDC2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5455 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C12orf53-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5456 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT106550 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5457 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624958 AL359510.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5458 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551271 AL928654.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5459 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000479311 LINC01118-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5460 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LARP6-4:1 lnc-LARP6-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5461 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613715 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5462 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AHR-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5463 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC25A21-3:1 lnc-SLC25A21-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5464 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT095731.2 NONHSAT095731 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5465 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ANKIB1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5466 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MTCH1-3:1 lnc-MTCH1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5467 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BRI3-2:1 lnc-BRI3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5468 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000573982 AC006111.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5469 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000501702 LINC01184-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5470 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHRS12-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5471 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COLEC12-4:2 lnc-COLEC12-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5472 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C9orf21-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5473 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122107 KU-MEL-3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5474 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DNTTIP2-2:1 lnc-DNTTIP2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5475 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000543486 AP003170.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5476 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CYP11B2-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5477 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NME5-2:1 lnc-NME5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5478 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TRH-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5479 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP44-2:1 lnc-USP44-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5480 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623816 AC040160.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5481 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UBQLNL-1:1 lnc-UBQLNL-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5482 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP001793.1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5483 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC004696.1-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5484 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445235 AC069542.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5485 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110997 MIR3936HG lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5486 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000525473 ALG1L9P-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5487 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000516910 AL356785.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5488 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNFSF8-2:1 lnc-TNFSF8-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5489 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000488720 FLNB-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5490 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RABGGTB-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5491 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602736 AC012065.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5492 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000384676 AC023950.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5493 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000466740 AC141424.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5494 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HSPB11-1:1 lnc-HSPB11-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5495 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KCNJ14-1:1 lnc-KCNJ14-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5496 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NR1I2-1:4 lnc-NR1I2-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5497 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FREM1-1:1 lnc-FREM1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5498 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ACOT12-5:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5499 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDC42SE1-1:2 lnc-CDC42SE1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5500 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608028 AC069222.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5501 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000596963 AC010139.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5502 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038236 LINC00968 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5503 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CRYGN-3:2 lnc-CRYGN-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5504 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038991 RBM26-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5505 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C9orf95-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5506 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C21orf63-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5507 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614150 AL354950.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5508 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606048 AC107952.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5509 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559410 AC016595.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5510 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAIM3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5511 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BDNF-7:1 lnc-BDNF-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5512 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MADD-2:1 lnc-MADD-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5513 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MBOAT1-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5514 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPAPDC2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5515 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015359 WDFY3-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5516 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103495 GIGYF2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5517 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000453011 AC093157.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5518 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MCART1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5519 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PHF15-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5520 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000499178 AP002026.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5521 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF483-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5522 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433110 AL158166.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5523 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TRH-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5524 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607153 AC073065.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5525 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608396 OLMALINC-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5526 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610185 AP000894.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5527 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MORC3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5528 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452844 MUC20-OT1-218 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5529 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000553425 AL121790.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5530 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_039985 FLJ22447 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5531 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046632 NHS-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5532 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000625142 AL022393.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5533 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMC3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5534 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000413496 AC008440.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5535 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584649 AC090844.3-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5536 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110472 LINC-PINT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5537 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000384688 AL022724.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5538 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNASEH2C-1:1 lnc-RNASEH2C-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5539 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RCAN2-2:1 lnc-RCAN2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5540 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617833 SNHG22-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5541 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HDHD1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5542 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IL5RA-15:1 lnc-IL5RA-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5543 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000534036 NAV2-AS3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5544 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554558 KTN1-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5545 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SYT1-10:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5546 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ELF5-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5547 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000550029 AC025265.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5548 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WDR73-3:7 lnc-WDR73-3:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5549 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1orf229-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5550 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554678 AL355075.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5551 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXorf69-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5552 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT090840 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5553 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NUDT21-5:1 lnc-NUDT21-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5554 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UBL3-5:1 lnc-UBL3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5555 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000564977 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5556 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000501397 AP001351.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5557 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034125 C10orf143 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5558 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC5A6-2:1 lnc-SLC5A6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5559 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514291 LIFR-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5560 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RAD1-1:1 lnc-RAD1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5561 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SPG20-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5562 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TUBE1-1:1 lnc-TUBE1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5563 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMPPE-2:1 lnc-TMPPE-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5564 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026902 RBM48 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5565 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PIGN-6:1 lnc-PIGN-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5566 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037597 LOC442028 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5567 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120593 PRSS23 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5568 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KDELC2-2:1 lnc-KDELC2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5569 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520885 AC040970.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5570 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568593 AC099778.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5571 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109943 LINC01273 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5572 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IGFBP3-1:1 lnc-IGFBP3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5573 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT106613 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5574 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C4orf34-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5575 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TRIB3-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5576 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PABPC1L-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5577 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCC5-2:1 lnc-ABCC5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5578 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAP-3:1 lnc-FAP-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5579 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF366-17:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5580 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073568 GHRLOS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5581 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581533 AC005304.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5582 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130941 LNPK lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5583 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-706O15.1.1-8:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5584 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-A-3:1 lnc-HLA-A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5585 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419614 LINC01701-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5586 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TOX3-7:1 lnc-TOX3-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5587 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000525309 AC090159.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5588 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCDC1-5:5 lnc-DCDC1-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5589 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000410513 RN7SKP56-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5590 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf65-8:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5591 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GJE1-3:5 lnc-GJE1-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5592 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CA5B-1:6 lnc-CA5B-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5593 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000423323 COX10-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) up-regulated resistant NA NA NA predicted 5594 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130179 LOC100421746 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5595 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073080 PHLDA3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5596 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001564 XIST lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5597 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ST8SIA5-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5598 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT101069.2 NONHSAT101069 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5599 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027457 LINC00221 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5600 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047570 PAX8-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5601 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038435 HOXD-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5602 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000446630 AL731683.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5603 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RBP1-1:1 lnc-RBP1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5604 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SEL1L2-3:1 lnc-SEL1L2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5605 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034119 LINC00460 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5606 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435264 BX927168.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5607 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036442 CEROX1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5608 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA1462-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5609 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520819 AC090204.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5610 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FMN2-4:1 lnc-FMN2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5611 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422956 PAX8-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5612 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NEUROD6-7:3 lnc-NEUROD6-7:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5613 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MOG-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5614 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038346 MAGI2-AS3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5615 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424850 AL035541.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5616 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SSX1-5:1 lnc-SSX1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5617 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034031 LOC389906 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5618 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CREB5-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5619 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAGE1C-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5620 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620019 AL031651.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5621 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CREM-2:1 lnc-CREM-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5622 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-1220K2.2.1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5623 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028366 SSX6P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5624 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120607 LINCR-0003 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5625 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-DRB1-4:1 lnc-HLA-DRB1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5626 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_023915 IPW lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5627 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580278 CCDC144NL-AS1-213 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5628 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SDIM1-3:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5629 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000456563 BX890604.2-212 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5630 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034133 LINC02864 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5631 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT117807.2 NONHSAT117807 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5632 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026860 LINC00473 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5633 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RRM2B-7:3 lnc-RRM2B-7:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5634 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003336 SNORD116-22 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5635 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027409 GOLGA8A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5636 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103835 LINC02584 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5637 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-706O15.1.1-1:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5638 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110720 LINC01535 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5639 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024553 ZNF204P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5640 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIMM21-12:1 lnc-TIMM21-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5641 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027049 ZNF788 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5642 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003329 SNORD116-14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5643 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609265 AL031587.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5644 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122034 LINC01419 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5645 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622592 AP003900.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5646 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026664 MGC16025 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5647 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DAOA-4:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5648 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040028 ZNF790-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5649 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038434 LOC100506474 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5650 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF506-8:1 lnc-ZNF506-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5651 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ADD2-2:1 lnc-ADD2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5652 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560097 AC104041.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5653 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000440315 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5654 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430471 AC096677.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5655 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000506106 AC025470.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5656 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_029420 LOC650226 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5657 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038279 LINC00665 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5658 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDC73-9:1 lnc-CDC73-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5659 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPP1R3F-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5660 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT075636.2 NONHSAT075636 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5661 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VTI1A-3:1 lnc-VTI1A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5662 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624858 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5663 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003330 SNORD116-15 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5664 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027767 TNIK lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5665 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZBTB20-5:1 lnc-ZBTB20-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5666 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110468 HAGLR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5667 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567197 LINC02562-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5668 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073432 CSAG4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5669 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015377 PAX8-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5670 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617955 MAGI2-AS3-221 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5671 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF570-2:1 lnc-ZNF570-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5672 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581862 AC079062.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5673 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003338 SNORD116-24 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5674 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ATF7IP2-3:7 lnc-ATF7IP2-3:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5675 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHRM3-1:5 lnc-CHRM3-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5676 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C11orf44-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5677 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435024 LINC00460-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5678 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPBP1-5:1 lnc-GPBP1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5679 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PTPRD-7:1 lnc-PTPRD-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5680 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027291 NAP1L6P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5681 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LEMD1-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5682 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000555300 AL136018.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5683 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP51-5:1 lnc-USP51-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5684 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VN1R4-3:1 lnc-VN1R4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5685 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000483854 BX890604.2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5686 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109758 LINC02315 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5687 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606809 AL109659.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5688 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600644 AC021504.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5689 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433732 XIST-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5690 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ABCE1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5691 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP3-377D14.1.1-3:19 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5692 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002785 GNAS-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5693 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424415 BX890604.2-215 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5694 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033838 LOC158435 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5695 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026656 LINC02381 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5696 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000521718 AC022784.1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5697 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000534117 LINC01301-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5698 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000432783 AL449403.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5699 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598084 LINC01198-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5700 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ALX1-2:4 lnc-ALX1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5701 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000458394 CUTALP-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5702 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000458001 GAS6-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5703 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000557618 AL049874.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5704 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003334 SNORD116-20 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5705 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622757 AL133325.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5706 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026861 LINC00473 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5707 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FLT3-2:2 lnc-FLT3-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5708 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026776 LOC100270746 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5709 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SHROOM4-3:1 lnc-SHROOM4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5710 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125751 TBX2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5711 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BAI3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5712 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617888 LINC01971-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5713 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF534-1:2 lnc-ZNF534-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5714 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514811 AC011389.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5715 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FANCC-6:1 lnc-FANCC-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5716 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NEUROD6-7:2 lnc-NEUROD6-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5717 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120647 LINC01515 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5718 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSEN2-4:1 lnc-TSEN2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5719 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073396 ZNF818P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5720 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122077 LERFS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5721 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110618 NFIA-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5722 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-APLN-1:3 lnc-APLN-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5723 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT138945 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5724 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FANK1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5725 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FEZ1-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5726 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF827-8:1 lnc-ZNF827-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5727 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623737 AC078925.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5728 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435485 LINC01505-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5729 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDK20-4:2 lnc-CDK20-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5730 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000603198 AL162413.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5731 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584273 LINC01956-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5732 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034100 LINC00668 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5733 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584544 AC079062.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5734 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCAF4L2-3:1 lnc-DCAF4L2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5735 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567527 AC124312.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5736 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037595 HHIP-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5737 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000498731 SOX2-OT-218 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5738 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_075092 SOX2-OT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5739 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT070687 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5740 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431060 AC015712.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5741 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000603720 AC017033.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5742 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126355 LINC01389 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5743 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024493 SMIM10L2B lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5744 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104228 LINC00632 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5745 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AP1S3-1:1 lnc-AP1S3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5746 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAGE1C-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5747 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT118504 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5748 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001280 PCDHB17P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5749 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552826 LINC02588-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5750 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AMY1B-5:1 lnc-AMY1B-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5751 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000596766 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5752 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPL7-4:1 lnc-RPL7-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5753 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLYATL3-2:3 lnc-GLYATL3-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5754 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_108107 FAM230B lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5755 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AMY1B-6:1 lnc-AMY1B-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5756 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POTED-4:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5757 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C20orf197-3:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5758 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125740 LOC100505938 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5759 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622987 AC018445.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5760 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FOXG1-9:1 lnc-FOXG1-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5761 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000524132 AC090809.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5762 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-1220K2.2.1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5763 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF527-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5764 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027250 SSX8P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5765 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EXTL1-1:1 lnc-EXTL1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5766 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109931 LOC101928796 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5767 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598892 ZNF528-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5768 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605586 Z99289.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5769 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR4E2-7:1 lnc-OR4E2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5770 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTDSPL-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5771 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT086647 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5772 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000593577 AC021504.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5773 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000601979 LINC01515-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5774 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002833 DPY19L2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5775 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC040934.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5776 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000493248 AC004889.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5777 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LRFN5-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5778 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000557067 AL121821.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5779 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GORAB-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5780 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510016 AC079160.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5781 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000498032 AC112487.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5782 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PZP-12:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5783 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_075093 SOX2-OT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5784 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM60A-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5785 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AGAP2-1:3 lnc-AGAP2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5786 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608354 AC004264.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5787 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559321 LINC02253-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5788 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CD59-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5789 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR157-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5790 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033418 ZNF542P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5791 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002835 HAS2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5792 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431071 LINC02476-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5793 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000530350 AC108136.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5794 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027278 FAM230C lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5795 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000558254 AC015712.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5796 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PZP-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5797 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAGE2B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5798 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF502-1:2 lnc-ZNF502-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5799 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110849 SCAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5800 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623919 LINC01667-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5801 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038916 PRR7-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5802 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623067 LINC02109-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5803 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LINGO2-3:1 lnc-LINGO2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5804 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000446720 AC112178.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5805 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110546 LINC02298 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5806 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TUBB-14:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5807 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NOVA1-9:4 lnc-NOVA1-9:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5808 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000443593 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5809 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CABIN1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5810 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SGIP1-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5811 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120606 LINCR-0002 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5812 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000425271 AL596087.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5813 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CTNNA2-3:2 lnc-CTNNA2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5814 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103850 CASC9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5815 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NACA2-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5816 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130763 LOC102723968 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5817 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002795 HOXA11-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5818 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRPS9-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5819 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BCAT1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5820 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-POU3F2-5:1 lnc-POU3F2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5821 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SNURFL-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5822 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577841 CCDC144NL-AS1-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5823 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GLYAT-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5824 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036484 FEZF1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5825 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610941 AC016597.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5826 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000412639 LNCTAM34A-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5827 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OGFR-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5828 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT001996.2 NONHSAT001996 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5829 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TUBA3C-9:2 lnc-TUBA3C-9:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5830 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT071500 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5831 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026869 LINC00052 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5832 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000363883 AC004130.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5833 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDK20-4:1 lnc-CDK20-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5834 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604994 AC106900.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5835 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC22A16-1:1 lnc-SLC22A16-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5836 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514769 LINC02163-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5837 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451350 AC012368.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5838 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 lncRNAdb NA cdr1-as_homosapiens_1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5839 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422996 AC064875.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5840 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606154 Z97200.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5841 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 lncRNAdb NA ara_hg_1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5842 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000412855 LINC01703-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5843 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512343 RASGEF1B-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5844 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120426 LINC01198 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5845 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024359 SMIM10L2A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5846 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF187-3:3 lnc-RNF187-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5847 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF527-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5848 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM69B-2:1 lnc-FAM69B-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5849 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000508752 FAM198B-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5850 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM60A-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5851 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000429109 AC093151.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5852 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000523050 AC008464.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5853 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-POTEC-5:2 lnc-POTEC-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5854 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561592 AL031058.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5855 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL28RA-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5856 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000507387 AC010595.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5857 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003062 SPRR2C lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5858 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP51-5:2 lnc-USP51-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5859 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PKN2-2:2 lnc-PKN2-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5860 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM27B-22:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5861 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FLT3-2:3 lnc-FLT3-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5862 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OPRD1-1:2 lnc-OPRD1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5863 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000460407 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5864 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MED10-11:4 lnc-MED10-11:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5865 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IRF4-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5866 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT034716 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5867 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZC3H12B-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5868 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000587099 AC010980.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5869 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015352 CECR7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5870 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CLEC2D-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5871 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_023342 KRTAP20-4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5872 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCNJ-1:8 lnc-CCNJ-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5873 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DDT-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5874 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046228 ANKRD20A12P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5875 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037850 PROX1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5876 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000515227 AC112206.2-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5877 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609736 AC253536.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5878 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-177G6.2.1-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5879 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000442684 AL445493.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5880 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027072 LINC00189 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5881 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KYNU-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5882 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577743 AC005291.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5883 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF125-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5884 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM212-1:2 lnc-TMEM212-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5885 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003551 DPY19L2P4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5886 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UGT8-1:1 lnc-UGT8-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5887 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-UBE2E3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5888 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047504 HOXC-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5889 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FOXG1-6:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5890 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000515218 LINC02315-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5891 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000528800 AC079089.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5892 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130772 ENPP7P13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5893 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-177G6.2.1-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5894 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038220 LINC00858 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5895 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HMCN1-3:2 lnc-HMCN1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5896 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT088008.2 NONHSAT088008 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5897 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TTC23-4:1 lnc-TTC23-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5898 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621901 MAGI2-AS3-225 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5899 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000429530 SCAT8-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5900 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000369391 AL158212.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5901 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125909 LOC101928978 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5902 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HIGD2A-1:1 lnc-HIGD2A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5903 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616253 AL353770.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5904 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CLEC2D-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5905 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000443576 LINC02344-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5906 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRGPRX1-1:1 lnc-MRGPRX1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5907 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT117149 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5908 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003337 SNORD116-23 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5909 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514368 AC112206.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5910 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037586 LINC01549 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5911 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM14A-2:2 lnc-TMEM14A-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5912 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000527270 AC113192.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5913 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033869 LINC01060 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5914 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF534-1:3 lnc-ZNF534-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5915 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609210 PAX8-AS1-212 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5916 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028345 LINC00632 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5917 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PEX2-3:1 lnc-PEX2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5918 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARF6-10:1 lnc-ARF6-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5919 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT117152 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5920 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026916 ANKRD30BP2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5921 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024408 CUTALP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5922 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRAK1-7:1 lnc-TRAK1-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5923 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003578 ZNF702P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5924 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMTN-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5925 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MINA-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5926 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT137258.2 NONHSAT137258 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5927 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024065 LINC00312 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5928 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551938 SNHG14-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5929 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POLR2F-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5930 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PZP-12:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5931 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120623 TCERG1L-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5932 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLGN-5:1 lnc-CLGN-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5933 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM59B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5934 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-177G6.2.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5935 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL17RA-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5936 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000442796 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5937 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UTS2-5:5 lnc-UTS2-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5938 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FHL5-2:1 lnc-FHL5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5939 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MEF2D-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5940 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109948 LOC101929645 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5941 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559673 AC015712.4-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5942 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SDIM1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5943 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT030854.2 NONHSAT030854 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5944 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000556070 PAX8-AS1-211 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5945 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC011239.1.1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5946 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM135B-5:1 lnc-FAM135B-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5947 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF33B-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5948 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NAA35-1:2 lnc-NAA35-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5949 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000562945 AC023824.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5950 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C19orf63-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5951 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552334 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5952 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLGN-2:1 lnc-CLGN-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5953 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TNFRSF19-5:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5954 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454681 AL139383.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5955 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTNNA2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5956 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GSX2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5957 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-177G6.2.1-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5958 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104256 ZFAND4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5959 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036438 SVIL2P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5960 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126023 OR2A1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5961 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DHRS7B-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5962 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC10A7-7:1 lnc-SLC10A7-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5963 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLCO5A1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5964 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GOLGA7B-1:1 lnc-GOLGA7B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5965 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1orf180-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5966 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NEUROD6-8:1 lnc-NEUROD6-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5967 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003321 SNORD116-6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5968 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 lncRNAdb NA prins_homosapiens_1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5969 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583852 AC012588.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5970 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451574 FAM230H-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5971 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMARCC2-7:1 lnc-SMARCC2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5972 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPA3-6:1 lnc-RPA3-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5973 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110026 LINC01234 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5974 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566457 AC105046.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5975 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000601795 AL132655.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5976 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FFAR1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5977 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASCC1-2:1 lnc-ASCC1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5978 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608389 AC133041.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5979 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1orf115-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5980 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C11orf44-14:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5981 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038343 MAGI2-AS3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5982 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC25A14-1:1 lnc-SLC25A14-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5983 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000426965 HOXD-AS2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5984 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT136912 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5985 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000437698 AL139383.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5986 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL28RA-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5987 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452037 LINC01918-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5988 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PPP4R1-2:5 lnc-PPP4R1-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5989 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CLEC2D-9:1 lnc-CLEC2D-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5990 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RBP1-5:4 lnc-RBP1-5:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5991 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF595-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5992 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PAQR9-3:2 lnc-PAQR9-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5993 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103767 LINC01311 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5994 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF595-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5995 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF345-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5996 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTD-2144E22.5.1-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5997 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ABCB5-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5998 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503611 FAM198B-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 5999 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OAZ3-2:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6000 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MOK-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6001 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003324 SNORD116-9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6002 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL901608.1-45:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6003 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505196 LINC01194-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6004 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NAPEPLD-5:2 lnc-NAPEPLD-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6005 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110764 LINC01910 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6006 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566366 AL033527.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6007 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PMEPA1-2:1 lnc-PMEPA1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6008 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF222-1:1 lnc-RNF222-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6009 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF534-1:4 lnc-ZNF534-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6010 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000420759 AL445250.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6011 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC39A11-1:8 lnc-SLC39A11-1:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6012 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552101 LINC02588-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6013 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000544842 AC006206.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6014 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-B4GALT6-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6015 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109959 LINC01687 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6016 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT117487 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6017 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103783 BLACAT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6018 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620859 LINC01515-217 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6019 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000416416 GORAB-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6020 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120659 LINC01518 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6021 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PGGT1B-7:1 lnc-PGGT1B-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6022 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG2C-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6023 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WARS2-2:1 lnc-WARS2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6024 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607592 AC116036.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6025 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000486571 BX890604.2-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6026 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003320 SNORD116-5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6027 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602862 AC092127.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6028 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_121637 FOXD3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6029 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598194 AC020909.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6030 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602992 AC010719.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6031 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000574411 DLGAP1-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6032 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XRCC4-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6033 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TGFA-2:1 lnc-TGFA-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6034 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505537 TENM3-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6035 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AP000708.1.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6036 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000448436 AL935212.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6037 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024391 MIR924HG lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6038 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT121093 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6039 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DPY19L2-3:1 lnc-DPY19L2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6040 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DROSHA-9:1 lnc-DROSHA-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6041 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NTSR2-5:7 lnc-NTSR2-5:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6042 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000575647 AC127496.5-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6043 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BEND7-4:1 lnc-BEND7-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6044 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024420 LINC00937 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6045 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046260 FAR2P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6046 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DUX4L7-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6047 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT103374.2 NONHSAT103374 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6048 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000556405 LINC02302-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6049 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCB5-7:1 lnc-ABCB5-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6050 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-VPS41-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6051 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000617303 FAM230G-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6052 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046848 FAM155A-IT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6053 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZBTB20-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6054 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047671 BANCR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6055 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125345 ZNF528-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6056 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HMCN1-3:1 lnc-HMCN1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6057 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ST6GALNAC3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6058 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZEB2-1:3 lnc-ZEB2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6059 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SEMA3D-5:2 lnc-SEMA3D-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6060 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103854 LINC01301 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6061 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419440 AP000844.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6062 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C8B-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6063 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CLEC18A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6064 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PDIK1L-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6065 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000590697 AC011477.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6066 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000467896 AC092919.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6067 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024101 DLGAP1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6068 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PLXNA4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6069 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554798 LINC02251-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6070 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C6orf138-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6071 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568143 AL445471.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6072 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038371 LINC01446 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6073 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003316 SNORD116-1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6074 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LINC00273-21:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6075 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HOXB4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6076 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047664 MEG9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6077 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SGIP1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6078 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623323 AC104791.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6079 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581801 LINC00511-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6080 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614771 NKILA-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6081 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000519680 AC104232.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6082 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607594 AC010424.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6083 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000523063 AF279873.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6084 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130735 WASIR2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6085 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT039999.2 NONHSAT039999 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6086 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038832 HOXA-AS3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6087 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452769 DLX6-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6088 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445227 AL139383.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6089 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125856 LOC101928304 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6090 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126372 LINC01202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6091 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DAXX-1:1 lnc-DAXX-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6092 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TBX20-3:2 lnc-TBX20-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6093 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT071501.2 NONHSAT071501 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6094 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000498693 AC004889.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6095 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C12orf77-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6096 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622616 AL590227.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6097 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027768 DPY19L2P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6098 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR4C13-4:1 lnc-OR4C13-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6099 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TAMM41-4:1 lnc-TAMM41-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6100 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-COL4A5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6101 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-DPA1-2:1 lnc-HLA-DPA1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6102 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FFAR1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6103 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422194 BX276092.7-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6104 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL033381.1-17:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6105 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606069 LINC02084-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6106 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NAPEPLD-5:1 lnc-NAPEPLD-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6107 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433770 MACORIS-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6108 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC25A2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6109 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027504 MST1P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6110 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-POTEC-11:3 lnc-POTEC-11:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6111 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000429282 AC133785.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6112 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433410 BX276092.7-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6113 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000420243 POU6F2-AS2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6114 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NBN-1:1 lnc-NBN-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6115 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125398 GATA2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6116 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026979 DRAIC lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6117 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC140-1:9 lnc-CCDC140-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6118 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045787 CERS6-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6119 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040027 ZNF790-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6120 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103532 RUNX2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6121 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613130 AC023310.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6122 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WISP1-15:3 lnc-WISP1-15:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6123 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT142064 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6124 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAGEA10-1:4 lnc-MAGEA10-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6125 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589556 ZNF790-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6126 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000425352 LINC01739-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6127 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMAD5-4:2 lnc-SMAD5-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6128 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125996 LINC01770 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6129 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000611641 AL445989.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6130 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GTDC1-8:1 lnc-GTDC1-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6131 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036488 LINC00673 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6132 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000441971 AC002456.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6133 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000426547 AL360175.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6134 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TP53TG3-9:2 lnc-TP53TG3-9:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6135 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000513405 LINC02714-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6136 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLI3-4:1 lnc-GLI3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6137 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUMF1-2:4 lnc-SUMF1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6138 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ATP1B3-1:3 lnc-ATP1B3-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6139 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARSD-4:1 lnc-ARSD-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6140 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038940 SH3PXD2A-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6141 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TUBE1-5:1 lnc-TUBE1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6142 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCE1-5:1 lnc-ABCE1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6143 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASCC3-7:1 lnc-ASCC3-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6144 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000519764 AC069120.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6145 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623716 AL390755.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6146 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038362 ZNF345 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6147 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP9Y-2:2 lnc-USP9Y-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6148 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPIAL4B-2:20 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6149 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF514-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6150 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAP3K8-13:1 lnc-MAP3K8-13:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6151 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HOXA4-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6152 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036540 LINC00622 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6153 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF816-2:9 lnc-ZNF816-2:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6154 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-DMA-2:1 lnc-HLA-DMA-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6155 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130777 LINC02109 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6156 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505877 LINC01194-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6157 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040248 ZEB2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6158 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608871 AL159169.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6159 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026658 LOC100240735 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6160 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-VN1R4-2:1 lnc-VN1R4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6161 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-603J24.9.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6162 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GNAI2-1:24 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6163 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110617 NFIA-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6164 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110409 LOC101928495 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6165 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430988 AC011239.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6166 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PSMD10-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6167 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC115989.1.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6168 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604451 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6169 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF503-AS2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6170 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TRIML1-3:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6171 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024369 CNTFR-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6172 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000519655 AF117829.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6173 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125408 MYEF2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6174 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027094 SYT14P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6175 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NSDHL-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6176 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM86A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6177 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SYT14-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6178 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SYN3-1:1 lnc-SYN3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6179 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430320 LINC01778-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6180 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110120 LOC101927811 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6181 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609742 AL365203.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6182 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WDFY1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6183 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-JMJD4-4:1 lnc-JMJD4-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6184 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF891-1:1 lnc-ZNF891-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6185 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NEUROD6-9:1 lnc-NEUROD6-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6186 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003319 SNORD116-4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6187 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_121647 LINC01410 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6188 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CYP4V2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6189 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584179 PDE10A-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6190 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF347-1:1 lnc-ZNF347-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6191 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_037161 ZNF582-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6192 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612824 AL138999.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6193 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT079642 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6194 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038283 PTPRG-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6195 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122069 HOXA-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6196 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHIC1-2:1 lnc-CHIC1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6197 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000585765 AC005746.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6198 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000426413 LINC02476-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6199 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000470435 OR2A1-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6200 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600850 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6201 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_036508 LOC100128398 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6202 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZBTB38-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6203 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRIM61-3:1 lnc-TRIM61-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6204 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000513793 LINC02428-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6205 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NID2-5:1 lnc-NID2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6206 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000513051 LINC01194-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6207 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OCIAD2-8:1 lnc-OCIAD2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6208 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WNT16-2:1 lnc-WNT16-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6209 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000594054 LINC01515-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6210 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602806 LINC01703-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6211 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514255 PURPL-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6212 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OMG-1:2 lnc-OMG-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6213 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARHGAP26-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6214 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FFAR1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6215 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GSG1L-1:6 lnc-GSG1L-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6216 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SREK1-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6217 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ALX1-3:1 lnc-ALX1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6218 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000417218 LINC02798-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6219 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC008132.1-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6220 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DTNA-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6221 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606959 AC010904.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6222 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000572855 AC015909.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6223 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-OR4M2-23:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6224 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026969 LINC00326 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6225 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614612 AL138689.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6226 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-APLN-1:2 lnc-APLN-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6227 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM75A6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6228 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000534666 LINC02722-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6229 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613144 AMYH02020865.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6230 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CKAP2L-1:6 lnc-CKAP2L-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6231 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110919 LOC101928530 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6232 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598902 LINC01515-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6233 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MED1-2:1 lnc-MED1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6234 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPIAL4G-25:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6235 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HIST1H2AI-3:8 lnc-HIST1H2AI-3:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6236 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF677-1:1 lnc-ZNF677-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6237 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PFN2-4:1 lnc-PFN2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6238 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ACTBL2-1:1 lnc-ACTBL2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6239 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000400023 C22orf34-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6240 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000442666 PKP4-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6241 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SH3RF1-2:1 lnc-SH3RF1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6242 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPATA6-1:1 lnc-SPATA6-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6243 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABHD12-1:1 lnc-ABHD12-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6244 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MYEF2-6:1 lnc-MYEF2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6245 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF503-AS2-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6246 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618776 NR2F2-AS1-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6247 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566293 AL353746.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6248 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445976 AL583808.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6249 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-408E5.4.1-19:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6250 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR4C11-2:1 lnc-OR4C11-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6251 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607216 AC244517.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6252 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF93-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6253 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AKNAD1-1:2 lnc-AKNAD1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6254 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024462 RAMP2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6255 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610409 AC011700.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6256 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC084851.1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6257 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DGKB-3:1 lnc-DGKB-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6258 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TSPAN12-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6259 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000522856 BAALC-AS1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6260 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NDNF-2:1 lnc-NDNF-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6261 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MMD-8:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6262 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CKAP2L-1:9 lnc-CKAP2L-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6263 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR125-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6264 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC145676.2.1-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6265 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589379 AC011511.5-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6266 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503066 HHIP-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6267 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_121600 PTPRD-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6268 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-24B21.1.1-2:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6269 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015450 LINC01096 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6270 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454712 AC078993.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6271 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602362 RP1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6272 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-JAK1-6:1 lnc-JAK1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6273 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000390127 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6274 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000574178 AC027281.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6275 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616473 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6276 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CIITA-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6277 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT087672.2 NONHSAT087672 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6278 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DLGAP1-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6279 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TBC1D8-4:1 lnc-TBC1D8-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6280 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000534431 AL049629.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6281 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-50B3.2.1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6282 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PHGDH-1:1 lnc-PHGDH-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6283 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CPLX1-2:10 lnc-CPLX1-2:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6284 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583184 AC011825.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6285 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000625195 AC005609.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6286 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL355149.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6287 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002728 KCNQ1OT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6288 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027433 LINC01124 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6289 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038840 LINC00693 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6290 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103474 DMC1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6291 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000550290 AC048341.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6292 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-272B17.2.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6293 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000590657 LINC00665-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6294 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LIN7A-3:1 lnc-LIN7A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6295 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ATP1A1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6296 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TSTA3-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6297 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000432621 AP001347.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6298 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPR180-8:1 lnc-GPR180-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6299 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC45A2-1:1 lnc-SLC45A2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6300 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-UTS2-5:4 lnc-UTS2-5:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6301 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT098514.2 NONHSAT098514 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6302 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 lncRNAdb NA SPRY4-IT1_hg_1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6303 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000517927 MIR3142HG-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6304 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000588689 Z99289.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6305 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_111893 CNTNAP3P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6306 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024484 LINC00909 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6307 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024380 LOC441666 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6308 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CNTN2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6309 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604183 AC007029.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6310 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM105B-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6311 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000438322 LINC00475-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6312 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435915 AL359182.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6313 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MB-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6314 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000469148 PTPRG-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6315 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610193 AC008264.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6316 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033871 FLJ42351 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6317 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PF4-1:1 lnc-PF4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6318 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000540392 AC022509.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6319 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038345 MAGI2-AS3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6320 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ARRDC4-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6321 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT087700 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6322 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZC3H12B-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6323 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566208 LINC02152-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6324 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IGSF11-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6325 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMC5-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6326 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000502209 AC106771.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6327 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419666 AL158013.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6328 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000455718 AC244394.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6329 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRPS6-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6330 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDC26-2:1 lnc-CDC26-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6331 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT122062.2 NONHSAT122062 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6332 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EMB-6:1 lnc-EMB-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6333 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613231 NKILA-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6334 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038995 LINC00327 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6335 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_022008 PWAR5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6336 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110846 LOC101928674 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6337 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608373 AC006946.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6338 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KLHL31-2:4 lnc-KLHL31-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6339 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512036 AC020551.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6340 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110717 LINC01351 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6341 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000490005 SOX2-OT-211 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6342 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000592302 AC021504.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6343 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HOOK2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6344 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612613 AC091825.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6345 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046551 DLEU7-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6346 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RAB3C-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6347 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104185 CCDC144NL-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6348 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SNAP91-3:1 lnc-SNAP91-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6349 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF150-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6350 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624705 AC109326.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6351 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623177 AC127070.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6352 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUN3-4:1 lnc-SUN3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6353 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104224 SH3YL1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6354 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000553108 SNHG14-216 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6355 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110457 HAGLROS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6356 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SNURF-1:30 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6357 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CKAP2L-1:4 lnc-CKAP2L-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6358 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PCK1-2:1 lnc-PCK1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6359 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-POLR2B-12:1 lnc-POLR2B-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6360 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C2orf89-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6361 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PHF19-1:1 lnc-PHF19-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6362 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM242-1:1 lnc-TMEM242-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6363 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC008132.1-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6364 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-160N1.10.1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6365 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609687 MIR663AHG-234 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6366 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424933 FRGCA-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6367 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIAL1-1:1 lnc-TIAL1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6368 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-STIL-3:2 lnc-STIL-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6369 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607456 AC112487.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6370 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431752 TTN-AS1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6371 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000521025 AC037459.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6372 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000500487 AC068446.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6373 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WSB1-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6374 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NME6-2:1 lnc-NME6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6375 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MTHFD2L-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6376 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC4A3-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6377 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT029682.2 NONHSAT029682 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6378 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130738 LOC101929719 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6379 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-32I10.10.1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6380 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCNG1-2:1 lnc-CCNG1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6381 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_126379 LINC01033 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6382 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC015804.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6383 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDK20-6:1 lnc-CDK20-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6384 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026758 FAR2P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6385 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003679 HAND2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6386 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KCNJ12-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6387 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA1614-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6388 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451396 PROX1-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6389 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-160N1.10.1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6390 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CYP4F31P-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6391 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001282 PCDHB19P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6392 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583460 LINC00511-216 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6393 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAGE1C-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6394 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POLI-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6395 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110429 GAPLINC lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6396 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-THNSL1-1:1 lnc-THNSL1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6397 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SUCLG1-9:1 lnc-SUCLG1-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6398 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLG1-3:1 lnc-GLG1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6399 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF583-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6400 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT012538.2 NONHSAT012538 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6401 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1orf180-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6402 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620496 AC009318.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6403 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOR2-5:1 lnc-NCOR2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6404 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619530 LINC00221-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6405 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435257 AC002076.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6406 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000611334 AC091825.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6407 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609524 AC107294.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6408 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000556750 AC122685.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6409 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000507950 LINC02121-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6410 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000488584 LINC00886-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6411 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF217-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6412 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125869 LOC102723883 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6413 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003713 LOC728613 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6414 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046873 TPRG1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6415 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ANKRD18A-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6416 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FEZF2-9:2 lnc-FEZF2-9:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6417 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DLX6-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6418 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000417843 CR786580.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6419 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565518 AC068987.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6420 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POLI-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6421 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026980 FRG2DP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6422 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000520306 AF117829.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6423 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000531086 AP000759.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6424 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104603 CRB2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6425 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT081664 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6426 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433734 LINC02814-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6427 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002838 KC6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6428 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG1-4:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6429 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF595-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6430 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000524166 AF117829.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6431 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607333 IER3-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6432 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000446213 AC133785.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6433 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445293 AC078845.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6434 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033963 HRAT92 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6435 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612025 AC064801.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6436 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607309 AL360267.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6437 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM27B-18:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6438 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EPB41-1:2 lnc-EPB41-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6439 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL17RA-2:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6440 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CMTM6-3:2 lnc-CMTM6-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6441 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FGFRL1-3:1 lnc-FGFRL1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6442 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMEM188-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6443 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC079341.1-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6444 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610171 AL157904.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6445 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC073416.2-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6446 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000408413 RNU6ATAC18P-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6447 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561332 CCDC33-210 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6448 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LYPD5-1:2 lnc-LYPD5-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6449 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TNFSF11-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6450 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000581850 PDE10A-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6451 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTTG1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6452 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC012414.1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6453 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038378 LOC441242 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6454 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621571 AC018445.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6455 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000576696 LINC00327-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6456 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPRY4-3:1 lnc-SPRY4-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6457 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000437551 PAX8-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6458 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038377 LINC01667 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6459 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANKRD30BL-8:1 lnc-ANKRD30BL-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6460 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026567 ESPNP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6461 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BAIAP2L2-1:1 lnc-BAIAP2L2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6462 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000577828 LINC00511-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6463 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000611082 GAS6-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6464 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RG9MTD1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6465 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000444476 LINC00475-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6466 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027481 ZNF876P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6467 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPS3A-2:1 lnc-RPS3A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6468 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125801 PACERR lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6469 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000569677 AC092376.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6470 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIMP3-2:1 lnc-TIMP3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6471 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120523 LOC101928168 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6472 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMC5-10:1 lnc-SMC5-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6473 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ERMP1-3:1 lnc-ERMP1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6474 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TNNT2-3:2 lnc-TNNT2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6475 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASB1-4:1 lnc-ASB1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6476 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024059 MIMT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6477 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTD-2144E22.5.1-28:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6478 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046909 DENND5B-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6479 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_074088 ATRNL1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6480 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-STARD13-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6481 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BRD8-2:1 lnc-BRD8-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6482 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT090850 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6483 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RAB1A-8:1 lnc-RAB1A-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6484 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125795 FOXC2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6485 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000453229 AC103923.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6486 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000516424 RN7SKP253-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6487 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449749 AC068580.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6488 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000502125 NR2F2-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6489 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000399342 AC005323.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6490 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SMAD2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6491 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510622 AC122710.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6492 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565938 AC013565.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6493 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FBXO3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6494 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000439446 AC005083.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6495 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000453915 AC116666.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6496 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602495 XIST-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6497 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000580580 AC093330.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6498 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LRCH1-5:2 lnc-LRCH1-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6499 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038291 LINC00707 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6500 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510967 AC096711.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6501 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CMTM6-4:2 lnc-CMTM6-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6502 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551631 SNHG14-213 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6503 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ELOVL5-2:2 lnc-ELOVL5-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6504 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BRD2-3:1 lnc-BRD2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6505 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PTPN14-3:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6506 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610937 ZEB2-AS1-212 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6507 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000595094 AC010636.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6508 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZBTB38-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6509 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604239 AC091488.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6510 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618591 AC023282.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6511 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC073416.2-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6512 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRP63-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6513 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KCNJ3-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6514 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608759 AP000238.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6515 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046845 DNM3-IT1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6516 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRAM1-2:2 lnc-TRAM1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6517 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA0528-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6518 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110294 NCKAP5-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6519 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MEX3B-4:3 lnc-MEX3B-4:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6520 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LSAMP-4:1 lnc-LSAMP-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6521 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZFP14-1:19 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6522 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CFHR5-6:1 lnc-CFHR5-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6523 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560314 LINC02253-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6524 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454735 AC078845.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6525 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AMBN-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6526 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA0528-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6527 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF469-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6528 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT098643.2 NONHSAT098643 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6529 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NDST3-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6530 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606030 AC244517.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6531 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616832 AC124319.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6532 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NRG1-2:7 lnc-NRG1-2:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6533 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-VSIG7-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6534 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FOXD4L4-1:1 lnc-FOXD4L4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6535 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASNS-1:10 lnc-ASNS-1:10 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6536 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026989 LINC01140 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6537 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430586 AC092168.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6538 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623111 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6539 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF563-1:1 lnc-ZNF563-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6540 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C6orf164-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6541 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-STBD1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6542 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRPL39-35:1 lnc-MRPL39-35:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6543 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM75A6-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6544 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000448570 AC017067.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6545 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034128 LINC01191 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6546 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HOXD11-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6547 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561344 NR2F2-AS1-210 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6548 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT138948 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6549 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000545923 AC140847.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6550 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624066 AC018445.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6551 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000526703 LINC02732-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6552 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623996 AC007546.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6553 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MST1P9-4:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6554 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMPD1-3:2 lnc-SMPD1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6555 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-195B21.3.1-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6556 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624206 AC134043.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6557 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000513899 VCAN-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6558 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000438790 LINC01778-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6559 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CMC1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6560 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WIPF3-1:4 lnc-WIPF3-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6561 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SOCS6-15:1 lnc-SOCS6-15:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6562 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110273 ATP6V1B1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6563 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC17-1:1 lnc-CCDC17-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6564 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000625066 AC244517.2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6565 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RCAN1-1:1 lnc-RCAN1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6566 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120420 LOC100507006 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6567 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000428676 U82695.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6568 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM150B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6569 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110084 LOC101927391 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6570 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RPL10L-1:1 lnc-RPL10L-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6571 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL139008.2-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6572 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C20orf7-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6573 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000442815 LINC01679-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6574 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FOXG1-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6575 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130779 LOC101928858 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6576 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FANK1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6577 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF502-1:1 lnc-ZNF502-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6578 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551565 AL929601.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6579 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TPTE-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6580 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000437334 AL359502.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6581 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SMAD7-1:1 lnc-SMAD7-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6582 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PRAMEF11-3:3 lnc-PRAMEF11-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6583 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110702 SEMA3B-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6584 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000414661 AC064875.1-215 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6585 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RNF113B-6:1 lnc-RNF113B-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6586 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PDE4B-1:2 lnc-PDE4B-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6587 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000527726 AC104031.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6588 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA1462-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6589 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000564287 AC092803.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6590 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT018709 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6591 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG1-4:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6592 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109964 TRPM2-AS lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6593 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000500169 LINC02377-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6594 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103451 LOC101448202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6595 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027267 LINC00310 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6596 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000557721 AL161752.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6597 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120436 WWOX lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6598 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDR1-3:1 lnc-CDR1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6599 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZC3H12B-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6600 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457833 BX322234.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6601 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLI3-1:2 lnc-GLI3-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6602 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000559428 AC104041.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6603 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANKRD31-2:1 lnc-ANKRD31-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6604 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610469 AC015813.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6605 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560882 DRAIC-214 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6606 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZMAT3-5:1 lnc-ZMAT3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6607 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000446383 FGF13-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6608 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033829 MIR4500HG lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6609 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567273 AL121578.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6610 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM105B-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6611 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619646 AC068234.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6612 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRPL39-37:1 lnc-MRPL39-37:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6613 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610061 AL159169.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6614 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF569-1:1 lnc-ZNF569-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6615 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF174-1:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6616 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CHIC1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6617 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000516599 AC005787.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6618 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615941 AL445649.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6619 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552781 SNHG14-215 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6620 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000619507 AC021424.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6621 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615324 AP001042.1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6622 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF816-2:4 lnc-ZNF816-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6623 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LSM5-3:1 lnc-LSM5-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6624 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-262H14.4.1-18:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6625 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM185A-2:1 lnc-TMEM185A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6626 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GCNT3-3:3 lnc-GCNT3-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6627 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584433 CCDC144NL-AS1-219 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6628 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ADAMTS12-2:2 lnc-ADAMTS12-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6629 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000510150 AC113346.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6630 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC073043.2.1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6631 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000564121 AC012508.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6632 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000434072 GNG12-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6633 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FOXL1-2:4 lnc-FOXL1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6634 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PRRC1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6635 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LMNA-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6636 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618162 AL590096.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6637 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000557736 AL136018.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6638 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GTF2A2-6:1 lnc-GTF2A2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6639 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHRM3-1:1 lnc-CHRM3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6640 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCNJ-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6641 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125973 LINC01762 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6642 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000542084 DIAPH2-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6643 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606899 BX284668.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6644 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000438702 AL117382.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6645 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DDC-3:5 lnc-DDC-3:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6646 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609485 AL592494.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6647 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ASB12-1:1 lnc-ASB12-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6648 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000423979 AC005009.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6649 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104179 LOC100289333 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6650 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHAD-6:1 lnc-CHAD-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6651 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001281 PCDHB18P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6652 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6653 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104170 LOC149684 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6654 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000531654 LINC01301-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6655 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WRNIP1-13:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6656 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC25A2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6657 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026830 SATB2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6658 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXCR3-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6659 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_029374 LEF1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6660 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000563780 AC099668.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6661 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FOXG1-5:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6662 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622345 AC090825.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6663 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OXGR1-6:1 lnc-OXGR1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6664 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000521872 AC103952.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6665 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026947 C1RL-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6666 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110796 TTC39C-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6667 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602731 LRRIQ1-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6668 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000416200 SATB2-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6669 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LONRF1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6670 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000558499 AC087477.2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6671 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NTSR2-7:1 lnc-NTSR2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6672 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-POLR3GL-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6673 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C7orf23-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6674 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110809 LOC101927666 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6675 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ALDH3B2-2:1 lnc-ALDH3B2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6676 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SVIL-5:1 lnc-SVIL-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6677 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RALGAPA2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6678 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C14orf166-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6679 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618407 AC006449.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6680 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000524190 AF117829.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6681 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000570153 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6682 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT098131.2 NONHSAT098131 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6683 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000451368 AC004540.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6684 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120453 ALOX12P2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6685 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM201-2:1 lnc-TMEM201-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6686 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP3-377D14.1.1-3:23 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6687 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT050845 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6688 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC25A2-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6689 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125958 GORAB-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6690 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TTC26-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6691 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618697 AC118658.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6692 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_023382 ZNF815P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6693 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000519319 PCAT1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6694 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SSX2B-5:2 lnc-SSX2B-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6695 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LPCAT1-3:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6696 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015419 LOC145783 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6697 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560056 LINC02853-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6698 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MID1-4:1 lnc-MID1-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6699 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NETO1-1:14 lnc-NETO1-1:14 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6700 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000460400 AL121721.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6701 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARHGAP5-1:1 lnc-ARHGAP5-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6702 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589907 TTN-AS1-235 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6703 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG1-5:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6704 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EIF2AK3-4:44 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6705 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT133370.2 NONHSAT133370 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6706 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ANKRA2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6707 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KIAA0141-3:1 lnc-KIAA0141-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6708 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPLP1-1:15 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6709 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002196 H19 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6710 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FGF9-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6711 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SERPINI1-17:7 lnc-SERPINI1-17:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6712 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CDH6-2:18 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6713 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000584911 PDE10A-209 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6714 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IGSF11-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6715 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CREB5-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6716 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000546968 LINC02298-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6717 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606330 AC022001.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6718 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620901 AC004080.12-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6719 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000582564 AC005821.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6720 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015415 DICER1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6721 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC10A7-8:1 lnc-SLC10A7-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6722 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CGNL1-5:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6723 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CNTNAP3-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6724 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AMY1B-4:1 lnc-AMY1B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6725 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MST1P9-4:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6726 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109865 MRPS30-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6727 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609596 CECR7-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6728 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-LRMP-10:1 lnc-LRMP-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6729 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HLA-DQA1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6730 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120510 ELFN1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6731 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DLGAP1-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6732 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000511165 AC112178.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6733 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110753 LINC02466 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6734 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ATG12-8:1 lnc-ATG12-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6735 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TP53TG3-12:1 lnc-TP53TG3-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6736 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HDAC9-1:2 lnc-HDAC9-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6737 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SNRPA-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6738 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612365 AC002401.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6739 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-XIRP2-2:1 lnc-XIRP2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6740 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110628 LOC101926964 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6741 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000426044 AC012618.3-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6742 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TMEM144-5:1 lnc-TMEM144-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6743 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TTC26-4:1 lnc-TTC26-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6744 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505637 MRPS30-DT-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6745 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038278 LINC00665 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6746 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_111908 MAST4-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6747 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C6orf138-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6748 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514073 AC226119.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6749 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HLA-DOA-1:1 lnc-HLA-DOA-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6750 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF729-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6751 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1QTNF9-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6752 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024358 LINC00028 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6753 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612495 AC006538.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6754 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609012 MIR663AHG-230 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6755 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPTSSA-3:1 lnc-SPTSSA-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6756 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000597110 U62631.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6757 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000432518 RBMS3-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6758 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EGLN1-1:1 lnc-EGLN1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6759 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GOLT1B-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6760 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518749 AP000426.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6761 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606901 AC005618.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6762 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567129 AL162412.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6763 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PRCD-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6764 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WAC-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6765 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003699 ZNF525 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6766 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GINS2-2:2 lnc-GINS2-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6767 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000529082 AC009652.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6768 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606790 AC254633.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6769 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COL8A1-3:3 lnc-COL8A1-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6770 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024562 HPN-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6771 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDH10-11:1 lnc-CDH10-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6772 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000439795 LINC02794-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6773 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_015448 DLX6-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6774 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT072334 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6775 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-STOX2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6776 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000586591 AP001029.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6777 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMEM117-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6778 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP53-1:3 lnc-USP53-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6779 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561320 AC087473.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6780 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CPT1A-1:2 lnc-CPT1A-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6781 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000399446 AL008729.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6782 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TMEM194B-5:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6783 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000414438 AC069277.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6784 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033766 FOXP2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6785 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CNNM3-3:1 lnc-CNNM3-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6786 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000427022 AP000317.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6787 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC005323.1.1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6788 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624350 AC245060.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6789 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NUDT4-6:1 lnc-NUDT4-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6790 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCNYL2-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6791 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NCOA3-4:4 lnc-NCOA3-4:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6792 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RSAD2-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6793 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000419836 LINC02663-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6794 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PROM1-4:6 lnc-PROM1-4:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6795 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GLYATL2-5:1 lnc-GLYATL2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6796 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MNS1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6797 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RIPK2-2:1 lnc-RIPK2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6798 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024237 C2CD4D-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6799 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-AGGF1-2:1 lnc-AGGF1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6800 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000527281 LINC02713-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6801 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003260 DNM1P46 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6802 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT003731.2 NONHSAT003731 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6803 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DCT-16:1 lnc-DCT-16:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6804 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EXOC3L4-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6805 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000604818 AC079610.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6806 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602892 MIR99AHG-217 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6807 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000317114 DLGAP1-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6808 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT053925.2 NONHSAT053925 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6809 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XRCC4-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6810 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-408E5.4.1-11:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6811 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-YIF1A-6:4 lnc-YIF1A-6:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6812 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000448412 AL357793.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6813 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SPANXN5-2:3 lnc-SPANXN5-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6814 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT055985 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6815 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_103717 LINC01561 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6816 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000569134 AC009812.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6817 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IKZF2-5:1 lnc-IKZF2-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6818 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110682 PKN2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6819 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_104664 LINC01948 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6820 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120533 LOC101929427 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6821 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561358 AC103982.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6822 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000421509 AL160272.1-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6823 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000424735 LINC01351-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6824 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551067 AL929601.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6825 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000433592 ID2-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6826 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000413145 AL162411.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6827 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPC5-7:1 lnc-GPC5-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6828 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616485 HAND2-AS1-238 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6829 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457457 AC016735.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6830 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-HNRNPR-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6831 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000449537 AC004540.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6832 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000413818 AL031666.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6833 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MND1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6834 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC002365.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6835 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR4F3-1:1 lnc-OR4F3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6836 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C5orf17-8:13 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6837 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC39A11-1:34 lnc-SLC39A11-1:34 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6838 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CTSZ-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6839 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003255 TSIX lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6840 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-597K23.2.1-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6841 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TGFB1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6842 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MYL4-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6843 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-YPEL2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6844 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPIAL4A-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6845 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000578787 AP001025.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6846 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-KIAA1967-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6847 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623256 LINC01727-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6848 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618966 AL161431.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6849 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-E2F7-6:1 lnc-E2F7-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6850 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614633 AL138995.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6851 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000568389 MAFTRR-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6852 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606401 AC026801.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6853 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT000960 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6854 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615831 AC090510.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6855 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL1RL1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6856 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TWIST1-1:3 lnc-TWIST1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6857 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000588925 AC027097.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6858 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_130923 LOC102724434 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6859 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRPS6-4:2 lnc-MRPS6-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6860 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000551974 AC048344.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6861 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_001559 VENTXP1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6862 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ST3GAL6-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6863 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000431661 LINC00189-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6864 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MSX2-1:2 lnc-MSX2-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6865 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RIT2-2:6 lnc-RIT2-2:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6866 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ARHGAP26-4:8 lnc-ARHGAP26-4:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6867 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ATF3-1:3 lnc-ATF3-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6868 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DRD5-16:1 lnc-DRD5-16:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6869 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623878 Z97633.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6870 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-N4BP2-4:1 lnc-N4BP2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6871 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RAB4A-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6872 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038866 BSN-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6873 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024483 HDHD5-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6874 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000437523 AL592494.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6875 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000622621 AC092376.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6876 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-XAGE1D-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6877 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL901608.1-42:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6878 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000448887 FREM2-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6879 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FADD-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6880 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024366 FAM225A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6881 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000569860 AC009486.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6882 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GPR137B-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6883 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110732 LOC101928517 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6884 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609088 AC005291.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6885 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ABCA12-6:1 lnc-ABCA12-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6886 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CEP170-12:1 lnc-CEP170-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6887 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000506465 PRR7-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6888 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C9orf3-6:1 lnc-C9orf3-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6889 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518865 HAS2-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6890 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000601445 AC021504.1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6891 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003505 PPP4R1L lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6892 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_027333 GPR158-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6893 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CHRM3-1:6 lnc-CHRM3-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6894 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125967 LINC01719 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6895 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000621023 AC063961.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6896 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000414790.6 H19-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6897 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000466893 PTPRG-AS1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6898 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM75A3-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6899 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HDAC2-7:1 lnc-HDAC2-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6900 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602419 BX546450.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6901 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC233263.1-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6902 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000591836 AC006116.10-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6903 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026963 TTC28-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6904 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIGD6-1:1 lnc-TIGD6-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6905 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454416 AC017104.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6906 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CHRM2-2:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6907 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EFCAB4B-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6908 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT029070 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6909 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000566729 MAFTRR-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6910 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNASEH2B-3:38 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6911 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-BMS1-9:1 lnc-BMS1-9:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6912 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512067 PURPL-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6913 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000608243 AC104458.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6914 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MED1-1:1 lnc-MED1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6915 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430001 AF124730.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6916 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NYNRIN-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6917 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110839 LINC02087 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6918 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TGFB1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6919 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000558641 AC015712.4-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6920 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000590491 AC092068.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6921 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AHR-8:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6922 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000620337 LINC00221-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6923 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-IL28RA-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6924 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GUCA2A-1:1 lnc-GUCA2A-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6925 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618815 AC253576.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6926 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LPHN3-8:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6927 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000565944 AC079148.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6928 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623570 AC008103.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6929 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAP1LC3B-7:3 lnc-MAP1LC3B-7:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6930 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616504 AC021424.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6931 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000562921 MAFTRR-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6932 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KLF14-3:2 lnc-KLF14-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6933 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-80A15.1.1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6934 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT123414.2 NONHSAT123414 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6935 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000586478 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6936 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000450783 AL445524.1-206 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6937 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002809 LINC01089 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6938 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RAB5A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6939 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000612818 AC087893.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6940 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110523 C22orf34 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6941 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AMDHD2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6942 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AGBL1-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6943 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TSPY10-10:1 lnc-TSPY10-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6944 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF184-3:1 lnc-ZNF184-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6945 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110904 ITFG1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6946 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-WRNIP1-13:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6947 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EPSTI1-10:1 lnc-EPSTI1-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6948 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623777 AC009336.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6949 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RPS6KA3-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6950 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NPL-2:2 lnc-NPL-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6951 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606221 AL445647.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6952 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GNAI2-1:22 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6953 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SFPQ-2:5 lnc-SFPQ-2:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6954 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003070 SNORD89 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6955 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCNJ-1:6 lnc-CCNJ-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6956 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514571 MEF2C-AS1-213 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6957 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_123730 LOC339260 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6958 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623581 AC244517.12-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6959 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF800-5:1 lnc-ZNF800-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6960 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038432 LOC100506274 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6961 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PPIL2-2:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6962 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RHOF-1:22 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6963 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000453179 LINC02828-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6964 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_125872 LOC101928307 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6965 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TEKT3-1:1 lnc-TEKT3-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6966 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000609491 AC064836.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6967 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FGF10-3:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6968 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LRAT-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6969 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FAM86C1-1:3 lnc-FAM86C1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6970 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AL353791.1.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6971 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000573950 TAPT1-AS1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6972 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC110080.1-17:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6973 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ANO3-5:1 lnc-ANO3-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6974 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BRD2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6975 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038902 JAKMIP2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6976 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZFPM2-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6977 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000509463 FAM198B-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6978 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_024256 GATA3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6979 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000503140 LINC02268-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6980 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C12orf75-5:1 lnc-C12orf75-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6981 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PROM2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6982 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110744 ZIM2-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6983 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034182 MATN1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6984 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623764 AC022784.6-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6985 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC005609.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6986 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000567862 AC009081.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6987 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SUV420H1-2:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6988 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-FOXC1-12:1 lnc-FOXC1-12:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6989 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-P4HA2-3:4 lnc-P4HA2-3:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6990 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRIM29-3:1 lnc-TRIM29-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6991 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT055957.2 NONHSAT055957 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6992 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG1-5:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6993 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C19orf29-AS1-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6994 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000512370 AC097515.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6995 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454631 AL445524.1-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6996 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000624795 AC105114.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6997 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM70A-1:9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6998 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000553678 AL049775.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 6999 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038259 TPTE2P5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7000 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000569460 AL359851.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7001 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033872 PCBP1-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7002 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514241 MAST4-IT1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7003 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-COL8A1-3:1 lnc-COL8A1-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7004 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000457870 PCBP1-AS1-241 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7005 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000615619 AL160412.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7006 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000421112 AC064875.1-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7007 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000589360 AC005786.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7008 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CDC73-2:1 lnc-CDC73-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7009 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SCRT2-1:1 lnc-SCRT2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7010 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF266-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7011 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT101554 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7012 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000591379 AC011591.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7013 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452919 CHL1-AS2-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7014 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606967 AL451050.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7015 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DEC1-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7016 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PRKCDBP-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7017 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT069232.2 NONHSAT069232 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7018 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-RRM2B-7:1 lnc-RRM2B-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7019 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNASEH2B-3:39 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7020 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_047662 LOC729732 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7021 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C1orf133-1:7 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7022 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000489557 AC016746.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7023 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-AC025287.1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7024 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-KAT6A-3:1 lnc-KAT6A-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7025 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046242 LINC00920 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7026 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT127683.2 NONHSAT127683 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7027 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_022011 PWARSN lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7028 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C3orf65-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7029 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000614751 AC005746.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7030 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000518129 AC037450.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7031 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000445300 AL034417.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7032 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SAA2-4:1 lnc-SAA2-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7033 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF514-10:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7034 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRPL43-1:1 lnc-MRPL43-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7035 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TTC12-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7036 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002139 HCG4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7037 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRGPRF-2:1 lnc-MRGPRF-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7038 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-OR4F6-1:4 lnc-OR4F6-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7039 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-C5orf63-1:4 lnc-C5orf63-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7040 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000560148 CCDC33-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7041 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028344 LINC00632 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7042 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP1-228P16.5.1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7043 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAGEE2-1:3 lnc-MAGEE2-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7044 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-COL9A3-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7045 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF717-5:1 lnc-ZNF717-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7046 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ADCY4-1:1 lnc-ADCY4-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7047 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-EMP3-1:4 lnc-EMP3-1:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7048 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRE11A-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7049 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000598131 AC008554.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7050 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_021485 EGFEM1P lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7051 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-VEZT-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7052 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000438115 AC012368.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7053 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033903 MED15P9 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7054 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT059050.2 NONHSAT059050 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7055 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_073084 CRIP2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7056 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034007 LINC00880 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7057 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GRHL2-7:5 lnc-GRHL2-7:5 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7058 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_109954 BAALC-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7059 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM135A-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7060 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_034019 TP53TG3HP lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7061 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-BICD1-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7062 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-XRCC2-3:1 lnc-XRCC2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7063 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000414377 AL078645.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7064 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610394 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7065 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-EIF2AK3-4:28 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7066 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-NOG-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7067 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT018889 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7068 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026774 LINC00239 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7069 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452471 AC005009.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7070 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000454538 AL136456.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7071 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXorf28-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7072 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_038251 DPH6-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7073 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-INSC-6:1 lnc-INSC-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7074 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000450445 BNC2-AS1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7075 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000526385 LINC02713-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7076 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000564697 Z97205.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7077 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC140-1:6 lnc-CCDC140-1:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7078 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000613309 BX255923.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7079 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C8orf83-7:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7080 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SKAP2-1:1 lnc-SKAP2-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7081 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT143842.2 NONHSAT143842 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7082 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GOLGA6L6-6:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7083 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000522264 AL160262.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7084 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000610170 Z73429.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7085 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-UST-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7086 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PCDH9-13:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7087 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-UMODL1-2:8 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7088 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM149B1-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7089 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-MRPS5-14:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7090 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-METTL13-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7091 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TIAL1-1:2 lnc-TIAL1-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7092 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000422683 AC073987.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7093 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_028328 ELMOD1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7094 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046535 GPC6-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7095 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-ZNF506-1:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7096 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PBX1-3:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7097 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046312 KIAA1656 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7098 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000583497 AP000829.1-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7099 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000605849 AC106881.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7100 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-160N1.10.1-8:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7101 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C10orf31-10:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7102 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT023724.2 NONHSAT023724 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7103 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT137101 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7104 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-PTRH2-2:1 lnc-PTRH2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7105 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000500076 AC010198.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7106 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-NDNF-1:1 lnc-NDNF-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7107 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-LEPR-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7108 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SERPINA5-1:1 lnc-SERPINA5-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7109 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600805 AC026202.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7110 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046326 PCAT6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7111 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GTF3A-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7112 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046625 MEIS1-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7113 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-HSD17B14-3:2 lnc-HSD17B14-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7114 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-6F2.7.1-2:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7115 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-ZNF860-2:1 lnc-ZNF860-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7116 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT117452.2 NONHSAT117452 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7117 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_002834 DUSP5P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7118 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000607781 RN7SL832P-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7119 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CCDC74A-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7120 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120619 LINC01163 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7121 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-TPRG1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7122 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000592319 AC016590.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7123 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SETD4-12:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7124 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NA NONHSAT023557 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7125 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-TRIM71-2:1 lnc-TRIM71-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7126 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000552933 DDN-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7127 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-CCDC82-4:1 lnc-CCDC82-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7128 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF2-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7129 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-664D7.4.1-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7130 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000435271 AC022537.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7131 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040058 RAD51-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7132 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MRGPRF-4:6 lnc-MRGPRF-4:6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7133 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000524017 AC068672.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7134 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000456087 STARD13-IT1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7135 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_108074 LINC00706 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7136 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FRG1-5:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7137 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_120532 LOC101929427 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7138 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-DYRK2-6:2 lnc-DYRK2-6:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7139 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-CXorf28-3:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7140 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000430844 AC073343.2-202 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7141 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-PAM16-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7142 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000606754 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7143 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000507627 AC010395.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7144 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SUZ12-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7145 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000511707 LINC01411-205 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7146 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000597288 AC009955.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7147 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623854 AC009229.4-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7148 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RNF13-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7149 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-WDSUB1-1:1 lnc-WDSUB1-1:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7150 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110152 ZNF585A lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7151 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000514846 PRR7-AS1-204 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7152 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-RP11-195B21.3.1-6:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7153 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM108B1-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7154 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-STARD4-4:2 lnc-STARD4-4:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7155 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C2orf42-3:67 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7156 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FAM27E2-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7157 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT139031.2 NONHSAT139031 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7158 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-F7-5:3 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7159 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000600183 AC021504.1-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7160 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-GRASP-2:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7161 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000505498 AC110800.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7162 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SLC10A7-5:1 lnc-SLC10A7-5:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7163 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-SLC24A4-3:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7164 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_045115 MLLT10P1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7165 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 NONCODE NONHSAT077117.2 NONHSAT077117 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7166 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000547326 AC121761.1-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7167 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-DLX6-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7168 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-C6orf164-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7169 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-IRAK3-4:1 lnc-IRAK3-4:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7170 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-MAG-1:2 lnc-MAG-1:2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7171 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_003341 SNORD116-27 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7172 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_122044 SH3TC2-DT lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7173 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_110069 LOC101927021 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7174 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-GPATCH2-6:4 lnc-GPATCH2-6:4 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7175 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000602211 NA lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7176 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000561705 LINC02562-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7177 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_046681 PDZRN3-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7178 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000616071 AP003419.3-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7179 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000439406 HCG20-208 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7180 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_040079 LINC02649 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7181 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000623938 AC068254.2-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7182 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-USP9X-7:1 lnc-USP9X-7:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7183 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000452465 C1orf61-207 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7184 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia NA lnc-FOXD4L5-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7185 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_033691 ZNF436-AS1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7186 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_026548 TSPEAR-AS2 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7187 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 RefSeq NR_102308 CACNG6 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7188 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000618125 AC025164.1-203 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7189 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 LNCipedia lnc-SERPINA12-2:1 lnc-SERPINA12-2:1 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7190 Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun 2019 31053733 Ensembl ENST00000554773 LINC02322-201 lncRNA DB00853 (APRD00557) Temozolomide glioblastoma microarray The RNA expression profiling was performed using Agilent custom human lncRNA and mRNA microarrays in TMZ resistant glioblastoma cells cell line (LN229,229R) down-regulated resistant NA NA NA predicted 7191 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0007031 hsa_circ_0007031 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7192 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0000504 hsa_circ_0000504 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7193 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0007006 hsa_circ_0007006 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7194 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0000237 hsa_circ_0000237 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7195 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0074930 hsa_circ_0074930 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7196 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0084353 hsa_circ_0084353 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7197 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0022080 hsa_circ_0022080 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7198 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0008494 hsa_circ_0008494 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7199 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0005949 hsa_circ_0005949 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7200 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0074806 hsa_circ_0074806 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) up-regulated resistant NA NA NA predicted 7201 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0048232 hsa_circ_0048232 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) down-regulated resistant NA NA NA predicted 7202 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0006174 hsa_circ_0006174 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) down-regulated resistant NA NA NA predicted 7203 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0008509 hsa_circ_0008509 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) down-regulated resistant NA NA NA predicted 7204 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0084021 hsa_circ_0084021 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) down-regulated resistant NA NA NA predicted 7205 Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. Biomed Res Int 2017 28656150 circBase hsa_circ_0087862 hsa_circ_0087862 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qRT-PCR In this study, we focused on clarifying the modulation of the expression profiles of circRNAs in CRR. Microarray analysis identified 71 circRNAs differentially expressed in chemoradiation-resistant CRC cells. Among them, 47 were upregulated and 24 were downregulated by more than twofold. Furthermore, expression modulation of five representative circRNAs was validated by quantitative reverse transcription PCR (qRT-PCR). Moreover, these modulated circRNAs were predicted to interact with 355 miRNAs. cell line (HCT116) down-regulated resistant NA NA NA predicted 7206 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0002113 hsa_circ_0002113 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7207 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0001667 hsa_circ_0001667 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7208 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0006528 hsa_circ_0006528 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7209 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0002874 hsa_circ_0002874 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7210 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0002168 hsa_circ_0002168 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7211 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0086241 hsa_circ_0086241 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7212 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0007769 hsa_circ_0007769 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7213 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0092276 hsa_circ_0092276 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7214 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0044556 hsa_circ_0044556 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7215 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0003183 hsa_circ_0003183 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7216 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0085567 hsa_circ_0085567 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7217 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0085495 hsa_circ_0085495 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) up-regulated resistant NA NA NA predicted 7218 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0008131 hsa_circ_0008131 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7219 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0003838 hsa_circ_0003838 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7220 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0007551 hsa_circ_0007551 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7221 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0005004 hsa_circ_0005004 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7222 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0006903 hsa_circ_0006903 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7223 Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics 2017 28803498 circBase hsa_circ_0018293 hsa_circ_0018293 circRNA DB00997 (APRD00185, DB05331, DB05847) Adriamycin breast cancer qRT-PCR CircRNA microarray expression profiles were obtained from Adriamycin (ADM) resistant MCF-7 breast cancer cells (MCF-7/ADM) and parental MCF-7 cells and were validated using quantitative real-time reverse transcription PCR. The expression data were analyzed bioinformatically. cell line (MCF-7,MCF-7/ADM) down-regulated resistant NA NA NA predicted 7224 Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci 2018 29559849 circBase hsa_circ_0001821 circPVT1 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR The role of circPVT1 in osteosarcoma cells was detected using qRT-PCR, CCK8 assay, colony formation assay and western blot analysis, etc. cell line (SaoS2, KHOS, U2OS, MG63,U2OSR,KHOSR) up-regulated resistant ABCB1 ABCB1 NA validated 7225 Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci 2018 29559849 circBase hsa_circ_0001821 circPVT1 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR The role of circPVT1 in osteosarcoma cells was detected using qRT-PCR, CCK8 assay, colony formation assay and western blot analysis, etc. cell line (SaoS2, KHOS, U2OS, MG63,U2OSR,KHOSR) up-regulated resistant ABCB1 ABCB1 NA validated 7226 Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2018 29922161 circBase NA chr14:101402109-101464448 + circRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR In this study, we established Gemcitabine resistant PANC-1 (PANC-1-GR) cell lines and compared the circular RNAs (circRNAs) profiles between PANC-1 cells and PANC-1-GR cells by RNA sequencing. Differentially expressed circRNAs were demonstrated using scatter plot and cluster heatmap analysis. Gene ontology and pathway analysis were performed to systemically map the genes which are functionally associated to those differentially expressed circRNAs identified from our data. The expression of the differentially expressed circRNAs picked up by RNAseq in PANC-1-GR cells was further validated by qRT-PCR and two circRNAs were eventually identified as the most distinct targets. cell line (PANC-1,PANC-1-GR) up-regulated resistant NA NA NA validated 7227 Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2018 29922161 circBase NA chr4:52729603-52780244 + circRNA DB00441 (APRD00201) Gemcitabine pancreatic ductal adenocarcinoma qRT-PCR In this study, we established Gemcitabine resistant PANC-1 (PANC-1-GR) cell lines and compared the circular RNAs (circRNAs) profiles between PANC-1 cells and PANC-1-GR cells by RNA sequencing. Differentially expressed circRNAs were demonstrated using scatter plot and cluster heatmap analysis. Gene ontology and pathway analysis were performed to systemically map the genes which are functionally associated to those differentially expressed circRNAs identified from our data. The expression of the differentially expressed circRNAs picked up by RNAseq in PANC-1-GR cells was further validated by qRT-PCR and two circRNAs were eventually identified as the most distinct targets. cell line (PANC-1,PANC-1-GR) up-regulated resistant NA NA NA validated 7228 Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol 2018 30015883 circBase hsa-circRNA-007874 circRNA-MTO1 circRNA DB04331 (EXPT02296) Monastrol breast cancer RT-qPCR The role of Circular RNA-MTO1 in breast cancer cells was detected using CCK-8 assay, RT-qPCR, RNA pulldown and mass spectrometry, Fluorescence in situ hybridization analysis (FISH),Immunohistochemistry (IHC), western blotting and cell invasion assay, etc. cell line (MDA-MB-231, MCF-7, MDA-MB-453, SKBR-3, T47D, MDA-MB-468,MCF-7-R and MDA-MB-231R) up-regulated sensitive NA NA NA validated 7229 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0011292 hsa_circ_0011292 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7230 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0011298 hsa_circ_0011298 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7231 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0058608 hsa_circ_0058608 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7232 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0005642 hsa_circ_0005642 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7233 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0004841 hsa_circ_0004841 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7234 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0011293 hsa_circ_0011293 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7235 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0020301 hsa_circ_0020301 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7236 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0063877 hsa_circ_0063877 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7237 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0055114 hsa_circ_0055114 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7238 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0058731 hsa_circ_0058731 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7239 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0071799 hsa_circ_0071799 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7240 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0076100 hsa_circ_0076100 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7241 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0072408 hsa_circ_0072408 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7242 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0072410 hsa_circ_0072410 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7243 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0041523 hsa_circ_0041523 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7244 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0024842 hsa_circ_0024842 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7245 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0067352 hsa_circ_0067352 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7246 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0043843 hsa_circ_0043843 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7247 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0031364 hsa_circ_0031364 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7248 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0055256 hsa_circ_0055256 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) up-regulated resistant NA NA NA predicted 7249 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0087963 hsa_circ_0087963 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7250 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0029345 hsa_circ_0029345 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7251 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0017474 hsa_circ_0017474 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7252 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0040603 hsa_circ_0040603 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7253 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0036056 hsa_circ_0036056 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7254 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0036054 hsa_circ_0036054 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7255 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0091931 hsa_circ_0091931 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7256 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0022217 hsa_circ_0022217 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7257 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0022434 hsa_circ_0022434 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7258 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0091842 hsa_circ_0091842 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7259 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0017485 hsa_circ_0017485 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7260 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0063776 hsa_circ_0063776 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7261 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0001565 hsa_circ_0001565 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7262 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0043739 hsa_circ_0043739 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7263 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0002483 hsa_circ_0002483 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7264 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0030998 hsa_circ_0030998 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7265 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0006608 hsa_circ_0006608 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7266 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0091986 hsa_circ_0091986 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7267 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0054013 hsa_circ_0054013 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7268 Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells. Cell Physiol Biochem 2018 30099455 circBase hsa_circ_0030999 hsa_circ_0030999 circRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Taxol lung non-small cell carcinoma qRT-PCR High-throughput circRNA microarrays were employed to investigate the circRNA profiles of parental A549 and taxol-resistant A549/Taxol cells. We predicted the miRNA targets of differentially expressed circRNAs via miRNA prediction software and then constructed a circRNA/miRNA network using Cytoscape. Bioinformatics analyses were performed to annotate dysregulated circRNAs in detail. cell line (A549, A549/Taxol) down-regulated resistant NA NA NA predicted 7269 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr10:32588594-32589641 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7270 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr12:179378341 179392104 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7271 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr10:32588594-32589641 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7272 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr12:179378341 179392104 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7273 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr10:32588594-32589641 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7274 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase NA chr12:179378341 179392104 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7275 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63) up-regulated resistant NA NA NA predicted 7276 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63) up-regulated resistant NA NA NA predicted 7277 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63) up-regulated resistant NA NA NA predicted 7278 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7279 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0080975 hsa_circ_0080975 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7280 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0081001 hsa_circ_0081001 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7281 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000419 hsa_circ_0000419 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7282 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006873 hsa_circ_0006873 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7283 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002060 hsa_circ_0002060 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7284 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006101 hsa_circ_0006101 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7285 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004254 hsa_circ_0004254 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7286 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005721 hsa_circ_0005721 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7287 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7288 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0017728 hsa_circ_0017728 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7289 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0057518 hsa_circ_0057518 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7290 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006318 hsa_circ_0006318 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7291 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005046 hsa_circ_0005046 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7292 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002654 hsa_circ_0002654 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7293 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002314 hsa_circ_0002314 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7294 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000192 hsa_circ_0000192 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7295 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0060927 hsa_circ_0060927 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7296 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7297 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0080975 hsa_circ_0080975 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7298 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0081001 hsa_circ_0081001 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7299 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000419 hsa_circ_0000419 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7300 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006873 hsa_circ_0006873 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7301 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002060 hsa_circ_0002060 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7302 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006101 hsa_circ_0006101 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7303 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004254 hsa_circ_0004254 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7304 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005721 hsa_circ_0005721 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7305 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7306 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0017728 hsa_circ_0017728 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7307 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0057518 hsa_circ_0057518 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7308 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006318 hsa_circ_0006318 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7309 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005046 hsa_circ_0005046 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7310 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002654 hsa_circ_0002654 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7311 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002314 hsa_circ_0002314 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7312 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000192 hsa_circ_0000192 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7313 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0060927 hsa_circ_0060927 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7314 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7315 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0080975 hsa_circ_0080975 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7316 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0081001 hsa_circ_0081001 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7317 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000419 hsa_circ_0000419 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7318 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006873 hsa_circ_0006873 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7319 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002060 hsa_circ_0002060 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7320 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006101 hsa_circ_0006101 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7321 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0004254 hsa_circ_0004254 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7322 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005721 hsa_circ_0005721 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) up-regulated resistant NA NA NA predicted 7323 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7324 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0017728 hsa_circ_0017728 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7325 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0057518 hsa_circ_0057518 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7326 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0006318 hsa_circ_0006318 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7327 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0005046 hsa_circ_0005046 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7328 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002654 hsa_circ_0002654 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7329 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0002314 hsa_circ_0002314 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7330 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0000192 hsa_circ_0000192 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7331 Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018 30191736 circBase hsa_circ_0060927 hsa_circ_0060927 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma qRT-PCR CircRNA expression profile was performed in three paired human chemoresistant and chemosensitive OS cell lines by next-generation sequencing. Quantitative real-time-PCR (qRT-PCR) was used to confirm next-generation sequencing data. Bioinformatics analysis was conducted to predict their functions. tissue and cell line (MG63,MG63/DXR,U2OS,U2OS/DXR,KHOS and KHOS/DXR) down-regulated resistant NA NA NA predicted 7332 CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis 2018 30224298 circBase NA circBA9.3 circRNA DB00619 (APRD01028, EXPT02967, DB03261) Imatinib chronic myeloid leukemia qRT-PCR The role of CircBA9.3 in leukaemic cancer was detected using Third-generation digital PCR system (3D-dPCR), quantitative real-time PCR, proliferation and drug resistance assays, flow cytometry analyses and western blots, etc. cell line ( K562 and Ku812) up-regulated resistant NA NA NA validated 7333 CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis 2018 30224298 circBase NA circBA9.3 circRNA DB04868 Nilotinib chronic myeloid leukemia qRT-PCR The role of CircBA9.3 in leukaemic cancer was detected using Third-generation digital PCR system (3D-dPCR), quantitative real-time PCR, proliferation and drug resistance assays, flow cytometry analyses and western blots, etc. cell line ( K562 and Ku812) up-regulated resistant NA NA NA validated 7334 CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis 2018 30224298 circBase NA circBA9.3 circRNA DB01254 Dasatinib chronic myeloid leukemia qRT-PCR The role of CircBA9.3 in leukaemic cancer was detected using Third-generation digital PCR system (3D-dPCR), quantitative real-time PCR, proliferation and drug resistance assays, flow cytometry analyses and western blots, etc. cell line ( K562 and Ku812) up-regulated resistant NA NA NA validated 7335 CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol 2019 30395908 circBase NA circPAN3 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin acute myeloid leukemia qRT-PCR In this study, we established a doxorubicin (ADM)-resistant THP-1 AML cell line (THP-1/ADM). A high-throughput microarray was used to identify circRNA expression profiles of THP-1/ADM cells and naive THP-1 cells. The identified potential functional circRNA molecule was further validated in THP-1/ADM cells and bone marrow (BM) specimens from 42 AML patients. The interactions with target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were also explored. As a result, 49 circRNAs that are significantly differentially expressed between THP-1/ADM and THP-1 cells were identified. Of these circRNAs, downregulation of circPAN3 by small interfering RNA significantly restored ADM sensitivity of THP-1/ADM cells. Furthermore, BM samples from patients with refractory and recurrent AML showed increased expression of circPAN3. A detailed circRNA/miRNA/mRNA interaction network was predicated for this circRNA. Subsequent mechanistic experiments showed that downregulation of circPAN3 could decrease the expression of X-linked inhibitor of apoptosis protein (XIAP), but this effect was counteracted by miR-153-3p or miR-183-5p specific inhibitors. Luciferase experiments further demonstrated that these molecules are involved in the circPAN3 regulatory network. Our results revealed that circPAN3 may be a key mediator for chemoresistance of AML cells, which may depend on the circPAN3-miR-153-5p/miR-183-5p-XIAP axis. tissue and cell line (THP-1) down-regulated sensitive miR-153-5p/miR-183-5p XIAP NA validated 7336 Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance. Neoplasma 2019 30509102 circBase hsa_circ_0000285 hsa_circ_0000285 circRNA DB00515 (APRD00359) Cisplatin bladder cancer qPCR qPCR measured the expression of hsa_circRNA_100783, hsa_circ_0000285 and hsa_circRNA_100782 in bladder cancer tissues. tissue and cell line ( CCC-HB-2,HTB-9, T24,J82, SW780 and RT4) down-regulated resistant NA NA NA validated 7337 Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys Res Commun 2019 30509491 circBase hsa_circ_0004015 hsa_circ_0004015 circRNA DB00317 (APRD00997, DB07998) Gefitinib lung non-small cell carcinoma qRT-PCR we identified hsa_circ_0004015 was upregulated in NSCLC tissues, and was associated with the poor overall survival rate of NSCLC patients. Knockdown of hsa_circ_0004015 significantly decreased cell viability, proliferation, and invasion, whereas overexpression exhibited opposed effects in vivo and in vitro. Furthermore, hsa_circ_0004015 could enhance the resistance of HCC827 to gefitinib. In mechanism, hsa_circ_0004015 acted as a sponge for miR-1183, and PDPK1 was revealed to be target gene of miR-1183. Subsequently, functional assays illustrated that the oncogenic effects of hsa_circ_0004015 was attributed to the regulation of miR-1183/PDPK1 axis. In conclusion, circ_0016760/miR-1183/PDPK1 signaling pathway might play vital roles in the tumorigenesis of NSCLC. tissue and cell line ( A549, H1975,H358, H1299, HCC827,16HBE,HCC827I/R ) up-regulated resistant miR-1183 PDPK1 miR-1183/PDPK1 signaling pathway validated 7338 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 7339 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00563 (APRD00353) Methotrexate osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 7340 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 7341 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 7342 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 7343 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB00515 (APRD00359) Cisplatin osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 7344 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0004674 hsa_circ_0004674 circRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated resistant NA NA NA predicted 7345 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0068458 hsa_circ_0068458 circRNA DB01181 (APRD00007) Ifosfamide osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) down-regulated resistant NA NA NA predicted 7346 Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019 30692017 circBase hsa_circ_0001258 hsa_circ_0001258 circRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin osteosarcoma RT-PCR-qPCR In the current study, we developed whole-transcriptome sequencing (RNA sequencing [RNA-seq]) in the three paired multi-drug chemo-resistant and chemo-sensitive OS cell lines to comprehensively identify differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for mRNAs with significantly different expression. Then the ceRNA networks combining lncRNAs, circRNAs, miRNAs, and mRNAs were predicted and constructed on the basis of the authoritative miRanda and TargetScan databases combined with the widely accepted vital drug resistance-related genes and signal transduction pathways. In addition, two constructed ceRNA regulatory pathways, lncRNAMEG3/hsa-miR-200b-3p/AKT2 and hsa_circ_0001258/hsa-miR-744-3p/GSTM2, were randomly selected and validated by real-time qPCR, RNA immunoprecipitation (RIP), RNA pull-down assay, and dual luciferase reporter gene system. cell line (MG63, KHOS, U2OS,MG63/DXR, KHOS/DXR, U2OS/DXR) up-regulated sensitive NA NA NA predicted 7347 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0043632 hsa_circ_0043632 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) up-regulated resistant NA NA NA predicted 7348 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0048856 hsa_circ_0048856 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) up-regulated resistant NA NA NA predicted 7349 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0043634 hsa_circ_0043634 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) up-regulated resistant NA NA NA predicted 7350 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0002130 hsa_circ_0002130 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) up-regulated resistant NA NA NA predicted 7351 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0019088 hsa_circ_0019088 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) up-regulated resistant NA NA NA predicted 7352 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0050581 hsa_circ_0050581 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) down-regulated resistant NA NA NA predicted 7353 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0023302 hsa_circ_0023302 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) down-regulated resistant NA NA NA predicted 7354 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0069997 hsa_circ_0069997 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) down-regulated resistant NA NA NA predicted 7355 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0050580 hsa_circ_0050580 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) down-regulated resistant NA NA NA predicted 7356 Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer 2019 30883029 circBase hsa_circ_0069996 hsa_circ_0069996 circRNA DB09330 Osimertinib lung non-small cell carcinoma qRT-PCR Considering the important role of circular RNAs (circRNAs) in cancers, we established AZD9291-resistant NSCLC cell lines (H1975/AZDR and HCC827/AZDR) and used microarray analysis to determine the circRNA expression profiles of the cells. The H1975/AZDR and HCC827/AZDR cell lines were induced by gradually increasing the drug concentration. CircRNA microarray expression profiles were obtained from H1975, HCC827, H1975/AZDR, and HCC827/AZDR cells and validated by quantitative reverse transcription PCR. Expression data were analyzed bioinformatically. cell line (H1975, HCC827, H1975/AZDR, and HCC827/AZDR) down-regulated resistant NA NA NA predicted 7357 Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer 2019 30927924 circBase hsa_circ_0000199 hsa_circ_0000199 circRNA DB00515 (APRD00359) Cisplatin stomach cancer qRT-PCR circAKT3 (hsa_circ_0000199, a circRNA originating from exons 8, 9, 10, and 11 of the AKT3 gene) was identified by RNA sequencing and verified by quantitative reverse transcription PCR. The role of circAKT3 in CDDP resistance in GC was assessed both in vitro and in vivo. Luciferase reporter assay, biotin-coupled RNA pull-down and fluorescence in situ hybridization (FISH) were conducted to evaluate the interaction between circAKT3 and miR-198. Functional experiments were measured by western blotting, a cytotoxicity assay, clonogenic assay and flow cytometry. cell line ( SGC7901,BGC823,SGC7901CDDP,BGC823CDDP) up-regulated resistant miR-198 PIK3R1 PI3K/AKT signaling pathway validated 7358 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0064555 hsa_circRNA_103306 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7359 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0004846 hsa_circRNA_101356 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7360 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_404790 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7361 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0027491 hsa_circRNA_101096 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7362 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0042359 hsa_circRNA_042359 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7363 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0025506 hsa_circRNA_101017 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7364 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_100925 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7365 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406135 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7366 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_403127 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7367 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0000544 hsa_circRNA_000544 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7368 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405769 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7369 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405296 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7370 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0000858 hsa_circRNA_000858 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7371 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_404994 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7372 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406829 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7373 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406430 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7374 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405743 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7375 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406075 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7376 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0049237 hsa_circRNA_049237 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7377 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406937 circRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7378 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0064555 hsa_circRNA_103306 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7379 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0004846 hsa_circRNA_101356 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7380 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_404790 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7381 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0027491 hsa_circRNA_101096 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7382 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0042359 hsa_circRNA_042359 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7383 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0025506 hsa_circRNA_101017 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7384 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_100925 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7385 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406135 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7386 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_403127 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7387 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0000544 hsa_circRNA_000544 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) up-regulated resistant NA NA NA predicted 7388 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405769 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7389 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405296 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7390 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0000858 hsa_circRNA_000858 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7391 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_404994 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7392 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406829 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7393 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406430 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7394 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_405743 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7395 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406075 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7396 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase hsa_circ_0049237 hsa_circRNA_049237 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7397 Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 2019 31020847 circBase NA hsa_circRNA_406937 circRNA DB00526 (APRD00186) Oxaliplatin colorectal cancer qPCR We developed a chemoresistant cell line model and profiled the circRNAs via microarray. We further validated the expression of two circRNAs in 25 formalin-fixed paraffin-embedded (FFPE) tissue specimens (13 nonresponders and 12 responders) via quantitative polymerase chain reaction (qPCR). cell line (HCT-116,HCT-116R) down-regulated resistant NA NA NA predicted 7398 Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway. BMC Cancer 2019 31035951 circBase hsa_circ_0005379 Hsa_circ_0005379 circRNA DB00002 (BTD00071, BIOD00071) Cetuximab oral squamous cell carcinoma qRT-PCR By using high-throughput transcriptome sequencing technology, we conducted a comprehensive study of circRNAs in human OSCC. The effect of circRNA hsa_circ_0005379 on OSCC tissues and cell lines was monitored by qRT-PCR, Transwell assay, flow cytometry, and western blot analysis. Xenograft mouse models were used to assess tumor growth and animal survival. tissue and cell line (SCC9, SCC15, SCC25, and CAL27) up-regulated sensitive NA NA EGFR pathway validated 7399 Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075/BCL-9. Chem Biol Interact 2019 31112718 circBase NA circRNA-104075 circRNA NA matrine glioma qRT-PCR Glioma cell line U251cells were treated with matrine to assess viability and proliferation using CCK8 and EdU assays. PI/FITC staining was performed for apoptosis assay. Transfections were performed for circRNA-104075 or Bcl-9 overexpression. Western blot analysis was performed to evaluate changes of protein levels and changes of gene level were detected by qRT-PCR in U251cells. cell line (U251) up-regulated resistant NA NA Wnt/Beta-catenin and PI3K/AKT signaling pathway validated 7400 circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther 2019 31153828 circBase hsa_circ_0025202 hsa_circ_0025202 circRNA DB00675 (APRD00123) Tamoxifen breast cancer qRT-PCR To investigate roles of circular RNAs (circRNAs) in tamoxifen resistance, a tamoxifen-resistant MCF-7 cell line was established and screened for its circRNA expression profile by RNA sequencing.hsa_circ_0025202, a circRNA that was significantly downregulated, was selected for further investigation.Using a large cohort of clinical specimens, we found that hsa_circ_0025202 exhibited low expression in cancer tissues and was negatively correlated with lymphatic metastasis and histological grade.Gain- and loss-of-function assays indicated that hsa_circ_0025202 could inhibit cell proliferation, colony formation, and migration and increase cell apoptosis and sensitivity to tamoxifen.Bioinformatics and luciferase reporter assays verified that hsa_circ_0025202 could act as a miRNA sponge for miR-182-5p and further regulate the expression and activity of FOXO3a.Functional studies revealed that tumor inhibition and tamoxifen sensitization effects of hsa_circ_0025202 were achieved via the miR-182-5p/FOXO3a axis.Foreover, in vivo experiments confirmed that hsa_circ_0025202 could suppress tumor growth and enhance tamoxifen efficacy. cell line (MCF7 and T47D and HEK293T) down-regulated resistant miR-182-5p FOXO3a NA validated 7401 Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway. Front Oncol 2019 31249811 circBase hsa_circ_0001946 Hsa_circ_0001946 circRNA DB00515 (APRD00359) Cisplatin lung non-small cell carcinoma qRT-PCR We focused on investigating the circular RNA, hsa_circ_0001946. RNA interference of hsa_circ_0001946 was carried out in A549 cell lines to determine the effect of reduced hsa_circ_0001946 expression on lung cancer progression and was analyzed by Cell Counting Kit-8 (CCK-8), 5-ethynyl-20-deoxyuridine, clone formation, Hoechst, wound healing, and transwell assays. The nucleotide excision repair (NER) signaling pathway was identified by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Moreover, cellular responses to cisplatin were assessed through CCK-8 and flow cytometry assays. Western blot analysis and host-cell reactivation assay were used to determine the effect of hsa_circ_0001946 on NER signaling. cell line (A549,A549/DDP) down-regulated resistant NA NA the Nucleotide Excision Repair Signaling Pathway validated 7402 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0034067 hsa_circRNA_101460 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7403 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000673 hsa_circRNA_101707 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7404 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002961 hsa_circRNA_002961 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7405 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006156 hsa_circRNA_103514 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7406 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0029409 hsa_circRNA_029409 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7407 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004870 hsa_circRNA_103044 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7408 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0071174 hsa_circRNA_103754 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7409 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009582 hsa_circRNA_100036 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7410 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089762 hsa_circRNA_089762 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7411 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087862 hsa_circRNA_104854 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7412 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087861 hsa_circRNA_104853 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7413 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402002 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7414 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400277 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7415 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001874 hsa_circRNA_001547 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7416 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407092 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7417 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089763 hsa_circRNA_089763 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7418 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026512 hsa_circRNA_101070 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7419 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008394 hsa_circRNA_103437 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7420 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008551 hsa_circRNA_008551 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7421 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001445 hsa_circRNA_092547 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7422 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087856 hsa_circRNA_087856 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7423 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018744 hsa_circRNA_018744 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7424 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086490 hsa_circRNA_104743 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7425 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008044 hsa_circRNA_103193 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7426 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003489 hsa_circRNA_101237 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7427 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000525 hsa_circRNA_092405 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7428 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0011245 hsa_circRNA_100130 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7429 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063623 hsa_circRNA_063623 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7430 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0078605 hsa_circRNA_104258 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7431 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0041252 hsa_circRNA_101938 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7432 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0077216 hsa_circRNA_104150 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7433 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007148 hsa_circRNA_007148 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7434 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084021 hsa_circRNA_104597 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7435 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0015796 hsa_circRNA_100422 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7436 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0049462 hsa_circRNA_102452 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7437 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406769 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7438 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003908 hsa_circRNA_100886 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7439 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006884 hsa_circRNA_103436 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7440 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008539 hsa_circRNA_101307 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7441 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403236 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7442 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000339 hsa_circRNA_100884 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7443 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0060539 hsa_circRNA_060539 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7444 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062610 hsa_circRNA_062610 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7445 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0039216 hsa_circRNA_101802 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7446 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007404 hsa_circRNA_101309 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7447 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008389 hsa_circRNA_008389 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7448 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022383 hsa_circRNA_100833 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7449 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000792 hsa_circRNA_001082 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7450 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001880 hsa_circRNA_001880 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7451 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003323 hsa_circRNA_103114 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7452 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075320 hsa_circRNA_075320 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7453 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068465 hsa_circRNA_068465 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7454 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0071196 hsa_circRNA_103758 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7455 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0071210 hsa_circRNA_071210 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7456 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063089 hsa_circRNA_063089 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7457 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001660 hsa_circRNA_001946 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7458 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002807 hsa_circRNA_101305 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7459 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403517 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7460 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0011448 hsa_circRNA_011448 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7461 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402094 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7462 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000102 hsa_circRNA_000102 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7463 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004217 hsa_circRNA_101278 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7464 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022589 hsa_circRNA_100841 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7465 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0060540 hsa_circRNA_060540 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7466 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023610 hsa_circRNA_023610 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7467 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003426 hsa_circRNA_103024 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7468 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059060 hsa_circRNA_059060 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7469 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405668 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7470 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061346 hsa_circRNA_061346 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7471 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004596 hsa_circRNA_100885 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7472 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062603 hsa_circRNA_103181 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7473 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000714 hsa_circRNA_101861 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7474 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002545 hsa_circRNA_002545 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7475 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0031027 hsa_circRNA_101308 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7476 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009012 hsa_circRNA_009012 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7477 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0071185 hsa_circRNA_103755 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7478 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008359 hsa_circRNA_008359 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7479 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005907 hsa_circRNA_100014 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7480 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003438 hsa_circRNA_101860 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7481 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405965 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7482 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040188 hsa_circRNA_101859 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7483 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0078607 hsa_circRNA_104259 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7484 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009594 hsa_circRNA_100040 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7485 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018905 hsa_circRNA_100632 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7486 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001985 hsa_circRNA_001985 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7487 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005354 hsa_circRNA_100245 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7488 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004390 hsa_circRNA_004390 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7489 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020353 hsa_circRNA_100715 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7490 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008432 hsa_circRNA_102469 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7491 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007312 hsa_circRNA_103180 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7492 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022392 hsa_circRNA_100834 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7493 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000919 hsa_circRNA_000274 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7494 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001258 hsa_circRNA_103267 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7495 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008817 hsa_circRNA_008817 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7496 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007245 hsa_circRNA_007245 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7497 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007059 hsa_circRNA_007059 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7498 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002082 hsa_circRNA_002082 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7499 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086779 hsa_circRNA_086779 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7500 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051908 hsa_circRNA_051908 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7501 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006174 hsa_circRNA_104852 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7502 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0074598 hsa_circRNA_074598 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7503 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072803 hsa_circRNA_103869 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7504 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042451 hsa_circRNA_042451 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7505 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404926 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7506 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002965 hsa_circRNA_104698 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7507 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076989 hsa_circRNA_076989 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7508 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072837 hsa_circRNA_072837 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7509 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075896 hsa_circRNA_075896 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7510 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000315 hsa_circRNA_092388 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7511 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404300 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7512 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0039261 hsa_circRNA_101805 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7513 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402692 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7514 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004954 hsa_circRNA_004954 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7515 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004032 hsa_circRNA_104066 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7516 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006608 hsa_circRNA_100533 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7517 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003885 hsa_circRNA_104577 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7518 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003136 hsa_circRNA_100556 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7519 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001318 hsa_circRNA_001318 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7520 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003251 hsa_circRNA_003251 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7521 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000907 hsa_circRNA_102471 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7522 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087400 hsa_circRNA_087400 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7523 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0085278 hsa_circRNA_085278 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7524 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001147 hsa_circRNA_103045 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7525 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017449 hsa_circRNA_017449 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7526 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092329 hsa_circRNA_400005 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7527 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403876 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7528 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001449 hsa_circRNA_103747 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7529 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400105 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7530 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401220 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7531 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008122 hsa_circRNA_008122 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7532 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406841 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7533 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075048 hsa_circRNA_104016 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7534 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007250 hsa_circRNA_007250 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7535 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407033 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7536 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401955 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7537 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003302 hsa_circRNA_100978 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7538 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063158 hsa_circRNA_103211 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7539 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003655 hsa_circRNA_104466 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7540 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006795 hsa_circRNA_006795 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7541 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0049627 hsa_circRNA_049627 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7542 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002153 hsa_circRNA_105023 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7543 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0074595 hsa_circRNA_074595 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7544 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0060516 hsa_circRNA_103069 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7545 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406908 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7546 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047818 hsa_circRNA_102377 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7547 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0088128 hsa_circRNA_104885 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7548 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005572 hsa_circRNA_104745 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7549 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006606 hsa_circRNA_006606 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7550 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0019841 hsa_circRNA_019841 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7551 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001022 hsa_circRNA_000926 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7552 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0058058 hsa_circRNA_102913 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7553 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048695 hsa_circRNA_102425 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7554 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0012673 hsa_circRNA_100239 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7555 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051899 hsa_circRNA_102590 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7556 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063329 hsa_circRNA_103224 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7557 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003605 hsa_circRNA_003605 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7558 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026153 hsa_circRNA_101052 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7559 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0037130 hsa_circRNA_101666 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7560 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000872 hsa_circRNA_092458 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7561 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084606 hsa_circRNA_104633 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7562 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001573 hsa_circRNA_104055 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7563 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0014879 hsa_circRNA_100367 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7564 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076251 hsa_circRNA_104103 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7565 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005161 hsa_circRNA_005161 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7566 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000074 hsa_circRNA_000074 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7567 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000648 hsa_circRNA_000195 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7568 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003643 hsa_circRNA_101314 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7569 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047663 hsa_circRNA_102368 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7570 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062865 hsa_circRNA_062865 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7571 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0013055 hsa_circRNA_013055 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7572 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0052154 hsa_circRNA_052154 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7573 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0011385 hsa_circRNA_100146 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7574 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001203 hsa_circRNA_001203 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7575 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063305 hsa_circRNA_103221 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7576 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0019589 hsa_circRNA_100665 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7577 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000030 hsa_circRNA_000030 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7578 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004087 hsa_circRNA_004087 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7579 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0030162 hsa_circRNA_030162 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7580 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003505 hsa_circRNA_102002 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7581 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406336 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7582 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042459 hsa_circRNA_102004 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7583 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008554 hsa_circRNA_008554 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7584 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000336 hsa_circRNA_000336 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7585 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0088059 hsa_circRNA_104875 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7586 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009357 hsa_circRNA_100015 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7587 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001372 hsa_circRNA_092534 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7588 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092315 hsa_circRNA_400064 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7589 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400527 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7590 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000604 hsa_circRNA_092419 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7591 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000141 hsa_circRNA_001026 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7592 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002303 hsa_circRNA_104923 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7593 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022487 hsa_circRNA_022487 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7594 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000521 hsa_circRNA_000521 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7595 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403715 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7596 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080210 hsa_circRNA_104374 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7597 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0045219 hsa_circRNA_102163 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7598 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003315 hsa_circRNA_101874 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7599 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0069574 hsa_circRNA_069574 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7600 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036399 hsa_circRNA_101602 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7601 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004837 hsa_circRNA_103871 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7602 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006004 hsa_circRNA_006004 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7603 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072876 hsa_circRNA_103881 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7604 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405620 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7605 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0025135 hsa_circRNA_101001 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7606 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000517 hsa_circRNA_001678 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7607 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0014772 hsa_circRNA_014772 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7608 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005974 hsa_circRNA_100786 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7609 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402510 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7610 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0082139 hsa_circRNA_104468 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7611 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000773 hsa_circRNA_000773 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7612 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051238 hsa_circRNA_051238 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7613 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403250 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7614 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040786 hsa_circRNA_101898 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7615 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004680 hsa_circRNA_100364 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7616 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000557 hsa_circRNA_101406 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7617 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001517 hsa_circRNA_001523 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7618 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0025513 hsa_circRNA_101018 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7619 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080209 hsa_circRNA_104373 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7620 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017077 hsa_circRNA_017077 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7621 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042265 hsa_circRNA_042265 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7622 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0056281 hsa_circRNA_056281 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7623 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084275 hsa_circRNA_084275 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7624 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008334 hsa_circRNA_104372 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7625 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026457 hsa_circRNA_026457 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7626 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0028864 hsa_circRNA_101174 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7627 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002955 hsa_circRNA_100976 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7628 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051239 hsa_circRNA_051239 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7629 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006131 hsa_circRNA_006131 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7630 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407254 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7631 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005931 hsa_circRNA_005931 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7632 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009456 hsa_circRNA_100021 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7633 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001377 hsa_circRNA_103553 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7634 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008771 hsa_circRNA_008771 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7635 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092022 hsa_circRNA_092022 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7636 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0066290 hsa_circRNA_103399 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7637 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0044014 hsa_circRNA_044014 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7638 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018652 hsa_circRNA_100614 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7639 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018440 hsa_circRNA_018440 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7640 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026349 hsa_circRNA_101068 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7641 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000324 hsa_circRNA_000324 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7642 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047444 hsa_circRNA_102350 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7643 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001691 hsa_circRNA_001691 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7644 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000500 hsa_circRNA_000500 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7645 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402748 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7646 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0038366 hsa_circRNA_101749 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7647 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000516 hsa_circRNA_001379 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7648 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000524 hsa_circRNA_101319 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7649 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000763 hsa_circRNA_000763 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7650 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040185 hsa_circRNA_101858 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7651 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003441 hsa_circRNA_101270 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7652 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008242 hsa_circRNA_101825 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7653 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009654 hsa_circRNA_100044 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7654 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405719 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7655 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0032825 hsa_circRNA_101418 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7656 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020394 hsa_circRNA_100720 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7657 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0088485 hsa_circRNA_104915 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7658 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017695 hsa_circRNA_017695 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7659 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0066556 hsa_circRNA_066556 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7660 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026074 hsa_circRNA_026074 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7661 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005414 hsa_circRNA_005414 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7662 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000042 hsa_circRNA_100126 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7663 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0058192 hsa_circRNA_058192 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7664 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020460 hsa_circRNA_100724 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7665 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002259 hsa_circRNA_102468 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7666 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000417 hsa_circRNA_101099 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7667 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000549 hsa_circRNA_000178 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7668 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0028861 hsa_circRNA_028861 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7669 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0088681 hsa_circRNA_104925 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7670 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403101 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7671 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0031288 hsa_circRNA_101325 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7672 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0056790 hsa_circRNA_102836 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7673 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063526 hsa_circRNA_103237 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7674 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0019591 hsa_circRNA_100666 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7675 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402705 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7676 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003940 hsa_circRNA_003940 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7677 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001829 hsa_circRNA_000482 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7678 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084615 hsa_circRNA_104634 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7679 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404736 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7680 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004058 hsa_circRNA_104153 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7681 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075402 hsa_circRNA_104039 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7682 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402622 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7683 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036750 hsa_circRNA_101643 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7684 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001450 hsa_circRNA_103751 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7685 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0058361 hsa_circRNA_058361 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7686 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004083 hsa_circRNA_004083 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7687 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0032682 hsa_circRNA_032682 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7688 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0015494 hsa_circRNA_015494 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7689 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005185 hsa_circRNA_005185 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7690 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023249 hsa_circRNA_100867 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7691 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0037511 hsa_circRNA_101684 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7692 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000861 hsa_circRNA_000644 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7693 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009577 hsa_circRNA_100031 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7694 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005528 hsa_circRNA_005528 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7695 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087063 hsa_circRNA_104781 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7696 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059914 hsa_circRNA_059914 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7697 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005087 hsa_circRNA_005087 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7698 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000835 hsa_circRNA_102315 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7699 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403150 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7700 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0082179 hsa_circRNA_104474 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7701 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008030 hsa_circRNA_102510 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7702 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0037972 hsa_circRNA_101713 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7703 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001235 hsa_circRNA_103239 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7704 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006614 hsa_circRNA_103532 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7705 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0066874 hsa_circRNA_066874 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7706 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000326 hsa_circRNA_000543 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7707 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089761 hsa_circRNA_089761 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7708 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0049241 hsa_circRNA_049241 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7709 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401089 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7710 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079163 hsa_circRNA_104288 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7711 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020354 hsa_circRNA_020354 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7712 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040466 hsa_circRNA_040466 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7713 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404994 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7714 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003967 hsa_circRNA_103990 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7715 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000614 hsa_circRNA_101553 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7716 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004808 hsa_circRNA_100093 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7717 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0091692 hsa_circRNA_091692 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7718 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0055943 hsa_circRNA_055943 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7719 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0029562 hsa_circRNA_029562 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7720 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000554 hsa_circRNA_001059 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7721 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086159 hsa_circRNA_086159 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7722 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0091894 hsa_circRNA_105038 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7723 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000008 hsa_circRNA_100017 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7724 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0085923 hsa_circRNA_104722 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7725 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000040 hsa_circRNA_000571 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7726 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080790 hsa_circRNA_080790 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7727 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079166 hsa_circRNA_104290 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7728 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008621 hsa_circRNA_103827 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7729 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080649 hsa_circRNA_104406 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7730 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006491 hsa_circRNA_006491 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7731 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062857 hsa_circRNA_062857 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7732 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059880 hsa_circRNA_059880 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7733 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0046263 hsa_circRNA_102231 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7734 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002590 hsa_circRNA_103622 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7735 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404285 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7736 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000323 hsa_circRNA_000323 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7737 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003273 hsa_circRNA_102939 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7738 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075281 hsa_circRNA_075281 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7739 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079048 hsa_circRNA_079048 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7740 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001099 hsa_circRNA_102911 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7741 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008618 hsa_circRNA_103757 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7742 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008337 hsa_circRNA_008337 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7743 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003484 hsa_circRNA_003484 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7744 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405807 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7745 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062545 hsa_circRNA_103176 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7746 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004029 hsa_circRNA_102795 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7747 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075494 hsa_circRNA_075494 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7748 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001122 hsa_circRNA_102974 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7749 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401275 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7750 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072387 hsa_circRNA_103829 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7751 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007149 hsa_circRNA_007149 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7752 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0011462 hsa_circRNA_100157 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7753 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000963 hsa_circRNA_092476 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7754 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0028299 hsa_circRNA_101153 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7755 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062400 hsa_circRNA_062400 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7756 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005415 hsa_circRNA_102001 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7757 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001974 hsa_circRNA_103392 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7758 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086474 hsa_circRNA_086474 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7759 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000036 hsa_circRNA_000042 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7760 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006392 hsa_circRNA_102409 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7761 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000120 hsa_circRNA_000120 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7762 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040203 hsa_circRNA_040203 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7763 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003552 hsa_circRNA_003552 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7764 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002987 hsa_circRNA_104246 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7765 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022378 hsa_circRNA_100832 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7766 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017693 hsa_circRNA_017693 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7767 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400433 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7768 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0085616 hsa_circRNA_104692 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7769 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006382 hsa_circRNA_102433 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7770 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0038090 hsa_circRNA_101719 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7771 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001361 hsa_circRNA_103512 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7772 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001887 hsa_circRNA_000993 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7773 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076522 hsa_circRNA_104112 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7774 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036688 hsa_circRNA_101639 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7775 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036683 hsa_circRNA_101638 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7776 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404935 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7777 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063179 hsa_circRNA_063179 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7778 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000255 hsa_circRNA_100667 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7779 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008623 hsa_circRNA_008623 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7780 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0065871 hsa_circRNA_103383 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7781 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0032683 hsa_circRNA_101407 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7782 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003423 hsa_circRNA_102378 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7783 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007632 hsa_circRNA_103046 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7784 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002971 hsa_circRNA_002971 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7785 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004771 hsa_circRNA_103110 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7786 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003963 hsa_circRNA_003963 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7787 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402670 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7788 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000724 hsa_circRNA_101899 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7789 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006168 hsa_circRNA_103670 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7790 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000881 hsa_circRNA_092459 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7791 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004271 hsa_circRNA_103469 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7792 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0033024 hsa_circRNA_101430 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7793 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0038343 hsa_circRNA_038343 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7794 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0044837 hsa_circRNA_044837 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7795 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000457 hsa_circRNA_000457 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7796 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000150 hsa_circRNA_000150 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7797 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000518 hsa_circRNA_000167 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7798 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002089 hsa_circRNA_100977 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7799 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009618 hsa_circRNA_009618 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7800 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009362 hsa_circRNA_100019 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7801 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001055 hsa_circRNA_102787 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7802 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068464 hsa_circRNA_103542 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7803 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006239 hsa_circRNA_100979 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7804 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068462 hsa_circRNA_103541 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7805 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020397 hsa_circRNA_100722 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7806 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0050124 hsa_circRNA_050124 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7807 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002669 hsa_circRNA_100718 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7808 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000915 hsa_circRNA_102487 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7809 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0050898 hsa_circRNA_050898 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7810 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0090122 hsa_circRNA_090122 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7811 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0011571 hsa_circRNA_100166 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7812 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0082672 hsa_circRNA_082672 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7813 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0057105 hsa_circRNA_102855 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7814 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061891 hsa_circRNA_103140 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7815 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072088 hsa_circRNA_103809 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7816 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401327 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7817 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007352 hsa_circRNA_007352 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7818 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036287 hsa_circRNA_101592 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7819 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089630 hsa_circRNA_089630 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7820 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008702 hsa_circRNA_008702 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7821 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001311 hsa_circRNA_001311 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7822 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063575 hsa_circRNA_063575 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7823 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401539 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7824 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022382 hsa_circRNA_022382 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7825 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007275 hsa_circRNA_101683 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7826 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061260 hsa_circRNA_061260 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7827 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0090328 hsa_circRNA_090328 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7828 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007333 hsa_circRNA_007333 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7829 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084927 hsa_circRNA_104651 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7830 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400780 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7831 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047253 hsa_circRNA_102327 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7832 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001355 hsa_circRNA_103499 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7833 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089033 hsa_circRNA_104936 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7834 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403486 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7835 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405872 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7836 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009732 hsa_circRNA_100049 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7837 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051041 hsa_circRNA_051041 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7838 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047270 hsa_circRNA_102329 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7839 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072025 hsa_circRNA_072025 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7840 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072389 hsa_circRNA_103830 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7841 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0091934 hsa_circRNA_105039 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7842 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001386 hsa_circRNA_001386 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7843 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001851 hsa_circRNA_104766 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7844 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0071106 hsa_circRNA_071106 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7845 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405187 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7846 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406612 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7847 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009624 hsa_circRNA_100043 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7848 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072805 hsa_circRNA_103870 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7849 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022142 hsa_circRNA_100820 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7850 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0037447 hsa_circRNA_037447 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7851 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0050119 hsa_circRNA_102486 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7852 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000873 hsa_circRNA_000873 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7853 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001518 hsa_circRNA_001518 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7854 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048164 hsa_circRNA_048164 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7855 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042474 hsa_circRNA_042474 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7856 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001818 hsa_circRNA_104670 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7857 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006473 hsa_circRNA_006473 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7858 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0043469 hsa_circRNA_102064 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7859 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0031241 hsa_circRNA_101318 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7860 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023255 hsa_circRNA_100868 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7861 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002078 hsa_circRNA_101720 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7862 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040730 hsa_circRNA_040730 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7863 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404755 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7864 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001568 hsa_circRNA_001653 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7865 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004315 hsa_circRNA_101873 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7866 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004891 hsa_circRNA_102399 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7867 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063776 hsa_circRNA_103255 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7868 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000458 hsa_circRNA_000458 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7869 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0034642 hsa_circRNA_034642 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7870 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0036391 hsa_circRNA_036391 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7871 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000787 hsa_circRNA_000787 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7872 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076917 hsa_circRNA_104128 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7873 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018722 hsa_circRNA_018722 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7874 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0063577 hsa_circRNA_103241 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7875 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072857 hsa_circRNA_103879 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7876 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008910 hsa_circRNA_103772 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7877 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000287 hsa_circRNA_000287 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7878 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000520 hsa_circRNA_001846 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7879 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005671 hsa_circRNA_005671 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7880 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000519 hsa_circRNA_002178 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7881 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004636 hsa_circRNA_103756 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7882 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072797 hsa_circRNA_103868 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7883 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042200 hsa_circRNA_042200 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7884 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009360 hsa_circRNA_100016 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7885 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075650 hsa_circRNA_075650 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7886 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000370 hsa_circRNA_100989 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7887 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000471 hsa_circRNA_101245 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7888 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0077007 hsa_circRNA_077007 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7889 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406223 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7890 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0050125 hsa_circRNA_050125 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7891 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004851 hsa_circRNA_100791 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7892 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405430 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7893 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404643 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7894 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000499 hsa_circRNA_000499 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7895 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0038138 hsa_circRNA_101726 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7896 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001329 hsa_circRNA_103435 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7897 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405463 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7898 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005418 hsa_circRNA_100716 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7899 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000053 hsa_circRNA_002106 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7900 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400689 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7901 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004594 hsa_circRNA_004594 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7902 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400248 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7903 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003373 hsa_circRNA_003373 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7904 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089371 hsa_circRNA_104954 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7905 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0013058 hsa_circRNA_013058 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7906 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000075 hsa_circRNA_100244 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7907 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008087 hsa_circRNA_008087 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7908 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001531 hsa_circRNA_001531 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7909 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406299 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7910 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401640 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7911 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087234 hsa_circRNA_104791 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7912 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001689 hsa_circRNA_092568 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7913 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087357 hsa_circRNA_104808 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7914 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048232 hsa_circRNA_102402 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7915 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000825 hsa_circRNA_102293 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7916 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000742 hsa_circRNA_000742 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7917 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003461 hsa_circRNA_103774 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7918 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001646 hsa_circRNA_001646 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7919 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405421 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7920 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0049587 hsa_circRNA_049587 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7921 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005615 hsa_circRNA_101835 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7922 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040792 hsa_circRNA_040792 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7923 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0082864 hsa_circRNA_082864 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7924 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005741 hsa_circRNA_100664 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7925 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007761 hsa_circRNA_103407 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7926 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080212 hsa_circRNA_104375 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7927 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403373 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7928 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009004 hsa_circRNA_103209 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7929 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0078654 hsa_circRNA_104264 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7930 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006691 hsa_circRNA_006691 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7931 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048775 hsa_circRNA_102428 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7932 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0045234 hsa_circRNA_045234 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7933 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001545 hsa_circRNA_000422 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7934 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0082140 hsa_circRNA_104469 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7935 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0085173 hsa_circRNA_104669 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7936 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0020816 hsa_circRNA_100738 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7937 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008223 hsa_circRNA_101784 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7938 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000760 hsa_circRNA_000760 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7939 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059216 hsa_circRNA_102982 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7940 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0018499 hsa_circRNA_018499 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7941 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089863 hsa_circRNA_089863 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7942 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062163 hsa_circRNA_103153 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7943 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400114 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7944 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001014 hsa_circRNA_001123 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7945 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059910 hsa_circRNA_103028 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7946 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003620 hsa_circRNA_101610 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7947 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0046265 hsa_circRNA_046265 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7948 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089414 hsa_circRNA_089414 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7949 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000192 hsa_circRNA_100475 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7950 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005855 hsa_circRNA_005855 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7951 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0083530 hsa_circRNA_083530 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) down-regulated resistant NA NA NA predicted 7952 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0066536 hsa_circRNA_066536 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7953 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026462 hsa_circRNA_026462 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7954 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0069821 hsa_circRNA_069821 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7955 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000463 hsa_circRNA_001233 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7956 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404646 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7957 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0028912 hsa_circRNA_101179 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7958 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000129 hsa_circRNA_000129 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7959 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002754 hsa_circRNA_104598 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7960 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009172 hsa_circRNA_100604 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7961 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404959 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7962 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047641 hsa_circRNA_047641 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7963 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003534 hsa_circRNA_103664 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7964 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006941 hsa_circRNA_006941 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7965 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406683 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7966 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001178 hsa_circRNA_103112 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7967 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005513 hsa_circRNA_104401 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7968 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009043 hsa_circRNA_102761 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7969 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0037274 hsa_circRNA_037274 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7970 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405412 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7971 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075736 hsa_circRNA_104075 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7972 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001278 hsa_circRNA_103312 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7973 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026143 hsa_circRNA_101051 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7974 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406350 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7975 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0065384 hsa_circRNA_065384 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7976 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0044907 hsa_circRNA_102138 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7977 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008896 hsa_circRNA_100696 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7978 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002782 hsa_circRNA_103706 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7979 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0070617 hsa_circRNA_103717 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7980 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003511 hsa_circRNA_104537 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7981 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405708 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7982 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001721 hsa_circRNA_104423 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7983 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079262 hsa_circRNA_104293 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7984 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007990 hsa_circRNA_102062 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7985 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_401117 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7986 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0070616 hsa_circRNA_070616 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7987 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001605 hsa_circRNA_001654 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7988 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017643 hsa_circRNA_100544 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7989 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000211 hsa_circRNA_100543 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7990 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405270 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7991 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0075900 hsa_circRNA_075900 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7992 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000510 hsa_circRNA_000510 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7993 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008806 hsa_circRNA_103244 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7994 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407160 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7995 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406091 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7996 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008310 hsa_circRNA_101975 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7997 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406763 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7998 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001440 hsa_circRNA_001440 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 7999 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405920 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8000 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0083092 hsa_circRNA_104533 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8001 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003247 hsa_circRNA_100353 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8002 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004934 hsa_circRNA_101457 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8003 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048956 hsa_circRNA_102431 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8004 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0056048 hsa_circRNA_102802 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8005 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007311 hsa_circRNA_104934 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8006 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0039930 hsa_circRNA_101838 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8007 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000407 hsa_circRNA_000407 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8008 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0047467 hsa_circRNA_047467 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8009 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005164 hsa_circRNA_100629 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8010 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003748 hsa_circRNA_103372 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8011 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0070098 hsa_circRNA_103671 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8012 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001222 hsa_circRNA_103206 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8013 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068514 hsa_circRNA_103548 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8014 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007283 hsa_circRNA_100111 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8015 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406871 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8016 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001898 hsa_circRNA_001898 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8017 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004964 hsa_circRNA_102772 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8018 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061107 hsa_circRNA_061107 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8019 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000817 hsa_circRNA_102239 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8020 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079385 hsa_circRNA_104310 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8021 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0084727 hsa_circRNA_104644 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8022 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042444 hsa_circRNA_102000 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8023 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0029426 hsa_circRNA_101213 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8024 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009044 hsa_circRNA_009044 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8025 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0078150 hsa_circRNA_104207 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8026 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0041019 hsa_circRNA_101914 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8027 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004703 hsa_circRNA_104297 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8028 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006862 hsa_circRNA_006862 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8029 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005086 hsa_circRNA_005086 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8030 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023115 hsa_circRNA_023115 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8031 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004182 hsa_circRNA_004182 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8032 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001275 hsa_circRNA_000361 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8033 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005281 hsa_circRNA_102248 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8034 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005785 hsa_circRNA_101141 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8035 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008616 hsa_circRNA_101740 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8036 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0033144 hsa_circRNA_101435 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8037 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000453 hsa_circRNA_001038 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8038 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0033149 hsa_circRNA_033149 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8039 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002024 hsa_circRNA_102876 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8040 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002755 hsa_circRNA_104398 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8041 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000711 hsa_circRNA_101836 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8042 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008870 hsa_circRNA_103171 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8043 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404091 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8044 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0089652 hsa_circRNA_089652 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8045 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007326 hsa_circRNA_007326 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8046 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402799 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8047 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0091419 hsa_circRNA_091419 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8048 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086694 hsa_circRNA_104756 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8049 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002976 hsa_circRNA_104758 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8050 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023404 hsa_circRNA_100876 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8051 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007217 hsa_circRNA_104158 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8052 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005655 hsa_circRNA_005655 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8053 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000423 hsa_circRNA_001676 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8054 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000044 hsa_circRNA_100134 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8055 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0035482 hsa_circRNA_101536 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8056 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405814 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8057 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008382 hsa_circRNA_008382 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8058 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405551 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8059 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001461 hsa_circRNA_103777 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8060 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400896 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8061 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004865 hsa_circRNA_101234 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8062 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001439 hsa_circRNA_103740 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8063 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406207 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8064 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400766 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8065 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0073647 hsa_circRNA_103923 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8066 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407059 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8067 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000419 hsa_circRNA_101102 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8068 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000504 hsa_circRNA_101300 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8069 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0016123 hsa_circRNA_100434 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8070 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006784 hsa_circRNA_104526 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8071 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404642 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8072 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001490 hsa_circRNA_001490 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8073 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087564 hsa_circRNA_104828 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8074 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006117 hsa_circRNA_102984 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8075 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406157 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8076 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005272 hsa_circRNA_005272 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8077 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002722 hsa_circRNA_002722 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8078 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023903 hsa_circRNA_100914 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8079 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0060733 hsa_circRNA_103076 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8080 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003550 hsa_circRNA_003550 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8081 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005623 hsa_circRNA_101841 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8082 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007924 hsa_circRNA_007924 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8083 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406728 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8084 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007117 hsa_circRNA_102334 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8085 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0034682 hsa_circRNA_101486 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8086 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0045697 hsa_circRNA_045697 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8087 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0057948 hsa_circRNA_057948 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8088 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405587 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8089 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406401 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8090 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_407121 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8091 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006913 hsa_circRNA_100110 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8092 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0021727 hsa_circRNA_100796 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8093 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0032154 hsa_circRNA_032154 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8094 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0058191 hsa_circRNA_058191 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8095 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0052258 hsa_circRNA_052258 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8096 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061251 hsa_circRNA_103107 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8097 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005965 hsa_circRNA_005965 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8098 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0055954 hsa_circRNA_102796 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8099 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008584 hsa_circRNA_008584 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8100 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0031554 hsa_circRNA_101336 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8101 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000038 hsa_circRNA_100120 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8102 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006900 hsa_circRNA_101251 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8103 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0086684 hsa_circRNA_086684 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8104 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005941 hsa_circRNA_101816 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8105 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001726 hsa_circRNA_001726 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8106 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092303 hsa_circRNA_400043 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8107 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003695 hsa_circRNA_100912 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8108 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406326 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8109 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002131 hsa_circRNA_002131 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8110 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0040773 hsa_circRNA_040773 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8111 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001811 hsa_circRNA_104645 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8112 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006002 hsa_circRNA_006002 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8113 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0070612 hsa_circRNA_103715 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8114 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405265 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8115 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0065264 hsa_circRNA_065264 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8116 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0077628 hsa_circRNA_077628 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8117 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001204 hsa_circRNA_001409 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8118 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0042435 hsa_circRNA_101998 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8119 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068563 hsa_circRNA_103551 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8120 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008001 hsa_circRNA_102576 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8121 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0080576 hsa_circRNA_104399 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8122 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402125 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8123 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000206 hsa_circRNA_100529 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8124 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008518 hsa_circRNA_008518 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8125 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001649 hsa_circRNA_104206 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8126 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017628 hsa_circRNA_100540 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8127 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026302 hsa_circRNA_101063 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8128 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003997 hsa_circRNA_003997 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8129 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001847 hsa_circRNA_104761 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8130 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0062980 hsa_circRNA_062980 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8131 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0070520 hsa_circRNA_070520 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8132 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0066113 hsa_circRNA_066113 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8133 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0038095 hsa_circRNA_101721 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8134 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403556 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8135 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001772 hsa_circRNA_104532 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8136 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001055 hsa_circRNA_102787 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8137 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002402 hsa_circRNA_100091 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8138 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0019607 hsa_circRNA_100668 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8139 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0061260 hsa_circRNA_061260 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8140 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005397 hsa_circRNA_102034 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8141 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001296 hsa_circRNA_103361 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8142 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0052767 hsa_circRNA_102628 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8143 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0029031 hsa_circRNA_029031 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8144 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005235 hsa_circRNA_100630 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8145 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092367 hsa_circRNA_400027 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8146 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404925 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8147 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0065932 hsa_circRNA_103387 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8148 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405304 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8149 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0014737 hsa_circRNA_014737 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8150 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0092289 hsa_circRNA_400059 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8151 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0064808 hsa_circRNA_064808 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8152 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001572 hsa_circRNA_001572 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8153 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000818 hsa_circRNA_102249 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8154 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003602 hsa_circRNA_103357 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8155 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406470 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8156 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000746 hsa_circRNA_000746 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8157 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0056159 hsa_circRNA_056159 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8158 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007215 hsa_circRNA_007215 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8159 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005210 hsa_circRNA_005210 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8160 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0077930 hsa_circRNA_104193 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8161 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0023685 hsa_circRNA_100891 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8162 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0045862 hsa_circRNA_102205 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8163 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001599 hsa_circRNA_104101 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8164 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006759 hsa_circRNA_006759 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8165 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0049356 hsa_circRNA_102446 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8166 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_400738 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8167 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001345 hsa_circRNA_103486 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8168 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000813 hsa_circRNA_102217 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8169 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0068697 hsa_circRNA_068697 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8170 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007146 hsa_circRNA_101695 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8171 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072904 hsa_circRNA_103883 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8172 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0017726 hsa_circRNA_100550 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8173 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0009792 hsa_circRNA_100051 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8174 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004709 hsa_circRNA_100165 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8175 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_405713 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8176 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0022963 hsa_circRNA_022963 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8177 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006491 hsa_circRNA_006491 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8178 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0087293 hsa_circRNA_104797 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8179 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0083026 hsa_circRNA_083026 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8180 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0050055 hsa_circRNA_050055 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8181 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003738 hsa_circRNA_104086 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8182 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0059665 hsa_circRNA_059665 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8183 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001600 hsa_circRNA_002161 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8184 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0030724 hsa_circRNA_101290 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8185 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006522 hsa_circRNA_006522 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8186 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076155 hsa_circRNA_076155 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8187 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0028098 hsa_circRNA_101135 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8188 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005763 hsa_circRNA_101537 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8189 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0072567 hsa_circRNA_103844 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8190 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0076413 hsa_circRNA_104109 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8191 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0021506 hsa_circRNA_100770 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8192 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003759 hsa_circRNA_103547 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8193 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0051799 hsa_circRNA_051799 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8194 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_403328 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8195 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008016 hsa_circRNA_104595 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8196 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0069980 hsa_circRNA_069980 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8197 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0004368 hsa_circRNA_104203 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8198 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_402632 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8199 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008952 hsa_circRNA_008952 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8200 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006935 hsa_circRNA_103716 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8201 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003402 hsa_circRNA_003402 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8202 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0025054 hsa_circRNA_025054 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8203 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0006776 hsa_circRNA_006776 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8204 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001005 hsa_circRNA_001005 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8205 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000676 hsa_circRNA_101717 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8206 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0041100 hsa_circRNA_041100 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8207 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0048766 hsa_circRNA_048766 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8208 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008926 hsa_circRNA_101487 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8209 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007630 hsa_circRNA_007630 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8210 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406986 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8211 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001642 hsa_circRNA_001642 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8212 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0007068 hsa_circRNA_007068 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8213 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404497 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8214 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0002761 hsa_circRNA_002761 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8215 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0026616 hsa_circRNA_026616 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8216 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0008615 hsa_circRNA_102571 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8217 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0005730 hsa_circRNA_103864 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8218 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0055957 hsa_circRNA_055957 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8219 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001497 hsa_circRNA_103889 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) resistant NA NA NA predicted 8220 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0079743 hsa_circRNA_079743 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8221 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0000157 hsa_circRNA_001359 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8222 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001171 hsa_circRNA_000662 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8223 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0003201 hsa_circRNA_003201 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8224 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404317 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8225 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase hsa_circ_0001849 hsa_circRNA_104764 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8226 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_404841 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8227 Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep 2019 31341219 circBase NA hsa_circRNA_406281 circRNA DB08899 (DB05094) Enzalutamide prostate cancer qPCR In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughout microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. cell line (LNCaP) up-regulated resistant NA NA NA predicted 8228 A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma. Mol Ther Nucleic Acids 2017 28325293 piRBase NA piR-L-138 piRNA DB00515 (APRD00359) Cisplatin lung squamous cell carcinoma RT-PCR The role of piR-L-138 in Lung Squamous Cell Carcinoma cells was detected using RT-PCR, Real-Time PCR, cell cycle and apoptosis analysis, western blot, animal models, Pull-Down Analysis and IP, etc. cell line up-regulated sensitive p60-MDM2 NA NA validated 8229 PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics 2018 30555542 piRBase NA piRNA-54265 piRNA DB00544 (APRD00516, EXPT03204) Fluorouracil colorectal adenocarcinoma RT-qPCR We first analyzed the expression profile of piRNAs in CRC using the TCGA and GEO databases. The top 20 highly expressed piRNAs were selected and tested in our CRC tumor and non-tumor tissue samples. We then examined the relevance of the significantly differentially expressed piRNA to the CRC outcomes in 218 patients receiving postoperative chemotherapy and 317 patients receiving neoadjuvant chemotherapy. A series of biochemical and molecular biological assays were conducted to elucidate the functional mechanism of a piRNA of interest in CRC. Furthermore, experiments with mice xenografts were performed to evaluate the therapeutic effect of an inhibitor specific to the piRNA. cell line (HCT116, LoVo, 293T) up-regulated resistant PIWIL2 PIWIL2 STAT3 signaling pathway validated 8230 PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics 2018 30555542 piRBase NA piRNA-54265 piRNA DB00526 (APRD00186) Oxaliplatin colorectal adenocarcinoma RT-qPCR We first analyzed the expression profile of piRNAs in CRC using the TCGA and GEO databases. The top 20 highly expressed piRNAs were selected and tested in our CRC tumor and non-tumor tissue samples. We then examined the relevance of the significantly differentially expressed piRNA to the CRC outcomes in 218 patients receiving postoperative chemotherapy and 317 patients receiving neoadjuvant chemotherapy. A series of biochemical and molecular biological assays were conducted to elucidate the functional mechanism of a piRNA of interest in CRC. Furthermore, experiments with mice xenografts were performed to evaluate the therapeutic effect of an inhibitor specific to the piRNA. cell line (HCT116, LoVo, 293T) up-regulated resistant PIWIL2 PIWIL2 STAT3 signaling pathway validated 8231 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 piRBase NA piRNA-36712 piRNA DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Paclitaxel breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive NA NA NA validated 8232 PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer 2019 30636640 piRBase NA piRNA-36712 piRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin breast cancer RT-PCR We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. cell line up-regulated sensitive NA NA NA validated 8233 PIWI-interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in neuroblastoma cells. J Cell Physiol 2019 31478570 piRBase NA piR-39980 piRNA DB00997 (APRD00185, DB05331, DB05847) Doxorubicin neuroblastoma qRT-PCR The role of piR-39980 in neuroblastoma cells was detected using qRT-PCR, MTT assay, flow cytometry assay, chromatin condensation assay, wound-healing assay, transwell invasion assay, anchorage independent growth assay and dual-luciferase reporter assay, etc. cell line (IMR-32 and HEK293T) up-regulated resistant JAK3 JAK3 NA validated